<SEC-DOCUMENT>0000950170-23-005345.txt : 20230301
<SEC-HEADER>0000950170-23-005345.hdr.sgml : 20230301
<ACCEPTANCE-DATETIME>20230301080238
ACCESSION NUMBER:		0000950170-23-005345
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230301
DATE AS OF CHANGE:		20230301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PMV Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001699382
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				463218129
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39539
		FILM NUMBER:		23689852

	BUSINESS ADDRESS:	
		STREET 1:		8 CLARKE DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		(609) 642-6664

	MAIL ADDRESS:	
		STREET 1:		8 CLARKE DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pmvp-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-02-28T09:45:30.7424+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:pmvp="http://pmvpharma.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_637e6d3e-1c4a-4011-bf94-4da18c87eb69" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201912Member</ix:nonNumeric><ix:nonNumeric id="F_68272f31-ac51-43d0-89b6-b5574371c7f3" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_abd743b6-67e8-483f-a3cf-127525d0673d" format="ixt-sec:duryear">1</ix:nonNumeric><ix:nonNumeric id="F_2e41832f-24ee-4add-8485-3b9e6b7ae42f" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_b0735f3a-edd9-4d2b-84ba-f95bfad593a4" format="ixt-sec:duryear">1</ix:nonNumeric><ix:nonNumeric id="F_82dfdf8f-411c-4717-af9e-206e2366f08e" name="us-gaap:OpenTaxYear" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d">2013 2014 2015 2016 2017 2018 2019 2020 2021</ix:nonNumeric><ix:nonNumeric id="F_3a46e714-ad0c-48f4-96db-55dc5d713a9d" name="dei:AmendmentFlag" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d">false</ix:nonNumeric><ix:nonNumeric id="F_4604235b-11b9-4105-9a93-5870e969a273" name="pmvp:IncomeTaxExaminationPeriod" contextRef="C_62a9b101-ab75-4638-a91d-240e17253b55">P3Y</ix:nonNumeric><ix:nonNumeric id="F_b4874bf9-8bff-43b2-82b8-cb8c9e7dc9f5" name="dei:DocumentFiscalPeriodFocus" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d">FY</ix:nonNumeric><ix:nonNumeric id="F_af92f22e-15dc-40d1-892d-72674131cdfc" name="dei:EntityCentralIndexKey" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d">0001699382</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pmvp-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_58ef5181-20d9-4f31-9be5-bbaff729be34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05247025-7721-46fd-b9a4-9209202d385c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59228c38-0358-4b55-8691-88e77e7b5f20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_978ba6d3-3e46-4525-91db-17cd972dc4ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11ed8784-858f-40ad-9cbb-1dbbf928a291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f19e1fd-4356-482e-bb63-fcc3de69c641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2667deff-220f-4412-adb0-e8fc0d6ca3f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0599473c-789b-4f09-b3fb-e6b52320799c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7826d7cd-2cdc-4c9e-b57f-b6e1dfb7b459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cba766c3-a95a-452a-8d08-ceb25213b983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1d65801-b9d6-4c7d-ba94-0cee28a011c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1034c385-e799-4334-bd67-e7a75f20b60c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-25</xbrli:startDate><xbrli:endDate>2020-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1989c17-cc2f-4cba-a956-12217925213d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc9e11c2-3eae-4c34-8935-47bc9239ba59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a13ba9e-9b6c-49f5-9585-76663577d207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0cf2842-991a-497a-ad23-0d484ab89803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0044e892-3fea-44d5-872f-e25925415e12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-25</xbrli:startDate><xbrli:endDate>2020-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_430e7e98-a75c-447c-94c7-2b300c9ae2c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:SouthBrunswickNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14af34ae-ca01-4273-9ecd-fd1963bc0d32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ff7f970-97f9-4cb7-a2a0-8883a87d4dca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed2937ce-4797-431c-bb85-119506b27457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7ede4d5-1f79-4121-9b1d-f81bbef5bc5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0a73230-1c9b-4996-8fdd-7164c9f9c45f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmvp:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54e6aacb-2840-4e37-bef3-a3d7dc27785c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eeba018d-c970-42c2-b7e8-39bb44c1c232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cff8f1fb-dda0-4691-8c83-2a825ba5821d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:SouthBrunswickNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de0eb331-80ac-42d7-a504-423cc2cfa8d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e30e375d-2146-4abd-ab44-0f83c21f02ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-25</xbrli:startDate><xbrli:endDate>2020-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50eb0442-301d-4fd1-8119-3f5ac5089ea2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b49092ec-8ffe-4a12-88e3-3c14783b877c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01ffbae4-047b-4cdf-97c5-b607f5f8288c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmvp:AssetsNotPlacedInServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7d7545a-22ed-48ea-9de9-36b175caa031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6997eaf7-2d14-4514-abb0-3d4e030cd2ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:SouthBrunswickNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e80c7c5-b3d0-4620-b5bc-d434b48624a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_069c5ae4-3c69-4167-b429-fe8497be6762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6b007b1-2fc8-4c95-a477-b9b71fb8a813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86745cc2-3f0c-450a-840f-efc74e3b9311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5ec1baa-405a-4660-a084-861474f9bfdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_350081f7-b9c6-4878-9982-48ec05493f21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f668206-d681-40de-bb20-c42cee8ec88f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e800e2c-3450-44fa-bbf1-ab0a826218a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandAndThirteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6007dfa3-622c-49c1-9860-180a9069696e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmvp:UnvestedEmployeeStockPurchasePlanSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f699388-d277-4279-ad4b-3dc305343bb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a77505cc-2f39-49ee-ad0b-48a03ab00343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0971ead3-d21f-4a45-a148-3e60a1cdbe48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8eb3a307-a471-4ef6-b42e-874598113768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b75762f-88bc-457f-a72d-6cf0e39501d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eecb9d6d-ac0a-487e-a86a-abf840012bdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f992ea57-8d32-4b0e-81ef-cb65a45d19d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50c95562-5171-48b3-9b59-edd5b2537c4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26d83b9d-f0fd-40e2-b4ab-7163ee3e8e1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmvp:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c162453-8ec6-47e9-94ab-ae196146b8ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmvp:UnvestedRestrictedCommonStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4c247c9-f1e3-4efe-9b18-0915c829f126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee1cceca-c5e2-4901-967c-47736d420d59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e9b7374-006a-4280-8ffb-f7a56c5987fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7da1954-d795-42d9-9a41-c04ab601e771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9893b5b-4a1f-4410-b019-9a69763b7f7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a05cc4e-dcbc-40a3-8e6d-3479699de18c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abd743b6-67e8-483f-a3cf-127525d0673d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:SouthBrunswickNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bfc2514-cfef-48de-a925-42f04c369057"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f9792c0-bc7a-4f8f-9b3a-22089cbb1363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_845a7222-a0c1-4e92-a848-92db3ee210f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6082b64b-c8b4-41e9-ba59-4bf5900eec0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmvp:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f918825-5928-4608-b71c-9f4456b6f047"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3202e22d-2468-4cd8-9005-96d662a4e257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandAndThirteenStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7482c8b1-66e1-413c-a4f6-0956e9d78239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95c6ff9a-7273-447e-b18f-9405d1b0061e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_498dfeb5-4f73-4ec9-8f1c-60dbf3d79a5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8e287d6-b299-4d5e-a156-3e903f57677f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57689871-3d90-40ca-a6f9-460f78c06285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c875a660-6997-4368-89c4-d6bfbe6ef5e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01965527-3ea2-4759-b0e5-d6e7a69bf0ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05748ee3-8f14-434c-b214-63235c977b9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cbe3afa-3782-4ddb-a255-b2011580f639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0aac07e3-04d3-478a-9920-5fb843d4ae5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc64aa3a-019b-48b2-8343-7467cc9d0a91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f92056d-1339-471e-a03a-fba16e49f069"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abb7ff4b-f4ff-4208-b730-ff89fd4d2f48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c1da20a-2594-4596-9560-1c31c1640622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_52495b65-0118-40a4-bfc2-7a226cb39fe6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12649a32-1900-4175-a9b7-929ef30b495c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00093d41-7321-438a-9568-7a6890ae8c2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0736b229-258c-40dd-838a-47547c627b77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9eac9d1b-d481-4882-beb9-94f63124f8eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1dba3b6b-5641-4b1b-9e12-052771f7ced4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b4380ac-1ddd-4289-8638-eefde924a0cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee831443-0cb9-4eaf-ae6d-7a321beb8833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-24</xbrli:startDate><xbrli:endDate>2020-09-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62a9b101-ab75-4638-a91d-240e17253b55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d1c2064-9b95-4b0c-95f4-5061ac19468e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_026560c8-db2c-4e87-a51c-0c88050f90a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72d9367d-2b3c-4d93-892a-028d7de01843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b95af3e-4692-4a4e-9684-b24ec983c018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a991aacb-ef93-40b5-b119-f3a9a2d28d00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be6aad5a-a831-43c8-a05f-822cdf5cf4a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-09</xbrli:startDate><xbrli:endDate>2022-09-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1cbfb514-89c7-42d8-9873-9e01e255563c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9a7f863-44e3-4b8b-a088-33b385350544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-25</xbrli:startDate><xbrli:endDate>2020-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_016af1b3-ff49-4bb0-867b-902d174c68ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-09</xbrli:startDate><xbrli:endDate>2022-09-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a6c24a3-d3cb-43ea-9818-038cc97b8e65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_afc8cc4f-8592-4a73-b6b1-bc62607689d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efbb7361-2dda-41c4-81c1-8e49b935005c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56fadc42-3ad0-4e3b-8b73-b2226b84481a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bce60bd0-958e-42c0-9f7d-65828fc53e9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41b52ed3-f105-4a33-84d9-920833d5abcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_720aa091-f1ff-40f6-9052-0af429d30c44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_236fce2d-e055-4239-92a3-3e87093d5a21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99e58b14-8dbf-449f-8271-666e6962200a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99a529b5-6188-4ab9-8f9d-4322c6925579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f97e2ad4-444f-4f38-9b94-59f51d99a446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmvp:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2f1afb2-0883-4bf4-890d-a477cbd94b5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee80540b-08ef-4bfb-a16e-dc6e2b4b20b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_502f3121-e154-46be-b42e-f83a002a53e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9d8a5eb-415a-4f96-ba6c-84acbe6f1562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fa2099b-812e-4e76-9690-196d1a864954"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05006ac3-674f-4f86-a1fb-57904ae43650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96ef7e99-5645-4f46-9a50-9275689d19f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7006422b-42e5-4830-9abd-4af424a83925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f825d4ed-c7b9-49be-993b-f8659d7899e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95fdd9a8-ebe7-4208-ba3b-05e6405b6c61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d23af98b-9ff8-4b89-9401-a895cac8088c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d1fa26c-38d2-4b57-a550-1a0282289c2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_313a014b-8256-4401-b4ea-e5d597a024c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f21d65be-13a2-4ece-a7b5-17985dc50636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b870873f-a136-48b3-b1fb-15b46f12781f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_276e8ed2-4f66-40e4-bdb0-8985bcee8033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AZ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dde39134-e5f7-476a-97bc-d31efae7f2a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5066952e-d95e-40c8-a2b4-77c7e137ae45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_394efadb-0831-4ded-a4d6-2abf18188b08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e66fbef-977e-4452-91f9-9a4ee3656882"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-20</xbrli:startDate><xbrli:endDate>2022-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24c200ea-42b0-4b4d-9f36-e114465d1de9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfda4846-cb6b-43ca-955c-e5766847123d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4bdae4ec-dd1e-490f-b8a5-74529602509a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd70bc18-5773-4da6-a7eb-54ca7d7cf4d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmvp:AssetsNotPlacedInServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fb33a8b-4881-4337-b607-5aca6c7a973b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmvp:UnvestedEmployeeStockPurchasePlanSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb839397-f2dc-4167-a221-47e4547f3e6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8894ea23-6468-4b4b-9fe0-13e05959ff40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24ca9645-4213-432d-9825-b9d9754a3d26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f6a712d-9111-4481-8345-32cee4988f74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77450a26-c91f-4546-8962-eb03770dbd9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5a63292-5285-4e55-9178-b0cf6d47d493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e189a9e4-ad1c-4932-a0a3-75d29fa8bacd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmvp:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b29a161-8a1d-462e-b2b3-67a19d48100c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4cfd3a5-85b9-4820-af60-1d16ec12ddf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_205220c0-e91d-4339-8383-bedd964b0c1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2dfb4cde-06c3-4435-a144-2e3f21d7e9ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00d11f95-a34f-4d02-91c8-51c60eec5c22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmvp:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0735f3a-edd9-4d2b-84ba-f95bfad593a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8260db6-bbe1-4939-9c5f-a844164fe721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7636c7c-5d0d-43b6-ae8e-cf22b92c32be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27aea8e1-2efd-4fae-b253-57813f8540e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8daf283d-3684-4e97-b173-64076dd32fca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_341901e2-89fa-4177-845b-613f934b9099"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9720ff11-f138-4224-ba3c-9c427709c9e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46e3720d-b4bb-422c-94c9-0403252a56b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb5c078d-3484-49d9-922e-5414ab268c7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be4f127e-beed-49d8-9fd5-8cc013547c17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001699382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_U_iso4217USD_utrsqft"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Member"><xbrli:measure>pmvp:Member</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>pmvp:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Lease"><xbrli:measure>pmvp:Lease</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e7ec3fb1-b42f-48c3-b7d7-ca1cbe27abc5" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">!</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_313cd79a-f3cb-47ba-8de7-26805f455f36" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a44c37ba-f27c-4d38-bd87-a9683ebc63f6" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7c852359-9c5b-4560-85d2-48840e9003f0" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b7d64782-be30-43e7-b609-b24413eff148" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_8ce9d4b1-b3c2-4fba-a081-7fca28cf7f0b" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_db222691-512e-4ec8-afdd-0a853743f8db" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39539</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:19.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_38d4bbf7-f54e-4a2e-978b-e8d82c700f66" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:19.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV PHARMACEUTICALS, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5d408285-f8f2-4ecc-bed4-a6bbcdc301d2" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_17943996-7dfc-4747-8b4e-ed8a54d0956c" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46-3218129</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2e81b61f-ed1a-4123-ad8d-84e58676e29b" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 Research Way</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_54bcb6e5-1e05-40e1-98ab-6f9dda006501" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Princeton</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f09ed1d5-882e-4ccd-9443-fc17b5eed6e3" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NJ</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9a8ba0a1-7b18-4a27-a76a-29f50fcda992" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">08536</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_42aa5253-d161-4278-9c02-c9105fe32895" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">609</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fd33b139-3661-477c-9310-8f44c26b2580" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">642-6670</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:39.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9087f6ad-7249-4113-b8c7-f310b5a587eb" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, par value $0.00001</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a609fe81-c3ac-4346-b2a0-53e18db26b03" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMVP</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f7cb6a23-4eab-459f-9689-725e73ac0c76" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6723608c-008e-4702-ac3d-a88738c06e8c" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_968cf320-45c1-47af-888b-6196889b51d5" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e1ced4e9-387d-40d5-a6fc-79a03c707d6d" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_41124558-8b73-4127-9048-2ea45cb91454" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:16.963%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:60.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:18.157%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.88%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1e3e7905-e92e-458b-b803-c00698fd220f" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_cf142b15-690d-4d32-b739-4c887a0860e0" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_69246f14-b1cf-4971-9f73-e42f06145443" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_7044224c-b7f4-414a-b1b1-85341da8020f" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> No </span><span style="font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_739daef7-4f9d-4031-ba1c-dfcb48b28f2e" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The Nasdaq Stock Market on June 30, 2022 (the last business day of the Registrant&#x2019;s most recently completed second fiscal quarter), was $</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_243577d7-2d72-455b-9c49-3d58d45af4f5" contextRef="C_845a7222-a0c1-4e92-a848-92db3ee210f0" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">543,361,107</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Shares of the Registrant's common stock held by each executive officer, director and holder of 10% or more of the outstanding common stock have been excluded because such persons may be deemed affiliates. This calculation does not reflect a determination that certain persons are affiliates of the Registrant for any oth</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">er purpose.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of Registrant&#x2019;s Common Stock outstanding as of February 28, 2023 w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_576825c3-499f-47f5-a478-0b6ae64c1cfd" contextRef="C_24ca9645-4213-432d-9825-b9d9754a3d26" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">45,773,361</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_035c6a7b-1692-4ec6-9192-f307b7ec068b" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Registrant&#x2019;s definitive Proxy Statement relating to the 2023 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.096%;"></td>
    <td style="width:82.821%;"></td>
    <td style="width:7.083%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5__market_for_registrants_common_eq"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8__financial_statements_supplementa"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9__changes_in_disagreements_with_ac"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a__controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b__or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdiction that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10__directors_executive_ficers_corp"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11__executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12__security_ownership_certain_bene"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13__certain_relationships_related_t"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14__principal_accounting_fees_servi"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15__exhibits_financial_statement_sc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, development plans, planned preclinical studies and clinical trials, future results of clinical trials, expected research and development costs, regulatory strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some cases, you can identify forward-looking statements by terms such as &#x201c;may&#x201d;, &#x201c;will&#x201d;, &#x201c;should&#x201d;, &#x201c;would&#x201d;, &#x201c;expect&#x201d;, &#x201c;plans&#x201d;, &#x201c;anticipate&#x201d;, &#x201c;could&#x201d;, &#x201c;intend&#x201d;, &#x201c;target&#x201d;, &#x201c;project&#x201d;, &#x201c;contemplate&#x201d;, &#x201c;believe&#x201d;, &#x201c;estimate&#x201d;, &#x201c;predict&#x201d;, &#x201c;potential&#x201d; or &#x201c;continue&#x201d; or the negative of these terms or other similar expressions. Forward-looking statements contained in this Annual Report include, but are not limited to, statements about:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our financial performance;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the sufficiency of our existing cash, cash equivalents and short-term marketable securities to fund our future operating expenses and capital expenditure requirements;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our need to raise additional funding before we can expect to generate any revenues from product sales;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain additional funding for our operations, when needed, including funding necessary to complete further development and commercialization of our product candidates, if approved;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the implementation of our strategic plans for our business and product candidates;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the market opportunity for our product candidates and our ability to maximize those opportunities;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials and investigational new drug applications, or IND, and other regulatory submissions;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our estimates of the number of patients for each of our programs including patients expected to have certain p53 mutations and the number of patients that will enroll in our clinical trials;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other favorable results;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans relating to the clinical development of our product candidates, including the disease areas to be evaluated;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing, progress and focus of our clinical trials, and the reporting of data from those trials;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans relating to commercializing our product candidates, if approved;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the expected benefits of potential future strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of competing therapies that are or may become available;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing or likelihood of regulatory filings and approvals, including our expectation to seek accelerated reviews or special designations, such as breakthrough therapy and orphan drug designation, for our product candidates;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans relating to the further development and manufacturing of our product candidates, including for additional indications that we may pursue;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">iii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">existing regulations and regulatory developments in the United States and other jurisdictions;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans to rely on third parties to conduct and support preclinical and clinical development;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to retain the continued service of our key personnel and to identify, hire and then retain additional qualified personnel; and</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of the ongoing coronavirus disease 2019, or COVID-19, pandemic, geopolitical tensions such as the Ukraine-Russia war, macroeconomic events such as global supply chain challenges, elevated inflation and interest rates and monetary policy changes, or other related disruptions on our business</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of risks, uncertainties and assumptions described in the section titled &#x201c;Item 1A. Risk Factors&#x201d; and elsewhere in this Annual Report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, statements that &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">iv</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1. B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">usiness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the &#x201c;guardian of the genome,&#x201d; and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. We have leveraged more than four decades of research experience and developed unique insights into p53 to create a precision oncology platform designed to generate selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant p53 proteins to restore their wild-type function. We are deploying our precision oncology platform to target the top ten most frequent, or hotspot, p53 mutations that are collectively associated with approximately 10-15% of all cancers.  In addition, we continue to utilize our platform to target other p53-related cancers.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead product candidate, PC14586, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. The Y220C mutation is associated with 1.0-1.5% of all cancers, including breast, non-small cell lung cancer, or NSCLC, colorectal, pancreatic and ovarian cancers. PC14586 is designed to restore the wild-type conformation by occupying the crevice created by the tyrosine to cysteine mutation in amino acid position 220. While we are in the early stages of discovery and development of our product candidates and our novel approach is unproven, we are initially pursuing a tumor-agnostic development strategy and initiated a Phase 1/2 clinical trial in October 2020. Our strategy is to seek approval under an accelerated pathway, and we believe our Phase 1/2 clinical trial has the potential to serve as a pivotal study. In October 2020, we were granted U.S. Food and Drug Administration, or FDA, Fast Track designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.  We presented our preliminary Phase 1 clinical data in June 2022 and we continue to enroll patients in this trial. In December 2022, we opened a separate arm within the existing Phase 1/2 clinical trial combining PC14586 with KEYTRUDA&#174; (pembrolizumab) in collaboration with Merck and Co.  In addition, we are leveraging our precision oncology platform to develop a pipeline of oral small molecule product candidates that structurally correct other p53 hotspot mutations to restore their wild-type function and product candidates that target other p53-related cancers.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A better understanding of mutations that drive cancers have facilitated the development of precise, gene- and protein-specific drugs known as targeted therapies. Targeted therapies have the potential to transform treatment of some cancers by providing robust clinical benefit to patients. In many cases, clinical responses can be dramatic enough to support expedited regulatory approval of these therapies. Further, recent advancements in next-generation-sequencing, or genomic NGS, have accelerated the development of targeted therapies. A recent study found that 75% of oncologists in the United States employ genetic sequencing. We believe p53 mutations are particularly well-suited for the evolving precision oncology paradigm, as a single mutation can cause p53 malfunction, and p53 is one of the genes commonly sequenced, to our knowledge, in NGS panels. We believe that our precision oncology platform offers a substantial opportunity to expand the number of patients who will benefit from targeted therapies.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our innovation engine consists of three complementary drivers:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">deep understanding of, and leadership in, p53 biology that enable unique insights into drugging individual mutations as well as targeting other p53-related cancers;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ability to design on a structural basis selective, oral small molecule product candidates; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assays, screens, preclinical model systems and biomarkers that enable us to assess and optimize orally available selective small molecule drug product candidates for specific p53 mutants, and for inhibitors of wild-type p53 function</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 and Pipeline</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are leveraging our precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule product candidates that are designed to structurally correct specific mutant p53 proteins to restore their wild-type function. In addition, we are expanding the utilization of our platform to target other p53-related cancers.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An overview of our development pipeline is shown in the table below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img249132499_0.jpg" alt="img249132499_0.jpg" style="width:624px;height:296px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Discovery, we screen compounds against biological assays to identify lead compounds.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Lead Optimization, we modify the lead compound to improve potency, selectivity, pharmacokinetic and toxicity parameters and physical chemical properties important for clinical development.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In IND-Enabling Studies, we conduct preclinical studies, in accordance with Good Laboratory Practice, or GLP, required for an IND submission to the FDA.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead product candidate, PC14586, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. The Y220C mutation results from tyrosine being substituted by a cysteine at amino acid position 220 and is associated with 1.0-1.5% of all cancers, including breast, NSCLC, colorectal, pancreatic and ovarian cancers. There are currently no products approved by the FDA, and we are not aware of any other products in clinical development, that selectively target the p53 Y220C mutation.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 is designed to bind to the mutation site and structurally correct the misfolded p53 protein, while sparing wild-type p53. Our approach has yielded a highly selective product candidate, which we believe can maximize the potential therapeutic potency and minimize risk to normal functioning cells. In preclinical studies, PC14586 has shown selective on-target activity (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">i.e.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, primarily functions in cells with the p53 Y220C mutation) and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition, or TGI, and strong tumor regression as a single agent.  Further, preclinical studies have demonstrated significant synergistic effects in combination with anti-PD-1 therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We initiated a Phase 1/2 clinical trial for PC14586 in October 2020. In addition, we were granted FDA Fast Track designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation in October 2020. We dosed our first patient in this clinical trial in the fourth quarter of 2020. The Phase 1 portion of the trial is designed to evaluate escalating doses of PC14586 to determine the maximum tolerated dose, or MTD, and recommended Phase 2 dose of PC14586 when administered orally to patients. Safety, tolerability and effects on biomarkers such as macrophage inhibitory cytokine-1, or MIC-1, will also be assessed. The Phase 1 portion is also designed to assess preliminary anti-tumor efficacy in patients with advanced solid tumors that have the p53 Y220C mutation. In June 2022, we presented initial Phase 1 data, as of a May 10, 2022 efficacy data cutoff date, from our Phase 1/2 clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting: PC14586 was generally well-tolerated and the MTD was determined to be 1500mg BID. A total of 41 patients with the p53 Y220C mutation were enrolled, including 25 patients with measurable disease who were treated in the efficacious dose range, which was defined as a dose from 1150mg QD to 1500mg BID. In the efficacious dose range, partial responses were observed by investigator review (RECIST v1.1) in 32% (six confirmed partial responses and two partial responses pending confirmation as of May 10, 2022) across six different tumor types.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe the mechanism of action employed by PC14586 to structurally correct a specific p53 mutant and restore wild-type p53 activity could provide benefit to patients and offer a unique value proposition in oncology, and is a strategy that can be pursued broadly across other p53 mutations. To that point, we are developing a pipeline of candidates targeting other p53 hotspot mutations. We have other preclinical programs that have demonstrated biochemical validation, for which we are leveraging knowledge from our PC14586 Y220C program. We believe we can scale our discovery and development principles across all p53 hotspot mutations to streamline the process of further developing our pipeline.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to targeting p53 hotspot mutants, we believe that our expertise and platform can also be applied to target other p53-related cancers.  We are deploying our deep understanding of structure-based small molecule design, assays, screens, preclinical model systems and biomarkers to create a pipeline of therapeutics in this field.  We believe that we can continue to scale our platform to develop novel therapeutics that structurally correct mutant p53 or other p53-related cancers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our vision is to become a leading precision oncology company by designing, developing and commercializing novel precision medicines for every patient with a p53-driven tumor.  We believe we are well positioned to leverage our deep experience in p53 biology, precision oncology platform and foundational knowledge acquired through our lead program to bring these therapies to patients. The critical components of our strategy include:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advancing our lead product candidate, PC14586, as a tumor-agnostic, oral small molecule therapy for cancer patients</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have designed PC14586 to be an orally available, tumor-agnostic therapeutic and, if approved, we believe it could become the first agent to address the p53 Y220C mutation-defined patient population. In October 2020, we initiated a Phase 1/2 clinical trial for PC14586 in multiple solid tumors with the p53 Y220C mutation. We plan to conduct our clinical trials in this genetically-defined patient population and leverage learnings from recently approved tumor-agnostic drugs to inform the clinical and regulatory pathways for PC14586. In June 2022, we presented our initial Phase 1 clinical data for PC14586 and observed partial responses across six different tumor types.  In December 2022, we opened a separate arm within the existing Phase 1/2 clinical trial, to evaluate the combination of PC14586 with Merck&#x2019;s KEYTRUDA (pembrolizumab), in patients with advanced solid tumors harboring a p53 Y220C mutation.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Harnessing the power of our precision oncology platform to discover and develop additional differentiated product candidates that are designed to precisely target p53 mutant protein and inhibitors of wild-type p53 in cancer</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We believe that the general principles for our PC14586 Y220C program can be applied to other p53 hotspot mutations. Using our extensive in-house expertise, deep understanding of chemistry and decades of experience researching the p53 protein, we believe that we will be able to leverage and apply foundational knowledge from the advancement of PC14586 to the discovery and development of small molecules targeting other p53 mutations. We are advancing several early-stage programs focused on targeting the p53 hotspot mutations and other p53-related cancers. In an ongoing effort to bring forward new product candidates, we plan to continue to invest in our precision oncology platform, including our high-throughput screens that allow for quantitative visualization of the conversion from mutant to wild-type p53 in a dose-dependent manner.  </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leveraging the advantages of precision medicine and our expertise in p53 biology to pursue accelerated approval of our product candidates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. For our lead product candidate, PC14586, we are actively working with physicians and leading academic centers to enroll patients with the p53 Y220C mutation identified through NGS in our Phase 1/2 clinical trial. In order to rapidly confirm mechanistic and clinical proof of concept, we utilize assays to measure target engagement and biomarkers, as well as assess clinical responses in patients. We expect this strategy, which we also plan to replicate for our other future product candidates, will enable a rapid determination of target engagement and has potential to serve as a predictive marker of efficacy, thereby providing clear decision points for clinical development and efficient advancement of our product candidates towards approval. If we obtain early and encouraging clinical results, we may seek breakthrough therapy designation from the FDA, which, if granted, is intended to expedite clinical development and regulatory review. We intend to maximize the benefit of our product candidates by pursuing a tumor-agnostic approach.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identifying and exploring combination therapy approaches for our product candidates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Though PC14586 has demonstrated clear and robust tumor regression as a single agent in preclinical animal models, we believe that the mechanism of correcting the structure of mutant p53 can be complementary to other oncology therapies. Leveraging our expertise in p53 biology, chemistry and cancer pharmacology, we plan to identify and explore combination strategies with multiple cancer therapies. For example, chemotherapy and radiation therapy, approaches that result in deoxyribonucleic acid, or DNA, damage and upregulate p53 are natural candidates for combining with our product candidates. In addition, we believe that p53 plays a role in influencing the tumor microenvironment. Therefore, immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 agents, could also be considered as potential combination agents for use with our product candidates. We believe that our unique expertise will enable us to prioritize therapeutic strategies and optimize outcomes for clinical studies.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Background on Targeted Therapies</span></p>
  <p style="text-indent:5.867%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancer is a genetic disease that results from changes in a person&#x2019;s DNA that causes cells to grow and divide uncontrollably. Genes are the distinct segments in a cell&#x2019;s DNA that can encode proteins with structural or functional roles in the body. Alterations in some genes can lead to the expression of mutant proteins with impaired or abnormal functions that can cause cancer. Cancer has historically been both diagnosed and treated based on a tumor&#x2019;s organ site, such as the breast, lung, ovary, brain, pancreas, skin, bone or blood.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent advances in genetic sequencing and a better understanding of the genetic alterations that drive tumor development and growth have facilitated precise, gene and protein-specific drug development, known as targeted therapies. Targeted therapies have the potential to transform treatment of some cancers by providing robust clinical benefit to patients. In notable cases, the clinical outcomes have been dramatic enough to support expedited regulatory approval of these therapies. For example, Retevmo in RET-altered NSCLC and thyroid cancers (Lilly/Loxo); Ayvakit, in platelet-derived growth factor receptor alpha exon 18 mutated advanced gastrointestinal stromal tumor, or GIST (Blueprint); Rozlytrek, in solid tumors with a neurotrophic tropomyosin receptor kinase, or NTRK, gene fusion (Roche); Vitrakvi, in solid tumors with an NTRK gene fusion (Loxo/Bayer); Zykadia, in anaplastic lymphoma kinase-positive, or ALK+, advanced NSCLC (Novartis); Zelboraf, in advanced melanoma with a BRAF V600E mutation (Roche Genentech); Xalkori, in ALK+ advanced NSCLC (Pfizer); Tagrisso, in epidermal growth factor receptor mutation-positive, or EGFR+, advanced NSCLC (AstraZeneca); Qinlock, in GIST (Deciphera), and Krazati and Lumakras in KRAS G12C mutated NSCLC (Mirati and Amgen) all received approvals within five years of first dosing in humans. This time period is significantly reduced compared to conventional drug development timelines. Despite this progress, a recent analysis found that only 8% of patients with metastatic cancer have tumors with genetic profiles eligible for treatment with an approved targeted agent, which leaves a large opportunity for precision oncology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is an emerging change in the development of targeted therapies, in that cancer is increasingly being targeted through a tumor-agnostic approach with a focus on selectively targeting a genetic or protein mutation irrespective of tumor type. For example, there are now multiple tumor-agnostic product approvals that are based on a genetic mutation that defines the disease, as opposed to the tumor type. These include the aforementioned Vitrakvi and Rozlytrek approvals as well as KEYTRUDA and Jemperli, respectively, approval in metastatic microsatellite instability-high, or MSI-high, or deficient mismatch repair, or dMMR, solid tumors. KEYTRUDA is also approved in tumor mutational burden-high-(TMB-H) solid tumors.  In addition, the combination of Taflinar and Mekinist was approved for BRAF V600E mutation positive unresectable or metastatic solid tumors (with the exception of colorectal cancer). We believe that these approvals represent a fundamental shift in the development of targeted therapies and will increasingly lead to cancer being characterized for treatment in a genetic, rather than in a tumor-specific, manner, based on a biological rationale.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The widespread recognition that cancer is a genetic disease, as much as it is a disease defined by histology or anatomical location, has driven the increased use of genetic sequencing, which is now employed by approximately 75% of oncologists in the United States. As DNA sequencing technology advances, the availability of well-defined genetic sequencing tests increases. With the increasing number of approved targeted therapies, we believe that physicians will seek a better understanding of the underlying genetic and protein abnormalities associated with a specific type of cancer in order to determine the optimal course of treatment. Advances in genetic sequencing are leading to transformations in the discovery and development of new targeted oncology drugs.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe p53 mutations are prime targets for precision oncology, as more than 50% of all human cancers contain a p53 mutation. Identifying the specific p53 gene mutation and structurally correcting the corresponding mutant p53 protein can potentially serve as a basis of treatment for these cancers. Diagnostic tests are currently used by physicians in their practice to identify patients with p53 mutations. Given the high prevalence of p53 mutations in cancers, we believe that an effective way to address p53-driven cancers is by targeting individual p53 mutations using a precision oncology approach and significantly expanding the scope of patients who can benefit from targeted therapies.  In addition, we believe that our platform can also be leveraged to expand our pipeline by identifying targets that modulate wild-type p53.  Given our deep understanding of and expertise in p53 biology, we believe that pursuing product candidates that target inhibitors of wild-type p53 can also expand the scope of patients who can benefit from targeted therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Background on p53, the Most Frequently Mutated Gene in Human Cancer</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The p53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">gene provides instructions for the production of tumor suppression protein p53 and is the most widely mutated gene in human cancers. Since its discovery in 1979 by our co-founder Dr. Arnold Levine, p53 has been extensively studied by researchers and the pharmaceutical industry due to its central role in preventing the initiation and proliferation of liquid and solid tumors. p53 has long been referred to as the &#x201c;guardian of the genome&#x201d; because it regulates expression of a number of genes that comprise the body&#x2019;s first line of cellular defense against cancers. Among its multiple biologic functions, p53 regulates a variety of tumor suppressive responses including cell cycle arrest, DNA repair, senescence and apoptosis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">p53 is a transcriptional factor, which binds to the promoters of its target genes in a sequence-specific manner and regulates their expression, thereby controlling cell cycle and cell death. p53 is activated when DNA damage is detected and when oxidative or other cellular stresses exceed thresholds for normal cellular function. p53 activation facilitates the repair of the cell&#x2019;s damaged DNA or triggers the killing of the damaged cell through a process known as programmed cell death, or apoptosis, before the cell can become cancerous and proliferate.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under normal cellular conditions, p53 is kept at low levels by expression of murine double minute 2, or MDM2, a ubiquitin ligase that promotes the degradation of p53. Upon p53 activation by damaged DNA, and other types of stresses, p53 is upregulated and blocks the proliferation of pre-malignant and malignant cells or eliminates them by inducing apoptosis. Mutant p53 loses the ability to eliminate the proliferation of pre-malignant and malignant cells. Given that the mutational status of p53 in a tumor has a strong impact on sensitivity to commonly used anti-cancer drugs and radiotherapy, p53 is important both as a biomarker and as a novel therapeutic target.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A key challenge in the development of p53-targeted therapies is the vast number of p53 mutants that lose tumor suppression activity. To date, more than 25,000 unique p53 mutations have been discovered. The p53 hotspot mutations occur as a result of site-specific substitution of one amino acid for another and lead to loss of tumor suppression function for the p53 protein. Strategies that attempt to restore wild-type p53 activity in a non-selective manner (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">i.e.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, regardless of which p53 mutation the tumor is harboring) are likely to face significant challenges, as a &#x201c;one size fits all&#x201d; drug is unlikely to address all p53 mutants and could have the potential for off-target toxicities. We are focusing on targeting the p53 hotspot mutations and other p53-related cancers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Focus: Top Ten Most Frequent p53 Mutations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.0%;"></td>
    <td style="width:3.001%;"></td>
    <td style="width:45.998%;"></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(12,12,12,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(12,12,12,1);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(12,12,12,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">p53 Hotspot Mutation</span></p><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(12,12,12,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(12,12,12,1);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.028in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Frequency Among p53 Mutations</span></p><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R175H</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.028in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.6%</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R248Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.028in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4%</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R273H</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.028in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0%</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R248W</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.028in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5%</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R273C</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.028in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3%</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R282W</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.028in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8%</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">G245S</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.028in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1%</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R249S</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.028in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0%</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Y220C</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.028in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8%</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">V157F</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.028in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Approach to Targeting p53</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our goal is to bring precision oncology therapies to a greater number of patients. Decades of p53 research has unveiled its potential as a precision oncology target, but prior drug development efforts have been unsuccessful. Mutant p53 historically has been classified as &#x201c;undruggable&#x201d; due to the difficulty of restoring wild-type p53 function. Mutations in p53 can give rise to mutant p53 proteins with different conformational structures. As a result, we are designing oral small molecule therapies that selectively target a specific p53 mutation while not binding to wild-type p53. We believe our novel approach designed to reactivate p53 function through the structural correction of mutant p53 protein to wild-type p53 represents a novel therapeutic strategy to target p53.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our drug development efforts leverage our understanding that:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mutations throughout the p53 protein can drive tumor formation and growth;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a mutant p53 protein resulting from a specific mutation can potentially be structurally corrected by a selective small molecule, thereby reactivating wild-type p53 activity;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the p53 hotspot mutations comprise approximately 30% of all p53 mutations and each p53 hotspot mutation represents an individual therapeutic target for drug discovery and development; and</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in addition to p53 mutant cancers, certain cancers result when wild-type p53 function is inhibited. </span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe we can address certain key limitations of current-generation precision oncology therapies by applying our platform to identify and generate therapies that address functional deficiencies associated with specific p53 mutations and other p53-related cancers. We believe this will allow us to design and develop potential therapies for patients with a high unmet medical need for whom there are currently no targeted treatment options.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Innovation Engine</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have built an innovation engine that allows us to discover and develop potential targeted therapies for mutant p53-driven cancers and other p53-related cancers. This engine consists of three complementary drivers:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deep understanding of, and leadership in, p53 biology that enable unique insights into targeting individual mutations and targeting other p53-related cancers. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have leveraged more than four decades of research experience and developed unique insights into p53 biology, a field that was discovered and established by our co-founder Dr. Arnold Levine. Additionally, our SAB consists of some of the most prominent thought leaders in p53 biology. p53 is a highly complex gene, and thousands of distinct p53 mutations have been identified. A blanket approach to targeting mutant p53 has significant challenges, as a &#x201c;one size fits all&#x201d; drug is unlikely to address all p53 mutants. Based on our experience and expertise, we are developing oral small molecules that each selectively structurally correct a specific p53 hotspot mutation. </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ability to design structure-based oral small molecule product candidates that selectively target and correct specific p53 mutants and inhibitors of wild-type p53.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Designing molecules for p53 mutants requires an intricate understanding of the p53 protein structure and the associated biology. We leverage structure-based technologies to give our oral small molecule product candidates access to challenging binding sites that are generally not accessible using conventional small molecule drug discovery approaches. For each target, we take detailed data from structural and functional studies of mutated p53 proteins to design development candidates against the challenging binding sites. Our design techniques help us to identify potential product candidates that can selectively target a single p53 mutant, while sparing wild-type p53.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assays, screens, preclinical model systems and biomarkers that enable us to assess and optimize selective small molecule product candidates.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We test our product candidates across a diverse set of human cancer cells based on research and understanding of bioinformatics and functional genomics. We also identify and monitor pharmacodynamic biomarkers and surrogates of clinical activity to help measure target engagement, including MIC-1, a serum-based biomarker. The biological insights we generate help us to better target various p53 mutants based on their structure and biology. In addition, we have built assays, screens and preclinical model systems and biomarkers that help assess and optimize our product candidates that target other p53-related cancers.  We develop innovative preclinical</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> models to advance potential therapeutic programs for translation to the clinic.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Product Candidate and Development Programs</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are leveraging our precision oncology platform to develop a pipeline of oral small molecule product candidates that structurally correct other p53 hotspot mutations to restore their wild-type function and product candidates that target other p53-related cancers. We own worldwide commercial rights to all of our programs. An overview of our development pipeline is shown in the table below.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img249132499_1.jpg" alt="img249132499_1.jpg" style="width:624px;height:296px;" />&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Discovery, we screen compounds against biological assays to identify lead compounds.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Lead Optimization, we modify the lead compound to improve potency, selectivity, pharmacokinetic and toxicity parameters and physical chemical properties important for clinical development.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In IND-Enabling Studies, we conduct preclinical studies, in accordance with GLP required for an IND submission to the FDA.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to initially seek approval of our product candidates in most instances, including with PC14586, at least as a second line therapy or for patients with no satisfactory alternative treatments or where the cancer has progressed following other treatment. Subsequently, depending on the nature of the clinical data and experience with any approved products or product candidates, if any, we may pursue approval as an earlier line therapy and potentially as a first line therapy. Cancer therapies are sometimes characterized as first line, second line or third line, and the FDA customarily approves new therapies for a second line or later lines of use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapies, usually chemotherapy, antibody drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery or a combination of these, proves unsuccessful, second line therapies may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules, or a combination of these. Third line therapies can include chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more invasive forms of surgery and new technologies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PC14586: A Selective Structural Corrector of p53 Y220C Mutations</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">p53 is the most widely mutated gene in human cancers. The vast majority of these mutations occur as a result of missense mutations that are found in the DNA binding domain. p53 Y220C mutations are found in approximately 1.0-1.5% of all cancers. This particular mutation is expressed in a large variety of solid tumors, including breast, NSCLC, colorectal, pancreatic and ovarian cancers. Our lead product candidate, PC14586, is designed to be an orally available small molecule that structurally corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Wild-type p53 in a normal cell is at low to undetectable levels, but an external insult such as UV radiation or exposure to a carcinogen results in activation and upregulation of the protein. In these instances, wild-type p53 pauses the cell-cycle to survey the integrity of the genome, and if the damage to the genome cannot be repaired, wild-type p53 induces a potent program of cell suicide or programed cell death. Given wild-type p53&#x2019;s profound ability to induce cell death, it is tightly regulated in normal biology by an auto-regulatory loop with MDM2, a downstream induced target of wild-type p53 transcriptional activation. MDM2 production results in degradation of the wild-type p53 protein and re-sets the cell to normal function.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the case of a mutant p53, there is a loss of p53 wild-type tumor suppression function due to a loss of downstream wild-type p53 transcriptional activation, including MDM2 induction. A consequence of this dysregulation is the inability of the cancer cell to degrade mutant forms of p53, resulting in a profound accumulation of mutant p53 protein in the cancer cell.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While treatment options such as surgery, chemotherapy, radiotherapy and immuno-therapy are available for breast, NSCLC, colorectal, pancreatic and ovarian cancer, there are no approved precision oncology therapies for the subset of patients with the p53 Y220C mutation. The availability of an oral small molecule selective for the p53 Y220C mutation may offer a novel precision therapy for this population, which we believe could potentially change the treatment paradigm for such patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Mechanism of Action</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 is an orally available small molecule candidate that is designed to selectively bind to the crevice created by the p53 Y220C mutation, and thereby restore the wild-type p53 protein structure and tumor suppressing function. In the diagram below, wild-type p53 protein is compared with a mutant p53 Y220C protein and a mutant p53 Y220C protein with PC14586 bound in the crevice created by the Y220C mutation. By docking into the crevice created by the Y220C mutation, PC14586 is designed to restore the wild-type p53 conformation and function.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img249132499_2.jpg" alt="img249132499_2.jpg" style="width:624px;height:355px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In preclinical studies, we have demonstrated that PC14586 rapidly converts the large protein pool of mutant p53 Y220C protein to wild-type structure. As seen in the graphic below, in an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">study, PC14586 induced conversion of p53 protein from mutant to wild-type conformation in a dose-dependent manner as evidenced by a decrease in mutant p53 and an increase in wild-type p53, while total p53 remains relatively unchanged.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 Demonstrated Structural Conversion from Mutant p53 to Wild-type p53 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:12.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img249132499_3.jpg" alt="img249132499_3.jpg" style="width:293px;height:228px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 selectively binds to the crevice created by the Y220C mutation as this molecule does not bind to wild-type p53 or other p53 mutations, including R273H, R273C, R175H, G245S, R248Q and R282W, as demonstrated by the lack of activity (as measured by p21 and MDM2 gene expression seen in the below diagrams). PC14586 only binds to the crevice created by the Y220C mutation, and none of the other tested p53 hotspot mutations, as illustrated by gene expression changes in the Y220C cell line when PC14586 is added in increasing concentrations.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, structural correction from a mutant p53 Y220C conformation to a wild-type p53 conformation by PC14586 restored p53-dependent transcription of downstream targets, which is indicative of wild-type p53 biological activity. For example, as shown in the figures below, p21 and MDM2, two of the downstream targets of p53, were selectively upregulated by PC14586 in a dose-dependent manner in cells where the p53 Y220C mutation was present. Since PC14586 is highly selective for the p53 Y220C mutation, it did not affect expression levels of p21 and MDM2 in tumor cell lines containing wild-type p53, p53 knock-out or other p53 hotspot mutations as noted in the figures below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 Induced Transcription of p21 and MDM2 Only in Cell Lines with the p53 Y220C Mutation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img249132499_4.jpg" alt="img249132499_4.jpg" style="width:624px;height:229px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical In Vivo Data</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 exhibited single-agent anti-tumor activity in a dose-dependent manner against mutant p53 Y220C tumors, evidenced by both potent TGI and tumor regression. Oral once-daily dosing over 21 days of PC14586 was well tolerated in nude mice (ten mice per dosing group) bearing p53 Y220C NUGC3 xenograft tumors up to 100 mg/kg, as evidenced by the lack of body weight loss, which is the generally accepted surrogate for toxicity in mice. PC14586 demonstrated dose-dependent TGI at daily doses ranging from 25 mg/kg to 50 mg/kg and robust tumor regression at 100 mg/kg daily.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 Single-Agent Administration in NUGC3 Xenograft Model Resulted in Tumor Regression and was Well Tolerated</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img249132499_5.jpg" alt="img249132499_5.jpg" style="width:624px;height:306px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also created a human p53 knock-in, or HUPKI, mouse that expresses a p53 protein with the human p53 DNA binding domain and the p53 Y220C mutation. The HUPKI mouse presents spontaneously with sarcomas at six to eight months of age, which we can harvest and re-implant in a wild-type mouse to create a mouse tumor model that has an intact immune system harboring a human p53 Y220C mutation. We believe this syngeneic mouse model better represents the patient population that we expect to see in the clinic, as compared to mouse xenograft models that incorporate human tumors in mice with no immune system. While some patients with cancer may have weakened immune systems, we believe that few patients have severely or fully dysfunctional immunocompromised systems, and therefore a syngeneic model may better represent the patient population than an immunocompromised mouse model. In addition, with an intact immune system, this model allows us to test anti-tumor activity of PC14586 in combination with immune checkpoint inhibitors.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As illustrated by the table below, PC14586, administered as a single-agent at a daily oral dose of 100 mg/kg for 70 days, demonstrated regression in tumors that express the p53 Y220C mutation in the syngeneic mouse model. The durability of the response was measured by median survival, where median survival for a 100 mg/kg dose of PC14586 exceeded 156 days, even though drug treatment was discontinued on day 70. This compared with median survival of only 17 days for the vehicle.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 Tumor Regression and Durable Responses in Syngeneic Mouse Model</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img249132499_6.jpg" alt="img249132499_6.jpg" style="width:557px;height:211px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Note: Each line represents each mouse where each group has 10 mice</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.997%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:45.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:1.0pt;">
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(12,12,12,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(12,12,12,1);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(12,12,12,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Group</span></p><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(12,12,12,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(12,12,12,1);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Median Survival Time</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Days)</span></p><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:1.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vehicle</span></p><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:1.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 100 mg/kg</span></p><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&gt;156</span></p><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Note: Dosing ceased on day 70 in the PC14586 arm.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 also exhibited anti-tumor activity in combination with anti-PD-1 therapy in syngeneic mouse models with the human p53 Y220C mutation. The scientific rationale for such a combination comes from the emerging literature suggesting an interplay between p53 and the immune system, which is the key mechanism of action of cancer immunotherapies such as anti-PD-1 antibodies. When PC14586 was administered at a sub-therapeutic daily oral dose of 50 mg/kg for 70 days in combination with a therapeutic dose of a PD-1 antibody, regression of tumors that express the p53 Y220C mutation was observed. As illustrated by the table below, median survival for a sub-therapeutic dose of PC14586 combined with anti-PD-1 treatment exceeded 156 days, even though drug treatment was discontinued on day 70, compared with median survival of only 24 days for anti-PD-1 treatment alone.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 + Anti-PD-1 Combination Showed Regression of Tumor Growth in Syngeneic Mouse Model</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img249132499_7.jpg" alt="img249132499_7.jpg" style="width:557px;height:344px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Note: Each line represents each mouse where each group has 10 mice</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.031%;"></td>
    <td style="width:19.584%;"></td>
    <td style="width:26.385%;"></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(12,12,12,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(12,12,12,1);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(12,12,12,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Group</span></p><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(12,12,12,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(12,12,12,1);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.028in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Median Survival Time (Days)</span><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span></p><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vehicle</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anti-PD-1 200 mg/kg</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 50 mg/kg</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);padding-left:0.111in;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 50 mg/kg + Anti-PD-1 200 mg/kg</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&gt;156</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Note: Dosing ceased on day 70 in the PC14586 + Anti-PD-1 arm.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Development Plan of PC14586</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We initiated a Phase 1/2 clinical trial, PYNNACLE, for PC14586 in October 2020. In addition, we were granted FDA Fast Track designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation in October 2020. We dosed our first patient in this clinical trial in the fourth quarter of 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, we provided an update on the Phase 1/2 trial at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting. The interim data, as of a May 10, 2022 efficacy data cutoff date, included enrollment of 41 patients with the p53 Y220C mutation, 33 of whom had measurable disease and were included in the primary analysis.  Patients in the study had a median age of 62 (range of 32-74 years of age) with a range of tumor types and were heavily pretreated with a median of three prior lines of therapy. Of these patients, 25 patients with measurable disease were treated in the efficacious dose range, which was defined as a dose from 1150mg QD to 1500mg BID.  In the efficacious dose range, partial responses were observed by investigator review (RECIST v1.1) in 32% (six confirmed partial responses and two partial responses pending confirmation as of the cutoff date) across six different tumor types. Best response of stable disease (SD) or PR was observed in 19 of the 25 patients (76%) in the efficacious dose range.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ongoing monotherapy dose escalation phase of our trial, we continue to enroll patients to evaluate the preliminary safety, efficacy, and pharmacokinetics of PC14586 to establish the recommended dose for Phase 2.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img249132499_8.jpg" alt="img249132499_8.jpg" style="width:624px;height:321px;" />&#160;</p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PC14586 was observed to be generally well-tolerated (across 41 patients treated with PC14586 monotherapy as of May 10, 2022). The majority of adverse events were mild or moderate (Grade 1 or 2) in severity with the most frequent adverse events being nausea, vomiting, aspartate transaminase (AST)/alanine transaminase (ALT) increase, anemia, blood creatine increase and fatigue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PC14586 in a Clinical Collaboration with Merck</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the preclinical combination data with PC14586 and an anti-PD1 antibody, we are evaluating this combination in patients.  In July 2022, we announced a clinical collaboration agreement with Merck to evaluate the combination of PC14586 and Merck&#x2019;s anti-PD1 antibody, KEYTRUDA (pembrolizumab), in patients with advanced solid tumors in patients with a p53 Y220C mutation.  This study is being conducted as a separate arm of  our ongoing Phase 1/2 PYNNACLE trial in patients with advanced solid tumors. Approximately 36 patients are expected to be enrolled in the combination arm of the trial. This combination arm will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PC14586 in combination with KEYTRUDA in patients with advanced solid tumors harboring a p53 Y220C mutation. Under the terms of the agreement, we will sponsor the trial and Merck will supply KEYTRUDA.  In December 2022, we initiated enrollment in the PC14586 + pembrolizumab arm of the PYNNACLE study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">R282W: Our Second Mutant p53 Program</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R282W is the sixth most frequent p53 mutation and accounts for approximately 2.8% of all TP53 mutations. The R282W mutation results from arginine being substituted by a tryptophan at amino acid position 282 and is considered a structural mutation. This structural mutation is thermodynamically unstable and cause the protein to lose shape and therefore its wild-type DNA binding activity at physiological temperature.  This results in a lack of p53 transcription and pathway activation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img249132499_9.jpg" alt="img249132499_9.jpg" style="width:311px;height:311px;" />&#160;</p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are generating molecules designed to structurally correct the R282W p53 protein to restore its binding to the DNA.  Our R282W program continues to progress towards lead optimization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Pipeline Programs</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to our PC14586 Y220C and R282W programs, we are focused on developing a pipeline of product candidates targeting other p53 hotspot mutations and targeting inhibitors of wild-type p53. These programs have been developed internally using our precision oncology platform and expertise.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are able to utilize the same general principles and similar drug discovery methods developed from our PC14586 Y220C program across other p53 hotspot mutations to facilitate the discovery of additional new product candidates. We study the structural and functional properties of the target. We use assays, screens, preclinical model systems and biomarkers to assess and optimize selective small molecules for specific p53 mutants. Specifically, many of the efficiencies from assays and model systems developed for our PC14586 Y220C program are being applied to other p53 hotspot mutations. In addition, the key insights gained from the medicinal chemistry campaigns are being leveraged across other p53 hotspot mutations. By leveraging our team&#x2019;s depth of expertise around p53, we are positioned to accelerate our efforts to expand the pipeline of therapies that selectively target p53 hotspot mutations and other p53-related cancers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our industry is intensely competitive and subject to rapid and significant technological change, as well as strong defense of intellectual property. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face substantial competition from major pharmaceutical companies and biotechnology companies worldwide. Many of our competitors have significantly greater financial, technical and human resources. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers. We are aware of other product candidates that are in clinical development as potential treatments of various cancers through the modulation of p53. There are many product candidates that may affect the p53 pathway, such as through MDM2 inhibition. We are aware of molecules in development that also are being explored for p53 upregulation/activation in various stages of preclinical or clinical development being tested by Aprea Therapeutics and Jacobio Pharmaceuticals, among others. We are also aware of selective small molecule inhibitors that are designed to target wild-type p53 containing tumors through the p53-MDM2 interaction, which are in various stages of clinical development being tested by Aileron Therapeutics, Ascentage Pharma, Boehringer Ingelheim, Daiichi Sankyo (out-licensed worldwide rights to Rain Therapeutics), Kartos Therapeutics, Kymera Therapeutics, Otsuka Pharmaceutical, Novartis and Roche, including testing MDM2 inhibitors in combination with a variety of other anti-cancer agents.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face competition with respect to our current product candidates and will face competition with respect to future product candidates, from segments of the pharmaceutical, biotechnology and other related markets that pursue targeted therapies for patients with genetically-defined cancers. If PC14586 or our future product candidates do not offer sustainable advantages over competing products, we may otherwise not be able to successfully compete against current and future competitors.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing their products.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we will likely need to develop our product candidates in collaboration with companion diagnostic companies, and we will face competition from other companies in establishing these collaborations. Our competitors will also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, we also face competition more broadly across the market for cost-effective and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy or a combination of such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates, if any are approved, may compete with these existing drug and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic, including branded generic, products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will be as our product candidates progress through clinical development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have any manufacturing facilities or personnel. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates undergoing preclinical and clinical testing, as well as for commercial manufacture if our product candidates receive marketing approval.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All of our product candidates are small molecules and are manufactured in synthetic processes from available starting materials. The chemistry appears amenable to scale up and does not currently require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We generally expect to rely on third parties for the manufacture of companion diagnostics for our products, which are assays or tests to identify an appropriate patient population. Depending on the technology solutions we choose, we may rely on multiple third parties to manufacture and sell a single test.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with current Good Manufacturing Practice, or cGMP, requirements which impose certain production, manufacturing, procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP requirements and other aspects of regulatory compliance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercialization</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to receiving marketing approvals, we expect to commence commercialization activities by building a focused sales and marketing organization to sell our products. We believe that such an organization will be able to address the community of oncologists who are the key specialists in treating the patient populations for which our product candidates are being developed.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also plan to build a marketing and sales management organization to create and implement marketing strategies for any products that we market through our own sales organization and to oversee and support our sales force. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved products and establishing relationships with researchers and practitioners in relevant fields of medicine.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We strive to protect the proprietary technology, inventions and improvements that are commercially important to our business, including seeking, maintaining and defending patent rights. We also rely on know-how relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position. We also plan to rely on data exclusivity, market exclusivity and patent term extensions when available. Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions and improvements; to defend and enforce our proprietary rights, including any patents that we may own in the future; and to operate without infringing the valid and enforceable patents and other proprietary rights of third parties. Intellectual property rights may not address all potential threats to our competitive advantage.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to our existing and future product candidates and processes we intend to develop and commercialize in the normal course of business, we intend to pursue further patent protection covering, when possible, compositions, methods of use, dosing and formulations. We also may pursue patent protection with respect to manufacturing and drug development processes and technologies. Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies. We may not be able to obtain patent protections for our compositions, methods of use, dosing and formulations, manufacturing and drug development processes and technologies throughout the world. Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In general, patents issued for applications filed in the United States can provide exclusionary rights for 20 years from the earliest effective filing date. In addition, in certain instances, the term of an issued U.S. patent that is directed to or claims an FDA-approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. This process is called &#x201c;patent term extension.&#x201d; The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The term of patents outside of the United States varies in accordance with the laws of the foreign jurisdiction, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Patent term may be inadequate to protect our competitive position on our products for an adequate amount of time.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of biopharmaceuticals has emerged in the United States. The relevant patent laws and their interpretation outside of the United States are also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, even our issued patents do not guarantee us the right to practice our technology in relation to the commercialization of our products. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have, or may obtain, blocking patents of which we are currently unaware that could be used to prevent us from developing or commercializing our product candidates and practicing our proprietary technology. Further, defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, pay royalties or redesign our products. Doing so may be impossible or require substantial time and monetary expenditure. We may also elect to enter into a license agreement to settle litigation or to resolve disputes prior to litigation. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. Should a license to a third party patent become necessary, we cannot predict whether we would be able to obtain a license, or if a license were available, whether it would be available on commercially reasonable terms. If such a license is necessary and a license under the applicable patent is unavailable on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed. This scenario could materially adversely affect our business. Even if we obtain a license to third party intellectual property, we may later decide, or it may later become necessary, to terminate the license. If we do so, we may no longer be free to use the technology protected by the patents no longer under license. Also, if a competitor developed the technology protected by the patents no longer under license, we would not be able to block the competitor&#x2019;s progress. If the competitor&#x2019;s product was competitive with ours, then we may suffer economic harm from the competitive product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its scope, validity or enforceability and our issued patents may be challenged, invalidated, deemed unenforceable or circumvented. These scenarios could limit our ability to stop competitors from marketing-related products or could limit the term of patent protection that otherwise may exist for our product candidates. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Moreover, any efforts to enforce our intellectual property rights are likely to be costly and may divert the efforts of our scientific and management personnel. We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We may also be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent directed to such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We generally file a provisional patent application with the U.S. Patent and Trademark Office, or USPTO, first and then subsequently file a corresponding non-provisional patent application. This process enables us to establish an earlier effective filing date in the subsequently filed non-provisional patent application. To benefit from the earlier effective filing date, we must file a corresponding non-provisional patent application, such as a utility application in the United States or an international application under the Patent Cooperation Treaty, or PCT, within 12 months of the date of the provisional patent application filing. Based on a PCT filing, we may file national and regional patent applications in the United States or foreign jurisdictions, such as the European Union, China, Japan and possibly others. To date, we have not filed for patent protection in all national and regional jurisdictions where such protection may be available, and we may decide to abandon national and regional patent applications before a patent is granted. In addition, the patent grant proceeding for each national or regional patent application that we file is an independent proceeding. As a result, it is possible for a patent application to be granted in one jurisdiction and denied in another jurisdiction, and depending on the jurisdiction, the scope of patent protection may vary. As of January 31, 2023, we owned three issued US patents and five granted foreign patents relating to methods of use and composition of matter of PMV compounds, including PC14586, at least 20 pending US patent applications, and at least 40 pending foreign patent applications, each of which relates to methods of use and composition of matter of PMV compounds. The three issued US patents are expected to expire in 2037, without taking into account any possible patent term adjustment or extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation and Product Approval</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, preclinical and clinical testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are developing. Generally, before a new drug can be marketed, considerable data must be generated, which demonstrates the drug&#x2019;s quality, safety and efficacy. Such data must then be organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Drug Development Process</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the FDA regulates drugs under the Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations. The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></p>
  <div style="margin-left:5.861%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6949510829730503%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with FDA&#x2019;s good laboratory practice requirements and other applicable regulations;</span></div></div>
  <div style="margin-left:5.861%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6949510829730503%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div></div>
  <div style="margin-left:5.861%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6949510829730503%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before each trial may be initiated;</span></div></div>
  <div style="margin-left:5.861%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6949510829730503%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug for its intended use;</span></div></div>
  <div style="margin-left:5.861%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6949510829730503%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an NDA after completion of all pivotal trials;</span></div></div>
  <div style="margin-left:5.861%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6949510829730503%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">determination by the FDA within 60 days of its receipt of an NDA to accept the filing for substantive review;</span></div></div>
  <div style="margin-left:5.861%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6949510829730503%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable;</span></div></div>
  <div style="margin-left:5.861%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6949510829730503%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#x2019;s identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with GCP requirements; and</span></div></div>
  <div style="margin-left:5.861%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6949510829730503%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product; chemistry, manufacturing and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB or ethics committee for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2: The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some cases, FDA may require, or sponsors may voluntarily pursue, post-approval trials, sometimes referred to as Phase 4 studies, that are conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, such as with accelerated approval drugs, the FDA may mandate the performance of post-approval clinical trials as a condition of approval of an NDA.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 1 and Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">testing suggesting a significant risk to humans and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent our clinical trial plans and future planned clinical trials may be adversely affected, delayed or interrupted by the ongoing COVID-19 pandemic, we may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects participating in clinical trials during the COVID-19 pandemic. For example, since March 2020, the FDA has issued various COVID-19 related guidance documents for trial sponsors and manufacturers, including guidance on conducting clinical trials during the pandemic, cGMP requirements, remote interactive evaluations of drug manufacturing and bioresearch monitoring facilities, and drug product manufacturing and supply chain inspections, among others. The extent to which the COVID-19 pandemic impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence. Recently, President Biden announced that the administration intends to end the COVID-19 national and public health emergencies on May 11, 2023. The full impact of the termination of the public health emergencies on FDA and other regulatory policies and operations are unclear.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NDA Review and Approval Process</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing complies with cGMP requirements to assure and preserve the product&#x2019;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#x201c;filing&#x201d; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#x201c;filing&#x201d; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA to address all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#x2019;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has various programs, including Fast Track designation, breakthrough therapy designation, accelerated approval and priority review, that are intended to expedite the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions. For example, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life- threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. The sponsor of a Fast Track product has opportunities for frequent interactions with the review team during product development and, once a NDA is submitted, the product may be eligible for priority review. With regard to a Fast Track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any product submitted to the FDA for approval, including a product with a Fast Track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review, accelerated approval and breakthrough therapy designation. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product. On December 29, 2022, the Consolidated Appropriations Act, 2023, including the Food and Drug Omnibus Reform Act (FDORA), was signed into law. FDORA made several changes to the FDA&#x2019;s authorities and its regulatory framework, including, among other changes, reforms to the accelerated approval pathway, such as requiring the FDA to specify conditions for post-approval study requirements and setting forth procedures for the FDA to withdraw a product on an expedited basis for non-compliance with post-approval requirements.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#x201c;breakthrough therapies&#x201d; that may be eligible to receive breakthrough therapy designation. A sponsor may seek FDA designation of a product candidate as a &#x201c;breakthrough therapy&#x201d; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will work to expedite the development and review of such drug.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fast Track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-approval Requirements</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements, which impose certain production, manufacturing, procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters or untitled letters;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical holds on clinical studies;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating to safety and efficacy that are approved by the FDA and in accordance with the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#x2019;s FDA-approved labelling.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drugs</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan drug designation, or ODD, to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with either a patient population of fewer than 200,000 individuals in the United States, or a patient population greater of than 200,000 individuals in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States of that drug or biologic. ODD must be requested before submitting an NDA. After the FDA grants ODD, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has received ODD and subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to market the same biologic for the same indication for seven years from the approval of the NDA, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of ODD are tax credits for certain research and a waiver of the NDA application user fee.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received ODD. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Catalyst Pharms., Inc. v. Becerra</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 14 F.4th 1299 (11th Cir. 2021), the court disagreed with the FDA&#x2019;s longstanding position that the orphan drug exclusivity only applies to the approved use or indication within an eligible disease. This decision created uncertainty in the application of the orphan drug exclusivity. On January 24, 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the court&#x2019;s order in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Catalyst</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, FDA intends to continue to apply its longstanding interpretation of the regulations to matters outside of the scope of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Catalyst</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">order &#x2013; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease or condition that have not yet been approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions will impact the scope of the orphan drug exclusivity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketing Exclusivity</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market exclusivity provisions authorized under the FDCA can delay the submission and approval of certain marketing applications for products containing the same active ingredient. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2), or 505(b)(2) NDA, by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from accepting ANDAs or 505(b)(2) NDAs for drugs referencing the approved application for review. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Healthcare Laws</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pharmaceutical manufacturers are subject to additional healthcare fraud and abuse laws, regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal anti-kickback, false claims, civil monetary penalty, consumer fraud, pricing reporting, data privacy and security and physician payment transparency laws and regulations as well as similar foreign laws in the jurisdictions outside the U.S. Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information; state and local laws which require tracking gifts and other remuneration and transfer of value provided to physicians, other healthcare providers and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state and local laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by the Health Insurance Portability and Accountability Act of 1996, thus complicating compliance efforts.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The risk of being found in violation of these or other laws and regulations is increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts and their provisions are open to various interpretations. These laws and regulations are subject to change, which can increase the resources needed for compliance and delay drug approval or commercialization. Any action brought against us for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business. Also, we may be subject to private &#x201c;qui tam&#x201d; actions brought by individual whistleblowers on behalf of the federal or state governments. Violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, significant administrative, civil and criminal penalties, damages, fines, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, the curtailment or restructuring of operations, exclusion from participation in government healthcare programs and imprisonment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#x2019;s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufacturers to provide scientific, cost-effectiveness and clinical support for the use of a product to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests that are used with applicable pharmaceutical products require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical products, will apply to companion diagnostics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, third-party payors are increasingly reducing coverage and reimbursement for pharmaceutical products and related services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available or that the third-party payors&#x2019; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the Affordable Care Act, or ACA, was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. By way of example, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#x201c;branded prescription drugs&#x201d; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; creates a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective April 1, 2013, which will remain in effect through 2031, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments can vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products. Specifically, there have been several recent U.S. Presidential executive orders, Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of approved products, which could have a material impact on our business. In August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. The impact of these and future reform measures on us and the pharmaceutical industry as a whole is unclear.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FDA Approval and Regulation of Companion Diagnostics</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our product candidates may require use of a diagnostic to identify appropriate patient populations for our products. These diagnostics, often referred to as companion diagnostics, are medical devices, often in vitro devices, which provide information that is essential for the safe and effective use of a corresponding drug. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA approval. We expect that any companion diagnostic developed for our product candidates will utilize the PMA pathway.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#x2019;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, a PMA application typically requires data regarding analytical and clinical validation studies. As part of the PMA review, the FDA will typically inspect the manufacturer&#x2019;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA&#x2019;s evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant&#x2019;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA&#x2019;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards are not maintained, or problems are identified following initial marketing.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> companion diagnostics. According to the guidance, if FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic device is not approved or cleared for that indication at the same time. The review of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> companion diagnostics in conjunction with the review of our therapeutic treatments for cancer will, therefore, likely involve coordination of review by the FDA&#x2019;s Center for Drug Evaluation and Research and the FDA&#x2019;s Center for Devices and Radiological Health Office of In Vitro Diagnostics. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#x2019;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#x2019;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employees and Human Capital Resources</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 28, 2023, we had 62 full-time employees, including 22 employees with Ph.D., M.D. or Pharm.D. degrees. Of these full-time employees, 45 employees are engaged in research and development activities.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.  Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and new employees, advisors and consultants.  The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel though the granting of stock-based and cash-based compensation awards, to increase stockholder value and our success by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Environmental, Social and Governance (ESG) Initiatives</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As an early clinical-stage precision oncology company, we are rooted in our mission to fundamentally disrupt the course of cancer for patients with p53 gene mutations and other p53-related cancers. We believe integrating responsible environmental, social, and governance principles into our corporate strategy will drive sustainable value creation for our shareholders, employees, patients, and caregivers over the long term. We have formed an internal ESG Working Group with cross-functional senior leadership, and oversight by the nominating and corporate governance committee of our board of directors to oversee our sustainability efforts and have documented our initiatives in our inaugural 2022 ESG Highlights Report, which is available on our website at ir.pmvpharma.com. The content provided in our 2022 ESG Highlights Report or accessible through our website is not incorporated by reference as part of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated in Delaware in March 2013 under the name &#x201c;PJ Pharmaceuticals, Inc.&#x201d; In July 2013, we changed our name to &#x201c;PMV Pharmaceuticals, Inc.&#x201d; Our principal executive offices are located at 1 Research Way, Princeton, New Jersey 08536. Our telephone number is (609) 642-6670. Our website address is www.pmvpharma.com. Information contained on, or that can be accessible through, our website is not a part of this Annual Report on Form 10-K and the inclusion of our website address in this Annual Report on Form 10-K is an inactive textual reference only.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use the name &#x201c;PMV Pharma,&#x201d; the &#x201c;PMV Pharma&#x201d; logo and other marks as unregistered trademarks in the United States and other countries. This Annual Report on Form 10-K contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate in any way that we or their owners will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable owner to these trademarks and trade names. We do not intend our use or display of other entities&#x2019; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:5.867%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Internet address is www.pmvpharma.com. We will file or furnish periodic reports and amendments thereto, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K (and amendments to those reports), proxy and information statements and other information filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, with the Securities and Exchange Commission, or the SEC. The SEC maintains a website that contains reports, proxy and information statement, and other information regarding issuers that file electronically, which may be accessed through the SEC at http://www.sec.gov. Our reports, amendments thereto, proxy statements and other information are also made available, free of charge, on our investor relations website at ir.pmvpharma.com as soon as reasonably practicable after we electronically file or furnish such information with the SEC. The information contained on the websites referenced in this Annual Report on Form 10-K is not incorporated by reference into this filing.  Further, our references to website URLs are intended to be inactive textual references only. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Ri</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sk Factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K and in our other filings with the SEC, before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could materially adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors Summary</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk because our business is subject to numerous risks and uncertainties, as fully described below. The principal factors and uncertainties that make investing in our common stock risky include, among others:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we have a limited operating history, have not completed any clinical trials, and have no products approved for commercial sale;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we have incurred significant losses since our inception, and we expect to incur significant net losses for the foreseeable future and may not be able to achieve or sustain revenue or profitability in the future;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we have not generated any revenue from our product candidates and may never generate revenue or be profitable and our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery, development and commercialization of our product candidates;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we will require substantial additional capital to finance our operations;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our discovery and preclinical and clinical development is focused on the development of precision medicines for patients with genetically defined cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs targeting p53 hotspot mutations and other p53-related cancers is novel, may never lead to marketable products and may not ultimately represent a significant market;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we are very early in our development efforts and are substantially dependent on our lead product candidate, PC14586. If we are unable to advance, obtain regulatory approval for and commercialize PC14586, our business, financial condition and results of operations will be materially adversely affected;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interim &#x201c;top-line&#x201d; and preliminary data that we announce for our initial open-label Phase 1/2 clinical trial for PC14586 may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. If the interim, top-line or preliminary data that we report differ from actual results, our ability to obtain approval for our product candidates may be adversely affected, which could materially adversely affect our business, financial condition and results of operations;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the subset of cancer patients that we are targeting are expected to have certain p53 mutations and we may not be able to identify a sufficient number of patients whom we can recruit and retain for our clinical trials to obtain approval for our current or future product candidates;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the regulatory approval processes of the U.S. Food and Drug Administration, or FDA, and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain required regulatory approvals for our product candidates, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we currently rely, and plan to rely in the future, on third parties to conduct and support preclinical and clinical development, and these third parties may not meet expectations;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if we are unable to obtain and maintain sufficient patent and other intellectual property protection for our product candidates and technology, our competitors could develop and commercialize products and technology similar or identical to ours;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our success depends in part on our ability to protect our intellectual property; and</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to develop companion diagnostics with third party collaborators, which must also separately be approved as medical devices by the FDA.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Limited Operating History, Business, Financial Condition, Results of Operations and Need for Additional Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have a limited operating history, have not completed any clinical trials, and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical stage biotechnology company with a limited operating history. We commenced operations in March 2013, and our operations to date have been primarily limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies and, more recently, clinical studies, and establishing arrangements with third parties for the manufacture of initial quantities of product candidates. In September 2020, our lead product candidate, PC14586, received authorization to proceed under an investigational new drug application, or IND, with the FDA. Then, in October 2020, we received Fast Track designation for PC14586, from the FDA, and in the fourth quarter of 2020, we initiated patient dosing in our Phase 1/2 clinical trial of PC14586. We announced preliminary results from the Phase 1/2 clinical trial of PC14586 in June 2022, and have entered into a clinical trial collaboration with Merck to evaluate PC14586 in combination with Merck&#x2019;s anti-PD-1 therapy, KEYTRUDA, in patients with advanced solid tumors harboring a p53 Y220C mutation. We have not demonstrated an ability to successfully complete any clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as a company with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred significant losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain revenue or profitability in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investment in biopharmaceutical product development is a highly speculative undertaking and entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We are still in the early stages of development of our product candidates. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. We have financed our operations primarily through private placements of our preferred stock and our initial public offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred significant net losses in each period since we commenced operations in March 2013. Our net losses were $73.3 million and $57.8 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $241.0 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Additionally, the net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indicator of our future performance.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue our research and development efforts and submit investigational new drug, or IND, applications for our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">conduct preclinical studies and clinical trials;  </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fail to demonstrate adequate efficacy or an acceptable safety profile in our clinical trials;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities, whether alone or with third parties, to commercialize any product candidates for which we may obtain regulatory approval, if any; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain, expand, maintain, enforce and protect our intellectual property portfolio; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional clinical, regulatory and scientific personnel; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operate as a public company.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop, seek regulatory approval for and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have not generated any revenue from our product candidates and may never generate revenue or be profitable. Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery, development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to become profitable depends upon our ability to generate revenue. We have not received marketing approval for any product candidate, and we have not generated any revenue from any product sales. We do not expect to generate revenue unless or until we successfully complete preclinical and clinical development and obtain regulatory approval of, and then successfully commercialize, at least one product candidate. We announced preliminary results for our Phase 1/2 clinical trial of our lead product candidate, PC14586, in June 2022. We are continuing to transition from a company with a research focus to a company capable of supporting clinical development and commercial activities. We have not yet demonstrated our ability to successfully complete large-scale, pivotal clinical trials, obtain marketing approvals, manufacture a commercial-scale product, or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. In addition, all of our other product candidates are still in preclinical development and have not been evaluated in humans. We face significant translational risk as our product candidates advance to the clinical stage, and promising results in preclinical studies may not be replicated in clinical trials. All of our current and future product candidates will require preclinical and clinical development, regulatory review and approval, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. Our ability to generate revenue depends on a number of factors, including, but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful enrollment and timely completion of our clinical trials for our lead product candidate, PC14586, and timely initiation and completion of our preclinical studies for our future product candidates, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing and maintaining relationships with contract research organizations, or CROs, and clinical sites for the clinical development of PC14586 and our future product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to complete IND-enabling studies and successfully submit and receive authorization to proceed under INDs or comparable applications; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether we are required by the FDA or other comparable foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to demonstrate to the satisfaction of the FDA and comparable foreign regulatory authorities the safety, efficacy, consistent manufacturing quality and acceptable risk-benefit profile of our small molecule product candidates or any future product candidates, and such regulatory authorities&#x2019; acceptance of our tumor-agnostic development strategy; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future product candidates, if any; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timely receipt of necessary marketing approvals from the FDA and comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or future product candidates over alternative or more conventional therapies, such as chemotherapy, to treat solid tumors; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the actual and perceived availability, cost, risk profile and side effects and efficacy of our product candidates, if approved, relative to existing and future alternative cancer therapies and competitive product candidates and technologies; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability and the ability of third parties with whom we contract to manufacture adequate clinical and commercial supplies of our product candidates or any future product candidates, remain in good standing with regulatory authorities and develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMP requirements; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patient demand for our product candidates and any future product candidates, if approved; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining coverage and adequate reimbursement by third-party payors for our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addressing any competing therapies and technological and market developments; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">attracting, hiring and retaining qualified personnel.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of the factors listed above are beyond our control and could cause us to experience significant delays or prevent us from obtaining regulatory approvals or commercializing our product candidates. Successful completion of preclinical studies and clinical trials does not mean that any of our current or future product candidates will receive regulatory approval. Even if regulatory approvals are obtained, we could experience significant delays or an inability to successfully commercialize our current and any future product candidates, which would materially harm our business. Even if we are able to commercialize our product candidates, we may not achieve profitability soon after generating product sales, if ever. If we are unable to generate sufficient revenue through the sale of our product candidates or any future product candidates, we may be unable to continue operations without continued funding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and product development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek marketing approval for, PC14586, and advance our future product candidates. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing, manufacturing and distribution activities. Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies to perform preclinical studies or clinical trials in addition to those that we currently anticipate. Other unanticipated costs may also arise. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully complete the development and commercialization of any product candidate we develop. Accordingly, we will need to obtain substantial additional funding in order to continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had $243.5 million in cash, cash equivalents, and marketable securities.  Although we believe that our available cash and cash equivalents will be sufficient to fund our planned operations at least through 2024, this belief is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future capital requirements depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, results and costs of researching and developing our current product candidates or any future product candidates we choose to pursue, and conducting preclinical studies and clinical trials, including our clinical trials of PC14586; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates or any future product candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number and characteristics of any additional product candidates we develop or acquire; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and amount of any milestone, royalty and/or other payments we are required to make pursuant to any future license or collaboration agreements; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of manufacturing our product candidates or any future product candidates and any products we successfully commercialize; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of building a sales force in anticipation of product commercialization; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of commercialization activities of our product candidates, if approved for sale, including marketing, sales and distribution costs; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish future collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any product liability or other lawsuits related to our products; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the expenses needed to attract, hire and retain skilled personnel; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs associated with being a public company; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing, receipt and amount of sales of any future approved products; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have any committed external source of funds and adequate additional financing may not be available to us on acceptable terms, or at all. In addition, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions, inflation expectations, rising interest rates and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and geopolitical tensions, such as the Ukraine-Russia war. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Product Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our discovery and product development is focused on the development of precision medicines for patients with genetically defined cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs targeting p53 is novel, may never lead to marketable products and may not ultimately represent a significant market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The discovery and development of precision medicines for patients with genetically defined cancers is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. Further, despite decades of research on p53 as a target for precision medicines, prior product development efforts have been unsuccessful. Although we believe, based on our preclinical work and p53 research generally, that the top ten most frequent, or hotspot, p53 mutations have potential as precision oncology targets, clinical results may not confirm this hypothesis or may only confirm it for certain mutations or certain tumor types.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, even if our approach is successful in showing clinical benefit for tumors harboring the p53 mutation targeted by our lead product candidate, PC14586, we may never successfully identify additional product candidates for targeting p53 through our platform. Therefore, we do not know if our approach of treating patients with genetically defined cancers will be successful, and if our approach is unsuccessful, our business will be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, because our approach targets genetically defined cancer patients and not specific tumors based on tumor or cancer types, we are initially pursuing a tumor-agnostic development strategy (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">i.e.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, pursuing approval for a potential indication based on a specific genetic mutation rather than a specific type of tissue). There is currently a limited number of approved tumor-agnostic therapies and we may not receive approval for a broad tumor-agnostic indication or may be delayed in receiving broad tumor-agnostic approval. If our Phase 1/2 trial for PC14586 does not support a tumor-agnostic indication, but we observe clinical benefit in certain tumor or cancer types, we may decide to pursue a tumor- or cancer-specific indication which may require additional clinical trials. Further, even if our Phase 1/2 trial for PC14586 is successful, the FDA may not agree that such study can serve as a pivotal study, which would require us to conduct additional clinical trials prior to approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are very early in our development efforts and are substantially dependent on our lead product candidate, PC14586. If we are unable to advance PC14586 or any of our future product candidates through clinical development, obtain regulatory approval and ultimately commercialize PC14586 or any of our future product candidates, or experience significant delays in doing so, our business, financial condition and results of operations will be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are very early in our development efforts. We announced preliminary results for our Phase 1/2 clinical trial of our lead product candidate, PC14586, in June 2022. All of our other product candidates are still in preclinical development and have never been tested in human subjects. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful clinical development and eventual commercialization of PC14586 and one or more of our future product candidates. In addition, our product development programs contemplate the development with third party collaborators of companion diagnostics, which are assays or tests used to identify an appropriate patient population for our product candidates. Companion diagnostics are subject to regulation as medical devices and must themselves be approved for marketing by the FDA and comparable foreign regulatory agencies before we may commercialize such companion diagnostics with our product candidates. The success of our product candidates will depend on several factors, including the following:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to continue our business operations and product candidate research and development, and adapt to any changes in the regulatory approval process, manufacturing supply or clinical trial requirements and timing due to the ongoing COVID-19 pandemic and otherwise, including complying with new regulatory guidance or requirements on conducting clinical trials during the COVID-19 pandemic; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">timely and successful completion of preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receipt of authorization to proceed under INDs for our planned clinical trials or future clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA acceptance of our tumor-agnostic development strategy; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful patient enrollment in and completion of clinical trials, which may be impacted by the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful development with third party collaborators of companion diagnostics for use with our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safety, tolerability and efficacy profiles for our product candidates that are satisfactory to the FDA or any foreign regulatory authority for marketing approval; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receipt of marketing approvals for our product candidates and any companion diagnostics from applicable regulatory authorities, which must be approved contemporaneously; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of any required post-marketing approval commitments to applicable regulatory authorities; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates, if any product candidates are approved; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effectively competing with other cancer therapies; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining and maintaining third-party coverage and adequate reimbursement; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintaining a continued acceptable safety profile of our products following approval.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of these factors are beyond our control, and it is possible that we may never obtain regulatory approval for our product candidates even if we expend substantial time and resources seeking their development and approval. If we do not achieve regulatory approval in a timely manner or at all, we could experience significant delays or an inability to commercialize our current or future product candidates, which would materially adversely affect our business. If we do not receive regulatory approvals for our current or future product candidates, we will not be able to continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The success of our business, including our ability to finance our company and generate revenue from products in the future, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of the product candidates we develop, which may never occur. Our current product candidates, and any future product candidates we develop, will require additional preclinical and clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other markets, demonstrating cost-effectiveness to pricing and reimbursement authorities, obtaining sufficient manufacturing supply for both clinical development and commercial production in accordance with cGMP, building of a commercial organization, and substantial investment and significant marketing efforts before we generate any revenue from product sales. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all. Changes in the manufacturing process or facilities will require further comparability analysis and approval by FDA before implementation, which could delay our clinical trials and product candidate development, and could require additional clinical trials, including bridging studies, to demonstrate consistent and continued safety and efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not previously submitted a NDA to the FDA or similar approval filings to a comparable foreign regulatory authority, for any product candidate. An NDA or other relevant regulatory filing must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe and effective for each desired indication. The NDA or other relevant regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product. We cannot be certain that our current or future product candidates will be successful in clinical trials or receive regulatory approval. Further, even if they are successful in clinical trials, our product candidates or any future product candidates may not receive regulatory approval. If we do not receive regulatory approvals for current or future product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approval to market a product candidate, our revenue will depend, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights for each product candidate, as well as the availability of competitive products, whether there is sufficient third-party reimbursement and adoption by physicians.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The subset of cancer patients that we are targeting are expected to have certain p53 mutants and we may not be able to identify a sufficient number of patients whom we can recruit and retain for our clinical trials to obtain approval for our current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patient populations for our current product candidates are limited to those with specific p53 mutations, which represents a substantially smaller subset of the generally treated cancer patient population. We expect our future product candidates to be similarly limited. We will need to screen and identify patients with these targeted mutations. Further, even if we are successful in identifying patients, we cannot be certain that the resulting patient populations with each p53 hotspot mutation will be large enough to allow us to successfully conduct the requisite clinical trials necessary to obtain marketing approval for each mutation-specific product candidate before we can commercialize our products, if approved, and achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The results of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities. Successful preclinical studies and clinical trials cannot provide assurance of successful commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective before we can seek marketing approvals for their commercial sale. Success in preclinical studies does not mean that future clinical trials will be successful. For instance, we do not know whether PC14586 will perform in its clinical trials as PC14586 has performed in preclinical studies, nor can we predict how our future product candidates will perform in future preclinical studies or clinical trials. Product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and other comparable foreign regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials. Regulatory authorities may also limit the scope of later-stage trials until we have demonstrated satisfactory safety, which could delay regulatory approval, limit the size of the patient population to which we may market our product candidates or prevent regulatory approval. In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dose and dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product candidates. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain approval to market any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we succeed in developing and commercializing our product candidates, we may never generate sufficient or sustainable revenue to enable us to be profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may need to use existing commercial diagnostic tests or develop or enter into a collaboration or partnership in the future to develop, novel companion diagnostics for some of our current or future product candidates. If we or our future partners are unable to successfully develop, validate and obtain approval for such companion diagnostics, or experience significant delays in doing so, we may not realize the full commercial potential of our future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As one of the key elements of our product development strategy, we seek to identify cancer patient populations that may derive meaningful benefit from our current or future product candidates. Because specific genetic mutations will be used to identify the appropriate patients for our programs and our current or future product candidates, we believe that our success may depend, in part, on our ability to use existing diagnostic tests and genetic sequencing, or to develop novel companion diagnostics in collaboration with partners.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such companion diagnostics would be used during our clinical trials as well as in connection with the commercialization of our product candidates. In our Phase 1/2 clinical trial, we are working with physicians and leading academic centers to enroll patients with the p53 Y220C mutation identified through next generation sequencing, or NGS. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have little experience as a company in the development of diagnostics. As such, we expect to rely on future partners for the design, development and manufacture of appropriate diagnostics to pair with our current or future product candidates. We have not yet begun discussions with any potential partners with respect to the development of companion diagnostics and may be unsuccessful in entering into collaborations for the development of companion diagnostics for our programs and our current or future product candidates. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities outside the United States as medical devices and require separate regulatory approval or clearance prior to commercialization. Moreover, the FDA generally requires the contemporaneous approval of companion diagnostics and the associated therapeutic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our product candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we, our partners, or any third parties that we engage to assist us, are unable to successfully develop and supply companion diagnostics for our current product candidates and any future product candidates, or experience delays in doing so:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the development of our current product candidates and any future product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not be able to obtain approval of our current product candidates and any future product candidates that require companion diagnostics on a timely basis or at all.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of these events were to occur, our business would be adversely impacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The COVID-19 pandemic could materially adversely impact our business, results of operations and financial condition, including our preclinical studies and clinical trials.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted, especially with respect to goods from China; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen.  While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material adverse effect on our business, financial condition and results of operations. As a result of the COVID-19 pandemic, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in enrolling and retaining patients in our clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruptions in preclinical studies due to restricted or limited operations at our laboratory facility; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption or delays to our sourced discovery and clinical activities; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in clinical site procedures and requirements as well as regulatory requirements for conducting clinical trials during the pandemic.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the COVID-19 pandemic, we continue to monitor changes in FDA policies and work with our clinical sites and investigators to mitigate potential risks to our ongoing clinical trials. The FDA, along with other global health authorities, has issued various guidance on COVID-19 related matters, including, among others, guidance for conducting clinical trials during the pandemic, manufacturing, supply chain, and drug and biological product inspections during the COVID-19 public health emergency; and GMP considerations for responding to COVID-19 infection in employees in biopharmaceutical manufacturing. If new guidance and policies are promulgated by the FDA that require changes in our clinical protocol or clinical development plans, our anticipated timelines and regulatory approval may be delayed or materially impacted. The extent to which the COVID-19 pandemic impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic continues to evolve, with the status of operations and government restrictions evolving monthly. The extent to which the outbreak impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading prices for shares of other biopharmaceutical companies have been highly volatile partially as a result of the COVID-19 pandemic and the trading prices for shares of our common stock could also experience high volatility. In addition, broader markets have experienced significantly increased volatility due to, among other things, increases in inflation expectations, the corresponding increases in interest rate expectations and the Ukraine-Russia war. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the COVID-19 could materially and adversely affect our business and the value of our common stock.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ultimate impact of the COVID-19 pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, the ultimate geographic spread of the disease, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19 and the actions taken to contain COVID-19 or address its impact in the short and long term, among others. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy. We will continue to monitor the situation closely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the enrollment and/or retention of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to initiate or continue clinical trials on a timely basis or at all for our product candidates if we are unable to recruit and enroll a sufficient number of eligible patients to participate in these trials through completion of such trials as required by the FDA or other comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials. Our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. For example, our enrollment for clinical trials of PC14586 will require patients to have the specific p53 Y220C mutation. If we are unable to locate a sufficient number of such patients, our clinical trial and development plans could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrollment of patients in our clinical trials may be delayed or limited as our clinical trial sites limit their onsite staff or temporarily close as a result of the COVID-19 pandemic. In addition, patients may not be able to visit clinical trial sites for dosing or data collection purposes due to limitations on travel and physical distancing imposed or recommended by federal or state governments or patients&#x2019; reluctance to visit the clinical trial sites during the pandemic. The drop-out rates in our clinical trials may be increased during the pandemic. Clinical trial patients who become infected with the COVID-19 virus may complicate the clinical trial data, procedures and analysis. These factors resulting from the COVID-19 pandemic could delay the anticipated readouts from our PC14586 clinical trials and our regulatory submissions, and increase the costs associated of the clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patient enrollment may also be affected if our competitors have ongoing clinical trials for programs that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#x2019; programs. Patient enrollment for our current or any future clinical trials may be affected by other factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">size and nature of the patient population; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">severity of the disease under investigation; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">availability and efficacy of approved drugs for the disease under investigation; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patient eligibility criteria for the trial in question as defined in the protocol; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">perceived risks and benefits of the product candidate under study; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved or future product candidates being investigated for the indications we are investigating; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinicians&#x2019; willingness to screen their patients for biomarkers to indicate which patients may be eligible for enrollment in our clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in or temporary suspension of the enrollment of patients in our clinical trials due to the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ability to obtain and maintain patient consents; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patient referral practices of physicians; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">proximity and availability of clinical trial sites for prospective patients; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion, including as a result of contracting COVID-19 or other health conditions or being forced to quarantine, or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining participation in our clinical trials through the treatment and any follow-up periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The market opportunities for our product candidates may be relatively small as it will be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancer therapies are sometimes characterized as first line, second line, or third line, and the FDA customarily approves new therapies only for a second line or later lines of use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapies, usually chemotherapy, antibody drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules or a combination of these. Third line therapies can include chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more invasive forms of surgery and new technologies. We expect to initially seek approval of our product candidates in most instances at least as a second line therapy. Subsequently, depending on the nature of the clinical data and experience with any approved products or product candidates, if any, we may pursue approval as an earlier line therapy and potentially as a first line therapy. But there is no guarantee that our product candidates, even if approved as a second or subsequent line of therapy, would be approved for an earlier line of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our projections of both the number of people who have the p53 hotspot mutations we are targeting, who may have their tumors genetically sequenced, as well as the subset of people with these mutations in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our assumptions and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new therapies may change the estimated incidence or prevalence of the cancers that we are targeting. Consequently, even if our product candidates are approved for a second or third line of therapy, the number of patients that may be eligible for treatment with our product candidates may turn out to be much lower than expected. In addition, we have not yet conducted market research to determine how treating physicians would expect to prescribe a product that is approved for multiple tumor types if there are different lines of approved therapies for each such tumor type.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business may become subject to economic, political, regulatory, and other risks associated with international operations directly or indirectly. A variety of risks associated with marketing our product candidates, if approved, internationally may materially adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is subject to risks associated with business operations we conduct internationally, as well as indirect impacts from our relationships with collaborators, partners, or contractors who conduct business internationally. To the extent we seek regulatory approval of any of our product candidates outside of the United States, we expect that we will be subject to additional risks related to our operations in foreign countries. Accordingly, our future results could be harmed directly or indirectly by a variety of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">differing regulatory requirements in foreign countries, changes in existing regulatory requirements, or implementation of new regulatory requirements or policies that impact our clinical development and business operations in foreign countries; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials or our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval policies or regulations of foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">impact of the COVID-19 pandemic on our ability to produce our product candidates and conduct clinical trials in foreign countries; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sociopolitical instability in particular foreign economies and markets;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign taxes, including withholding of payroll taxes; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and obligations incident to doing business in another country; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties staffing and managing foreign operations; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments; production or supply shortages resulting directly or indirectly from any events affecting raw material supply or manufacturing capabilities abroad, including, but not limited to, impacts due to the ongoing Ukraine-Russia war, addition of certain suppliers or companies to the Unverified List under the Export Administration Regulations, implementation of other export controls, restrictions or sanctions that can impact the supply chain, our business, or business operations of our suppliers, contractors or partners; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business interruptions resulting directly or indirectly from geo-political actions, including the ongoing Ukraine-Russian war, other regional or geo-political conflicts, and terrorism; and supply and other disruptions resulting from the impact of public health epidemics, including the COVID-19 pandemic, on our strategic partners, third-party manufacturers, suppliers and other third parties upon which we rely.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These and other risks associated with international operations may materially adversely affect our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our industry is intensely competitive and subject to rapid and significant technological change as well as strong defense of intellectual property. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face substantial competition from major pharmaceutical companies and biotechnology companies worldwide. Many of our competitors have significantly greater financial, technical and human resources. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In particular, we are aware of molecules in development that also are being explored for p53 upregulation/activation in various stages of preclinical or clinical development being tested by Aprea Therapeutics and Jacobio Pharmaceuticals, among others. We are also aware of selective small molecule inhibitors that are designed to target wild-type p53 containing tumors through the p53-murine double minute 2, or MDM2, interaction, which are in various stages of clinical development being tested by Aileron Therapeutics, Ascentage Pharma, Boehringer Ingelheim, Daiichi Sankyo (out-licensed worldwide rights to Rain Therapeutics), Kartos Therapeutics, Kymera Therapeutics, Otsuka Pharmaceutical, Novartis and Roche, including testing MDM2 inhibitors in combination with a variety of other anti-cancer agents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face competition with respect to our current product candidates and will face competition with respect to future product candidates, from segments of the pharmaceutical, biotechnology and other related markets that pursue targeted therapies for patients with genetically-defined cancers. If PC14586 or our future product candidates do not offer sustainable advantages over competing products, we may otherwise not be able to successfully compete against current and future competitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we will likely need to develop our product candidates in collaboration with companion diagnostic companies, and we will face competition from other companies in establishing these future collaborations. Our competitors will also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, we also face competition more broadly across the market for cost-effective and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy or a combination of such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates, if any are approved, may compete with these existing drug and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic, including branded generic, products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will be as our product candidates progress through clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product candidates that we may successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our long-term prospects depend in part upon discovering, developing and commercializing additional product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future operating results are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize product candidates beyond our lead product candidate, PC14586, and those we currently have in preclinical development. A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable variables. The results from preclinical testing or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later stage clinical trials of the product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The success of future product candidates we may develop will depend on many factors, including the following and the other factors relating to product development described elsewhere in this &#x201c;Risk Factors&#x201d; section:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">generating sufficient data to support the initiation or continuation of clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining regulatory permission to initiate clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">contracting with the necessary parties to conduct clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful enrollment of patients in, and the completion of, clinical trials on a timely basis; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timely manufacture of sufficient quantities of the product candidate for use in clinical trials; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse events in the clinical trials.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize additional product candidates, which would materially adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we successfully advance any future product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this &#x201c;Risk Factors&#x201d; section. Accordingly, we cannot assure you that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from our future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may adversely affect our business, financial condition and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While our lead product candidate, PC14586, is still in early clinical development and although it has been generally well-tolerated per our preliminary data release, as is the case with all oncology drugs, it is likely that there may be significant side effects associated with its use. PC14586 or future product candidates may be used in populations for which safety concerns may be reviewed by regulatory agencies. In addition, we recently opened a separate arm within the existing Phase 1/2 clinical trial to evaluate the combination of PC14586 with Merck&#x2019;s anti-PD1 therapy, KEYTRUDA, and we may study PC14586 in combination with other additional therapies, which may exacerbate adverse events associated with the therapy. Further, our product candidates will be used in patients that have weakened immune systems, which may exacerbate any potential side effects associated with their use. Patients treated with PC14586 or any of our future product candidates may also be undergoing surgical, radiation and chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#x2019; illnesses. For example, it is expected that some of the patients enrolled in our PC14586 clinical trials will die or experience major clinical events either during the course of our clinical trials or after participating in such trials. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If further significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, other comparable regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially adversely affect our business, financial condition and prospects. Further, if any of our product candidates obtains marketing approval, toxicities associated with such product candidates previously not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early stage clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are currently developing PC14586 in a combination study, and expect to develop our current or future product candidates in combination with other therapies, which exposes us to additional risks.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recently opened a separate arm within the existing Phase 1/2 clinical trial to evaluate the combination of PC14586 with Merck&#x2019;s anti-PD1 therapy, KEYTRUDA, in patients with advanced solid tumors harboring a p53 Y220C mutation.  We also intend to develop our current or future product candidates in combination with one or more other approved cancer therapies or therapies in development. Patients may not be able to tolerate PC14586 or any of our future product candidates in combination with other therapies or dosing of PC14586 or any of our future product candidates in combination with other therapies may have unexpected consequences. Even if any of our current or future product candidates were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or other comparable foreign regulatory authorities could revoke approval of the therapy used in combination with any of our product candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies. In addition, it is possible that existing therapies with which our product candidates are approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify other combination therapies for our product candidates or our own products being removed from the market or being less successful commercially.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also evaluate our current or future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell any product candidate in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the FDA or other comparable foreign regulatory authorities do not approve or withdraw their approval of these other therapies, or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies we choose to evaluate in combination with PC14586 or any future product candidate, we may be unable to obtain approval of or successfully market any one or all of the current or future product candidates we develop. Additionally, if the third-party providers of therapies or therapies in development used in combination with our current or future product candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our current or future product candidates, or if the cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interim, initial, &#x201c;top-line&#x201d; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may publicly disclose preliminary or top-line data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could materially adversely affect our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be adversely affected, which could materially adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The use of precision medicines as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. Various factors will influence whether our product candidates are accepted in the market, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the clinical indications for which our product candidates are approved; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential and perceived advantages of our product candidates over alternative treatments; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to demonstrate the advantages of our product candidates over other cancer medicines; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any side effects; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any side effects for other precision medicines and public perception of other precision medicines; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product labeling or product insert requirements of the FDA or other regulatory authorities; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations or warnings contained in the labeling approved by the FDA; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of market introduction of our product candidates as well as competitive products; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of treatment in relation to alternative treatments; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors and government authorities; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effectiveness of our sales and marketing efforts.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our product candidates receive regulatory approval but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, although our product candidates differ in certain ways from other precision medicine approaches, serious adverse events or deaths in other clinical trials involving precision medicines, even if not ultimately attributable to our product or product candidates, could result in increased government regulation, unfavorable public perception and publicity, potential regulatory delays in the testing or licensing of our product candidates, stricter labeling requirements for those product candidates and a decrease in demand for any such product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The insurance coverage and reimbursement status of newly-approved products is uncertain. Our product candidates may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices, or healthcare reform initiatives, which would adversely affect our business. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted legislation may materially change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments such as gene therapy products. Sales of these or future product candidates that we may identify will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#x2019;s determination that use of a product is:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a covered benefit under its health plan; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safe, effective and medically necessary; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">appropriate for the specific patient; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost-effective; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neither experimental nor investigational.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the CMS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement in certain European countries. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our business, financial condition and results of operations, our ability to raise capital needed to commercialize product candidates and our overall financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable reimbursement rates third-party payors for any approved products that we develop could have a material adverse effect on our business, financial condition and results of operations, our ability to raise capital needed to commercialize products and our overall financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to obtain reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we may develop companion diagnostic tests for use with our product candidates. We, or our collaborators, may be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our product candidates, once approved. Even if we obtain regulatory approval or clearance for such companion diagnostics, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates. Medicare reimbursement methodologies, whether under Part A, Part B or clinical laboratory fee schedule may be amended from time to time, and we cannot predict what effect any change to these methodologies would have on any product candidate or companion diagnostic for which we receive approval. Our inability to promptly obtain coverage and adequate reimbursement from both third-party payors for the companion diagnostic tests that we develop and for which we obtain regulatory approval could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for our product candidates or products that we may develop; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of clinical trial participants </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiation of investigations by regulators; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">diversion of management&#x2019;s time and our resources; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exhaustion of any available insurance and our capital resources; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to commercialize any product candidate; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a decline in our share price.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Although we have clinical trial insurance, our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA or other comparable foreign regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. FDA or other comparable foreign regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#x2019;s time and our resources and substantial monetary awards to trial participants or patients. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have no sales, marketing or distribution capabilities and have no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue arrangements with third-party sales, marketing and distribution collaborators regarding the sales and marketing of our products, if approved. However, there can be no assurance that we will be able to establish or maintain such arrangements on favorable terms or if at all, or if we are able to do so, that these third-party arrangements will provide effective sales forces or marketing and distribution capabilities. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Regulatory Process and Other Legal Compliance Matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot commercialize product candidates in the United States without first obtaining regulatory approval from the FDA. Similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of our product candidates, including our lead product candidate PC14586, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for each targeted indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted IND, NDA or equivalent application types, may cause delays in the approval or rejection of an application. For example, FDA has issued various COVID-19 related guidance documents for trial sponsors and manufacturers, including guidance on conducting clinical trials during the pandemic, among others. Recently, President Biden announced that the administration intends to end the COVID-19 national and public health emergencies on May 11, 2023. The full impact of the termination of the public health emergencies on FDA and other regulatory policies and operations are unclear.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA&#x2019;s Oncology Center of Excellence initiated Project Optimus to reform the dose optimization and dose selection paradigm in oncology drug development and Project FrontRunner to help develop and implement strategies to support approvals in the early clinical setting, among other goals. How the FDA plans to implement these goals and their impact on specific clinical programs and the industry are unclear. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials, including our Phase 1/2 clinical trial design for PC14586, or require us to modify the design of our clinical trials, including additional procedures and contingency measures in response to the COVID-19 pandemic or as required by clinical sites, IRBs, FDA or other regulatory authorities; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our tumor-agnostic development strategy; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a drug candidate is safe and effective for its proposed indication, or a related companion diagnostic is suitable to identify appropriate patient populations; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or other comparable regulatory authorities may fail to approve companion diagnostic tests that may be required for our product candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks, or that a product candidate has an acceptable benefit-risk ratio for its proposed indication; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures, specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or otherwise fail or be unable to adequately perform their obligations to allow for the conduct of our planned or future clinical studies; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would materially adversely affect our business, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA or a comparable foreign regulatory authority may require more information, including additional preclinical or clinical data to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program. If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request (including failing to approve the most commercially promising indications), may grant approval contingent on the performance of costly post-marketing clinical studies, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to obtain orphan drug designation or obtain or maintain the benefits associated with orphan drug designation, such as orphan drug exclusivity and, even if we do, that exclusivity may not prevent the FDA or other comparable foreign regulatory authorities, from approving competing products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our business strategy, we may seek orphan drug designation, or ODD, for any eligible product candidates we develop, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing and making available the drug will be recovered from sales in the United States. Our target indications may include diseases with large patient populations or may include orphan indications. However, there can be no assurances that we will be able to obtain orphan designations for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, ODD entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has ODD subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan drug exclusivity. Orphan drug exclusivity in the United States provides that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan product exclusivity or if FDA finds that the holder of the orphan exclusivity has not shown that it can ensure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the product was designated. The applicable exclusivity period is 10 years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for ODD or if the drug is sufficiently profitable so that market exclusivity is no longer justified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain ODD for a product candidate, we may not be able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the first to obtain marketing approval of any product candidate for which we have obtained ODD for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to ensure that we will be able to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the product candidate any advantage in the regulatory review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Catalyst Pharms., Inc. v. Becerra</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 14 F.4th 1299 (11th Cir. 2021), the court disagreed with the FDA&#x2019;s longstanding position that the orphan drug exclusivity only applies to the approved use or indication within an eligible disease. This decision created uncertainty in the application of the orphan drug exclusivity. On January 24, 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the court&#x2019;s order in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Catalyst</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, FDA intends to continue to apply its longstanding interpretation of the regulations to matters outside of the scope of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Catalyst</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> order &#x2013; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease or condition that have not yet been approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions will impact the scope of the orphan drug exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may seek and fail to obtain or maintain breakthrough therapy or Fast Track designations for our current or future product candidates. Even if we are successful, such programs may not lead to a faster development or regulatory review process, and they do not guarantee we will receive approval for any product candidate. We may also seek to obtain accelerated approval for one or more of our product candidates but the FDA may disagree that we have met the requirements for such approval.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track designation. In October 2020, we received Fast Track designation for PC14586 from the FDA. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular future product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Further, even though we have received Fast Track designation for PC14586, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also seek breakthrough therapy designation for any product candidate that we develop. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Like Fast Track designation, breakthrough therapy designation is within the discretion of the FDA. Accordingly, even if we believe a product candidate we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate we develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separately from Fast Track or breakthrough therapy designation, we may seek accelerated approval for one or more of our product candidates. A product candidate intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval if it is determined to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-approval clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires pre-approval of promotional materials for accelerated approval products, once approved. We cannot guarantee that the FDA will agree any of our product candidates has met the criteria to receive accelerated approval, which would require us to conduct additional clinical testing prior to seeking FDA approval. Even if any of our product candidates received approval through this pathway, the required post-approval confirmatory clinical trials may fail to verify the predicted clinical benefit of the product, and we may be required to remove the product from the market or amend the product label in a way that adversely impacts its marketing. In addition, on December 29, 2022, the Consolidated Appropriations Act, 2023, including the Food and Drug Omnibus Reform Act (FDORA), was signed into law. FDORA made several changes to the FDA&#x2019;s authorities and its regulatory framework, including, among other changes, reforms to the accelerated approval pathway, such as requiring the FDA to specify conditions for post-approval study requirements and setting forth procedures for the FDA to withdraw a product on an expedited basis for non-compliance with post-approval requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our potential product candidates will be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical and clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead product candidate, PC14586, is in early clinical development and all of our other product candidates are in discovery or preclinical development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical development testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. Our preclinical studies and clinical trials may not be successful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot be certain that our preclinical study and clinical trial results will be sufficient to support regulatory approval of our product candidates, or that FDA or other comparable regulatory authorities will find our planned clinical strategy to be acceptable. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Failure or delay can occur at any time during the clinical trial process. In addition, the COVID-19 pandemic is still evolving as of this time and much of its impact remains unknown, and it is impossible to predict the impact the COVID-19 pandemic may have on the development of our product candidates, our preclinical studies and clinical trials and our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, our PC14586 Phase 1/2 clinical trial is, and other clinical trials we conduct in the future may be, open-label in study design and conducted at a limited number of clinical sites on a limited number of patients. An &#x201c;open-label&#x201d; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#x201c;patient bias&#x201d; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Moreover, patients selected for early clinical studies often include the most severe sufferers and their symptoms may have been bound to improve notwithstanding the new treatment. In addition, open-label clinical trials may be subject to an &#x201c;investigator bias&#x201d; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may experience delays in obtaining the FDA&#x2019;s authorization to initiate clinical trials, completing ongoing clinical trials of PC14586 and preclinical studies of our other product candidates and initiating our planned preclinical studies and clinical trials. Additionally, we cannot be certain that preclinical studies or clinical trials for our product candidates will begin on time, not require redesign, enroll an adequate number of research subjects or patients on time, or be completed on schedule, if at all. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of financial resources to commence and complete clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities disagreeing with our tumor-agnostic development strategy; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in obtaining regulatory approval or authorization to commence a clinical trial, including delays or issues relating to any future companion diagnostics which we may develop; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining IRB or ethics committee approval at each clinical trial site; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recruiting an adequate number of suitable patients to participate in a clinical trial; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate, for example, if we experience delays or challenges in identifying patients with the mutations required for our clinical trials, we may have to reimburse sites for genetic sequencing costs in order to encourage sequencing of additional patients; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">having subjects complete a clinical trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trial sites deviating from clinical trial protocol or dropping out of a clinical trial; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">having third-party contractors fail to complete their obligations in a timely manner or failing to comply with applicable regulatory requirements; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addressing subject safety concerns that arise during the course of a clinical trial; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adding a sufficient number of clinical trial sites; or </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining sufficient product supply of product candidate for use in preclinical studies or clinical trials from third-party suppliers.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, our business and results of operations may be adversely affected and we may incur significant additional costs. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the product candidates, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, principal investigators for our future clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we experience delays in the completion, or termination, of any preclinical study or clinical trial of our product candidates, the commercial prospects of our product candidates may be adversely affected, and our ability to generate revenue from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our preclinical studies or clinical trials may increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may materially adversely affect our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. If one or more of our product candidates generally prove to be ineffective, unsafe or commercially unviable, our entire pipeline and platform would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in funding or disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes and other events that may otherwise affect the FDA&#x2019;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19 public health emergency, since March 2020 when foreign and domestic inspections facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. In 2020 and 2021, a number of companies announced receipt of complete response letters due to the FDA&#x2019;s inability to complete required inspections for their applications. While the FDA has largely caught up with domestic preapproval inspections, it continues to work through its backlog of foreign inspections. If a prolonged government shutdown or other disruption occurs, including delays or disruptions due to travel restrictions, foreign COVID-19-related policies, staffing shortages or public health reasons, or if global health or other concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities in a timely manner, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval of our product candidates, we will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following potential approval of any of our current or future product candidates, the FDA or other comparable regulatory authorities may impose significant restrictions on a product&#x2019;s indicated uses or marketing or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product. The FDA may also require a risk evaluation and mitigation strategy, or REMS, in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP requirements, GLP requirements and good clinical practice, or GCP, requirements, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposition of a REMS, which may include distribution or use restrictions; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements to conduct additional post-market clinical trials to assess the safety of the product; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning or untitled letters or holds on clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of our product candidates; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. For example, certain policies and regulations promulgated during the Trump administration as well as those implemented by the Biden administration may impact our business and industry. To the extent any current or future executive or legislative actions impose significant changes in or burdens on, or otherwise materially delay, FDA&#x2019;s ability to engage in routine oversight activities, such as implementing regulations through rulemaking, issuance of guidance, and agency review and approval of marketing applications on a timely basis, our business and clinical development plans could be negatively impacted. It remains to be seen how the Biden administration and new leadership at the HHS and FDA will impact our business. If we, as well as our contractors, are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or are not able to maintain regulatory compliance, we may be delayed in obtaining regulatory approval, lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates, if approved, and generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Affordable Care Act, or ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjected biological products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Other legislative changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect through 2031, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments may vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, for example, under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. In July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at increasing competition for prescription drugs. In August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. The impact of these legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the demand for our product candidates, if we obtain regulatory approval; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to set a price that we believe is fair for our products; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain coverage and reimbursement approval for a product; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of taxes that we are required to pay; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of capital.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, if approved. In particular, while the FDA permits the dissemination of truthful and non-misleading information about an approved product, a manufacturer may not promote a product for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#x2019;s approved labeling. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees, corporate integrity agreements or permanent injunctions under which specified promotional conduct must be changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, research, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and material adversely affect to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. The laws that may affect our ability to operate include, but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment and exclusion from government healthcare programs. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal civil and criminal false claims laws, including the False Claims Act, or FCA, which can be enforced through civil &#x201c;qui tam&#x201d; or &#x201c;whistleblower&#x201d; actions, and civil monetary penalty laws, impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Physician Payment Sunshine Act, created under the ACA and its implementing regulations, which require applicable manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with certain exceptions) to report annually to HHS information related to payments or other transfers of value made to covered recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other non-physician healthcare providers (such as physician assistants and nurse practitioners, among others), and teaching hospitals, as well as ownership and investment interests held by physicians, as defined by law, and their immediate family members;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock or stock options for services provided to us and may be in the position to influence the ordering of or use of our product candidates, if approved, may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our clinical trials or enrollment of patients in any future clinical trials, we will be subject to additional privacy restrictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the EU General Data Protection Regulation, or GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#x20ac;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR increased our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation and reputational harm in connection with our European activities. Further, the United Kingdom&#x2019;s vote in favor of exiting the EU, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations. HIPAA impose requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions. Even when HIPAA does not apply, according to the Federal Trade Commission, or FTC, failing to take appropriate steps to keep consumers&#x2019; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, 15 U.S.C &#167; 45(a). The FTC expects a company&#x2019;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, certain states have enacted additional laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. By way of example, California recently enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#x2019; data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information, and provide consumers with additional causes of action. The CCPA went into effect on January 1, 2020, and the California Attorney General may bring enforcement actions for violations beginning July 1, 2020. The CCPA was amended on September 23, 2018. In November 2020, California passed the California Privacy Rights Act, or CPRA, which amends and expands the CCPA. Although the CCPA includes exemptions for certain clinical trial data, the law may increase our compliance costs and potential liability with respect to other personal information. The CCPA and CPRA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could materially adversely affect our business, financial condition and results of operations. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#x2019; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations may also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including our Chief Executive Officer and President, our Chief Operating Officer and Chief Financial Officer, our Chief Medical Officer and our Chief Regulatory and Quality Officer. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could materially adversely affect our business, financial condition and results of operations. We could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources in our employee recruitment and retention efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide higher compensation, more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we rely on our founders and other scientific and clinical advisors and consultants to assist us in formulating our research, development and clinical strategies. These advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, these advisors and consultants typically will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. Furthermore, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours. In particular, if we are unable to maintain consulting relationships with our scientific founders or if they provide services to our competitors, our development and commercialization efforts will be impaired and our business will be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 28, 2023, we had 62 full-time employees, including 45 employees engaged in research and development activities. In order to successfully implement our development and commercialization plans and strategies, and as we are a relatively new public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identifying, recruiting, integrating, maintaining and motivating additional employees; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">managing our internal development efforts effectively, including the clinical, FDA and other comparable foreign regulatory agencies&#x2019; review process for PC14586 and any future product candidates, while complying with any contractual obligations to contractors and other third parties we may have; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future financial performance and our ability to successfully develop and, if approved, commercialize PC14586 and future product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of clinical development and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third-party service providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of PC14586 and any future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing third-party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third-party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize PC14586 and future product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and the increasing amounts of information maintained on our internal information technology systems, and those of our third-party CROs, other contractors (including sites performing our clinical trials) and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data. For example, companies have experienced an increase in phishing and social engineering attacks from third parties in connection with the COVID-19 pandemic. To the extent that any disruption or security breach were to result in a loss, destruction, unavailability, alteration or dissemination of, or damage to, our data or applications, or for it to be believed or reported that any of these occurred, we could incur liability and reputational damage and the development and commercialization of our product candidates could be delayed. We cannot assure you that our data protection efforts and our investment in information technology, or the efforts or investments of CROs, consultants or other third parties, will prevent significant breakdowns or breaches in systems or other cyber incidents that cause loss, destruction, unavailability, alteration or dissemination of, or damage to, our data that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation and/or unauthorized access, use or disclosure of, or the prevention of access to, data (including trade secrets or other confidential information, intellectual property, proprietary business information and personal information), which could result in financial, legal, business and reputational harm to us. For example, any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notifications and follow-up actions related to a security incident could impact our reputation and cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We expect to incur significant costs in an effort to detect and prevent security incidents, and we may face increased costs and requirements to expend substantial resources in the event of an actual or perceived security breach. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security incident were to result in a loss, destruction or alteration of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or international privacy and security laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in or, failure or security breach of our systems or third-party systems where information important to our business operations or commercial development is stored. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business disruptions could materially adversely affect our future revenue and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations, and those of our CROs, CMOs and other contractors, consultants and third parties could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, pandemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously adversely affect our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had federal and state net operating loss, or NOL, carryforwards of $174.7 million, and research and development credit carryforwards of approximately $9.7 million. Our federal NOLs generated in tax years ending on or prior to December 31, 2017 are only permitted to be carried forward for 20 taxable years, and therefore could expire unused. Under the Tax Cuts and Jobs Act, as amended by the CARES Act, our federal NOLs generated in tax years beginning after December 31, 2017 may be carried forward indefinitely, but for taxable years beginning after December 31, 2020, the deductibility of federal NOLs generated in tax years beginning after December 31, 2017 is limited to 80% of current year taxable income. Our federal NOL carryforwards will begin to expire in 2033, and our federal credit carryforwards will begin to expire in 2034, if not fully utilized. Some of our state NOL carryforwards and state credit carryforwards may also expire unused.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, under Sections 382 and 383 of the Code, if a corporation undergoes an &#x201c;ownership change&#x201d; (generally defined as a cumulative change (by value) in the corporation&#x2019;s ownership by &#x201c;5-percent shareholders&#x201d; that exceeds 50 percentage points over a rolling three-year period), the corporation&#x2019;s ability to use its pre-change NOLs and certain other pre-change tax attributes to offset its post-change taxable income or tax liabilities may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. We have not conducted any studies to determine whether we have experienced an ownership change or the annual limitations, if any, that could result from such an ownership change. Our ability to utilize our NOLs and certain other tax attributes could be limited by an ownership change as described above and consequently, we may not be able to utilize a material portion of our NOLs and certain other tax attributes, which could have a material adverse effect on our cash flows and results of operations. There is also a risk that due to federal or state regulatory changes, such as suspensions on the use of NOLs, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New income, sales, use or other tax laws or regulations could be enacted at any time, which could affect our tax profile and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act of 2017 eliminates the option to deduct research and development expenditures currently and requires taxpayers to capitalize and amortize them over five or fifteen years pursuant to Section 174 of the Code, beginning in 2022. Further, the Inflation Reduction Act of 2022, among other changes, imposes a one-percent excise tax on stock repurchases made on or after January 1, 2023. Any further changes in tax laws or regulations that are applied adversely to us could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">A portion of our chemistry-based product development and sourcing of certain manufacturing raw materials for our product candidates takes place in China through third-party manufacturers. A significant disruption in the operation of those manufacturers, a trade war or political unrest in China could materially adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently contract certain product development and manufacturing operations to third parties outside the United States, including in China, and we expect to continue to use such third-party manufacturers for such product candidates. Any disruption in production or inability of our manufacturers in China to produce adequate quantities to meet our needs, whether as a result of a natural disaster or other causes, including COVID-19, could impair our ability to operate our business on a day-to-day basis and to continue our development of our product candidates. Furthermore, since these manufacturers are located in China, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, a trade war could lead to tariffs on the chemical intermediates we use that are manufactured in China. Any of these matters could materially adversely affect our business, financial condition and results of operations. Any recall of the manufacturing lots or similar action regarding our product candidates used in clinical trials could delay the trials or detract from the integrity of the trial data and its potential use in future regulatory filings. In addition, manufacturing interruptions or failure to comply with regulatory requirements by any of these manufacturers could significantly delay clinical development of potential products and reduce third-party or clinical researcher interest and support of proposed trials. These interruptions or failures could also impede commercialization of our product candidates and impair our competitive position. Further, we may be exposed to fluctuations in the value of the local currency in China. Future appreciation of the local currency could increase our costs. In addition, our labor costs could continue to rise as wage rates increase due to increased demand for skilled laborers and the availability of skilled labor declines in China.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Reliance on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, CMOs and strategic partners to conduct and support our preclinical studies and clinical trials under agreements with us. We are continuing to build our internal chemistry, manufacturing and controls, biology and preclinical development capabilities to supplement activities conducted by third parties on our behalf. As part of this personnel build out, we may incur additional costs or experience delays in engaging directly with other third-party CROs and CMOs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to have to negotiate budgets and contracts with CROs, trial sites and CMOs and we may not be able to do so on favorable terms, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with pharmaceutical product produced under cGMP regulations and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our product candidates. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be adversely affected, our costs could increase and our ability to generate revenue could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Switching or adding third parties to conduct our preclinical studies and clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture our product candidates, and we may rely on third parties to produce and process our products, if approved. Our business could be adversely affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers fail to provide us with sufficient quantities of our product candidates or fail to do so at acceptable quality levels or prices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and must currently rely on outside vendors to manufacture our product candidates. We have not yet caused our product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates. We will need to negotiate and maintain contractual arrangements with these outside vendors for the supply of our product candidates and we may not be able to do so on favorable terms. We have not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or other comparable foreign regulatory authorities following inspections that will be conducted after we submit an application to the FDA or other comparable foreign regulatory authorities. We may not control the manufacturing process of, and may be completely dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or other regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs and materially adversely affect our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Similarly, if any third-party manufacturers on which we will rely fail to manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition and prospects could be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our anticipated reliance on a limited number of third-party manufacturers exposes us to a number of risks, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA must inspect any manufacturers for cGMP compliance as part of our marketing application; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a new manufacturer would have to be educated in, or develop substantially equivalent processes for, the production of our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our third-party manufacturers might be unable to timely manufacture our product candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">contract manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our future contract manufacturers may not perform as agreed, may not devote sufficient resources to our product candidates or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products, if any; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards and we have no control over third-party manufacturers&#x2019; compliance with these regulations and standards; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our third-party manufacturers could breach or terminate their agreements with us; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our contract manufacturers and critical reagent suppliers may be subject to inclement weather, as well as natural or man-made disasters; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our contract manufacturers may have unacceptable or inconsistent product quality success rates and yields, and we have no direct control over our contract manufacturers&#x2019; ability to maintain adequate quality control, quality assurance and qualified personnel.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business could be materially adversely affected by business disruptions to our third-party providers that could materially adversely affect our potential future revenue and financial condition and increase our costs and expenses. Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our product candidates by the FDA, result in higher costs or adversely impact commercialization of our product candidates. In addition, we will rely on third parties to perform certain specification tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm and the FDA could place significant restrictions on our company until deficiencies are remedied.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently, and may in the future, depend on single-source suppliers for some of the ingredients, components and materials used in, and the manufacturing processes required to develop, our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently, and may in the future, depend on single-source suppliers for some of the ingredients, components and materials used in, and manufacturing processes required to develop, our product candidates. There are, for certain of these components, relatively few alternative sources of supply and there is limited need for multiple suppliers at this stage of our business. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, ingredients, components, key processes and finished goods exposes us to several risks, including disruptions in supply, price increases or late deliveries. These suppliers may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would materially adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates may be interrupted for an extended period, which could materially adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in or for our product candidates, if required, may not be accomplished quickly and would create increased cost. If we are able to find a replacement supplier, the replacement supplier would need to be qualified, would need to process our technology transfer and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single-source ingredients, components and materials used in our products, any interruption or delay in the supply of ingredients, components or materials or our inability to obtain ingredients, components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#x2019; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our manufacturing process needs to comply with FDA regulations relating to the quality and reliability of such processes. Any failure by us or our third-party manufacturers to comply with relevant regulations could result in delays in or termination of our clinical programs and suspension or withdrawal of any regulatory approvals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to commercially produce our products either at our own facility or at a third party&#x2019;s facility, we will need to comply with the FDA&#x2019;s cGMP regulations and guidelines. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable foreign regulatory authorities to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our precision medicines as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of our precision medicines for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant non-compliance could also result in the imposition of sanctions, including warning or untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation and our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may, in the future, form or seek collaborations or strategic alliances or enter into licensing arrangements, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may, in the future, form or seek strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy and obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, collaborations involving our product candidates are subject to numerous risks, which may include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization of our product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result, if we enter into future collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into future collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If conflicts arise between us and our future collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If conflicts arise between our future corporate or academic collaborators or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Future collaborators or strategic partners may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these collaborations. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for our current or future product candidates. Our current or future collaborators or strategic partners may preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, or fail to devote sufficient resources to the development and commercialization of products. Any of these developments could adversely affect our product development efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increased operating expenses and cash requirements; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the assumption of additional indebtedness or contingent liabilities; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the issuance of our equity securities; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the diversion of our management&#x2019;s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and/or acquire intangible assets that could result in significant future amortization expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain sufficient patent and other intellectual property protection for our product candidates and technology, our competitors could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our market or successfully commercialize any product candidates we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our technologies. We will only be able to protect our product candidates, proprietary technologies and their uses from unauthorized use by third parties to the extent that valid and enforceable patents or trade secret protections cover them. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Composition-of-matter patents on the active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our products for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#x201c;off-label.&#x201d; Although off-label prescriptions may infringe or contribute to the infringement of method-of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own may fail to result in issued patents in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability, inventorship or scope thereof. Such a challenge may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. This will require us to be cognizant of the time from invention to filing of a patent application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent filing. However, trade secret protection will not protect us from innovations that a competitor develops independently of our proprietary know how. If a competitor independently develops a technology that we protect as a trade secret and files a patent application on that technology, then we may not be able to patent that technology in the future, may require a license from the competitor to use our own know-how, and if the license is not available on commercially-viable terms, then we may not be able to launch our product. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, and this scenario could materially adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to protect our intellectual property rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates. These candidates include PC14586 and others, their respective components, formulations, methods used to manufacture them and methods of treatment. Our commercial success will also depend on successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Our pending and future patent applications may not result in issued patents that protect our technology or products, in whole or in part. In addition, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we delay in filing a patent application, and a competitor files a patent application on the same or a similar technology before we do, we may face a limited ability to secure patent rights. We may not be able to patent the technology at all. Even if we can patent the technology, we may be able to patent only a limited scope of the technology, and the limited scope may be inadequate to protect our products, or to block competitor products that are similar or adjacent to ours. Our earliest patent filings have been published. A competitor may review our published patents and arrive at the same or similar technology advances for our products as we developed. If the competitor files a patent application on such an advance before we do, then we may no longer be able to protect the technology, we may require a license from the competitor, and if the license is not available on commercially-viable terms, then we may not be able to launch our product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the future we may in-license intellectual property from licensors. We may rely on these licensors to file and prosecute patent applications and maintain patents and otherwise protect the intellectual property we license from them. We may have limited control over these activities or any other intellectual property that may be in-licensed. For example, we cannot be certain that such activities by licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. It is possible that the licensors&#x2019; infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The growth of our business may depend in part on our ability to acquire or in-license additional proprietary rights. For example, our programs may involve additional product candidates that may require the use of additional proprietary rights held by third parties. Our product candidates may also require specific formulations to work effectively and efficiently. These formulations may be covered by intellectual property rights held by others. We may develop products containing our compounds and pre-existing pharmaceutical compounds. These pharmaceutical compounds may be covered by intellectual property rights held by others. We may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our product candidates. These diagnostic test or tests may be covered by intellectual property rights held by others. We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would adversely affect our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license under such intellectual property rights, any such license may be non-exclusive, and may allow our competitors access to the same technologies licensed to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we may sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institution&#x2019;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive for commercializing our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the course of business we have decided not to pursue certain products or processes and have terminated certain corresponding intellectual property license agreements, and we may do so again in the future. If it is later determined that our activities or product candidates infringe this intellectual property we may be liable for damages, enhanced damages or subjected to an injunction, any of which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain and involves complex legal and factual questions for which many legal principles remain unresolved. In recent years, patent rights have been the subject of significant litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued in the United States or in other jurisdictions which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. In addition, the U.S. Patent and Trademark Office, or USPTO, might require that the term of a patent issuing from a pending patent application be disclaimed and limited to the term of another patent that is commonly owned or names a common inventor. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. For example, we may become involved in opposition, interference, derivation, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">review or other proceedings challenging our patent rights, and the outcome of any proceedings are highly uncertain. Such challenges may result in the patent claims of our owned or in-licensed patents being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours or otherwise provide us with a competitive advantage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect, and we have limited control over the protection of trade secrets used by our collaborators and suppliers. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors or use such information to compete with us. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. If our confidential or proprietary information is divulged to or acquired by third parties, including our competitors, our competitive position in the marketplace will be adversely affected and this would have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our patents are found to be invalid or unenforceable, or if we are otherwise unable to adequately protect our rights, it could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates. Likewise, our current patents covering our proprietary technologies and our product candidates are expected to expire through 2037, without taking into account any possible patent term adjustments or extensions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other countries. Competitors may use our technologies in countries where we have not obtained patent protection to develop their own products and further, may infringe our patents in territories where we have patent protection, but enforcement is not as strong as in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain countries. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement or protection of patents, trade secrets and other intellectual property, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign countries could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. We have contract research and manufacturing relationships with contract organizations that operate in certain countries that are at heightened risk of theft of technology, data and intellectual property through direct intrusion by private parties or foreign actors, including those affiliated with or controlled by state actors. Accordingly, our efforts to protect or enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment (such as annuities) and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any issued patents we may own covering our product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of our intellectual property rights could be challenged or invalidated despite measures we take to obtain patent and other intellectual property protection with respect to our product candidates and proprietary technology. For example, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the U.S. and in some other jurisdictions, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld material information from the USPTO or the applicable foreign counterpart, or made a misleading statement, during prosecution. A litigant or the USPTO itself could challenge our patents on this basis even if we believe that we have conducted our patent prosecution in accordance with the duty of candor and in good faith. The outcome following such a challenge is unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to challenges to the validity of our patents, there might be invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on a product candidate. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others. The cost of defending such a challenge, particularly in a foreign jurisdiction, and any resulting loss of patent protection could have a material adverse impact on one or more of our product candidates and our business. Enforcing our intellectual property rights against third parties may also cause such third parties to file other counterclaims against us, which could be costly to defend, particularly in a foreign jurisdiction, and could require us to pay substantial damages, cease the sale of certain products or enter into a license agreement and pay royalties (which may not be possible on commercially reasonable terms or at all). Any efforts to enforce our intellectual property rights are also likely to be costly and may divert the efforts of our scientific and management personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may become involved in lawsuits or litigation at the USPTO to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, we may be required to file claims, which can be expensive and time consuming. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court may decide that one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patent&#x2019;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications or those of our future licensors is threatened, it could dissuade other companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO. The USPTO hears post-grant proceedings, including PGR, IPR and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the possibility of post-grant proceedings could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours for a meaningful amount of time, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depending upon the timing, duration and conditions of any FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union and certain other countries. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. Only one patent per approved product can be extended, the extension cannot extend the total patent term beyond 14 years from approval and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for the applicable product candidate will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be expected, and our competitive position, business, financial condition, results of operations and prospects could be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA to obtain permission to sell a generic version of such product candidate. Any of the foregoing could adversely affect our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us. United States Congress has in recent years considered legislation to reduce the term of certain drug patents in order to ease generic entry and increase competition. Evolving judicial interpretation of patent law could also adversely affect our business. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Also, former employees may become employed by competitors who develop similar technology, and could assist the competitor in designing around our patents. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or our ownership of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use and will continue to use registered and/or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain. Defending against such lawsuits will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields relating to our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that others may assert our product candidates infringe the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries generally. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a third party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to: infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#x2019;s attention from our core business; substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party&#x2019;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#x2019;s attorneys&#x2019; fees; a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third party licenses its product rights to us; however, the third party is not required to grant the license; if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products; and redesigning our product candidates or processes so they do not infringe; redesign may not be possible or may require substantial monetary expenditures and time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may choose to challenge the patentability of claims in a third party&#x2019;s U.S. patent by requesting that the USPTO review the patent claims in an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ex-parte</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> re-exam, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#x2019;s patent in patent opposition proceedings in the EPO, or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of non-competition or non-solicitation agreements with our competitors or their former employers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is common in the biotechnology and pharmaceutical industries, we employ individuals and engage the services of consultants who previously worked for other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that our consultants have used or disclosed trade secrets or other proprietary information of their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may in the future enter into license agreements with third parties under which we receive rights to intellectual property that are important to our business. These intellectual property license agreements may impose on us various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy-related proceedings, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also in the future enter into license agreements with third parties under which we are a sublicensee. If our sublicensor fails to comply with its obligations under its upstream license agreement with its licensor, the licensor may have the right to terminate the upstream license, which may terminate our sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be able to do on reasonable terms, or at all, which may impact our ability to continue to develop and commercialize our product candidates incorporating the relevant intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may need to obtain licenses in the future from third parties to advance our research or allow commercialization of our product candidates, and we cannot provide any assurances that there are no third-party patents which might be enforced against our product candidates in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our right to sublicense patents and other rights to third parties; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our right to transfer or assign the license; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, certain of our future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, we may in the future enter into license agreements that are not assignable or transferable, or that require the licensor&#x2019;s express consent in order for an assignment or transfer to take place.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The price of our stock may be volatile, and you could lose all or part of your investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#x201c;Risk Factors&#x201d; section and elsewhere in this Annual Report on Form 10-K, these factors include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of our ongoing, planned or any future preclinical studies, clinical trials or clinical development programs; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the commencement, enrollment, or results of clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse results or delays in preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial, including due to the suspension of a clinical trial by the FDA or other regulatory authorities; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any delay in our regulatory filings or any adverse regulatory decisions, including failure to receive regulatory approval of our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse developments concerning our manufacturers or our manufacturing plans; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to obtain adequate product supply for any licensed product or inability to do so at acceptable prices; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to establish collaborations if needed; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our failure to commercialize our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additions or departures of key scientific or management personnel; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unanticipated serious safety concerns related to the use of our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">introduction of new products or services offered by us or our competitors; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to effectively manage our growth; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size and growth of our initial cancer target markets; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to successfully treat additional types of cancers or at different stages; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or anticipated variations in quarterly operating results; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our cash position; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the market valuations of similar companies; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">overall performance of the equity markets; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales of our common stock by us or our stockholders in the future;  </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trading volume of our common stock; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in accounting practices; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ineffectiveness of our internal controls; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes or other developments relating to intellectual property or proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant lawsuits, including intellectual property or stockholder litigation; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of any natural disasters or public health emergencies, such as the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general economic, political, industry and market conditions, including the rising rate of inflation and the Ukraine-Russia war; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other events or factors, many of which are beyond our control.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The realization of any of the above risks or any of a broad range of other risks, including those described in this &#x201c;Risk Factors&#x201d; section, could have a dramatic and adverse impact on the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In particular, the trading prices for pharmaceutical, biopharmaceutical and biotechnology companies have been highly volatile as a result of the COVID-19 pandemic. In addition, broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#x2019;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#x2019;s attention and resources, which would materially adversely affect our business, financial condition and results of operation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">An active trading market for our common stock may not be sustained.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the closing of our initial public offering in September 2020, there was no public trading market for our common stock. Although our common stock is listed on the Nasdaq Global Select Market, the market for our shares has demonstrated varying levels of trading activity. Furthermore, an active trading market for our common stock may not be sustained in the future. The lack of an active market may impair investors&#x2019; ability to sell their shares at the time they wish to sell them or at a price that they consider reasonable may reduce the market value of their shares and may impair our ability to raise capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us, our business or our market.  We do not have any control over these analysts.  If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships, alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain holders of shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradeable in the public market, subject to the restrictions of Rule 144 in the case of our affiliates. Any sales of securities by these stockholders could have a material adverse effect on the market price for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 83% of our voting stock. As a result, this group of stockholders may be able to impact matters requiring stockholder approval. For example, they may be able to impact elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We do not intend to pay dividends on our capital stock, so any returns will be limited to the value of our stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid any cash dividends on our capital stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, we may enter into agreements that prohibit us from paying cash dividends without prior written consent from our contracting parties, or which other terms prohibiting or limiting the amount of dividends that may be declared or paid on our capital stock. Any return to stockholders will therefore be limited to any appreciation in the value of their stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. These provisions, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish a classified board of directors so that not all members of our board are elected at one time; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">permit only the board of directors to establish the number of directors and fill vacancies on the board; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide that directors may only be removed &#x201c;for cause&#x201d; and only with the approval of two-thirds of our stockholders; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">authorize the issuance of &#x201c;blank check&#x201d; preferred stock that our board could use to implement a stockholder rights plan (also known as a &#x201c;poison pill&#x201d;); </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">eliminate the ability of our stockholders to call special meetings of stockholders; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prohibit cumulative voting; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">authorize our board of directors to amend the bylaws; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require a super-majority vote of stockholders to amend some provisions described above.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, Section 203 of the General Corporation Law of the State of Delaware, or DGCL, prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) is the exclusive forum for the following (except for any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court or for which such court does not have subject matter jurisdiction):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action asserting a claim of breach of fiduciary duty; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action asserting a claim against us that is governed by the internal affairs doctrine.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This provision would not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or Securities Act, the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These exclusive forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#x2019; charter documents has been challenged in legal proceedings. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find these types of provisions to be inapplicable or unenforceable, and if a court were to find the exclusive forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could materially adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would materially adversely affect our business and the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to Section 404 of the Sarbanes-Oxley Act and the related rules of the SEC and Nasdaq, which, among other things, require that we maintain effective internal control over financial reporting.  In addition, Section 404 requires our management to report on the effectiveness of our internal control over financial reporting. We are also required to disclose changes made in our internal controls and procedures on a quarterly basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The requirements of these rules and regulations are difficult, time-consuming and costly, and place significant strain on our personnel, systems and resources. Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended and anticipate we will continue to expend significant resources, including accounting-related costs, and provide significant management oversight.  Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on the Nasdaq Global Select Market.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any testing by us conducted in connection with Section 404, or any subsequent testing, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. In addition, undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to assert that our internal control over financial reporting is effective, we could lose investor confidence in the accuracy and completeness of our financial reports, which would cause the price of our common stock to decline, and we may be subject to investigation or sanctions by the SEC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These inherent limitations include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to increased risk of securities class action litigation, which is expensive and could divert management attention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. Securities litigation against us could result in substantial costs and divert our management&#x2019;s attention from other business concerns, which could materially adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements or strategic partnerships with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors, and recognize the cost as an expense over the employee&#x2019;s requisite service period. As the variables that we use as a basis for valuing these awards change over time, our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and cost of, and level of investment in, research and development activities relating to our current product candidates and any future product candidates and research-stage programs, which will change from time to time; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to enroll patients in clinical trials and the timing of enrollment; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of manufacturing our current product candidates and any future product candidates, which may vary depending on FDA or other comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenditures that we will or may incur to acquire or develop additional product candidates and technologies or other assets; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and outcomes of clinical trials for our future product candidates, or competing product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competition from existing and potential future products that compete with our product candidates and any of our future product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any delays in regulatory review or approval of our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of demand for our future product candidates, if approved, which may fluctuate significantly and be difficult to predict; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to commercialize our product candidates, if approved, inside and outside of the United States, either independently or working with third parties; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish and maintain future collaborations, licensing or other arrangements; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to adequately support future growth; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential unforeseen business disruptions that increase our costs or expenses; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies; and </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the changing and volatile global economic and political environment.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolve</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Pro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">perties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our corporate headquarters is located at 1 Research Way, Princeton, New Jersey 08540, where we lease a facility containing 50,581 square feet of office and laboratory space. The lease term extends through 2032, and has a five-year extension option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company leases a facility at 8 Clarke Drive, Cranbury, New Jersey 08512, containing 18,446 square feet of office and laboratory space pursuant to a lease agreement that expires in June 2022 with an option to renew on a month-to-month basis for up to one year. We also lease 6,297 square feet of laboratory space at 3000 Eastpark, South Brunswick, New Jersey 08512 pursuant to a lease that expires in July 2022 with an option to renew on a month-to-month basis for up to one year. In January 2022, the Company signed lease extensions for both leases through June 2023 and July 2023, respectively, with the option to terminate upon 120 days of written notice, with an increase in base rent as per the lease extension.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we lease 3,292 square feet of office space at 420 Bedford Drive, Lexington, Massachusetts 02420 pursuant to a lease that expires in August 2023, with an option to extend for an additional three years.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our current facilities are suitable and adequate for our current and near term conduct of our business operations and that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. As of February 28, 2023, we were not a party to any legal matters or claims that, in the opinion of management, are likely to have a material effect on our business. In the future, we may become party to legal matters and claims in the ordinary course of business, the resolution of which we do not anticipate would have a material adverse impact on our financial position, results of operations or cash flows.  Regardless of outcome, litigation, or other legal proceedings can have an adverse impact on us because of legal fees and settlement costs, diversion of management resources, and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5__market_for_registrants_common_eq"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.    Market for Registrant&#x2019;s Common Equity, Related Sto</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ckholder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock has been listed on the Nasdaq Global Select Market under the symbol &#x201c;PMVP&#x201d; since September 25, 2020.  Prior to that date there was no public trading market for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 28, 2023, there were approximately six holders of record of our common stock.  We believe actual number of stockholders is greater than this number of record holders.  The approximate number of holders includes holders who are beneficial owners, but whose shares are held in street name by brokers and other nominees.  This number of holders of record also does not include holders whose share may be held in trust by other entities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid cash dividends on our common stock.  We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future.  Any future determination related to dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors might deem relevant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no unregistered sales of our equity securities during the fiscal year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Proceeds</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 24, 2020, our registration statement on Form S-1 (File No. 333-248627) relating to our IPO of common stock was declared effective by the SEC.  The IPO closed on September 25, 2020 at which time we issued 13,529,750 shares of common stock (including the exercise in full by the underwriters of their option to purchase an additional 1,764,750 shares of common stock) at a public offering price of $18.00 per share.  We received net proceeds from the IPO of approximately $223.2 million, after deducting the underwriting discounts and commissions of approximately $17.0 million and estimated offering related expenses of approximately $3.3 million.  None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to our affiliates.  Goldman Sachs &amp; Co. LLC, BofA Securities, Cowen, and Evercore IS acted as joint book-running managers for the offering.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There has been no material change in the planned use of proceeds from the IPO from that described in the prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on September 24, 2020.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 4, 2021, our shelf registration statement on Form S-3 (File No. 333-260012) was automatically declared effective by the SEC for our future follow-on offering. The potential gross proceeds from this future offering are approximately $150.0 million.  The company has not issued any shares of common stock pursuant to the offering.  There has been no material change in the planned use of proceeds from the follow-on offering as described in the Form S-3 Registration Statement.  None of the expenses associated with the follow-on offering were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to our affiliates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchases</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. R</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">eserved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with the financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in &#x201c;Part I, Item 1A. Risk Factors&#x201d; and in other parts of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A discussion of our financial performance for the year ended December 31, 2022 as compared to the year ended December 31, 2021 appears below under the captions &#x201c;Results of Operations&#x201d; and &#x201c;Liquidity and Capital Resources.&#x201d; A discussion of our financial performance for the year ended December 31, 2021 compared to the year ended December 31, 2020 can be found in our Annual Report filed on Form 10-K, in the &#x201c;Part II, Item 7, Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d;, under the same captions, filed with the SEC on March 1, 2022, which is available free of charge on the SEC&#x2019;s website at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">www.sec.gov</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and our Investor Relations website at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ir.pmvpharma.com/financial-information/sec-filings</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These website addresses are intended to be inactive, textual references only. None of the materials on, or accessible through, these websites are part of this report or are incorporated by reference herein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the &#x201c;guardian of the genome,&#x201d; and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. We have leveraged more than four decades of research experience and developed unique insights into p53 to create a precision oncology platform designed to generate selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant p53 proteins to restore their wild-type function. We are deploying our precision oncology platform to target the top ten most frequent, or hotspot, p53 mutations that are collectively associated with approximately 10-15% of all cancers.  In addition, we are expanding the utilization of our platform to target other p53-related cancers.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our formation in March 2013, we have devoted substantially all of our time and efforts to performing research and development activities and raising capital. We are not profitable and have incurred losses in each year since our inception. Our net losses were $73.3 million, $57.8 million, and $34.4 million for the years ended December 31, 2022, 2021, and 2020, respectively. As of December 31, 2022, we had an accumulated deficit of $241.0 million. We do not currently have any product candidates approved for sale, and we continue to incur significant research and development and general administrative expenses related to our operations. We initiated a Phase 1/2 clinical trial in October 2020 for our lead product candidate, PC14586. In October 2020, we were granted FDA Fast Track Designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation. We dosed our first patient in this clinical trial in the fourth quarter of 2020. In June 2022, we presented our initial Phase 1 clinical data for PC14586. We expect that our operating expenses will increase significantly as we advance our product candidates through preclinical and clinical development, seek regulatory approval, and prepare for and, if approved, proceed to commercialization; acquire, discover, validate, and develop additional product candidates; obtain, maintain, protect, and enforce our intellectual property portfolio; and hire additional personnel. Furthermore, we have incurred and will continue to incur additional costs associated with operating as a public company that we did not experience as a private company. We expect to continue to incur significant losses for the foreseeable future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to generate product revenue will depend on the successful development, regulatory approval, and eventual commercialization of one or more of our product candidates. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through private or public equity or debt financings, collaborative, or other arrangements with corporate sources, or through other sources of financing. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our product candidates.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We plan to continue to use third-party service providers, including clinical research organizations, or CROs, and contract manufacturing organization, or CMOs, to carry out our preclinical and clinical development and to manufacture and supply the materials to be used during the development and commercialization of our product candidates. We do not currently have a sales force.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all.</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development expenses consist primarily of costs incurred to conduct research, such as the discovery and development of our product candidates as well as the development of future product candidates. Research and development expenses include personnel costs, including stock-based compensation expense, third-party contractor services, laboratory materials and supplies, and depreciation and maintenance of research equipment. We expense research and development costs as they are incurred.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we are at a very early stage of development, we do not allocate our costs by product candidate or development program, as a significant amount of research and development expenses include compensation costs, materials, supplies, depreciation on and maintenance of research equipment, and the cost of services provided by outside contractors, which are not tracked by product candidate or development program. In particular, with respect to internal costs, several of our departments support multiple product candidate research and development programs, and therefore the costs cannot be allocated to a particular product candidate or development program. Substantially all of our research and development costs are associated with our lead product candidate, PC14586.  We initiated a Phase 1/2 clinical trial in October 2020 for our lead product candidate, PC14586. In October 2020, we were granted FDA Fast Track Designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation. We dosed our first patient in this clinical trial in the fourth quarter of 2020. In June 2022, we presented our initial Phase 1 clinical data for PC14586 at the 2022 ASCO Annual Meeting.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our research and development expenses to increase substantially in absolute dollars in the future as we advance our product candidates into and through clinical trials and pursue regulatory approval of our product candidates. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: the safety and efficacy of our product candidates, early clinical data, investment in our clinical program, the ability of any future collaborators to successfully develop our licensed product candidates, competition, manufacturing capability, and commercial viability. We may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses include personnel costs, expenses for outside professional services and other allocated expenses. Personnel costs consist of salaries, bonuses, benefits, and stock-based compensation. Outside professional services consist of legal, accounting and audit services and other consulting fees. Allocated expenses consist of rent expense related to our office and research and development facilities. We have incurred additional expenses as a public company, including expenses related to compliance with the rules and regulations of the SEC, and those of any national securities exchange on which our securities are traded, additional insurance expenses, investor relations activities and other administrative and professional services. We have increased our headcount significantly to support our operations as a public company. We also expect to increase our general and administrative expenses as we advance our product candidates through preclinical research and development, manufacturing, clinical development, and commercialization.</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Income, Net</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income, net primarily consists of interest income from our interest-bearing cash, cash equivalents and marketable securities and interest costs related to amortization of premiums and discounts on marketable securities.</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our results of operations (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.032%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.327%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.402%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:14.235%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statement of operations data:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,988</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,493</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,495</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,052</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,800</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,252</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77,040</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,293</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,747</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(77,040</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(58,293</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(18,747</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,627</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">449</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,178</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (expense)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,714</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">470</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,244</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before (benefit) provision for income taxes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(73,326</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(57,823</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(15,503</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Benefit) provision for income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(9</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(32</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(73,317</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(57,846</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(15,471</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our research and development expenses incurred during the periods indicated (in thousands):</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.15%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.127%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.007%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.438%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.007%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:14.274000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statement of operations data:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,712</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,296</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,584</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,470</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,436</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,034</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel related</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,340</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,321</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,466</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,440</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,026</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,988</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,493</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,495</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses were $52.0 million for the year ended December 31, 2022, compared to $36.5 million for the year ended December 31, 2021. The increase of $15.5 million was primarily due to the following:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$1.6 million decrease in research expenses, largely driven by decreased contractual research organization costs focused on discovery research;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$13.0 million increase in development expenses, primarily associated with increased effort advancing our lead compound PC14586 through the Phase 1/2 clinical trial; and</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$4.0 million increase in expenses for personnel related costs and stock-based compensation, primarily driven by increased headcount.</span></div></div>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses were $25.1 million for the year ended December 31, 2022, compared to $21.8 million for the year ended December 31, 2021. The increase of $3.3 million was primarily due to the following:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$2.4 million increase in personnel related expenses due to increased headcount to build out general and administrative infrastructure; and</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$0.2 million decrease in finance and legal support, $0.3 million decrease for directors and officers insurance, and a $1.4 million increase due to facility and equipment related costs for our new headquarters in Princeton, New Jersey.</span></div></div>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Income, Net</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income, net primarily consists of interest income from our interest-bearing cash, cash equivalents and marketable securities and interest costs related to amortization of premiums and discounts on marketable securities. Interest income, net was $3.7 million for the year ended December 31, 2022, compared to $0.5 million for the year ended December 31, 2021. The increase of $3.2 million in 2022 is driven by increased interest rates from cash investments in marketable securities and U.S. treasuries and was partially offset by lower average balances in cash and investments in marketable securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our financial condition is summarized as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.145%;"></td>
    <td style="width:1.007%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.126000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.007%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.437000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.007%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:14.273000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets:</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,297</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">172,467</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(64,170</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities &#x2013; current</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,757</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124,696</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,061</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities &#x2013; noncurrent</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,495</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,911</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(14,416</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total financial assets</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">243,549</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">314,074</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(70,525</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Working capital:</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">247,006</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">301,286</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(54,280</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,832</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,219</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,387</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total working capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">236,174</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">289,067</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(52,893</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if at all. As of December 31, 2022, we had cash, cash equivalents, and marketable securities of $243.5 million and an accumulated deficit of $241.0 million. We have financed our operations primarily through issuances of our convertible preferred and common stock. In July 2020, we sold an aggregate of 5,321,864 shares of our Series D convertible preferred stock to accredited investors, generating gross proceeds of $70.0 million. In September 2020, we completed an IPO of 13,529,750 shares of our common stock, which includes the exercise in full by the underwriters of their option to purchase 1,764,750 additional shares of common stock, at a public offering price of $18.00 per share for aggregate gross proceeds of $243.5 million. We received $223.2 million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by us.  In October 2021, we filed a shelf registration statement on Form S-3, which may result in aggregate gross process of up to $150.0 million. We did not sell any shares pursuant to the shelf registration statement and did not receive any gross proceeds in fiscal year 2022.</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contractual Obligations and Commitments</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We enter into contracts in the normal course of business with CROs and other vendors to assist in the performance of our research and development activities and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancelable contracts and not included in the table of contractual obligations and commitments.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, we signed a lease for 50,581 square feet of office and laboratory space at 1 Research Way in Princeton, New Jersey. That lease term extends through 2032, has a five-year extension option, and is intended to replace our two existing facilities. Payments under this lease will total $19.9 million through May 2032. Amounts related to future lease payments under the 1 Research Way lease as of December 31, 2022, totaled $19.4 million, with $2.3 million to be paid within the next 12 months.</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Plan of Operation and Future Funding Requirements</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use our capital resources primarily to fund operating expenses, mainly research and development expenditures. We plan to increase our research and development expenses for the foreseeable future as we continue the preclinical and clinical development of our product candidates. At this time, due to the inherently unpredictable nature of preclinical and clinical development and given the early stage of our product candidates, we cannot reasonably estimate the costs we will incur and the timelines that will be required to complete development, obtain marketing approval and commercialize our current product candidates or any future product candidates, if at all. For the same reasons, we are also unable to predict when, if ever, we will generate revenue from product sales or whether, or when, if ever, we may achieve profitability. Clinical and preclinical development timelines, the probability of success, and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to our significant research and development expenditures, we have generated substantial operating losses in each period since inception. We have incurred an accumulated deficit of $241.0 million through December 31, 2022. We expect to incur substantial additional losses in the future as we expand our research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our cash operating expenditures were $63.8 million in 2022 and $46.6 million in 2021, and we expect to increase our investment in operations in 2023.  Based on our research and development plans, we expect that our cash balances as of December 31, 2022 will be sufficient to fund our operations at least through 2024.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have based this estimate on assumptions that may prove to be wrong, however, and we could use our capital resources sooner than we expect.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The timing and amount of our operating expenditures will depend largely on:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and progress of preclinical and clinical development activities;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number and scope of preclinical and clinical programs we decide to pursue;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and amount of milestone payments we may receive under any future collaboration agreements;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain future licenses and research and development programs and to establish new collaboration and/or in-licensing arrangements;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs involved in prosecuting and enforcing patent and other intellectual property claims;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost and timing of regulatory approvals; and</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our efforts to build out our new office and laboratory headquarters, enhance operational systems and hire additional personnel, including personnel to support development of our product candidates and satisfy our obligations as a public company.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial revenue from product sales, we expect to fund our operations and capital funding needs through equity and/or debt financing. We may also consider entering into collaboration arrangements or selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our stockholders. The incurrence of debt financing would result in debt service obligations and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations or our ability to incur additional indebtedness or pay dividends, among other items. If we raise additional funds through governmental funding, collaborations, strategic partnerships and alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are not able to secure adequate additional funding, we may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially and adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our cash flows for the period indicated (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.573%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.491999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.016%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.491999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.016%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.406%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(63,760</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(46,571</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(32,739</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash (used in) provided by investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,368</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(143,584</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,911</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">958</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">292,972</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(64,170</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(188,133</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">288,144</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2022, was $63.8 million, which consisted primarily of net loss of $73.3 million decreased by non-cash charges of $10.1 million and a net change of $0.6 million in our net operating assets. The non-cash charges primarily consisted of stock-based compensation of $10.2 million, depreciation of $0.3 million, and non-cash lease expense of $0.3 million, partially offset by changes in premiums on marketable securities of $0.6 million. The change in our net operating assets and liabilities was primarily due to an increase in prepaid expenses and other assets, an decrease in accrued expenses, and a decrease in outstanding payables.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2021, was $46.6 million, which consisted primarily of net loss of $57.8 million decreased by non-cash charges of $7.2 million and a net change of $4.1 million in our net operating assets. The non-cash charges primarily consisted of stock-based compensation of $5.3 million, amortization of premiums on marketable securities and depreciation of $0.9 million, and non-cash lease expense of $1.0 million. The change in our net operating assets and liabilities was primarily due to a decrease in prepaid expenses and other assets, an increase in accrued expenses, and an increase in outstanding payables.</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our investing activities used $1.4 million of cash during the year ended December 31, 2022, which consisted primarily of purchases of marketable securities of $229.2 million, along with purchase of property and equipment of $8.0 million, partially offset by maturities of marketable securities of $235.8 million.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our investing activities used $143.6 million of cash during the year ended December 31, 2021, which consisted primarily of purchases of marketable securities of $256.8 million, along with purchase of property and equipment of $1.3 million partially offset by maturities of marketable securities of $114.6 million.</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our financing activities provided $1.0 million of cash during the year ended December 31, 2022, which consisted primarily of common stock issued under the employee stock purchase plan and proceeds from the exercise of stock options.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our financing activities provided $2.0 million of cash during the year ended December 31, 2021, which consisted primarily of common stock issued under the employee stock purchase plan and proceeds from the exercise of stock options.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting and Estimates</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and judgments that affect the amounts reported in those financial statements and accompanying notes. Although we believe that the estimates we use are reasonable, due to the inherent uncertainty involved in making those estimates, actual results reported in future periods could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that the accounting policies described below involve a high degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our financial condition and results of our operations.</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs, Accrued Research and Development Costs and Related Prepaid Expenses</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including sourcing of raw materials and manufacturing of our product candidates, allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development advance payments are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or services are performed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">vendors, including research laboratories, in connection with preclinical development activities;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CROs and investigative sites in connection with preclinical studies and clinical trials; and</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CMOs in connection with drug substance and drug product formulation of preclinical studies and clinical trial materials.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span></p>
  <p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We measure all stock options and other stock-based awards granted to our employees, directors, consultants, and other non-employee service providers based on the fair value on the date of the grant. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is typically the vesting term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We classify stock-based compensation expense in our statement of operations in the same way the award recipient&#x2019;s payroll costs are classified or in which the award recipients&#x2019; service payments are classified.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use the Black-Scholes option pricing model to estimate the fair value of stock options on the date of grant. Using the Black-Scholes option pricing model requires management to make significant assumptions and judgments. We determined these assumptions for the Black-Scholes option-pricing model as discussed below.</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;The expected term represents the period that the stock-based awards are expected to be outstanding. As we</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">do not have sufficient historical experience for determining the expected term of the stock option awards granted, we based our expected term for awards issued to employees and non-employees using the simplified method which is presumed to be the midpoint between the vesting date and the end of the contracted term.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards&#x2019; expected term.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Since we do not have adequate trading history of our common stock, the expected volatility was derived from the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">average historical stock volatilities of the common stock of several public companies within the industry that we consider to be comparable to our business over a period equivalent to the expected term of the stock-based awards.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividend Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;The expected dividend rate is zero as we have not paid and do not anticipate paying any dividends in the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreseeable future.</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Since our IPO, the fair value of shares of our common stock are measured by the stock price on the date of grant. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a description of recent accounting pronouncements, see Note 2 of the notes to our audited financial statements for the year ended December 31, 2022 included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7A.  </span><span id="item_7a__quantitative_qualitative_disclo"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">eserved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8__financial_statements_supplementa"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.    Financial Stateme</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nts and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Audited Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:89.84%;"></td>
    <td style="width:10.16%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent_registered"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;(PCAOB ID: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cd3858cd-dc03-4619-a1d0-874bf699cc82" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheets as of December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_operations_comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2022, 2021, and 2020</span></a><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_convertible_preferred_stock_s"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit) for the Years Ended December 31, 2022, 2021, and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Cash Flows for the Years Ended December 31, 2022, 2021, and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_independent_registered"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Stockholders and the Board of Directors of PMV Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying balance sheets of PMV Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) as of December 31, 2022 and 2021, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.363%;"></td>
    <td style="width:2.479%;"></td>
    <td style="width:82.158%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.04861111111111111in;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Research and Development Expenses</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of the Matter</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.04861111111111111in;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As disclosed in Note 2 to the financial statements, the Company is required to estimate research and development expenses from its obligations under contracts and purchase orders with vendors, clinical research organizations, clinical manufacturing organizations and others and for clinical site agreements at each balance sheet date.  The Company recorded accrued expenses for the research and development expenses, which are included in accrued expenses on the December 31, 2022 balance sheet, and prepaid research and development expenses, which are included in prepaid expenses and other current assets on the December 31, 2022 balance sheet. The amounts recorded for accrued research and development expenses and for the related prepaid expenses, within the aforementioned balance sheet captions, represent the Company&#x2019;s estimate of the unpaid and prepaid research and development expenses based on the progress of the research and development services compared to the amounts paid for those services through December 31, 2022.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.04861111111111111in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Auditing the Company&#x2019;s accrued research and development expenses and related prepaid expenses involved a high degree of subjectivity due to the estimation required by management in determining the progress to completion of services that have been performed that will be invoiced by the vendors, clinical research organizations and consultants and under clinical site agreements subsequent to the date that the financial statements are issued.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.04861111111111111in;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To test the research and development accruals and prepaid expenses, our audit procedures included, among others, reviewing a sample of agreements with the service providers to corroborate key financial and contractual terms, and testing the accuracy and completeness of the underlying data used in the accrual and prepaid expense computations. We also evaluated management&#x2019;s estimates of the progress of a sample of research and development activities by making direct inquiries of the Company&#x2019;s operations personnel that oversee the external research and development activities and obtaining information directly from a sample of service providers. Additionally, we assessed the historical accuracy of management&#x2019;s estimates when evaluating the current period estimate. To evaluate the completeness of the accruals, we also examined subsequent invoices from the service providers and cash disbursements to the service providers, to the extent such invoices were received, or payments were made prior to the date that the financial statements were issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_07266c68-8e87-45fa-b998-3fa85a4ff89f" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2017.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0a88b6e1-d91f-4bcb-93a4-a7671656c8dc" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Philadelphia, Pennsylvania</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sheets</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.998%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.392000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.606%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9040e09e-b08e-456c-bcb0-036eac8e492b" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,297</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b77b8c63-c3b8-4ab3-b41d-684845f06d6f" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">172,467</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d74940dd-c325-431d-aec9-97da0d3568af" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">822</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c643f78-e593-494d-ae3c-c6bc7f560499" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">822</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities, current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40523e03-c1d1-41ba-98d1-6c10b5658987" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">132,757</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f1fde84-c0c1-4b4f-9620-e61587679e2f" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">124,696</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_123a062e-0040-4719-b173-d780fb2cc817" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,130</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_436ce222-d1df-4178-acd6-344fd66b69f4" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,301</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1474ab60-bd87-4944-ba69-9afa0a7905d5" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">247,006</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab9e5c2b-278a-432a-b088-f342c282453a" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">301,286</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da4c22b4-cb64-40cc-97eb-5c4f0b939da8" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24816fab-fad4-4e6f-96a5-c532211b5c55" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,090</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_450134ad-0517-411b-bd36-31778170a931" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,495</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71a9aca4-7ae4-4fc0-bd15-9669d9ae0a96" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,911</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d32e803-3335-46a9-b0a2-1a5c5b7775e2" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,539</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09ed14bf-1f26-466e-933a-f76fc5790ab5" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,060</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a40e0226-f4dc-421b-bcc3-9449c5d158ab" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">313</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d658d64-b03e-43f6-bf81-31dfb8da139a" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">221</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f1bfbd4-a472-433d-8853-ec3bde2875f6" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">270,308</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cced5c27-95be-45f0-9b8c-e8cf33595ee8" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">331,568</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and Stockholders&#x2019; Equity</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdb186fc-c1f5-4ac5-817d-f243700ab840" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,996</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf8ab56f-d498-44eb-8652-1805122f5e1e" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,189</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cfc7492-0802-4af4-af76-35c3395b89d5" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,308</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a745dea3-bd23-4168-a969-b09720a7ed59" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdbb12a8-8d43-42d9-ae31-198e40f61fc7" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_621bc82e-5529-414e-8e10-1cd3fa3a4389" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">403</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecb99b9f-c72a-4b28-91b5-204287b96792" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,832</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab98f0f7-e7f0-440e-8c1d-5e3feca8e170" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,219</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e3a219f-985a-4976-a727-59f56dc2f06c" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,448</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1347936d-4f95-473b-bf16-110d9e26fbd0" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a7c459e-d726-426a-bfdd-7b81bd416c98" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c336769-d90e-4019-bf42-9fef8fe35216" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,009</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (see Note 6)</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0be922ee-2c64-40dd-9426-4451a30c1279" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5" format="ixt:numdotdecimal"><ix:nonFraction id="F_dacad429-67ea-4362-88b3-59c97c473b44" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5" format="ixt:numdotdecimal">0.00001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f2545a5-5cf3-4f28-b3d1-071e9df95ece" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_a19211d2-57fa-4803-93b8-3319c3c29314" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized as of<br />&#160;&#160;&#160;December 31, 2022 and December 31, 2021.  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b40e4ef9-86af-4de3-95c1-a321002d537c" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7525bc96-a118-46fb-9272-e1d126bd61ea" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e80d0776-ad49-4ad4-9e78-32f5f9930836" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_861b3eec-1ec8-4bd2-af60-c7598071ef0a" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued or<br />&#160;&#160;&#160;outstanding as of December 31, 2022 and December 31, 2021.</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88be40de-661d-4a3f-9522-15f98dfa86c8" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5" format="ixt:numdotdecimal"><ix:nonFraction id="F_26a3fef5-2540-4a57-8d65-076cde8576c9" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5" format="ixt:numdotdecimal">0.00001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb854527-8c38-4f98-add5-81ef25714ef5" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_b205f1e9-0bf3-4b59-ac33-f4da932a5d97" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,000,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized;<br /></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8715b060-7ebc-4d51-9914-29e072863770" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_b9de6b0e-7f7c-4a01-b4a4-a8566ad02ed7" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">45,771,332</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1e0c432-cea0-4d52-b77f-44a503260890" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_b484c0f1-7e70-4707-9c35-86db570c8f6c" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">45,433,684</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding at<br />&#160;&#160;&#160;December 31, 2022 and December 31, 2021, respectively.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85aacb98-e02e-4985-a26b-75a30878e8fe" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487,516</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a3ba248-8638-4b06-82fc-65b5c8072139" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">476,363</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2e07ce3-f57c-4b41-9d95-1c374adbc391" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">241,043</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_addfe286-314e-4657-a688-5a9524666bbd" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">167,726</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f22b73b-c837-4ea6-99b8-cd45b3800306" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">445</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b647cbf3-2c2f-409d-aab5-d09c0a3829a0" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">78</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fdffa76-86e9-47d6-92e7-e4da1defc7d9" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">246,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30327c06-6d21-4f73-8fc0-41ca0e30a2ab" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">308,559</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2c88a3e-16ee-48d1-8421-5c406cf7dbb7" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">270,308</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e362c1d-b51c-4ae6-9a37-22fe0274cb1d" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">331,568</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_operations_comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Operations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.07%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.747%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.202000000000002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.977%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6b7b4ea-d1e5-4715-8cca-69df614e8f15" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,988</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c8c13b3-4f29-4603-92ca-d787fcd7c4fd" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,493</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d287beb-02ed-4d9f-8cff-a0c608315feb" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5e339e6-9d46-491b-92a3-dd18ff45ff54" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,052</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_158f6120-477d-4421-b4b0-408d3b82e0f8" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,800</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_534bc67f-de18-44d0-afd9-56acab5d9a03" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,009</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_783a9a81-22ff-4a45-9a16-3892f76e01c7" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,040</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7da7c1d4-1f6d-4593-b192-0db9f1b8cc71" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,293</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c4e6e77-c705-464f-af67-1d4f3f44b476" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_241b33e9-0825-4796-82e9-599dfcf8d207" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">77,040</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c51e2a9d-1580-463d-b66b-69f7c9312ef3" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,293</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d72f57bc-9b6b-4790-9109-5987cfae294f" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da58fd47-acdc-4c3d-b267-f5f877078d3d" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f847b29-0c49-49e3-9071-7c41ff25da40" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3">449</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7135e94-423c-444e-965a-74e4a0f09b9f" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3">651</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d64bc5da-8cf7-4d72-88ce-2c7997221c33" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:OtherNonoperatingIncomeExpenseOther" unitRef="U_USD" scale="3" decimals="-3">87</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61a66b45-3bfc-40fd-95a5-0a17ec4d2f31" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="pmvp:OtherNonoperatingIncomeExpenseOther" unitRef="U_USD" scale="3" decimals="-3">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a93868eb-796a-4b55-ac17-a93ac2384d4c" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="pmvp:OtherNonoperatingIncomeExpenseOther" unitRef="U_USD" scale="3" decimals="-3" sign="-">143</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (expense)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99053f56-1787-41ea-84f6-45069b5c6018" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,714</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7dc6db10-573f-4a29-9d05-2ccb886a2975" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3">470</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb3a6e5f-11ee-4386-a313-ba7c51400218" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3">508</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before (benefit) provision for income taxes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_621c99ae-370a-4b1e-abf4-90e3d189d932" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73,326</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5c08f33-aaff-486e-94d7-5620405e5947" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">57,823</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91dac537-aa4f-4e0c-bf79-e95ab8982243" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,434</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Benefit) provision for income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2de4e3e-99c9-4cc9-a4cb-216875485ad9" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74635cc6-75d8-4aac-8619-73f6fbd1b756" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14f0c761-a7d2-4fe8-b8ab-fdaf1926266f" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75ac3260-33e6-4e75-9e9a-666f1d7fde4d" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a16951ea-f36c-404c-a449-6d69289e32f6" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">57,846</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da42584a-95dc-4724-ad84-2298001ccb28" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,440</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized (loss) gain on available for sale investments, net of tax</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_462eefe4-edd7-464a-90d9-0ac185c42e17" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">367</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1efe9e17-8ac7-4f18-bce0-e760d4988207" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">78</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebb7b16e-8ffe-4f40-ad99-09f6420db112" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_635d93f2-18df-49e2-9e95-258b66630756" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73,684</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_beac0093-80ff-49af-a43c-bf331b250ffa" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">57,924</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3815fbb-10af-4459-8546-9ab8f71180bf" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,437</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share -- basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f89426a-2bba-4909-acad-da47b9b88c15" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-"><ix:nonFraction id="F_efe84a1c-50b4-4449-9dd3-9aca128939b2" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">1.61</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e7ff0bc-d698-47e3-a0ff-c2bc5f475463" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-"><ix:nonFraction id="F_29f588bd-224f-42de-a7cd-516a3b44284f" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">1.28</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_746c6f8b-e2d6-43a6-b10b-4294f9e44a1a" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-"><ix:nonFraction id="F_0e5c38b3-f52e-44b4-b51a-9072e063e15a" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">2.40</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3149c70-2dc2-4452-924b-71732e38b72b" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_5d4138c2-3f1d-4998-a0d4-f7525ac9511a" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">45,594,824</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6efbf1e2-0661-459f-80bc-fe76ec419d0f" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_0b42d126-8d09-4bb6-9a3a-9a206f651e10" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">45,137,656</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a11b0ab-8bab-449b-b1d5-8d678f74ce05" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_2abb9574-031f-4c3a-a74a-c934e5916dc1" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">14,364,475</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_convertible_preferred_stock_s"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Convertible Preferred St</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ock and Stockholders&#x2019; Equity (Deficit)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.601%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.411%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.6160000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.825%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.221%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.221%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.221%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.221%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.684%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Convertible<br />Preferred Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional<br />Paid-in<br />Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Other<br />Comprehensive<br />Loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total<br />Stockholders&#x2019;<br />Equity (Deficit)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances at December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e275ab39-205a-4521-b9e0-a5552e19300c" contextRef="C_afc8cc4f-8592-4a73-b6b1-bc62607689d9" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">22,866,246</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b58acaa-2d9c-408d-841e-ffa98fa22bd5" contextRef="C_afc8cc4f-8592-4a73-b6b1-bc62607689d9" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">168,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08eb1e34-7692-420a-acb9-6690d8047a75" contextRef="C_41b52ed3-f105-4a33-84d9-920833d5abcb" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,046,200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9a570a0-a299-419d-bdcc-ce057845865e" contextRef="C_9720ff11-f138-4224-ba3c-9c427709c9e4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,969</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_caf931fc-619e-4a77-8eb6-67e335ebcb2f" contextRef="C_d23af98b-9ff8-4b89-9401-a895cac8088c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2199cff6-4d77-43ca-9861-05f1bddb3f39" contextRef="C_cc9e11c2-3eae-4c34-8935-47bc9239ba59" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,440</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d6ef5b1-4a28-4c8d-a9f3-59f304c6ed9c" contextRef="C_14af34ae-ca01-4273-9ecd-fd1963bc0d32" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">70,474</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of Series D convertible preferred stock, net<br />&#160;&#160;&#160;of issuance costs of $</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a545753-9b7b-4b42-856a-98d1657af6c3" contextRef="C_d7d7545a-22ed-48ea-9de9-36b175caa031" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">208</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0204f37d-6b09-4383-8679-385a63ede869" contextRef="C_d7d7545a-22ed-48ea-9de9-36b175caa031" name="pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,321,864</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b363dfb2-9b86-4212-9ef9-20d704aa1f3c" contextRef="C_d7d7545a-22ed-48ea-9de9-36b175caa031" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of convertible preferred stock to<br />&#160;&#160;&#160;common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eae22260-49ef-48fc-8629-c7e09a04ec11" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="pmvp:ReclassificationsOfTemporaryToPermanentEquityShares" unitRef="U_shares" decimals="0" sign="-" format="ixt:numdotdecimal">28,188,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93aa48e5-63d6-4753-8113-01f38935bb9a" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">238,723</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9df28f3c-d9fd-4c69-bb57-bbddbab571f3" contextRef="C_b870873f-a136-48b3-b1fb-15b46f12781f" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">28,188,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79f27a03-9fa2-4a1e-84ba-94dfafb0e7ce" contextRef="C_7482c8b1-66e1-413c-a4f6-0956e9d78239" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238,723</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9f9f786-4445-48c9-9575-36649fb9e492" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238,723</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of warrants</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f421ad8-fa6e-4ab2-a9de-b872989f8378" contextRef="C_b870873f-a136-48b3-b1fb-15b46f12781f" name="pmvp:StockIssuedDuringPeriodSharesExerciseOfWarrants" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">9,688</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5ca4e7d-5d09-4d41-86ed-a7512d86596b" contextRef="C_7482c8b1-66e1-413c-a4f6-0956e9d78239" name="pmvp:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5099d47a-f22f-417b-a712-1957cfcf40d8" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="pmvp:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock, net of issuance costs of<br />&#160;&#160;&#160;$</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1582b8d1-071a-417e-951e-7523bb82ec59" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">20,359</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22a77657-ae95-4897-93b3-dd5b8da3eef9" contextRef="C_b870873f-a136-48b3-b1fb-15b46f12781f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">13,529,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45c851db-816a-4165-acfc-2197ff17012b" contextRef="C_7482c8b1-66e1-413c-a4f6-0956e9d78239" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">223,176</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbe433f4-0d37-437b-90c4-b5249c73c03b" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">223,176</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c488ad0f-9c61-4115-901e-a627dbc89a20" contextRef="C_b870873f-a136-48b3-b1fb-15b46f12781f" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,070</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_989af349-3a8d-4616-a793-2e19f60bc86a" contextRef="C_7482c8b1-66e1-413c-a4f6-0956e9d78239" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_545e273f-6f4f-4f78-b711-6b385fd24863" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ba34993-1ab8-4dbf-aa40-39cbba0c3745" contextRef="C_7482c8b1-66e1-413c-a4f6-0956e9d78239" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_153e2d96-3ac9-45b2-b2d4-14973f2c26f1" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_145b0540-7688-4857-8287-7175c8ee3e24" contextRef="C_e1d65801-b9d6-4c7d-ba94-0cee28a011c6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,440</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3753b995-0b49-4e11-830f-b71180929cde" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,440</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain on available for sale marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37818c9b-f8a0-462e-90c9-ee0087d948d2" contextRef="C_7826d7cd-2cdc-4c9e-b57f-b6e1dfb7b459" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3e0c022-e21a-41ba-8025-2485c4187c51" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cbb2b1f-a4f4-451d-bbc5-d485f8fd3ef9" contextRef="C_c0cf2842-991a-497a-ad23-0d484ab89803" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">44,777,818</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d47b6a68-5b5c-45ee-9f62-0f344434bbd8" contextRef="C_77450a26-c91f-4546-8962-eb03770dbd9d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">469,001</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd9be9b2-e013-4966-9cb7-5a34e08eb055" contextRef="C_394efadb-0831-4ded-a4d6-2abf18188b08" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">109,880</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a81d9cf0-6dcf-4f07-8205-14df8a888226" contextRef="C_abb7ff4b-f4ff-4208-b730-ff89fd4d2f48" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">359,121</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options and common stock issued under the 2020 ESPP</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a201683-3587-4361-913e-49ccf7173264" contextRef="C_2bfc2514-cfef-48de-a925-42f04c369057" name="pmvp:ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">655,866</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7d4f3b1-8809-41b1-b4bb-1fe04ddf4b0e" contextRef="C_7c1da20a-2594-4596-9560-1c31c1640622" name="pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e7b7252-4205-47e2-b3b8-83d1d093f1b1" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f23f3f2-d50c-4d85-a3b5-b04b78ec64e4" contextRef="C_7c1da20a-2594-4596-9560-1c31c1640622" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,340</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bb9d072-431b-448b-8598-cd1c672a45d2" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,340</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a29301af-55b1-4b36-8180-d5a0162bb9e9" contextRef="C_7a13ba9e-9b6c-49f5-9585-76663577d207" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">57,846</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9db4b0c8-e514-4bdd-96e0-656a422a1e36" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">57,846</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on available for sale marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f65859f5-976e-4dfd-8398-4825b6d92ce6" contextRef="C_99e58b14-8dbf-449f-8271-666e6962200a" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">78</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e7965c0-3f13-431f-9078-5793d85d87ff" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">78</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_074bb275-177c-4aa1-8263-a76c8dedfec8" contextRef="C_4fa2099b-812e-4e76-9690-196d1a864954" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">45,433,684</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e792aa53-6a04-4d32-b7fa-220cf8c47720" contextRef="C_96ef7e99-5645-4f46-9a50-9275689d19f9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">476,363</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc64667d-bad1-4bb4-b109-8d99be5fb24f" contextRef="C_c9d8a5eb-415a-4f96-ba6c-84acbe6f1562" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">78</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d57038c6-83d5-45b3-93e3-c2ffe4a77dbd" contextRef="C_57689871-3d90-40ca-a6f9-460f78c06285" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">167,726</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14b9856a-dfc8-4cd2-b60f-30ac68537bf8" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">308,559</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options and common stock issued under the 2020 ESPP</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_295118f6-c414-49d0-9c7c-1681945cd1e2" contextRef="C_95c6ff9a-7273-447e-b18f-9405d1b0061e" name="pmvp:ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">337,648</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d406c76-bfe1-4128-bd3e-4ba234044aae" contextRef="C_8eb3a307-a471-4ef6-b42e-874598113768" name="pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">958</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6948b9cc-0bfc-455d-a7f2-faa34d6e4f29" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">958</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c448abae-dc4e-4c7c-98e7-8bfd8014aecb" contextRef="C_8eb3a307-a471-4ef6-b42e-874598113768" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,195</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_621cc56b-8640-4d98-a199-27c26b26d21d" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,195</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebd60805-b0e7-477b-8322-700127124275" contextRef="C_05748ee3-8f14-434c-b214-63235c977b9a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e18e784-93ed-4b48-b274-e6cbbf587d5e" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on available for sale marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c238542-92f5-45f4-8282-08ab32d0dcea" contextRef="C_de0eb331-80ac-42d7-a504-423cc2cfa8d0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">367</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1e06da7-ea96-4c19-805a-87a7d451b74d" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">367</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50d0ca84-1674-47a7-8dd3-74e758e1e06b" contextRef="C_f825d4ed-c7b9-49be-993b-f8659d7899e8" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">45,771,332</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d9867e8-cb1c-41d5-ac3d-af50cebe656f" contextRef="C_6b29a161-8a1d-462e-b2b3-67a19d48100c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487,516</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_797a7cba-9570-4432-ae52-b4d744b5b5dd" contextRef="C_cb839397-f2dc-4167-a221-47e4547f3e6e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">445</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d4efbbe-677f-47a7-b82e-d99ee03bc360" contextRef="C_3f92056d-1339-471e-a03a-fba16e49f069" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">241,043</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da5dca84-5a43-426e-8577-9e0a5577e000" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">246,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">f Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.245%;"></td>
    <td style="width:1.441%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.445%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.452%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.445%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.452%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.519%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82bc436f-2baa-4581-9210-7fa8efc438cf" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c5713c5-465d-4ba4-8a12-f1252d4edeb8" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">57,846</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f0b8580-21ba-4665-bc07-8c79291f0edd" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,440</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90fb96c9-1eaf-4d03-9ab5-a88c00a02bf2" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,195</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0866b12b-642e-4907-8304-38439312eb3c" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,340</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1555c2ac-69e3-42ba-9eea-6e688eac6f52" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ddf8f80-ac68-433b-95cb-ca6a13d154d7" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">315</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94757e2e-bcfa-4819-a119-272f20836084" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">307</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3591191b-9552-45a1-96df-767053faf3b1" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">318</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization (accretion) of premiums on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c436db3a-55b6-440f-baad-a9c19c4ed99a" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">628</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95426267-e4ac-446a-941e-2840e0d9d968" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">550</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f210d9e3-42c1-4d6d-b60e-4fa17569fcd7" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">152</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash lease expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_172b710d-416e-41f9-9d33-87e3a8e12f6a" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:OtherNonCashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">335</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08f3256d-f4d1-4d16-bf9c-bb413467130f" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="pmvp:OtherNonCashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">974</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b90dafcd-e53d-42d4-ad1a-f27d0ed36ca8" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_113465e7-42ca-4645-ba22-384a57a880a1" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be78e119-ea75-497d-920c-f3b35d3e73d0" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">143</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3d519d6-43c3-4ec9-8326-e510aca5ef9f" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0273c0a9-bd09-45e1-bb36-7c1b96c9ec77" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">38</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5e4bf33-7353-4de0-af72-7ae2f14c3577" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,732</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76d7819c-4872-46b3-af50-df1273874f9f" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,969</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53c915ac-2d03-47a0-811d-db539416bc56" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">389</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b77fb448-7045-4bf5-9ad6-27cb87e582d3" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">191</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccf3d39a-a435-4252-ba20-a8a747035563" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,230</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2df3b5d-b1a1-4f1b-ab5e-99906bd964fe" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,319</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_986252c9-b61e-4de5-973b-0f0f933e5497" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,894</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39867814-b037-4e45-847f-0c5cdb5ad16c" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,117</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f928b79-731e-47d2-81e4-7d58884e1c46" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">63,760</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de5ebe7a-e5d7-4b80-804c-848479057931" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">46,571</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2392a04-0756-4bad-b460-1b060fe45d15" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">32,739</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6932b510-c523-4cdb-96a9-4f4a4c839e61" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,984</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bdf9361-b670-4d8b-8401-8c54cce19fcd" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,349</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed6f678b-9674-4948-802a-8a909e964c89" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fcc9cdf5-b24b-41fe-b0c6-ed8e7b5f40a1" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">229,199</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3069e32-f899-4d3c-bbaf-133577854613" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">256,845</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38db671e-18ec-4973-8756-cfb9ecd85d4d" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,512</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a03cb849-f8ef-4d69-8bc9-5a3b8d4f2315" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">235,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d17e576-d17b-41e5-8bcc-64a1cc7a8bac" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114,610</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80330007-3800-4d10-8bd6-e6f65951cd2b" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,571</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ccf427e-59bf-4467-a0b2-9f19f1477401" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3672a2f-1673-470c-8b9e-92fe19aeee6b" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">143,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_715b7298-d6a5-4c49-b987-1f2c078dfaec" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,911</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of convertible preferred stock, net <br />&#160;&#160;&#160;issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3324c3b3-a07b-4e47-881e-38ac508e69e8" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from the issuance of common stock, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f69ef35a-5a22-42f1-b4e8-1803c70f0666" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">223,176</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from the exercise of stock options and common stock <br />&#160;&#160;&#160;issued under the 2020 ESPP</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aad9b5af-58d3-4ad3-a8da-c9c9615814a1" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">958</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e6dcd26-13fe-4fff-ada2-4b51d2682a9b" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4dcb17f1-1131-42cd-9cd2-b0a75bff37df" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_baea27e3-7974-4f02-9cca-de3a5994cca2" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">958</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f80e1b1c-ed48-4654-8441-cd8ba6e0971a" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18ef0dc7-a0ac-4bdf-b66c-a9291738cf0c" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">292,972</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddaecb9b-b326-4ec8-b691-4cb657972ecf" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">64,170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1418d740-3f07-44cd-91ec-92488d1f5463" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">188,133</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60a1abcb-d10d-4128-afe2-713dfcc6ea74" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">288,144</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents, and restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents, and restricted cash - beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a325cc56-1c2b-4eb4-8c67-fc706956a8a4" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">173,289</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0567596-9d15-473d-a816-d3e7ed4f8339" contextRef="C_abb7ff4b-f4ff-4208-b730-ff89fd4d2f48" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">361,422</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bf9f97d-49f1-4655-a7ab-9ca4249fee13" contextRef="C_14af34ae-ca01-4273-9ecd-fd1963bc0d32" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents, and restricted cash - end of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62873dff-eed1-4b79-b068-b07962c2403d" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,119</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d4ef860-6fe4-49fd-b92f-281cf61baf5f" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">173,289</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdb1d07f-edbc-4634-8a85-48b90fa3c16e" contextRef="C_abb7ff4b-f4ff-4208-b730-ff89fd4d2f48" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">361,422</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosures of noncash investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease incentives used for leasehold improvements</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f33ca38-88b3-431f-b887-f920f7b158e1" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="pmvp:LeaseIncentivesUsedForLeaseholdImprovements" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">88</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e22ed22-5ef7-4a3f-808c-05eaf24a5cee" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:PaymentsToAcquireProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">196</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2c5d356-dd1f-4c2d-98c4-ea859289fc32" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:PaymentsToAcquireProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,391</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosures of noncash financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of convertible preferred stock to common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0fd05338-f58f-4ace-b3ab-8973ff0b21b9" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="pmvp:ConversionOfConvertiblePreferredStockToCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238,723</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of warrant liability to common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0df4bf4a-0451-44cd-b895-cd78f5d19ec8" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="pmvp:ConversionOfWarrantLiabilityToCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosures of cash flow information</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for income tax</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49225348-face-4823-958e-84c9e74174b6" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_309a5932-c2a5-4a76-a509-1ac5e8e33491" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_87afb994-2791-43e5-b591-8d75397969c8" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">1.  Formation and Business of the Company</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Organization</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) was incorporated in the state of Delaware in March 2013. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities and raising capital. The Company is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company&#x2019;s headquarters are located at 1 Research Way, Princeton, New Jersey.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 25, 2020, the Company completed an initial public offering (the &#x201c;IPO&#x201d;) of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5eb39057-cd80-4d54-a10d-6ff6c31ed12c" contextRef="C_0044e892-3fea-44d5-872f-e25925415e12" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,529,750</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94998931-ef4f-4a2b-b8f1-1dbf362c5435" contextRef="C_c875a660-6997-4368-89c4-d6bfbe6ef5e5" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">18.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share including the exercise in full by the underwriters of their option to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ba42a4a-bad2-4565-8a19-82136e021489" contextRef="C_1034c385-e799-4334-bd67-e7a75f20b60c" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,764,750</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of commons stock, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33c69c6a-028a-49c2-a30a-86b9860ace79" contextRef="C_e9a7f863-44e3-4b8b-a088-33b385350544" name="pmvp:ProceedsFromIssuanceOfCommonStockGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">243,536</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and its shares started trading on The Nasdaq Global Select Market under the ticker symbol &#x201c;PMVP.&#x201d;  The Company received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_808b0d9a-56a3-470e-8844-5600b34392fc" contextRef="C_e9a7f863-44e3-4b8b-a088-33b385350544" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">223,176</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by the Company.  In connection with the closing of the IPO, all of the Company&#x2019;s outstanding shares of convertible preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24b45272-fe12-4c4f-8a6a-82f8c9dfe4f3" contextRef="C_e30e375d-2146-4abd-ab44-0f83c21f02ca" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,188,110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has incurred net losses and negative cash flows from operations since its inception. During the year ended December 31, 2022, the Company incurred a net loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0e890c0-36aa-43c8-8cea-ce3f33273f2a" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73,317</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and used $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0faa8777-8154-4265-8bd0-7ef742ce2716" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">63,760</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of cash for operations. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3b33f18-cfcb-41f7-b47e-2fe1d5985f11" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">241,043</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Cash, cash equivalents, and marketable securities were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a364941e-0137-4253-a226-de921b4ddd2b" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">243,549</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Management expects to incur substantial additional operating losses for the next several years and may need to obtain additional debt or equity financings in order to complete development of its products, obtain regulatory approvals, launch and commercialize its products and continue research and development programs. The Company believes it has adequate cash, cash equivalents, and marketable securities to operate for at least the next twelve months from the date of issuance of these financial statements.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2ff6d629-2c35-4d40-b444-203e597572a3" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2.  Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2d99e72b-88d8-4f49-94e3-2d9f6a3ffb8d" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e9aa0f4e-82e6-4a41-ade6-8f3903a65e70" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a47ad657-5c8e-44b1-a02b-c45db219f1fc" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:ReverseStockSplitPolicyTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2020, the Company&#x2019;s board of directors and stockholders approved an amendment to the Company&#x2019;s amended and restated certificate of incorporation to affect a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_17a27043-797c-4507-ade3-bf66c8d30e5f" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f825643-30db-4519-b860-379ea6072865" contextRef="C_ee831443-0cb9-4eaf-ae6d-7a321beb8833" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" unitRef="U_pure" scale="0" decimals="4" format="ixt:numdotdecimal">5.2651</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-for-1 reverse stock split of the Company&#x2019;s common stock and convertible preferred stock</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was effected on September 24, 2020. The par value of the common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, convertible preferred stock, stock options, and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_70ed12fb-6495-4890-82b6-5ef00e12d931" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:</span></p><div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div></div><div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.</span></div></div><div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 - Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.</span></div></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cdef8786-2702-45ba-83ec-a7e900ab3f26" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Marketable Securities</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument&#x2019;s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. The Company&#x2019;s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders&#x2019; equity. Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security and recorded on the interest income, net line of the income statement. For the years ended December 31, 2022, 2021, and 2020, the Company recorded </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9769d460-0175-4695-ad92-aed84f6c4073" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">628</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of accretion, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b51c6963-1c89-4cc2-a4f6-759320bcdd63" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">550</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of amortization and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bebfb578-6c16-4cb9-b099-466a72ed506d" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">152</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of amortization, respectively.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash as of December 31, 2022 included </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb201b64-fc69-44f8-a2df-e0b82cc1f6b7" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3">822</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> de</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">posit at the Company&#x2019;s commercial bank underlying a stand-by letter of credit issued in favor of a landlord (See Note 6) and is classified in current assets.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_13140f64-f39e-4a05-bc6d-4f65bbd8a4de" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company presents comprehensive loss in a single statement within its financial statements. Other comprehensive loss consists of unrealized gains and losses on marketable securities, net of tax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a787f120-050d-41e5-9e04-d480eddafaf1" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#x2019;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.  The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#x2019;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. Furthermore, the Company has elected the practical expedient to not separate lease and non-lease components by class of underlying asset for its existing leases. The Company&#x2019;s only existing leases are for office and laboratory space.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#x2019;s share of the lessor&#x2019;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. Neither of the Company&#x2019;s leases contain residual value guarantees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bdd69645-16ef-4102-9863-8c3b0608a8f5" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight&#x2011;line method over the estimated useful lives of the assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c6a3f2a2-0f68-4a73-92ff-801a44f13ffe" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, except for leasehold improvements, which are amortized over the shorter of the useful life of the asset or the remaining term of the lease.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a5ee411c-950c-468b-b385-a76250961535" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets, are tested for recoverability whenever events or changes in the business environment indicate that the carrying amount of the assets may not be fully recoverable. Factors considered by the Company when deciding when to perform an impairment review include significant underperformance of the business against expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows resulting from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows resulting from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its current fair value. To date, the Company has not recorded any impairment losses on long-lived assets.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_81a0a2de-2e1c-4be8-83b8-b09773bacd84" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All costs associated with research and development are expensed as incurred.  Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes allocated stock-based compensation, salary payroll taxes, employee benefits; materials; supplies; depreciation on and maintenance of research equipment; the cost of services provided by outside contractors; and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. The Company records accruals for estimated research and development expenses, comprising payments for work performed by third party vendors, clinical research organizations, clinical manufacturing organizations and others. Some of these vendors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones.  For the latter, the Company accrues the expenses as goods or services are used or rendered.  Research and development activities related to patient enrollment are accrued as patients enter and progress through the trial.  In the event that the Company prepays fees, the Company records the prepayment as a prepaid asset and periodically evaluate the prepaid asset in conjunction with the related accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_046c98db-ada6-4a4c-b4c3-f86e80d7b81d" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock&#x2011;Based Compensation</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s share-based compensation program allows for grants of stock options and restricted stock units. Grants are awarded to employees and non-employees, including directors.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for stock-based employee compensation arrangements in accordance with provisions of ASC 718,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Compensation &#x2013; Stock Compensation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;ASC 718&#x201d;)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option pricing or equity valuation model that is applied in a manner consistent with the fair value measurement objectives of ASC 718, is based on established principles of financial theory and reflects all of the substantive terms and conditions of the award. The Company uses the Black-Scholes option-pricing model (&#x201c;Black-Scholes&#x201d;) to value stock option grants to employees, non-employees and directors. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock units and stock options.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to the lack of a public market for the Company&#x2019;s common stock until September 2020 and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67dfe70d-0d8c-469c-b07c-a71965bd85b7" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the Company&#x2019;s IPO, due to the absence of an active market for the Company&#x2019;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for options granted, the Company considered the estimated fair value of the common stock as of the measurement date. Prior to the Initial Public Offering, the estimated fair value of the common stock was determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#x2019;s-length sales of the Company&#x2019;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event. Other factors considered were the Company&#x2019;s financial position and historical financial performance, the status of technological developments within the Company&#x2019;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#x2019;s competition, and the current business climate in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s stock-based compensation awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is typically the vesting term.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d7e72018-561f-4ee4-adfa-a799dcbd2168" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the Company&#x2019;s Chief Operating Decision Maker to make decisions with respect to resource allocation and assessment of performance. To date, the Company has viewed its operations and manages its business as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2c4de72-f6cf-4431-9c2b-1c162b34726d" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_23f39bfa-6da8-4941-8c7f-d9f9228f6b8c" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating and reporting segment.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8010a419-6655-4385-a753-97b10d75eb82" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Common Share</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is computed using the &#x201c;two-class&#x201d; method which includes the weighted average number of shares of common stock outstanding during the period and other securities that participate in dividends (a participating security). The Company&#x2019;s convertible preferred stock are participating securities as defined by ASC 260-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Earnings per Share</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the periods where the Company incurs net losses, the Company allocates no loss to participating securities because these securities have no contractual obligation to share in the losses of the Company. Under the two-class method, basic net loss per share applicable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional shares for the potential dilutive effects of a warrant, convertible preferred stock and stock options outstanding during the period calculated in accordance with the treasury stock method, or the two-class method, whichever is more dilutive. The Company allocates net earnings on a </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">pari passu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (equal) basis to both common and preferred stockholders. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company&#x2019;s net losses. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3e363e7a-dfcc-42ee-9cbd-1ecb5b31c35d" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes in accordance with ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#34;ASC 740&#34;), which requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Under ASC 740, the liability method is used in accounting for income taxes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and law that will be in effect when the differences are expected to reverse. ASC 740 also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates annually the realizability of the deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. In 2022 and 2021, the Company recorded a full valuation allowance for the deferred tax assets based on the historical loss and the uncertainty regarding the ability to project future taxable income. In future periods if the Company is able to generate income, the Company may reduce or eliminate the valuation allowance.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for uncertain tax positions in accordance with ASC 740. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax provision that an entity takes or expects to take in a tax return. Additionally, ASC 740 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. Under ASC 740, an entity may only recognize or continue to recognize tax positions that meet a &#34;more likely than not&#34; threshold. In accordance with this accounting policy, the Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_be6d7bc9-1da8-4afa-89e8-f6d58b7dcf2d" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, the FASB issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_637e6d3e-1c4a-4011-bf94-4da18c87eb69;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASU 2019-12</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Income Taxes &#x2013; Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The new guidance simplifies the accounting for income taxes by removing several exceptions in the current standard and adding guidance to reduce complexity in certain areas, such as requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The Company </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d903e981-764a-4927-8879-65d00722194a" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> this standard as of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_60b8359d-3e8e-40d4-a294-b68208840d9d" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The adoption did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1d2a2aad-1d11-424f-87ab-195851afbe9f" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> have a material impact on the Company&#x2019;s financial statements.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a6e3db93-f3d7-458f-a940-b12481e9aa5a" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and marketable securities. The Company maintains its cash, cash equivalents and marketable securities in accounts at high quality financial institutions. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds. Cash and cash equivalents include a checking account and a money market account held at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company&#x2019;s marketable debt securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#x2019;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#x2019;s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_0b3ce88b-23bd-4f92-ad6c-2216b59e72d0" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">3.  Financial Instruments and Fair Value Measurements</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s financial instruments consist of money market funds, U.S. government debt securities and corporate debt securities. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fc317aaf-b840-43de-b1a7-45ddfa38464f" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true" continuedAt="F_fc317aaf-b840-43de-b1a7-45ddfa38464f_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables show the Company&#x2019;s cash equivalents and available-for-sale securities&#x2019; carrying amounts and fair values as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021:</span></ix:nonNumeric></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_fc317aaf-b840-43de-b1a7-45ddfa38464f_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:21.434%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.08%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.055%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.262%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.08%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.08%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.08%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.76%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="26" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying<br />Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted<br />priced in<br />active<br />markets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />other<br />observable<br />inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />unobservable<br />inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_839edbc9-cba2-447b-8844-2427b6478cf8" contextRef="C_58ef5181-20d9-4f31-9be5-bbaff729be34" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f885d733-f82a-4b04-b12b-17aa16e870ef" contextRef="C_58ef5181-20d9-4f31-9be5-bbaff729be34" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9a95d71-2300-4f65-9e28-a56879ea67b0" contextRef="C_1b95af3e-4692-4a4e-9684-b24ec983c018" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f170b53f-4961-4611-8703-2a74c4aa053a" contextRef="C_b5a63292-5285-4e55-9178-b0cf6d47d493" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103,755</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a046f459-85da-4498-a5f9-548b8e9465ad" contextRef="C_b5a63292-5285-4e55-9178-b0cf6d47d493" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbcede59-bd88-4518-9cff-462845cc536c" contextRef="C_b5a63292-5285-4e55-9178-b0cf6d47d493" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">185</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e93d4104-c1fc-4330-962e-2c1807b20f8c" contextRef="C_b5a63292-5285-4e55-9178-b0cf6d47d493" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103,591</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6bb73c9a-7dbf-4136-8e46-140cbeaea9a6" contextRef="C_5f699388-d277-4279-ad4b-3dc305343bb9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103,591</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_049e9c7d-d916-49e6-8416-1c16f743db4a" contextRef="C_a77505cc-2f39-49ee-ad0b-48a03ab00343" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,942</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54816023-3fb2-4ac1-9583-b9382aec4c1b" contextRef="C_a77505cc-2f39-49ee-ad0b-48a03ab00343" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d537f96-261b-459d-b60d-2262c724b23b" contextRef="C_a77505cc-2f39-49ee-ad0b-48a03ab00343" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,661</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e64e97f-5d21-4d3a-bdfd-69861d3e0b13" contextRef="C_ed2937ce-4797-431c-bb85-119506b27457" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,981</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87ec25cf-71c4-4a84-b4f7-dabd73b34541" contextRef="C_a7da1954-d795-42d9-9a41-c04ab601e771" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,680</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_408f7cb2-c672-4647-982e-f8ac75f87a14" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">242,558</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97edee2c-0c40-4fc7-a0de-dc7489f923c8" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_104f8db5-b09e-4481-b656-e2d79e75017c" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">466</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03c7f9df-199a-498e-8bc9-a62e3b0337c0" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">242,113</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e925f6d-b1f5-434a-90de-5b127e925dfa" contextRef="C_720aa091-f1ff-40f6-9052-0af429d30c44" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127,842</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef990ac8-87ba-482d-99ff-60b4719121d6" contextRef="C_00093d41-7321-438a-9568-7a6890ae8c2f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114,271</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="26" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying<br />Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted<br />Priced in<br />Active<br />Markets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Unobservable<br />Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_698cf9d7-6d36-4176-b316-2c213ea2562c" contextRef="C_efbb7361-2dda-41c4-81c1-8e49b935005c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,960</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9e071b4-c7f3-4376-b01b-cf941fb643ac" contextRef="C_efbb7361-2dda-41c4-81c1-8e49b935005c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,960</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b69b3fcd-2ebc-40d0-bb02-642f87ac014e" contextRef="C_a991aacb-ef93-40b5-b119-f3a9a2d28d00" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,960</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae9b5583-43e8-4160-87c6-d0029a4c90fd" contextRef="C_11ed8784-858f-40ad-9cbb-1dbbf928a291" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">227,378</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_136a072c-6846-4c5d-b587-5dac323773f1" contextRef="C_11ed8784-858f-40ad-9cbb-1dbbf928a291" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f33366a-6db2-4366-b41d-2cb8013ce318" contextRef="C_11ed8784-858f-40ad-9cbb-1dbbf928a291" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_affcdeb6-ea12-4b39-9366-ca5e8da82caf" contextRef="C_11ed8784-858f-40ad-9cbb-1dbbf928a291" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">227,362</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e345c39a-d9c2-4c73-8ef9-5d7b51029580" contextRef="C_b49092ec-8ffe-4a12-88e3-3c14783b877c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">227,362</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_759b0e83-7e9c-4fef-9ab5-802433f31346" contextRef="C_6d1c2064-9b95-4b0c-95f4-5061ac19468e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,307</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce85dff5-8f6b-420b-971b-72d1954a2d94" contextRef="C_6d1c2064-9b95-4b0c-95f4-5061ac19468e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff8fdad7-25c6-4223-995a-5d58607a8f5f" contextRef="C_6d1c2064-9b95-4b0c-95f4-5061ac19468e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,245</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9a55b57-1b94-4582-a5e7-db6383a8ef0a" contextRef="C_f4cfd3a5-85b9-4820-af60-1d16ec12ddf9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,245</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42f5ff49-4880-4f42-90f6-01ae17aa2d04" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">310,645</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc95bb5a-cf7f-433d-b371-6e0d400969b2" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b97a673-7876-49b8-82d8-3843f3beb6b3" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fcf9cea2-b95d-48a2-b83e-89062f143619" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">310,567</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41cd926b-e3dc-4a17-aff6-35395c23d541" contextRef="C_7f668206-d681-40de-bb20-c42cee8ec88f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,960</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_753adcee-5c97-415c-8eec-11fe30b83ea4" contextRef="C_0b75762f-88bc-457f-a72d-6cf0e39501d3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">269,607</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:continuation></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2013; As of December 31, 2022, the Company had cash of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f65546eb-88a4-48e4-a172-2bb4a24ba8fc" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:Cash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,436</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and cash equivalents, consisting of money market funds, of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_879ceb86-1bbd-4a7e-aeb5-021b406392a9" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106,861</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2021, the Company had cash of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fde43db-0ce5-4696-af54-dc40f0eb012f" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:Cash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,507</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and cash equivalents of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_307bc950-d768-4bc2-8370-168773c5ae99" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">168,960</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Cash equivalents consisted of money market funds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0dba8082-45ba-4eb3-9358-31e4159641e2" contextRef="C_f8e287d6-b299-4d5e-a156-3e903f57677f" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,960</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and corporate debt securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fff331e-ebfe-478d-90fc-c9ca83d28bd8" contextRef="C_b49092ec-8ffe-4a12-88e3-3c14783b877c" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Money market funds are classified within level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets, whereas corporate debt securities are classified within level 2 of the fair value hierarchy because they are valued using inputs other than quoted prices that are observable for the asset or liability either directly or indirectly.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable Securities </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2013; Marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97f554cc-3886-4ea9-bc0f-24f35338e0df" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135,252</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022, consisted of corporate debt securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae806a2a-32b3-4f98-adc9-0c8d544bbd58" contextRef="C_b5a63292-5285-4e55-9178-b0cf6d47d493" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103,591</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and government debt securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d631a10b-27d7-4aad-a108-5169645369d1" contextRef="C_a77505cc-2f39-49ee-ad0b-48a03ab00343" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,661</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. There were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_deb3544e-e4fb-42ed-b66b-2c192ec473a2" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">132,757</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> current marketable securities and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20c2652c-3a95-4884-bbc4-26165e681dd2" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,495</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> noncurrent marketable securities as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94247407-15cc-48e2-a08d-e30ccffdda67" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">141,607</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2021, consisted of corporate debt securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5990f664-8ce9-464b-8968-22dd0ff11b70" contextRef="C_11ed8784-858f-40ad-9cbb-1dbbf928a291" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,362</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and government debt securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5edec19-6459-4182-b0b7-d46caef877ee" contextRef="C_6d1c2064-9b95-4b0c-95f4-5061ac19468e" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,245</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. There were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6eb91521-80a2-4061-a3f9-c9a861803ea3" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">124,696</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> current marketable securities and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbb88d9f-1ed6-4dee-a0ab-caabfa6baad3" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,911</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> noncurrent marketable securities as of December 31, 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, aggregated gross unrealized losses of available-for-sale investments were not material, and accordingly, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_381c41bd-789d-4716-a2df-e93ad36d074f" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f1db483a-3414-4777-9150-20d563aaba79" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> allowance for credit losses was recorded.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_1322076f-df8e-4ff3-8c54-4011e4dc8112" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">4.  Property and Equipment, Net</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_780cb3d9-0d38-4de9-bd44-af8b7bef2340" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.649%;"></td>
        <td style="width:0.994%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.329%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.005%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.024%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Machinery &amp; equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdc2e46c-6d8b-4217-8546-b58451063b17" contextRef="C_2dfb4cde-06c3-4435-a144-2e3f21d7e9ea" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,448</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca1e1e5c-87cd-4926-9590-d2d841e5ba1f" contextRef="C_24c200ea-42b0-4b4d-9f36-e114465d1de9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,261</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computers</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48a18646-a645-4219-9acd-3c16b7ea8f08" contextRef="C_e7ede4d5-1f79-4121-9b1d-f81bbef5bc5d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c009f8de-ba10-4ff2-92fa-bf8359d19094" contextRef="C_0599473c-789b-4f09-b3fb-e6b52320799c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture &amp; fixtures</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4af9be68-ef17-4448-abc3-d36eb65befe2" contextRef="C_27aea8e1-2efd-4fae-b253-57813f8540e5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac81a2b3-bd97-4a0d-b775-0f8dfa719df3" contextRef="C_cba766c3-a95a-452a-8d08-ceb25213b983" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80b505a6-d2ef-4813-a3e1-63547576a06a" contextRef="C_be4f127e-beed-49d8-9fd5-8cc013547c17" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">409</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e61463de-f1a8-4234-8a1b-2ed295be34eb" contextRef="C_1cbfb514-89c7-42d8-9873-9e01e255563c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">161</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets not placed in service</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99027b3c-e52f-4373-9a65-22da30d3e04b" contextRef="C_cd70bc18-5773-4da6-a7eb-54ca7d7cf4d2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,200</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d98271ed-02d3-4e6f-ad41-2d02fc6ae028" contextRef="C_01ffbae4-047b-4cdf-97c5-b607f5f8288c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,519</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_618fd198-e2c2-444d-9f2c-6fe916ffbe44" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,139</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_403515a1-e39b-41a2-b454-8acc38e80728" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,958</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad7bc2ef-7b8b-433f-9018-c6a391bf5804" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,184</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a150a9ee-1713-475a-a34c-67af28fabc66" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,868</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59d3e626-946c-4f7e-8ebc-142649c0f1c2" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,955</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05093257-fd0c-4ece-a67f-cbf6c74642a1" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,090</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense for the years ended December 31, 2022, 2021, and 2020 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a218ef4-3824-4a6a-8ef4-b47d04cfe20f" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3">315</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5435ada7-be3d-4708-97ca-bae46e724934" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3">307</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af8f9ccd-efb0-4dae-a6c4-52a0c662b04f" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3">318</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_35697ee4-c604-4fc1-9d14-2d13f3a061f2" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">5.  Accrued Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_b1228504-2f48-4c90-968d-8df0ac609976" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consists of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.42%;"></td>
        <td style="width:1.007%;"></td>
        <td style="width:1.007%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.904%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.007%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.654%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6a48963-1e01-4d9e-b51e-777c98e36881" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:WorkersCompensationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,897</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6feff41b-7dd6-44e4-af23-23e417a6d7ef" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:WorkersCompensationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b18c951-9a0a-4240-81e5-cae7e43a5fe2" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:AccruedResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,259</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d882807-87b6-4557-98e4-a257b200253e" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="pmvp:AccruedResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,734</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36107cbd-6de2-4ace-b92f-5d5469e529c3" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04821f0a-6d3b-444b-8a23-3a1225e5101e" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91ae121f-1d2f-4a87-960d-3679df993f05" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,308</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6e39f64-0472-4c75-971b-631f206c4b85" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,627</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2eb2b3b6-0a01-4938-ae0b-12d69056f41b" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">6.  Commitments and Contingencies</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2015, the Company executed a noncancelable operating lease for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37027c20-4af5-4d25-b0e4-f5ce3d6ff26d" contextRef="C_313a014b-8256-4401-b4ea-e5d597a024c1" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">13,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of laboratory, research and development, and office space in Cranbury, New Jersey for an initial base rent of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb12f00c-bd02-49f4-8726-f82be35293f6" contextRef="C_313a014b-8256-4401-b4ea-e5d597a024c1" name="pmvp:InitialBaseRentPerSquareFoot" unitRef="U_U_iso4217USD_utrsqft" scale="0" decimals="2" format="ixt:numdotdecimal">20.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per square foot. This location operates as the Company&#x2019;s current headquarters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2017, the Company obtained an additional noncancelable operating lease for about </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9aebdb47-8fd5-4900-9f8c-27487d1dad5d" contextRef="C_4bdae4ec-dd1e-490f-b8a5-74529602509a" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">6,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of laboratory space in the same corporate center at an initial rental rate at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffbfd5cd-9132-4a85-ae76-bdb282676ce3" contextRef="C_4bdae4ec-dd1e-490f-b8a5-74529602509a" name="pmvp:InitialBaseRentPerSquareFoot" unitRef="U_U_iso4217USD_utrsqft" scale="0" decimals="2" format="ixt:numdotdecimal">22.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per square foot. As a result of the additional space, both leases expired </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4f64ba16-364e-4509-ae92-41a41f46a7dc" contextRef="C_05247025-7721-46fd-b9a4-9209202d385c" name="pmvp:OperatingLeaseExpirationPeriod" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a0bcd124-3e1b-4f8d-b1a6-a1ef79af960c" contextRef="C_ee80540b-08ef-4bfb-a16e-dc6e2b4b20b1" name="us-gaap:LesseeOperatingLeaseOptionToTerminate"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2022, the Company signed a lease extension for both leases for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_2e41832f-24ee-4add-8485-3b9e6b7ae42f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional year through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cff4567a-50db-4183-a5d5-8eddc7baa40b" contextRef="C_ee80540b-08ef-4bfb-a16e-dc6e2b4b20b1" name="pmvp:LesseeOperatingLeaseRenewalMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with the option to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4738da7b-4103-4851-9f2d-cb3d1755c4f1" contextRef="C_ee80540b-08ef-4bfb-a16e-dc6e2b4b20b1" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">terminate</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> upon 120 days of written notice, with an increase in base rent as per the lease extension.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_61e4869b-312b-475c-8284-74472fd2ecbc" contextRef="C_05247025-7721-46fd-b9a4-9209202d385c" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Both leases include a common area maintenance expense for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f9af43a-787b-4ff9-8ab4-0c643619bfce" contextRef="C_6a05cc4e-dcbc-40a3-8e6d-3479699de18c" name="pmvp:OperatingLeaseMaintenanceExpensePerSquareFoot" unitRef="U_U_iso4217USD_utrsqft" scale="0" decimals="2" format="ixt:numdotdecimal">3.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per square foot with an increase of 3% on the first month of each calendar year during the lease term and a management fee of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee7713e8-5bdb-47db-8083-9b4c17198af8" contextRef="C_6a05cc4e-dcbc-40a3-8e6d-3479699de18c" name="pmvp:ManagementFeeOfBaseRentPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the base rent.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company is obligated to pay, on a pro-rata basis, real estate taxes and operating costs related to the premises.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2018, the Company executed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f313158f-5db8-44b6-af17-d3ef4a3e7bfc" contextRef="C_0aac07e3-04d3-478a-9920-5fb843d4ae5d" name="pmvp:NumberOfNoncancelableOperatingLeases" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> noncancelable operating leases. One lease for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fcc638dd-e13c-4f12-a2e3-30989ad4e89d" contextRef="C_430e7e98-a75c-447c-94c7-2b300c9ae2c1" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">6,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet for vivarium, laboratory and general office space in South Brunswick, New Jersey. The initial annual base rent is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4efce871-7238-4a8c-a92f-7a6cb953b92d" contextRef="C_430e7e98-a75c-447c-94c7-2b300c9ae2c1" name="pmvp:InitialBaseRentPerSquareFoot" unitRef="U_U_iso4217USD_utrsqft" scale="0" decimals="2" format="ixt:numdotdecimal">15.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per square foot and a management fee of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_962186f8-8bb7-4285-864d-19b4ace2b9e7" contextRef="C_430e7e98-a75c-447c-94c7-2b300c9ae2c1" name="pmvp:ManagementFeeOfBaseRentPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the base rent. The Company is obligated to pay, on a pro-rata basis, insurance premiums, real estate taxes and operating costs related to the premises. The lease expired in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ebfeb86f-0de6-43e3-8965-4ad25cfbe6b1" contextRef="C_6997eaf7-2d14-4514-abb0-3d4e030cd2ba" name="pmvp:OperatingLeaseExpirationPeriod" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d00a5b68-1839-40e5-9c6b-4e746c6c2216" contextRef="C_cff8f1fb-dda0-4691-8c83-2a825ba5821d" name="us-gaap:LesseeOperatingLeaseOptionToTerminate"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2022, the Company signed a lease extension for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_68272f31-ac51-43d0-89b6-b5574371c7f3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional year through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_486ea270-2886-4564-bae6-afcb9956b212" contextRef="C_cff8f1fb-dda0-4691-8c83-2a825ba5821d" name="pmvp:LesseeOperatingLeaseRenewalMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with the option to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_144eb738-498b-4bcd-8cfb-34787a91a6a9" contextRef="C_cff8f1fb-dda0-4691-8c83-2a825ba5821d" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">terminate</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> upon 120 days of written notice, with an increase in base rent as per the lease extension.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The second lease is for office space in Lexington, Massachusetts, that expires </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8e146ed5-1996-4199-9729-915c2d893dbe" contextRef="C_72d9367d-2b3c-4d93-892a-028d7de01843" name="pmvp:OperatingLeaseExpirationPeriod" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with an option to renew for a one-time, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_74b89c4f-ff6c-4631-8439-92d2dc0ae5a9" contextRef="C_f992ea57-8d32-4b0e-81ef-cb65a45d19d0" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> extension. The initial annual base rent is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c49d5dcc-92f9-4cca-978c-59a4e4b9f0f5" contextRef="C_f992ea57-8d32-4b0e-81ef-cb65a45d19d0" name="pmvp:InitialBaseRentPerSquareFoot" unitRef="U_U_iso4217USD_utrsqft" scale="0" decimals="2" format="ixt:numdotdecimal">28.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per square foot and will increase $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c39d2c16-4334-4ad5-99ee-7f03b322124b" contextRef="C_f992ea57-8d32-4b0e-81ef-cb65a45d19d0" name="pmvp:InitialBaseRentIncreasedPerSquareFoot" unitRef="U_U_iso4217USD_utrsqft" scale="0" decimals="2" format="ixt:numdotdecimal">1.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per square foot at the end of each rent year.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2018, the Company received a lease incentive for the buildout of 420 Bedford Street in Lexington, MA. The Company was given an allowance for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74ad56c3-ed99-47a9-bd11-6e69ee331fea" contextRef="C_12649a32-1900-4175-a9b7-929ef30b495c" name="pmvp:AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" unitRef="U_USD" scale="3" decimals="INF" format="ixt:numdotdecimal">165</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on behalf of the lessor for construction of office space. Management recognizes this allowance as a lease incentive in its Right-of-Use asset and straight-lines the allowance throughout the term of the lease.  As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the remaining rent incentive pertaining to the Lexington, MA lease totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce6c3a13-82f6-4767-9308-0a222061fe7e" contextRef="C_e6b007b1-2fc8-4c95-a477-b9b71fb8a813" name="us-gaap:DeferredRentCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, the Company signed a lease for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_064f5c85-af38-4fbe-9e7d-1bb739ec725d" contextRef="C_e1989c17-cc2f-4cba-a956-12217925213d" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">50,581</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office and laboratory space at 1 Research Way in Princeton, New Jersey. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ed3e43a4-3349-4c6f-bc6b-0c8a6078db27" contextRef="C_dde39134-e5f7-476a-97bc-d31efae7f2a7" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">That lease term extends through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3e207d48-9da9-4390-ad6a-77bdceb51639" contextRef="C_341901e2-89fa-4177-845b-613f934b9099" name="pmvp:OperatingLeasesExtendedYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2032</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, has a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8673c421-2cc6-4b7e-9182-824a158e90ba" contextRef="C_341901e2-89fa-4177-845b-613f934b9099" name="pmvp:OperatingLeasesExtensionPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> extension option, and is intended to replace the Company&#x2019;s two existing facilities and the space is expected to become the Company&#x2019;s future headquarters.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Payment under this lease will total $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de5a866f-8519-4a7e-abce-258e99cceee7" contextRef="C_341901e2-89fa-4177-845b-613f934b9099" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,889</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_21dadedb-80b2-4b52-a9ab-33da75b07eeb" contextRef="C_341901e2-89fa-4177-845b-613f934b9099" name="pmvp:OperatingLeasesExtendedMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 2032</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company received a lease incentive of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_853ccb65-d972-4a91-9075-779fb69b15e0" contextRef="C_341901e2-89fa-4177-845b-613f934b9099" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,046</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the lessor for a buildout of laboratory, vivarium, and office space, to be reimbursed to the Company in 2022 and 2023. Management estimated the timing and amounts of reimbursements and included them as a reduction of lease payments when initially measuring the lease liability and right-of-use asset upon commencement. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ece269c-e2e0-4e29-8248-501a83df683a" contextRef="C_0f6a712d-9111-4481-8345-32cee4988f74" name="pmvp:ReimbursementsReceivedFromLessee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,969</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of reimbursements were received.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5728f329-2ebe-4e88-b0c5-1bb4e1f7efbd" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lea</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">se cost for the year ended December 31, 2022, and 2021, are as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.752%;"></td>
        <td style="width:1.618%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.851%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.618%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.16%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fcffb32-dc12-49e9-b459-8041c827f019" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,215</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63ffbd14-5029-4dd6-9729-d936cbe88982" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,691</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e71d09d-5127-4489-b017-e68ea9f483ee" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">991</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cdbcc73-be12-43b9-98aa-8cf39cf637d3" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">704</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f059912-ea03-46c2-8d30-92e330f79a2f" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,206</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b9de31a-f69e-4415-9e20-aa552e55238b" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,395</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6fa8a9b1-09f7-4841-813b-f52ac7e2b07e" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts reported in the balance sheet for leases where the Company is the lessee as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, and 2021, were as follows, in thousands:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.631%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.403%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.403%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets, operating leases</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce9af9f1-4872-4057-9e87-31b18395cb3c" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,539</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dcd91f3-54b0-4383-80be-5f20cbafbb7a" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,060</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23be844a-ef7a-436b-b941-75e93353746e" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1ae1b22-bb7b-4c94-b2ac-ff7928cf9063" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">403</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_affa8591-aa9e-4c16-84c6-0dbab817a7b4" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,448</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc76a8ae-c39b-4669-bf3f-9abcbd5e604b" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,790</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87566751-80c2-4696-a738-2d88f36b7eed" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,976</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e91bc201-5a4b-4a21-b6a3-cf0721f7a469" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,193</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_abadf855-99b5-440f-9d3a-2ae38fe04f04" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.08</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_888843e0-141c-47fd-88c9-fe01768a8651" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.02</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d63ed445-619d-4ad6-a8c3-a92275c4a805" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0022c04-417c-46b3-8c71-586abd9b7580" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5c61b4ac-fa2c-47da-a4fe-bcc32d6fd00e" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other information related to leases for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, and 2021, are as follows, in thousands:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.599%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.049%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.123%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash paid (received) for amounts included in the measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1845d0f-c0cb-4fb0-b09c-ec2863ed148a" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,089</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3f5b339-2f80-4548-8ad8-d19551612ad8" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="pmvp:NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">717</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leased assets obtained in exchange for new or modified operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1979292e-5fb2-4528-b819-e7c151ae7484" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_314ddd63-ff61-4c6a-ae2e-e1c323cc56dc" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,318</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f8530617-70b0-4e3c-86fc-45311029dd20" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments, net of reimbursements, remaining as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 under operating leases by fiscal year were as follows, in thousands:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.773%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:14.835%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.165%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fiscal year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_084354b5-9c7e-478e-80ef-d0a6747fbfc9" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,219</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6edc6f9e-3de3-4132-abd1-c83c567983d7" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,814</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd8d2ad4-8bb2-4b5f-8b6a-5d2874b177b3" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,869</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb8cc051-7067-4375-a4f5-01c1a6a7053a" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,925</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_609c31c0-7e6e-458e-9bf9-98f63deedeec" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,983</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7ed9705-426d-4660-a11a-20fdbaa0ad0d" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22568179-ce89-4a63-9ff4-ac50eef2c72d" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,304</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Amounts representing imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ad88b6a-ed4a-4cb4-8df4-6f34fd54ef9b" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,328</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e306c679-c142-4ba7-ba4b-e6ea5d358926" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,976</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rent expense recorded for the years ended December 31, 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_544ef8b0-1a76-4ae0-8067-0d4d2ae0715d" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,215</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc9ea41a-f205-4b8f-9b79-c020dad835a3" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,691</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently subleases the office space at 420 Bedford Street in Lexington, MA to another company.  This sublease agreement expires in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f7d12feb-433f-453a-8f2c-935882fb177e" contextRef="C_8894ea23-6468-4b4b-9fe0-13e05959ff40" name="pmvp:SubleaseExpirationPeriod" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In April 2021, the Company entered into a sublease agreement with the previous tenants of the office space at 1 Research Way in Princeton, NJ, from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3d66f722-469b-4386-9dae-f6dd7a1edd9f" contextRef="C_498dfeb5-4f73-4ec9-8f1c-60dbf3d79a5b" name="pmvp:SubleaseWithTenantOfficeSpaceStartingPeriod" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9873d22b-0e38-4591-85a7-b6689116d5e1" contextRef="C_498dfeb5-4f73-4ec9-8f1c-60dbf3d79a5b" name="pmvp:SubleaseWithTenantOfficeSpaceEndingPeriod" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. For the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, sublease income for the Company was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4075cc0f-def6-4e05-9bad-54b54640d10c" contextRef="C_dde39134-e5f7-476a-97bc-d31efae7f2a7" name="pmvp:SubleaseAndAdditionalSubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">107</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f67c7519-9f37-4c45-84ef-721b7e90a187" contextRef="C_b2f1afb2-0883-4bf4-890d-a477cbd94b5a" name="pmvp:SubleaseAndAdditionalSubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingencies</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_84c58345-b57d-4a76-99d3-b7148173e57e" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:PreferredStockTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">7.  Convertible Preferred Stock</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2020, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5230361-8561-4fe3-90a2-fa909fedafd7" contextRef="C_c0a73230-1c9b-4996-8fdd-7164c9f9c45f" name="pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,321,864</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series D Preferred Stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ed3c863-ff26-4d97-a60a-f02873193df2" contextRef="C_e189a9e4-ad1c-4932-a0a3-75d29fa8bacd" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">13.1533</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecd7d1f9-3455-498e-95a5-e9868d6165b2" contextRef="C_c0a73230-1c9b-4996-8fdd-7164c9f9c45f" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In connection with the IPO on September 25, 2020, all of the Company&#x2019;s convertible preferred stock, including Series D Preferred Stock, outstanding at the time of the IPO automatically converted into an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b30b8a74-f5d5-4047-aca9-2f4ada1e8b7f" contextRef="C_e30e375d-2146-4abd-ab44-0f83c21f02ca" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,188,110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_56f86b4f-a9a4-4ce8-8e26-e2ddfc568d35" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">8.  Stockholders' Equity</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is authorized to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97c187b1-fecc-4533-b25f-f454b8188678" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,000,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_434d31ca-fe0b-4119-a936-58647089c5b6" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.00001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad6809ad-702d-4566-975f-714377ce9361" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_def7e542-1616-4939-a62b-d282fc0a0759" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.00001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15d3bc46-d167-49a6-8c91-ce86bd0bd1ab" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_01ddd42a-2609-4d82-8f91-ce5d9bdaaeca" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">45,771,332</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d377af62-df29-4b1d-8d01-c7b1fa3212eb" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_52bdad32-54d0-4098-b568-2e977bd6fd80" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">45,433,684</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issued and outstanding, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stockholders are entitled to receive dividends if and when declared by the board of directors subject to the rights of any preferred stockholders.  As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0dc0d1b-df86-47a6-8e33-19a715f98467" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:DividendsCommonStock" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends on common stock had been declared by the Company.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_17f14def-53fb-4446-a6b5-cd35e1a4db37" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ScheduleOfStockByClassTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, the Company had reserved shares of common stock for issuance as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.217%;"></td>
        <td style="width:1.423%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.806999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.434%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.12%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aaab9745-d460-44ec-b232-1e082682902b" contextRef="C_1dba3b6b-5641-4b1b-9e12-052771f7ced4" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,278,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78c469c1-658b-4e8b-a775-b698fca0dee7" contextRef="C_0736b229-258c-40dd-838a-47547c627b77" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,246,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares available for future stock option and RSU grants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cd8bf12-77eb-46c5-b2bb-d96f2c6f11bb" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,618,292</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf87bf20-ed49-4c51-8cc4-723eb12a8a81" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,951,680</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares available for employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eca134b8-8341-44f2-81c6-6033965b566e" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">705,559</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20519a29-8188-4318-bfcc-3511fdf2a736" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">801,464</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4e2194b-d177-496a-acc7-d53ddc017f26" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,602,622</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59b4defa-a79b-4a75-9859-6d06dede6f38" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,999,151</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4088528f-3636-47c9-bcb0-13efad0df790" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">9.   Stock Plan</span></p><p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) was approved by the board of directors on September 24, 2020.  The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#x2019;s officers, employees, directors and consultants. The number of shares of common stock initially reserved for issuance under the 2020 Plan was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44a52fe9-c41e-4cbc-86f8-475801346261" contextRef="C_ee1cceca-c5e2-4901-967c-47736d420d59" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,406,374</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, in an amount equal to the least of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25b73d53-c47e-48e7-8c9e-008477d1b6f4" contextRef="C_ee1cceca-c5e2-4901-967c-47736d420d59" name="pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,406,374</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, (ii) five percent  (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_399d29c4-e3ac-4a56-941a-6388a20eb9dd" contextRef="C_ee1cceca-c5e2-4901-967c-47736d420d59" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%) of the outstanding common stock on the immediately preceding December 31, or (iii) such number of common stock determined by the board of directors no later than the immediately preceding December 31.  For 2022, the board&#x2019;s compensation committee, as the 2020 Plan administrator, exercised its discretion under clause (iii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by a lesser amount of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5d381bc-11c0-4328-ad59-cd6259cc7486" contextRef="C_56fadc42-3ad0-4e3b-8b73-b2226b84481a" name="pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,363,084</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, effective as of January 1, 2022. For 2023, the board&#x2019;s compensation committee, as the 2020 Plan administrator, exercised its discretion under clause (iii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by a lesser amount of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15b520b7-4b52-4bdc-9e6b-513d6cb06666" contextRef="C_bc64aa3a-019b-48b2-8343-7467cc9d0a91" name="pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,830,853</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, effective as of January 1, 2023. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5d279cc-b1ff-4d3e-a3ce-5d977f12ab4b" contextRef="C_978ba6d3-3e46-4525-91db-17cd972dc4ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,618,292</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for issuance under the 2020 Plan.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 9, 2022, the Company granted </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27ae3c02-e288-43ef-a39a-acea845b897d" contextRef="C_be6aad5a-a831-43c8-a05f-822cdf5cf4a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">374,899</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Restricted Stock Units (RSUs) to employees pursuant to an employee retention program approved by the Board's compensation committee.  The RSU&#x2019;s have graded vesting on an annual basis for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7f8801bb-f895-4fea-b151-92e8d3edea4f" contextRef="C_016af1b3-ff49-4bb0-867b-902d174c68ec" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of continuous service, as per the 2020 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6a771154-38a1-4194-a353-695b5bd842d1" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true" continuedAt="F_6a771154-38a1-4194-a353-695b5bd842d1_1"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below summarizes the annual grant activity under the 2020 Plan as of  December 31, 2022:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.364%;"></td>
        <td style="width:1.007%;"></td>
        <td style="width:12.678%;"></td>
        <td style="width:1.007%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.100000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.843%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares Available <br />for Grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances, December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22f2aca7-a5cc-47ab-8b97-7f50f1036cc8" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,951,680</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares reserved for issuance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7900ba2-da8c-44ac-865d-0fa82e82de6f" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,363,084</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57349649-f549-4d27-83db-3b1402f8727c" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,419,197</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSU&#x2019;s granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dc968c4-1b00-4b4a-8fa4-21cf82bdd58a" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">374,899</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited / cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fe89a00-3f75-45cc-a7e3-57afd27d2f6c" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">97,624</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbd5706b-fe97-441e-89ee-b3362e2db7a3" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,618,292</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;) was approved by the board of directors on September 24, 2020.  A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc2edc1a-4e6c-40ee-9219-e321be9bab04" contextRef="C_46e3720d-b4bb-422c-94c9-0403252a56b3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">400,752</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, to the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8c5b740-de0f-46b7-8328-d4fbedfcf501" contextRef="C_46e3720d-b4bb-422c-94c9-0403252a56b3" name="pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">801,504</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, (ii) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08ec3d82-121f-4e91-8925-391389c8be6c" contextRef="C_46e3720d-b4bb-422c-94c9-0403252a56b3" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="2">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (iii) an amount determined by the board of directors or any of its committees no later than the last day of the immediately preceding fiscal year. For 2022, the board waived the annual increase to the shares reserved under the 2020 ESPP. For 2023, the 2020 ESPP reserved shares were increased under clause (iii) by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69f90998-b8ff-4e79-b4b9-204bd98aa56d" contextRef="C_a8260db6-bbe1-4939-9c5f-a844164fe721" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">457,713</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, effective as of January 1, 2023. On May 20, 2022, employees exercised their right to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac73d25b-870b-40b1-abe1-62339817abc4" contextRef="C_4e66fbef-977e-4452-91f9-9a4ee3656882" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,454</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares under the 2020 ESPP. On November 21, 2022, employees exercised their right to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40a41b0e-d8c9-4654-88d5-0c4d1efabc32" contextRef="C_9eac9d1b-d481-4882-beb9-94f63124f8eb" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,385</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares under the 2020 ESPP. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9e4eede-b702-4dcc-bfac-9e41ace6cbbd" contextRef="C_1e80c7c5-b3d0-4620-b5bc-d434b48624a5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_102d2138-af61-474b-8050-29bbd61ecfb0" contextRef="C_1e80c7c5-b3d0-4620-b5bc-d434b48624a5" name="pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">95,905</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares are issued or outstanding, and there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a21a28c-151d-4b9c-b41b-1ed523485ef0" contextRef="C_1f918825-5928-4608-b71c-9f4456b6f047" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">705,559</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for issuance, under the 2020 ESPP.</span></p><p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2013 Equity Incentive Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2013, the Company adopted the 2013 Stock Plan (the &#x201c;2013 Plan&#x201d;). On September 24, 2020, this plan was replaced by the 2020 Plan, and future issuances of incentive instruments will be governed by that plan.  Subject to the provisions of the 2020 Plan, the Company had the option to either forfeit or repurchase remaining shares under the 2013 Equity Incentive Plan on or after the registration date.  The Company chose to forfeit the remaining shares.</span></p><p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fcdc8400-9249-4922-bcd4-fce4b43d2933" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents RSU activity under the 2020 Plan as of December 31, 2022:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"></td>
        <td style="width:1.008%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.363000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.008%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.879999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.759%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Stock Units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average <br />Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested shares at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a1cabc7-0190-4474-8fdc-830a18b62b13" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">374,899</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccfdd90f-ba3a-452d-a9c9-2568aa16142d" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="1" format="ixt:numdotdecimal">13.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested shares at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d86198c-fcdb-4339-8c45-1382aa724b3e" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">374,899</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93148f30-6fb6-4f66-b515-6ad6e959fb13" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="1" format="ixt:numdotdecimal">13.6</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d7e2e64-aadf-4a32-a1c9-d70f0fcc8983" contextRef="C_c7636c7c-5d0d-43b6-ae8e-cf22b92c32be" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,317</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of unrecognized compensation cost related to RSUs that are expected to vest. These costs are expected to be recognized over a weighted average remaining vesting period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e5c55fc3-d246-422f-a29c-194841d08659" contextRef="C_350081f7-b9c6-4878-9982-48ec05493f21" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_6a771154-38a1-4194-a353-695b5bd842d1_1"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.542%;"></td>
        <td style="width:0.074%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.773000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.074%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.184000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.074%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.983%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.074%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.219%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />Average</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Remaining</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Average</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Life</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in 000s)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d20c4ab-b28a-4f3c-8c15-1ecdfe72df3d" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,246,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3892331-8b28-4956-b5b4-bf6d5dbd3836" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">8.22</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_46787d1c-1399-4b19-a530-618024fe342d" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.86</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df9f501f-2356-465f-b834-e7dc663da5e9" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,506</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df080ac5-0207-4fb1-9f03-e669e2abb0e3" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,419,197</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_272e42e5-68a8-470b-a3ea-6047860cde8a" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">15.83</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited / cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a20d7ad6-839a-4ede-a7b4-9fbaa4c491ca" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">97,624</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e9cb418-1593-4674-8418-b409e791d331" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">20.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7c00b89-370e-4c07-a4d1-61f112a31284" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">288,809</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_890c9365-6c2c-436c-906e-65ca254223b1" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.67</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2564756c-df6e-4d30-a07a-b730e331ebd5" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,278,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80cf929a-a4c4-4626-b8db-4e9beb1a537f" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_29e18dd4-5934-45ae-99a1-bfe6daff98e0" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.82</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2950ff85-26c2-49b3-b1fb-9678abd2ae54" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,244</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5752287d-a0b4-4de4-9439-97bff5ec78b3" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,278,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_335c4c6b-a733-4f13-989e-8f70eafd0312" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d0b98064-b4b8-417c-8b9a-590c4b68a195" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.82</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c35ee171-ec65-47b0-b2b7-0f2c95d35602" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,244</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_618fd17d-2611-4821-bc4f-bac7c9909c03" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,281,213</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f63d24e3-a876-4a0c-ad85-ab61a3c122bb" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.91</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3c7de38c-de91-4192-a0b7-d7f5cf22fa94" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.76</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2f38160-1363-4f9a-be31-9bad8564fc39" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,520</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average grant date fair value of stock options granted during the year ended December 31, 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61a8fe03-c8a0-4621-8e0a-b611d1abe144" contextRef="C_3202e22d-2468-4cd8-9005-96d662a4e257" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.92</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c58b886e-7d73-469c-bf45-aee2d756b102" contextRef="C_5e800e2c-3450-44fa-bbf1-ab0a826218a5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">20.03</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of options vested and exercisable as of December 31, 2022 and 2021 is calculated based on the difference between the exercise price and the fair value of our common stock.  The intrinsic value of options exercised in 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa971600-90e9-499a-8ac0-b8c0948472ea" contextRef="C_3202e22d-2468-4cd8-9005-96d662a4e257" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,764</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14756d24-dc31-46de-8438-b6454c9b2860" contextRef="C_5e800e2c-3450-44fa-bbf1-ab0a826218a5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,534</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the total compensation cost related to nonvested service-based awards not yet recognized is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2abc6a73-fb2b-47d1-8bda-867d3cad4815" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,005</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The weighted-average period over which the nonvested awards is expected to be recognized is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_402159d6-fa7d-4a16-b4ff-e294c5cd2e41" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7788f073-fa83-4196-880f-4976e3184880" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company estimated the fair value of stock options using the Black-Scholes options valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following assumptions:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.987%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:16.998%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:16.004%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:15.556%;"></td>
        <td style="width:1.442%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_277f2873-f0ab-4fa3-9313-48304a88180f" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.48</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ff0becd-8014-494b-9022-d2958d08c082" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">4.34</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_385a3bb7-88d9-443f-843f-675e55e13baf" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c03b943d-c917-4409-8892-fa9b69577e28" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.30</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b69a50b-e9b4-47f5-87db-3932d28f4361" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.31</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dbed33f-f7a1-416f-9173-3c68d22043eb" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.51</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_258450b0-179a-4aec-8772-d5c72294ebb2" contextRef="C_d4c247c9-f1e3-4efe-9b18-0915c829f126" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a4269a7b-0181-4109-b08c-12b329939222" contextRef="C_50eb0442-301d-4fd1-8119-3f5ac5089ea2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.44</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_257f7964-2aea-4b18-9c54-6cf3aee299dd" contextRef="C_86745cc2-3f0c-450a-840f-efc74e3b9311" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_46e6267c-d5a6-4902-ae01-4d9c06d41b8a" contextRef="C_0971ead3-d21f-4a45-a148-3e60a1cdbe48" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.44</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_43869823-b93e-4b5b-9f28-debc26069ec8" contextRef="C_c5ec1baa-405a-4660-a084-861474f9bfdc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.92</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0953349e-7a15-4c03-98b7-e4f618662dd7" contextRef="C_502f3121-e154-46be-b42e-f83a002a53e3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.40</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e6a9a02-185b-4ad6-8301-6cc5cbfb38cb" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0338485b-84bc-4b0a-8966-766638e33863" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c72e4fe5-ab2a-4ee2-8e4a-f9d529f7f5c0" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5710aca2-6efd-4cc2-905d-f40dd5a20d43" contextRef="C_d4c247c9-f1e3-4efe-9b18-0915c829f126" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">76.33</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cc8cd38-1b5a-463a-a2bf-f7e10d7c3805" contextRef="C_50eb0442-301d-4fd1-8119-3f5ac5089ea2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">81.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01683c58-fbea-4560-a6a0-b160472bb56e" contextRef="C_86745cc2-3f0c-450a-840f-efc74e3b9311" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">76.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_037b1d45-f64d-42ef-8c20-5608d17cf8df" contextRef="C_0971ead3-d21f-4a45-a148-3e60a1cdbe48" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">79.90</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_553772d5-009a-4ec1-b552-e1cb3ae99853" contextRef="C_c5ec1baa-405a-4660-a084-861474f9bfdc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">70.70</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a3973eb-ffd2-4241-87ca-13839757eed1" contextRef="C_502f3121-e154-46be-b42e-f83a002a53e3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">77.60</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b7a1f282-ac6a-4dac-9f58-079cf7d44b92" contextRef="C_5066952e-d95e-40c8-a2b4-77c7e137ae45" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average assumptions used to estimate the fair value of stock purchase rights under the 2020 ESPP are as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.998%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:12.895%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:13.996%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:13.098%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45af4f84-77db-400c-b430-c3924d64af5c" contextRef="C_5066952e-d95e-40c8-a2b4-77c7e137ae45" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">3.44</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0def21aa-e65a-4df3-8b79-4e5521bdfd5f" contextRef="C_2667deff-220f-4412-adb0-e8fc0d6ca3f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="6" format="ixt:numdotdecimal">0.0004</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_916fd685-90d3-4a8f-b5d5-768f1d9b4e40" contextRef="C_5066952e-d95e-40c8-a2b4-77c7e137ae45" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.49</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7f15783e-a5b2-4535-ba11-b66d161ab7da" contextRef="C_2667deff-220f-4412-adb0-e8fc0d6ca3f3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8287cdb1-33dc-49cf-bebc-c38b2230e8ce" contextRef="C_5066952e-d95e-40c8-a2b4-77c7e137ae45" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bf1cd95-e703-4e5b-aec0-2551f70b31a0" contextRef="C_2667deff-220f-4412-adb0-e8fc0d6ca3f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e7c7241-6edf-4a5b-b19a-7ce63e947a38" contextRef="C_5066952e-d95e-40c8-a2b4-77c7e137ae45" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">77.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f072f799-f264-4d7c-9429-fe4e13d8f063" contextRef="C_2667deff-220f-4412-adb0-e8fc0d6ca3f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">77.83</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected Term: The Company uses the simplified method to calculate expected term described in the SEC&#x2019;s Staff Accounting Bulletin No. 107, which takes into account vesting term and expiration date of the options.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility: Volatility is based on an average of the historical volatilities of comparable publicly traded companies for the expected term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Free Interest Rate: The risk-free rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term of the option.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Yield: The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95b0e374-cf85-4fbc-bebe-64e660d2ab2b" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the valuation model.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_10f47fe4-b0eb-4d69-883d-34169c19015f" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense recorded under ASC 718 was allocated to research and development and general and administrative expense as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.28%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.176%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.434%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.649000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.429%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25888882-1ed4-4a0f-83d3-a1f8ce5ebc5e" contextRef="C_205220c0-e91d-4339-8383-bedd964b0c1d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,466</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c116a2da-1138-4cca-b73f-1b62715ffc89" contextRef="C_01965527-3ea2-4759-b0e5-d6e7a69bf0ed" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,440</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cd82710-c793-426f-bb4d-2ec05dae0e43" contextRef="C_4a6c24a3-d3cb-43ea-9818-038cc97b8e65" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">836</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b400dd0-127f-4794-a4b3-7b5c400e94fc" contextRef="C_6ff7f970-97f9-4cb7-a2a0-8883a87d4dca" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,729</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5789e6d-34c7-41f1-8388-ba420b7a5f58" contextRef="C_50c95562-5171-48b3-9b59-edd5b2537c4f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5e4a03e-a231-48cc-9adc-381686317a01" contextRef="C_0e9b7374-006a-4280-8ffb-f7a56c5987fa" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,097</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_488e4f68-aed1-429d-8484-5515d9def321" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,195</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c1bc95c-f973-42a9-b98d-60b38bfa2167" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,340</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ea07a61-a397-471d-875d-5b8dcd80539c" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,933</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_98e51f83-0122-45ed-a410-b252aba9700c" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.301%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.173%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.430000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.01%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.636%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.429%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc71383d-1eb5-4cae-9e17-542ce1b7986b" contextRef="C_026560c8-db2c-4e87-a51c-0c88050f90a2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,174</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68c379a9-8fe9-4684-a739-e61b2d6de15e" contextRef="C_f21d65be-13a2-4ece-a7b5-17985dc50636" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,938</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed88cdb8-6bcd-4eeb-82ce-41c2af8db454" contextRef="C_7006422b-42e5-4830-9abd-4af424a83925" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,933</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07f16641-1cde-42ae-95b3-ace2e16c1138" contextRef="C_350081f7-b9c6-4878-9982-48ec05493f21" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">790</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_049f6fe7-12de-4937-888b-ab5ccc034937" contextRef="C_f97e2ad4-444f-4f38-9b94-59f51d99a446" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">231</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bcf2a46-c8d9-40e0-bf92-6d1f0d4a4264" contextRef="C_26d83b9d-f0fd-40e2-b4ab-7163ee3e8e1d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">402</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e20edb44-0746-4515-a554-d0f8f7c9d8be" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,195</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4dc07803-237f-4170-bff8-c8f18fe80fef" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,340</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d95a45d-b604-4705-826d-339991f39cff" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,933</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_f015e0cf-2e07-4a83-8476-7b6396f2a6b3" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">10.  Income Taxes</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bd601d6f-da70-47d1-ab5c-5d764a957dbc" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The income tax (benefit) provision for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.82%;"></td>
        <td style="width:1.748%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.382000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.748%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.138%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.748%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.416%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c45a117-3c2f-40d8-9755-b5035455d3f0" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e47cac2d-b40c-4329-bae2-455849774576" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d702405-5266-4583-b02c-d10f43dc56cf" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfc6f825-fad5-4c46-bc00-10f9257cd32f" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc213ca1-2cf5-4c28-93a2-de2a9975f698" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_982253af-3037-4e92-be30-81f40a58c5d2" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total (benefit) provision</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7398535-8b95-497c-9f64-ba05e70de8e4" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09b99690-f33b-4ad4-8e41-67f9cf7a3e6e" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31cd108b-4e03-452f-abbf-1d173d20abd9" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_473365d8-b294-473c-9c21-bac68e99094a" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of income tax computed at the statutory federal income tax rate to the (benefit) provision for income taxes included in the accompanying statements of operations for the Company is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.036%;"></td>
        <td style="width:0.973%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.891%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.973%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.917%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.973%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.236%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax provision at statutory rate</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a37a647-8d5f-4d26-8be1-1fe3dd966256" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27c0a022-0d63-4482-99d4-8403861c7b3c" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9aff90c-a14b-497f-ba84-b9c6ce8724f7" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b1432e6-2299-416d-86fb-317fa17d7e35" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_482a15e9-23f2-46b3-b479-8a0cb7449f04" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15f07f7a-95bb-48ec-a1e1-12210e7b1a56" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ab89b81-08b2-4b55-887f-30315d2eb4aa" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_176b2497-c029-423f-b118-7ce46948aa9a" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8e8cce9-52a0-4751-ad57-02d792fd5632" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d087aa4b-0fb7-49bb-8718-508ed52b9bfa" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ff7569b-c7c2-4691-a35c-f2be680259de" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b6ef6bd-f5a6-459b-9d4a-1fe3dfd5501b" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive compensation limitation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad47e74e-34d9-4116-a13c-42dd006858e3" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="pmvp:EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1a1d0ca-59a7-4950-b438-6e929c8d75c5" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="pmvp:EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74d9cda3-f1c2-458b-925b-1ff528788cea" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="pmvp:EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_270e63bc-3bd5-46dc-932b-02f5e47ebf95" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c112ba4d-40dc-4089-98c8-97540e9cac99" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe9cf716-68c7-47ed-bdb6-0c0d00887ed9" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a46a16d-9891-49dd-9005-842dfb771d76" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecbeb1d8-669f-4632-a2e9-2e30f213ae6a" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af190a01-c38c-4ead-9b57-17e400196f7b" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5ae0f5c-9555-4e53-b710-c0c25a24d8d0" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e10f5bdc-7a46-4520-8356-8dc15dda0b3e" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_531a8b8f-95f8-46a6-b643-cace6c95c928" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company&#x2019;s effective tax rate is below the federal statutory income tax rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c717175a-1698-449e-a879-54c1ef0515eb" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF"><ix:nonFraction id="F_eb82f3a0-3734-4150-b042-50f0c8298f53" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF"><ix:nonFraction id="F_ae69d03d-8e96-4d70-803f-a52eb3f95163" contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF">21</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% primarily due to state income taxes, net of federal benefit and the Company&#x2019;s position to establish a full valuation allowance on its deferred tax assets.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8f49fc18-938c-491b-8975-025d4b58cd2d" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets and liabilities are presented below:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.233%;"></td>
        <td style="width:1.667%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.679%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.667%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.753%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1e490a8-366c-4811-bc17-409a5df2c65c" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,451</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11f7b429-7c17-43b3-a6a8-8e2d5147a93a" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,231</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eedbb33d-387e-4a7f-9f6b-aa7b23681673" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,905</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f49c4f25-6678-4f21-9a6c-c1f6414182c1" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,587</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dde5e86-51ff-4fd9-91e9-67e66b3a24c8" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:DeferredTaxAssetsCapitalizedResearchExpenditures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,563</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9e8abab-a656-47c4-8f66-19caf1036fb0" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,856</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24ee3fde-cf70-4a03-90de-340b7cd37e2f" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,593</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accruals and other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aabb0e8c-ff26-4629-8949-3eb1183284ef" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">911</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_562d5ba7-67b8-4062-98a4-7929734c98f8" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,033</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_659bbf99-47cc-4db7-b256-f40cbf804e92" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:DeferredTaxAssetsOperatingLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,969</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a542e54e-4ecd-4d38-b9b5-9816ba453afa" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="pmvp:DeferredTaxAssetsOperatingLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,175</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd4e347f-aa3f-4ff7-b65e-6b9b84c4849a" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,655</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55776bd9-c2c1-4eb7-940c-44afad249779" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,619</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_093b734f-4507-4e6b-a1ec-723e30036ed8" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74,917</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_264f1796-05dc-4df9-b970-bb61f9225c15" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,728</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets recognized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f040362e-c020-4b08-835b-654b8ccfd038" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,738</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3da1fe4f-acb8-4817-84ff-6ff445ebb239" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,891</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db8e4a03-108d-4e4d-96de-20665333d726" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:DeferredTaxLiabilitiesOperatingLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,709</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6abd5d9c-9425-4618-9945-cfbe19f3779a" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="pmvp:DeferredTaxLiabilitiesOperatingLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,854</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Fixed assets and depreciation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e962642-ee0d-491a-b264-182803f6194e" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8903e446-f75b-4d5b-b6a7-ea69f73ba519" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77ee60cd-3a39-4593-9f24-7e12cc36a7ad" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,738</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4108bfb-90f7-4c77-b9dc-6d32bb94553a" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,891</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has recorded a valuation allowance for its deferred tax assets that it does not believe will be realizable at a more likely than not level based on analysis of all available sources of taxable income.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company had federal net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95200b9b-ae61-4ee3-a33e-239268467798" contextRef="C_0b4380ac-1ddd-4289-8638-eefde924a0cc" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">174,736</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c42e2dfb-5f03-4a1a-8ec8-752d842ddc5c" contextRef="C_eecb9d6d-ac0a-487e-a86a-abf840012bdb" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">159,886</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the Company had state net operating loss carryforwards for New Jersey, California, Massachusetts, and Arizona of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ad3663e-6c75-44e2-872f-05430d5afa1e" contextRef="C_bce60bd0-958e-42c0-9f7d-65828fc53e9a" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169,847</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76d5887d-8a7e-48d0-8b87-dc8763d1cdd8" contextRef="C_95fdd9a8-ebe7-4208-ba3b-05e6405b6c61" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,912</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c29248e-f862-4cb3-b0e1-0b853c79113d" contextRef="C_9cbe3afa-3782-4ddb-a255-b2011580f639" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,277</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43315b13-11a8-4f5f-b27d-525b9959c7c5" contextRef="C_276e8ed2-4f66-40e4-bdb0-8985bcee8033" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had state net operating loss carryforwards for New Jersey, California and Massachusetts of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58005ef1-24fe-465e-b7e7-c623ae8a4030" contextRef="C_2f9792c0-bc7a-4f8f-9b3a-22089cbb1363" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154,972</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6778d308-c94d-425c-b292-52ab37b933d6" contextRef="C_7f19e1fd-4356-482e-bb63-fcc3de69c641" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,912</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3356579-b5bc-4be3-bb30-6d0ed3c69a73" contextRef="C_f9893b5b-4a1f-4410-b019-9a69763b7f7b" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,640</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> respectiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ely.  Federal net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae616e40-fc21-45f2-b748-43e0beab48d5" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:OperatingLossCarryforwardsBeginToExpireInFutureAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expire beginning in the year </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_63bdcc2d-303c-4861-a6e9-7c728afa9d41" contextRef="C_62a9b101-ab75-4638-a91d-240e17253b55" name="pmvp:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2033</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State net operating loss carryforwards begin to expire in the year </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_104aa205-99c4-4b42-aab7-eb1d9769bc63" contextRef="C_eeba018d-c970-42c2-b7e8-39bb44c1c232" name="pmvp:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2033</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_23291c45-5e85-41f8-9af3-d2c06f2418d4" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards related to tax years after 2017 of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c7c78de-abe1-4af9-b555-c43e8ebd4df2" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="pmvp:OperatingLossCarryforwardsAmountsDoNotExpire" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">147,236</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> do not expire.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company also has federal and state research and development credit carryforward of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8023098e-a1f8-4075-ad48-f529ee505bec" contextRef="C_99a529b5-6188-4ab9-8f9d-4322c6925579" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,749</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bbb05a8-ffb6-4d70-92d4-d8160ab3b51c" contextRef="C_05006ac3-674f-4f86-a1fb-57904ae43650" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,588</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The federal credits will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_325c122d-1af3-4b7b-9a69-4cebf47e4a86" contextRef="C_62a9b101-ab75-4638-a91d-240e17253b55" name="pmvp:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2034</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> if not utilized.  The California state credits carryforward indefinitely and the New Jersey state credits expire starting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_99ce279a-c8f4-4a2f-b757-85dec2f697a2" contextRef="C_54e6aacb-2840-4e37-bef3-a3d7dc27785c" name="pmvp:TaxCreditCarryforwardExpirationYear"><ix:nonNumeric id="F_7c5db4fd-bf97-492d-a937-0115a05afbe9" contextRef="C_236fce2d-e055-4239-92a3-3e87093d5a21" name="pmvp:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2030</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> above net operating losses and research and development credits are subject to Sections 382 and 383 of the Internal Revenue Code. In the event of a change in ownership as defined by these code sections, the usage of the net operating losses and research and development credits may be limited.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accrues interest and penalties related to unrecognized tax benefits in the (benefit) provision for income taxes line item in the statements of operations and comprehensive loss</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6aca4530-000b-4a68-ac50-d0dd19fc3193" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_63dc4fa0-e447-4374-a883-5e45d8628535" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t accrued any interest or penalties related to uncertain tax positions.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the ending balance of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af1b5e63-dfcd-4013-badd-20fbe4efbaed" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,437</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4834c7e5-4136-4006-83bf-cc57faf6b951" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,654</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of unrecognized tax benefits as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, were recognized, none of the recognition would affect the income tax rate. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_82507501-e3db-48d8-b195-6e76c2108784" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" escape="true" continuedAt="F_82507501-e3db-48d8-b195-6e76c2108784_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarized the activity related to the Company&#x2019;s unrecognized tax benefits:</span></ix:nonNumeric></span></p><div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_82507501-e3db-48d8-b195-6e76c2108784_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.128%;"></td>
        <td style="width:1.657%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.667%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.657%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.892%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits, beginning of year</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_688483d7-c3c2-42d6-a8f4-769f8f43b2d1" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,654</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c868bc90-6f9d-4620-8503-e9b3d4351c7f" contextRef="C_abb7ff4b-f4ff-4208-b730-ff89fd4d2f48" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">877</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e172aa2-74b8-4d6e-b8b3-22179393abd0" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to current year tax positions</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8220b151-b377-4514-93a9-470bb0af8d07" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">783</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78abb5ca-53ba-4b1b-8f6a-249ca900030a" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">734</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits, end of year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_602cc666-8446-4c62-b4cf-490d46613c63" contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,437</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_234119eb-b6f8-438c-80db-ca281645ce85" contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,654</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company does not anticipate any material change in its unrecognized tax benefits over the next twelve months. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company files U.S. federal and state income tax returns with varying statutes of limitations. The Company&#x2019;s tax years </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_82dfdf8f-411c-4717-af9e-206e2366f08e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2013 to 2021</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> will remain open for examination by the federal and state authorities for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_4604235b-11b9-4105-9a93-5870e969a273;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a8c9b087-e137-4a0d-adfa-21c13673a265" contextRef="C_eeba018d-c970-42c2-b7e8-39bb44c1c232" name="pmvp:IncomeTaxExaminationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, from the date of utilization of any net operating losses and research and development credits.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_d5eec11f-0bde-48bf-b936-2c0c45a825d5" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">11.  Net Loss per Share</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excluded all outstanding stock options and restricted stock units at each period end from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect.  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_233b9823-c08e-4677-8e0e-03e522249a3e" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_233b9823-c08e-4677-8e0e-03e522249a3e_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following common stock equivalents were excluded from the calculation of diluted net loss per share:</span></ix:nonNumeric></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_233b9823-c08e-4677-8e0e-03e522249a3e_1"><p style="text-indent:4.44%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.596%;"></td>
        <td style="width:2.017%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.878%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.157%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.455%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.898%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a2b0c6d-0f7c-4bc5-84bd-0c34f3d498e6" contextRef="C_00d11f95-a34f-4d02-91c8-51c60eec5c22" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,278,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1aba492e-5847-4ddb-bd17-6baf964d56aa" contextRef="C_6082b64b-c8b4-41e9-ba59-4bf5900eec0f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,246,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted common stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e871c05b-7244-40a0-838f-98b75611b6da" contextRef="C_5c162453-8ec6-47e9-94ab-ae196146b8ef" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">374,899</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested employee stock purchase plan shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_093ac16f-bd85-4a55-a19c-ab7c40b1beae" contextRef="C_6007dfa3-622c-49c1-9860-180a9069696e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">95,905</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1bb788d-148b-47af-a7d6-dc714e2e92c2" contextRef="C_6fb33a8b-4881-4337-b607-5aca6c7a973b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">47,066</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52d83167-5c3b-4db8-81a8-d09c690b8e82" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,749,575</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_562a3c5b-3f0d-47e5-be0c-5ab8e9cc279e" contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,293,073</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands except share and per share amounts)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d25125bb-fb21-4768-b27a-251273aa963a" contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">12.  Related Parties</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has consulting agreements with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16ab11a1-536a-4645-a30b-3e08b49682be" contextRef="C_4d1fa26c-38d2-4b57-a550-1a0282289c2b" name="pmvp:NumberOfConsultingAgreementsMembers" unitRef="U_Member" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> members of its board of directors; one of which waived his consulting fees as of September 2021. Total consulting fees paid in in the year ended December 31, 2022, were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7175b4e-c10d-4cae-a2e8-6f1631dd35d5" contextRef="C_4d1fa26c-38d2-4b57-a550-1a0282289c2b" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">111</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e27f4709-5079-4810-87ba-6a2182e7fa72" contextRef="C_069c5ae4-3c69-4167-b429-fe8497be6762" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> amounts owed under the consulting agreements as of December 31, 2022.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total consulting fees paid as of the year ended December 31, 2021, were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf0123c2-4d57-4f5d-8ab1-ff195f5b467e" contextRef="C_52495b65-0118-40a4-bfc2-7a226cb39fe6" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In May of 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1dbb419d-d821-4b3f-a462-0a2be067eda6" contextRef="C_cb5c078d-3484-49d9-922e-5414ab268c7e" name="pmvp:NumberOfConsultingAgreementsMembers" unitRef="U_Member" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> members of  the board of directors were awarded </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81cf8c83-9de0-4fae-90e2-1617e12d8923" contextRef="C_cb5c078d-3484-49d9-922e-5414ab268c7e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,781</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options of Company stock each, as per their updated Scientific Advisory Board agreements. T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">here were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f3d77bc-4fd0-4964-b015-acdcfd500811" contextRef="C_8daf283d-3684-4e97-b173-64076dd32fca" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> amounts owed under the consulting agreements as of December 31, 2021.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9__changes_in_disagreements_with_ac"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.    Changes in and Disagreements with Acc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a__controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.    Control</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company conducted an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (&#x201c;the Exchange Act&#x201d;). Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is also responsible for establishing and maintaining for us adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Internal Control&#x2014;Integrated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Framework (2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under this framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any changes in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting during the fourth quarter of the year ended December 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b__or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.    Othe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">r Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_regarding_foreign_jur"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.    Disclosure Regarding Foreign J</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">urisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10__directors_executive_ficers_corp"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.    Directors, Executive O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fficers and Corporate Governance.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item will be included under the captions &#x201c;Directors and Corporate Governance,&#x201d; &#x201c;and &#x201c;Other Matters&#x2014;Section 16(a) Beneficial Ownership Reporting Compliance&#x201d; in our definitive proxy statement for the annual meeting of stockholders to be held in June 2023 to be filed with the SEC on or before April 30, 2023, or the Proxy Statement, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11__executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.    Execut</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ive Compensation.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item will be included under the captions &#x201c;Executive Compensation,&#x201d; and &#x201c;Directors and Corporate Governance&#x201d; in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12__security_ownership_certain_bene"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.    Security Ownership of Certain Beneficial O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">wners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item will be included under the captions &#x201c;Beneficial Ownership of Shares of Common Stock&#x201d; and &#x201c;Executive Compensation&#x2014;Equity Compensation Plan Information&#x201d; in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13__certain_relationships_related_t"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.    Certain Relationships and Relate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d Transactions, and Director Independence.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item will be included under the captions &#x201c;Certain Relationships and Related Person Transactions&#x201d; and &#x201c;Directors and Corporate Governance&#x201d; in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14__principal_accounting_fees_servi"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.    Principal Acco</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unting Fees and Services.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item will be included under the captions &#x201c;Ratification of Appointment of Independent Registered Public Accounting Firm&#x201d; in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span id="item14"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15__exhibits_financial_statement_sc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.    Exhibits and Finan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT INDEX</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.932%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:48.002%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:6.998%;"></td>
    <td style="width:1.421%;"></td>
    <td style="width:8.504%;"></td>
    <td style="width:1.998%;"></td>
    <td style="width:7.222%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:3.6%;"></td>
    <td style="width:9.124%;"></td>
    <td style="width:1.004%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1699382/000119312520257820/d95525dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant, as amended, as currently in effect.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39539</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 29, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1699382/000119312520257820/d95525dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of the Registrant, as currently in effect.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39539</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 29, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1699382/000156459021010578/pmvp-ex41_260.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Securities of the Registrant.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39539</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 3, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Investors&#x2019; Rights Agreement, dated July 17, 2020, by and among the Registrant and certain of its stockholders.</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520249570/d922470dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specimen common stock certificate of the Registrant.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 21, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1699382/000119312521290972/d231282dex44.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indenture.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-3ASR</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-260012</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 4, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520249570/d922470dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2013 Equity Incentive Plan, as amended, and forms of agreement thereunder.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 21, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520249570/d922470dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Equity Incentive Plan and forms of agreements thereunder.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 21, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520249570/d922470dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Employee Stock Purchase Plan and forms of agreements thereunder.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 21, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Offer Letter, dated August 17, 2020, by and between the Registrant and David H. Mack, Ph.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Offer Letter, dated August 17, 2020, by and between the Registrant and Winston Kung</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Offer Letter, dated August 18, 2020, by and between the Registrant and Leila Alland, M.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1699382/000156459022007860/pmvp-ex108_331.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Offer Letter, dated February 22, 2021, by and between the Registrant and Deepika Jalota, Pharm.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39539</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Incentive Compensation Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in Control and Severance Policy.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.932%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:48.002%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:6.998%;"></td>
    <td style="width:1.421%;"></td>
    <td style="width:8.504%;"></td>
    <td style="width:1.998%;"></td>
    <td style="width:7.222%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:3.6%;"></td>
    <td style="width:9.124%;"></td>
    <td style="width:1.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Change in Control and Severance Policy Participation Agreement, dated August 17, 2020, by and between the Registrant and David H. Mack, Ph.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Change in Control and Severance Policy Participation Agreement, dated August 17, 2020, by and between the Registrant and Winston Kung.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex1013.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Change in Control and Severance Policy Participation Agreement, dated August 18, 2020, by and between the Registrant and Leila Alland, M.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1699382/000156459022007860/pmvp-ex1014_338.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Change in Control and Severance Policy Participation Agreement, dated January 14, 2022, by and between the Registrant and Deepika Jalota, Pharm.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39539</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15+*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pmvp-ex10_15.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended Outside Director Compensation Policy.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex1016.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement, dated January 1, 2016, by and between the Registrant and Arnold Levine, Ph.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1699382/000156459022007860/pmvp-ex1017_538.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement, dated May 21, 2021, by and between the Registrant and Richard Heyman, Ph.D., as amended on July 16, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39539</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001699382/000119312520240132/d922470dex1018.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement, dated March 3, 2015, by and between the Registrant and Cedar Brook 2005, LP, as amended by the First Amendment to Lease dated April 24, 2017.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-248627</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1699382/000156459021010578/pmvp-ex1019_261.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement, dated January 8, 2021, by and between the Registrant and BMR-ONE RESEARCH WAY LLC.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39539</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 3, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1699382/000119312521290972/d231282dex12.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Open Market Sale Agreement, dated as of October 4, 2021, between the Registrant and Jefferies LLC</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-3ASR</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-260012</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 4, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1699382/000156459022007860/pmvp-ex211_332.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39539</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pmvp-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (contained in the signature page to this Annual Report on Form 10-K).</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pmvp-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pmvp-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.932%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:48.002%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:6.998%;"></td>
    <td style="width:1.421%;"></td>
    <td style="width:8.504%;"></td>
    <td style="width:1.998%;"></td>
    <td style="width:7.222%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:12.724%;"></td>
    <td style="width:1.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1*#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pmvp-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.2*#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pmvp-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document-the Instance Document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+ </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicated management contract or compensatory plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"># The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:13.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:13.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:13.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:13.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16.    Form 10-K Summary</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has elected not to include summary information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNAT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">URES</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr style="height:7.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.5pt solid;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ David H. Mack</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David H. Mack, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.4%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER OF </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATTORNEY</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David H. Mack, Ph.D. and Winston Kung, jointly and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.974%;"></td>
    <td style="width:1.068%;"></td>
    <td style="width:39.936%;"></td>
    <td style="width:1.058%;"></td>
    <td style="width:28.964%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signature</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:5.05pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ David H. Mack</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David H. Mack, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2023</span></p></td>
   </tr>
   <tr style="height:5.05pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Winston Kung</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Winston Kung</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Operating Officer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Chief Financial Officer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2023</span></p></td>
   </tr>
   <tr style="height:5.05pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Richard Heyman</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Richard Heyman, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director and Chairman of the Board of</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2023</span></p></td>
   </tr>
   <tr style="height:5.05pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Arnold Levine</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Arnold Levine, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2023</span></p></td>
   </tr>
   <tr style="height:5.05pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Carol Gallagher</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carol Gallagher, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2023</span></p></td>
   </tr>
   <tr style="height:5.05pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Laurie Stelzer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laurie Stelzer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2023</span></p></td>
   </tr>
   <tr style="height:5.05pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Charles M. Baum</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Charles M. Baum, MD., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kirsten Flowers</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kirsten Flowers</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>pmvp-ex10_15.htm
<DESCRIPTION>EX-10.15
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10.0pt;margin-top:3.6pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.15</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10.0pt;margin-top:3.6pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reviewed &amp; Updated by PMV Board as of:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10.0pt;margin-top:3.6pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">February 24, 2023 (&#x201c;Updated Effective Date&#x201d;)</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10.0pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.573%;text-indent:13.599%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:19.13%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV PHARMACEUTICALS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) believes that providing cash and equity compensation to its members of the Board of Directors (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,&#x201d; and members of the Board, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside Directors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). This Outside Director Compensation Policy (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Policy</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) is intended to formalize the Company&#x2019;s policy regarding the compensation to its Outside Directors. Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given to such terms in the Company&#x2019;s 2020 Equity Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), or if the Plan is no longer in place, the meaning given to such terms or any similar terms in the equity plan then in place. Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a result of the equity and cash payments such Outside Director receives under this Policy.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to Section 6 of this Policy, this Policy will be effective as of the effective date of the first registration statement that is filed by the Company and declared effective pursuant to Section 12(b) of the Exchange Act, with respect to any class of the Company&#x2019;s securities (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash Compensation</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Annual Cash Retainer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.102%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each Outside Director will be paid an annual cash retainer of $40,000.  There are no per-meeting attendance fees for attending Board meetings. This cash compensation will be paid quarterly in arrears on a prorated basis.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Committee Annual Cash Retainer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each Outside Director who serves as the chair of the Board, the lead Outside Director, or the chair or a member of a committee of the Board listed below will be eligible to earn additional annual cash fees (paid quarterly in arrears on a prorated basis) as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chair of the Board	$35,000</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chair of Audit Committee:	$15,000</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Member of Audit Committee:	$7,500</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chair of Compensation Committee:	$10,000</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:21.639%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Member of Compensation Committee:	$5,000 Chair of Nominating and Governance Committee:	$8,000 Member of Nominating and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:21.639%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governance Committee:	$4,000</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10.0pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For clarity, each Outside Director who serves as the chair of a committee shall receive only the additional annual cash fee as the chair of the committee, and not the additional annual cash fee as a member of the committee.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Compensation</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside Directors will be eligible to receive all types of Awards (except Incentive Stock Options) under the Plan (or the applicable equity plan in place at the time of grant), including discretionary Awards not covered under this Policy. All grants of Awards to Outside Directors pursuant to Section 2 of this Policy will be automatic and nondiscretionary, except as otherwise provided herein, and will be made in accordance with the following provisions:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.729788930723652%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Discretion</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. No person will have any discretion to select which Outside Directors will be granted any Awards under this Policy or to determine the number of Shares to be covered by such Awards.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.729788930723652%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Following the Updated Effective Date, each individual who becomes a newly appointed Outside Director will be granted an award of stock options (an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) covering 43,000 Shares (subject to adjustment for changes in capitalization under the Plan). The Initial Award will be made on the first trading date on or after the date on which such individual first becomes an Outside Director, whether through election by the stockholders of the Company or appointment by the Board to fill a vacancy. If an individual was a member of the Board and also an employee, becoming an Outside Director due to termination of employment will not entitle the Outside Director to an Initial Award.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.056%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to Section 3 of this Policy, each Initial Award will vest in equal amounts on the same day of the month as the date the individual first becomes an Outside Director over the 36 months following the month during which the individual first becomes an Outside Director, subject to the Outside Director continuing to be a Service Provider through the applicable vesting date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.729788930723652%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. On the date of each annual meeting of the Company&#x2019;s stockholders following the Updated Effective Date (each, an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Meeting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), each Outside Director will be automatically granted an award of stock options (an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) covering 21,500 Shares (subject to adjustment for changes in capitalization under the Plan).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to Section 3 of this Policy, each Annual Award will vest on the earlier of (i) the one- year anniversary of the date the Annual Award is granted or (ii) the day prior to the date of the Annual Meeting next following the date the Annual Award is granted, in each case, subject to the Outside Director continuing to be a Service Provider through the applicable vesting date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in Control</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.111%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of a Change in Control, each Outside Director outstanding Company equity awards will accelerate and vest.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.187%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:3.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Travel Expenses</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.056%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each Outside Director&#x2019;s reasonable, customary and documented travel expenses to Board or Board committee meetings will be reimbursed by the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Provisions</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All provisions of the Plan not inconsistent with this Policy will apply to Awards granted to Outside Directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ECTION </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">409A</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.056%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In no event will cash compensation or expense reimbursement payments under this Policy be paid after the later of (i) 15th day of the 3rd month following the end of the Company&#x2019;s fiscal year in which the compensation is earned or expenses are incurred, as applicable, or (ii) 15th day of the 3rd month following the end of the calendar year in which the compensation is earned or expenses are incurred, as applicable, in compliance with the &#x201c;short-term deferral&#x201d; exception under Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and guidance thereunder, as may be amended from time to time (together, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). It is the intent of this Policy that this Policy and all payments hereunder be exempt from or otherwise comply with the requirements of Section 409A so that none of the compensation to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to be so exempt or comply. In no event will the Company reimburse an Outside Director for any taxes imposed or other costs incurred as a result of Section 409A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revisions</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Board may amend, alter, suspend or terminate this Policy at any time and for any reason. No amendment, alteration, suspension or termination of this Policy will materially impair the rights of an Outside Director with respect to compensation that already has been paid or awarded, unless otherwise mutually agreed between the Outside Director and the Company. Termination of this Policy will not affect the Board&#x2019;s or the Compensation Committee&#x2019;s ability to exercise the powers granted to it under the Plan with respect to Awards granted under the Plan pursuant to this Policy prior to the date of such termination.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.187%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>3
<FILENAME>pmvp-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-3 No. 333-260012) of PMV Pharmaceuticals, Inc., </font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-249094) pertaining to the 2013 Equity Incentive Plan, 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan of PMV Pharmaceuticals, Inc., </font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 Nos. 333-256346 and 333-269394) pertaining to the 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan of PMV Pharmaceuticals, Inc.,</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-262308) pertaining to the 2020 Equity Incentive Plan of PMV Pharmaceuticals, Inc.;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of our report dated March 1, 2023, with respect to the consolidated financial statements of PMV Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of PMV Pharmaceuticals, Inc. for the year ended December 31, 2022.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:1.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.05in;vertical-align:top;padding-right:0.05in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.05in;vertical-align:top;padding-right:0.05in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Philadelphia, Pennsylvania</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br></font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>4
<FILENAME>pmvp-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;" id="section1"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, David H. Mack, certify that:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of PMV Pharmaceuticals, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 1, 2023</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:42.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.854%;"></td>
    <td style="width:15.165%;"></td>
    <td style="width:79.981%;"></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:top;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV PHARMACEUTICALS, INC.</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ David H. Mack</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David H. Mack, Ph.D.</font></p></td>
   </tr>
   <tr style="height:33.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:top;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;margin-right:0.6076388888888888in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>pmvp-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;" id="section1"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Winston Kung, certify that:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of PMV Pharmaceuticals, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 1, 2023</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:42.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.854%;"></td>
    <td style="width:15.165%;"></td>
    <td style="width:79.981%;"></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:top;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV PHARMACEUTICALS, INC.</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Winston Kung</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Winston Kung</font></p></td>
   </tr>
   <tr style="height:55.45pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:top;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;margin-right:0.6076388888888888in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Operating Officer and Chief Financial Officer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>pmvp-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;" id="section1"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	In connection with the Annual Report of PMV Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, David H. Mack, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> FILENAME   \* MERGEFORMAT Normal.dotm</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 1, 2023</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:45.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.87%;"></td>
    <td style="width:15.158%;"></td>
    <td style="width:79.973%;"></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:top;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV PHARMACEUTICALS, INC.</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ David H. Mack</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David H. Mack, Ph.D.</font></p></td>
   </tr>
   <tr style="height:33.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:top;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;margin-right:0.6076388888888888in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> FILENAME   \* MERGEFORMAT Normal.dotm</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>pmvp-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;" id="section1"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	In connection with the Annual Report of PMV Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Winston Kung, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 1, 2023</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:45.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.87%;"></td>
    <td style="width:15.158%;"></td>
    <td style="width:79.973%;"></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:top;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV PHARMACEUTICALS, INC.</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Winston Kung</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Winston Kung</font></p></td>
   </tr>
   <tr style="height:59.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:top;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;margin-right:0.6076388888888888in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Operating Officer and Chief Financial Officer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img249132499_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img249132499_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2$"8$# 2(  A$! Q$!_\0
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M]@^LU>Y[+_POA/\ H 2?]_Q_A1_POA/^@!)_W_'^%>-44?5*/8/K-7N>R_\
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MSV7_ (7PG_0 D_[_ (_PH_X7PG_0 D_[_C_"O&J*/JE'L'UFKW/9?^%\)_T
M)/\ O^/\*/\ A?"?] "3_O\ C_"O&J*/JE'L'UFKW/9?^%\)_P! "3_O^/\
M"C_A?"?] "3_ +_C_"O&J*/JE'L'UFKW/9?^%\)_T )/^_X_PH_X7PG_ $ )
M/^_X_P *\:HH^J4>P?6:O<]E_P"%\)_T )/^_P"/\*/^%\)_T )/^_X_PKQJ
MBCZI1[!]9J]SV7_A?"?] "3_ +_C_"C_ (7PG_0 D_[_ (_PKQJBCZI1[!]9
MJ]SV7_A?"?\ 0 D_[_C_  H_X7PG_0 D_P"_X_PKQJBCZI1[!]9J]SV7_A?"
M?] "3_O^/\*/^%\)_P! "3_O^/\ "O&J*/JE'L'UFKW/9?\ A?"?] "3_O\
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M]11B[GL__"^$_P"@!)_W_'^%'_"^$_Z $G_?\?X5XU16OU2CV,_K-7N>R_\
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M]@^LU>Y[+_POA/\ H 2?]_Q_A1_POA/^@!)_W_'^%>-44?5*/8/K-7N>R_\
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M_P +X3_H 2?]_P ?X4?\+X3_ * $G_?\?X5XU11]4H]@^LU>Y[+_ ,+X3_H
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M_P +X3_H 2?]_P ?X4?\+X3_ * $G_?\?X5XU11]4H]@^LU>Y[+_ ,+X3_H
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M?X4?\+X3_H 2?]_Q_A7C5%'U2CV#ZS5[GLO_  OA/^@!)_W_ !_A1_POA/\
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M\*/^%\)_T )/^_X_PKQJBCZI1[!]9J]SV7_A?"?] "3_ +_C_"C_ (7PG_0
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M $G_ '_'^%>-457U2CV)^LU>Y[+_ ,+X3_H 2?\ ?\?X4?\ "^$_Z $G_?\
M'^%>-44?5*/8/K-7N>R_\+X3_H 2?]_Q_A1_POA/^@!)_P!_Q_A7C5%'U2CV
M#ZS5[GLO_"^$_P"@!)_W_'^%'_"^$_Z $G_?\?X5XU11]4H]@^LU>Y[+_P +
MX3_H 2?]_P ?X4?\+X3_ * $G_?\?X5XU11]4H]@^LU>Y[+_ ,+X3_H 2?\
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M?] "3_O^/\*P9_\ D@UE_P!?S?S-><UE2PU*5[KJS2I7J*UGT/9?^%\)_P!
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M$DB^U3+%O,P.W/?&*E\1_&!/#_B&\THZ,\QMGV^8)@-W&>F*\D\%?\CSH?\
MU^)_.K?Q'_Y*'K/_ %U'\A67U:E[7EMI8T]O4]G>_4[W_A?"?] "3_O^/\*/
M^%\)_P! "3_O^/\ "O&J*U^J4>QG]9J]SV7_ (7PG_0 D_[_ (_PH_X7PG_0
M D_[_C_"O&J*/JE'L'UFKW/9?^%\)_T )/\ O^/\*/\ A?"?] "3_O\ C_"O
M&J*/JE'L'UFKW/9?^%\)_P! "3_O^/\ "C_A?"?] "3_ +_C_"O&J*/JE'L'
MUFKW/9?^%\)_T )/^_X_PH_X7PG_ $ )/^_X_P *\:HH^J4>P?6:O<]E_P"%
M\)_T )/^_P"/\*/^%\)_T )/^_X_PKQJBCZI1[!]9J]SV7_A?"?] "3_ +_C
M_"C_ (7PG_0 D_[_ (_PKQJBCZI1[!]9J]SV7_A?"?\ 0 D_[_C_  H_X7PG
M_0 D_P"_X_PKQJBCZI1[!]9J]SV7_A?"?] "3_O^/\*/^%\)_P! "3_O^/\
M"O&J*/JE'L'UFKW/9?\ A?"?] "3_O\ C_"C_A?"?] "3_O^/\*\:HH^J4>P
M?6:O<]E_X7PG_0 D_P"_X_PH_P"%\)_T )/^_P"/\*\:HH^J4>P?6:O<]E_X
M7PG_ $ )/^_X_P */^%\)_T )/\ O^/\*\:HH^J4>P?6:O<]E_X7PG_0 D_[
M_C_"C_A?"?\ 0 D_[_C_  KQJBCZI1[!]9J]SV7_ (7PG_0 D_[_ (_PKNO
M_C$>,M,GO!9-:^5)Y>TONSQG-?,%>[? [_D6;[_KY'\JY\5AZ<*?-%:F]"M.
M<[-GJ5%%%>8=QX1\</\ D8;#_KC_ %->75ZC\</^1AL/^N/]37EU>YAOX43R
M:_\ $84445T&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '2?#_ /Y'[1O^OA:3Q_\ \E!US_KY/\A2_#__ )'[1O\ KX6D
M\?\ _)0=<_Z^3_(5A_R^^7ZFO_+KY_H<Y1116YD%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'HWPY_Y%+QC_ ->?]#7FZ?ZM?H*](^'/_(I>,?\ KS_H:\W3_5K]!6%/
MXY_+\C6?P1'4445N9!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >A_"'_D-ZK_UY-7 W7_'Y<?]=&_G
M7??"'_D-ZK_UY-7 W7_'Y<?]=&_G6$/XLOD:R_AQ^9%1116YD%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'I#_\ )"H_^OJO-Z](?_DA4?\ U]5YO6%'[7JS6KT] HHH
MK<R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT?^MC_ -X4VG1_
MZV/_ 'A2 ]"^,'_(8T3_ +!J_P Z\[KT3XP?\AC1/^P:O\Z\[K'#_P )&M;^
M(PHHHK<R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KL_A5_R42P
M_P!Q_P"5<979_"K_ )*)8?[C_P JRK?PY>AI2^-&#XF_Y&G4_P#KX;^=95:O
MB;_D:=3_ .OAOYUE5</A1,MV%%%%42%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 >C3_\ )!K+_K^;^9KSFO1I_P#D
M@UE_U_-_,UYS6%#[7JS6KT]$%%%%;F04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!N^"O^1YT/_K\3^=6_B/\ \E#U
MG_KJ/Y"JG@K_ )'G0_\ K\3^=6_B/_R4/6?^NH_D*P_Y??+]37_EU\SEZ***
MW,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KW;X'?\BS??\ 7R/Y5X37NWP._P"19OO^OD?RKDQO\)G3A?XB/4J*
M**\8],\(^.'_ ",-A_UQ_J:\NKU'XX?\C#8?]<?ZFO+J]S#?PHGDU_XC"BBB
MN@Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH Z3X?\ _(_:-_U\+2>/_P#DH.N?]?)_D*7X?_\ (_:-_P!?"TGC_P#Y*#KG
M_7R?Y"L/^7WR_4U_Y=?/]#G****W,@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]&^'/
M_(I>,?\ KS_H:\W3_5K]!7I'PY_Y%+QC_P!>?]#7FZ?ZM?H*PI_'/Y?D:S^"
M(ZBBBMS(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#T/X0_\AO5?^O)JX&Z_P"/RX_ZZ-_.N^^$/_(;
MU7_KR:N!NO\ C\N/^NC?SK"'\67R-9?PX_,BHHHK<R"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#TA_^2%1_]?5>;UZ0_P#R0J/_ *^J\WK"C]KU9K5Z>@4445N9!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4Z/_6Q_P"\*;3H_P#6Q_[P
MI >A?&#_ )#&B?\ 8-7^=>=UZ)\8/^0QHG_8-7^=>=UCA_X2-:W\1A1116YD
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !79_"K_ )*)8?[C_P J
MXRNS^%7_ "42P_W'_E65;^'+T-*7QHP?$W_(TZG_ -?#?SK*K5\3?\C3J?\
MU\-_.LJKA\*)ENPHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#T:?_D@UE_U_-_,UYS7HT_\ R0:R_P"OYOYF
MO.:PH?:]6:U>GH@HHHK<R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** -WP5_R/.A_]?B?SJW\1_P#DH>L_]=1_(54\
M%?\ (\Z'_P!?B?SJW\1_^2AZS_UU'\A6'_+[Y?J:_P#+KYG+T445N9!1110
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z-\.?^12\8_\
M7G_0UYNG^K7Z"O2/AS_R*7C'_KS_ *&O-T_U:_05A3^.?R_(UG\$1U%%%;F0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'H?PA_Y#>J_P#7DU<#=?\ 'Y<?]=&_G7??"'_D-ZK_ ->3
M5P-U_P ?EQ_UT;^=80_BR^1K+^''YD5%%%;F04444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 >D/_R0J/\ Z^J\WKTA_P#DA4?_ %]5YO6%'[7JS6KT] HHHK<R"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ IT?^MC_P!X4VG1_P"MC_WA2 ]"
M^,'_ "&-$_[!J_SKSNO1/C!_R&-$_P"P:O\ .O.ZQP_\)&M;^(PHHHK<R"BB
MB@ HHHH **MZ;IE[K%^ECI\!GN7!*Q@XR!UJ?5/#^JZ)>PV>I6;6]Q, 8T)!
MW<X[>]3S*]KZCL[7,VBM_4/!'B72M/>_OM*DAM8QEI"P.!^%8]E9W&HWL-G:
M1&6XG;9&@.-Q]*%*+5TQN+3LT045J:SX<UCP\8AJUDUKYN=FY@=WY5I0?#SQ
M;<P1SPZ-(T4BAE;>O(/XTG4@E>X<DKVL<S174/\ #CQA&A=M$EP.N'4_UKFI
MH9;:=X)XVBE0X9'&"*<9QEL[@XM;H9115_2=%U+7;LVNEVK7,X7<44@<?C3;
M25V))O1%"BNJ_P"%:^,?^@')_P!_%_QILGPX\7Q1M(^BR!%!9CYB\ ?C4>UI
M_P R^\KV<^S.7HHHK0@**** "BBM31O#FL>(6F72;)KHPX\S:P&W/3K2;25V
M-)O1&715B^L;G3+Z6RO8C#<PG;)&3G::KT)W **V[#PAX@U32_[3LM->:RPQ
M\T, ..O%0Z-X:UGQ#Y_]DV+W7D$"7:P&TGIU^AJ>>.NNP^678RJ*FO+2XL+R
M6TNHC%<0MMD0]5/I4-4(****8@HHHH **** "BBB@ HHHH *[/X5?\E$L/\
M<?\ E7&5V?PJ_P"2B6'^X_\ *LJW\.7H:4OC1@^)O^1IU/\ Z^&_G656KXF_
MY&G4_P#KX;^=957#X43+=A1115$A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'HT__ "0:R_Z_F_F:\YKT:?\ Y(-9
M?]?S?S-><UA0^UZLUJ]/1!1116YD%%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^ O!,?C2YO(I+Y[3R &RB!MV?K77V_P.W32K=ZV8EWD0[8P6=?4@]ZB^!?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ IT?\ K8_]X4VG1_ZV/_>%(#T+XP?\AC1/^P:O\Z\[KT3XP?\
M(8T3_L&K_.O.ZQP_\)&M;^(PHHHK<R"BBB@ HHHH ZWX975O9^/;*>ZGC@A5
M'R\C;5''K6]\5M0LK[QQI$]I=PSQ(B[GC<,%^?N17F9 (P1D4!0!@ "L723J
M>TOTL:JI:'(>U?%S5]-O_!=C#9W]M<2K<1DI%(&(&T\X%9GP@\9PZ:\VAZE<
M)%;-F2"21L*I[C)]:\H"J#D "@@$8(S4+#1]E[-E.N^?G1ZI\:M2L=1FTLV-
MY!<[-V[RG#8^N*[EY?#6O^!+;1M0UJVBCD@C#[+A58$8/>OG(*%Z #Z4FQ?[
MH_*D\*N2,4]AJO[SE;<]VTOP?\.]#O%OCK$-RT?S*LURK@$=\"N.^)_CR'Q/
M/'ING9.GV[;FD/'F/[>PKSK8G]T?E3J<,/:7/)W8I5KQY8JR)%N;A5"K<SJH
MZ!9& 'ZUW?PEU&"T\7R3ZA>)$GDD>9/)C\,FN I" >H!K6<%.+CW,X3<9)GO
M_B7PUX(\4:L=1O?$"),5"XBNT Q6,_PX^'H1B/$;9 _Y_$KQC8G]T?E1L3^Z
M/RK".'E%64V;.M%N[BCUGX1WNFZ1KNM)/?00P@A8GFD"[P/0GK7*^(;JWF^+
M%S=1SQO;F_1A*K94CCG/I7(E5/4 T8&,8XK544IN=]U8S=2\5&VQ[/\ &#6M
M/NM(T5K&]MKJ2"[$A2*0-P%[X[5JZK?^'OB'X'@MCK5O83 *VV5PNUP,$$$\
MBO PJCH /I054G)4'\*S6%2BDGJB_K#;;:W/HGPE?>%-#T&?P_9ZW;NT(/F2
MR.%#LXZJ3U%<C\(;RRT35O$$5_?VL/SJ%9I0%?D]#WKR38I_A'Y4%5( (''M
M2^JJTE?</K#NG;8]^O+#X>^*-976)[^".YC?]XIF""0CU!ZUS7Q5\<6&H64?
MA_1Y1)$A!GD3[F!T4>M>2[%/\(_*G  # &*<,,HR3;;ML$J[::2M<]P\ ZQI
MEK\*6M;C4+6*XVS?NGE ;DG'%8WP5U.PTUM;^VWL%MO=-GFR!=W7IFO)RJDY
M*@GZ4%0W4 _6F\,FI*_Q J[3B[;'IGAG4+*#XVW5[+=PI:DS8F9P$.5XYJC\
M8;VUU#Q5'+9W,5Q']GP6B<, <].*X':",8&/2@ #H /I5*BE-3OLK$.JW!Q\
M[GN?B[6-+N/A'':0ZC:R7'V6)?*64%LA1D8JG\-?'&E7'AYO#>O3)&44HC3'
M"/&>V>V*\7V+UVC/TKTSP=XJ\)G0/['\4:?#^[)VS^7G<#V)'-8U*"C3:U>M
MS:%9RG?;0[KPUIG@KP]XB2+1KA+O4;O<4VR!_+7O@CH*X;XW-N\868_NVF/_
M !XUT^E>)/A=X9EDO-(\I+DKCY$<L1Z#/2O*_&'B67Q7XAFU%U*18V0H>JJ*
MBA"3J\[OMU*K2BJ?*K?(P:***] X@HHHH **** "NS^%7_)1+#_<?^5<979_
M"K_DHEA_N/\ RK*M_#EZ&E+XT8/B;_D:=3_Z^&_G656KXF_Y&G4_^OAOYUE5
M</A1,MV%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >C3_P#)!K+_ *_F_F:\YKT:?_D@UE_U_-_,UYS6%#[7
MJS6KT]$%%%%;F04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!N^"O\ D>=#_P"OQ/YU;^(__)0]9_ZZC^0JIX*_Y'G0
M_P#K\3^=6_B/_P E#UG_ *ZC^0K#_E]\OU-?^77S.7HHHK<R"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O=O@=_R
M+-]_U\C^5>$U[M\#O^19OO\ KY'\JY,;_"9TX7^(CU*BBBO&/3/"/CA_R,-A
M_P!<?ZFO+J]1^.'_ ",-A_UQ_J:\NKW,-_"B>37_ (C"BBBN@Q"BBB@ J2."
M>8$Q02R =2B%L?E4==GX'^(+^"K2\@335N_M,@DW&3;MP,8Z5$W)*\5=E12;
MM)V.2^Q7G_/E=?\ ?EO\*#9W8&39W( [F%O\*^F_!?BIO%GAQM5>S%L0[IY8
M;=T]Z\ZN?C/=7XFTZ'P\'DF+0(%FR23D=,5RQQ%23:4-O,Z)4(12;EOY'D=%
M=[%\(?%-P@F86<!E.X1RRX89[8KG?$GA/5_"DR)JD "N/EDC.5/MFNF-6$G9
M/4Q=.<5=HQ**[6U^%GB2\TNVU"W^R/%<*K1J)#NP>E4_$?P^USPM8QW>H&V:
M.1PBK"^YB3[4E6IMV3U!TYI7L<M17<V/PD\57]E'=+%;0AQN$<SX;'TJ"W^%
M_B6XM+JX,=O"+7=YB2N0W SQ1[:G_,'LI]CC:*N:3I5]KE\EGIUN\T[]E'0>
MIKLI/@YXLC@,N+-R!G8LAW']*<JL(.TG8482DKI' TN#MW[3MSC=CC/UK=\/
M>&+W6/%T6AR0^5.C%IXY3M(5?O#ZU[#X[^'<FI^'=/T[P];VMNMM*9) YVY&
MW'7N:SJ8B$)*+ZEPHRE%R70\ HI\\+6]Q+ ^-\3E&QTR*96YD%%%%,04444
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M$?\ Y*'K/_74?R%5/!7_ "/.A_\ 7XG\ZM_$?_DH>L_]=1_(5A_R^^7ZFO\
MRZ^9R]%%%;F04444 %/C@FF!,4$L@'78A;'Y4RO:O@3_ ,@W6.!_KU_E65:I
M[.#E8TI0YY<IXW]BO/\ GRNO^_+?X5&\<D3;9(WC;T=2#^M>U7_QI_L[7;FQ
MFT4&&WG,32K+S@'KC%:_CG2M)\5^ 'UV"%4D6 7,,NW#8]#6'UB<6N>-DS7V
M$6GRRNT> );SRJ6BMYI%'4I&6'Z5'T.",&O=/@J=W@;4#CG[2_;_ &17&?\
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M[+UT**C7A;L8N3=*5^YY'1117><84444 %%%% !1110!Z-\.?^12\8_]>?\
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MK'P5=-K.K:C%-/$IV.?D1 >IY[UY].O"-#DOKJ=LZ4G6YNAC?&@0?VYX>/\
MR\;QC_=WC^M:WQE(7P;8,>@NHR?I7G7CKQ1'XI\<6TML<VEM*D4+?WOF&3^=
M>B_&=0?!=B&.U?M48)].*:BXNDF',I>T:-G4=,M/'O@>WM=+U+[/&50AHNQ
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MR:73L?\ #15UCU?_ -%UU]N/#WPJ\-2(;A7N6&X@D>9*_88]*\S^'>HS:O\
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MR_4(OI]37?PZ*VD^&_[,T)HK:1(]L3R+D _WB!U->2:K\&M8\NZU*ZUZWGE
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M[,T$D1F5&_Y9G/1?:N?\>W%SIWQ?%QIMJD]XHC:*(IN#.1Z=Z/@A_P CA/\
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M23WJS'J6H0QB.+4+N.,=$29@/RJM11:X"DEB2Q))Y)/>DHHIB"BBB@ HHHH
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M<:!$U*\51T59V _G55W>5R\CL[MU9CDG\:2BBR"Y9BU'4((A%#?W448Z(DS
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M$?\ Y*'K/_74?R%5/!7_ "/.A_\ 7XG\ZM_$?_DH>L_]=1_(5A_R^^7ZFO\
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M\^L__?LT?V->_P#/K/\ ]^S1SQ#D9G45H_V->_\ /K/_ -^S1_8U[_SZS_\
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M1SQ#D9G45H_V->_\^L__ '[-']C7O_/K/_W[-'/$.1F=16C_ &->_P#/K/\
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M(H^SP?\ /&/_ +Y%244 1?9X/^>,?_?(I?L\'_/&/_OD5)10!']G@_YXQ_\
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M@_YXQ_\ ?(H^SP?\\8_^^14E% $?V>#_ )XQ_P#?(H^SP?\ /&/_ +Y%244
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* (_L\'_ #QC_P"^11]G@_YXQ_\ ?(J2B@"/[/!_SQC_ .^11]G@_P">,?\
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M_?(J2B@"/[/!_P \8_\ OD4?9X/^>,?_ 'R*DHH C^SP?\\8_P#OD4?9X/\
MGC'_ -\BI** (_L\'_/&/_OD4?9X/^>,?_?(J2B@"/[/!_SQC_[Y%.5$3A%5
M1[#%.HH ****  44"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  44"B@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ****  44"B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M***  44"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***H:UK6G^'M)GU35+C[/90;?,EV,^W<P4<*"3R0.E-)
MMV0%^BN#_P"%S_#_ /Z#_P#Y)S__ !%'_"Y_A_\ ]!__ ,DY_P#XBMOJM?\
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M'_\ R3G_ /B*/JM?^1_<PYD=Y17!_P#"Y_A__P!!_P#\DY__ (BC_A<_P_\
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M'_\ R3G_ /B*/^%S_#__ *#_ /Y)S_\ Q%'U6O\ R/[F',CO**X/_A<_P_\
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M4?5:_P#(_N8<R.\HK@_^%S_#_P#Z#_\ Y)S_ /Q%'_"Y_A__ -!__P DY_\
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M /DG/_\ $4?5:_\ (_N8<R.\HK@_^%S_  __ .@__P"2<_\ \11_PN?X?_\
M0?\ _).?_P"(H^JU_P"1_<PYD=Y17!_\+G^'_P#T'_\ R3G_ /B*/^%S_#__
M *#_ /Y)S_\ Q%'U6O\ R/[F',CO**X/_A<_P_\ ^@__ .2<_P#\11_PN?X?
M_P#0?_\ ).?_ .(H^JU_Y']S#F1WE%<'_P +G^'_ /T'_P#R3G_^(H_X7/\
M#_\ Z#__ ))S_P#Q%'U6O_(_N8<R.\HK@_\ A<_P_P#^@_\ ^2<__P 11_PN
M?X?_ /0?_P#).?\ ^(H^JU_Y']S#F1WE%<'_ ,+G^'__ $'_ /R3G_\ B*/^
M%S_#_P#Z#_\ Y)S_ /Q%'U6O_(_N8<R.\HK@_P#A<_P__P"@_P#^2<__ ,11
M_P +G^'_ /T'_P#R3G_^(H^JU_Y']S#F1WE%<'_PN?X?_P#0?_\ ).?_ .(H
M_P"%S_#_ /Z#_P#Y)S__ !%'U6O_ "/[F',CO**X/_A<_P /_P#H/_\ DG/_
M /$4?\+G^'__ $'_ /R3G_\ B*/JM?\ D?W,.9'>45P?_"Y_A_\ ]!__ ,DY
M_P#XBC_A<_P__P"@_P#^2<__ ,11]5K_ ,C^YAS([RBN#_X7/\/_ /H/_P#D
MG/\ _$4?\+G^'_\ T'__ "3G_P#B*/JM?^1_<PYD=Y17!_\ "Y_A_P#]!_\
M\DY__B*/^%S_  __ .@__P"2<_\ \11]5K_R/[F',CO**X/_ (7/\/\ _H/_
M /DG/_\ $4?\+G^'_P#T'_\ R3G_ /B*/JM?^1_<PYD=Y17!_P#"Y_A__P!!
M_P#\DY__ (BC_A<_P_\ ^@__ .2<_P#\11]5K_R/[F',CO**X/\ X7/\/_\
MH/\ _DG/_P#$4?\ "Y_A_P#]!_\ \DY__B*/JM?^1_<PYD=Y17!_\+G^'_\
MT'__ "3G_P#B*/\ A<_P_P#^@_\ ^2<__P 11]5K_P C^YAS([RBN#_X7/\
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MQFG_ !8\$:IJ$%C::ZCW$[B.-7MY4#,>@W,@ _$UV=9SIS@[337J.]PHHHJ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH !10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =7\/_&UUX'\1
MQWT>Z2REPEW;@_ZQ/4?[0ZC\NA-?7NG:A:ZMIUO?V,RS6MP@DCD7HP-?"]>M
M?!CXC?\ "/:BOA_59L:5=O\ N9'/%O*?Y*W?T//K7E9E@_:Q]K#=?B7"5M#Z
M7HHHKYPV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#Z2^"WQ&_MRP7PWJLV=2M4_P!'E<\SQ#M[
MLOZCGL:]?KX6L;ZYTV^@O;.9X;F!Q)'(AY5AT-?7?P[\<6WCGPXEVNV._@Q'
M>0 _<?\ O#_9;J/Q':OG<RP?LY>UAL_P-H2OH==1117DEA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?0OP-^(4E_"OA/4W9YX$)L
M93SNC')C/^Z.GMQV&?GM$:1U1%+,QP% R2?2OJCX2?#Q?!VB_;[^,?VU>H#+
MG_E@G41CW[GWX[5YN:2IJC:>_0N%[GI%%%%?,FP4444 %%%% !1110 4444
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M[57BO[.B.GAS4@Z,I\\?>4CM7M5 !1110 4444 %%%% !1110 4444 %%%%
M'R7XKEUJ'X[:K)X>1GU07G[A54$D[1V/%=%J<'QL\36;:9J%G/';3<.0L<8Q
M[E3G%1>7(/VF+E_+?;]N^]M./NBOI>@#S3X=_#Q_ GA#4A=R++J-W$S2E.B
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M445]B<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 445WOPL^'\GC;7O,ND9='M&#7+]/,/:,'U/?T'U%9U:D:
M4'.6R&E<[;X(?#GSY(_%NKP_NT.=/B<?>8?\M2/0?P^_/85[]3(88[>".&&-
M8XHU"(BC 50,  =A3Z^3Q.(E7J.<C=*R"BBBN<84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%%  **!10 4444 -9%==KJ&'H1FA$2,815
M4>@&*=10 Q88D;<L:*WJ% -#PQ2$%XT8CH2H-/HH *8L,2MN6- WJ%&:?10
MQ8HT8LL:!CU(49I7C208=%8>C#-.HH :L:*NU44+Z <4B0Q1G*1HI]0H%/HH
M 8D,4;$I&BD]2% H>*.3&^-6QTW#-/HH 8T,;*%:-"HZ J,"G*JJH50 !T %
M+10 QX8I#EXT8^K*#3@H484  =A2T4 ,>*.0@O&C$="R@TXJK+M*@KTP1Q2T
M4 -2-(QA$51_LC%.HHH **** "BBB@ HHHH **** "BBB@ HHHH 9Y,6_?Y:
M;_[VT9I]%% !00",$9%%% $8MX5;<L,8/J%%2444 %,2&*,Y2-%)[A0*?10
M4UXXY !(BMCIN&:=10 BJJ*%4  =@*:\4<F-\:-C^\,T^B@!%54&%  ] *"
MPP0"#V-+10 Q(8HSE(D4^H4"GT44 ,:&)VW/$C'U*@T\  8 P*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ H)P,GI17.>.]='ASP5JFI9'F1PD1@
MGJQX'\Z /"KS/Q#_ &@?(QOM+638PZ@QQ\$_CFHM))^&WQY>T*&.QN)O*0=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 445)!!+=7$=O!&TLTK!$1!DLQ.  /7- &IX7
M\-W_ (LU^WTC3TS+*<NY'RQ(/O.WL/\  =Z^P_#7AVP\*Z#;:1IT>V&%>6/W
MI&/5F]R?\.@KF_A?X B\$: #<*CZO=@-=2#G;Z1@^@_4_A7=5\QF&,]O/EC\
M*_$VA&P4445YQ84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 "B@44 %%%% !1110 $9!%?-/Q BU[X:?$.UUBUU"]FTN>;SHTD
MF9D']Y",X]<5]+5SGCCPG;>,?"]UI<ZCS"I:"0CE)!T/]* *FJ^/=,LOA\WB
MJ*57ADA#0KGEG(X7ZYKRCX-Z7KOBWQ)<^*-6U&^-E#*6CC,S!))#VQG&!Q7F
MVGZ=XBUC5K;P TS"."[8&+/RQMGYFKZZ\/:%:>&]"M-)LD"PVZ!<]V/<GWH
M\'\9^+O%'CCXB2>$?#UX]I;*YC78Q7=@99B1SCK61JK>.O@]K=G+=:P][;3G
M)_>,Z. >5^;D&OHZ>ST+1O-U>:VLK5HE+/<F-5('?FOG;Q9K%[\9O'MII>B6
MSG3;5MHD/3;GYG;T]J /1/B=\3KC1?!.EW>C_NKS5HEDC<C/EH1DGZ\UYRW@
MKXB-X6_X3'^WYLF/[2;?SWWA>N<=/PKZ*B\-Z4-+L["XLK>YCM(EBC\Z,-@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K@_C/_R2;6_^V'_H^.N\K@_C/_R2;6_^V'_H^.M\
M+_'AZK\Q2V/DJBBBOL3G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !10** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH !10** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M !10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH !10** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH !10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^_E &MN'J*-P]163_P ([:?\])_^_E'_  CMI_STG_[^4 :VX>HHW#U%9/\
MPCMI_P ])_\ OY1_PCMI_P ])_\ OY0!K;AZBC</45D_\([:?\])_P#OY1_P
MCMI_STG_ ._E &MN'J*-P]163_PCMI_STG_[^4?\([:?\])_^_E &MN'J*-P
M]163_P ([:?\])_^_E'_  CMI_STG_[^4 :VX>HHW#U%9/\ PCMI_P ])_\
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M^_E &MN'J*-P]163_P ([:?\])_^_E'_  CMI_STG_[^4 :VX>HHW#U%9/\
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MRC_A';3_ )Z3_P#?R@#6W#U%&X>HK)_X1VT_YZ3_ /?RC_A';3_GI/\ ]_*
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MU%&X>HK)_P"$=M/^>D__ '\H_P"$=M/^>D__ '\H UMP]11N'J*R?^$=M/\
MGI/_ -_*/^$=M/\ GI/_ -_* -;</44;AZBLG_A';3_GI/\ ]_*/^$=M/^>D
M_P#W\H UMP]11N'J*R?^$=M/^>D__?RC_A';3_GI/_W\H UMP]11N'J*R?\
MA';3_GI/_P!_*/\ A';3_GI/_P!_* -;</44;AZBLG_A';3_ )Z3_P#?RC_A
M';3_ )Z3_P#?R@#6W#U%&X>HK)_X1VT_YZ3_ /?RC_A';3_GI/\ ]_* -;</
M44;AZBLG_A';3_GI/_W\H_X1VT_YZ3_]_* -;</44;AZBLG_ (1VT_YZ3_\
M?RC_ (1VT_YZ3_\ ?R@#6W#U%&X>HK)_X1VT_P">D_\ W\H_X1VT_P">D_\
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M (1VT_YZ3_\ ?R@#6W#U%&X>HK)_X1VT_P">D_\ W\H_X1VT_P">D_\ W\H
MUMP]11N'J*R?^$=M/^>D_P#W\H_X1VT_YZ3_ /?R@#6W#U%&X>HK)_X1VT_Y
MZ3_]_*/^$=M/^>D__?R@#6W#U%&X>HK)_P"$=M/^>D__ '\H_P"$=M/^>D__
M '\H UMP]11N'J*R?^$=M/\ GI/_ -_*/^$=M/\ GI/_ -_* -;</44;AZBL
MG_A';3_GI/\ ]_*/^$=M/^>D_P#W\H UMP]11N'J*R?^$=M/^>D__?RC_A';
M3_GI/_W\H UMP]11N'J*R?\ A';3_GI/_P!_*/\ A';3_GI/_P!_* -;</44
M;AZBLG_A';3_ )Z3_P#?RC_A';3_ )Z3_P#?R@#6W#U%&X>HK)_X1VT_YZ3_
M /?RC_A';3_GI/\ ]_* -;</44;AZBLG_A';3_GI/_W\H_X1VT_YZ3_]_* -
M;</44;AZBLG_ (1VT_YZ3_\ ?RC_ (1VT_YZ3_\ ?R@#6W#U%&X>HK)_X1VT
M_P">D_\ W\H_X1VT_P">D_\ W\H UMP]11N'J*R?^$=M/^>D_P#W\H_X1VT_
MYZ3_ /?R@#6W#U%&X>HK)_X1VT_YZ3_]_*/^$=M/^>D__?R@#6W#U%&X>HK)
M_P"$=M/^>D__ '\H_P"$=M/^>D__ '\H UMP]11N'J*R?^$=M/\ GI/_ -_*
M/^$=M/\ GI/_ -_* -;</44;AZBLG_A';3_GI/\ ]_*/^$=M/^>D_P#W\H U
MMP]11N'J*R?^$=M/^>D__?RC_A';3_GI/_W\H UMP]11N'J*R?\ A';3_GI/
M_P!_*/\ A';3_GI/_P!_* -;</44;AZBLG_A';3_ )Z3_P#?RC_A';3_ )Z3
M_P#?R@#6W#U%&X>HK)_X1VT_YZ3_ /?RC_A';3_GI/\ ]_* -;</44;AZBLG
M_A';3_GI/_W\H_X1VT_YZ3_]_* -;</44;AZBLG_ (1VTZ>9/_W\H_X1VT_Y
MZ3_]_* -;</44;AZBLG_ (1VT_YZ3_\ ?RC_ (1VT_YZ3_\ ?R@#6W#U%&X>
MHK)_X1VT_P">D_\ W\H_X1VT_P">D_\ W\H UMP]11N'J*R?^$=M/^>D_P#W
M\H_X1VT_YZ3_ /?R@#6W#U%&X>HK)_X1VT_YZ3_]_*/^$=M/^>D__?R@#6W#
MU%&X>HK)_P"$=M/^>D__ '\H_P"$=M/^>D__ '\H UMP]11N'J*R?^$=M/\
MGI/_ -_*/^$=M/\ GI/_ -_* -;</44;AZBLG_A';3_GI/\ ]_*/^$=M/^>D
M_P#W\H UMP]11N'J*R?^$=M/^>D__?RC_A';3_GI/_W\H UMP]11N'J*R?\
MA';3_GI/_P!_*/\ A';3_GI/_P!_* -;</44;AZBLG_A';3_ )Z3_P#?RC_A
M';3_ )Z3_P#?R@#6W#U%&X>HK)_X1VT_YZ3_ /?RC_A';3_GI/\ ]_* -;</
M44;AZBLG_A';3_GI/_W\H_X1VT_YZ3_]_* -;</44;AZBLG_ (1VT_YZ3_\
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M %% HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ %% HH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ %% HH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ %% HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ %% HH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ %% HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "O!_P!I+_F6?^WK_P!HU[Q7@_[27_,L_P#;U_[1KNRW
M_>H_/\F3/X3P:BBBOJC **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O!_VDO^99_[>O\ VC7O%>#_ +27
M_,L_]O7_ +1KNRW_ 'J/S_)DS^$\&HHHKZHP"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^C/@G\1O[5M$\+ZM-_IUN
MG^ARN>9HQ_!_O*/S'TKV6OA2TN[BPO(;NUE>&XA<21R(<%6!R"*^N/AOX[M_
M'/AY9V*1ZG;@)>0CLW9P/[K?IR.U?.YG@_9OVL-GOY&L)7T.SHHHKR30****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !16!K_C;P[X7GB@UK4XK265=R*X8DCUX%8_\ PM[P'_T,5O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M([*%[>];7P_\=^(?"WC;_A#?%<SS1E_*1Y#DQMV(/<&@#Z#HKY[_ &A=4O\
M3?$VA-9W=Q#_ *.S%8Y&4,0_< \UC>(?#'Q"N_"G_"::AKCJBQ";[-'*RM''
MV.!Q0!].T5YE\$O%FH>)O"4BZG*9KBTE\L2MU9<<9]Z]-H **** "BBB@ HH
MHH *X/XQ65U?_#B_M[.VEN)V9,1Q(68\^@KO** /,/@5IU[IG@5X+^TGM9?M
M+'9,A4XP.<&O3Z** .:\<^#[3QMX;FTNY;RWSOAE_N..AKPW2S\4/A69=.M=
M,>_LF8E%$9F0>XV\C-?2]% 'S/#X0\=_%?Q'!?>)(9+&PC.#YB% BYY"J><F
MOH_3[&#3-/M[*V0)! @C11Z 59HH \6_:"TG4M5T[2ET^PN;LK(Q801E]O'?
M%>@^#]-6;X;Z1INI6IVM81QSP2@@_=Y!%=110!QO_"I_ G_0M6?_ (]_C7AG
M@_P"]Q\6C:ZIX<N3HGFS#$L+"/: =O/UQWKZEHH \=^+GPNN=;LM/OO#<*K<
M:?'Y0ME. 4'(QGN*X2]UGXI^*]$C\*3:/.D9 BDF:!D,@']YCQBOIVB@#S#2
M/A/':?"BY\+S3+]MNP99)>H67M^ KS#1+GXF?"]+G1[317N8)'+*1 TJ@]-R
ME?PKZ>HH \(^$_P\UUO%4GC#Q-&T,^6>*.3[[,PY)'88)%3?%GX=ZT?$L7C+
MPP&DND*M+$GWE91PR^N>]>XT4 ?,>L2?$OXIFUTB]T9K2WB<,S-"T2D_WB6Z
M_A7T)X5T&/PSX8L-'C?>+6((7_O'N:V** .3^)/ANY\5^!K_ $JS8"Y<*\8)
MP&*G./QKR/P'KOC+PGH%SX6B\'7<UXTC""X*%(U)ZECC!_.OHBB@#YN^%.B>
M(O#GQ8D?6M*NT,\<D4DXB)CW,0<[NF.*M?$+0M7NOCC87MOI=Y-:J\&9DA)0
M8///3BOH>B@#SCXV6%YJ/PZEM[&UFN9C-&?+A0LV,^@J+X6:#++\)%T?5+66
MW:82H\<R%6 ).#@_G7IE% 'R_8Z9\0?A+XANXM(TV6]M)R0-L1ECD'\+';T-
M9'C3PYX^UG4[;7=:TRYFN+O[L4$181(.@P.G6OK>B@"O8J5T^V5@01$H(/;@
M58HHH **** "BBB@ HHHH **** "BBB@ HHHH *^=/C-H6KZA\2+&XLM+O+B
M!5CS)%"S*/F'<5]%T4 86OZ*=?\ !5WHY.QKJT\K)[' KYV\+?\ "R/AQJ%Y
MINGZ%+-]H(!WPL\8(Z,&'%?4U% 'RO8^%?&$/Q6TW4-;T^ZFN)KE)[B9(RR+
MD]V'' KJOCOHFJZGXST*:PTV[NHHX '>&(N%/F$X)'2O?J* //\ XC65W=_"
M.ZM+:VFFN3;Q@11H6;/':LSX$Z;?:9X%F@O[.>UE-RY"31E"1ZX->IT4 ?/'
M@#0M7M?CQ=7UQIEY%:,;C$SPL$Y7CGIS6O\ %CX9:S=^(H_%GAA=UTN'FC4X
M?<O1AZ_2O<** /F?5-=^*GCK3U\.S:-+;QR8663[.T7F ?WF/'Y5ZGX<\"_\
M(9\,;_3$'GW\\+O,T8R6<CA1ZXZ5Z+10!X%^S_HNJZ7KFLOJ&FW=HCQ+M:>(
MH"<G@9KWVBB@ HHHH **** "BBB@ HHHH *\'_:2_P"99_[>O_:->\5X/^TE
M_P RS_V]?^T:[LM_WJ/S_)DS^$\&HHHKZHP"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#5\.>(;_ ,+Z
M[;:MITFV>%N5/W9%[JWJ"*^P_"WB:P\6^'[?5]/;]W*,/&3\T3CJC>X_48/>
MOBN"&6YGC@@C:261@B(@R68G  'K7UK\+O Q\$>&/)N'+:C=D2W6&RJ''"#M
MP.I[G/;%>-F\*?(I/XC2G<[BBBBO -0HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU^-5]<>*?B-IOA6S?B(!!M/!D?U^F*7X&ZG<>'/'>I>%;\E6F! !/"R)_B*
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MKWBO!_VDO^99_P"WK_VC7=EO^]1^?Y,F?PG@U%%%?5& 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV?Q'U.;6/V?]&U"X_P!;/Y+-]<X_I3_@GX \/ZEX2_M;5=.@O;F2?*-,N?+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_H8S_P"# _X5]"44 >-?$3P%XV\5^'?#^F6]Q;2_9;=3>F:?!DG  SG'/?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>#_M)?\ ,L_]O7_M&O>*\'_:2_YEG_MZ
M_P#:-=V6_P"]1^?Y,F?PG@U%%%?5& 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%%  **!10 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %8/B3P9X?\7_9?[=T_[7]E
MW^3^^DCV[L;ON,,YVCKZ5O45492@^:+LP.#_ .%,?#__ * '_DY/_P#%T?\
M"F/A_P#] #_R<G_^+KO**U^M5_YW][%RHX/_ (4Q\/\ _H ?^3D__P 71_PI
MCX?_ /0 _P#)R?\ ^+KO**/K5?\ G?WL.5'!_P#"F/A__P! #_R<G_\ BZ/^
M%,?#_P#Z '_DY/\ _%UWE%'UJO\ SO[V'*C@_P#A3'P__P"@!_Y.3_\ Q='_
M  ICX?\ _0 _\G)__BZ[RBCZU7_G?WL.5'!_\*8^'_\ T /_ "<G_P#BZ/\
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M_P"@!_Y.3_\ Q==Y11]:K_SO[V'*C@_^%,?#_P#Z '_DY/\ _%T?\*8^'_\
MT /_ "<G_P#BZ[RBCZU7_G?WL.5'!_\ "F/A_P#] #_R<G_^+H_X4Q\/_P#H
M ?\ DY/_ /%UWE%'UJO_ #O[V'*C@_\ A3'P_P#^@!_Y.3__ !='_"F/A_\
M] #_ ,G)_P#XNN\HH^M5_P"=_>PY4<'_ ,*8^'__ $ /_)R?_P"+H_X4Q\/_
M /H ?^3D_P#\77>44?6J_P#._O8<J.#_ .%,?#__ * '_DY/_P#%T?\ "F/A
M_P#] #_R<G_^+KO**/K5?^=_>PY4<'_PICX?_P#0 _\ )R?_ .+H_P"%,?#_
M /Z '_DY/_\ %UWE%'UJO_._O8<J.#_X4Q\/_P#H ?\ DY/_ /%T?\*8^'__
M $ /_)R?_P"+KO**/K5?^=_>PY4<'_PICX?_ /0 _P#)R?\ ^+H_X4Q\/_\
MH ?^3D__ ,77>44?6J_\[^]ARHX/_A3'P_\ ^@!_Y.3_ /Q='_"F/A__ - #
M_P G)_\ XNN\HH^M5_YW][#E1P?_  ICX?\ _0 _\G)__BZ/^%,?#_\ Z '_
M ).3_P#Q==Y11]:K_P [^]ARHX/_ (4Q\/\ _H ?^3D__P 71_PICX?_ /0
M_P#)R?\ ^+KO**/K5?\ G?WL.5'!_P#"F/A__P! #_R<G_\ BZ/^%,?#_P#Z
M '_DY/\ _%UWE%'UJO\ SO[V'*C@_P#A3'P__P"@!_Y.3_\ Q='_  ICX?\
M_0 _\G)__BZ[RBCZU7_G?WL.5'!_\*8^'_\ T /_ "<G_P#BZ/\ A3'P_P#^
M@!_Y.3__ !==Y11]:K_SO[V'*C@_^%,?#_\ Z '_ ).3_P#Q='_"F/A__P!
M#_R<G_\ BZ[RBCZU7_G?WL.5'!_\*8^'_P#T /\ R<G_ /BZ/^%,?#__ * '
M_DY/_P#%UWE%'UJO_._O8<J.#_X4Q\/_ /H ?^3D_P#\71_PICX?_P#0 _\
M)R?_ .+KO**/K5?^=_>PY4<'_P *8^'_ /T /_)R?_XNC_A3'P__ .@!_P"3
MD_\ \77>44?6J_\ ._O8<J.#_P"%,?#_ /Z '_DY/_\ %T?\*8^'_P#T /\
MR<G_ /BZ[RBCZU7_ )W][#E1P?\ PICX?_\ 0 _\G)__ (NC_A3'P_\ ^@!_
MY.3_ /Q==Y11]:K_ ,[^]ARHX/\ X4Q\/_\ H ?^3D__ ,71_P *8^'_ /T
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M ,77>44?6J_\[^]ARHX/_A3'P_\ ^@!_Y.3_ /Q='_"F/A__ - #_P G)_\
MXNN\HH^M5_YW][#E1P?_  ICX?\ _0 _\G)__BZ/^%,?#_\ Z '_ ).3_P#Q
M==Y11]:K_P [^]ARHX/_ (4Q\/\ _H ?^3D__P 71_PICX?_ /0 _P#)R?\
M^+KO**/K5?\ G?WL.5'!_P#"F/A__P! #_R<G_\ BZ/^%,?#_P#Z '_DY/\
M_%UWE%'UJO\ SO[V'*C@_P#A3'P__P"@!_Y.3_\ Q='_  ICX?\ _0 _\G)_
M_BZ[RBCZU7_G?WL.5'!_\*8^'_\ T /_ "<G_P#BZ/\ A3'P_P#^@!_Y.3__
M !==Y11]:K_SO[V'*C@_^%,?#_\ Z '_ ).3_P#Q='_"F/A__P! #_R<G_\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !10**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH !10** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH !10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !10** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH H7E[=6[JL-D\X(R2IZ56_M74/^@3+_ -]5L"B@
M#'_M74/^@3+_ -]4?VKJ'_0)E_[ZK8HH Q_[5U#_ *!,O_?5']JZA_T"9?\
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M#'_M74/^@3+_ -]4?VKJ'_0)E_[ZK8HH Q_[5U#_ *!,O_?5']JZA_T"9?\
MOJMBB@#'_M74/^@3+_WU1_:NH?\ 0)E_[ZK8HH Q_P"U=0_Z!,O_ 'U1_:NH
M?] F7_OJMBB@#'_M74/^@3+_ -]4?VKJ'_0)E_[ZK8HH Q_[5U#_ *!,O_?5
M']JZA_T"9?\ OJMBB@#'_M74/^@3+_WU1_:NH?\ 0)E_[ZK8HH Q_P"U=0_Z
M!,O_ 'U1_:NH?] F7_OJMBB@#'_M74/^@3+_ -]4?VKJ'_0)E_[ZK8HH Q_[
M5U#_ *!,O_?5']JZA_T"9?\ OJMBB@#'&J7YS_Q*I>!_>H_M74/^@3+_ -]5
ML44 8_\ :NH?] F7_OJC^U=0_P"@3+_WU6Q10!C_ -JZA_T"9?\ OJC^U=0_
MZ!,O_?5;%% &/_:NH?\ 0)E_[ZH_M74/^@3+_P!]5L44 8_]JZA_T"9?^^J/
M[5U#_H$R_P#?5;%% &/_ &KJ'_0)E_[ZH_M74/\ H$R_]]5L44 8_P#:NH?]
M F7_ +ZH_M74/^@3+_WU6Q10!C_VKJ'_ $"9?^^J/[5U#_H$R_\ ?5;%% &/
M_:NH?] F7_OJC^U=0_Z!,O\ WU6Q10!C_P!JZA_T"9?^^J/[5U#_ *!,O_?5
M;%% &/\ VKJ'_0)E_P"^J/[5U#_H$R_]]5L44 8_]JZA_P! F7_OJC^U=0_Z
M!,O_ 'U6Q10!C_VKJ'_0)E_[ZH_M74/^@3+_ -]5L44 8_\ :NH?] F7_OJC
M^U=0_P"@3+_WU6Q10!C_ -JZA_T"9?\ OJC^U=0_Z!,O_?5;%% &/_:NH?\
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M5L44 8_]JZA_T"9?^^J/[5U#_H$R_P#?5;%% &/_ &KJ'_0)E_[ZH_M74/\
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M^U=0_P"@3+_WU6Q10!C_ -JZA_T"9?\ OJC^U=0_Z!,O_?5;%% &/_:NH?\
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M5L44 8_]JZA_T"9?^^J/[5U#_H$R_P#?5;%% &/_ &KJ'_0)E_[ZH_M74/\
MH$R_]]5L44 8_P#:NH?] F7_ +ZH_M74/^@3+_WU6Q10!C_VKJ'_ $"9?^^J
M/[5U#_H$R_\ ?5;%% &/_:NH?] F7_OJC^U=0_Z!,O\ WU6Q10!C_P!JZA_T
M"9?^^J/[5U#_ *!,O_?5;%% &/\ VKJ'_0)E_P"^J/[5U#_H$R_]]5L44 8_
M]JZA_P! F7_OJC^U=0_Z!,O_ 'U6Q10!C_VKJ'_0)E_[ZH_M74/^@3+_ -]5
ML44 8_\ :NH?] F7_OJC^U=0_P"@3+_WU6Q10!C_ -JZA_T"9?\ OJC^U=0_
MZ!,O_?5;%% &/_:NH?\ 0)E_[ZH_M74/^@3+_P!]5L44 8_]JZA_T"9?^^J/
M[5U#_H$R_P#?5;%% &/_ &KJ'_0)E_[ZH_M74/\ H$R_]]5L44 8_P#:NH?]
M F7_ +ZH_M74/^@3+_WU6Q10!C_VKJ'_ $"9?^^J/[5U#_H$R_\ ?5;%% &/
M_:NH?] F7_OJC^U=0_Z!,O\ WU6Q10!C_P!JZA_T"9?^^J/[5U#_ *!,O_?5
M;%% &/\ VKJ'_0)E_P"^J/[5U#_H$R_]]5L44 8_]JZA_P! F7_OJC^U=0_Z
M!,O_ 'U6Q10!C_VKJ'_0)E_[ZH_M74/^@3+_ -]5L44 8_\ :NH?] F7_OJC
M^U=0_P"@3+_WU6Q10!C_ -JZA_T"9?\ OJC^U=0_Z!,O_?5;%% &/_:NH?\
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MK8HH Q_[5U#_ *!,O_?5']JZA_T"9?\ OJMBB@#'_M74/^@3+_WU1_:NH?\
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M HHHH **** "BBB@ HHHH !10** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !
M10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH !10** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH !10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !10** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ %% HH **** "BBB@ HHHH **** /D2
MX\/WOBCXRZAI.GWHLKF:XD*SDD;<+D].>U=P/V>]?NY%74_%230 Y*CS&/X;
MN*M^&? _B6R^.4FNW.E21Z8996%P67&"A [YZU[Q0!S.@^&M%\#>$GL(ABSC
M0M<2OU?U)K$\%67PXU&[O9/#%E933)CSSY9;&>GWOQZ5WES;Q7=K+;3*&BE0
MHP/<&OG:Y^&GCWP#XBGO?!;M<6\Q(7RRN0O8,K<&@#.^)NFV?A[XRZ8VBQK
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MI)KB&WC\R::.-/[SL /S- $E%1PSPW$?F02I*G]Y&##\Q3V944LQ 4=23TH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLES=2I#!&-SR.<!1ZDU4TK7M)UU)'TK4;:\6,X<P2!MI]\4 :-%%% !1110
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MBI_B#\4O# \"WB:?J=O>75Y%Y<4,;9(S_>':N7^$&AW6G_"[Q'J4ZE$OD/E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'0"O#O'7Q&GUOX@QWVVY2PL)P%M#+P2AY/'KBM_X)_\ )5]5_P"VW_H1JO\
M$FUMX_CG:11V\*1-)#N14 4YQG(H ]GT+XGZ3JW@B?Q5=Q2:?90R-&RR,'8D
M>F.I/I7+O\>[?R6O(?"FK2Z<K8^V#A,>O2NK\?0>#-/\+ >);6%=-24,D$0*
M;I,'& N.:\RU+X@MJ?P_O]&\*>#;F+1XK1T:>?A$C[L#W/>@#U;1_B#I&O>$
M+WQ#IV^6*SC=Y8#\K@JN<?\ UZ^;X?B?,?BA%XLO([FXM878QVAEY12I  /3
MO7H_[.*+)HVLQNH9&D 96&01CN*Y70K2U?\ :-^S-:PFW^TR#R3&-GW#VZ4
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MG?LV@#2]:..?-3^1KK?B5X)T!OAO?I#IMM;O8P;[>2- K*1ZGJ?QKD_V;?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444  HH%% !1110!YW\;HI)OAG>)%&\CF6/"HI)Z^U4_@
M-#+!\.PDT4D;?:7^5U*GMZUZ@0#UH  Z"@#YL^$%I<P_%[4Y);:9$9Y\,T9
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;CGU]/RH Q?AK\1/%5IX[C\(>)9'NVD=HM\AR\;@9Z]QQ61\4&5/C_9,[!5
MMLD].E>I>!?A1;>%=4EUK4;Y]3U>7.9W'"D]2/>JOQ+^$2^.=2AU2SU!;*^1
M0C%U)5@.G3G- %KXU,&^%E_@@X9 <&N(\ 6\UU^S]K<4 )?,IP/0 $UU$'PH
MU*/X8WGA:;6TFNKF<3?:)%8JOM@\]JZ+X<^"9O!7A=]'O+J&\+RLY9$(4@]L
M&@#SK]F[4K1-.UC3FE5;MYUE5">67;CC\:]/G\?^%[;Q*^B3:C$FH#:""."3
MT&[U]J\]\2_ %+O5I+_PWJYTSS6+/$P.%S_=*\XJ]X)^!UIX>U>/5]9O_P"T
MKR)MT8"D(&]3GDF@#UVBBB@ HHHH **** "BBB@#Q/7?^1@U+_KZE_\ 0S6?
M6AKO_(P:E_U]2_\ H9K/K[2E\$?0_,:_\67J_P PHHHJS(**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "K-A?3Z;>Q7=L^V6,Y'H?
M4'V-5JZ;P?X<.L7GVFY3_0H3\V?^6C?W?IZ__7K*O4A3IN4]CHPM&K6K1A2^
M+\O,],TV]_M'3;>\\MH_.0-L8<BK5     P!T%%?'2:;;1^DQ344I.["BBBD
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >)Z[_ ,C!J7_7
MU+_Z&:SZT-=_Y&#4O^OJ7_T,UGU]I2^"/H?F-?\ BR]7^844459D%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %>E^"?#?V& :G=I_I,J_
MNE(YC4]_J?Y?C6%X*\-_VE<C4+M,VD+?(I'^L8?T'^>]>G5XF9XS_ES#Y_Y'
MU.19;MB:J]/\_P#+[PHHHKPSZH**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ %% HH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q/7?\
MD8-2_P"OJ7_T,UGUH:[_ ,C!J7_7U+_Z&:SZ^TI?!'T/S&O_ !9>K_,****L
MR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *UO#VARZ[J2P+E85
M^::3^ZO^)[50L[2:^NXK6W0O+(VU0/\ /2O8M"T:'0]-2UBPSGYI9,??;U^G
MI7!C\6J$+1^)_P!7/7RG+GBZO-+X%OY^1>MK>*TMH[>! D4:[54=A4M%%?,-
MMN[/NTDE9!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 "B@44 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\!W_ ,*/["U?_H%7W_@._P#A1[6'\R#V%7^5_<S/HZFM#^PM7_Z!5]_X#O\
MX5U/@WPI*;K^T-2MWB6%OW44JE26_O$'L.WO]*RK8JG2@YMG1AL#6KU5346K
M];;&UX-\-_V3:?;+E/\ 3)EZ$?ZM?3Z^M=3117RM:K*K-SENS[_#8>&'I*E3
MV04445D;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%%  **!10 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M  **!10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%%  **!10 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%%  **9YB#^-?SI?,C_OK^= #J*;YD?]]?SH\R/^^OYT .HI
MOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YD?]]?SH\R/^^OYT .
MHIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YD?]]?SH\R/^^OYT
M .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YD?]]?SH\R/^^O
MYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YB?WU_.CS$_O
MK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C
M_OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/
M,C_OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\
MZ/,C_OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?
M7\Z/,C_OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'
M_?7\Z/,C_OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^
M8G]]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^=
M #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/
M^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]
M?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*
M;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OY
MT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\
MR/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?
M]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .H
MIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\
MOK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?S
MH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1
M_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^=
M #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/
M^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]
M?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*
M;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OY
MT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\
MR/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?
M]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .H
MIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\
MOK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?S
MH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1
M_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^=
M #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/
M^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]
M?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*
M;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OY
MT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\
MR/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?
M]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .H
MIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\
MOK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?S
MH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1
M_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF)_?7\Z/,C_OK^= #J
M*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_OK^=
M#J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_OK^
M= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_O
MK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C
M_OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS$_OK^= #J*;YD?\ ?7\Z
M/,C_ +Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YD?\ ?7\Z/,C_ +Z_G0 ZBF^9
M'_?7\Z/,C_OK^= #J*;YD?\ ?7\Z/,C_ +Z_G0 ZBF^9'_?7\Z/,C_OK^= #
MJ*;YD?\ ?7\Z/,C_ +Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YD?\ ?7\Z/,C_
M +Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YD?\ ?7\Z/,C_ +Z_G0 ZBF^9'_?7
M\Z/,C_OK^= #J*;YD?\ ?7\Z/,C_ +Z_G0 ZBF^9'_?7\Z ZD\,#]#0 ZBBB
M@#+DT"QED9V$FYCDX<TW_A';#TE_[[-%% !_PCMAZ2_]]FC_ (1VP])?^^S1
M10 ?\([8>DO_ 'V:/^$=L/27_OLT44 '_".V'I+_ -]FC_A';#TE_P"^S110
M ?\ ".V'I+_WV:/^$=L/27_OLT44 '_".V'I+_WV:/\ A';#TE_[[-%% !_P
MCMAZ2_\ ?9H_X1VP])?^^S110 ?\([8>DO\ WV:/^$=L/27_ +[-%% !_P (
M[8>DO_?9H_X1VP])?^^S110 ?\([8>DO_?9H_P"$=L/27_OLT44 '_".V'I+
M_P!]FC_A';#TE_[[-%% !_PCMAZ2_P#?9H_X1VP])?\ OLT44 '_  CMAZ2_
M]]FC_A';#TE_[[-%% !_PCMAZ2_]]FC_ (1VP])?^^S110 ?\([8>DO_ 'V:
M/^$=L/27_OLT44 '_".V'I+_ -]FC_A';#TE_P"^S110 ?\ ".V'I+_WV:/^
M$=L/27_OLT44 '_".V'I+_WV:/\ A';#TE_[[-%% !_PCMAZ2_\ ?9H_X1VP
M])?^^S110 ?\([8>DO\ WV:/^$=L/27_ +[-%% !_P ([8>DO_?9H_X1VP])
M?^^S110 ?\([8>DO_?9H_P"$=L/27_OLT44 '_".V'I+_P!]FC_A';#TE_[[
M-%% !_PCMAZ2_P#?9H_X1VP])?\ OLT44 '_  CMAZ2_]]FC_A';#TE_[[-%
M% !_PCMAZ2_]]FC_ (1VP])?^^S110 ?\([8>DO_ 'V:/^$=L/27_OLT44 '
M_".V'I+_ -]FC_A';#TE_P"^S110 ?\ ".V'I+_WV:/^$=L/27_OLT44 '_"
M.V'I+_WV:/\ A';#TE_[[-%% !_PCMAZ2_\ ?9H_X1VP])?^^S110 ?\([8>
MDO\ WV:/^$=L/27_ +[-%% !_P ([8>DO_?9H_X1VP])?^^S110 ?\([8>DO
M_?9H_P"$=L/27_OLT44 '_".V'I+_P!]FC_A';#TE_[[-%% !_PCMAZ2_P#?
M9H_X1VP])?\ OLT44 '_  CMAZ2_]]FC_A';#TE_[[-%% !_PCMAZ2_]]FC_
M (1VP])?^^S110 ?\([8>DO_ 'V:/^$=L/27_OLT44 '_".V'I+_ -]FC_A'
M;#TE_P"^S110 ?\ ".V'I+_WV:/^$=L/27_OLT44 '_".V'I+_WV:/\ A';#
MTE_[[-%% !_PCMAZ2_\ ?9H_X1VP])?^^S110 ?\([8>DO\ WV:/^$=L/27_
M +[-%% !_P ([8>DO_?9H_X1VP])?^^S110 ?\([8>DO_?9H_P"$=L/27_OL
MT44 '_".V'I+_P!]FC_A';#TE_[[-%% !_PCMAZ2_P#?9H_X1VP])?\ OLT4
M4 '_  CMAZ2_]]FC_A';#TE_[[-%% !_PCMAZ2_]]FC_ (1VP])?^^S110 ?
M\([8>DO_ 'V:/^$=L/27_OLT44 '_".V'I+_ -]FC_A';#TE_P"^S110 ?\
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M110 ?\([8>DO_?9H_P"$=L/27_OLT44 '_".V'I+_P!]FC_A';#TE_[[-%%
M!_PCMAZ2_P#?9H_X1VP])?\ OLT44 '_  CMAZ2_]]FC_A';#TE_[[-%% !_
MPCMAZ2_]]FC_ (1VP])?^^S110 ?\([8>DO_ 'V:/^$=L/27_OLT44 '_".V
M'I+_ -]FC_A';#TE_P"^S110 ?\ ".V'I+_WV:/^$=L/27_OLT44 '_".V'I
M+_WV:/\ A';#TE_[[-%% !_PCMAZ2_\ ?9H_X1VP])?^^S110 ?\([8>DO\
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M%% !_P ([8>DO_?9H_X1VP])?^^S110 ?\([8>DO_?9H_P"$=L/27_OLT44
M'_".V'I+_P!]FC_A';#TE_[[-%% !_PCMAZ2_P#?9H_X1VP])?\ OLT44 '_
M  CMAZ2_]]FC_A';#TE_[[-%% !_PCMAZ2_]]FC_ (1VP])?^^S110 ?\([8
M>DO_ 'V:/^$=L/27_OLT44 '_".V'I+_ -]FC_A';#TE_P"^S110 ?\ ".V'
MI+_WV:/^$=L/27_OLT44 '_".V'I+_WV:/\ A';#TE_[[-%% !_PCMAZ2_\
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M0 ?\([8>DO\ WV:/^$=L/27_ +[-%% !_P ([8>DO_?9H_X1VP])?^^S110
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MH /^$=L/27_OLT?\([8>DO\ WV:** #_ (1VP])?^^S1_P ([8>DO_?9HHH
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L([8>DO\ WV:** #_ (1VP])?^^S4UMHUI:3++$)-PZ9?(HHH T**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img249132499_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img249132499_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2$"8$# 2(  A$! Q$!_\0
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M]@^LU>Y[+_POA/\ H 2?]_Q_A1_POA/^@!)_W_'^%>-44?5*/8/K-7N>R_\
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MSV7_ (7PG_0 D_[_ (_PH_X7PG_0 D_[_C_"O&J*/JE'L'UFKW/9?^%\)_T
M)/\ O^/\*/\ A?"?] "3_O\ C_"O&J*/JE'L'UFKW/9?^%\)_P! "3_O^/\
M"C_A?"?] "3_ +_C_"O&J*/JE'L'UFKW/9?^%\)_T )/^_X_PH_X7PG_ $ )
M/^_X_P *\:HH^J4>P?6:O<]E_P"%\)_T )/^_P"/\*/^%\)_T )/^_X_PKQJ
MBCZI1[!]9J]SV7_A?"?] "3_ +_C_"C_ (7PG_0 D_[_ (_PKQJBCZI1[!]9
MJ]SV7_A?"?\ 0 D_[_C_  H_X7PG_0 D_P"_X_PKQJBCZI1[!]9J]SV7_A?"
M?] "3_O^/\*/^%\)_P! "3_O^/\ "O&J*/JE'L'UFKW/9?\ A?"?] "3_O\
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M]11B[GL__"^$_P"@!)_W_'^%'_"^$_Z $G_?\?X5XU16OU2CV,_K-7N>R_\
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M]@^LU>Y[+_POA/\ H 2?]_Q_A1_POA/^@!)_W_'^%>-44?5*/8/K-7N>R_\
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M_P +X3_H 2?]_P ?X4?\+X3_ * $G_?\?X5XU11]4H]@^LU>Y[+_ ,+X3_H
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M_P +X3_H 2?]_P ?X4?\+X3_ * $G_?\?X5XU11]4H]@^LU>Y[+_ ,+X3_H
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M?X4?\+X3_H 2?]_Q_A7C5%'U2CV#ZS5[GLO_  OA/^@!)_W_ !_A1_POA/\
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M\*/^%\)_T )/^_X_PKQJBCZI1[!]9J]SV7_A?"?] "3_ +_C_"C_ (7PG_0
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M $G_ '_'^%>-457U2CV)^LU>Y[+_ ,+X3_H 2?\ ?\?X4?\ "^$_Z $G_?\
M'^%>-44?5*/8/K-7N>R_\+X3_H 2?]_Q_A1_POA/^@!)_P!_Q_A7C5%'U2CV
M#ZS5[GLO_"^$_P"@!)_W_'^%'_"^$_Z $G_?\?X5XU11]4H]@^LU>Y[+_P +
MX3_H 2?]_P ?X4?\+X3_ * $G_?\?X5XU11]4H]@^LU>Y[+_ ,+X3_H 2?\
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M?] "3_O^/\*P9_\ D@UE_P!?S?S-><UE2PU*5[KJS2I7J*UGT/9?^%\)_P!
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M$DB^U3+%O,P.W/?&*E\1_&!/#_B&\THZ,\QMGV^8)@-W&>F*\D\%?\CSH?\
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M_0 D_P"_X_PKQJBCZI1[!]9J]SV7_A?"?] "3_O^/\*/^%\)_P! "3_O^/\
M"O&J*/JE'L'UFKW/9?\ A?"?] "3_O\ C_"C_A?"?] "3_O^/\*\:HH^J4>P
M?6:O<]E_X7PG_0 D_P"_X_PH_P"%\)_T )/^_P"/\*\:HH^J4>P?6:O<]E_X
M7PG_ $ )/^_X_P */^%\)_T )/\ O^/\*\:HH^J4>P?6:O<]E_X7PG_0 D_[
M_C_"C_A?"?\ 0 D_[_C_  KQJBCZI1[!]9J]SV7_ (7PG_0 D_[_ (_PKNO
M_C$>,M,GO!9-:^5)Y>TONSQG-?,%>[? [_D6;[_KY'\JY\5AZ<*?-%:F]"M.
M<[-GJ5%%%>8=QX1\</\ D8;#_KC_ %->75ZC\</^1AL/^N/]37EU>YAOX43R
M:_\ $84445T&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '2?#_ /Y'[1O^OA:3Q_\ \E!US_KY/\A2_#__ )'[1O\ KX6D
M\?\ _)0=<_Z^3_(5A_R^^7ZFO_+KY_H<Y1116YD%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'HWPY_Y%+QC_ ->?]#7FZ?ZM?H*](^'/_(I>,?\ KS_H:\W3_5K]!6%/
MXY_+\C6?P1'4445N9!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >A_"'_D-ZK_UY-7 W7_'Y<?]=&_G
M7??"'_D-ZK_UY-7 W7_'Y<?]=&_G6$/XLOD:R_AQ^9%1116YD%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4Z/_6Q_P"\*;3H_P#6Q_[P
MI >A?&#_ )#&B?\ 8-7^=>=UZ)\8/^0QHG_8-7^=>=UCA_X2-:W\1A1116YD
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !79_"K_ )*)8?[C_P J
MXRNS^%7_ "42P_W'_E65;^'+T-*7QHP?$W_(TZG_ -?#?SK*K5\3?\C3J?\
MU\-_.LJKA\*)ENPHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#T:?_D@UE_U_-_,UYS7HT_\ R0:R_P"OYOYF
MO.:PH?:]6:U>GH@HHHK<R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** -WP5_R/.A_]?B?SJW\1_P#DH>L_]=1_(54\
M%?\ (\Z'_P!?B?SJW\1_^2AZS_UU'\A6'_+[Y?J:_P#+KYG+T445N9!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MNWP._P"19OO^OD?RKPFO=O@=_P BS??]?(_E7)C?X3.G"_Q$>I4445XQZ9X1
M\</^1AL/^N/]37EU>H_'#_D8;#_KC_4UY=7N8;^%$\FO_$84445T&(4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '2?#_P#Y
M'[1O^OA:3Q__ ,E!US_KY/\ (4OP_P#^1^T;_KX6D\?_ /)0=<_Z^3_(5A_R
M^^7ZFO\ RZ^?Z'.4445N9!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z-\.?^12\8_\
M7G_0UYNG^K7Z"O2/AS_R*7C'_KS_ *&O-T_U:_05A3^.?R_(UG\$1U%%%;F0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'H?PA_Y#>J_P#7DU<#=?\ 'Y<?]=&_G7??"'_D-ZK_ ->3
M5P-U_P ?EQ_UT;^=80_BR^1K+^''YD5%%%;F04444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 >D/_R0J/\ Z^J\WKTA_P#DA4?_ %]5YO6%'[7JS6KT] HHHK<R"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ IT?^MC_P!X4VG1_P"MC_WA2 ]"
M^,'_ "&-$_[!J_SKSNO1/C!_R&-$_P"P:O\ .O.ZQP_\)&M;^(PHHHK<R"BB
MB@ HHHH **MZ;IE[K%^ECI\!GN7!*Q@XR!UJ?5/#^JZ)>PV>I6;6]Q, 8T)!
MW<X[>]3S*]KZCL[7,VBM_4/!'B72M/>_OM*DAM8QEI"P.!^%8]E9W&HWL-G:
M1&6XG;9&@.-Q]*%*+5TQN+3LT045J:SX<UCP\8AJUDUKYN=FY@=WY5I0?#SQ
M;<P1SPZ-(T4BAE;>O(/XTG4@E>X<DKVL<S174/\ #CQA&A=M$EP.N'4_UKFI
MH9;:=X)XVBE0X9'&"*<9QEL[@XM;H9115_2=%U+7;LVNEVK7,X7<44@<?C3;
M25V))O1%"BNJ_P"%:^,?^@')_P!_%_QILGPX\7Q1M(^BR!%!9CYB\ ?C4>UI
M_P R^\KV<^S.7HHHK0@**** "BBM31O#FL>(6F72;)KHPX\S:P&W/3K2;25V
M-)O1&715B^L;G3+Z6RO8C#<PG;)&3G::KT)W **V[#PAX@U32_[3LM->:RPQ
M\T, ..O%0Z-X:UGQ#Y_]DV+W7D$"7:P&TGIU^AJ>>.NNP^678RJ*FO+2XL+R
M6TNHC%<0MMD0]5/I4-4(****8@HHHH **** "BBB@ HHHH *[/X5?\E$L/\
M<?\ E7&5V?PJ_P"2B6'^X_\ *LJW\.7H:4OC1@^)O^1IU/\ Z^&_G656KXF_
MY&G4_P#KX;^=957#X43+=A1115$A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'HT__ "0:R_Z_F_F:\YKT:?\ Y(-9
M?]?S?S-><UA0^UZLUJ]/1!1116YD%%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^ O!,?C2YO(I+Y[3R &RB!MV?K77V_P.W32K=ZV8EWD0[8P6=?4@]ZB^!?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ IT?\ K8_]X4VG1_ZV/_>%(#T+XP?\AC1/^P:O\Z\[KT3XP?\
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MW'7N:SJ8B$)*+ZEPHRE%R70\ HI\\+6]Q+ ^-\3E&QTR*96YD%%%%,04444
M=)\/_P#D?M&_Z^%I/'__ "4'7/\ KY/\A2_#_P#Y'[1O^OA:3Q__ ,E!US_K
MY/\ (5A_R^^7ZFO_ "Z^?Z'.4445N9!1110 4444 %%%(>AH F2UN9%#1VL[
MJ>C+&2#^.*7[%>?\^5S_ -^6_P *^A/ -Y_9WPHAOA&)#;V[RA.F[ )QFN?T
MCXW0WVH06]]HQ@BF94#I)O().!QBN/ZQ4;:C&]O,Z?8P23E*USQ8@JQ5E*L.
MH(P125[+\:/#MA!96>LVT*17,DPA<H,!P>Y]ZY'_ (51XG-I;7,:6LJ7!4*$
MDR5W=S[5K#$0E!2>ER)T91DXK4XBBNC\3^"-6\(QV\FIO;$3L5C$+EB2/:M+
M2OA5XIU:R2Z2"&W1QE5N&VL1ZXJ_:P2YKZ$^SG>UM3BJ*Z#Q'X+UOPKL;4K<
M>2_ FB.Y,^F:H:)H6H^(=06QTV RS'DG^%1ZDTU.+CS)Z$N,D[6U,ZBNWU'X
M3^*=-M?M$D5O,F0&$+DE<]S[5E^)_!.K>$;2VN=3:W,=RQ5/)?)R!GFE&K"3
MLF4Z<UJT<Y17<1_";Q/+9V]U%]D=)U5D"R<X(SS5#7_A[KOAP6WVM8)7N9/+
MB2!]S%OI25:FW9,'2FE=HY:BN]A^#_BJ6)';[%"7&1')+AORKF_$?A;5O"MR
MD.J0!1(/DD0Y1OH:<:L).R8G3G%7:,:BNU'PJ\3OID-_#';S1S!2J1OE\'OB
MI+_X2^*=/L);QX[:98UW-'"Y+X]A2]O3_F0_93['#45V>D?"WQ/K6G1WT,4$
M$4@RBSN58CUQ7-:QH]]H.I2:?J,)BG3GV8>H]JJ-2$G9/43A)*[11HHHJR H
MHHH **** "BBB@#T;X<_\BEXQ_Z\_P"AKS=/]6OT%>D?#G_D4O&/_7G_ $->
M;I_JU^@K"G\<_E^1K/X(CJ***W,@HHHH *<B/(VV.-W;^ZBDG]*;7;?"?_D?
M;;_<-1.7+%R[%0CS22./^Q7G_/E=?]^6_P *9)#-",RP2QCU="O\Z^@_'7Q(
MD\':K#9)I:W0D3?O,FW'Z5+H'B+0/B;IUS8W5@%E1?WD3@$C/=37+]:FHJ;A
MIZG1["/-RJ6I\ZJK.P559F/0*,DTZ2&:''FP2QYZ;T*Y_.NIET'4O#GQ%72]
M.=#=1S#[+)./E8'IFM7XDQ^+PMB/$TMC)DD0BU7!S[UO[5.22ZF7L]&WT//J
M*[;3_A3XGU&Q2[\NVMD?[JW$FUORJGX@^'GB'PW:?:[R".2W'WI(&W!?K35:
MFW9/43IS2O8Y6BM30O#VI^)+[[)IEN97 RS'[J#W-=/>?"'Q79VKS^7:S!!D
MI#(2Q^@IRJPB[-B5.4E=(X2BIH[6XEO!9I YN2^P18^;=Z8KMX?@_P"*I8D=
MOL4)<9"22X;\J<JD(?$[!&$I;(X*BMGQ%X5U;PK=)!JD 42#*2(<HWL#6AH'
MP\\0>(['[;:0Q0VQ^[)<-M#^XH=2"CS7T!0DWRVU.6HKM=2^%7BC3+"2\,5O
M<QH-Q%N^YL?2N2L+"[U.]CL[*W>:XD.%C4<T1J1DKI@X2B[-%>BN_P#^%-^+
M/)\S%EG&=GFG=_*N)N]/O+"_>PNK:2*Z5MAB8<YI1J0G\+N$H2CNBM17<67P
MF\47MG'<E+6V609"7$FUORK-\1> =?\ #%N+F_@1[<G!EA.Y5^OI25:FW9/4
M;IS2NT<S1116IF%%%% !1110!Z'\(?\ D-ZK_P!>35P-U_Q^7'_71OYUWWPA
M_P"0WJO_ %Y-7 W7_'Y<?]=&_G6$/XLOD:R_AQ^9%1116YD%%%% !2JK,P55
M+,>@ R325M^#?^1UT7_KZ6ID[)L:5W8ROL5Y_P ^5U_WY;_"FO;W$2[I;::-
M?5XR!^M?1_C_ ,=/X*6R*:>MW]I+#F3;MQ^%4/"_C[1?'CMI.H:<D5RZ$^3)
MAE<>Q]:Y%BJCCS\FGJ=3P\%+EYM3Y['/3G/I4CV\\2[I;>:-?5XRH_6NK\=>
M%CX5\8QV]I@07#K+:[NQST/L#6_\1$\;IX<A/B2;3GL?.78+9<-NQQ^%;^U3
MY;=3'V;5[]#S&BNMT/X;>(]>T];^WBAM[=^4:Y;9N'J/:I=7^%_B;1M/>]EA
MAN(4&6^SON('KBG[:G>U]1>RG:]CC:*M:=IUWJU]%96,#37$APJ**[8?!KQ8
M8]_^A9QG;YIS_*G*K"&DG84:<I?"CS^BKFJZ5>Z)J$ECJ$#0SQ]01U'J/:NB
MT+X:^)?$%DMY;6\<$#?<:X;;O'J/:G*I&*YF]!*$F[)'(T5T_B+P!X@\,6WV
MF^MTDM_XI8#N5?K2^'? 6L>*--EOM-EM#'$2KH\F&!QGI2]K#EYKZ#]G*_+;
M4Y>BK$5C<3:BNGI&?M32>4$/][TK>\2^!-6\)VD5QJ<MIB5MJ)')EB?I3<XI
MI-ZL2BVKV.9HKL-$^&7B;7K%;RW@B@A;[AN&VEAZCVK/\2>"];\*E&U*W'DO
MP)HCN3/IGUI*K!RY4]1NG)*]M#GZ*ZO0_AWKOB+1!JU@;8VY+*%=\,2.O%:8
M^#OBGRT=VL8]Y  >7!!]*3K4T[.0U2FU=(X&BMSQ-X2U3PE<PP:F(B9EW(\3
M94^WUJYX<\ :WXHTZ6_L#;QV\;;2T[[<\9R/:G[2'+S7T%R2ORVU,+2],N]9
MU*&PL8FDGE;:,#@>Y]!5SQ+X=N_"VLMI=[+%),L:R;HL[<'ZUU7@?Q3<:%J%
MMX?M+2V6>2[V7%Z/F:1?[H_QJ/XQ_P#)0Y?^O6+^M9JI+VO*]K%N$?9\W4X*
MBBBN@Q"BBB@ HHHH ](?_DA4?_7U7F]>D/\ \D*C_P"OJO-ZPH_:]6:U>GH%
M2-;W$:;WMYD3^\T9 _.HQ]]?]X?SKWSXD_\ )(4.!T@[>XIU*O)*,;;A"GS)
MOL>!T45+;6T][<QVUM$TLTAVHBC))K4S(J*[Z+X.>+);<2[;-"1G8\A##VKC
MM6TF^T/4'L=1MVAG3LPX8>H]JB-6$W:+N5*G**NT4J*Z[1?AIXCUW3UOH(H;
M>W;[C7+[=P]1[4SQ!\.O$/ANP-]>10RVR_>>!MVWW-'M:=^6^H_9SM>VARE*
M 6("@DGH ,DUHZ'H.H^(M0%EIL!EE(R3_"H]2:[:Q^%OB;1=8T^_GBMYH8KA
M6<0ON*CUQ2G5A#1O4(TY2U2/.I()H0#+!+&#TWH5S^=,KVGX[?\ (-T/C_EM
M)_Z"*\6HHU/:04K!5AR2Y0)QUJ5;2Z<96TN&'J(F/]*].^%/@6UU9&U[58Q)
M;1MB")ONL1U8_2M[6OC%INC:@UAI6E_:8H6V.^0B\?W?6LI5WS\E.-VBXT5R
M\TW8\/='C;;(CHWHZD']:2OH=+;PU\5/#DMQ%;"*Z7*;RH$D;C^8KQ*Q\*ZE
MJ'BE_#L(C2^5G'[TX&%Y_E54ZZE?FT:W%.BXVMJF8M%=XGP?\5O=20;+0; #
MYAD.T_2L/Q+X*UOPFJ/J4"F%^!-"=R9]"?6KC6IR=DR73FE=HY\9)"@$D] .
M2:7:V[9L;?G&W'.?I7N'PI\#06^F+K6I6T$\MP ]L2=VQ?IV-<7XF\):YX?\
M8V5[NM1+?7P^QX;(#YR-P]*A8B,IN"Z%NA)14CA9()H<>;!+'GIO0KG\Z97H
MWQ&M_&3QZ;%XEFT]UDFV0?9AC#'U]JIS?"/Q5#Y&V.VE\Y@ 8Y,[/=O:JC6C
MRIR:5R72E=J*.%HKLM:^%_B;0].:^GAAGB3[PMV+,H]<58M/A'XJO+%+I8[:
M(.NX1ROA\?2G[>G:_,A>RG>UCA0"2  23T [U))!/" 98)HP>A="H/YU;2RO
M].\00V3Q>3J$5PJJD@X#YXS[5WOQ$M_&SZ=81>))M.>"2Y"0BV7!#GCGVHE4
MM)+N$873?8\SHKT(?!?Q60#YEAS_ --3_A574_A/XDTG3+C4+E[(P6Z&1]DA
M)P/3BDJ])Z<P_8U%T.'HKH/#7@O6_%:22:; H@CX,TQVIGTS6Q??";Q18V4E
MULM;A(QN*P2;FQ["J=6"=F]1*G-JZ1PY('6E*LN-RLN1D9&,BO0/A7X/3Q!K
M$U[?01RV-FP1XG."7/(X[BMKXJ>!M0DU*?7K1;6/3+>V1-@.&&WT%0\1!5/9
ME*C)PYSR@V]PJ>8UM,$_OF,X_.HZ]5U2/Q[_ ,*_#7<^F'1O(7Y47]YL[?C7
MGV@^'=3\27@M=+MFE8#+.>%0>YJH54TV[:$RIV:2,NBN]N?@]XLMK=I@EI-M
M&=D4A+'Z5PTD$L%RUM-&T<ROL9'&"ISCFJA4A/X7<4H2C\2(Z*[F;X2^*8HX
M'6.VF\X@ 1N20#W/M3-4^%/BC2=/DO9(K>>.,;F6!RS >N*GV]-_:0_93[&#
MX<\,ZEXIU'['IT8^4;I)7X2,>I-;6O\ PTUK0-);4VFM;RVC.)#;,3L'J:S?
M#GBG7=$AGTW1MA-\=K*8MSDD8X]*]!EV?#SX93Z;J=QYNJZF"4M2V[9GO]!W
M]ZRJ3J1FK?=^9I"$)1=_O/'J='_K8_\ >%-%.C_UL?\ O"NDYST+XP?\AC1/
M^P:O\Z\[KT3XP?\ (8T3_L&K_.O.ZQP_\)&M;^(PHHHK<R"BBB@ HHHH ***
M* "BBB@ HHKI_A_H$'B/Q?:V=W@VRYDD7."V.0*F4E&+D^A48N3LCG4MKF1=
MT=M.Z^JQDC^5,DCDB($L4D9/0.I7/YU]"^,?&T?@(V]G9:"98F'#*-B >F0.
MM9MWXG\$^.?"SG4Y[6RO&4A5E.)(V]0?2N6.)FTI<FC.AT(JZYM3PHD <FE9
M67&Y67/(W#&:]%^%G@K^W-4_M2]A@GTJ$O&4<\LXZ''I6C\7?"-[%<OK\*VZ
M:9;Q)$44X8'..!6CQ$?:>S,U1ER<YY1175ZO\/-<T70!K5VUJ;0JK81R6PW3
MBJ_A?P3JWB^.X?3&MP+=@K^<^.3Z5I[6'+S7T(]G*]K:G.45<N-*O(-9DTD1
M^=>1R^3LBYW-[5V'_"GO%AM//\NUSMW>5YGS_3'K1*I"/Q,%3E+9'#_9KCR_
M,^S3>7UW^6<?G21P3S F*"60#J40MC\J^A]0MY;3X/O!/&8Y8[7:ZD<@@UYU
M\,D\9/I=_P#\(O-81P>://%TN26V\8]L5C'$<T7+LS65&TDNYYV002""".H(
MY%)6G-I^I:GXDN+-8?M&HR3L'6$<%L\D>U=9_P *;\6>3YF++.,[/-.[^5;2
MJPC;F=C)4Y2V1P%%6;O3[RPOWL+JVDBNE;88F'.:Z^R^$WBB]LX[DI:VRR#(
M2XDVM^5.52$5=L(PE+1(X>NK\-?#[6?$]A)?P/!:6B':LUR2H<]\5%XB\ Z_
MX8MQ<7\"/;G@RPG<J_7TJ#1-9"RPV6OW>I-H(^]! Q SVQ42FY1O38XQ496F
MB/Q+X5U+PI>I;:@J,)!NCFCY1Q[5B5ZI\75N+RQT74K1UDT0Q!8,#YE;'<_2
MO*Z=&;G!-[A5BHR:04445J9A1110 4444 %%%% !1110 5V?PJ_Y*)8?[C_R
MKC*[/X5?\E$L/]Q_Y5E6_AR]#2E\:,'Q-_R-.I_]?#?SK*K5\3?\C3J?_7PW
M\ZRJN'PHF6["BBBJ)"BBB@"1+>XE7=%;32+ZI&6'Z4[[%>?\^5U_WY;_  KW
MKX/R>5\/WEV@[))&QZXK#M/CI&]VJ7FB>5 6VLZ2[B.<=,5R?6*CE*,8WMYG
M3[&"BG*5KGCC*R,5=61A_"PP:>MO<-'YBV\S1_WQ&2/SKV_XOZ%IMQX477X8
M%CNHV3#J,%U;L:T/!,3S?!M(HDWR/;2JJ@<DG.!2^M?NU-+K8/J_ON-^ESY\
MHKNH/@_XL>Q6?R[524W>4TGS_3'K7%S6=S;WK6<L#K<J^PQ$?-N]*Z8U(2^%
MW,90E'=$-%=U:?"/Q3=6T4[+:6_F#(CFDPP^HK"\2>#]8\*21#4X5"2\)+&<
MJ3Z9I1JPD[)ZC=.:5VC"HKIO#O@+7_$]L;JQ@CCMATEG;:K?2M.]^$OBFRLW
MN0EK<J@R5@DW,?H*3K4T[-Z@J<VKI'#45-;VES=7:6EO!))<NVQ8E'S$^F*[
MF/X.>+)(%DQ9H2,[&D.X>W2G*I"'Q.PHPE+X4<!15S4]+O=&OGLM0MW@G3JK
M#J/4>U4ZM-/5$M6"GF&98Q*T$HC/1RA"G\:[3P+\.[OQ6T=].ZPZ2KD.^?F<
MCJ!7I?Q7M;>R^%[6UJBI!%)$B*O0 &N>>)C&HH+5LVC0;@YL^?:***Z3 ***
M* "BBB@#T:?_ )(-9?\ 7\W\S7G->C3_ /)!K+_K^;^9KSFL*'VO5FM7IZ(*
M***W,@HHHH 4 L0%!)/0 9)J7[%>?\^5U_WY;_"KGA[_ )&;2_\ KY3^=?0G
MCWQJW@JPL+A+!;LW,A0@OMVX&?2N>K6E"2C%7;-Z=)2BY-VL?-S6MU&I9[6X
M11U+1,!_*HU5I&"HK.QZ*HR37T1X,\?6'CQ[C3KK31%.D>]HVPZ%<XZUP*Z+
M;:!\=[&PLUVP><LBK_=W*3BICB'=QE&S2N.5%63B[IGF\D,L) EADC)Z!T*Y
M_.F5[K\3_"&K^*];T^+2X4*Q1MODD.U5^IKS#Q)X!U[PK:I=:A%&]NQVF2!M
MP4^_I54L1&:5W9OH34HRBWV.9HK7\/\ AG5?$]X;;2[?S"HR\C<(GU-=/)\'
M?%21.ZFQE*CE$ER?I6DJL(NTF1&G.2ND<#15D:=>MJ?]FK;2&]\SRO)"_-N]
M*[6/X.^*9$1F:QC9AD(\N&HE4A'XF$82ELC@:*V_$?A+6/"LT::G;A4D^Y*A
MRA/IFIO#?@C7/%0=].MU$*]9I3M0GT!I^TCR\U] Y)7Y;:G/45UVN_#3Q)X?
ML6O;F"*>!?OM;L6V#U/M7(T1G&:O%W%*+B[-!4B6UQ*NZ.VG=?[R1DC^5;?@
MG2+?7?%UE8W;A+<DR/N. 0O./QKV3Q5X_P!+\!7%GIEEIL<R,F]Q$0 B?U-9
M5:SC)0BKLTITE*/-)V1\^LK1ML=&1O[K#!I*]W^)>C:7K?@?_A)+>%89TC6=
M7"X9E/\ "?SKP@=*JC556-[6%5I^S=@HHHK8R"BBB@#=\%?\CSH?_7XG\ZM_
M$?\ Y*'K/_74?R%5/!7_ "/.A_\ 7XG\ZM_$?_DH>L_]=1_(5A_R^^7ZFO\
MRZ^9R]%%%;F04444 %/C@FF!,4$L@'78A;'Y4RO:O@3_ ,@W6.!_KU_E65:I
M[.#E8TI0YY<IXW]BO/\ GRNO^_+?X5&\<D3;9(WC;T=2#^M>U7_QI_L[7;FQ
MFT4&&WG,32K+S@'KC%:_CG2M)\5^ 'UV"%4D6 7,,NW#8]#6'UB<6N>-DS7V
M$6GRRNT> );SRJ6BMYI%'4I&6'Z5'T.",&O=/@J=W@;4#CG[2_;_ &17&?\
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M[+UT**C7A;L8N3=*5^YY'1117><84444 %%%% !1110!Z-\.?^12\8_]>?\
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MK'P5=-K.K:C%-/$IV.?D1 >IY[UY].O"-#DOKJ=LZ4G6YNAC?&@0?VYX>/\
MR\;QC_=WC^M:WQE(7P;8,>@NHR?I7G7CKQ1'XI\<6TML<VEM*D4+?WOF&3^=
M>B_&=0?!=B&.U?M48)].*:BXNDF',I>T:-G4=,M/'O@>WM=+U+[/&50AHNQ
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MR:73L?\ #15UCU?_ -%UU]N/#WPJ\-2(;A7N6&X@D>9*_88]*\S^'>HS:O\
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MR_4(OI]37?PZ*VD^&_[,T)HK:1(]L3R+D _WB!U->2:K\&M8\NZU*ZUZWGE
M:60F)LMCDU,)TIU.>6B6R*E&I"GRQU?4C\)R>/-6\))I.CVMI!I>TQ?:'&QV
M!ZD'N:]&^'GAJY\,:7=65UJB7S-)NVJ<^5QTJI9H?$7PK6S\.7203^1Y8"M@
MJ1U4^F?ZT[X9^'+KPQIMS::E>1R:C.PF>$2;VC7IS4U9\T9;+7;J53C:4>NF
MYQ/PWO;J'XH:Q8QSNEI)+*[PC[K,#P:K?%_7=6@\6RZ5%J$Z:>]O&6MP?D)/
M6H_"$ZZ+\9+Z.^S"9II$4OQU.0:Z3XI^!3J$MUXH6]5%@MU!A(^]MZ8/XUO>
M,:Z<NJ,K2=%I=&:WB'CX-+_UZI1X32/PC\)UU"*)#<F S.P'WF/3/Z4>( 3\
M&5X_Y=4-9_PVU_3/$'@G_A&K^=4N$C:':[ %U/0K],UA9NF^W-J:W7.N]CE_
M WQ'\0W7C"VMM0O#<V][)M:-AQ'_ +OI4_QJTVWM/$FE7L,822ZXE('4J1@_
MK72>&OA/:^&-=&KWNIK+#;$M "-NWW8FN$^)_BFW\2^*K:*R826EDP1)!_$Q
M(W?A6\'&5=.EM;4QDI1I6J;W/5_'FOW?ASP"+RQ(6X81Q*_]W(ZCWJG\*->U
M'Q#X6NFU6<W,D,QC$C]67'>JWQ<!_P"%:0^TD-5O@>#_ ,(KJ'_7T?Y5S\L?
MJ[E;6YOS/VZ72QQ_@G7/"_AGQ%J]_K7F_;!<NEN$BWJBY.2/0]J?XEU'X>:Y
M->:BVH:S/J4@)C\S.T'LN,<"N"U7_D-:A_U\R?\ H1JI7H^Q3ESW=SB]JTN6
MRL%.C_UL?^\*;3H_];'_ +PK8Q/0OC!_R&-$_P"P:O\ .O.Z]$^,'_(8T3_L
M&K_.O.ZQP_\ "1K6_B,****W,@HHHH **** "BBB@ HHHH *OZ+K%SH&L6^I
MVG^NA;(&,@CN*H5U_P ./$%EX?\ $X;48XVM+I?*=W4-L/8_G45':+TN7#XE
MK8]0TKXK>&-?M5MM7B^S2N,/',FY/SJ#6/AEX6\46#WOAZ6*"4 [&MVW1D^X
MI?%WPMLO%MX-5T>_@MWE4;\+NC;'0@"M+P[H6F?"[0+N>^U+>T@#R%C@$@=$
M6O+YH17-2;3['?:4G:HDUW. ^$=UJ=AXZ?1);B1+=(Y3);Y^4N.])\9M8U(>
M(7TH7LHT]X59K?/R$YZU!\/=:@NOBW+J<Q6!+P2[0YQ@MT%=+\6_!,M[]J\2
M+>(JPPJHA(Y)SSS70W&.(3EU7XF*3=%J/<U_B)_R22+_ *X0_P#H(K&^!'_'
MKK/_ %T3^5=6;.R\??#>&RM;M5WP(N\<['4 <C\*E\ ^$K3P?:7%DEXMS>R$
M/<%>W8<=JYN=*C*F][F_(W54UM8XWP!IL5S\5O$5](,O;2N$!Z98]:S/B#\1
MM=L_&,UEIEVUM!8/L*+TE;_:]13?#7B2+P]\7-72[D$=I=W+QNQZ*V>"?:NL
M\6_"RU\3ZXFL6VHI;Q38:YXR''JI]:V;C&JG4VMH96E*G:GO<U_$&HMJWPLG
MOF4*TUJ&8#U[US'P)_Y .L_]?"_^@UU?B:*TB^&5W%I\BR6L=OL1U.00#C^=
M<I\"!G0=9_Z^%_\ 0:RC;V$[=S1_QH^A9^%NE1G7_$FJ21J9/M1BB;N!WJZU
MG\1QXV^VK-;'1_-V_9S,,>5ZX_O5SGP\\2V>D^-->TN^E$2WET3&S'"AAQC\
M:V=1^$KZAXBDOH]?NHM.F8NT2R-N!/\ =.<8JIZ5'S]5U5Q1U@N7N-^)T&G:
M?XG\-:U=Q)M^T^5*Q]!R"?I6SXU\'-XY@LKK3]9:W$*YCV'*/W!X[UY3XI\,
MZ/IGBBRTK_A)))K>5OWK2L9/)^IZ5UMS\/\ Q#HD,%SX'UR6XC=?WBO,,$^J
MD\8JN514&I6?2ZT)YFW*\=#,\;?\+ T[PXUCJGDS:4$$3SP#+,OJ_I5+0?&/
MAR]\'CPYXL@E6* @PSVR?,P'3IT(_6O2-6U>;0?AW*GBJXMY]1DA*&-"/G)Z
M#']:^<?7W.:UH)58--6L]T9U6Z<DT[W74[CQYXSL=<L['1]$BDBTJR'REQ@O
MQCD5P]%%=<(*"Y4<TI.3NPHHHJR0HHHH **** "BBB@ HHHH *[/X5?\E$L/
M]Q_Y5QE=G\*O^2B6'^X_\JRK?PY>AI2^-&#XF_Y&G4_^OAOYUE5J^)O^1IU/
M_KX;^=957#X43+=A1115$A1110!] ?!Y4?X?NLAPAD<,?0=ZS+3P=\,+.Z6X
M.L13;&SY<MX&4G/<5H?"4'_A7$W'5I?Y5X"47<WRC[Q[>]>="FYU)VDUJ=LY
MJ,(75SUOXJ>.]-U/2DT#2'6>,E6EE7[H"] *[#X?7;6/PEM[M0"T,$C@'U&2
M*^=, #@8KZ#\&@_\*5_[=)OZT\12C3I1BNX4:CG4<GV,/X5>--<\0>*;VWU&
M[,T$D1F5&_Y9G/1?:N?\>W%SIWQ?%QIMJD]XHC:*(IN#.1Z=Z/@A_P CA/\
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M23WJS'J6H0QB.+4+N.,=$29@/RJM11:X"DEB2Q))Y)/>DHHIB"BBB@ HHHH
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M<:!$U*\51T59V _G55W>5R\CL[MU9CDG\:2BBR"Y9BU'4((A%#?W448Z(DS
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M$?\ Y*'K/_74?R%5/!7_ "/.A_\ 7XG\ZM_$?_DH>L_]=1_(5A_R^^7ZFO\
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M\^L__?LT?V->_P#/K/\ ]^S1SQ#D9G45H_V->_\ /K/_ -^S1_8U[_SZS_\
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M1SQ#D9G45H_V->_\^L__ '[-']C7O_/K/_W[-'/$.1F=16C_ &->_P#/K/\
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M(H^SP?\ /&/_ +Y%244 1?9X/^>,?_?(I?L\'_/&/_OD5)10!']G@_YXQ_\
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M@_YXQ_\ ?(H^SP?\\8_^^14E% $?V>#_ )XQ_P#?(H^SP?\ /&/_ +Y%244
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* (_L\'_ #QC_P"^11]G@_YXQ_\ ?(J2B@"/[/!_SQC_ .^11]G@_P">,?\
MWR*DHH C^SP?\\8_^^11]G@_YXQ_]\BI** (_L\'_/&/_OD4?9X/^>,?_?(J
M2B@"/[/!_P \8_\ OD4?9X/^>,?_ 'R*DHH C^SP?\\8_P#OD4?9X?\ GC'_
M -\BI** (_L\'_/&/_OD4?9X/^>,?_?(J2B@"/[/!_SQC_[Y%'V>#_GC'_WR
M*DHH C^SP?\ /&/_ +Y%'V>#_GC'_P!\BI** (_L\'_/&/\ [Y%'V>#_ )XQ
M_P#?(J2B@"/[/!_SQC_[Y%'V>#_GC'_WR*DHH C^SP?\\8_^^11]G@_YXQ_]
M\BI** (_L\'_ #QC_P"^11]G@_YXQ_\ ?(J2B@"/[/!_SQC_ .^11]G@_P">
M,?\ WR*DHH C^SP?\\8_^^11]G@_YXQ_]\BI** (_L\'_/&/_OD4?9X/^>,?
M_?(J2B@"/[/!_P \8_\ OD4?9X/^>,?_ 'R*DHH C^SP?\\8_P#OD4?9X/\
MGC'_ -\BI** (_L\'_/&/_OD4?9X/^>,?_?(J2B@"/[/!_SQC_[Y%.5$3A%5
M1[#%.HH ****  44"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  44"B@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ****  44"B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M***  44"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***H:UK6G^'M)GU35+C[/90;?,EV,^W<P4<*"3R0.E-)
MMV0%^BN#_P"%S_#_ /Z#_P#Y)S__ !%'_"Y_A_\ ]!__ ,DY_P#XBMOJM?\
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M'_\ R3G_ /B*/JM?^1_<PYD=Y17!_P#"Y_A__P!!_P#\DY__ (BC_A<_P_\
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M'_\ R3G_ /B*/^%S_#__ *#_ /Y)S_\ Q%'U6O\ R/[F',CO**X/_A<_P_\
M^@__ .2<_P#\11_PN?X?_P#0?_\ ).?_ .(H^JU_Y']S#F1WE%<'_P +G^'_
M /T'_P#R3G_^(H_X7/\ #_\ Z#__ ))S_P#Q%'U6O_(_N8<R.\HK@_\ A<_P
M_P#^@_\ ^2<__P 11_PN?X?_ /0?_P#).?\ ^(H^JU_Y']S#F1WE%<'_ ,+G
M^'__ $'_ /R3G_\ B*/^%S_#_P#Z#_\ Y)S_ /Q%'U6O_(_N8<R.\HK@_P#A
M<_P__P"@_P#^2<__ ,11_P +G^'_ /T'_P#R3G_^(H^JU_Y']S#F1WE%<'_P
MN?X?_P#0?_\ ).?_ .(H_P"%S_#_ /Z#_P#Y)S__ !%'U6O_ "/[F',CO**X
M/_A<_P /_P#H/_\ DG/_ /$4?\+G^'__ $'_ /R3G_\ B*/JM?\ D?W,.9'>
M45P?_"Y_A_\ ]!__ ,DY_P#XBC_A<_P__P"@_P#^2<__ ,11]5K_ ,C^YAS(
M[RBN#_X7/\/_ /H/_P#DG/\ _$4?\+G^'_\ T'__ "3G_P#B*/JM?^1_<PYD
M=Y17!_\ "Y_A_P#]!_\ \DY__B*/^%S_  __ .@__P"2<_\ \11]5K_R/[F'
M,CO**X/_ (7/\/\ _H/_ /DG/_\ $4?\+G^'_P#T'_\ R3G_ /B*/JM?^1_<
MPYD=Y17!_P#"Y_A__P!!_P#\DY__ (BC_A<_P_\ ^@__ .2<_P#\11]5K_R/
M[F',CO**X/\ X7/\/_\ H/\ _DG/_P#$4?\ "Y_A_P#]!_\ \DY__B*/JM?^
M1_<PYD=Y17!_\+G^'_\ T'__ "3G_P#B*/\ A<_P_P#^@_\ ^2<__P 11]5K
M_P C^YAS([RBN#_X7/\ #_\ Z#__ ))S_P#Q%'_"Y_A__P!!_P#\DY__ (BC
MZK7_ )']S#F1WE%<'_PN?X?_ /0?_P#).?\ ^(H_X7/\/_\ H/\ _DG/_P#$
M4?5:_P#(_N8<R.\HK@_^%S_#_P#Z#_\ Y)S_ /Q%'_"Y_A__ -!__P DY_\
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M /DG/_\ $4?5:_\ (_N8<R.\HK@_^%S_  __ .@__P"2<_\ \11_PN?X?_\
M0?\ _).?_P"(H^JU_P"1_<PYD=Y17!_\+G^'_P#T'_\ R3G_ /B*/^%S_#__
M *#_ /Y)S_\ Q%'U6O\ R/[F',CO**X/_A<_P_\ ^@__ .2<_P#\11_PN?X?
M_P#0?_\ ).?_ .(H^JU_Y']S#F1WE%<'_P +G^'_ /T'_P#R3G_^(H_X7/\
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MG/\ _$4?\+G^'_\ T'__ "3G_P#B*/JM?^1_<PYD=Y17!_\ "Y_A_P#]!_\
M\DY__B*/^%S_  __ .@__P"2<_\ \11]5K_R/[F',CO**X/_ (7/\/\ _H/_
M /DG/_\ $4?\+G^'_P#T'_\ R3G_ /B*/JM?^1_<PYD=Y17!_P#"Y_A__P!!
M_P#\DY__ (BC_A<_P_\ ^@__ .2<_P#\11]5K_R/[F',CO**X/\ X7/\/_\
MH/\ _DG/_P#$4?\ "Y_A_P#]!_\ \DY__B*/JM?^1_<PYD=Y17!_\+G^'_\
MT'__ "3G_P#B*/\ A<_P_P#^@_\ ^2<__P 11]5K_P C^YAS([RBN#_X7/\
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MQFG_ !8\$:IJ$%C::ZCW$[B.-7MY4#,>@W,@ _$UV=9SIS@[337J.]PHHHJ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH !10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =7\/_&UUX'\1
MQWT>Z2REPEW;@_ZQ/4?[0ZC\NA-?7NG:A:ZMIUO?V,RS6MP@DCD7HP-?"]>M
M?!CXC?\ "/:BOA_59L:5=O\ N9'/%O*?Y*W?T//K7E9E@_:Q]K#=?B7"5M#Z
M7HHHKYPV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#Z2^"WQ&_MRP7PWJLV=2M4_P!'E<\SQ#M[
MLOZCGL:]?KX6L;ZYTV^@O;.9X;F!Q)'(AY5AT-?7?P[\<6WCGPXEVNV._@Q'
M>0 _<?\ O#_9;J/Q':OG<RP?LY>UAL_P-H2OH==1117DEA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?0OP-^(4E_"OA/4W9YX$)L
M93SNC')C/^Z.GMQV&?GM$:1U1%+,QP% R2?2OJCX2?#Q?!VB_;[^,?VU>H#+
MG_E@G41CW[GWX[5YN:2IJC:>_0N%[GI%%%%?,FP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%%  **!10 4444 ><?'+_DF%[_ -=8_P"9
MKEO@9X.T+4/!5Q?W^GP7=Q<2M&S3(&VJ .!GI]:ZKXX*S?#&]"JS$RQ\*,]S
M5/X!JR?#H!U93]I?AACTH \?^&7AG3M9^*\]G>0K)9VLLK"%NC;6( -:OQOT
M;3]'\>:1_9UI%:B9%9UA4*,A@,X%3_!Z*1/C!JC-&Z@O/@E2!]\U:^/\<C^.
MM#*1NP$0R54G^,4 =+\>R6^&^F$DDF:/)/\ NUV'PB_Y)?HG_7'^M8_Q<\-W
M_B/X:01Z="TUQ;&.;REZLH7G'O7F/@[XE^*]*\-_\(EI^@/<WR;HX)<$&//J
MN.WUH F^"?\ R5?5?^VW_H1JI\2+"SA^.%K;Q6D"0/)"7C5 %;/7(]ZL_ VV
MN[?XEWJWD3K.(G\S*D#=GFI?C9INIZ1\1K3Q'#:R36Q$;JP4E=R_PDT >N^.
MM*\%6?A+R?$$,5KI,<H=88/W0:3M@+C)KS34_B#8WGP^OM \)>%+U]+BM61I
MYEPD:=WSW(ZU4\=W^N_$[X>VVN0:3-;K9SL);9,ME?[_ #UJ6U^(#:E\*U\)
M:)X>O9=5:U-M,J0XC5<89\^M &E^SG&DVB:S%*H>-Y &1AD$$<@BN3T/3K&3
M]HC["]E;M9_:9!Y!C!3&P_P]*Z?]G*X\G^V=.FC>.92LF&4C(Z?TKE/%+ZKX
M ^,\VO?V;)<1B8R0Y!"RAEP<$?6@#N?VAK>&T\&:5!;Q)%$EUA410JCY3T K
M.\4ZI<:;^SAHL=NY0W2QQ.P_N<Y'XU'\7=9N?%'PMT'59;&2VEN+DDP8)*\&
MNGM_"3^,?@'INEI\ETMNLL&[CYUS@&@"/X-> ]!/@2WU*]L+>\N;[+,TT8;:
MO0*,]*\[UFS3X??'.T71B8K>6XCQ$IX"N0"OTYJ7PQ\0O%7PMLI?#^IZ!).B
M.3"LI*E#[$ Y%:7@/PGK_CSQ_P#\)CXAM6@LTD$JJXV[R!\H4>@XH 3]H]/-
M\3Z!'G&ZV9<_5ZZWQ-X&\/Z;\$;EHM-@%S;V(F6XV#>7P,G=UKE_VAXY'\6>
M'BD;L! V=JD_\M!7IGC96;X+:FH4ECI@X YZ"@#D?V<F8^&=17<=HN,@9XZ5
M[57BO[.B.GAS4@Z,I\\?>4CM7M5 !1110 4444 %%%% !1110 4444 %%%%
M'R7XKEUJ'X[:K)X>1GU07G[A54$D[1V/%=%J<'QL\36;:9J%G/';3<.0L<8Q
M[E3G%1>7(/VF+E_+?;]N^]M./NBOI>@#S3X=_#Q_ GA#4A=R++J-W$S2E.B
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M445]B<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 445WOPL^'\GC;7O,ND9='M&#7+]/,/:,'U/?T'U%9U:D:
M4'.6R&E<[;X(?#GSY(_%NKP_NT.=/B<?>8?\M2/0?P^_/85[]3(88[>".&&-
M8XHU"(BC 50,  =A3Z^3Q.(E7J.<C=*R"BBBN<84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%%  **!10 4444 -9%==KJ&'H1FA$2,815
M4>@&*=10 Q88D;<L:*WJ% -#PQ2$%XT8CH2H-/HH *8L,2MN6- WJ%&:?10
MQ8HT8LL:!CU(49I7C208=%8>C#-.HH :L:*NU44+Z <4B0Q1G*1HI]0H%/HH
M 8D,4;$I&BD]2% H>*.3&^-6QTW#-/HH 8T,;*%:-"HZ J,"G*JJH50 !T %
M+10 QX8I#EXT8^K*#3@H484  =A2T4 ,>*.0@O&C$="R@TXJK+M*@KTP1Q2T
M4 -2-(QA$51_LC%.HHH **** "BBB@ HHHH **** "BBB@ HHHH 9Y,6_?Y:
M;_[VT9I]%% !00",$9%%% $8MX5;<L,8/J%%2444 %,2&*,Y2-%)[A0*?10
M4UXXY !(BMCIN&:=10 BJJ*%4  =@*:\4<F-\:-C^\,T^B@!%54&%  ] *"
MPP0"#V-+10 Q(8HSE(D4^H4"GT44 ,:&)VW/$C'U*@T\  8 P*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ H)P,GI17.>.]='ASP5JFI9'F1PD1@
MGJQX'\Z /"KS/Q#_ &@?(QOM+638PZ@QQ\$_CFHM))^&WQY>T*&.QN)O*0=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 445)!!+=7$=O!&TLTK!$1!DLQ.  /7- &IX7
M\-W_ (LU^WTC3TS+*<NY'RQ(/O.WL/\  =Z^P_#7AVP\*Z#;:1IT>V&%>6/W
MI&/5F]R?\.@KF_A?X B\$: #<*CZO=@-=2#G;Z1@^@_4_A7=5\QF&,]O/EC\
M*_$VA&P4445YQ84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 "B@44 %%%% !1110 $9!%?-/Q BU[X:?$.UUBUU"]FTN>;SHTD
MF9D']Y",X]<5]+5SGCCPG;>,?"]UI<ZCS"I:"0CE)!T/]* *FJ^/=,LOA\WB
MJ*57ADA#0KGEG(X7ZYKRCX-Z7KOBWQ)<^*-6U&^-E#*6CC,S!))#VQG&!Q7F
MVGZ=XBUC5K;P TS"."[8&+/RQMGYFKZZ\/:%:>&]"M-)LD"PVZ!<]V/<GWH
M\'\9^+O%'CCXB2>$?#UX]I;*YC78Q7=@99B1SCK61JK>.O@]K=G+=:P][;3G
M)_>,Z. >5^;D&OHZ>ST+1O-U>:VLK5HE+/<F-5('?FOG;Q9K%[\9O'MII>B6
MSG3;5MHD/3;GYG;T]J /1/B=\3KC1?!.EW>C_NKS5HEDC<C/EH1DGZ\UYRW@
MKXB-X6_X3'^WYLF/[2;?SWWA>N<=/PKZ*B\-Z4-+L["XLK>YCM(EBC\Z,-@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MX/XI>"]7\<Z+;:9IM[;6L2R^9*9MWS8' XKO** .:\!^%O\ A#O"-IH[2))+
M'EI70?*SGJ13O'/A=?&'A*\T;>L<DH#1._17'()KHZ* /+O W@RY^'WA35['
MQ-J%G<:1-EV\L-\@(PV<CI7GI^$]G-?M>^%?'=C;:?,<X>X,<B@]N.OXU]&W
M=K!?6DMK<QK)#*I1T8<$&O'M3_9ST&[NWELM5N[*-B2(@@<#\2: /+-1T#2M
M/^*>E:+I%R=0C22(2W ;<99#RW/UKWWXG^!;[QSH%KI]C=06[Q2!R9@<$8]J
MK^"?@[H/@R_74%DEOKY!A)I@ $]P/7WKT6@#F_"WARXT'P#9^'YYHI+B"V:$
MR)G:22>>>>]<?\,OA?J?@?Q)J>IWM]:W$=W$4580V02X;G(KU2B@#S'X@_!V
MQ\87QU:QNFL-4P 7 ^1R.A/<'Z5R6F_L_P"J76H12>)O$1N[6,\)&[LQ]LMT
M%>]T4 8&J>$--U+PF?#B^9:V00)&8&*M'CH17FVF?"[Q[X6$UKX:\7P16,C;
MMMQ&6;/Y$#\*]HHH \T\"_"A/#>LRZ_K&H'4M8DR?,(^5">I&><U5^)WPBE\
M;:M#JVFW\=I>J@1_-!VL!T.1SFO5:* /)XOA=KG_  JZ]\,76M17-]<W E$\
MK.RJ/3)Y[5T7PV\%7/@WPG)H^HSP7322,Q,0.TJ1C!S7;44 >'>(?@'<'6);
M_P *:S_9RRL2T3LR[,]E*\XJ]X)^!J:-K<>L^(=1&HW<3;XT7)3=V+%N37L=
M% !1110 4444 %%%% !7!_&?_DDVM_\ ;#_T?'7>5P?QG_Y)-K?_ &P_]'QU
MOA?X\/5?F*6Q\E4445]B<X4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K@_C/_R2;6_^V'_H^.N\K@_C/_R2;6_^V'_H^.M\
M+_'AZK\Q2V/DJBBBOL3G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KH?!?A*]\:>(X-*LP40_///C(AC'5C_(#N2*QK&RN=
M2OH+*SA::YG<1QQH.68]!7UW\._ UMX&\.I:#9)?SXDO)P/OO_='^R.@_$]Z
MX<=BUAX:?$]O\RHQNS?T71K+P_H]MI>G0B*UMT"(O<^I/J2>2?4U?HHKY9MM
MW9N%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH !10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !10** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH !10** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M !10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH !10** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH !10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^_E &MN'J*-P]163_P ([:?\])_^_E'_  CMI_STG_[^4 :VX>HHW#U%9/\
MPCMI_P ])_\ OY1_PCMI_P ])_\ OY0!K;AZBC</45D_\([:?\])_P#OY1_P
MCMI_STG_ ._E &MN'J*-P]163_PCMI_STG_[^4?\([:?\])_^_E &MN'J*-P
M]163_P ([:?\])_^_E'_  CMI_STG_[^4 :VX>HHW#U%9/\ PCMI_P ])_\
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M^_E &MN'J*-P]163_P ([:?\])_^_E'_  CMI_STG_[^4 :VX>HHW#U%9/\
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MRC_A';3_ )Z3_P#?R@#6W#U%&X>HK)_X1VT_YZ3_ /?RC_A';3_GI/\ ]_*
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MU%&X>HK)_P"$=M/^>D__ '\H_P"$=M/^>D__ '\H UMP]11N'J*R?^$=M/\
MGI/_ -_*/^$=M/\ GI/_ -_* -;</44;AZBLG_A';3_GI/\ ]_*/^$=M/^>D
M_P#W\H UMP]11N'J*R?^$=M/^>D__?RC_A';3_GI/_W\H UMP]11N'J*R?\
MA';3_GI/_P!_*/\ A';3_GI/_P!_* -;</44;AZBLG_A';3_ )Z3_P#?RC_A
M';3_ )Z3_P#?R@#6W#U%&X>HK)_X1VT_YZ3_ /?RC_A';3_GI/\ ]_* -;</
M44;AZBLG_A';3_GI/_W\H_X1VT_YZ3_]_* -;</44;AZBLG_ (1VT_YZ3_\
M?RC_ (1VT_YZ3_\ ?R@#6W#U%&X>HK)_X1VT_P">D_\ W\H_X1VT_P">D_\
MW\H UMP]11N'J*R?^$=M/^>D_P#W\H_X1VT_YZ3_ /?R@#6W#U%&X>HK)_X1
MVT_YZ3_]_*/^$=M/^>D__?R@#6W#U%&X>HK)_P"$=M/^>D__ '\H_P"$=M/^
M>D__ '\H UMP]11N'J*R?^$=M/\ GI/_ -_*/^$=M/\ GI/_ -_* -;</44;
MAZBLG_A';3_GI/\ ]_*/^$=M/^>D_P#W\H UMP]11N'J*R?^$=M/^>D__?RC
M_A';3_GI/_W\H UMP]11N'J*R?\ A';3_GI/_P!_*/\ A';3_GI/_P!_* -;
M</44;AZBLG_A';3_ )Z3_P#?RC_A';3_ )Z3_P#?R@#6W#U%&X>HK)_X1VT_
MYZ3_ /?RC_A';3_GI/\ ]_* -;</44;AZBLG_A';3_GI/_W\H_X1VT_YZ3_]
M_* -;</44;AZBLG_ (1VT_YZ3_\ ?RC_ (1VT_YZ3_\ ?R@#6W#U%&X>HK)_
MX1VT_P">D_\ W\H_X1VT_P">D_\ W\H UMP]11N'J*R?^$=M/^>D_P#W\H_X
M1VT_YZ3_ /?R@#6W#U%&X>HK)_X1VT_YZ3_]_*/^$=M/^>D__?R@#6W#U%&X
M>HK)_P"$=M/^>D__ '\H_P"$=M/^>D__ '\H UMP]11N'J*R?^$=M/\ GI/_
M -_*/^$=M/\ GI/_ -_* -;</44;AZBLG_A';3_GI/\ ]_*/^$=M/^>D_P#W
M\H UMP]11N'J*R?^$=M/^>D__?RC_A';3_GI/_W\H UMP]11N'J*R?\ A';3
M_GI/_P!_*/\ A';3_GI/_P!_* -;</44;AZBLG_A';3_ )Z3_P#?RC_A';3_
M )Z3_P#?R@#6W#U%&X>HK)_X1VT_YZ3_ /?RC_A';3_GI/\ ]_* -;</44;A
MZBLG_A';3_GI/_W\H_X1VT_YZ3_]_* -;</44;AZBLG_ (1VT_YZ3_\ ?RC_
M (1VT_YZ3_\ ?R@#6W#U%&X>HK)_X1VT_P">D_\ W\H_X1VT_P">D_\ W\H
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MU%&X>HK)_P"$=M/^>D__ '\H_P"$=M/^>D__ '\H UMP]11N'J*R?^$=M/\
MGI/_ -_*/^$=M/\ GI/_ -_* -;</44;AZBLG_A';3_GI/\ ]_*/^$=M/^>D
M_P#W\H UMP]11N'J*R?^$=M/^>D__?RC_A';3_GI/_W\H UMP]11N'J*R?\
MA';3_GI/_P!_*/\ A';3_GI/_P!_* -;</44;AZBLG_A';3_ )Z3_P#?RC_A
M';3_ )Z3_P#?R@#6W#U%&X>HK)_X1VT_YZ3_ /?RC_A';3_GI/\ ]_* -;</
M44;AZBLG_A';3_GI/_W\H_X1VT_YZ3_]_* -;</44;AZBLG_ (1VT_YZ3_\
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M %% HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ %% HH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ %% HH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ %% HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ %% HH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ %% HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "O!_P!I+_F6?^WK_P!HU[Q7@_[27_,L_P#;U_[1KNRW
M_>H_/\F3/X3P:BBBOJC **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O!_VDO^99_[>O\ VC7O%>#_ +27
M_,L_]O7_ +1KNRW_ 'J/S_)DS^$\&HHHKZHP"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^C/@G\1O[5M$\+ZM-_IUN
MG^ARN>9HQ_!_O*/S'TKV6OA2TN[BPO(;NUE>&XA<21R(<%6!R"*^N/AOX[M_
M'/AY9V*1ZG;@)>0CLW9P/[K?IR.U?.YG@_9OVL-GOY&L)7T.SHHHKR30****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !16!K_C;P[X7GB@UK4XK265=R*X8DCUX%8_\ PM[P'_T,5O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M([*%[>];7P_\=^(?"WC;_A#?%<SS1E_*1Y#DQMV(/<&@#Z#HKY[_ &A=4O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU^-5]<>*?B-IOA6S?B(!!M/!D?U^F*7X&ZG<>'/'>I>%;\E6F! !/"R)_B*
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MKWBO!_VDO^99_P"WK_VC7=EO^]1^?Y,F?PG@U%%%?5& 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV?Q'U.;6/V?]&U"X_P!;/Y+-]<X_I3_@GX \/ZEX2_M;5=.@O;F2?*-,N?+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_H8S_P"# _X5]"44 >-?$3P%XV\5^'?#^F6]Q;2_9;=3>F:?!DG  SG'/?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>#_M)?\ ,L_]O7_M&O>*\'_:2_YEG_MZ
M_P#:-=V6_P"]1^?Y,F?PG@U%%%?5& 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%%  **!10 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %8/B3P9X?\7_9?[=T_[7]E
MW^3^^DCV[L;ON,,YVCKZ5O45492@^:+LP.#_ .%,?#__ * '_DY/_P#%T?\
M"F/A_P#] #_R<G_^+KO**U^M5_YW][%RHX/_ (4Q\/\ _H ?^3D__P 71_PI
MCX?_ /0 _P#)R?\ ^+KO**/K5?\ G?WL.5'!_P#"F/A__P! #_R<G_\ BZ/^
M%,?#_P#Z '_DY/\ _%UWE%'UJO\ SO[V'*C@_P#A3'P__P"@!_Y.3_\ Q='_
M  ICX?\ _0 _\G)__BZ[RBCZU7_G?WL.5'!_\*8^'_\ T /_ "<G_P#BZ/\
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M_P"@!_Y.3_\ Q==Y11]:K_SO[V'*C@_^%,?#_P#Z '_DY/\ _%T?\*8^'_\
MT /_ "<G_P#BZ[RBCZU7_G?WL.5'!_\ "F/A_P#] #_R<G_^+H_X4Q\/_P#H
M ?\ DY/_ /%UWE%'UJO_ #O[V'*C@_\ A3'P_P#^@!_Y.3__ !='_"F/A_\
M] #_ ,G)_P#XNN\HH^M5_P"=_>PY4<'_ ,*8^'__ $ /_)R?_P"+H_X4Q\/_
M /H ?^3D_P#\77>44?6J_P#._O8<J.#_ .%,?#__ * '_DY/_P#%T?\ "F/A
M_P#] #_R<G_^+KO**/K5?^=_>PY4<'_PICX?_P#0 _\ )R?_ .+H_P"%,?#_
M /Z '_DY/_\ %UWE%'UJO_._O8<J.#_X4Q\/_P#H ?\ DY/_ /%T?\*8^'__
M $ /_)R?_P"+KO**/K5?^=_>PY4<'_PICX?_ /0 _P#)R?\ ^+H_X4Q\/_\
MH ?^3D__ ,77>44?6J_\[^]ARHX/_A3'P_\ ^@!_Y.3_ /Q='_"F/A__ - #
M_P G)_\ XNN\HH^M5_YW][#E1P?_  ICX?\ _0 _\G)__BZ/^%,?#_\ Z '_
M ).3_P#Q==Y11]:K_P [^]ARHX/_ (4Q\/\ _H ?^3D__P 71_PICX?_ /0
M_P#)R?\ ^+KO**/K5?\ G?WL.5'!_P#"F/A__P! #_R<G_\ BZ/^%,?#_P#Z
M '_DY/\ _%UWE%'UJO\ SO[V'*C@_P#A3'P__P"@!_Y.3_\ Q='_  ICX?\
M_0 _\G)__BZ[RBCZU7_G?WL.5'!_\*8^'_\ T /_ "<G_P#BZ/\ A3'P_P#^
M@!_Y.3__ !==Y11]:K_SO[V'*C@_^%,?#_\ Z '_ ).3_P#Q='_"F/A__P!
M#_R<G_\ BZ[RBCZU7_G?WL.5'!_\*8^'_P#T /\ R<G_ /BZ/^%,?#__ * '
M_DY/_P#%UWE%'UJO_._O8<J.#_X4Q\/_ /H ?^3D_P#\71_PICX?_P#0 _\
M)R?_ .+KO**/K5?^=_>PY4<'_P *8^'_ /T /_)R?_XNC_A3'P__ .@!_P"3
MD_\ \77>44?6J_\ ._O8<J.#_P"%,?#_ /Z '_DY/_\ %T?\*8^'_P#T /\
MR<G_ /BZ[RBCZU7_ )W][#E1P?\ PICX?_\ 0 _\G)__ (NC_A3'P_\ ^@!_
MY.3_ /Q==Y11]:K_ ,[^]ARHX/\ X4Q\/_\ H ?^3D__ ,71_P *8^'_ /T
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M ,77>44?6J_\[^]ARHX/_A3'P_\ ^@!_Y.3_ /Q='_"F/A__ - #_P G)_\
MXNN\HH^M5_YW][#E1P?_  ICX?\ _0 _\G)__BZ/^%,?#_\ Z '_ ).3_P#Q
M==Y11]:K_P [^]ARHX/_ (4Q\/\ _H ?^3D__P 71_PICX?_ /0 _P#)R?\
M^+KO**/K5?\ G?WL.5'!_P#"F/A__P! #_R<G_\ BZ/^%,?#_P#Z '_DY/\
M_%UWE%'UJO\ SO[V'*C@_P#A3'P__P"@!_Y.3_\ Q='_  ICX?\ _0 _\G)_
M_BZ[RBCZU7_G?WL.5'!_\*8^'_\ T /_ "<G_P#BZ/\ A3'P_P#^@!_Y.3__
M !==Y11]:K_SO[V'*C@_^%,?#_\ Z '_ ).3_P#Q='_"F/A__P! #_R<G_\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !10**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH !10** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH !10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !10** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH H7E[=6[JL-D\X(R2IZ56_M74/^@3+_ -]5L"B@
M#'_M74/^@3+_ -]4?VKJ'_0)E_[ZK8HH Q_[5U#_ *!,O_?5']JZA_T"9?\
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M#'_M74/^@3+_ -]4?VKJ'_0)E_[ZK8HH Q_[5U#_ *!,O_?5']JZA_T"9?\
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M^U=0_P"@3+_WU6Q10!C_ -JZA_T"9?\ OJC^U=0_Z!,O_?5;%% &/_:NH?\
M0)E_[ZH_M74/^@3+_P!]5L44 8_]JZA_T"9?^^J/[5U#_H$R_P#?5;%% &/_
M &KJ'_0)E_[ZH_M74/\ H$R_]]5L44 8_P#:NH?] F7_ +ZH_M74/^@3+_WU
M6Q10!C_VKJ'_ $"9?^^J/[5U#_H$R_\ ?5;%% &/_:NH?] F7_OJC^U=0_Z!
M,O\ WU6Q10!C_P!JZA_T"9?^^J/[5U#_ *!,O_?5;%% &/\ VKJ'_0)E_P"^
MJ/[5U#_H$R_]]5L44 8_]JZA_P! F7_OJC^U=0_Z!,O_ 'U6Q10!C_VKJ'_0
M)E_[ZH_M74/^@3+_ -]5L44 8_\ :NH?] F7_OJC^U=0_P"@3+_WU6Q10!C_
M -JZA_T"9?\ OJC^U=0_Z!,O_?5;%% &/_:NH?\ 0)E_[ZH_M74/^@3+_P!]
M5L44 8_]JZA_T"9?^^J/[5U#_H$R_P#?5;%% &/_ &KJ'_0)E_[ZH_M74/\
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M^U=0_P"@3+_WU6Q10!C_ -JZA_T"9?\ OJC^U=0_Z!,O_?5;%% &/_:NH?\
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M5L44 8_]JZA_T"9?^^J/[5U#_H$R_P#?5;%% &/_ &KJ'_0)E_[ZH_M74/\
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M^U=0_P"@3+_WU6Q10!C_ -JZA_T"9?\ OJC^U=0_Z!,O_?5;%% &/_:NH?\
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MK8HH Q_[5U#_ *!,O_?5']JZA_T"9?\ OJMBB@#'_M74/^@3+_WU1_:NH?\
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M HHHH **** "BBB@ HHHH !10** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !
M10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH !10** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH !10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !10** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHP/<&OG:Y^&GCWP#XBGO?!;M<6\Q(7RRN0O8,K<&@#.^)NFV?A[XRZ8VBQK
M\CPS,D7 #E_TSQ7O%]XZ\/V&IQ:)?:G'!J<P5!%@DAF''\Z\Q\#_  K\0:CX
MM7Q3XVDS,C^8L#-EF<="<< #TK6^+/PJO?$NH0^(- D5-2B $D1./,QT(/K0
M!Q_Q'^'?_"NQ#XOT75)6NOM>YA.JG#-DY'%>T?#[Q++XM\&6.K3H$GD4K*%Z
M%AU(KQ.?P3\5/'<EKIOB-FM[&W((>8J!]?EZG'K7OWAS0;7PSH%II%GDQ6Z!
M=QZL>Y/UH U:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **\T^)EU\18-1LQX+A:2V,1\[
M:B-\V>/O>U>2:S\2OBKX?U&/3]4N/LUU( 4C:",DYZ=!0!]345X+I&J?&DZI
M:/J4!CT\R*9WDCA50G<D]N*]TM[J"Z3=!/%,!P3&X8 _A0!-15=KZS2?R&NX
M%FSCRS( WY4LUY:V\BQSW,,3M]U7D"D_0&@">BJ\M_9PR".6[@CD/17D )_"
MI)KB&WC\R::.-/[SL /S- $E%1PSPW$?F02I*G]Y&##\Q3V944LQ 4=23TH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLES=2I#!&-SR.<!1ZDU4TK7M)UU)'TK4;:\6,X<P2!MI]\4 :-%%% !1110
M4444 %%%% !1110 4444 %%%% !7S)\<O^2H:=_NQ_\ H0KZ;KYD^.7_ "5#
M3_\ =C_]"% 'LWQ'_P"21:U_UX?X5Q/[.7_(M:E_UW'\J[GX@PR3_"?6(HE+
M.UAP!WX%>4_ ;QCH>AZ5J=EJVH063[Q(IF;:''M[T 9GB8?\9'0_]?<56_VC
M#(/&.A&$D2BT^3'7/F'%8$VNVOB3X]6^I6)+6LE\@B8C&X#C-='^T+_R//A[
M_KW'_HPT 9?BOX5ZOI_@I?%VH:[+<WZHDLD3Y^0'T;/459\'^&_$WQ;\/[-5
MU^6#3+!?*A 7<9&_VN>?K7J'Q._Y(Q>?]>T?]*ROV>_^2?3_ /7T] '$?!34
M-4T3XEW/A:2Y:2T*RJR%B5!0$@@=JO?%?Q=KGB#QS'X)T*>2&-76.7RS@R.>
MN2.P!K.^''_)PUW];G_T&H/&,TG@;X\C6[N)FM)9EF4^J$;2?PYH L>(_@OJ
MW@O07\0:5KDLMW;+YDZH"A [E2#S7=>"/&T_C+X5:L;Y@U_9P-%,P_B&W@_7
MBI_B#\4O# \"WB:?J=O>75Y%Y<4,;9(S_>':N7^$&AW6G_"[Q'J4ZE$OD/E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'0"O#O'7Q&GUOX@QWVVY2PL)P%M#+P2AY/'KBM_X)_\ )5]5_P"VW_H1JO\
M$FUMX_CG:11V\*1-)#N14 4YQG(H ]GT+XGZ3JW@B?Q5=Q2:?90R-&RR,'8D
M>F.I/I7+O\>[?R6O(?"FK2Z<K8^V#A,>O2NK\?0>#-/\+ >);6%=-24,D$0*
M;I,'& N.:\RU+X@MJ?P_O]&\*>#;F+1XK1T:>?A$C[L#W/>@#U;1_B#I&O>$
M+WQ#IV^6*SC=Y8#\K@JN<?\ UZ^;X?B?,?BA%XLO([FXM878QVAEY12I  /3
MO7H_[.*+)HVLQNH9&D 96&01CN*Y70K2U?\ :-^S-:PFW^TR#R3&-GW#VZ4
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MG?LV@#2]:..?-3^1KK?B5X)T!OAO?I#IMM;O8P;[>2- K*1ZGJ?QKD_V;?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444  HH%% !1110!YW\;HI)OAG>)%&\CF6/"HI)Z^U4_@
M-#+!\.PDT4D;?:7^5U*GMZUZ@0#UH  Z"@#YL^$%I<P_%[4Y);:9$9Y\,T9
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  **!10 4444 %%%% !
M1D>M<'\9)9(?A=J\D4CQN!'AD8@CYU[BO$? OPU\0^.=#;5+;Q,UJ@D,>R1Y
M&/'T- 'U517ROXL\)^,OA6MKJL?B)YXY'V[XW;AO0ANM>P#XBS+\'$\5M$#>
MF$)M4<>:>,_2@#TBBOEWPWX0\;?%*TNM>E\0O!MD*1B1F&\CG "]!VKHO@_X
MUUVT\83^#];N)+E5+I&7.3&Z]>?2@#Z HKYJ\=>(?$WC?XF2>$=-O7M+99O(
M5%?:"1U8D<U0U6/QA\&/$-@[ZRU[;7!W%0Q*2 ?>4ANE 'U)17F/Q<\=WWAC
MP;:2:9F.]U$ +(!GREP"3^M>70?#;QQJ7A8^+CK\GGM&;D6YD<.5'.<YQTYQ
M0!]/T5\]>%/%.L>._A9XCTB]N))-1LH1);W 8AB!SR1]*U_V=M<GO=+U73KF
M>21X)%D4R.6.#G/7Z4 >W45\J?&CQ'>ZC\1;JUL+FY6.QC$12%V R.6/'UKV
MGX1:_P#VG\,K2>>8R2V:M',[-D_+D\GZ4 >A45\V_"R2]\2_&._OI;N=X+9Y
M9POFMLQNV@8SCO7TE0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;CGU]/RH Q?AK\1/%5IX[C\(>)9'NVD=HM\AR\;@9Z]QQ61\4&5/C_9,[!5
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >)Z[_ ,C!J7_7
MU+_Z&:SZT-=_Y&#4O^OJ7_T,UGU]I2^"/H?F-?\ BR]7^844459D%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %>E^"?#?V& :G=I_I,J_
MNE(YC4]_J?Y?C6%X*\-_VE<C4+M,VD+?(I'^L8?T'^>]>G5XF9XS_ES#Y_Y'
MU.19;MB:J]/\_P#+[PHHHKPSZH**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ %% HH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q/7?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 "B@44 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\!W_ ,*/["U?_H%7W_@._P#A1[6'\R#V%7^5_<S/HZFM#^PM7_Z!5]_X#O\
MX5U/@WPI*;K^T-2MWB6%OW44JE26_O$'L.WO]*RK8JG2@YMG1AL#6KU5346K
M];;&UX-\-_V3:?;+E/\ 3)EZ$?ZM?3Z^M=3117RM:K*K-SENS[_#8>&'I*E3
MV04445D;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%%  **!10 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M  **!10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%%  **!10 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%%  **9YB#^-?SI?,C_OK^= #J*;YD?]]?SH\R/^^OYT .HI
MOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YD?]]?SH\R/^^OYT .
MHIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YD?]]?SH\R/^^OYT
M .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YD?]]?SH\R/^^O
MYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YB?WU_.CS$_O
MK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C
M_OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/
M,C_OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\
MZ/,C_OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?
M7\Z/,C_OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'
M_?7\Z/,C_OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^
M8G]]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^=
M #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/
M^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]
M?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*
M;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OY
MT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\
MR/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?
M]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .H
MIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\
MOK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?S
MH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1
M_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^=
M #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/
M^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]
M?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*
M;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OY
MT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\
MR/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?
M]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .H
MIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\
MOK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?S
MH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1
M_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^=
M #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/
M^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]
M?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*
M;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OY
MT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\
MR/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?
M]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .H
MIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\
MOK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?S
MH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1
M_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF)_?7\Z/,C_OK^= #J
M*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_OK^=
M#J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_OK^
M= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C_O
MK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS(_[Z_G0 ZBF^9'_?7\Z/,C
M_OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_WU_.CS$_OK^= #J*;YD?\ ?7\Z
M/,C_ +Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YD?\ ?7\Z/,C_ +Z_G0 ZBF^9
M'_?7\Z/,C_OK^= #J*;YD?\ ?7\Z/,C_ +Z_G0 ZBF^9'_?7\Z/,C_OK^= #
MJ*;YD?\ ?7\Z/,C_ +Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YD?\ ?7\Z/,C_
M +Z_G0 ZBF^9'_?7\Z/,C_OK^= #J*;YD?\ ?7\Z/,C_ +Z_G0 ZBF^9'_?7
M\Z/,C_OK^= #J*;YD?\ ?7\Z/,C_ +Z_G0 ZBF^9'_?7\Z ZD\,#]#0 ZBBB
M@#+DT"QED9V$FYCDX<TW_A';#TE_[[-%% !_PCMAZ2_]]FC_ (1VP])?^^S1
M10 ?\([8>DO_ 'V:/^$=L/27_OLT44 '_".V'I+_ -]FC_A';#TE_P"^S110
M ?\ ".V'I+_WV:/^$=L/27_OLT44 '_".V'I+_WV:/\ A';#TE_[[-%% !_P
MCMAZ2_\ ?9H_X1VP])?^^S110 ?\([8>DO\ WV:/^$=L/27_ +[-%% !_P (
M[8>DO_?9H_X1VP])?^^S110 ?\([8>DO_?9H_P"$=L/27_OLT44 '_".V'I+
M_P!]FC_A';#TE_[[-%% !_PCMAZ2_P#?9H_X1VP])?\ OLT44 '_  CMAZ2_
M]]FC_A';#TE_[[-%% !_PCMAZ2_]]FC_ (1VP])?^^S110 ?\([8>DO_ 'V:
M/^$=L/27_OLT44 '_".V'I+_ -]FC_A';#TE_P"^S110 ?\ ".V'I+_WV:/^
M$=L/27_OLT44 '_".V'I+_WV:/\ A';#TE_[[-%% !_PCMAZ2_\ ?9H_X1VP
M])?^^S110 ?\([8>DO\ WV:/^$=L/27_ +[-%% !_P ([8>DO_?9H_X1VP])
M?^^S110 ?\([8>DO_?9H_P"$=L/27_OLT44 '_".V'I+_P!]FC_A';#TE_[[
M-%% !_PCMAZ2_P#?9H_X1VP])?\ OLT44 '_  CMAZ2_]]FC_A';#TE_[[-%
M% !_PCMAZ2_]]FC_ (1VP])?^^S110 ?\([8>DO_ 'V:/^$=L/27_OLT44 '
M_".V'I+_ -]FC_A';#TE_P"^S110 ?\ ".V'I+_WV:/^$=L/27_OLT44 '_"
M.V'I+_WV:/\ A';#TE_[[-%% !_PCMAZ2_\ ?9H_X1VP])?^^S110 ?\([8>
MDO\ WV:/^$=L/27_ +[-%% !_P ([8>DO_?9H_X1VP])?^^S110 ?\([8>DO
M_?9H_P"$=L/27_OLT44 '_".V'I+_P!]FC_A';#TE_[[-%% !_PCMAZ2_P#?
M9H_X1VP])?\ OLT44 '_  CMAZ2_]]FC_A';#TE_[[-%% !_PCMAZ2_]]FC_
M (1VP])?^^S110 ?\([8>DO_ 'V:/^$=L/27_OLT44 '_".V'I+_ -]FC_A'
M;#TE_P"^S110 ?\ ".V'I+_WV:/^$=L/27_OLT44 '_".V'I+_WV:/\ A';#
MTE_[[-%% !_PCMAZ2_\ ?9H_X1VP])?^^S110 ?\([8>DO\ WV:/^$=L/27_
M +[-%% !_P ([8>DO_?9H_X1VP])?^^S110 ?\([8>DO_?9H_P"$=L/27_OL
MT44 '_".V'I+_P!]FC_A';#TE_[[-%% !_PCMAZ2_P#?9H_X1VP])?\ OLT4
M4 '_  CMAZ2_]]FC_A';#TE_[[-%% !_PCMAZ2_]]FC_ (1VP])?^^S110 ?
M\([8>DO_ 'V:/^$=L/27_OLT44 '_".V'I+_ -]FC_A';#TE_P"^S110 ?\
M".V'I+_WV:/^$=L/27_OLT44 '_".V'I+_WV:/\ A';#TE_[[-%% !_PCMAZ
M2_\ ?9H_X1VP])?^^S110 ?\([8>DO\ WV:/^$=L/27_ +[-%% !_P ([8>D
MO_?9H_X1VP])?^^S110 ?\([8>DO_?9H_P"$=L/27_OLT44 '_".V'I+_P!]
MFC_A';#TE_[[-%% !_PCMAZ2_P#?9H_X1VP])?\ OLT44 '_  CMAZ2_]]FC
M_A';#TE_[[-%% !_PCMAZ2_]]FC_ (1VP])?^^S110 ?\([8>DO_ 'V:/^$=
ML/27_OLT44 '_".V'I+_ -]FC_A';#TE_P"^S110 ?\ ".V'I+_WV:/^$=L/
M27_OLT44 '_".V'I+_WV:/\ A';#TE_[[-%% !_PCMAZ2_\ ?9H_X1VP])?^
M^S110 ?\([8>DO\ WV:/^$=L/27_ +[-%% !_P ([8>DO_?9H_X1VP])?^^S
M110 ?\([8>DO_?9H_P"$=L/27_OLT44 '_".V'I+_P!]FC_A';#TE_[[-%%
M!_PCMAZ2_P#?9H_X1VP])?\ OLT44 '_  CMAZ2_]]FC_A';#TE_[[-%% !_
MPCMAZ2_]]FC_ (1VP])?^^S110 ?\([8>DO_ 'V:/^$=L/27_OLT44 '_".V
M'I+_ -]FC_A';#TE_P"^S110 ?\ ".V'I+_WV:/^$=L/27_OLT44 '_".V'I
M+_WV:/\ A';#TE_[[-%% !_PCMAZ2_\ ?9H_X1VP])?^^S110 ?\([8>DO\
MWV:/^$=L/27_ +[-%% !_P ([8>DO_?9H_X1VP])?^^S110 ?\([8>DO_?9H
M_P"$=L/27_OLT44 '_".V'I+_P!]FC_A';#TE_[[-%% !_PCMAZ2_P#?9H_X
M1VP])?\ OLT44 '_  CMAZ2_]]FC_A';#TE_[[-%% !_PCMAZ2_]]FC_ (1V
MP])?^^S110 ?\([8>DO_ 'V:/^$=L/27_OLT44 '_".V'I+_ -]FC_A';#TE
M_P"^S110 ?\ ".V'I+_WV:/^$=L/27_OLT44 '_".V'I+_WV:/\ A';#TE_[
M[-%% !_PCMAZ2_\ ?9H_X1VP])?^^S110 ?\([8>DO\ WV:/^$=L/27_ +[-
M%% !_P ([8>DO_?9H_X1VP])?^^S110 ?\([8>DO_?9H_P"$=L/27_OLT44
M'_".V'I+_P!]FC_A';#TE_[[-%% !_PCMAZ2_P#?9H_X1VP])?\ OLT44 '_
M  CMAZ2_]]FC_A';#TE_[[-%% !_PCMAZ2_]]FC_ (1VP])?^^S110 ?\([8
M>DO_ 'V:/^$=L/27_OLT44 '_".V'I+_ -]FC_A';#TE_P"^S110 ?\ ".V'
MI+_WV:/^$=L/27_OLT44 '_".V'I+_WV:/\ A';#TE_[[-%% !_PCMAZ2_\
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M0 ?\([8>DO\ WV:/^$=L/27_ +[-%% !_P ([8>DO_?9H_X1VP])?^^S110
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MH /^$=L/27_OLT?\([8>DO\ WV:** #_ (1VP])?^^S1_P ([8>DO_?9HHH
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L([8>DO\ WV:** #_ (1VP])?^^S4UMHUI:3++$)-PZ9?(HHH T**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img249132499_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img249132499_2.jpg
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ML<'1!Q,BX?$4,A5"%U5BDI73%B,T-U)S=G>T<H+4)#-6)D-3LL+_V@ , P$
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MZL)@N9WEE966)YC6Q:[)JF,W,1)@.'].O8)=^!Z7#C/+7*AO1'5QDS8RUR&
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MECR(//EX!83P0HA0\>B(Y;AMLK7$D<@?X4EH^P.> 5.)Y]^@>./_ $=$6O\
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M4MZ.D_@J"DJ *L=C9YB!U6.9SRTEO\QZ!#$1*C_^>S>)3B0/7*8[+L9A9/\
M ?E #UR>>1D5/8%M39N_DA IN0^@WMZ76\TUQ'N8I?9!:>:669<92@IR,^$A
M1;4H !:5)4EQIP!/FVI)*4+\VT:$_NHLMT1/Q^>B+GIF^_7]JYNO#,27,@X%
M0N2F[R>%I:7ETYN0&&V.6B5MT; :6ZB/\P-D9+*YC:$L_;)R29V%R+O[V!VN
M)++H*6#Z[&PF//\ AG4SX_":G1&_LV?@FP0'X<J*"R]'6G_ 6EM<?&H#V".
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MQ#C:@"02E:"I) (()!/L$?QT15GWGN?",,6BBL[YK];<CJ4S2UK,JTMT_*0
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M:4$92[<QLA9=<4TZADNMM5+J$H4Y7/5;X1+KIC*5-J=8L&&IBPMMU8^%QKD
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MAY2'P.3[ 4I!X]#]W/1Y(Y CW=="Q!L')F&AF$[ACY<B%WLUW+4(<=]:>$$
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MRMOOR6Z0P ,ONS$])U8DW!TN50S9N#K=G&PA'XID=P+04 I7Y)5[X('!Y/\
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M4'ST^I_?Y=E:H#EV_M=SRZZ>>RK%JS$9+U35\MJ2E<9I7QH!Y_?XJY(XYYY
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M@& )]K[B?I>;L([C7V-MQX16I:W PRAL..\*><#: A*WE  +<6!Y+/">5'D
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M))X]<<"'_8S!%HTU@%P%FH@DL^GL&MW[Q>BM1:&(67DEEE*"%)\"0> H?M)
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M!<18[3)U>XE6.C=F4>LQY^/5MO+FR9 DJ1,4REMY"@E"T_L92$.(_<M"^5
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MFS-$N2_1C$WF>:P]A-O0/;S>#UV675IZ/6++D"(A/B2KELI"1Z]GQY'')Y'
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M8G]I#.6WE@;'0KQ#4;$WL.Y/KU6$V'J=>+H_5Z)"F'(Y/S):_NPZE/)(*4J
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M.XK3HHZOE9*ULKG*DS+U;/OXULOV[C3R"4O(4E2D&$01Y[!V$W?K)U>66O&
MT%A#N';HW;7NIMQ2HCX) CT[[,%F%':2E,=A"$--A('M7BD#G^2?(J5[Y//!
MZKECO+ 2;]-]6U!+K!<S]?.Y)]'6\5V64<N6AJ$_&5)!"0TCA*ASZXY'B>/7
MH D$^_Z]+7')]6YQ+E_HY(>*UF!9&PN&S7/I"'4GQ0I((*O(<#S_ !SQ[/L\
M_D'GJCOSGT3OOO12GYN>^"%)!(X\>1X^O1)Y/KC^I'KWU46OW;C\*.J7%/"1
M[=:3QY G\+23Q[)'!_DGCCU[Z*'3D9G15$VWL2Y^$T-8M<FSM5LUM;%\U?*]
M86+R(D-AOCV5.RG6FQP.>2/P!U+L6YB3[\^4[/*T  =QKK'(&>I$W*M3K37]
M1K7$J_&JI!6XCRFW%BZ?.7<7DSQ=L[26\0%..2'^4LH](C1&X\-A*&([2$U"
M7/RY#9;]T43HB=$3HBK3FV:/T662ZFIB2K:UN75055,-A,I^7'4A!>!8*5!+
M+30*GGW"AIAGY%+<0V2>IK#\^G)]V#SZ%; !#EF \[]L\ON JR=S6\=EZPQ?
M'*RII&\4M,WNXN*8]:6;U1-3$2B%)L[>7%I(-DMU1K:6 \U$,IL06+296??Q
M94,.P)D8Q+C5QRO?E[O)#J 4WD^I')V +<^1Y/65.N<9F16[C(V/[17\YA+U
MA<WCBK"TFNO?N4IZ5(\ED'GE+:2E"$^*$(2@ "ZB?F/K:6;U)0G8B7A@[6]V
MD1R"DC5O:]A>46 E_P!GJMHR% M!$1E " >>2H)'//)6>>>.>!^.G[[>0/[;
M*$G>TCET:W316J8[;:#"94*=%9CLL)?:0Y]J E !X_QL^ "@D<D<A7X]<<=#
M\VV'[\K])4??O7[GU5HGL;I(% XAF.RI+$8N(D%*>5J"?(+Y_'!Y] <I ]=4
M,+-&G?\ .JA=BU].NG?JJNY1;4K#CT6Y9C2(+J4AQA]"'&E^*PXDD$?M4A0"
M@H>TE((/(]9DVB\ZO8.-8WO!A7W[^G;A0]:X9A.1NMKI)+U0XYY%*6W#,AI7
M_P#KQI"OE'Y_#4EM*1^$DCH+20=3$-R-O5T6B7VK;NC2F0_7_JD-25%BRKFE
MRF/$_P#]5"4%Z,L#A*DOI2CRY\%N)_=UI% .3XE8/O*EU<)U2DJ"G?%M26FU
MI)\E.K\0AI)2G]RE<<$<<*4?$P]RUG=O5C;J%H50Q\G?DX/+7R:7967T9DU#
MCD,)+[2YTA#:)4T\!U?!!^!KGDM,-J _9SY.*2%NDJ"0AJ[VLWO/?J V3V^O
MVC^6*M-8UL;9$)5;!"7U2(Y2?$@\)"#YE9("1R/ZGCWQ[_D34]GW+CU$Z<P@
M $=6C<NW?HJ0V6&5V/9#.QNY@,QY;3RFVO-/Q"4VE7DRXCT"5H4!PI*O-IU)
M\2% *Z0)]3]^XZ*AS )Z/'9MU*G&'NS=>+XM(H<1JL8S*U;BI31768R[1B9#
M#9"4LW*H 2O(REK^[COOS:F8"@.6$^Q<6MSH\/-^1UY>D.=]48 \N6L/J8=_
M6RA.TP'?6WW18;3V0_&^0E?Z#@]?"Q*N8!*O[@S(7G?26@%>*A-N7PL?E">3
MTB]R1H+MSY\RRWX@(I$;DW.]O9;EB>M(NK8J(\!R.PPA7DIEAKQ6\M2O-;C[
M@/[W'%**G'%J4I:E$GGGGJ"PGT+RW*26F.9NQ6"347-^^Y6^?V[JVW$QW4NH
M42 2F*ZIGGU_B<#90!R!R3_(YYZNVGE]H'9L)G?<*?M=Y4(A2\E3;T68CQ)0
MI*D^O8\?$GA0X]_SSP".D6-PU^=IUV>^\IT[W5D6'Q(9:>:)2EU 6 "?ZG_M
M?S^/_P '\=5%^4UE3S+B4+*'DI)0I/(/D!SPO\>B!QQQZYYZ*<]9[^2K'LW-
MIM# D.+?6RL%2.2L^*OV'Q)\N!_'Y]?Y=0MJS<]WW?V;JM ;7T;?6-+WY>8V
MCMRPUJNQ5S/K2'XY7L!:K23+D)493&/)><&/5S)7[8B.PO"W6T@(+DBQ47_,
MLLAL T(3IMO=]7.NPY *Q?545(.[-G9LB;3C&+W*,>Q9-+)8FO8];SJQBPL)
M4AT2FK$US[#BTLPD1DLHDK\%)>DEI)_O.)WHWW=5^0ZGOOT7$W<^I5P<5<L:
M6.VX]BV2P,OGQ6PH.OTM>W+A7I3P%>3D:JL95B4+"BXF&M*05J;!2_1_-_1F
M\[ZE;I(>[/ FSN[2=0-B[:0;J:9ML+N<1KFH4."8;\=DJ#80I8<#:05+7[6Z
M3P.5N*4I0YY/(]#VWIY^<;K!!UY^AVT&I%I?6%E<RU_B4IIZ0]60"4 K:6$-
MH6KC_M5#@DD^_P"1_!'/0EK!W<OI U]@FE^1'*\<G'>M!\PSJJU5DR;'S1&K
MU.A3K:9"&_B\% %]M"B0H >/R(3P3Z4!^0I!U\_8_P CR73PW&CPYB]HDO>^
ME(*EV7WSX#18<_;+R.$L,QPTRPB:A4AQ]Q)#;3;#:EO*<<5Z2A"%*6K]J05<
M#I%XZ\[?M[+(H)/($S#M=^;@W^RJYA\[9G<CD-I=7]C<8Q@LI)12U$5#<:VE
M)*BHV4N5)9><C*>*@(\1*&_@:3Y2 IYWXHY_V&O4[=ZEA; &-9(CE87L7%VT
M <RE.[2KZJJI<[76RLIJ\I90'ZYK)["-88Y*>0"1#GHA54:?%:DDA'WS2Y:X
MI_O?LI@!:6WUY%F^3_-05V!G<W+Z,["#V;G4\*[D=S=O<^KIM_X/,H&+A]QJ
M#>,V5?=4DYQI2O)+-G33K"(R^IMM<A$.8J-/,<%Y4-"0KQ/H1[$CU;YLJ:::
MO[?K%[O=XMZF0NEV.;ZI\^QB+8P)<-^!,C!2/%?+RD*!'I"2"?P/$_N/( (!
M!2#;'<^?[R[-RU6&;IRUZ'R*VG3-387F4S[)IAYB'YM(8*AXK6>/PE(X( \^
M0#[)X' /Y&(N\;_,Z_N8=G[O(]OY+Z+HI7KL:"OCLLLO!T)^1T.)5XJY (3^
MX_X0/?/]>KII][1WS6)=Y'HT&YYD :0/;/(S>O;A*DS?[EQ'HMI//*@.5<E7
M 3Q_F>?Y XZ/WT5[^7>O5<X>\[?N+X;AN09!9V+$-F!#=> ^4%:EI :9; !Y
M^1;BVT@C@>2N.0/?6*JQ0#740*  29)DL\"TZ/OJM .PGI]O+M@J5=CN4+V1
M&RFWO!(C2[VQ1:08DR+*BN_IR8C<:.APR&D(^5;;:G?$+\O!8X! \NOYD_%S
MCV6SW%\EE<MF'&6P*Z?""1XL3Q^(U 6B0#4QBS2/=Y&BJC#)9GJ=V(($@Z !
MR( T(,V5DVWH^I=F53S+_P!O4Y#),>2GD%MB0I"G&'@ H?XRCX'/0\BIM0(\
M5>7R? <]FAF<OCX%9P\Q@UT@5BH_JH-4TDP0'DR79R%Y&+3350::AX@7#>^L
M-'LND+6S\?GTD6,W'7+4N$WYNR F.VE9; \VP/D6K@>P?V @GV>OZ]X?B8N+
MDLKBXY%6+B8.'5B5"*341)!9RYB9)]5\Y4 #4 ;$@'V_?HJI;GS2CJJ2>^^_
M';CI9<*UNK0$I"0HDDJX3SQZY/\ 'OG\]>6!KN_S=M^H=G=+G?VL/ES/4KF+
MK;LBO.\K*HVS<KO[3%='*G/_ *!3TR1 O]@_;//-.6D:PDM+118F](!:9LF6
M9%G>-,/KK/TV(Y N9%9RUQ;<NVIZ$<R^SK9J9]Y?8/+06+.;P)86:]</Z2&M
M\:KWG-;[IW'A%N\E2T(?L<<RO'VW."$)56S*"LLGVT>@>+]IQP#E3I5PKH.]
M/*W[K/BW /J/<6)U('E"FGMGU7@G;QF4W'LNMI&0['R%N/64>Q\L4$6%H5LI
M_4\7J8S"12XU%DRH+4^OAQ2F=;?.FNFV-M)@0"Z?OGWZN&4))_;EKY>PY+H3
MU5$Z(G1$Z(G1%XK*,[-KI\-E\1GI<*5&:DEOYA'=?8<:;?+7FW\H:6L.%OY&
M_/Q\?-//D"+1L4PBHPF [5UGRNNONIEV%E*+:["VG.(3\TN:XA" "?$I88:2
MB/%9"66&T('!(2YM?V[\^:XK]]T^WT7W30]GSJ6:S@NT\.Q:$UEZDEVI;SC%
MA<55CC;[J%$0)W]FHV/VL)I],9NQ8<LG()D.5EJ8\L=G]S'O$,M!S21$::L3
M=^K>D\]-Q+?^.W\Z(Z)S#J@^VH*2Z/20>3Y)/)_C\$CG\@?U=GOOTD#2P?G'
M,=?V'K"ZB:CWA00ZL-N2(JTN-I)'RI2>4(_8H*_<?8)Y!Y/]/YZ=\^WO8!UE
M?SE6]:Y^Z#L"4TAUH)^);+H_N4I\AP%I(/[N#R!QSSTEW>+,W._=KIW]>^=E
MC[;<,G(JPL*D*?6RDE*PKA/L<$D_R>?]I /'X!'4>]HN^DO(Z2[R;'55C!W@
M-[B/DJ2[,O,VES_#'67GU@E9?3Y)"%>_0 Y"PGD>B #S[5Z]T6U$:Z>NR:D7
MNUYZ,=8[OX\"V#M"@E(:OH$F8VIP*2\EOP4V21Z4GD@H _D'C@<D#J>;B\7'
M1M(Z\S9"TPQ&D_60?96VC9^O((3<:TA,. H1RW(91(Y)X_:&UH6GT2.00>"/
M?''MZ.!!/V!U8S'G*:>>WU^CJ--G8[(OJP,0X8B-(2%MJ80EHI4/WCAM  2>
M0GWPD_Q_'0%WU.XM'-N=G/D@B0H<Q%5]C\Y#-BY*80PI*D)=4L(=;22"H$\<
MIX3RD>N!SR.".KRO=]S;H.1_E"UP(_81ZOIZZ=0M0YCCMIC2:MYQE?W3:4N^
M1"D.?*@-J:< \BA/'(\C_*B"4D>70=OK'SY:-H&446[.[9''9DO)\ GN5EBL
MN/K90HO1700IPM2H:E(:E->1/"VRW("5<I6@^R^3#N9]?X>_T5/W<XS'!+9Z
MFR^L++J'.$28Y4(DA(44_(VM?/CSP"6ED+3SPK]OBHH/M<&.EB':]G#Z%5GM
M:=A[ZL_IMI,>/[%3;,I1'3(#B_'@>"UIY/!_*/(<_P"0(]#^@Z6N?4Z=[O>Y
M44PTVL+',8S<PH;CH7X^<B0?V@D?X4HY*B>."4IY(_D <<QA>8?:7GS$ZEOF
MBVN3V_P(M9)=,EJ1*:;4ZEQM"VU#P25'P5X@?L'OTK\@$$'V1IE_-@ Y,L7W
M[,(_;_1N0E_*%@\#N$P;1RIFNJ6_7O)92\HDJ\1_@\SR21P!XJYX/KGV.>J/
M5MYT;DQL2^Y$A#TYC37SB"%9I>54;4<OO3VVDM(*G?(E)'\G\\CWQZ'HD\_P
M!Q5.O?S90OE^\<28CO1F+)A*&RH+6I;?*_'R'H>1 X]\#G^/9]<=0_SHW?5]
MN541X%CJ-EY7_I<0],9HL9D*K<72SX)K[>[;2%S;SR6E2Y+5*5IA0'6%_;JM
M#8!97(K$I2 (Z1S.W?GY:)9]S?D'MY_)E;NAOY+LIJ#.>3(+_DVT[X)0XAUM
M#CA2YXI2%AQ*0D$I"PL)YY\SQ>_196\=$3HB=$3HBT.+AE-3WMKDK3;LFZOY
M#AFSY+GR/,1!X%BM@)"0B)!:#86XTV Y*? ?DN.EME+)4DD-M;[\SWJ2J(_4
M<UIF>6:DQ;.M>8T]E>3Z@S,9C+JH"4NW,G"I6/W-5EB::-[>L9T93M-<FKAI
M5,L&*AYN&Q*FB-&=A[Z<H/HK2SR2!>-Q;IU<+E)AW=E0WS$%E4]M2_A:06W%
M<'S*>"D<<?N3_(5P0!SXG\]!U^_F_*-_-4T]-^O0!RT&6%X#!=$]-]R^'XW&
M@R+&]K8 \ &DOR&PMPCQ2H-MCEUU/OA7QH/'/^J>NF%@8N,2,+#KQ"&\7A'Z
M0_\ XBX%+Z&HO-S*YUU4T!ZJJ:1+.1($1OZ3=3AEO=M@UTRPQ7Y%4*6%%26?
MN/ME*/BH%93*^-:@D?\ :I( ))''73%RF9P_[\&L/8@>(/H'I)'N"-)6*,7#
MK_MKI/6/8AR/(A:_4=Q-=9H54P\B@3@\/C^!JR86.2>$I2E#I!X4?24@J]\<
M'D#K)R^8I'BJP<>FEKG"K ',DTMYDLM>/#)88E!.WB#W:SWU_>%"VT;/(;=I
MYFH4I<QY12E'EP@ D@>BH*42>/2?W?C@?CCB+GE\BW\:V,K=O,<]P?.)\PH*
MI:S<>.ST3U29+S/D J(ZM?P*03Y%#?ER4$C\$DC_ "'Y+OKOO;YJQ,C4B"_2
MP'\V5M\1V)E"H++%DR6">$K;)4YXCCWZ "3S[_<"1[( _GI:WLSL?+1AZ:LQ
MC/KT>/X^ZV#($V.05+S2&CP\%$ESGR4"DCTGGD?D<>QR #Z/4%]_*'$.[;:/
M!CI%5%W!KS&K-<E#,Q%:I[E:Q\@"5*)400."$>O+R  3SQ^"KJQ>_3]K[>0V
M5<-LSZ/M'*7/JUV5V^W_ &/5USYKY3B'I*$_ X@+2IP(5XJ\TC@DGC^OY/E[
M XZ"/I/6!.G(".BBL%L/4&&;<@"P6RRBP6V?BEH2IM]+B>?!:G&U!UF0V3Z=
M;/D1[_CS!OFYB_<3R14!V'A.S=/606F3(OZ-"@A#CJ J:PT1P@..-@)EM_M
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M! N7<;7AE#W]#IH?0K:,J[PL1@-O"/;0(I84M#B1*:*VU)!"TJ4I?EZ4DC@
M<'GUR.10\=/?O;VUK$EFG:Q[^G)<[]I=[^!JR=B8K)J[X*TONR75SF4MM.J(
M2GY'EN)0"05*4%*!(XY]'I32:B*:156:BPI%-51)>  'F+ 3'):-( -5=0I
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M(U540(E;!BI425!F)":9CM)*^2H-MI"CR?9_'SEO:WI]NPO;2;MS<ZB1</\
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M:D@@J3_'7]2_"'PSA\!R% Q:::\YB4"K$KOX"9-(<4EY8[L7T?T69S!QJW#
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M&9\YQ 29TE*ZO&FFU!0<><GECRG.A1\40X")#SRO'Y%QV?-]'/%%7@-0PJO
M"/%7X2::78$NSU,- ^KD!V\',YG#RX%6)_F)I%-)!J-3/8E@Y# UU4ARP+D
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M@E8*5)"O%1_'\ =>.,/$JJ\(HJ-1M2*:O$2[&&=K+O4:0'\5+2Y\0:)#F.Q
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MX$\V'H6<:DN%RIPO!2!32!2-H @1M[F]S"@"!L:(BUE1V'U?-%>Y"4H\OB\
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M\IM8U34PD<N/OJ)<?>5R&8<&,V%R9]A+7PS#@0VGI<M]268[+CB@DE0";+A
M=,93EFP\NW+CT-='(S'+;_+V:-4<,!ENZMI5BF#,C(4H-RPQ)29+K17Y2OG4
MI*O(*.0 7OJ2)#N#$EGW:QB%T\0 8[ :$;:2S:'2S/-J=>9U;U$MJJRFI<B!
M/#3C:V5%(X(0ISDMCR00.0H<?R3P>>;/OI.MO77;0+! T(:=9CR'E[/K>^B3
M25]:C(<=DLH/VS9F0)!2GY?)(2XII8 4%<'D!05Y#@>:2.D 0.;#]E@_QUM]
M5J.0;#19M.P9*&'8ZAXKBK:;=95P?0<0L+2KC@?GGV!ZZA>&YOOY.&ONSZ*A
MM9VVYNTG[^2IKNG&39U%JY0,M5<^1$=2T&?)J$^I0)2%L(24L*)]?(P@!*3R
MMIT\ @U@-(,:""\W#L>1A;I,ARX\[]-2_7Y*"8>9PL"U4N7!7CE;E%/4O2+E
M6Q)658]AM$J%$<?MKB]RNFQ/)&6:J&EM;ZYA;CQ5Q$K=D38"4+\#3NP EM=1
MSY\F#FVS .KS=G$<]HA[.;KYHI'U+>_KNY[M<)[=-%Y_B%#J[.=X8_J-G9>E
M-;V4:MMJV7*^\R*SK<MV4S?7T5=;BL"^R&+,KVL5M)-/5N6S=?"84E* &I<'
MJ]M/XDZW(7/Q$0"&Z-U._<-"^QS*M61JNG=;>CN-2/M%*0J0M:GW 6P M;CB
ME.+6?R5J42HDD\G\<\4U4X>)X6-1IJBQ<@ZDAW8Z3HP9NE-0-0+6=C!V>&@_
M6%Q,S..NFVI?U:E*<;^^062L>_C63Z_CDH*5^^"5$?S^>OSCB=%?Y=)-(# ^
M(:P2[@ZL=9TE>UP:Z2*6>:FZ2!KIU]%.5OAL[.*^KH7ZFJN,2M*54"XKISS?
MC)DO//<?+#<24O*\?LWH4E*7)%?)CF5$,>6B.Z?SC/CB&6SF#F\EC5Y;$P*C
MB89\=6'3428>D5!V(U#>4+M2*&J%0!!-B'T8Z?N[K_:[L)N:BGEV'A?(H A$
MV+B]MFN07$)!95YI,:G?:;,EPI]MQ[NPELAQ+?Q--D>73/\ QI\2YK*U9''X
MC20U7Y@P,O@48N+ --!Q*326(!$DW.ZS^1@NU-)H+W+52&9B1!UCUWEW7&&5
M5=!B1J+'V:QZK;1&EO)B*1)6L(+2'7'%I^8%]+:RIKA)97YL^(2E*E>ER^=.
M;PJC74Q  Q,*H_VD$0T4G]0!J\.H?KMF )#,P#?,#UU \KW/[?M<63N3S;F>
M@K,V6VMGA!!;@L(2VT%$_@GQ=?)'^'Y0/SU^A?!6%A9CB=.%4 V#0*F-)(\1
MI)\,[6>(<!I7@YS$:GPNQJ8Q<S+M:"65P<ZRB-B3#K$N<TFM0Q\SRI#K3(B-
M@'S+CCBT#Q0D>7*U#Q3[//!/7[331112*::*:*02U(I  )J,@ -)+GJY7JF-
M1<DU$;F8&MI:&U#+G5D/?QJO7F1W&(T[36:V3$QV2_/CW4&HQ:"F0!)^T>R)
M;%@7I4?Y")2*^NF1HA'Q2);<IMZ.Q7+[/9[$^Q?U<"%T\+MLS,1:Y8BQZF9M
M*GG7W?CKK*:M"JC!=AW$A( E+QFIKK2D^3@$JK\AMK3'(MG&')\93,=#;G'"
M I7 .OHH:2#)'OSY<O=;I V_0;.R&#+IHEI6O5T>69M=>055MI#>*&$B/)8\
MWHZUMA84I<23*;"5-.)>4T^TI>3)D1#.=8V=B+7FVJU2((<$EW .C%C;5QI!
MZ%2=B5&C)[XOS4)D5U?XOR6E\J;?<2"F-'7[X*%O?WJT'E+C<9;3@4APCJZZ
M:GUMZ@F=94,#1S&\"#?F(^ID6&2E*4A*0$I2 E*4@!*4@<  #T !Z 'H#T.J
ML+_>B)T1.B)T1.B)T183(Y^.UM'9R<LEU$+'?LY#-N]?/1&*A4%]I;4EB<J<
MI,5<=]E2VG67N4/(4ILI4%%)M-1HJ%=)--5)%5-0+&DTEP01(((<'0H1X@00
MX(((NX-PW1?(+W*_3_P[$=E9=LG0M?E+&EIM^V[65US&>1*QT3&4R9$JK=6$
MV*</59+?C4AN6&[*#%3#C6:GS(;<3^L93XSS7Q/7E,KQFK"_K,GE*<K@YF*:
MLW335757B8M51_[0QH!\):L"JL4C]07S'^!X7"QF*\D2,+,8QQ:\$EQ@GPTT
MBC# _P#[;@ERQ!('B( *_;!IV7X8U%A3V79E:P$(0^&U!2VP1Q\W ]*(_P!;
MTD^_0/'7M*LOBX1!I?PN2#^_I[N\ ^+54*;^FWKZ2KK:RP^=M-Q,?$:2586@
M<\WWTAAB%7DI'[9\Z2XU"C)/(\$O/(6Z#PWR0GFXW%<CD,$8F=QJ,%V\(OBU
MG_8PJ7JK8P6! U,A=<'!Q<P6PZ"6@FP!D_JJ# .)!U<!6"QOM]R15HAK/VJW
M':YI1$AJMFP9]U.4" &HKD=,N!#2ZDDJE.OOK:X 3$=Y\T?/<1^-LK1A5#A_
MYF/C%Q37B4&C!H@CQU/4*Z]6H I!+O6(!\W"X3BFL?GUBG##$TTU>*NH7;_P
MCF9W +Q&&T^P_'\J4]+I<[EP82U*4ENUH(UI:1B03Y-V4&SI4.CR)(08+37B
M4I6'/$K5ZS!^/,P*0,?(8.+BLQKP\6K"!()/B-%5.(:6$147;F&\FKA.&013
MBU4TM8TBH@%@0_BI<$S;7J_,^V[!]GXC?9 FGOZ3+F9$DR:]?*J6?):\ C[1
M<>6_(A,OH4.4J79H86E?)4VI)2?H.&_B#PZ@549S*YK!J)<580PLQ0!#N37A
M8@8O%-$B'=PO!S' L:HBK"Q,*L,'IK-6&78M_EKI+B/[@9F+:Q#[/>Y2X?G&
MGUQ9/2:UH/R83.08HW9!HDI2MF&<@^68E9!2@P1*2XL!I)+BFTK^EPOC;X8K
M\'BX@:#40/#B97,AB=*B<$T!K^(U>$"Y#$CUM?!>(,6P ?"7C$PRXT;]0,Z!
M@268;8*VP3,=;1FU;$PW+\6E/A34<Y=06]&I]Q"?(HBBSAQ0[X\<DME8(_<#
MXGD_39;&X9Q&CQ9+.97,4D G\G%P\7PO9_#54SRX+5.X7IL?)YG"+8N#5A!V
M'CHJ#ZP=>H)#,RH%MJ\4G,H,E7J.XI:1P>4'A0\2!^ HCD<@<@?_ %?!?%F4
M.'561_FJ/ZRX$4EA9VI=BY8D,1"]MPVH4BJDT_VT1&Y'7GMN K?:?R%,"CCO
MM.QPOR;4$O@.-*!2H*24#CGT4J _E0'L=?A/Q1P7.\5R6+ELO7_3FJN@U8I_
M,II--!+@G#IJJ8U-4/TL32Q%RO?Y;&P*,:C$Q*!6!14!0!23^H#]1%4;@S#]
M'M%C?;QBF=2D9=_8>KKW7GG)4BQ,BTAN6CSO*WG[.!6RH$6X^91*G%VS;Z7O
M(^W$J\3\;BY7XGR>#^37\09JF@X8PFR^%7X1A@>%C4!A20)JJ<DDR;+SOZK
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MQ:$(97\7/R*<?04!#GH^,?&>0X13X,'PY[-$&G^FP<6D4X9!+U8^-33B"@-
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M6V[ WZS<1T0T2FBIU2&T)2I"4I*^>5!(X)/'Y)_ 'KG@@KOM<F1]!M=W$<D
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MGPA@PA@ P #$  6 T B)%E]6FIHKV(1($9MI#$2*AA+80/#Q2TA*05 ^S_A
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MP\GGUZR(L-K+!#=_S87G5Y$GIO1[LK(U&RA;L=Q;;(^-:W0/$%//!'H'Q))
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M \AI8.\PH(L^VE58M4_$[V]J[9!4\#]P]8,//$^7+[4X2%<*5[64.-*/\+
MYE,O[ZN!RG38[7=;?6".YT9CU^A]N-Z[[AK5UFOM<DI*^G2\&G)$2+*7=/1P
M0"6V/F>AMJ*">%.N<@\*#2A^WI+@'PWYFXF(&_[F^?T,2 2P](&M]@-03L)O
MOH>%)P1+^!32^\Q-7*N:Z;((6^]-2ED6*)3G"5*=D,!EYH!(;;3%>0CQ2I"$
MZ&VOT)++%1>;:-T'T?E#<VLQU5E.B+^5K0TA;CBTMMMI4MQQ:@A"$(!4M:U*
M(2E*4@J4I1 2 22 .J 20 "22   Y),  "22;!+77.QV _WW; 8DS [_ -!C
MJW)/F@Q%!3<7N>V7C<\I$^0D\*FZ5P&XB+3";/\ UOV#D\94E:)V/UC!?_1!
MB#X#R%5%#?\ 33BF6\.)7!K^%^&9F@'\NG2CC>?P:@:R/^LX?E:O"#AYC%J\
M/SAI_P ?S -0?@F4Q7I&G%<UA514?_%D,M7212#^G-8P-358.'2:^B3;;;3:
M&FD(:::0EMMMM*4-MMH2$H0A"0$H0A("4I2 E*0   .OSLDDDDDDDDDER29)
M),DDR2;KZ.UE_?41.B+C1]5[04_*X>"[;Q6E<DSJN+;XOFCL..XMZ;5O*@RL
M;4\4<M_/"?\ UAB*74H5*,IJ&AY<A$"(_BIX( B><3Z7_E=*#>DEMNNOTWZ%
M<G-,=Q\C4=#.PG+8DN37M*5'@6L*,J0Y&9!6E$2R@#F0EQH'XR4,J4?$'QY2
M4]5PWL[$[;C>)N1Y#55,NP8RSD7OIKS/.0H3VIGK61W7ZW03[*A8E*+C,V56
MRH#3ZQQPM@2FH2G "%)\DJ*P1X<G@$/$"\M+:?7<;[1S,8!ZD38M#^>IGW$U
M]O?<AL_7=E!&8UMO<88Y*CF1E:J^9#8KHJW$-)D/*?*FW(R%$?*^RM2$(Y<<
M"&TE0.#&Q9RU^7/R92JAY$%K?+5AM"^A'!]A5&5XW66<"2S)9DQVU!8<2?P@
M>_RH'E/')/(Y]>N.FX,P78>;..1V!+N-5SMN"#W_ "ZD>LNH49QA:WFVVRZV
MDA2A^"H#US_B21_^+^G0%F<AV+'E#N"S%NI#$Z*&?GM-_IH&^2VS;>SL?Q?!
MK*S^[CE#$%V2LDH"6VV&E.*'*BD#VG@D\<)Y)///5,P]PW?>]] DV.G\<_)Q
MH5PXQS52^[#(+C+<ZR6[JZ6YDR',<QZ)82JZ.Y4QW'&8L^>Y'<2MS[I/#\>*
MX/@0TX"ZETJ'#[].W/JMG],,"=RUITOKZQ("UG*^QJSPRT*M=YG-@F.XAYJ$
M\],=AJ425%*6UR'6^">/)25-DDE0 XXZ/K,Z='F;.+VT>5?$]P8,D;'Y"PB3
M\YWP?0FV[)F%'S"^:A5K3*5S$U!=7)E-M\<H=DO( 1\P(2?B05)Y/]XK_%T=
M[2_?>JR2-)+GGT/.&O$&)5_]:8-7815,?9P$M(;0%$('+BUD%2G'G5 +<6KV
M5*4I2E>SS_/0GT?F\-;>;[64D]9]&+^WKU4@7&10I,-;7FVEP)(^%9X)(YY
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M*D,1T)!^-7BVA("4I"0$!2$A(X60.>JW=]7!T/EY!  =CZOH^MIT=X))*D'
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MTV[V"XQ[7G=RW:)8NUVY,4LKK"H;Z(]3M_$H<F?@]W$</C%=GO-_,]BMHO\
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M3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$7#'Z&'^\/U4_^.D[Z?\
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M_4?FXV5H_H,7,Y8\$PJ:*:J</,G#Q<?&(J.6IH\0%!\U[&.Z++>Q3!M(TK>
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M+S"L+-(!8DP:@#'[K 4/=OW=85VZ]J7ZGJ3M\BYAF';W29_LW>7<!W8W6O\
MMYHUL1ZJ'B5$G9,O2MML'.=P[$QY]C-\GI'M>4-!ASIO&%9MEJ(L"PN2-229
M.C?I#E[QXF'KMY:GB/U9,YVMK+LWN=,]MF+9WM7NXW!W'Z&BXI_I_@,ZQPW-
M^V^%G\C)<LB[?IM=Y"SG&I;&-KVUR6!E=!B2+B=B3\6328W=7,B-4/E?#>8
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M2L_9AUH[ V)4K3L[9.FUYU<8>Y!UPC96JZ6UR7*,7_M.J>LKDG'*6PNJ^8U
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MFM=@8IEL!O'&[75FMG,.PW&:K$8E/455U,SO+YIF_'<Y9+A4U4VGZOX[^.>
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M;/,L5PJGO[F'BES:YIC:!G,:)*PQ-7;UN0IO%4%C L9)4M^H @_IH8N #X0
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M+36L^BI\QHWJC]-@WMI5.74F-76]I/O,894KZL_!/P_PL<0JRWPQF,SG.(_
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MANKS#JJAO(7S5[%BWD%=;4\ AI(#N+ M+M4'&C>ZM/W@?_-+[HO_ !==V_\
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M'E_HE_$SPTT_]%.*^&DDTT^++>&DEG-(_J6!+!R)+!T_TM_AH*C4/BSA0JJ
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M /27%(=IRT/=O_U$/KNK_I<_#4N_Q;PN6?\ 3F9:S_\ Z>6TV7Z?]-#[ O\
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M*^HO8O\ NJO9Z+-%S_\ 37__ *E4IG]O65Y/W(?6PRW'^Z'N;U4_I*)V]V&
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img249132499_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img249132499_3.jpg
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MZDNL$& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M^S!DY8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MYIP_^:9<'3POW:/J1N;)_P HK_E@_P"G6#H=F , 8 P!@# & , 8 P!@# &
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MTW;9//>G&RW[KB3_  D_D4C9XW/X?;%866P.--,4JCSS7MCOR\UE5Q5F6RM
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MZEQ?99KIC9ZT9K[(R1O;EQHG<0E)TD8I357)F_X"Z4G,GQXETJXPM'S;'2^
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M'OWIPSM1\*X^;.?B_NU_4S9+FCF, 8 P!@# & , 8 P!@# & , 8 P!@# &
M, A]V4?U;VE?X3^[_P""?&[/._BK^I^2/0OAH^E>;-M. , 8 P!@# & , 8
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MKTWK73?M\LFELJ_K[E?AQ_WX?"M/KAWG!5F3M>91+I4QPV*=G=SD]_'MR1H
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M<*OO(1[]Z<,[4?"N/FSGXO[M?U,V2YHYC & , 8 P!@# & , 8 P!@# & ,
M8 P!@# (@=E+]7=I7^$]NS^"'&W/._BK^I^2/0OAH^E>;-L^ , 8 P!@# &
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MPI:8[:*@9K0\A%I[[6OAF4AFY<4NU5-7EE7E:5&T0NF=?0>=.K)*+]J]P8&
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MY];&X5?>0CW[TX9VH^%<?-G+Q?W:_J9LES1S& , 8 P!@# & , 8 P!@# &
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MQ&/.BRK4#['$T0+76JCK!]D"!!(T#0D/<!5*A2DX:EM8:E-TG9Q=)6NG)?\
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M3,83KOJQ@VF\>4;JZ=H]VEDDCIX4\32Q3@[7;JKT1[I0J+9BU>VS,I>DZZ$
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MJSD: "9M3:+)/6+#M#](,:@?>UH.=;>;E]\#EXE*HJ5*P243Q/T-X,# & ,
28 P!@# & , 8 P!@# & ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img249132499_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img249132499_4.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( -\"70,!$0 "$0$#$0'_Q  ?  $  @,! 0$! 0$         " D%!@<*
M! ,! @O_Q  _$  !! ,!  $# @,#"P(%!0 % P0&!P ! @@)$1(3%!46(3$7
M.5$8(B,D06%Q=GBTMB6!&3(S0E(*)B<TH?_$ !L! 0 " P$!
M   ! @0%!@,'_\0 4!$  0,# @,& P4$" $)!@<  0 " P0%$1(A!C%!!Q,4
M46%Q(H&Q%3*1H? 6(\'1)#-"4F)RX?$E"!<F-$1358*R)T.4L[7"5F-S=)*D
MU/_:  P# 0 "$0,1 #\ ]_&$3")A$PB81,(F$3"+$GRN@0(V;VAMUH.()%=M
MM*?AVXT/9K.]H:6_&K^+:WX?Q_D_$I]GW?=^/OZ?;LBI*H#Y4KG]0H>>8JOY
MP&^6WGOOSY=\V\:VV8M45>C%A8]2Q%N9-(VG6HR'5^N*CPQ FC+HVNA*7JTS
M!#N6!9A#RQ%RP$%8MQG?.DX./GR/UVYGJM)\26K[NL!]['"43Z0&^T(!!PE.
MP:H?2OI>*QV%U2<]3Z.$AOJ16K']'P6,$)]1-<B%&Q$*.2:OFSR:#6L! 6%L
M:N;F"92[&VV#OD ],#3G).#SSL-M\*6GQ9^A+6M+XNJ<]$7=(BMLVFXB%U22
M7'-,1PTK+W<*M2T!K%HT'"&;4<S54$1X>('-FK/GA)-)OQOE537?:A0X .+1
MM@XY_P 54S!?6WH$'2'BOY!;P^0:^HT]]334),9'4D3\J#;:\11&KS5B#8DG
M1)=[!H&C+*TF:^I&"B<=LJ9W B>+2IL5WPQ)KLWV]%8M&7-#0<9&=6';=<%V
M#R.0!R\BI]0?YH(K.O8C[S@,I?2M=I^F+ \E,[-86;P5L9*TJ[8F$B,KD='-
M8%KB/4J8F (C!PM@=6:_)\E-BWY:(C!QALHF4%F!G.^ <=,'E@^?F-O<G9<X
MJCYRWQ^&T_<%W>2G].TC?/EGU'Z:K24@+M%6E,GC/R(':GK1C!V#)UW"FP;D
MP-<\J0(US*GRYKM1CP8!1[MV[3%E)CY@$$AS6G; R[(Y^A&^RE'\=_R=Z]RR
MR7P0]3HVK9*$J^!7-'W<-M/=SPTQ"IX\(#^X\=EG%>UVC%[7A3]LQ;S.#)L3
MK)N@9&$PLG,CUNE4RJYN.N=R-Q@[?CD'H1\\*L&#WIZZN3V%[%C#JS_E1>PN
MK?>4SI.$]^2:X\?'/.\'@ =K "#$%81VVQ/-D-B@?N2$'\I4$)%.$(6Z!N1R
MSDQV\1Y?+Z?S5S@-:,-W;DY#LY)/(C;ILK.@7R5S0S\@Y/XZ%/+SMC:@(H8G
M9N;=W )5KUMY.;Q\,^CU[LG7\$)'B4VD4K-MH#U2*(1-0,<1=$7MC*1U'9;H
MJ:?AU9V.W+^UY'RVWSU\O*,]2?-M,9K"J*M6Q?&3FL:K]0U)Z9G%"2-K?X6;
MF#\W\N0.86%+83-(XUK0"K"@4N"0:1<PF:HOI$[<+,T/WJ'B/W!#C@IT<\.R
M1C(QC8G&<^A(R,==B5A)#\X%BQ:L_-4MDWCN'P^:>LX!(;VJ"'3+U>/$@5//
MH" P"6LY?*)R/I UH-/9V<G243@-;-8R3VY_0*G9=*(>T4Y::*=&Y&20#@D#
M^UD[<^6V2>GEYYVS?G2!0B5^=&;3SZA&8-?M.U!;H^8>B[=<^=>'7=FFWH>2
M5W!"YZJ)/4)V?5"FR5?3H;8]R4\T<[Z0:1MX7Y=(O-E 9SW&02,#?EU\\'?&
MQ.W)=F$_+2F\^08AX<.TW%X!RWL]W6@<_95U+U[:DU:)Q3@^)M.NZJF-4A8'
M8U:R8NIQ'(^C!;[D5EONM_O']G/#3KE#9-/PYSTSL,C'J0<@^X ]5&WS3\KE
MR2^D?/,+IGS[,O5E]2CSK=GJJRMW!?L#K5['J;@'HB?T\*[[G<>I-E'IM/)+
M((T\!1.+C*WA@U@*&LEI)(];X=F'1-(WR0!D ;'F1G//8#J=UMDU^;\L\C!J
M?>?/)+JW(!$O!E>_(+,STQO 94Q$!5DG/3H)+(6F!XK>?=%;$B?4&?*#FK(E
MU'I-TB7YV<#<CQ'<F)HWP3@EQ;L,[[<]QMO[^AZ7FP27#[ @\-G@A%TW%3:*
M1Z7#&[[E/AZ@/D@AF99(O.$E%4N'239ZEPXY2553Y5Y[UPIWSK76RIR6U81,
M(F$3")A$PB81,(F$3")A$PB\?=@?)M[)K/TE\G%0.[?(ON;1M2?>6OCT'O0D
M9Z5KST!&K$\SU[R)B7X@O"IQ^U >P0%@[92']Z3TSK-RNKRHEI9!P7KI!#2&
M_= +M^8()\^>QY?[="\?W;[4]JG_ (\JI/>X;RJ9Q9O@/T%?-CSJL0-,_P 2
M3>QJ\]3<5E'7YMM-*QEH1,>G&"W#5TP#C172_P"W,]\N4^]N5%R'2-9T@[M
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M\I+/2;F.2%9\B/554V&5&[7==+DU'?D<^8!&1MG!&,XVY+J[_P".'R.[%V"
M95PO'X[97DT!XED$>CDC.AP[;SK%_P")M X>#:-WO_H[YEQ+37&Y(V[_ 'YS
M^=-1T_761Y4PFH[;\G:OGMO^2F/$HP(A$5C,+CR*K8!$8\%C -NLNJZ6;B
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M/920W$1K;A_WVU-].YD?<+3/I964NUWGZEX4<.N=K].::CU.=]6_GM\^BEU
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M1?/U[)IR!N![GG^9!^6%>KA53"+#2.1 (A'CLME9H5&HO%PQ.1221'7[44$
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MK.[6H5M888L]4CJQ)4*4C<TG%>R%@B;8;%GAB4GKR1Q61]@9".WRRD<<6**
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M=4S4E,#[-[Z68#_-$WV*K>\,<_)")LSU42=$O)UD*2BQAI0@"D-FDP',-*=
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MH]+Q9Q9N23D Y]TY9->NM)Z*KA@D8QZ$Y_/KGF#Y*;N%"815Q?+W_=B^W_\
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M*B5\T\TKW/EEEE<7R22/<2Y[WO)<YQ)))))73L8R-C(XVM8QC6L8QH :UK0
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M8=-B:KFA:;(ZU^1!?B2RL,ZL^5"727VJ1J!!&3KG;*6IZ5[BRG]GK!6\2O\
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MY7_5=II]=7PI83=*]M97T]0.'[9'47*\U;8I.Y\%;HA4STC)@W1XJL_=4<+
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M)343BQV-$?<TC60X9@X=C4[/Q'8+HZ&"JIX!'65KJ^;6YQJ'4\-,2TXTL[J
M-C ;O\6,G._15?\ H[S'ZIL:_O7D[HJW)G3>I5Y-\U0B%-&8>FR, NZ5P^8^
MLRDQKV7%I[6\^F<+Z;@9O'@;290QY']QE2PTY*Y&390"B%;[%9P(P-L[GY9
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M?112L(#XY:J".1I(! <Q\@<TD$$9 V(/(K-BMMQGC;+!05LT3\EDD5+/)&X
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M4AD'[&.7(?LX5LN4Y_.3(?@_3,DMZWKM=3C7T^F\^B9&,\P<8QZ\E\R.V1U
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M^T^W@PTW"G9.Z+6<.<WC>,R_$0))3'QA&]SG?><Y[G/W.7'FLY)?2WS.L#"
M-3B)#GKKSA*?4:70A&K73?FMXBZCK,HPZ<$:L?\ /$V45DX[8^*]:V\>)IO>
M^5M::]_7GY++VH/SIXRIH<]8[3:#CV[ZW2C\05MHN(>U&,_%P+V-3[@?O9>T
ML DYV_<=H$/E_JN)H>KOEQ.%@0MX4DBJ\D4\JI,.&A*O(\UXW[#ZD7-4_K'
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MMG&SM;![1'Z@ZCN0]LI%PE&C;-NZVBUWPW-\N!.^?RM^^NOH('&X  =PN ,
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MO$M'453J.9M.R.F=)*^H+"V(1N?31B,F3 ,KGEL0S*]DC6ECI1TS\=WR900
M4'GJ#HF1FW$A<D'AJ0>=O&UON'*_0P2T6Z:R:V;<@AM-'2[-;\[0=&$ "Q/9
M T*?E-&%R#BM/PS3T%/3TD/%=VH:>&"%M+2V^V6R\PP4YC:Z*%U9=JB&M[V
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MC5M4R>$&(U<G,_)68-J,\UEE=G=#S,7"0"<%60N;R=]K<?8[=C-"")M>01I
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C)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img249132499_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img249132499_5.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1C04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &+2^8R0X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   +^X1P"
M4  (<G(R.3,W-#D< @4 0$UI8W)O<V]F="!0;W=E<E!O:6YT("T@36]M96YT
M=6T@+2!'<F%P:&EC<R!F;W(@<')I;G1E<B V+C(Q+C(P+G  .$))300E
M   0[>$Z,T\[%,A>.>5A+CWK93A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!HQYW
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  )F   $X@         !                          $
M!.(   )F                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   )F     %)G:'1L;VYG   $X@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "9@    !29VAT
M;&]N9P  !.(    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     8X0DE-! P     #A8    !    H    $\   '@  "4(   #?H
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MZQB6AS#4-88W=[F[/<YK+6X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                      #_X4 B:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U
M33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@]
M(F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M
M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^
M"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY
M.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871O
M<E1O;VP^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A
M=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C M,#8M,C94
M,#DZ,CDZ-# K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP
M.D-R96%T941A=&4^,C R,"TP-BTR,E0P.#HQ-#HR,2LP-3HS,#PO>&UP.D-R
M96%T941A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C M,#8M
M,C94,#DZ,CDZ-# K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B
M870@1&ES=&EL;&5R(#$P+C N," H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O
M<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%!O=V5R4&]I;G0@
M+2!-;VUE;G1U;2 M($=R87!H:6-S(&9O<B!P<FEN=&5R(#8N,C$N,C N<'!T
M>#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C(Y,S<T.3PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E
M871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M
M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @
M>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B
M/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C(U-4(V141#
M-31"-T5!,3$X-S@X0C5#-C(P1CDS04,T/"]X;7!-33I);G-T86YC94E$/@H@
M(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.D$Y0D(S,3!#,D%"
M-$5!,3$X.#9&.3<Y0S=$-$8Q.#@R/"]X;7!-33I$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z03E"0C,Q
M,$,R04(T14$Q,3@X-D8Y-SE#-T0T1C$X.#(\+WAM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D$Y0D(S,3!#,D%"-$5!,3$X.#9&.3<Y
M0S=$-$8Q.#@R/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(P+3 V+3(R5#$P.C$Y.C0Y*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z,C0U0C9%1$,U-$(W14$Q,3@W.#A"-4,V,C!&.3-!0S0\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C M,#8M,C94,#DZ,CDZ-# K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV
M97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O
M(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C(U-4(V141#-31"-T5!,3$X-S@X0C5#
M-C(P1CDS04,T/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(P+3 V+3(V5# Y.C(Y.C0P*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@
M(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C(T-4(V141#-31"-T5!,3$X-S@X0C5#-C(P1CDS04,T/"]S=%)E9CII;G-T
M86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED
M.D$Y0D(S,3!#,D%"-$5!,3$X.#9&.3<Y0S=$-$8Q.#@R/"]S=%)E9CID;V-U
M;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/GAM<"YD:60Z03E"0C,Q,$,R04(T14$Q,3@X-D8Y-SE#-T0T1C$X.#(\+W-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I
M=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H
M;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^
M"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#
M;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI2
M1$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!*0)= P$1  (1 0,1
M ?_$ !\  0 !! (# 0             )!@<("@$# @0%"__$ %D0   & @$"
M! (#" P*!P8'  $" P0%!@ '" D1$A,4(14Q%D%1"A<9(B-A<9$R.#E5=(&8
MH;?1U_ 8-%)3<WF3L;+Q)%EWE,'8X24G0D-BMB@W1'B2HJ?_Q  < 0$  @,!
M 0$              P0! @4&!PC_Q !'$0 " @(! P," P4& P4&!@,! @,$
M  41!A(3%"$Q!R(505$C,F%Q\"1"@9&QP0@6H24S<M'Q%S0V0U+A-5-T=;.T
M=H*E_]H # ,!  (1 Q$ /P#?XQC&,9;_ &K.WBLZXN]@UI3D=A;!B*M.2%+H
MSB995U"V6AJP65@X%Q.R1TV,0WDI J#9Q(.3E2:HJ'6,(^  &O:>PD+&K&DM
M@E%C61BD8+R(C22, 6\<2L975?O=4*)][#)ZZP//&MF1HH"W,LB+WN$4%B$4
M^Q=^.Q>[A0S L0H)$#ECZIW+S3=!YW0FW*)H*\;OXMZITY<J\_T7&;'G]=1&
MSMZ3Y:Q :*V'%+STI.S=SI[QU&34VO4IQB:9@7A%6\5$+JMRJS2LDE-'I2F2
M7_G'6=*I<D@D-/9Q614GV&QH5H^;*?AU>:=)JSR3.MD01]Q=GB&D496S$+I2
M"*;I?<=125?/$MO7/KX['H:5V=NZL1M9DC2O.!&G8LTG!C[),JJE]2WD79-)
M4=A 6OC3LOD[N3E5"<9*JT::BW[IVG:7EWU.?W:76W=J_9=C4VL:4C8&$D92
M/9L'M>0FV4C$*-E4DO4+FL20F>QIZE!XV-VOU!>LWGD6Q5:MH(6GL05XX.V2
M*\':O3GBGD)KRSB9HV1 DL,<D<4&RL7A+&U-=/'%1[#%8>SNK*P5I#-*/')2
M,9DL)-$A65:TL*R=[AH_%/J<\K]DU/3^N]/:^T9%\GY)IRZDMRGOA+W(ZEC6
MW#2T-J9;F5(:0DG'687.SIZ4A0JCJ7E7"%7:.W)Y5*:5:E(M1EMP-4EW=9)#
MIZ?1M#K*S6D9?72Q7MA+K/PN"<*($EAM4=J6N/"RM%4A/IU-GF.S' JVY-3/
M.AV+=6-TI!8B4K35UUJ[=ME+&Y:9XEI6**^E1UE,UASWA(?ORWB>KCPXK6C^
M.&V>06UH#1LOR*U#7MK5^I3[.RRBZ321;HHS*#=W"P3]-9M%37JHXBZ_D*N"
M(IK@B!5/;K[.FE&_/6BE::%?%+7E90C25K,,=FL[J.0LC02QF102%?N4'VSE
M:VX;U1)W54E$MFM.J$E!8I6IJ5CQD^YC\]>3QD^Y3@GWYS*_C/S XV\Q:U9+
M?QJVS7MLURH6(*G9I2O(2R"4-8QCF<N$0]2F(Z-<INOAL@S=B (&)Y3@G93Q
M@8I:&7LR5QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,9;/<E7O-VU9?ZCK.\)ZRO]FJ,]!5'8BD(2R!29V5CEV<?9R0*DA%%E5X9
M=8KYLS/(-2*.$4_,5 H" U+T$MFM)!#.U=I>Q6E0$NL9=3*(R&7M=X@Z*_/V
M,P< E>#9IS15[,4TT(L1Q,7\+$!'=03&'!!#1A^UI$X^]04Y'=R(G>*'32Y6
M\8-#;$TG$\UJ>A)6=1M::]MJE<8Z]$[*6VH:QIS]@O>W)B]7[8Z.W#VY%,86
M<:R+2%D$(U8Y8*9ASMV0M^A/,TE2E!!''6.MFIM2@B7MURU*\4JV:<U12LCF
M[,T$\MF*S!/Y8G9G<2$"FD8]9<LSM)8_$8;HNRR-_;FLV"GI+4-K@QH->@EB
M@K25IJYC9%,:E"S>V;I171]6K/L"<Y-*R'-&P\C:5RB0Y!-]50K.B0^P]>TQ
M?7%8@6>E?I&JU4HA*.]D(F3C7%P4FI!R_7D!G$E4VZ:,*JM,:X:L>F-*;?3S
MO-Q8>Z_4]=*VY$G_ '8B5HX*OH_%_P"[O5B=Q.S3&2;R-8:^VQ5+ MT=5KX1
M"I@])!HK4E[6/&2TH><69K#6W=1YHK,T2"(>-D]:2Z2EI@]=Z@3U!R<D*#R!
MHB7(5E?=VR^L(&W,]FQ_*^6+8-XD6H2L[%LJX^=3R$?)T-XTF'A:H>+9H/$)
MU 5RJZ2P0,C:^%&ATDW353I.W2!#V)=32M>NADBN'M\.P:[+=FDG\+1'U]I!
M H\)3>&=UFEOS".7:MU$.IX;:QB.*/9"FVM[&K<N)*9H"M T7D5V:G!()5/>
M&D[T;H"@:)TOJO1]:BT9&KZCHM=H=>=3C9D^DW$?7XU!@#UZL*/EB]D%45'[
MT42)HF=N%3)ID)X2AT+]Q]A<GN.B1>9E[(8^3'!%&BQ00(6^XI! D<*%B6*Q
M@L22<YU*HM*M'65B_:TTLDA4*9;%F:2S9F*+]JM/8EEE95^U2Y"^P&1G=*EL
MW:\C>L0W;((MT$>H:]*DB@F1%),OWC]5CX2)IE*0I>X=^P  =^X_,1RGEO)H
ML8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&=+AP@U15<.
M5DV[=$AU5EUCE21123*)U%55#B4B::9"F.<YS 4A"B8P@ ".89@JEF(55!))
M(  'N222  !\DD ?GF0"2 H+$G@  DDGX  Y))_(#W.8*R/5#Z=<1?3:QD^:
MG'!E>4WHQJL$OM2JE,A)%6%N,<X?_$!BF[\%P\KT:[Y-SY@@3RO$8 '-<^K[
M?3?MN[V3L_O\G@>/GCOY)]NSGG,S*U?DS#Q\#EN[@%!P3RXYY7X_O ',XHV3
MCIADUDHE\TDXU\W1=L9"/<(O&+UHX("B#EH[;G4;N6ZR9BG2614.FH0P&(8Q
M1 1V961BCJR.IX96!5E/Z%3P0?YC(T97571@R,.592&4C^!!(/\ @<][-<VQ
MC&,8QC&0Q]+#]LEUC/\ 6'/?Z#M5XQDSF,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC(F>9=IY=;-W%9.*VM-0ZJ>:(GM.05AN6P-Q5C9
MMA@; A/6N0A+BA"*TR3@:W(O]81C&'FI'5,]-,9G9[&Q"A&2,;'Q;\SJFJ):
M&S:_V15M=9HO$IKM9EDB6K/L!<6M(5COI);JG5FK"&>E(\=ZP)HVCJR7&8UD
MU[4V>6W=CV".!*($CD26K52FUA TE&22M;EOI=D4QRK7>G%XIB;,7T>".B].
M;<XJU5_N'A5QYHL@Z>W"O! (<<:_0H:VU*!LLG!U>^(:WML&YL=)97RO,V-D
M2JM@<.Y**1?E06=+D\L^=2['')'1>1.V2SK*-NW3EECM&A;GA626F9HP$D,+
M>_[JR1EA$ZK)&PSGQ<P6+T,<OECJW[->"XD4E?U<<1 \XBD^]>':2 N&:.8P
MM/"QBE3B0O5&H=;Z/I[77VIJA$4.C1SM^\B:I7DCM("'-)N3/';>%C!4.VAX
MX7"BBB,7'$;1K,3F*S:($,)<C>6641"61Y/!"D$;2,7<1(6**78EG[>XA2Y8
MA0J ]JJ 2*.-I610IGE:>0*. 965%9^T?:"P12W: &;EB"S,3<K(\DQC&,8Q
MC&0Q]+#]LEUC/]8<]_H.U7C&3.8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QGB!@'Y=_U#_5_?Y#[]\8P4P&^7\_]_M[A_%]G
MOC&>6,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC/%0Y$B'54.5--,ACJ'.(%
M(0A $QCF,/8"E*4!$PB(   (C[8QE$ALW7!J\M;@OU,&J-W9F"]F"T0?T?1?
MD<>D.R5F?7?#DW9'7_1C-CN06!Q^1\'F?BXQE9HK).$DUT%"+(JD*HDJF8IT
MU4SE Q%$SE$2G3.40,0Y1$IRB!RB)1 18SMQC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9U*% "B( '<3!W_/_ !CF
M"/8_[#W/\/X_I[^V,U3Z1O2^73DMO5&S4KJY\AFU:Y?7BE5K:_':VFI'&F*K
M$#:HUBQJ:M,&W4U,L9KPX.J]<%DH:83G21SZ3-(.5'RC-LZ<7R4NFYV8I);+
M2SW-M]U2WQM[<:;!X_9H]<]=(PT'B01I',J+*.&;'4@\-C>Q*K-%7JP"&EJP
M%NUN_35)I*D<OVF2\UEWDAL&:3N-B%F:/@ ;.NSY:]P>NKE,:PK$?=-BQU7F
MGM(J,M,I5Z*L=J0CU3P</)SBQ3IQ,>]D000>/S$/Z9N=14I3'*0HP6C86!S5
M1)+'VJ@D8K&"SJK.Q7EBL:EI.U?N?M"!@6[A8JK7>>);,CQUR>971>^3L4%N
MU >!WR<"-68%4+=[*0I&0(N^J%R_T^UY6ZTVQ!\?-J[JU$;C'6ZG:=0M+E%:
MHJ&Y.4E[:T*,TSL<\E-3KV8F=:"_96N:?P,HP=3<&JF@M%03MTB);L,0V(U]
M77R%9KW6E;I"KM)XW]%?B.O_ !+8;6&L&25/P^&*:O-6$TB^ID@43 K,JUIG
M-!;-Z[$6@I]*;+JF[JZ\BR7Z*TYQ7IT9I^X1R?BDDJ-!.(XBD<%B3L=/%W5X
M'46Y9-*]+\=7\3I93F6TYNPO"YEL9M W!/1:HS^LTMQM=KKTE2PGMH(M:7ZI
MDM4R6D!/-))&^+E9G.)88B-E^"?AW]F-V/JMKXLDS>%NCS(ML5R@C[_Q#OHO
M")!_9ULS=QE,""2>6%M<=F=B1,L%/IVWKO ?$; ZGE\%:.8,)/&*,T%\2, Q
MLQUHB/ ]@^/XK?J4<O=I574.KM1UO2-;Y.N6O+^3W+-W6*N4UJHC?AA:V=*L
M<?1X:*G8V?07VK.RT*:$>2LLY2J+!=^+I"9<-DDU8);<+5)=Y6C?\*I=&4.L
MK%.5_P"US+>V%C5_A4<ZKXXVBLZ_9R&V\;=T4%;]DIG<IO#"HNS:6>97V+]7
M'I.M:C1DJQG\*3='920MW22A*=NA$:RR)S+-*QE B"-EI'=87A92M&\:]J\E
M-N0FB)[D;IZO[8@*C-0]SG54VC]%%M,HMGM;K4RBHUC9SU,>@JZ.V<.4DTW'
MD%*<>W7V=-*%Z:M%(TL($,U>5@%=ZUJ"*U79U'(60P31EU!(5^Y1[#.3K;AO
M5%G=5659K56=4!""Q1M34K!C[ON,1GKR-$6^YHRC-[DYCMT5-M:[WMLKJO;=
MU-9VESUS?.?+N;J5H8MI%DTF8L^E=8MRNT&LNSCY) @KMUD_ \9-U>Z8CY?A
M$IAH9>R>'&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,U;>IGP^UN/4^Z;-?9WKD;!P'-?<O(9'?T#6N3N]ZW!S[>FZE;V6O-J
MY$0M\9,**U8S)2NA;4]"'15+XD52'1,)!8S9BU]1X76E&I^O*VI,*UZC5F#J
M4&I8)V7L\ZI$UZ-;Q4>>9L<^[D)R>E#M6J1G\Q,/WLG).A5=O72[A510S&5A
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8RRO(Y*+<:"W2UG*';-I0[S5MZ9
MRFM*(\D(ZYW]B[K<DV<TVK2,5*0LE'SME15/#QSYE+Q;AFZ=I.4G[0R8+D8S
M4UUSQ-MRNA:+<++T_-WJT4O*ZR[-Y$\(8K7#.'J,77I;C)==0Z4C=34FRV]!
MKLIEKZ>^A\UL>]RSV.FYN\O9"XJ,EBMVZC9C)D-"Z+ZJVNN+'%.A47>?&JA.
MJ%QNUM6;_7-VZ?O>S[LRO\4P=?$F)[54]J5*(6CX6&/ 5I-L$>Z6*^A9!R:5
M>HNT3$8S,SIU[ZV-R:X<Z=W7MLM7+L6W(7-O:34N,?0U75?U;85LIY'$/%R4
MG,OF+5RU@6[CR',F\4(JJIW5[=BE8S-C&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,ZU._A]NWS^OOV^0]_D _W^O,$<
M_P#V_K_T^<9IZI:KW+L+EWNJ\<8=?]7">U4ER[MC:[6FB\VM1ZATP[O-?MS!
MGL%PUT]--$+(O3(YPV,Q4;. 4?3L&Q*BDKXCI@3'2P,%?IN6P2FO:QZBH^U)
MN1_A[;>SY);4$8#>!["V99JP".R]ZL.XDG3J=3+^/P0_=L!26"P-7Q6G%IM+
M":T52Q*63U"5I*J066)CCD[0#V( NV-MRI6R_:NOE+HE]7U=<;549ROUO8S2
M%2L3RD2\O'+,6=G90CA_%H23V&56!\R;+2#5(SI%$5% *40RM=KO;K2UTG>O
MYE"-+'SY%C+#R!"&4H[Q]T8?GNC+]Z_<H!N5)TK689Y(%L+$_?X7(['902@?
ME9%9 _:S(5*R*"A]F)R'[3_1SM=&XLW[B;?^6*-ZI5CD:S>ZC<JQQZJ6O-FU
MS=U3OD=L6.W)<+@O<[L\VO9'5BB6 RR%L(3UL>FJP*];ME"$0Z,D[<:B2JJ4
M[?3U_6WM&\*_V*B->LJM7.N'9%-'<\A-D^2-W+3LS.\W>E%859]HEHM;J;ZE
MLZ.[BF8FSL(]B%56-WWDA--01501R1Q]D'"A(C')<PG2G=&UY)O'?):RNN5T
MCR=CN7G^$[][2H)(-MQ0]61H<8DEI\'9ZV:AMZ,B-;/53SHNE4EEGOQTCLY3
M$@($ U(UP]$-4N[0E_[4UL=2-8;=>=I.TJ9VG0U?'P*GI*8XF$3B6QY'F.R]
M>1;&P@U590H].:D6BDBEU(K%2_!ADB=K!<-ZGU5Q>(EF"Q_)D.D>I$Z]U&PU
M3R?N6M]W:^0Y LKAO577-,MKS:##E1*EGMYI2]'D%F4-!NYF;18R5-?1<@<]
M,6C6)#)3J*:J:VDL,#*:<,;0:>7IRITI:UXD+2S:BE96["4NE0\-XW#:G>R(
MFC)V%U5KJ)(_'O%8E666[*(I=HW4'_,\-T1B-(=KZ237\-64F.:B*30PBH60
M\U*S^8=CK)(WI[CAJO3.G]6Z5@JU%S55U'1J_0:LXLT7%R\J,3 1[=B1=VZ7
M9>$7C\Z!GS\S=-!%5XNJH1$@"!0OWKCW[<]N1(XC*R]L,0(BABC18H8(^XEO
M'!"D<4?<2W8B\DGDGGTZJTZZ5U9I"IEDDE<*'EFGEDL6)F"A5#33RRRLJ@*"
MY"@#(T>E&R91W(CK#,HYFU8,F_4+>IMV;)NBU:H)AH_5@^!!N@1-%(G<1'PI
MD*7N(CV[B(Y4RUDTV,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,9 QU+_W5;H3_P#;3RM_H(0QC)Y\8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&<=@^P/U8QG4X_Q=?_ $*O_ ;,'X/\CC(S>CG^YU:"
M_AFX?Z<]E9A?[W_B.,DXS;&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&>J\70;(BJY6202 Q"BHLH1),#',!"%$Z@@4!.
M<Q2E 1[B80*4!,(!F#[\ #DD\ ?J3^0]P>3_  ]_T&./D_D 6/\ !5!))_@
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M,8QC&,8SY4Q.0U>9#(STM&0L>51-$[Z7?M8UF154WA23,Y>*HH HJ;\5,@J
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M'3BJ]/QR1TGJ4T$%6U,LH#G86H46;8/[J]II&0E3[9\YW<K9BGR^Y/0W$_6
M[-G7.O$F"+Q9!5OL#9D!K,C\C>-?2*C.N.I\#)V&P*D9F]+ ,0%ZX2!9=,!(
M@<,\?UOO=]TYI9=MH>GUZCEJ=\MREZQZDRU(XI':2JD=6W);G+JJ)6CC#OW$
MJ20 ?=?3SIOIWJSJ*MH^HNICTK#?:&M1V34%NU3>GL111QW7>W3CI50CO));
MDD9(PGW*![Y<K0NUVF[-85[8[![1I!K/#( DZUS?(;952/Z&1=,#%C[A ?\
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MSQ+[)3,1#-E'DQ*QL4T1(=15U)/FK%LDF0!,=11=TJDD0A"@)CG,8"E !$1
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M@==%%Z@LB58_A PW[U22A;GJ2LCO"R\21\F.6.1%DAFC) )CFB=)4) /:XY
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M6/CA8J<52G&@///8E>O$%]V)X'Y_IGNOPR@3W-6C=O;[G!<GCXY+$\_XYD#
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MILJQJ.+//J"RHFL*NV-8=E[$FE/Q&D-3ZBQ$\G(KNG(D;B\.FC&M3J%%V\1
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M/;$U#;;!;:I6=@U>2KDY9*)9G%-N,+'/$RF<R%>M30#.(&1;D3\:4BD4QD
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MW]LVY!^/?-_\_P#$$?ZX%0A?81[?Q#_X!_SS//\ M_U]L?U_J?\ 8X\P@_\
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MQ[79^.NEJ[JM">U]NO;^J(J049H).YMR:)UY<*LTD4EIHSD\>ZEFBT@BQ\I
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M<#VYS[C3IK;^>*(NMB\6*EN=\F4@'7VIU%N0ED0,J &!18C(*BU;I&6 0!0
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MRAW$1[%(4"AW$1]O<1'-RQ8EF/+,2S']68DD_P"))_3^6:*JHJH@"JBA54?
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MFM:[QUOME2X)4F?92AZ1;9.FS8$<-O:4BRHF67:^!4XN(Y;S@!J]('EKF36
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MT5G5)9TD11%'*_;%+*RK'&[B<5I6BA>-?)+;M&CKJBE?4[&\L7G:K50D*72
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M;DL<,%=9;-J5YYY1#6CB@B\DLCN4BC2-22%51[9\_P# 9<!/WJY#?RL^1O\
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M/6WR$G%/H^8=%[E=LG16[YDY0),\!6O':22*:)K=W72^(EFK;'6M$MZG-RH
MDA%BO*KH7AEAFCEBD96]H4G#3&$I(C&I4OPM(H5;%&\)C5LQ<,Q"NU>:-XY
MDT4D;"2-05+9?9!D^,8QC&=2RI$$55U![)HIF4./81[$( F,/8O<1[% 1[
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MLMQ;/266;Y/H-E!]T9^R6I;OP,I,X9,RDO3F@0^*SS(:=H*I>KZNO+K=B%/
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MM%V,C!V#IW5-M7J \2-*[/K>H-C[<8PEULGT>$"-H"TSM;K*=O6*WIZVP+M
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M%OWB_P!Y;W!]^[GGW /O^8!^<J9G6*W'2DC.1]?A&$U+^5\6F&44P:RDIY
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MGM3;J>J1;CO:&+515R!"X I)'=BALN"T/KGB@K2R!%*QP<=S0S2QOO0E2.>
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M4<=3OVII&4F"Q5I^'HL2O5I(9X/6QQU1+I*FOZGO[RM<KOY[-G5W=Y'O'UG
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img249132499_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img249132499_6.jpg
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M9YIE^=(*.B#AT[7&5I*J%B*?>E-^Y3+!(P!@# & , 8 P!@# & , 8 P!@#
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M22[]-\MRW_-.AJK5FTY53JA8;;PUHHMK:QD/T5\./H.P+.]8Q&JK1HT?Y?\
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M#GH,<@U9J$GL96TVTKRZ;Y7EIBS6;MSI90<'1?PG6!XQ\UV[6(.=LC55>@_
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MA[DV,6"EEP1=/:K%9\*<==K,5E4]?CV@IUUUKGKG?UWK>L$M--IY3@R_@P8
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MR;+1L3+5PVE/SJ8 @? F0[0GTEIJL1&/6O"FU4.^=!WWU1W' & , 8 P!@#
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M7L?0\^+Z/_LQ\;G@D-UQ]I5#Q[YS=.D_I]-\/2M310L^YWK_ /MR\>KZZ_\
MOK6]X/-7]57\G\LWKP2, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P"?'JKX[X?ZNNVH;\,^A_3M0S>BX\>"5FUIF4U:-CD;(RE5SS)9JR
M%6'3]D*-9V;$JM8V[DC%XT71CHUJ-8),^7!94D*IJV4U%+3S,Z<FK?DZBO\
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M;_G?@_:*0>H+3+-N=_7^9OC]<"N>^/W?BT[3[^G]>Q3^FGG4_P#JOP5 P2,
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M*)]?B26X36X[3Y&8)X_%9_TP]9?WE_R(_P":2?X*J^W^*_)3W!(P!@# & ,
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MZ:ZZX+MIXJL\=%=O.^5&J+5K^6XVAI7H=/%=ZD\*BVEZJEUM[)VW_0NP><8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#1GW/1?@Z>UPXMG
MW-&*U8PVI673I&XY8>)UQ**^9DWB++3..VQ$#$7G\>Y.%'C1BB#CLD;='S#E
M@S18/B*K1+K'&7%M7H:F\+733I@Q3X4\Z_&(.?.KH\7@8!/)<P%1M%U:A.=3
MNZ;4C >QX*!L&.C^9A=$GFEBPEC,8!+P!_@2W?!42H<HARZ:*;2511TVIU//
MPDLM3"A9F^^2GF"1@# & 3"^*S_IAZR_O+_D1_S23_!57V_Q7Y*>X)& , 8
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M2GB%-TN.)F^ZQ[CL' 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M2?!W"_6A*220KQDDFTY;J4\-FEKTS\GNWP><8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P"7/S!P.8V-XP(1R&!#LJ70N:@I+((?&KCKWSZ
M;EL2AUKQF52 (+NBR9#&0U=%>V@?3\+(QA34B:FV W@4V<;47XP53GT<2FTG
M&Y)SNB&=3^)D8J-A]R<*UO?-<[5D<3ZTUO7W?"_=#\G^$67UM>.GX99EDH5\
MS;;W]M\(?.1*IU91N]1;N>&':B0VO/VX^VET]4TK]5Q*Y8(& , 8!,+XK/\
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MZF_I5J5 P2, 8 P!@# & , 8 P"7/KO_ .2OD ^,6COWOA,.E'HWV/,1R?\
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M@# & , 8 P!@# & , 8 P!@# & , U"]M>@[%\PTT-MNN*?F%YN1EIU4$FL
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M* 03'E73?:O)4]MLV)R$KI0>;Q6W75.CA<E_?/J6XP<Q@# & , 8 P!@# &
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M*/WROT_$NY5[^O6#RMMMMW;NS)&#!@# & , 8 P!@# & , 8 P!@# & , 8
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M]W;H2:(_'W[ZG$,)^+KOJ*PII8BU@26X(S7=?^B?$]94&A6DI];+V%/;,ET
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MH\>,A*\2C::V:8E^:T-Z.(MC*UO!I;3_ ,2'RTM/+WII(?$O:M3@0;^H4?\
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MKA-1FR([(WLIVF>K]DE#AK<R,<$"+_H(S?'?4.B)EZU)6SLI.>$IK\EXL$#
M& , 8 P"4LD^4D+&)A\A(4W0MAQ:,^"O.J5\?M)8#A2#O[Q_ \N@4NPA$7(
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M\%F!3AV.(->N^.^>7#1PLEUUQUSKO>^=ZT!SN , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , PY??H"G_,%7'KHO>:LZ]K&,.@
M+$Y*GXXV5;L7<H/C8N ;[81T88+N%29\P-&(<M!Z^]+NT^E?MH\J*<#4FW"4
MMZ'2?.'LGS'ZY:2QUYUN"-66K!'HYA-0[!$R$D\3<&&ZSH-U(HC*18*4!VIE
M!L[4#OWP=!B5_)/N1[EQVR=\H@TUE1^>6\V9P8, 8 P!@# & , 8 P!@# &
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MGRE)H8]/C"#F+R!+2*/VS(15B13VBCOAQK:2>^0EK#S9\5N,C8 P!@# & ,
,8 P!@# & , 8!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img249132499_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img249132499_7.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M05$287&1\(&Q R(RH<'1$T)28G+ALO$CDC-#@J+"XO_:  P# 0 "$0,1 #\
M[^, 8 P!@# & , 8 P!@&NK?BDGG=467"H3,B==3260*6QV'V %[TF6A$I,
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M%:]Y#(S[7M?Y&)GY]D1CWO8] Z\R'FE9N_/J4;AUW2^IHMY4<0 @+ 2KFY[
MCL>%FV=CK39Q,61:0MRC*/O&7#=IV-.%\JIF*9E-S+2;>JA;1&;ZF0"?F,LY
M81$[7->=X&SH>_A'N#7FAX)MLR5MS<@\4P^T)<3YO*#JU\/"Q(-9#.II)RV4
MATHEKZ .W(49)TG2I'IVU&72E-[I)M1"AQ$.;Y6BW-"^@_EE]M)>?+!6C-34
MK3=JD_/'@?UC6<E#68?L-F,IWU[Z$'4P\C$G9R.GV+%"RAY+C31[T.'EX\(
MR F6$F"IV,BDS[[&N%6<MJ:J6HARE*B[E8\9)Z:?*3Z.@BGK(L5\XTZ0B7FN
M\JN\DB'3*ZY:R)SWTM<VO/S:)).^B%4<AX;2\>=W&3>2V>E"#F1*,1@1L*A6
MWS][MJ(J4XN[IO&*:>*=;OY;+J8[W[X] S?U=YE\[S06#J.RJQ]^&//_ *-$
MU%,R$\J"UXC(?#EC>@H,N!D<DB43D7#=-5S&W1^,$PS0K'9+'^$UG[QNZX33
M#A4-YFF5*AKYU3N^>NI?A@P, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MJIHIJ++*<)(I<=JJJJ]\III)I\[Z[44[ZWKGCCCG6^N^^MZYYYUO>]ZUK>\
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MQV:F!COZZ_A][VMK^G76]B5_R_XXVN[7Y1[G0?@P, 8 P!@# & , 8 P!@#
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MFIX_M<LX:I<=*\=2&52J1*-D_NVJDBE$E/=H=%SY=Z\$E[D7O*O_ 'N_D_\
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MNW9_8'W_ -?_ !??_J7[[[?_ (_O/M?7?UP>>K+GRW,L"P9& , 8 P!@# &
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ME=:4;=:T/+6TZFZ5"T[7[NY9=@R, 8 P!@# & , 8 P!@# & , 8 P!@# &
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MO6NM:WK76M\]:^NOK].N=ZUOG>OZ];UK>M_PWKZX.9_W & , 8 P!@# & ,
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M3)JA>!?BJJ:G%FZ;]*8]W:VYV[8.(P!@# & , 8 P!@# & , 8 P!@# & ,
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M^.OL-"BW"XE2X:4I4N)AIX=5K/FIYZ[=0V#F, 8 P!@# & , 8 P!@# & ,
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M6IV,TN5:NFXP@,==AD1ZJ/6M////R/C5.>&;0FU"S+UCS4[=L' 8 P!@# &
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M(.)W]6/?'$85;\,.&J#9PY?@X?$3IJAQ,4XZ)?@N<P8& , 8 P!@# & , 8
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M(</0YE^\;LECC5N[)IQ>?[LKG.NF.'&(]<[+=>C7(O<RF!@# & , 8 P!@#
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M48$G;4DR':MNCX:2TBF=N?7\W/T\:)\[4;YBA*M;^?*LAM00-8X_DJL3@H=
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M/BKN*AGK&# U"XLJ4^_)=CC6ZZXLU&DJ)^WY?,O=_E0_$?\ :G+/_0+T7_\
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M@7^_X _>77']H$)_UJ!?[_@#]Y=<?V@0G_6H%_O^ /WEUQ_:!"?]:@7^_P"
M/WEUQ_:!"?\ 6H%_O^ /WEUQ_:!"?]:@7^_X _>77']H$)_UJ!?[_@#]Y=<?
MV@0G_6H%_O\ @#]Y=<?V@0G_ %J!?[_@#]Y=<?V@0G_6H%_O^ /WEUQ_:!"?
M]:@7^_X _>77']H$)_UJ!?[_ ( _>77']H$)_P!:@7^_X _>77']H$)_UJ!?
M[_@#]Y=<?V@0G_6H%_O^ /WEUQ_:!"?]:@7^_P" /WEUQ_:!"?\ 6H%_O^ /
MWEUQ_:!"?]:@7^_X!EK-ZS(M4'P]VV?,G2?*S5XS72=-7*/>OKPJ@X0[[163
MZU_'E1/OKGK7\=;W@'TX P!@# & : J+RW0M$2RP9Q4]>,HC)[/==.9<01,2
M4JDHBI*)=.%0\<&'C145!8PM-I]-YDO$H,QCD77E<MD,C6$=F"SUZL*VVDM%
MCST6=$EA&I?.TB\WO?1WL?FJ+E'SRU)K8,2EEO0=%5/[,&+5U7T7\\K,@*VF
M#3@V/8$:I7$RMTQ?&^([/$348*N1I)I^5(BN8IE62A=V_P ]B;.#(P#%#<%A
M\DD<+EQZ."BLFKI^9*08V]:\+$(L1D(!_%CCP,OU_.:+E(Z4(!WG?'\56#Q=
M#?\ -[W@&5X P"(GKF<T&3A1?RA<-EJ08YZ\K:T*FBC 0**FI4^$RD2-K:2G
M1#8:%-,V/ !Y9<;1_-9"FU!($2XU-XOM+M7GD53E*8[>O8S'SI>M"6[''\8H
MRTX_9K>H40<)D2X==7MPSZ:,EAH@EWI9JT3(ASO(0ET%DP;EY&#RHTKR#*/=
M#GFD <S+422*P08!BD6@L/A*TJ<1*."H^M.)60G4N4%M>&W<AF!5B,&D9&4W
MQ_\ 4E7C ,*:.'7?\]1%@VXW_!/6 97@&,S.:1&N8I()W/I,"AD+B8IV<DTJ
MDQ1F%  0[!+:SPD5*D%D&;%FW3YWTHLNMQQK?TYUO?77.M@0;DMR^.IEZ7\E
MVF[]$1T?.]T381JG(RHZTP!S>L_38J'3(3+C!$D-1XC_ &7!>?3!*!,S)$$\
MDC0+.=LAY-6-D.!HU>&HM-W&M,ZXUOZ$I:0]"4OZ1BSZ:4?80.Q8R++\@21(
M+^-2VP*K! TG9MGC(FT8$&W)6+R..RD(Y6:<-#L7D .1AUWP4N.?.1EJ,FY<
M Q2<P6'V9$3\"G\<%2Z&2E@H*D4:.->'HDR.5ZX[49OVJG\Q=#OM/CKKCK^&
M]\ZW_5@&5X P#6,@NFJ(K9L!IB0S^,B[8M%E(R< KUP22W+).*B(UP7DI=@'
M2^\=\AP[%LMV[+.DVX[2_/+)-SV]42;]A&>62!-">K?!%%5,>D0'TZ$)5Y:G
MHJ\[+93&3,#8L>ZE%Y3N67]*$0CCN-CTGE?1%G+G3I6=ZX6BP2+(,RDEDS?E
M7;M0:BIO#POM;O;N6B:WK>OKK?UUO^.MZ_HWK_\ 7!D8 P!@# & , 8 P!@#
M & , 8 P!@# & , AU6_@CRQ6"]M_E%9-)()NH4I&9K$K))E+-A&H,M-I[9*
MU<@(;.G1V.1^O59_:$_EBL1&CDA"A*2+(]H;&# 0\4*ZFXY>GJ^?/_9&4#\4
M?D=GZYM*S27C#QNXHZ1>=J)@T-A_5 U&X:B;5AUD>ASUDR1*'J03\D%.#\2G
M%6#%Y(SZV4/IQMN,(ZTTC@O?4A8A1M!>)PE+LWJ]8_V2/_DWOCO_ +A7B_\
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M(2]WW9J#T)\6_BJ;T'>$+J[Q)XTCEF2^H++B]=2%#SI3D=7 SL_"S0J(F49
M+@G1($J+D#L>^3,CN=OA?:&GS36W"">L0MEV154Y4MYW,NKOXRO!H.OX,%E7
MA?QD2DX>'1D7(R*GFBEB2C\\/"LFAA[V1=073I_VZ((N%^GKG6EW6U-KK:TH
MIUB%LNR#J<N&\[F8_P F]\=_]PKQ?_LMT=_P-B%LNR)+W?=C^3>^._\ N%>+
M_P#9;H[_ (&Q"V79"7N^[-<13XFOCPBTZM.<?\D#S9(?WH%(J4U$Y+Y[H\G#
MH!^EHB-B?Y?7 7]WB/Z:'2#\M_4<D;?B'?YG)WQ I]M'\1]SPA;+L7BJM=VY
MLV/_ ";WQW_W"O%_^RW1W_ V(6R[(DO=]V/Y-[X[_P"X5XO_ -ENCO\ @;$+
M9=D)>[[LC?Z&^*/R1."GG-Q5OC#QO'&<%](0V>6LDA0-21S4EJ85#[ %GHRX
M2%P3KB2MWIXU%WO<9*_9%/>QR;U?K2XYM]4+9=BJIWN\6N]U^)1)#^3>^._^
MX5XO_P!ENCO^!L0MEV1)>[[LE;$(=$:^C .$P*+1R$0R,#FX>-1&( QD:C$>
M$M.?L-18, &:LA0D<VX_F-V3!HW;(\_S4TN=?PRD,CP!@# & , 8!7%Y:\$/
M_.5^S^W7MK-)G&WK&]0=51!K!W$<,1,%Z,].2OU78B4YE2TQ/MYZ383J3)1V
M(/QT<AO Z*"O^E&Q<J26=MAIU2DHQ%^E*I73%\_8L=P9& , 8 P"OKUQXB)^
MFK4IRQP\\AU>.ZT<1[E>5=5N6.7*"'@;6@5H/.:<LT78T30KMY+T(0K!I=HS
M$YR-*1T\LIV/WPR<"S J<)J\/2;8:EK4\?P)X'?^*5)KV5M9G9WYG6E&45!]
M#X.O"?T_3WG5>U'%=H2;;B8R[4IL%[W;LBU+I4QU&Q!/3 3L=%Q6^76EQ:JN
M)XB6W$ZN)]D6.X,C & , PJQH.'LJ"RF"G68M\.D@=T/^P8%-3;!J^^SI<06
MZ&//\@X= RR+$R/Z^VBLW(,&KILX;.445TQ4X:>SDI^*_#O^>)U%&"=^<[KB
M,4)Y*J&UQ+.MUVTPFL@\=5A=]<U]+()*^I\L/KP3)^KQ)&I?&2L9G;CZ186.
M$'V?YP6?<B\6;7EM/:8T:Y6=LOE$S?#/C^0>3(Y8R<ULT1:<VL@K5O10Y&X*
M[KB-LH_2]!U9YYA#%E&'\SGKS19[&:L9R24%%)%TW=R \^:"QHT0.'H;$;G_
M +G5O\DZ<$& , 8!%:X?, JU+SH2\FY<5&SU,(VBQ)*<11J1.3,//ZRET #A
MUY'H@P=,!T/?S(O)F#)TW,,UG#TFV;MQJI1T_P!BSE;_ +3_  51$/A(E+R"
MF8H*]&5_!=2&'633+R*5_P"?SH.F(W3-PT+%Z%LU>NZQ(WJ;5B%Q2AE$A<W6
MFO,I(Q3D^FFP>0$BGPY+/QI5WF&[IW=VTY4N,3IV:+^V#) :Q9#FWV_PS!HV
M9-_O>^E5/N&J/""7WBG7UZ4[^[3Y^WWUO[7?7UZW_'>\&#Z\ 8 P!@# & ,
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M>XVWME G+B;\^\FMG?E/;U\^LB2QKO\ ,'PT^&''7"3F7B,+ABV)T1T*8,#
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M$:I2?$W-J9MO*2RG:Y"=G\QS:KZ\X<^@*JW*9[#KNORF+0*T(<B/,7Z8T->
M2EB-K0VNYW8'5K.(B=>R8407;<-I"#B;\;)(R:L%0XW MI '#.'HFIEY4Q9/
M9[-VM#MN:0?+568A*TQXBBKXF<XHL?/7%TU]#P :0R:M'L4]%B/.T9;R!F),
M/7#@?8RSPW<,;,!FQ1LG2,-D\S=):>-68-Z'"^6D<Y4VE>G5HG-Y@]"Q7U-2
M,-O"&L]C TNV?;;$*22&RMR()QF2%XL7'/2\"D,GCVW:!(,YZ4'[)I'!/*G
MV4AH[)6I8 -$:AQ^_P P;]P08 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , ^(D2'AAQ P6>MAHH4R=$B9%ZLFW9L!
M[%!1T\>NW"O7*2#9JV247764ZY3223[[[ZUSSO> :*I+UCYB]*+&VOGWT%3M
MT/(VU8/I PK.Q(M,2(0>5VIR+(E1X,F\>L!Q+I%;@>_<H)LWJB*Z;9=7M%7G
M@5IK*:ZIHD%@@P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M&G+K\]TCZ/CH:)7O5\.M:-1V2MIB!#300@88B)4S%& ;60#DE]?\U*H!Y ;&
M)O$>N5>615\AKK[MPIK8J;6&UT-7&_!OB^1 85%B_E^DG$:KF.$XC!X^C7\?
M8!8W&3!MK)R(0<+'LVK+D>XE3)I+?N%45>49:@G*4/NI!K\QV$O=WYF-1#P+
M08@EZA.6$*4O0YZ]L.(S^XR-J@H$OP_U60@."J&,"!D,AL.$, ]4, 3%W#2Z
M[%[-T9'V[E9*6$9 NF_0"7;2$U;GGOKH2?K:L:]IV'C:_JV' ('#!"Y1VPCD
M:'H#1J3XX5>G3I)5)'G73LJ=.$2)LX5=]KD3!A^]*$G3I\[<+J"&=8 P!@#
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M32,AEDB3#I=HIPKT+#64T;:P08 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M4KY^]?UM\DTD(DZRM$OU.?D+F_H*2R$Y6M92KR0+\LSKS!H!Q+HE<QB**66
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MW*'C7IQTU=2+N'@P_1IPVZ=N^FZQ+;E1'ITXVEUSM=7[0K;>6WU<FYL$& ,
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MXIMI;"F'.I890_KUY<5OS6C)EYLOCSG8<+K:(VQV+N1[1)1O((7,Y1+8>*(
MR%(79<3'E9,Y"CK=XR,KAW2?"**Z:*R*Z??0RU"3E.6U:=(W2W)DX(, T;17
MH>M_10>QCM;.BS@;5ET6I0LJ6,"U!/V)]3DF<1.:<#M**JZ?A42[5;@<63ZY
M2?H<_?<II_QYT*TU$ZI/T=U]KFD_''R#^<_=;,H_H$C+B34/!(58KU23Q5U&
MOL1NP)K;T"C*G&G2ZV^WCLY2,X45:ZU]I$8F(?[[Z3*)<\"U4NG.\6<W23?N
MB;V]ZUK>][UK6M?7>]_PUK6OZ=[W_5K6#)J^D[?AGH"HJWNZNUR#F!VM#0,\
MA[DJP4%D7,<DK!$F)<NQRW7:C-9PR<(K;0[[ZZXUWKZ[W@K4-IY3:[&T,$&
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M[<\J]]_U_:ZW]?XX-5?55_D_<F/@R, 8 P!@# & , 8 P!@# & , 8 P!@#
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MO:G/_:YZP:>*?\7WXJOQ!8%@R, 8 P!@# & , 8 P!@# & , 8 P!@# (O\
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M-6T.;_>*;45C0X:)9#7G;KG0QJY4<ZZ&&YR;1P!@%?WRI_YO#UG_ /:@C_\
MDAF#5'U+U]F6 X,C & , K^\%?\ /"WNR0_T_J+Y ;N_RG\=_>?HV%U-6'].
M_P"G[K]"?A_X?77/W/V/_#],&JM.5*_?YDL!P9& , 8 P!@# & , 8 P!@#
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M9AU"2;SFOF/3P;(G#Q,=*U&C5WFA4]JE>KU.CS!S& , K^ _YU"UO_+^\_\
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M;MIQ$O;71>D%U6#(P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M@8,VH$=OR:S(H[CS(5L[O3U5%T;T1>-N&[9PBV1$J:;;5DW,,D'@@P!@# &
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M$2CQZ52!ZD. QD,4D!L@OO[*+ 0&8KD23U;?]235FV674W_5QQO>#S$*/C-
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MLV#-J^+N&[9HN5>-VZ:3DDLU9)HLVRKY;CMTHW:))-D>U>DT$^$N>.=#!]^
M, K^^5/_ #>'K/\ ^U!'_P#)#,&J/J7K[,L!P9& , KYK7_KY\EGJ26]?SQU
M#^:?-]$"-_Q[TC++)DUJW=97'V]_32/2T64H?OI'GZ]=\IIJJ[^S^'U@T_I6
M<M\M$O7)8-@R, 8 P!@# & , 8 P!@# & , 8 P!@# & 8-9^@FZUL/4F2(K
MQO<&ENI @(8-RA98)^0$/S5(6,=MGK0B148?B.&3!TS=MW;GI)NLV734Z2[
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M+DB2DD#<,!TFTX1:;CKYYT]TW:'=.W"#78APHF0TX710_#_>J<<] 0L^5/\
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M_6GG6*NB7K*_"98'@@P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P#G"^5:/?OE]I0RLWU1L;"8U5YW@5H#3$4^.I_[BFXLK/K3
MM<(J'L$JXL6O0D2@)'FKQ[^#Q'I&6MI2=&S\A(F8?@-']FANEQ==/JX>W/\
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MKP.'^ZGN/Y0J,_W4?D!_V-;=_P#:\#A_NI[GB2;Y+ZYAD;D$PE?FCWC'HM%
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M4*#%9%J>MFFN2KVNF,/?'."'*L81;+$.=.MB?POEXN)8F+1_[3!V)QXZ.E
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M\!H-GS9=%TR6<-U.%=@U#A_O[JQM3!!@# & , 8 P!@# & , 8 P!@# & ,
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M+UR!@T(C0=4AH@==LW1\R8*/Q&V\Z*/1?=^I*C!!@# & , 8 P!@# & , 8
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CMBBB\\Z$=3<3ICS;DK+1*Y-[!!@# & , 8 P!@# & , _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img249132499_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img249132499_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &! NT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/?CIP >Z45XOX(O+#2O&\%G+I6K:'=W"[!;&X+029!QN5UW<XX.X\CTKVB@
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ML?C6MK/@#1M8O[>_5[NPNX$5(YK&41,%487L<8''':NJHH Y&#X<Z)!I&HV
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M*0H7(+%5  SCOQ4TL8FA>)B0KJ5..N#3Z* .;\*>"M-\'_:_[/GNY?M6S?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7,Z<3::F=+MY+$[)-[,L<KL
M&V@8Y)53LP/O<#MSBNFKB[$[O'DLL,FH[)F+LI=EM2GE ?<//F9 ZC;CWQ@
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M]%%%=9L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM6#6]XU_Y'75_P#KY:L&NVG\"]#[N7Q,]!^'?_(N^+_^O(?^@R5S%=/\._\
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M_P#&NG^'NL:E<>-K&.XU"[FC*RDI),S*<1L>034SP3A%ROL<D<0I-*Q[O17
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M\8H DM]%L+6ZCN(8662-0B_O6*CY0N=I.,[5 W8S@=:J6O\ R.VJ?]@ZS_\
M1ES63X=N-8DOXOMDE\P9V^66W=8U@\L$99D4[PY*Y/+ $XQBKVERW,OC36#<
MVP@(L+,*!('W+YESST&/I0!T5%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5%9MUI#W31D:IJ$.R,(?)D4;L?Q'Y3S1<:0\\4"#5-0B\I=I:.107]V^7DT
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M\DC<3L7'7'/2BU_Y';5/^P=9_P#HRYH VJ*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3:
MO]T?E2T4 )L7^Z/RJ"[LK>^M)+6XC#PR8W*"1G!SU'TJQ11<4HJ2::T9@_\
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MZA_WQ_.HJEMO^/J'_?'\Z\Q;GDF'XM_Y&6Z^B?\ H K$K;\6_P#(RW7T3_T
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M9W<%PL=A9HYAD#A6$ESD''0^U '14444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5GZM:S744:PJ&*MD\XK0
MHJ914E9@SF?['O?^>0_[Z%20Z5>)/&S1C"L"?F'K7145E]7B3RH\T\6_\C+=
M?1/_ $ 5B5M^+?\ D9;KZ)_Z *Q*W*.I\"_\A2X_ZX_^S"N]K@O O_(4N/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% '$^(/#FI7^M3W-O"K1/MP2X'10/Z5F
M?\(AK/\ S[I_W]7_ !KTFB@#D_"NAW^EW\TMW$J(T>T$.#SD>E=9110 4444
M %%%% !1110 4444 %%%% !1110 5S$VKZ?I7C?41?7<=OYFG6FS><;L27.?
MYBNGJNEE#'J,U\H;SYHHX7YXVH7*\?61J ,W_A+O#_\ T%K;_OJC_A+O#_\
MT%K;_OJM&ZU&QL7B2\O+>W:4[8Q-*J%SZ#)Y-6: ,1?&'AYU#+J]JRGH0^<T
MO_"7>'_^@M;?]]5IV5G%86<=K "(HQA03D]<U6MM:L+N[-M#,QD^8*6B=4DQ
MUV.1M?'^R30!4/C#P\I4'5[4%C@ OU/7^AI?^$N\/_\ 06MO^^JTKBRANI[2
M:4$O:2F:+!QABC)SZ_*[4MW>6]A;F>ZE6*,$#)[DG  '4DGL* ,S_A+O#_\
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MA<+O DA>,LO]Y=P&Y?<9%3264,M_!>L#YT$;QH<\8<J3Q_P 4 9O_"7>'_\
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M %&'Q1H=Q/'!%JELTLC!$7=RS'H![UKU!=V<5['&DP)$<J2K@X^96##]14]
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M(,K*,;R.A/YT 6*X_P 4V5Q<:FIMXW4R0!'F-D+E/+ E=AMV-AN% Z9WCAL
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MSC.<4 /I&V[3NQMQSGIBEHH XCPJKMJ<#FZ\T+ RB$7J31Q *G* .3R=W)Z
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MC.*LWNF66HM ;NWCF,#ETWKG!((/U&#T^GH*L0PQ6\2Q0QI'&OW410 /H!0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0K#!$D42_=1%"J/H!4E%% &3<>&='NKB2>:R#RR'<S;V&3^!J[!86EM!!#%
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M!D44<*%8HTC4LS$*H R223]222?<T^BB@ HHHH **** "BBB@ HHHH ****
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M@&R523NSMQSWP?R/I3O[8TS=M_M&SSYGE8\]?O\ ]WKU]J +M%9MQX@TFTU
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M=LYQGVJ"T\1:3>6RS)?VZ JS[9)55@JD@DC/ R#0!J450_MS2!_S%;'[H?\
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M.O"@X)Z],\9H O45%;W5O=Q^9;3Q3)Q\T;AAR 1R/8@_0BI: "BBB@ HHHH
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M< '&YR.O3'.>:CT_PU*FEZI9W][)(-1#+)LVY53"D60=@R<)GICGH<9KHJ*
M.8'@BS5TE34+Z.X1BZRQK"N"3&?NB/9_RR7^'N?;&BNA1?V;<:<]S-+;7,4J
M3[]N^1I"2SY &#R>  !Z<5K44 <VG@G34NYKKSKMI9G+OEUP6+*V<;>Q#8]
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M!9VD5C;+;PF4QKT\V5I#^;$G]:GK-VOH6@HHHI %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img249132499_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img249132499_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +) LD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *!THH'2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@=**!TH
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ H'2B@=* "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M% Z44#I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%(65?O$#ZT +12*RM]U@?H:6@ HHHH **** "BBB
M@ HHHH **** "BBB@ K!U[$5]93$==T>[/KSC]*WJQ/%4$\NC-+;)OF@82!?
M8=?TH KZI>!/"$SAR, 1$]>IQ_6J<31:99PWUT 9V CMHCVSTK&L]5369K?2
M8VRLD@EE'H!V_.NAU."*YM=0NI$(6V3;"QZ97GC\: *X@DCNY#=,9;HD-YIZ
M1J>RBG2W 4%5XIEW=;DM+C_GK" 3[U2>3)S0!)),3G)JE-+2R28!K.GG)<(H
M+.W15&2: *^J2[K.0#GO5C1;D>6O-3MX;OY;/SKMTMEDX6,\NWX5@H)]'OFM
M;CAE/![$>M 'HMI<# YK52^*IUZ5Q%GJ:E1\U6[K5_)L9I%(RJ$C- %Z.ZW6
M=]?$$27<OEK_ +HX'Z53M[E(==LU!"JIQU[57N;E;/2K&$MP%W'WKGA=37E]
MNA4D@X!["@#V56#J&'0TM9FAR[M/2-Y-\R##UIT %%%% !1110 4444 %%%%
M !1110 444$@#)H **A:[@4X,@)]N:ADU%(P#Y4I^BT 7**R)M=6,$K"?^!-
MBLV7Q:L1);R0/3=0!U-%<O;^,()&PWEL#TVMS6S9:M;7IVJVQ_[K=_I0!?HH
MHH **** "BBB@ HHHH **** "BBB@ H'2B@=* "BBB@ HHHH **** "BBB@
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M#.\'7TDMQY39.4.3]*[2N%\..=/2:819=OE!;@ >M4-=\5PP;O-N7ED[+&2
M/RH ])HKEO NN3Z[I$TTV2(Y=B$CDC%=30 4444 %%%% !1110 4452FO2V5
MM@K8^](W"K_C0!-<W<=L!N.7;A4'4FLFXNG+[9%>:9N5MXS]T>YI8_-NY6%J
M2<_?NF'Z+6I:6<5G'M3)8_>=NK?6@#,2UU>=?EEALESPJIN)%(WA^:<O]HU.
MX(/W?+PN*TKO4K*Q4M<W,<6!G#-S^58TWB^W+[;&TN+L?\]%3"X^IH >/"&G
MMM^T27%P!U\R3K]<59C\+Z-$J!;",A.F[G^=9<OBR^4CRM$E=>Y+X_I52;QS
M>Q AM%96[9E_^M0!OW_AC2-07][9QJPZ-&-I'Y5Q^IZ7J/AES.\INM,SCS.C
MQ9]?\:B/BZ^G4FZ\Y6).4@8*N/Q&:R[[Q%A6WZ7//$WWPTY.?PH ]#T+5XIX
M%ADF!8+E69AR*W001D'(KPU/&.BJ<-H]TA7KM<\?I6I8>)]%O'Q!JUS8RD8V
M3,<"@#UZBN(MM9U>RA\Q9XM2M\YW @G'U%;NF>)K#4?W;-Y$_>.3C\C0!M44
M44 %%%% !1110 4444 % Z44#I0 4444 %%%% !1110 4444 %%%% !1110
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M)KC(!FO3_B#<0:MX/^T6K!C#.C-GJHYS7FULF0* .AT3DA>A/&:]:TN0R:;
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M*3*65PV^&4=$;^Z37H%0W5I;WMNT%S$LL3=589% &39:^NU$NU(/02J,J?\
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M %FBBB@ HHHH *BN!(8'$6/,(P">U2T4 4;>S2UAV(.3RS'J34A%6"N:8RT
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M)9?Z"J6GQ7UZWF6ULL<1&1//_%]!UIVF:='J-V=ZEK. \YZ2/_7%=6    ,
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M/2JBW'S!<?,> !WK=N],@N96E9F5R.2*R(Q%IEM)J4H\R3<4MHB<;O>@!/.
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M'G:RL,,C>A'XUC.A4@KR5C:&(I5':,KLTJ*Y?Q?%XCO&L['0V:WBF8_:;M6
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M3CJUXV?P5:[:UL+.QC>.TM(+='.YEBC"!CZD#K1:V-I80F&SM8+:,G<4AC"
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M%VO?\-EY&4,)4II\LE>UMO/=^9PO@S4?#O\ :GGS:P=0U^]X9V@D 7OM7*X
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M* "BBB@ HHHH **** "BBB@ HHK.M]8AN/M#;&6.&3R]Q_B/M0!HT4 Y&:*
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M V=.B"0EL8W'CZ5<IL:!(U4=A3J "BBB@ HHHH **** "BBB@ HHHH ****
M,#4B9/$%L 1MAB9F]CVK8LUVVD?J1DUA1M]KU.]FQPSB!3Z@=ZZ-1M4#T&*
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M6@#/TJ)K:\T^W1?WDC--(/0')/ZFNSK \/PFYDFU1Q\LOR0 CH@[_C_2M^@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH @O;E;.RFN&( 12>>F>U<E%;RS6UM9DD37TGF3$=0O4_X5N>)5:32Q$I
MX>5%8>HSTJ/3H2VN7$K8Q%$J)ZC/7^E &U'&D,2QQJ%10  .PIU%% !1110
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M3TH *\P\=0>3X@,G_/:,-^7%>BRZA!&2JMYC_P!U.37"^/5EE2VNG$:E25*
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MLY_A;NM &V%IX6G8I<4 +$N95^M:%4[<?O15R@ HHHH **** "BBB@ HHHH
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M8Z;;VSR>8\: %O4T 6Z**0L ,D@"@!:*C:XA49:5!]6JI<:S8VX.Z8,?1>:
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M/R.I !% %Y1Q2GI62OAGQ+D P.!Z^:*LKX&UJ9SOGC3ON9S_ $H DDD53\S
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M44 %%%% !1110 4444 % Z44#I0 4444 %%%% !1110 4444 %%%% !1110
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MC=BY\N;J;B\RG'8"@#L-#*K:R1 DNDAW$]\]ZU*PO#KL\EYR"H9<8]<<UNT
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4#I10.E !1110 4444
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MYK-LHU2:.R$C,7'[V?/4C^&@#6LH5D92H_<0\1_[3=VK2IJ(L:!%&% P!3J
M"BBB@ HHHH *AN[6.]M9+>8921<&IJ* .,L_.L[I[%F/VJT.Z)F_Y:)776\Z
MW%NDJD88?D:RO$-C))%'?VPS<6OS8'\:]Q3-*NXE9)$/[BYY![*_I^- &[11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4#I10.E !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7,ZAKLMW)+;6!\N),K)<GM_N
M_P"-6?$U[)';1V-NVV:Z.TG^ZG\1_P ^M96FZ0FI3"(;ET^V.U@I_P!8P['V
MH CTZUGOL_V?'A,X:ZFYW'OCUK>LO#EG;.)9]UU/G.^7D ^PZ"M9$6- B*%4
M#  & *=0!@ZQ;I;7<-V% CD_=2@#CV-7]-E.QK9SEHNA]5[59NK9+NV>"3[K
MC'TK&MS-&QC(S>6O'_71* -^BF0RK/$LB'(-/H **** "L'7?^/^U_W6K>K$
MUE-^H6H]%:@#1TW_ )!MO_N"K55M/XT^#_<%6: "BBB@ HHHH *SM2OGAVV]
MM@W#^O\  /4U8O;M+2'<>7;A%'5C65;V4CRM&6+2.=UQ)GIG^$4 1V5D\Y9(
MV;8<^9.QR7/H*IZ41$8HW.XQW1CSZG)KJXHTAC6.-0JJ, "N0N4-CJUW!&VT
MEA/'QZ]?UH [*BHX)5F@21>C#-24 %%%% !112$@=3B@!:*@>\MHWVO/&&]"
MPJ-]3L8F"O=PJ2,X+"@"V0",'H:Y8VXT[59;!OEM;K]Y ?[K=Q_7\:W?[5L/
M^?R'_OL5EZ[<:=?6!$=];K<1'S(F+CAA0!K6%P\]O^\&)4.UQ[BK58&G:@)X
MK?4(R/+E 2<#^%NQK?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *!THH'2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFR.(XG=NBJ
M2: .3U&=9]<NIQ\RV<?ECGHQY(_E6]HMJ;32H8S]]AO8^I/-<S9(]Q;H7_UM
M[<EC[C.?Y"NU "@ # '2@!:*** "L_4K-Y"EW;<7,/3_ &QZ&M"B@#(M+M %
MN8_]1*<2+_SS>M?K6)?PC3;AKM5!M9CBX3T)_BJUI]R _P!E8Y &8F_O+0!H
MT444 %8=[$DOB%)<G,-LP/IR:W"<#)K AE^V37,R'/GOY4>/[@ZF@#8LEV6<
M2^BBIZ11M4#T&*6@ HHHH *"<#)HJEJUP;;2YY%.'VX7ZGI0!1\X75R;S **
M?+MA_>/<UJVL MX=N<N>6;U-9NF1A6MX0.((LGZFMB@ K*UO3&O85FMU'VJ'
ME.VX>AK5HH Y;3]4FLR870C!^:%N"#[5M0ZQ9RX#2B-B<;7X-+?Z3::B 9D(
M=?NNIPP_&L:;P_?QL1;W,4L8Z"5?F^F10!NOJ=E&I9[J)0.I+55EUZS4E82\
M[8X\L9!_'I6,-%U(D 6]LA/5B<@5:@T"]; N+Q(U':!.OYT /DU6^E&=T-G'
MCJWS,/PZ5726WN&W[KR^)/\ #G9G^E:MOH5C 0S1F9Q_%*=QS6D%51A0 /84
M 8,45T 1'HT,8'W=S@YJ1(=3E8@V=E$ ."PW5MT4 8$FF:J_\6GC_@#56?0-
M3DZR6/X(U=110!Q%K%?Z#>R"^@4Z=<':S(<JI]<=A7107ILY%M[CF%O]3,.A
M'H?>M&:&.XA>*5 \;C#*>]<[<H^B9BF22?2WZ,.6@/O[>] '2JP905.0>]+7
M/P74UH@EAD-W:GD%>2!Z5J+JMF;?SC.JKCD-P1[8H MDA022 !U)K,EU^S0L
M(BTS*<$(./SK$U34I=3<*A>*P'X-*?IZ5:T_0&GCW7>8HB/DB0X/U)H NQ>(
M(V/[VVFC'K][^5:<%S!<KNAE5Q[&L*7PPT)WZ?>21M_<E.]3_6JK226$R?VA
M ;=V&%N83\OX^GXT =9169!?R0QJ;EEDB/2=.G_ O2M)6#*&4@@]"* %HHHH
M **** "BBB@ HHHH **** "@=**!TH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ JEJ\JPZ1=NS%1Y3#(Z@D8%7:S/$/\ R [GZ#^8H RM(3_2M.A+?,D&\Y[]
M!_6NHK!TF-#?128^<08!]N*WJ "BBB@ HHHH 9+&DT31R*&1A@@]Q7+8DL;E
M[0;MUN?,A8]T]/Z5UE8&O(4O[*XSPVZ(CZ\_TH VX91- DHZ,,U)5+2FS8(N
M<[25JU+-'!$TLTBHBC)9C@ 4 4]:NA9Z3<2YP=NU>>YX%9>@+OG48^6&,#Z,
M:Y'Q#XKCUK5DM[1RUC;-D,/^6K^WJ*[SP_:R6VE1F9=LTOSN.X]J -6BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** "@=**!TH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"*YA^T6TL.XIO4KN7J,UY"/A=K2WC@&W,.\[9&DY(]<5['
M10!Q6@> (+!UGU&47,J\K&!A%/\ 6NT50JA5  '  I:* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *!THH'2@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "@=**!TH **** "BBB@ HHHH **** "BBB@ HHHH
M**2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!
M:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!
M:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!
M:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:!TI*4=* "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>pmvp-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T09:45:29.7914+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://pmvpharma.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:pmvp="http://pmvpharma.com/20221231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" namespace="http://fasb.org/srt-types/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pmvp-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pmvp-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pmvp-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pmvp-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>100060 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompany" id="Role_DisclosureFormationAndBusinessOfCompany">
        <link:definition>100070 - Disclosure - Formation and Business of the Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements" id="Role_DisclosureFinancialInstrumentsAndFairValueMeasurements">
        <link:definition>100090 - Disclosure - Financial Instruments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100100 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100110 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100130 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>100140 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlan" id="Role_DisclosureStockPlan">
        <link:definition>100150 - Disclosure - Stock Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100170 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedParties" id="Role_DisclosureRelatedParties">
        <link:definition>100180 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" id="Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables">
        <link:definition>100200 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100210 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100220 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100230 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>100240 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables" id="Role_DisclosureStockPlanTables">
        <link:definition>100250 - Disclosure - Stock Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100260 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100270 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" id="Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails">
        <link:definition>100280 - Disclosure - Formation and Business of the Company - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails" id="Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails">
        <link:definition>100300 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100310 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>100320 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails">
        <link:definition>100340 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails">
        <link:definition>100360 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails">
        <link:definition>100370 - Disclosure - Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails">
        <link:definition>100380 - Disclosure - Commitments and Contingencies - Summary of Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails">
        <link:definition>100390 - Disclosure - Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails" id="Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails">
        <link:definition>100410 - Disclosure - Convertible Preferred Stock - Schedule of Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2">
        <link:definition>100420 - Disclosure - Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails" id="DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails">
        <link:definition>100440 - Disclosure - Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails" id="Role_DisclosureStockPlanAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Stock Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails" id="Role_DisclosureStockPlanScheduleOfStockOptionsDetails">
        <link:definition>100460 - Disclosure - Stock Plan - Schedule of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfRsuActivityUnderThe2020PlanDetails" id="DisclosureStockPlanScheduleOfRsuActivityUnderThe2020PlanDetails">
        <link:definition>100470 - Disclosure - Stock Plan - Schedule of RSU Activity Under the 2020 Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails" id="DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails">
        <link:definition>100480 - Disclosure - Stock Plan - Schedule of Estimated Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails" id="DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails">
        <link:definition>100490 - Disclosure - Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair Value of Stock Purchase Rights Under ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails" id="DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails">
        <link:definition>100500 - Disclosure - Stock Plan - Stock-based Compensation Expense Related to Recorded and Allocated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails" id="DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails">
        <link:definition>100510 - Disclosure - Stock Plan - Schedule of Stock-based Compensation Expense by Award Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails" id="DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails">
        <link:definition>100520 - Disclosure - Income Taxes - Summary of Income Tax (Benefit) Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails">
        <link:definition>100530 - Disclosure - Income Taxes - Summary of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100550 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails">
        <link:definition>100560 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100570 - Disclosure - Net Loss per Share - Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails" id="Role_DisclosureRelatedPartiesAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_AccruedResearchAndDevelopmentCostsCurrent" name="AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" name="AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" name="CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" name="CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ConversionOfConvertiblePreferredStockToCommonStock" name="ConversionOfConvertiblePreferredStockToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_ConversionOfWarrantLiabilityToCommonStock" name="ConversionOfWarrantLiabilityToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_DeferredTaxAssetsAccruedExpenses" name="DeferredTaxAssetsAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures" name="DeferredTaxAssetsCapitalizedResearchExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pmvp_DeferredTaxAssetsOperatingLeases" name="DeferredTaxAssetsOperatingLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pmvp_DeferredTaxLiabilitiesOperatingLeases" name="DeferredTaxLiabilitiesOperatingLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation" name="EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" name="ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" name="ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_IncomeTaxExaminationPeriod" name="IncomeTaxExaminationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_InitialBaseRentIncreasedPerSquareFoot" name="InitialBaseRentIncreasedPerSquareFoot" type="srt-types:perUnitItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_InitialBaseRentPerSquareFoot" name="InitialBaseRentPerSquareFoot" type="srt-types:perUnitItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_LeaseIncentivesUsedForLeaseholdImprovements" name="LeaseIncentivesUsedForLeaseholdImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" name="LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" name="LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" name="LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" name="LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" name="LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" name="LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" name="LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_LesseeOperatingLeaseRenewalMonthAndYear" name="LesseeOperatingLeaseRenewalMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ManagementFeeOfBaseRentPercentage" name="ManagementFeeOfBaseRentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities" name="NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_NumberOfConsultingAgreementsMembers" name="NumberOfConsultingAgreementsMembers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_NumberOfNoncancelableOperatingLeases" name="NumberOfNoncancelableOperatingLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_OperatingLeaseExpirationPeriod" name="OperatingLeaseExpirationPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" name="OperatingLeaseMaintenanceExpensePerSquareFoot" type="srt-types:perUnitItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_OperatingLeaseRenewalTermDescription" name="OperatingLeaseRenewalTermDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_OperatingLeasesExtendedMonthAndYear" name="OperatingLeasesExtendedMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_OperatingLeasesExtendedYear" name="OperatingLeasesExtendedYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_OperatingLeasesExtensionPeriod" name="OperatingLeasesExtensionPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" name="OperatingLossCarryforwardsAmountsDoNotExpire" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" name="OperatingLossCarryforwardsBeginToExpireInFutureAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pmvp_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_OtherNonCashLeaseExpense" name="OtherNonCashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pmvp_OtherNonoperatingIncomeExpenseOther" name="OtherNonoperatingIncomeExpenseOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" name="ReclassificationsOfTemporaryToPermanentEquityShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ReimbursementsReceivedFromLessee" name="ReimbursementsReceivedFromLessee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_SubleaseAndAdditionalSubleaseIncome" name="SubleaseAndAdditionalSubleaseIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pmvp_SubleaseExpirationPeriod" name="SubleaseExpirationPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" name="SubleaseWithTenantOfficeSpaceEndingPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" name="SubleaseWithTenantOfficeSpaceStartingPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_OrganizationConsolidationAndPresentationLineItems" name="OrganizationConsolidationAndPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_AssetsNotPlacedInServiceMember" name="AssetsNotPlacedInServiceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_BoardOfDirectorsMember" name="BoardOfDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_CranburyNewJerseyMember" name="CranburyNewJerseyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_PrincetonNewJerseyMember" name="PrincetonNewJerseyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_SeriesDConvertiblePreferredStockMember" name="SeriesDConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_SeriesSeedConvertiblePreferredStockMember" name="SeriesSeedConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_SouthBrunswickNewJerseyMember" name="SouthBrunswickNewJerseyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_TwoThousandAndThirteenStockPlanMember" name="TwoThousandAndThirteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_TwoThousandThirteenStockPlanMember" name="TwoThousandThirteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" name="TwoThousandTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_UnvestedEmployeeStockPurchasePlanSharesMember" name="UnvestedEmployeeStockPurchasePlanSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_UnvestedRestrictedCommonStockUnitsMember" name="UnvestedRestrictedCommonStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_OrganizationConsolidationAndPresentationTable" name="OrganizationConsolidationAndPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" name="CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" name="ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" name="ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" name="ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>pmvp-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T09:45:29.5591+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="pmvp-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="pmvp-20221231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:href="pmvp-20221231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="pmvp-20221231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="pmvp-20221231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="pmvp-20221231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="pmvp-20221231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompany" xlink:href="pmvp-20221231.xsd#Role_DisclosureFormationAndBusinessOfCompany" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="pmvp-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements" xlink:href="pmvp-20221231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="pmvp-20221231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:href="pmvp-20221231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="pmvp-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:href="pmvp-20221231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="pmvp-20221231.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlan" xlink:href="pmvp-20221231.xsd#Role_DisclosureStockPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="pmvp-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="pmvp-20221231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedParties" xlink:href="pmvp-20221231.xsd#Role_DisclosureRelatedParties" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pmvp-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xlink:href="pmvp-20221231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="pmvp-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:href="pmvp-20221231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="pmvp-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="pmvp-20221231.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables" xlink:href="pmvp-20221231.xsd#Role_DisclosureStockPlanTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="pmvp-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="pmvp-20221231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:href="pmvp-20221231.xsd#DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureStockPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureStockPlanScheduleOfStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfRsuActivityUnderThe2020PlanDetails" xlink:href="pmvp-20221231.xsd#DisclosureStockPlanScheduleOfRsuActivityUnderThe2020PlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails" xlink:href="pmvp-20221231.xsd#DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails" xlink:href="pmvp-20221231.xsd#DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails" xlink:href="pmvp-20221231.xsd#DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails" xlink:href="pmvp-20221231.xsd#DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails" xlink:href="pmvp-20221231.xsd#DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="pmvp-20221231.xsd#DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OtherNonoperatingIncomeExpenseOther" xlink:label="pmvp_OtherNonoperatingIncomeExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="pmvp_OtherNonoperatingIncomeExpenseOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:label="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_21"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_22"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_23"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_24"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LeaseIncentivesUsedForLeaseholdImprovements" xlink:label="pmvp_LeaseIncentivesUsedForLeaseholdImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ConversionOfConvertiblePreferredStockToCommonStock" xlink:label="pmvp_ConversionOfConvertiblePreferredStockToCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OtherNonCashLeaseExpense" xlink:label="pmvp_OtherNonCashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ConversionOfWarrantLiabilityToCommonStock" xlink:label="pmvp_ConversionOfWarrantLiabilityToCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pmvp_LeaseIncentivesUsedForLeaseholdImprovements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pmvp_ConversionOfConvertiblePreferredStockToCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pmvp_OtherNonCashLeaseExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pmvp_ConversionOfWarrantLiabilityToCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompany" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedParties" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ReverseStockSplitPolicyTextBlock" xlink:label="pmvp_ReverseStockSplitPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:label="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pmvp_ReverseStockSplitPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" xlink:label="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:label="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_EmployeeStockPurchasePlanMember" xlink:label="pmvp_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_EmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:label="pmvp_OrganizationConsolidationAndPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OrganizationConsolidationAndPresentationTable" xlink:label="pmvp_OrganizationConsolidationAndPresentationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ProceedsFromIssuanceOfCommonStockGross" xlink:label="pmvp_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="pmvp_OrganizationConsolidationAndPresentationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="pmvp_ProceedsFromIssuanceOfCommonStockGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="pmvp_OrganizationConsolidationAndPresentationLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pmvp_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:to="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="0" priority="2" use="optional" preferredLabel="http://fasb.org/us-gaap/role/label/axisDefault"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_Cash" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_AssetsNotPlacedInServiceMember" xlink:label="pmvp_AssetsNotPlacedInServiceMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pmvp_AssetsNotPlacedInServiceMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="pmvp_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="pmvp_AccruedResearchAndDevelopmentCostsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CranburyNewJerseyMember" xlink:label="pmvp_CranburyNewJerseyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SouthBrunswickNewJerseyMember" xlink:label="pmvp_SouthBrunswickNewJerseyMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_InitialBaseRentPerSquareFoot" xlink:label="pmvp_InitialBaseRentPerSquareFoot"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MA" xlink:label="country_MA"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeaseExpirationPeriod" xlink:label="pmvp_OperatingLeaseExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_PrincetonNewJerseyMember" xlink:label="pmvp_PrincetonNewJerseyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" xlink:label="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ManagementFeeOfBaseRentPercentage" xlink:label="pmvp_ManagementFeeOfBaseRentPercentage"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_NumberOfNoncancelableOperatingLeases" xlink:label="pmvp_NumberOfNoncancelableOperatingLeases"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeaseRenewalTermDescription" xlink:label="pmvp_OperatingLeaseRenewalTermDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseRenewalMonthAndYear" xlink:label="pmvp_LesseeOperatingLeaseRenewalMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_InitialBaseRentIncreasedPerSquareFoot" xlink:label="pmvp_InitialBaseRentIncreasedPerSquareFoot"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" xlink:label="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeasesExtendedYear" xlink:label="pmvp_OperatingLeasesExtendedYear"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeasesExtensionPeriod" xlink:label="pmvp_OperatingLeasesExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeasesExtendedMonthAndYear" xlink:label="pmvp_OperatingLeasesExtendedMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ReimbursementsReceivedFromLessee" xlink:label="pmvp_ReimbursementsReceivedFromLessee"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SubleaseExpirationPeriod" xlink:label="pmvp_SubleaseExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SubleaseAndAdditionalSubleaseIncome" xlink:label="pmvp_SubleaseAndAdditionalSubleaseIncome"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pmvp_CranburyNewJerseyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_CommitmentsAndContingenciesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pmvp_SouthBrunswickNewJerseyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_InitialBaseRentPerSquareFoot" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MA" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeaseExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:to="pmvp_CommitmentsAndContingenciesDisclosureLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pmvp_PrincetonNewJerseyMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_ManagementFeeOfBaseRentPercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_NumberOfNoncancelableOperatingLeases" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeaseRenewalTermDescription" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_LesseeOperatingLeaseRenewalMonthAndYear" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_InitialBaseRentIncreasedPerSquareFoot" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DeferredRentCredit" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfLand" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeasesExtendedYear" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeasesExtensionPeriod" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeasesExtendedMonthAndYear" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_ReimbursementsReceivedFromLessee" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseExpirationPeriod" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseAndAdditionalSubleaseIncome" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:label="pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" xlink:label="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SeriesDConvertiblePreferredStockMember" xlink:label="pmvp_SeriesDConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pmvp_SeriesDConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SeriesSeedConvertiblePreferredStockMember" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pmvp_SeriesSeedConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_DividendsCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="pmvp_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TwoThousandAndThirteenStockPlanMember" xlink:label="pmvp_TwoThousandAndThirteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandAndThirteenStockPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TwoThousandThirteenStockPlanMember" xlink:label="pmvp_TwoThousandThirteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandThirteenStockPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfRsuActivityUnderThe2020PlanDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_EmployeeStockPurchasePlanMember" xlink:label="pmvp_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_EmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_EmployeeStockPurchasePlanMember" xlink:label="pmvp_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pmvp_EmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation" xlink:label="pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ" xlink:label="stpr_NJ"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="country_CA"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" xlink:label="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MA" xlink:label="country_MA"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" xlink:label="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AZ" xlink:label="stpr_AZ"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLossCarryforwardsExpirationYear" xlink:label="pmvp_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TaxCreditCarryforwardExpirationYear" xlink:label="pmvp_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_IncomeTaxExaminationPeriod" xlink:label="pmvp_IncomeTaxExaminationPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NJ" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MA" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_AZ" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_OperatingLossCarryforwardsExpirationYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_TaxCreditCarryforwardExpirationYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_IncomeTaxExaminationPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_DeferredTaxLiabilitiesOperatingLeases" xlink:label="pmvp_DeferredTaxLiabilitiesOperatingLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:label="pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_DeferredTaxAssetsAccruedExpenses" xlink:label="pmvp_DeferredTaxAssetsAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_DeferredTaxAssetsOperatingLeases" xlink:label="pmvp_DeferredTaxAssetsOperatingLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="pmvp_DeferredTaxLiabilitiesOperatingLeases" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="pmvp_DeferredTaxAssetsAccruedExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="pmvp_DeferredTaxAssetsOperatingLeases" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OptionsToPurchaseCommonStockMember" xlink:label="pmvp_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_UnvestedRestrictedCommonStockUnitsMember" xlink:label="pmvp_UnvestedRestrictedCommonStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_UnvestedEmployeeStockPurchasePlanSharesMember" xlink:label="pmvp_UnvestedEmployeeStockPurchasePlanSharesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pmvp_OptionsToPurchaseCommonStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pmvp_UnvestedRestrictedCommonStockUnitsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pmvp_UnvestedEmployeeStockPurchasePlanSharesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_BoardOfDirectorsMember" xlink:label="pmvp_BoardOfDirectorsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_NumberOfConsultingAgreementsMembers" xlink:label="pmvp_NumberOfConsultingAgreementsMembers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pmvp_BoardOfDirectorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pmvp_NumberOfConsultingAgreementsMembers" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedParties" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>pmvp-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T09:45:29.7132+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="pmvp-20221231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="pmvp-20221231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="pmvp-20221231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2" xlink:href="pmvp-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails" xlink:href="pmvp-20221231.xsd#DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="pmvp_OtherNonoperatingIncomeExpenseOther" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OtherNonoperatingIncomeExpenseOther" xlink:label="pmvp_OtherNonoperatingIncomeExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pmvp_OtherNonCashLeaseExpense" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="5" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OtherNonCashLeaseExpense" xlink:label="pmvp_OtherNonCashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pmvp_AccruedResearchAndDevelopmentCostsCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="pmvp_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" order="5" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" xlink:label="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="pmvp_DeferredTaxLiabilitiesOperatingLeases" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pmvp_DeferredTaxAssetsAccruedExpenses" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="6" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pmvp_DeferredTaxAssetsOperatingLeases" order="7" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_DeferredTaxLiabilitiesOperatingLeases" xlink:label="pmvp_DeferredTaxLiabilitiesOperatingLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:label="pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_DeferredTaxAssetsAccruedExpenses" xlink:label="pmvp_DeferredTaxAssetsAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_DeferredTaxAssetsOperatingLeases" xlink:label="pmvp_DeferredTaxAssetsOperatingLeases"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>pmvp-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T09:45:29.9482+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="pmvp-20221231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="pmvp-20221231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables" xlink:href="pmvp-20221231.xsd#Role_DisclosureStockPlanTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:href="pmvp-20221231.xsd#DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureStockPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureStockPlanScheduleOfStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails" xlink:href="pmvp-20221231.xsd#DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails" xlink:href="pmvp-20221231.xsd#DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails" xlink:href="pmvp-20221231.xsd#DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails" xlink:href="pmvp-20221231.xsd#DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="pmvp-20221231.xsd#DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="pmvp-20221231.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:label="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_EmployeeStockPurchasePlanMember" xlink:label="pmvp_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:label="pmvp_OrganizationConsolidationAndPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OrganizationConsolidationAndPresentationTable" xlink:label="pmvp_OrganizationConsolidationAndPresentationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ProceedsFromIssuanceOfCommonStockGross" xlink:label="pmvp_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="pmvp_OrganizationConsolidationAndPresentationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="pmvp_ProceedsFromIssuanceOfCommonStockGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pmvp_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_AssetsNotPlacedInServiceMember" xlink:label="pmvp_AssetsNotPlacedInServiceMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pmvp_AssetsNotPlacedInServiceMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CranburyNewJerseyMember" xlink:label="pmvp_CranburyNewJerseyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SouthBrunswickNewJerseyMember" xlink:label="pmvp_SouthBrunswickNewJerseyMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_InitialBaseRentPerSquareFoot" xlink:label="pmvp_InitialBaseRentPerSquareFoot"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MA" xlink:label="country_MA"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeaseExpirationPeriod" xlink:label="pmvp_OperatingLeaseExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_PrincetonNewJerseyMember" xlink:label="pmvp_PrincetonNewJerseyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" xlink:label="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ManagementFeeOfBaseRentPercentage" xlink:label="pmvp_ManagementFeeOfBaseRentPercentage"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_NumberOfNoncancelableOperatingLeases" xlink:label="pmvp_NumberOfNoncancelableOperatingLeases"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeaseRenewalTermDescription" xlink:label="pmvp_OperatingLeaseRenewalTermDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseRenewalMonthAndYear" xlink:label="pmvp_LesseeOperatingLeaseRenewalMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_InitialBaseRentIncreasedPerSquareFoot" xlink:label="pmvp_InitialBaseRentIncreasedPerSquareFoot"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" xlink:label="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeasesExtendedYear" xlink:label="pmvp_OperatingLeasesExtendedYear"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeasesExtensionPeriod" xlink:label="pmvp_OperatingLeasesExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeasesExtendedMonthAndYear" xlink:label="pmvp_OperatingLeasesExtendedMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ReimbursementsReceivedFromLessee" xlink:label="pmvp_ReimbursementsReceivedFromLessee"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SubleaseExpirationPeriod" xlink:label="pmvp_SubleaseExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SubleaseAndAdditionalSubleaseIncome" xlink:label="pmvp_SubleaseAndAdditionalSubleaseIncome"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_CommitmentsAndContingenciesDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pmvp_CranburyNewJerseyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pmvp_SouthBrunswickNewJerseyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_InitialBaseRentPerSquareFoot" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeaseExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pmvp_PrincetonNewJerseyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_ManagementFeeOfBaseRentPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_NumberOfNoncancelableOperatingLeases" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeaseRenewalTermDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_LesseeOperatingLeaseRenewalMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_InitialBaseRentIncreasedPerSquareFoot" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DeferredRentCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfLand" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeasesExtendedYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeasesExtensionPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_OperatingLeasesExtendedMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_ReimbursementsReceivedFromLessee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_SubleaseAndAdditionalSubleaseIncome" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SeriesDConvertiblePreferredStockMember" xlink:label="pmvp_SeriesDConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pmvp_SeriesDConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SeriesSeedConvertiblePreferredStockMember" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pmvp_SeriesSeedConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="pmvp_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TwoThousandAndThirteenStockPlanMember" xlink:label="pmvp_TwoThousandAndThirteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandAndThirteenStockPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TwoThousandThirteenStockPlanMember" xlink:label="pmvp_TwoThousandThirteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_TwoThousandThirteenStockPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_EmployeeStockPurchasePlanMember" xlink:label="pmvp_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pmvp_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_EmployeeStockPurchasePlanMember" xlink:label="pmvp_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pmvp_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ" xlink:label="stpr_NJ"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="country_CA"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" xlink:label="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MA" xlink:label="country_MA"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" xlink:label="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AZ" xlink:label="stpr_AZ"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLossCarryforwardsExpirationYear" xlink:label="pmvp_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TaxCreditCarryforwardExpirationYear" xlink:label="pmvp_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_IncomeTaxExaminationPeriod" xlink:label="pmvp_IncomeTaxExaminationPeriod"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NJ" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_AZ" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="pmvp_IncomeTaxExaminationPeriod" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OptionsToPurchaseCommonStockMember" xlink:label="pmvp_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_UnvestedRestrictedCommonStockUnitsMember" xlink:label="pmvp_UnvestedRestrictedCommonStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_UnvestedEmployeeStockPurchasePlanSharesMember" xlink:label="pmvp_UnvestedEmployeeStockPurchasePlanSharesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pmvp_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pmvp_UnvestedRestrictedCommonStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pmvp_UnvestedEmployeeStockPurchasePlanSharesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_BoardOfDirectorsMember" xlink:label="pmvp_BoardOfDirectorsMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_NumberOfConsultingAgreementsMembers" xlink:label="pmvp_NumberOfConsultingAgreementsMembers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pmvp_BoardOfDirectorsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pmvp_NumberOfConsultingAgreementsMembers" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedParties" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>pmvp-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T09:45:31.6079+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#axisDefault" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:label="pmvp_OrganizationConsolidationAndPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AZ" xlink:label="stpr_AZ"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseRenewalMonthAndYear" xlink:label="pmvp_LesseeOperatingLeaseRenewalMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_DeferredTaxAssetsOperatingLeases" xlink:label="pmvp_DeferredTaxAssetsOperatingLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_EmployeeStockPurchasePlanMember" xlink:label="pmvp_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" xlink:label="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CranburyNewJerseyMember" xlink:label="pmvp_CranburyNewJerseyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:label="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeaseExpirationPeriod" xlink:label="pmvp_OperatingLeaseExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_DeferredTaxLiabilitiesOperatingLeases" xlink:label="pmvp_DeferredTaxLiabilitiesOperatingLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_NumberOfNoncancelableOperatingLeases" xlink:label="pmvp_NumberOfNoncancelableOperatingLeases"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_UnvestedRestrictedCommonStockUnitsMember" xlink:label="pmvp_UnvestedRestrictedCommonStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_InitialBaseRentPerSquareFoot" xlink:label="pmvp_InitialBaseRentPerSquareFoot"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" xlink:label="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SouthBrunswickNewJerseyMember" xlink:label="pmvp_SouthBrunswickNewJerseyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:label="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation" xlink:label="pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" xlink:label="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_BoardOfDirectorsMember" xlink:label="pmvp_BoardOfDirectorsMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OrganizationConsolidationAndPresentationTable" xlink:label="pmvp_OrganizationConsolidationAndPresentationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_AssetsNotPlacedInServiceMember" xlink:label="pmvp_AssetsNotPlacedInServiceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TwoThousandAndThirteenStockPlanMember" xlink:label="pmvp_TwoThousandAndThirteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:label="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SubleaseAndAdditionalSubleaseIncome" xlink:label="pmvp_SubleaseAndAdditionalSubleaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ConversionOfConvertiblePreferredStockToCommonStock" xlink:label="pmvp_ConversionOfConvertiblePreferredStockToCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TwoThousandThirteenStockPlanMember" xlink:label="pmvp_TwoThousandThirteenStockPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLossCarryforwardsExpirationYear" xlink:label="pmvp_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_UnvestedEmployeeStockPurchasePlanSharesMember" xlink:label="pmvp_UnvestedEmployeeStockPurchasePlanSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="country_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_IncomeTaxExaminationPeriod" xlink:label="pmvp_IncomeTaxExaminationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ConversionOfWarrantLiabilityToCommonStock" xlink:label="pmvp_ConversionOfWarrantLiabilityToCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" xlink:label="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:label="pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_LeaseIncentivesUsedForLeaseholdImprovements" xlink:label="pmvp_LeaseIncentivesUsedForLeaseholdImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" xlink:label="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SeriesDConvertiblePreferredStockMember" xlink:label="pmvp_SeriesDConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ReverseStockSplitPolicyTextBlock" xlink:label="pmvp_ReverseStockSplitPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="pmvp_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" xlink:label="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TaxCreditCarryforwardExpirationYear" xlink:label="pmvp_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeasesExtendedYear" xlink:label="pmvp_OperatingLeasesExtendedYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OtherNonoperatingIncomeExpenseOther" xlink:label="pmvp_OtherNonoperatingIncomeExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ" xlink:label="stpr_NJ"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeasesExtendedMonthAndYear" xlink:label="pmvp_OperatingLeasesExtendedMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:label="pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MA" xlink:label="country_MA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ReimbursementsReceivedFromLessee" xlink:label="pmvp_ReimbursementsReceivedFromLessee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="pmvp_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OptionsToPurchaseCommonStockMember" xlink:label="pmvp_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeaseRenewalTermDescription" xlink:label="pmvp_OperatingLeaseRenewalTermDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_PrincetonNewJerseyMember" xlink:label="pmvp_PrincetonNewJerseyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_NumberOfConsultingAgreementsMembers" xlink:label="pmvp_NumberOfConsultingAgreementsMembers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ProceedsFromIssuanceOfCommonStockGross" xlink:label="pmvp_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OtherNonCashLeaseExpense" xlink:label="pmvp_OtherNonCashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_DeferredTaxAssetsAccruedExpenses" xlink:label="pmvp_DeferredTaxAssetsAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_OperatingLeasesExtensionPeriod" xlink:label="pmvp_OperatingLeasesExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_ManagementFeeOfBaseRentPercentage" xlink:label="pmvp_ManagementFeeOfBaseRentPercentage"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SubleaseExpirationPeriod" xlink:label="pmvp_SubleaseExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_InitialBaseRentIncreasedPerSquareFoot" xlink:label="pmvp_InitialBaseRentIncreasedPerSquareFoot"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="pmvp-20221231.xsd#pmvp_SeriesSeedConvertiblePreferredStockMember" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OrganizationConsolidationAndPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization, consolidation and presentation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OrganizationConsolidationAndPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OrganizationConsolidationAndPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Provision for Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Priced in Active Markets (Level 1)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_AZ_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arizona</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_AZ_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ARIZONA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseRenewalMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease renewal month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseRenewalMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseRenewalMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease renewal month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_DeferredTaxAssetsOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_DeferredTaxAssetsOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_DeferredTaxAssetsOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Amounts representing imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Common Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standards update, immaterial effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, exercise of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments net of reimbursements due year five.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Machinery and Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery &amp; Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserved shares of common stock for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Productive Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Productive Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-12</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, number of shares available for grant, forfeitures in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant, Options forfeited / cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments, net of reimbursements, due next twelve months.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Net Of Reimbursements Due Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, number of shares available for grant, exercised in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Options Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of lease amount reported in balance sheet.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Lease Amount Reported In Balance Sheet Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Amounts Reported in Consolidated Balance Sheets for Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adoption of accounting standards update [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CranburyNewJerseyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cranbury, New Jersey.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CranburyNewJerseyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cranbury New Jersey [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CranburyNewJerseyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cranbury, New Jersey</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments, net of reimbursements, due year four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassifications of temporary to permanent equity, shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassifications Of Temporary To Permanent Equity Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments, net of reimbursements, due year three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, number of shares available for grant, shares reserved for issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Reserved For Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant, Shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Income Tax (Benefit) Provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Land</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease area of square feet</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding - basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeaseExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease expiration period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeaseExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeaseExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options weighted-average remaining life.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Life [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Formation and Business of the Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options forfeited / cancelled, Number of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_DeferredTaxLiabilitiesOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_DeferredTaxLiabilitiesOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_DeferredTaxLiabilitiesOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted at grant-date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Carrying Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_NumberOfNoncancelableOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of noncancelable operating leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_NumberOfNoncancelableOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Noncancelable Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_NumberOfNoncancelableOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of noncancelable operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award employees exercised their right to purchase shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Employees Exercised Their Right To Purchase Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees exercised their right to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments, net of repayments, due.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Net Of Repayments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share - diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of credit risk and other risks and uncertainties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Of Credit Risk And Other Risks And Uncertainties Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_UnvestedRestrictedCommonStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted common stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_UnvestedRestrictedCommonStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Common Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_UnvestedRestrictedCommonStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted common stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_InitialBaseRentPerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial base rent per square foot.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_InitialBaseRentPerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Base Rent Per Square Foot</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_InitialBaseRentPerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial base rent per square foot</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability to be paid net of repayments after year five.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability To Be Paid Net Of Repayments After Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.00001 par value, 5,000,000 shares authorized as of December 31, 2022 and December 31, 2021. No shares issued or outstanding as of December 31, 2022 and December 31, 2021.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Income (Expense), Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SouthBrunswickNewJerseyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">South Brunswick, New Jersey.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SouthBrunswickNewJerseyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">South Brunswick New Jersey [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SouthBrunswickNewJerseyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South Brunswick, New Jersey</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets and depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of other information related to leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Other Information Related To Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Other Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Workers' Compensation Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Available for Grant, RSU's granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant, RSU's granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Restricted Stock Units Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant restricted stock units grants in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments and Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted-Average Remaining Contractual Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of stock options and common stock issued under the 2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive compensation limitation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Executive compensation limitation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation executive compensation limitation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, annual increase of authorized shares, percent of common stock outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Of Authorized Shares Percent Of Common Stock Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of number of shares of common stock outstanding increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value exercise of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding - diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due to Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount owed to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due to Related Parties, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Corporate Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Portion at Fair Value Measurement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosure Item Amounts [Default]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://fasb.org/us-gaap/role/label/axisDefault">Portion at Fair Value Measurement [Member] [Default]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease with tenant office space starting period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease With Tenant Office Space Starting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease with tenant office space starting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards amounts do not expire.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Amounts Do Not Expire</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, do not expire amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuable upon conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total compensation cost related to nonvested awards not yet recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, stock issued during period, shares, new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_BoardOfDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Board of directors.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_BoardOfDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Board Of Directors [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_BoardOfDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Board of Directors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments, net of reimbursements, due year two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash - end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash - beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OrganizationConsolidationAndPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization, consolidation and presentation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OrganizationConsolidationAndPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OrganizationConsolidationAndPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of cash flow information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_AssetsNotPlacedInServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets not placed in service.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_AssetsNotPlacedInServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Not Placed In Service [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_AssetsNotPlacedInServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets Not Placed in Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total (benefit) provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Benefit) provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassifications of Temporary to Permanent Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standards update, adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, capital shares reserved for future issuance, additional shares reserved, minimum.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance Additional Shares Reserved Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares reserved for issuance, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, options retired in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Retired In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options retired, Number of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TwoThousandAndThirteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and thirteen stock plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TwoThousandAndThirteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Thirteen Stock Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TwoThousandAndThirteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reported Value Measurement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited / cancelled, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Carrying value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SubleaseAndAdditionalSubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SubleaseAndAdditionalSubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease and Additional Sublease Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SubleaseAndAdditionalSubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease and additional sublease income.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock to common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Convertible Preferred Stock To Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investor</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AOCI Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TwoThousandThirteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand thirteen stock plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TwoThousandThirteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Thirteen Stock Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TwoThousandThirteenStockPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 45,771,332 and 45,433,684 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (loss) gain on available for sale investments, net of tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive (loss) income related to unrealized (losses) gains on marketable securities, net of tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_UnvestedEmployeeStockPurchasePlanSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested employee stock purchase plan shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_UnvestedEmployeeStockPurchasePlanSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Employee Stock Purchase Plan Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_UnvestedEmployeeStockPurchasePlanSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested employee stock purchase plan shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CANADA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of operating lease property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_IncomeTaxExaminationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax examination period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_IncomeTaxExaminationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_IncomeTaxExaminationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total financial assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion (amortization) of available-for-sale debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Unrealized Gain (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, number of shares available for grant, grants in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Grants In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Available for Grant, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ConversionOfWarrantLiabilityToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of warrant liability to common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ConversionOfWarrantLiabilityToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Warrant Liability To Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ConversionOfWarrantLiabilityToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of warrant liability to common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Fair Value of Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Government Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Weighted-Average Remaining Contractual Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before (benefit) provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease maintenance expense per square foot.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Maintenance Expense Per Square Foot</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease maintenance expense per square foot</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Capitalized Research Expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, capitalized research expenditures.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of stock options and common stock issued under employee stock purchase plans.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Stock Options And Common Stock Issued Under Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options and common stock issued under the 2020 ESPP, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LeaseIncentivesUsedForLeaseholdImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease incentives used for leasehold improvements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LeaseIncentivesUsedForLeaseholdImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Incentives Used For Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_LeaseIncentivesUsedForLeaseholdImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease incentives used for leasehold improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards begin to expire in future amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Begin To Expire In Future Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards begin to expire in 2033</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost, weighted average period of recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted-Average Remaining Contractual Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SeriesDConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SeriesDConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SeriesDConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Options Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse stock split.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization (accretion) of premiums on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases related to current year tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (see Note 6)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Allowance on behalf of lessor for construction of office space.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allowance On Behalf Of Lessor For Construction Of Office Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance on behalf of lessor for construction of office space.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward, expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reserved Shares of Common Stock for Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeasesExtendedYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases, extended year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeasesExtendedYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Extended Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeasesExtendedYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases, extended year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, shares outstanding, number.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OtherNonoperatingIncomeExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OtherNonoperatingIncomeExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other nonoperating income (expense), other.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OtherNonoperatingIncomeExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_NJ_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NEW JERSEY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_NJ_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">New Jersey</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to terminate [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Terminate [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease with tenant office space ending period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease With Tenant Office Space Ending Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease with tenant office space ending period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeasesExtendedMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases extended month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeasesExtendedMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Extended Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeasesExtendedMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases extended month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, capital shares reserved for future issuance, additional shares reserved, maximum.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance Additional Shares Reserved Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares reserved for issuance, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future stock option and RSU grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares Available for Grant, Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares Available for Grant, Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash paid (received) for amounts included in the measurement of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Paid (Received) For Amounts Included In The Measurement Of Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net cash paid (received) for amounts included in the measurement of lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MOROCCO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lexington, Massachusetts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ReimbursementsReceivedFromLessee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursements received from lessee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ReimbursementsReceivedFromLessee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursements Received From Lessee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ReimbursementsReceivedFromLessee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursements received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leased assets obtained in exchange for new or modified operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of stock options and common stock value issued under employee stock purchase plans.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options and common stock issued under the 2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit carryforward, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Number of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of noncash investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due from Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount paid to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due from Related Parties, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Limitations on Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred Stock Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax provision at statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Federal statutory income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized tax benefits, end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized tax benefits, beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period on an annual basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options to Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Number of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidation preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial Offering Price to the Public</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Related to Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, Number of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options awarded</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Stock Units, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining rent incentives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeaseRenewalTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease renewal term description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeaseRenewalTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Renewal Term Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeaseRenewalTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease renewal term description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_PrincetonNewJerseyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Princeton, New Jersey.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_PrincetonNewJerseyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Princeton New Jersey [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_PrincetonNewJerseyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Princeton, New Jersey</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Outstanding, Number of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Outstanding, Number of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_NumberOfConsultingAgreementsMembers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of consulting agreements members.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_NumberOfConsultingAgreementsMembers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Consulting Agreements Members</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_NumberOfConsultingAgreementsMembers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of consulting agreement members</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share - basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options shares available for grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Shares Available For Grant Roll Forward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of RSU Activity Under the 2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OtherNonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other non-cash lease expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OtherNonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Non Cash Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OtherNonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends, common stock declared</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Common Stock, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_DeferredTaxAssetsAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_DeferredTaxAssetsAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_DeferredTaxAssetsAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeasesExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases, extension period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeasesExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Extension Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_OperatingLeasesExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, extension period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases related to prior year tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Basis [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on available for sale marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-based Compensation Expense by Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture &amp; Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options exercised, Number of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation Expense Recorded and Allocated</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options intrinsic value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ManagementFeeOfBaseRentPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Management fee of base rent percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ManagementFeeOfBaseRentPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Management Fee Of Base Rent Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_ManagementFeeOfBaseRentPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Management fee of base rent percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SubleaseExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease expiration period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SubleaseExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SubleaseExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_InitialBaseRentIncreasedPerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial base rent increased per square foot.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_InitialBaseRentIncreasedPerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Base Rent Increased Per Square Foot</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_InitialBaseRentIncreasedPerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial base rent increased per square foot</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series seed convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series Seed Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pmvp_SeriesSeedConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series Seed Preferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted stock units granted to employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Stock Units, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, Estimated useful lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimate of Fair Value Measurement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OrganizationConsolidationAndPresentationLineItems" xlink:to="pmvp_OrganizationConsolidationAndPresentationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_AZ" xlink:to="stpr_AZ_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseRenewalMonthAndYear" xlink:to="pmvp_LesseeOperatingLeaseRenewalMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_DeferredTaxAssetsOperatingLeases" xlink:to="pmvp_DeferredTaxAssetsOperatingLeases_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_EmployeeStockPurchasePlanMember" xlink:to="pmvp_EmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock" xlink:to="pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_CranburyNewJerseyMember" xlink:to="pmvp_CranburyNewJerseyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:to="pmvp_ReclassificationsOfTemporaryToPermanentEquityShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLeaseExpirationPeriod" xlink:to="pmvp_OperatingLeaseExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_DeferredTaxLiabilitiesOperatingLeases" xlink:to="pmvp_DeferredTaxLiabilitiesOperatingLeases_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_NumberOfNoncancelableOperatingLeases" xlink:to="pmvp_NumberOfNoncancelableOperatingLeases_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_UnvestedRestrictedCommonStockUnitsMember" xlink:to="pmvp_UnvestedRestrictedCommonStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_InitialBaseRentPerSquareFoot" xlink:to="pmvp_InitialBaseRentPerSquareFoot_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive" xlink:to="pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SouthBrunswickNewJerseyMember" xlink:to="pmvp_SouthBrunswickNewJerseyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:to="pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation" xlink:to="pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod" xlink:to="pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire" xlink:to="pmvp_OperatingLossCarryforwardsAmountsDoNotExpire_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_BoardOfDirectorsMember" xlink:to="pmvp_BoardOfDirectorsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo" xlink:to="pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OrganizationConsolidationAndPresentationTable" xlink:to="pmvp_OrganizationConsolidationAndPresentationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_AssetsNotPlacedInServiceMember" xlink:to="pmvp_AssetsNotPlacedInServiceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="pmvp_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum" xlink:to="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_TwoThousandAndThirteenStockPlanMember" xlink:to="pmvp_TwoThousandAndThirteenStockPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:to="pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SubleaseAndAdditionalSubleaseIncome" xlink:to="pmvp_SubleaseAndAdditionalSubleaseIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ConversionOfConvertiblePreferredStockToCommonStock" xlink:to="pmvp_ConversionOfConvertiblePreferredStockToCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_TwoThousandThirteenStockPlanMember" xlink:to="pmvp_TwoThousandThirteenStockPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLossCarryforwardsExpirationYear" xlink:to="pmvp_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_UnvestedEmployeeStockPurchasePlanSharesMember" xlink:to="pmvp_UnvestedEmployeeStockPurchasePlanSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_IncomeTaxExaminationPeriod" xlink:to="pmvp_IncomeTaxExaminationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ConversionOfWarrantLiabilityToCommonStock" xlink:to="pmvp_ConversionOfWarrantLiabilityToCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pmvp_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot" xlink:to="pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:to="pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans" xlink:to="pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_LeaseIncentivesUsedForLeaseholdImprovements" xlink:to="pmvp_LeaseIncentivesUsedForLeaseholdImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount" xlink:to="pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SeriesDConvertiblePreferredStockMember" xlink:to="pmvp_SeriesDConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_CommitmentsAndContingenciesDisclosureTable" xlink:to="pmvp_CommitmentsAndContingenciesDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ReverseStockSplitPolicyTextBlock" xlink:to="pmvp_ReverseStockSplitPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="pmvp_AccruedResearchAndDevelopmentCostsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace" xlink:to="pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_TaxCreditCarryforwardExpirationYear" xlink:to="pmvp_TaxCreditCarryforwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLeasesExtendedYear" xlink:to="pmvp_OperatingLeasesExtendedYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OtherNonoperatingIncomeExpenseOther" xlink:to="pmvp_OtherNonoperatingIncomeExpenseOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NJ" xlink:to="stpr_NJ_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod" xlink:to="pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLeasesExtendedMonthAndYear" xlink:to="pmvp_OperatingLeasesExtendedMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum" xlink:to="pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:to="pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MA" xlink:to="country_MA_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ReimbursementsReceivedFromLessee" xlink:to="pmvp_ReimbursementsReceivedFromLessee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="pmvp_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans" xlink:to="pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OptionsToPurchaseCommonStockMember" xlink:to="pmvp_OptionsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLeaseRenewalTermDescription" xlink:to="pmvp_OperatingLeaseRenewalTermDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_PrincetonNewJerseyMember" xlink:to="pmvp_PrincetonNewJerseyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_NumberOfConsultingAgreementsMembers" xlink:to="pmvp_NumberOfConsultingAgreementsMembers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ProceedsFromIssuanceOfCommonStockGross" xlink:to="pmvp_ProceedsFromIssuanceOfCommonStockGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SummaryOfSignificantAccountingPoliciesTable" xlink:to="pmvp_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OtherNonCashLeaseExpense" xlink:to="pmvp_OtherNonCashLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_DeferredTaxAssetsAccruedExpenses" xlink:to="pmvp_DeferredTaxAssetsAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_OperatingLeasesExtensionPeriod" xlink:to="pmvp_OperatingLeasesExtensionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_ManagementFeeOfBaseRentPercentage" xlink:to="pmvp_ManagementFeeOfBaseRentPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SubleaseExpirationPeriod" xlink:to="pmvp_SubleaseExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_InitialBaseRentIncreasedPerSquareFoot" xlink:to="pmvp_InitialBaseRentIncreasedPerSquareFoot_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pmvp_SeriesSeedConvertiblePreferredStockMember" xlink:to="pmvp_SeriesSeedConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315061415392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 24, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PMV PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3218129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1 Research Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Princeton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">642-6670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PMVP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,773,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 543,361,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001699382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Registrant&#8217;s definitive Proxy Statement relating to the 2023 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315064913600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 108,297<span></span>
</td>
<td class="nump">$ 172,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">822<span></span>
</td>
<td class="nump">822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">132,757<span></span>
</td>
<td class="nump">124,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,130<span></span>
</td>
<td class="nump">3,301<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">247,006<span></span>
</td>
<td class="nump">301,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,955<span></span>
</td>
<td class="nump">3,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, noncurrent</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="nump">16,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">9,539<span></span>
</td>
<td class="nump">10,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">270,308<span></span>
</td>
<td class="nump">331,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">3,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,308<span></span>
</td>
<td class="nump">8,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,832<span></span>
</td>
<td class="nump">12,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">13,448<span></span>
</td>
<td class="nump">10,790<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">24,280<span></span>
</td>
<td class="nump">23,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">487,516<span></span>
</td>
<td class="nump">476,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(241,043)<span></span>
</td>
<td class="num">(167,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(445)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">246,028<span></span>
</td>
<td class="nump">308,559<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 270,308<span></span>
</td>
<td class="nump">$ 331,568<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315064501680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">45,771,332<span></span>
</td>
<td class="nump">45,433,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">45,771,332<span></span>
</td>
<td class="nump">45,433,684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315064439504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 51,988<span></span>
</td>
<td class="nump">$ 36,493<span></span>
</td>
<td class="nump">$ 23,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">25,052<span></span>
</td>
<td class="nump">21,800<span></span>
</td>
<td class="nump">11,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">77,040<span></span>
</td>
<td class="nump">58,293<span></span>
</td>
<td class="nump">34,942<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(77,040)<span></span>
</td>
<td class="num">(58,293)<span></span>
</td>
<td class="num">(34,942)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">3,627<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OtherNonoperatingIncomeExpenseOther', window );">Other income (expense), net</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="num">(143)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">3,714<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before (benefit) provision for income taxes</a></td>
<td class="num">(73,326)<span></span>
</td>
<td class="num">(57,823)<span></span>
</td>
<td class="num">(34,434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit) provision for income taxes</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(73,317)<span></span>
</td>
<td class="num">(57,846)<span></span>
</td>
<td class="num">(34,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on available for sale investments, net of tax</a></td>
<td class="num">(367)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (73,684)<span></span>
</td>
<td class="num">$ (57,924)<span></span>
</td>
<td class="num">$ (34,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (1.61)<span></span>
</td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (2.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (1.61)<span></span>
</td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (2.40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="nump">45,594,824<span></span>
</td>
<td class="nump">45,137,656<span></span>
</td>
<td class="nump">14,364,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="nump">45,594,824<span></span>
</td>
<td class="nump">45,137,656<span></span>
</td>
<td class="nump">14,364,475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OtherNonoperatingIncomeExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income (expense), other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OtherNonoperatingIncomeExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315064729600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Series D Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>AOCI Attributable to Parent</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="num">$ (70,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,969<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (75,440)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,866,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,046,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,321,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="num">$ (238,723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ReclassificationsOfTemporaryToPermanentEquityShares', window );">Conversion of convertible preferred stock to common stock, Shares</a></td>
<td class="num">(28,188,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="nump">$ 238,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,188,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">223,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,529,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(34,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available for sale marketable securities</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">359,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109,880)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,777,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans', window );">Exercise of stock options and common stock issued under the 2020 ESPP</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans', window );">Exercise of stock options and common stock issued under the 2020 ESPP, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">655,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(57,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,846)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available for sale marketable securities</a></td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 308,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,363<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(167,726)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,433,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="nump">288,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans', window );">Exercise of stock options and common stock issued under the 2020 ESPP</a></td>
<td class="nump">$ 958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans', window );">Exercise of stock options and common stock issued under the 2020 ESPP, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">10,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(73,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available for sale marketable securities</a></td>
<td class="num">(367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 246,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 487,516<span></span>
</td>
<td class="num">$ (445)<span></span>
</td>
<td class="num">$ (241,043)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,771,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of stock options and common stock issued under employee stock purchase plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of stock options and common stock value issued under employee stock purchase plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ReclassificationsOfTemporaryToPermanentEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassifications of temporary to permanent equity, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ReclassificationsOfTemporaryToPermanentEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares, exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, stock issued during period, shares, new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90193-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315067110048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 20,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315064516816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (73,317)<span></span>
</td>
<td class="num">$ (57,846)<span></span>
</td>
<td class="num">$ (34,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">10,195<span></span>
</td>
<td class="nump">5,340<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">307<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization (accretion) of premiums on marketable securities</a></td>
<td class="num">(628)<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OtherNonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,829)<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="num">(2,732)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">2,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(389)<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="num">(1,230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,319)<span></span>
</td>
<td class="nump">3,894<span></span>
</td>
<td class="nump">3,117<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(63,760)<span></span>
</td>
<td class="num">(46,571)<span></span>
</td>
<td class="num">(32,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(7,984)<span></span>
</td>
<td class="num">(1,349)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(229,199)<span></span>
</td>
<td class="num">(256,845)<span></span>
</td>
<td class="num">(14,512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">235,815<span></span>
</td>
<td class="nump">114,610<span></span>
</td>
<td class="nump">42,571<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by in investing activities</a></td>
<td class="num">(1,368)<span></span>
</td>
<td class="num">(143,584)<span></span>
</td>
<td class="nump">27,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options and common stock issued under the 2020 ESPP</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">292,972<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(64,170)<span></span>
</td>
<td class="num">(188,133)<span></span>
</td>
<td class="nump">288,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash - beginning of period</a></td>
<td class="nump">173,289<span></span>
</td>
<td class="nump">361,422<span></span>
</td>
<td class="nump">73,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash - end of period</a></td>
<td class="nump">109,119<span></span>
</td>
<td class="nump">173,289<span></span>
</td>
<td class="nump">361,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of noncash investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_LeaseIncentivesUsedForLeaseholdImprovements', window );">Lease incentives used for leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Accrued purchases of property and equipment</a></td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ConversionOfConvertiblePreferredStockToCommonStock', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ConversionOfWarrantLiabilityToCommonStock', window );">Conversion of warrant liability to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ConversionOfConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ConversionOfConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ConversionOfWarrantLiabilityToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of warrant liability to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ConversionOfWarrantLiabilityToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LeaseIncentivesUsedForLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease incentives used for leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LeaseIncentivesUsedForLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OtherNonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other non-cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OtherNonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315149877360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Formation and Business of the Company</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">1.  Formation and Business of the Company</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Organization</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PMV Pharmaceuticals, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware in March 2013. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities and raising capital. The Company is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company&#8217;s headquarters are located at 1 Research Way, Princeton, New Jersey.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 25, 2020, the Company completed an initial public offering (the &#8220;IPO&#8221;) of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,529,750</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share including the exercise in full by the underwriters of their option to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,764,750</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of commons stock, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">243,536</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and its shares started trading on The Nasdaq Global Select Market under the ticker symbol &#8220;PMVP.&#8221;  The Company received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">223,176</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by the Company.  In connection with the closing of the IPO, all of the Company&#8217;s outstanding shares of convertible preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,188,110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has incurred net losses and negative cash flows from operations since its inception. During the year ended December 31, 2022, the Company incurred a net loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,317</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and used $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,760</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of cash for operations. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">241,043</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Cash, cash equivalents, and marketable securities were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">243,549</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Management expects to incur substantial additional operating losses for the next several years and may need to obtain additional debt or equity financings in order to complete development of its products, obtain regulatory approvals, launch and commercialize its products and continue research and development programs. The Company believes it has adequate cash, cash equivalents, and marketable securities to operate for at least the next twelve months from the date of issuance of these financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315063746816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2.  Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2020, the Company&#8217;s board of directors and stockholders approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to affect a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2651</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-for-1 reverse stock split of the Company&#8217;s common stock and convertible preferred stock</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was effected on September 24, 2020. The par value of the common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, convertible preferred stock, stock options, and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:</span></p><div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div></div><div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.</span></div></div><div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 - Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.</span></div></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Marketable Securities</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument&#8217;s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. The Company&#8217;s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity. Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security and recorded on the interest income, net line of the income statement. For the years ended December 31, 2022, 2021, and 2020, the Company recorded </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">628</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of accretion, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">550</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of amortization and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of amortization, respectively.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash as of December 31, 2022 included </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">822</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> de</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">posit at the Company&#8217;s commercial bank underlying a stand-by letter of credit issued in favor of a landlord (See Note 6) and is classified in current assets.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company presents comprehensive loss in a single statement within its financial statements. Other comprehensive loss consists of unrealized gains and losses on marketable securities, net of tax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.  The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#8217;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. Furthermore, the Company has elected the practical expedient to not separate lease and non-lease components by class of underlying asset for its existing leases. The Company&#8217;s only existing leases are for office and laboratory space.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#8217;s share of the lessor&#8217;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. Neither of the Company&#8217;s leases contain residual value guarantees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight&#8209;line method over the estimated useful lives of the assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, except for leasehold improvements, which are amortized over the shorter of the useful life of the asset or the remaining term of the lease.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets, are tested for recoverability whenever events or changes in the business environment indicate that the carrying amount of the assets may not be fully recoverable. Factors considered by the Company when deciding when to perform an impairment review include significant underperformance of the business against expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows resulting from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows resulting from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its current fair value. To date, the Company has not recorded any impairment losses on long-lived assets.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All costs associated with research and development are expensed as incurred.  Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes allocated stock-based compensation, salary payroll taxes, employee benefits; materials; supplies; depreciation on and maintenance of research equipment; the cost of services provided by outside contractors; and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. The Company records accruals for estimated research and development expenses, comprising payments for work performed by third party vendors, clinical research organizations, clinical manufacturing organizations and others. Some of these vendors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones.  For the latter, the Company accrues the expenses as goods or services are used or rendered.  Research and development activities related to patient enrollment are accrued as patients enter and progress through the trial.  In the event that the Company prepays fees, the Company records the prepayment as a prepaid asset and periodically evaluate the prepaid asset in conjunction with the related accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock&#8209;Based Compensation</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s share-based compensation program allows for grants of stock options and restricted stock units. Grants are awarded to employees and non-employees, including directors.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for stock-based employee compensation arrangements in accordance with provisions of ASC 718,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Compensation &#8211; Stock Compensation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;ASC 718&#8221;)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option pricing or equity valuation model that is applied in a manner consistent with the fair value measurement objectives of ASC 718, is based on established principles of financial theory and reflects all of the substantive terms and conditions of the award. The Company uses the Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;) to value stock option grants to employees, non-employees and directors. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock units and stock options.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to the lack of a public market for the Company&#8217;s common stock until September 2020 and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the Company&#8217;s IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for options granted, the Company considered the estimated fair value of the common stock as of the measurement date. Prior to the Initial Public Offering, the estimated fair value of the common stock was determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#8217;s-length sales of the Company&#8217;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event. Other factors considered were the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition, and the current business climate in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s stock-based compensation awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is typically the vesting term.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the Company&#8217;s Chief Operating Decision Maker to make decisions with respect to resource allocation and assessment of performance. To date, the Company has viewed its operations and manages its business as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating and reporting segment.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Common Share</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is computed using the &#8220;two-class&#8221; method which includes the weighted average number of shares of common stock outstanding during the period and other securities that participate in dividends (a participating security). The Company&#8217;s convertible preferred stock are participating securities as defined by ASC 260-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Earnings per Share</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the periods where the Company incurs net losses, the Company allocates no loss to participating securities because these securities have no contractual obligation to share in the losses of the Company. Under the two-class method, basic net loss per share applicable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional shares for the potential dilutive effects of a warrant, convertible preferred stock and stock options outstanding during the period calculated in accordance with the treasury stock method, or the two-class method, whichever is more dilutive. The Company allocates net earnings on a </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">pari passu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (equal) basis to both common and preferred stockholders. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company&#8217;s net losses. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes in accordance with ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ("ASC 740"), which requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Under ASC 740, the liability method is used in accounting for income taxes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and law that will be in effect when the differences are expected to reverse. ASC 740 also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates annually the realizability of the deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. In 2022 and 2021, the Company recorded a full valuation allowance for the deferred tax assets based on the historical loss and the uncertainty regarding the ability to project future taxable income. In future periods if the Company is able to generate income, the Company may reduce or eliminate the valuation allowance.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for uncertain tax positions in accordance with ASC 740. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax provision that an entity takes or expects to take in a tax return. Additionally, ASC 740 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. Under ASC 740, an entity may only recognize or continue to recognize tax positions that meet a "more likely than not" threshold. In accordance with this accounting policy, the Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, the FASB issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_637e6d3e-1c4a-4011-bf94-4da18c87eb69;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASU 2019-12</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Income Taxes &#8211; Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The new guidance simplifies the accounting for income taxes by removing several exceptions in the current standard and adding guidance to reduce complexity in certain areas, such as requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The Company </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> this standard as of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The adoption did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> have a material impact on the Company&#8217;s financial statements.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and marketable securities. The Company maintains its cash, cash equivalents and marketable securities in accounts at high quality financial institutions. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds. Cash and cash equivalents include a checking account and a money market account held at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company&#8217;s marketable debt securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#8217;s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315062962864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments and Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">3.  Financial Instruments and Fair Value Measurements</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial instruments consist of money market funds, U.S. government debt securities and corporate debt securities. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables show the Company&#8217;s cash equivalents and available-for-sale securities&#8217; carrying amounts and fair values as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021:</span></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:21.434%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.08%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.055%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.262%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.08%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.08%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.08%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.76%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="26" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted<br/>priced in<br/>active<br/>markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103,755</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,942</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">281</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,661</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,981</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,680</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">242,558</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">466</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">242,113</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,842</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114,271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="26" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted<br/>Priced in<br/>Active<br/>Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,960</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,960</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,960</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">227,378</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">227,362</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">227,362</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,307</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,245</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,245</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">310,645</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">310,567</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,960</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">269,607</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8211; As of December 31, 2022, the Company had cash of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,436</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and cash equivalents, consisting of money market funds, of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,861</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2021, the Company had cash of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,507</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and cash equivalents of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168,960</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Cash equivalents consisted of money market funds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,960</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and corporate debt securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Money market funds are classified within level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets, whereas corporate debt securities are classified within level 2 of the fair value hierarchy because they are valued using inputs other than quoted prices that are observable for the asset or liability either directly or indirectly.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable Securities </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8211; Marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135,252</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022, consisted of corporate debt securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103,591</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and government debt securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,661</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. There were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,757</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> current marketable securities and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,495</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> noncurrent marketable securities as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141,607</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2021, consisted of corporate debt securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,362</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and government debt securities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,245</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. There were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124,696</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> current marketable securities and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,911</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> noncurrent marketable securities as of December 31, 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, aggregated gross unrealized losses of available-for-sale investments were not material, and accordingly, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> allowance for credit losses was recorded.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315062992672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">4.  Property and Equipment, Net</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.649%;"/>
        <td style="width:0.994%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.329%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.005%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.024%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Machinery &amp; equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,448</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,261</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computers</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture &amp; fixtures</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets not placed in service</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,200</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,519</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,139</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,958</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,184</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,868</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,955</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,090</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense for the years ended December 31, 2022, 2021, and 2020 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">315</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">307</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">318</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315062927552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">5.  Accrued Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consists of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.42%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.904%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.654%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,897</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,797</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,259</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,734</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,308</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,627</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315062882320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">6.  Commitments and Contingencies</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2015, the Company executed a noncancelable operating lease for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of laboratory, research and development, and office space in Cranbury, New Jersey for an initial base rent of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per square foot. This location operates as the Company&#8217;s current headquarters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2017, the Company obtained an additional noncancelable operating lease for about </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of laboratory space in the same corporate center at an initial rental rate at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per square foot. As a result of the additional space, both leases expired </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2022, the Company signed a lease extension for both leases for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_2e41832f-24ee-4add-8485-3b9e6b7ae42f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional year through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with the option to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">terminate</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> upon 120 days of written notice, with an increase in base rent as per the lease extension.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Both leases include a common area maintenance expense for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per square foot with an increase of 3% on the first month of each calendar year during the lease term and a management fee of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the base rent.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company is obligated to pay, on a pro-rata basis, real estate taxes and operating costs related to the premises.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2018, the Company executed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> noncancelable operating leases. One lease for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet for vivarium, laboratory and general office space in South Brunswick, New Jersey. The initial annual base rent is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per square foot and a management fee of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the base rent. The Company is obligated to pay, on a pro-rata basis, insurance premiums, real estate taxes and operating costs related to the premises. The lease expired in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2022, the Company signed a lease extension for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_68272f31-ac51-43d0-89b6-b5574371c7f3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional year through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with the option to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">terminate</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> upon 120 days of written notice, with an increase in base rent as per the lease extension.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The second lease is for office space in Lexington, Massachusetts, that expires </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with an option to renew for a one-time, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> extension. The initial annual base rent is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per square foot and will increase $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per square foot at the end of each rent year.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2018, the Company received a lease incentive for the buildout of 420 Bedford Street in Lexington, MA. The Company was given an allowance for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on behalf of the lessor for construction of office space. Management recognizes this allowance as a lease incentive in its Right-of-Use asset and straight-lines the allowance throughout the term of the lease.  As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the remaining rent incentive pertaining to the Lexington, MA lease totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, the Company signed a lease for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,581</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office and laboratory space at 1 Research Way in Princeton, New Jersey. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">That lease term extends through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2032</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, has a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> extension option, and is intended to replace the Company&#8217;s two existing facilities and the space is expected to become the Company&#8217;s future headquarters.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Payment under this lease will total $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,889</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 2032</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company received a lease incentive of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,046</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the lessor for a buildout of laboratory, vivarium, and office space, to be reimbursed to the Company in 2022 and 2023. Management estimated the timing and amounts of reimbursements and included them as a reduction of lease payments when initially measuring the lease liability and right-of-use asset upon commencement. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,969</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of reimbursements were received.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lea</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">se cost for the year ended December 31, 2022, and 2021, are as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.752%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.851%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.16%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,215</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,691</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">991</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,206</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts reported in the balance sheet for leases where the Company is the lessee as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, and 2021, were as follows, in thousands:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.631%;"/>
        <td style="width:1.282%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.403%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.282%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.403%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets, operating leases</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,539</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,060</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">528</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">403</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,448</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,790</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,976</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,193</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.08</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.02</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.75</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.75</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other information related to leases for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, and 2021, are as follows, in thousands:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.599%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.049%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.123%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash paid (received) for amounts included in the measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,089</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">717</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leased assets obtained in exchange for new or modified operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">987</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,318</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments, net of reimbursements, remaining as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 under operating leases by fiscal year were as follows, in thousands:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.773%;"/>
        <td style="width:1.608%;"/>
        <td style="width:14.835%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.165%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fiscal year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,219</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,814</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,869</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,925</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,983</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,494</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,304</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Amounts representing imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,328</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,976</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rent expense recorded for the years ended December 31, 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,215</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,691</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently subleases the office space at 420 Bedford Street in Lexington, MA to another company.  This sublease agreement expires in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In April 2021, the Company entered into a sublease agreement with the previous tenants of the office space at 1 Research Way in Princeton, NJ, from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. For the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, sublease income for the Company was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingencies</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315062967344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">7.  Convertible Preferred Stock</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2020, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,321,864</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series D Preferred Stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.1533</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  In connection with the IPO on September 25, 2020, all of the Company&#8217;s convertible preferred stock, including Series D Preferred Stock, outstanding at the time of the IPO automatically converted into an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,188,110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315062852784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">8.  Stockholders' Equity</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is authorized to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,771,332</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,433,684</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issued and outstanding, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stockholders are entitled to receive dividends if and when declared by the board of directors subject to the rights of any preferred stockholders.  As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends on common stock had been declared by the Company.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, the Company had reserved shares of common stock for issuance as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.217%;"/>
        <td style="width:1.423%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.806999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.434%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.12%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,278,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,246,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares available for future stock option and RSU grants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,618,292</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,951,680</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares available for employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">705,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">801,464</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,602,622</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,999,151</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315063027136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Plan</a></td>
<td class="text"><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">9.   Stock Plan</span></p><p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) was approved by the board of directors on September 24, 2020.  The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The number of shares of common stock initially reserved for issuance under the 2020 Plan was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,406,374</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, in an amount equal to the least of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,406,374</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, (ii) five percent  (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%) of the outstanding common stock on the immediately preceding December 31, or (iii) such number of common stock determined by the board of directors no later than the immediately preceding December 31.  For 2022, the board&#8217;s compensation committee, as the 2020 Plan administrator, exercised its discretion under clause (iii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by a lesser amount of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,363,084</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, effective as of January 1, 2022. For 2023, the board&#8217;s compensation committee, as the 2020 Plan administrator, exercised its discretion under clause (iii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by a lesser amount of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,830,853</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, effective as of January 1, 2023. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,618,292</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for issuance under the 2020 Plan.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 9, 2022, the Company granted </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">374,899</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Restricted Stock Units (RSUs) to employees pursuant to an employee retention program approved by the Board's compensation committee.  The RSU&#8217;s have graded vesting on an annual basis for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of continuous service, as per the 2020 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below summarizes the annual grant activity under the 2020 Plan as of  December 31, 2022:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.364%;"/>
        <td style="width:1.007%;"/>
        <td style="width:12.678%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.100000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.843%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares Available <br/>for Grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances, December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,951,680</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares reserved for issuance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,363,084</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,419,197</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSU&#8217;s granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">374,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited / cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,624</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,618,292</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;) was approved by the board of directors on September 24, 2020.  A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">400,752</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, to the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">801,504</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, (ii) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (iii) an amount determined by the board of directors or any of its committees no later than the last day of the immediately preceding fiscal year. For 2022, the board waived the annual increase to the shares reserved under the 2020 ESPP. For 2023, the 2020 ESPP reserved shares were increased under clause (iii) by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">457,713</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, effective as of January 1, 2023. On May 20, 2022, employees exercised their right to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,454</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares under the 2020 ESPP. On November 21, 2022, employees exercised their right to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,385</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares under the 2020 ESPP. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95,905</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares are issued or outstanding, and there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">705,559</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for issuance, under the 2020 ESPP.</span></p><p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2013 Equity Incentive Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2013, the Company adopted the 2013 Stock Plan (the &#8220;2013 Plan&#8221;). On September 24, 2020, this plan was replaced by the 2020 Plan, and future issuances of incentive instruments will be governed by that plan.  Subject to the provisions of the 2020 Plan, the Company had the option to either forfeit or repurchase remaining shares under the 2013 Equity Incentive Plan on or after the registration date.  The Company chose to forfeit the remaining shares.</span></p><p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents RSU activity under the 2020 Plan as of December 31, 2022:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.363000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.879999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.759%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Stock Units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average <br/>Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested shares at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">374,899</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested shares at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">374,899</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.6</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,317</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of unrecognized compensation cost related to RSUs that are expected to vest. These costs are expected to be recognized over a weighted average remaining vesting period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.542%;"/>
        <td style="width:0.074%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.773000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.074%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.184000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.074%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.983%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.074%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.219%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Remaining</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Average</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Life</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in 000s)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,246,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.86</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,506</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,419,197</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.83</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited / cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,624</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.04</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">288,809</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.67</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,278,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.82</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,244</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,278,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.82</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,244</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,281,213</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.91</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.76</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,520</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average grant date fair value of stock options granted during the year ended December 31, 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.92</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.03</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of options vested and exercisable as of December 31, 2022 and 2021 is calculated based on the difference between the exercise price and the fair value of our common stock.  The intrinsic value of options exercised in 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,764</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,534</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the total compensation cost related to nonvested service-based awards not yet recognized is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,005</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The weighted-average period over which the nonvested awards is expected to be recognized is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company estimated the fair value of stock options using the Black-Scholes options valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following assumptions:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.987%;"/>
        <td style="width:1.004%;"/>
        <td style="width:16.998%;"/>
        <td style="width:1.004%;"/>
        <td style="width:16.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:15.556%;"/>
        <td style="width:1.442%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.48</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.31</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.51</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.44</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.44</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.92</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.40</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76.33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79.90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average assumptions used to estimate the fair value of stock purchase rights under the 2020 ESPP are as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.998%;"/>
        <td style="width:1.004%;"/>
        <td style="width:12.895%;"/>
        <td style="width:1.004%;"/>
        <td style="width:13.996%;"/>
        <td style="width:1.004%;"/>
        <td style="width:13.098%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.44</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0004</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.49</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.83</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected Term: The Company uses the simplified method to calculate expected term described in the SEC&#8217;s Staff Accounting Bulletin No. 107, which takes into account vesting term and expiration date of the options.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility: Volatility is based on an average of the historical volatilities of comparable publicly traded companies for the expected term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Free Interest Rate: The risk-free rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term of the option.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Yield: The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the valuation model.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense recorded under ASC 718 was allocated to research and development and general and administrative expense as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.28%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.176%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.434%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.649000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.429%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,466</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,440</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">836</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,729</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,900</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,097</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,195</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,340</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,933</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.301%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.173%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.430000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.636%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.429%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,938</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,933</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">790</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">231</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">402</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,195</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,340</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,933</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315063029616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">10.  Income Taxes</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The income tax (benefit) provision for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.82%;"/>
        <td style="width:1.748%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.382000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.748%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.138%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.748%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.416%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total (benefit) provision</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of income tax computed at the statutory federal income tax rate to the (benefit) provision for income taxes included in the accompanying statements of operations for the Company is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.036%;"/>
        <td style="width:0.973%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.891%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.973%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.917%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.973%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.236%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax provision at statutory rate</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive compensation limitation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company&#8217;s effective tax rate is below the federal statutory income tax rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% primarily due to state income taxes, net of federal benefit and the Company&#8217;s position to establish a full valuation allowance on its deferred tax assets.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets and liabilities are presented below:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.233%;"/>
        <td style="width:1.667%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.679%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.667%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.753%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,451</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,231</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,905</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,587</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,563</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,856</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,593</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accruals and other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">911</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,033</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,969</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,175</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77,655</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,619</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,917</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,728</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets recognized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,738</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,891</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,709</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,854</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Fixed assets and depreciation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,738</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,891</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has recorded a valuation allowance for its deferred tax assets that it does not believe will be realizable at a more likely than not level based on analysis of all available sources of taxable income.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company had federal net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">174,736</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159,886</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the Company had state net operating loss carryforwards for New Jersey, California, Massachusetts, and Arizona of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169,847</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,912</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,277</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had state net operating loss carryforwards for New Jersey, California and Massachusetts of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">154,972</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,912</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,640</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> respectiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ely.  Federal net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expire beginning in the year </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2033</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State net operating loss carryforwards begin to expire in the year </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2033</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards related to tax years after 2017 of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">147,236</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> do not expire.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company also has federal and state research and development credit carryforward of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,749</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,588</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The federal credits will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2034</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> if not utilized.  The California state credits carryforward indefinitely and the New Jersey state credits expire starting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2030</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> above net operating losses and research and development credits are subject to Sections 382 and 383 of the Internal Revenue Code. In the event of a change in ownership as defined by these code sections, the usage of the net operating losses and research and development credits may be limited.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accrues interest and penalties related to unrecognized tax benefits in the (benefit) provision for income taxes line item in the statements of operations and comprehensive loss</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t accrued any interest or penalties related to uncertain tax positions.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the ending balance of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,437</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,654</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of unrecognized tax benefits as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, were recognized, none of the recognition would affect the income tax rate. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarized the activity related to the Company&#8217;s unrecognized tax benefits:</span></span></p><div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.128%;"/>
        <td style="width:1.657%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.667%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.657%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.892%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits, beginning of year</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,654</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">877</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to current year tax positions</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">783</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">734</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits, end of year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,437</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,654</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company does not anticipate any material change in its unrecognized tax benefits over the next twelve months. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company files U.S. federal and state income tax returns with varying statutes of limitations. The Company&#8217;s tax years </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_82dfdf8f-411c-4717-af9e-206e2366f08e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2013 to 2021</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> will remain open for examination by the federal and state authorities for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_4604235b-11b9-4105-9a93-5870e969a273;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, from the date of utilization of any net operating losses and research and development credits.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315062938640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">11.  Net Loss per Share</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excluded all outstanding stock options and restricted stock units at each period end from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect.  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following common stock equivalents were excluded from the calculation of diluted net loss per share:</span></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.44%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.596%;"/>
        <td style="width:2.017%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.878%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.157%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.455%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.898%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,278,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,246,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted common stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">374,899</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested employee stock purchase plan shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95,905</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,066</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,749,575</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,293,073</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315063027952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">12.  Related Parties</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has consulting agreements with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> members of its board of directors; one of which waived his consulting fees as of September 2021. Total consulting fees paid in in the year ended December 31, 2022, were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> amounts owed under the consulting agreements as of December 31, 2022.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total consulting fees paid as of the year ended December 31, 2021, were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In May of 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> members of  the board of directors were awarded </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,781</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options of Company stock each, as per their updated Scientific Advisory Board agreements. T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">here were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> amounts owed under the consulting agreements as of December 31, 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315057339792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2020, the Company&#8217;s board of directors and stockholders approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to affect a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2651</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-for-1 reverse stock split of the Company&#8217;s common stock and convertible preferred stock</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was effected on September 24, 2020. The par value of the common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, convertible preferred stock, stock options, and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:</span></p><div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div></div><div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.</span></div></div><div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 - Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.</span></div></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Marketable Securities</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument&#8217;s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. The Company&#8217;s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity. Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security and recorded on the interest income, net line of the income statement. For the years ended December 31, 2022, 2021, and 2020, the Company recorded </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">628</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of accretion, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">550</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of amortization and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of amortization, respectively.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash as of December 31, 2022 included </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">822</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> de</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">posit at the Company&#8217;s commercial bank underlying a stand-by letter of credit issued in favor of a landlord (See Note 6) and is classified in current assets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company presents comprehensive loss in a single statement within its financial statements. Other comprehensive loss consists of unrealized gains and losses on marketable securities, net of tax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.  The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#8217;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. Furthermore, the Company has elected the practical expedient to not separate lease and non-lease components by class of underlying asset for its existing leases. The Company&#8217;s only existing leases are for office and laboratory space.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#8217;s share of the lessor&#8217;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. Neither of the Company&#8217;s leases contain residual value guarantees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight&#8209;line method over the estimated useful lives of the assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, except for leasehold improvements, which are amortized over the shorter of the useful life of the asset or the remaining term of the lease.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-lived assets, are tested for recoverability whenever events or changes in the business environment indicate that the carrying amount of the assets may not be fully recoverable. Factors considered by the Company when deciding when to perform an impairment review include significant underperformance of the business against expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows resulting from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows resulting from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its current fair value. To date, the Company has not recorded any impairment losses on long-lived assets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All costs associated with research and development are expensed as incurred.  Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes allocated stock-based compensation, salary payroll taxes, employee benefits; materials; supplies; depreciation on and maintenance of research equipment; the cost of services provided by outside contractors; and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. The Company records accruals for estimated research and development expenses, comprising payments for work performed by third party vendors, clinical research organizations, clinical manufacturing organizations and others. Some of these vendors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones.  For the latter, the Company accrues the expenses as goods or services are used or rendered.  Research and development activities related to patient enrollment are accrued as patients enter and progress through the trial.  In the event that the Company prepays fees, the Company records the prepayment as a prepaid asset and periodically evaluate the prepaid asset in conjunction with the related accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Based Compensation</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock&#8209;Based Compensation</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s share-based compensation program allows for grants of stock options and restricted stock units. Grants are awarded to employees and non-employees, including directors.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for stock-based employee compensation arrangements in accordance with provisions of ASC 718,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Compensation &#8211; Stock Compensation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;ASC 718&#8221;)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option pricing or equity valuation model that is applied in a manner consistent with the fair value measurement objectives of ASC 718, is based on established principles of financial theory and reflects all of the substantive terms and conditions of the award. The Company uses the Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;) to value stock option grants to employees, non-employees and directors. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock units and stock options.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to the lack of a public market for the Company&#8217;s common stock until September 2020 and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the Company&#8217;s IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for options granted, the Company considered the estimated fair value of the common stock as of the measurement date. Prior to the Initial Public Offering, the estimated fair value of the common stock was determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#8217;s-length sales of the Company&#8217;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event. Other factors considered were the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition, and the current business climate in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s stock-based compensation awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is typically the vesting term.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the Company&#8217;s Chief Operating Decision Maker to make decisions with respect to resource allocation and assessment of performance. To date, the Company has viewed its operations and manages its business as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating and reporting segment.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Common Share</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is computed using the &#8220;two-class&#8221; method which includes the weighted average number of shares of common stock outstanding during the period and other securities that participate in dividends (a participating security). The Company&#8217;s convertible preferred stock are participating securities as defined by ASC 260-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Earnings per Share</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the periods where the Company incurs net losses, the Company allocates no loss to participating securities because these securities have no contractual obligation to share in the losses of the Company. Under the two-class method, basic net loss per share applicable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional shares for the potential dilutive effects of a warrant, convertible preferred stock and stock options outstanding during the period calculated in accordance with the treasury stock method, or the two-class method, whichever is more dilutive. The Company allocates net earnings on a </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">pari passu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (equal) basis to both common and preferred stockholders. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company&#8217;s net losses. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes in accordance with ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ("ASC 740"), which requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Under ASC 740, the liability method is used in accounting for income taxes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and law that will be in effect when the differences are expected to reverse. ASC 740 also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates annually the realizability of the deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. In 2022 and 2021, the Company recorded a full valuation allowance for the deferred tax assets based on the historical loss and the uncertainty regarding the ability to project future taxable income. In future periods if the Company is able to generate income, the Company may reduce or eliminate the valuation allowance.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for uncertain tax positions in accordance with ASC 740. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax provision that an entity takes or expects to take in a tax return. Additionally, ASC 740 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. Under ASC 740, an entity may only recognize or continue to recognize tax positions that meet a "more likely than not" threshold. In accordance with this accounting policy, the Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, the FASB issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_637e6d3e-1c4a-4011-bf94-4da18c87eb69;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASU 2019-12</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Income Taxes &#8211; Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The new guidance simplifies the accounting for income taxes by removing several exceptions in the current standard and adding guidance to reduce complexity in certain areas, such as requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The Company </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> this standard as of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The adoption did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> have a material impact on the Company&#8217;s financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and marketable securities. The Company maintains its cash, cash equivalents and marketable securities in accounts at high quality financial institutions. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds. Cash and cash equivalents include a checking account and a money market account held at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company&#8217;s marketable debt securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#8217;s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration of credit risk and other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315062973456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables show the Company&#8217;s cash equivalents and available-for-sale securities&#8217; carrying amounts and fair values as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:21.434%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.08%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.055%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.262%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.08%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.08%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.08%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.76%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="26" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted<br/>priced in<br/>active<br/>markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,861</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103,755</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,942</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">281</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,661</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,981</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,680</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">242,558</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">466</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">242,113</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,842</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114,271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="26" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted<br/>Priced in<br/>Active<br/>Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,960</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,960</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,960</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">227,378</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">227,362</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">227,362</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,307</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,245</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,245</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">310,645</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">310,567</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,960</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">269,607</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315062848992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.649%;"/>
        <td style="width:0.994%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.329%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.005%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.024%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Machinery &amp; equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,448</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,261</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computers</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture &amp; fixtures</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets not placed in service</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,200</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,519</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,139</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,958</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,184</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,868</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,955</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,090</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315063027952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consists of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.42%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.904%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.654%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,897</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,797</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,259</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,734</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,308</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,627</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315067161264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Components of Lease Cost</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lea</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">se cost for the year ended December 31, 2022, and 2021, are as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.752%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.851%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.618%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.16%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,215</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,691</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">991</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,206</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock', window );">Schedule of Amounts Reported in Consolidated Balance Sheets for Leases</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts reported in the balance sheet for leases where the Company is the lessee as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, and 2021, were as follows, in thousands:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.631%;"/>
        <td style="width:1.282%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.403%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.282%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.403%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets, operating leases</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,539</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,060</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">528</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">403</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,448</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,790</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,976</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,193</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (years)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.08</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.02</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.75</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.75</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock', window );">Summary of Other Information Related to Leases</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other information related to leases for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, and 2021, are as follows, in thousands:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.599%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.049%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.123%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash paid (received) for amounts included in the measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,089</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">717</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leased assets obtained in exchange for new or modified operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">987</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,318</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments, net of reimbursements, remaining as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 under operating leases by fiscal year were as follows, in thousands:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.773%;"/>
        <td style="width:1.608%;"/>
        <td style="width:14.835%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.165%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fiscal year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,219</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,814</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,869</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,925</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,983</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,494</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,304</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Amounts representing imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,328</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,976</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of lease amount reported in balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of other information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315062934912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Reserved Shares of Common Stock for Issuance</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, the Company had reserved shares of common stock for issuance as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.217%;"/>
        <td style="width:1.423%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.806999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.434%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.12%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,278,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,246,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares available for future stock option and RSU grants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,618,292</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,951,680</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares available for employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">705,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">801,464</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,602,622</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,999,151</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315065158768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below summarizes the annual grant activity under the 2020 Plan as of  December 31, 2022:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.364%;"/>
        <td style="width:1.007%;"/>
        <td style="width:12.678%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.100000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.843%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares Available <br/>for Grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances, December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,951,680</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares reserved for issuance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,363,084</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,419,197</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSU&#8217;s granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">374,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited / cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,624</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,618,292</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.542%;"/>
        <td style="width:0.074%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.773000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.074%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.184000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.074%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.983%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.074%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.219%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Remaining</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Average</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Life</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in 000s)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,246,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.86</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,506</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,419,197</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.83</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited / cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,624</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.04</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">288,809</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.67</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,278,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.82</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,244</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,278,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.82</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,244</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,281,213</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.91</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.76</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,520</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of RSU Activity Under the 2020 Plan</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents RSU activity under the 2020 Plan as of December 31, 2022:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.363000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.879999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.759%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Stock Units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average <br/>Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested shares at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">374,899</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested shares at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">374,899</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.6</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value of Stock Options</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company estimated the fair value of stock options using the Black-Scholes options valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following assumptions:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.987%;"/>
        <td style="width:1.004%;"/>
        <td style="width:16.998%;"/>
        <td style="width:1.004%;"/>
        <td style="width:16.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:15.556%;"/>
        <td style="width:1.442%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.48</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.31</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.51</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.44</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.44</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.92</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.40</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76.33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79.90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Stock-based Compensation Expense Recorded and Allocated</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense recorded under ASC 718 was allocated to research and development and general and administrative expense as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.28%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.176%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.434%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.649000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.429%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,466</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,440</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">836</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,729</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,900</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,097</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,195</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,340</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,933</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense by Award Type</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.301%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.173%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.430000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.01%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.636%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.429%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,938</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,933</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">790</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">231</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">402</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,195</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,340</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,933</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value of Stock Options</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average assumptions used to estimate the fair value of stock purchase rights under the 2020 ESPP are as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.998%;"/>
        <td style="width:1.004%;"/>
        <td style="width:12.895%;"/>
        <td style="width:1.004%;"/>
        <td style="width:13.996%;"/>
        <td style="width:1.004%;"/>
        <td style="width:13.098%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.44</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0004</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.49</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.83</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmvp_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmvp_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315061385152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Income Tax (Benefit) Provision</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The income tax (benefit) provision for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.82%;"/>
        <td style="width:1.748%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.382000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.748%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.138%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.748%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.416%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total (benefit) provision</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of income tax computed at the statutory federal income tax rate to the (benefit) provision for income taxes included in the accompanying statements of operations for the Company is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.036%;"/>
        <td style="width:0.973%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.891%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.973%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.917%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.973%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.236%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax provision at statutory rate</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive compensation limitation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets and liabilities are presented below:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.233%;"/>
        <td style="width:1.667%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.679%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.667%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.753%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,451</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,231</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,905</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,587</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,563</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,856</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,593</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accruals and other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">911</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,033</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,969</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,175</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77,655</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,619</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,917</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,728</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets recognized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,738</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,891</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,709</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,854</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Fixed assets and depreciation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,738</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,891</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Activity Related to Unrecognized Tax Benefits</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarized the activity related to the Company&#8217;s unrecognized tax benefits:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.128%;"/>
        <td style="width:1.657%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.667%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.657%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.892%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Years Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits, beginning of year</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,654</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">877</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to current year tax positions</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">783</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">734</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits, end of year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,437</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,654</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315062938640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following common stock equivalents were excluded from the calculation of diluted net loss per share:</span><p style="text-indent:4.44%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.596%;"/>
        <td style="width:2.017%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.878%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.157%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.455%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.898%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,278,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,246,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted common stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">374,899</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested employee stock purchase plan shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95,905</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,066</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,749,575</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,293,073</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315061548576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 25, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OrganizationConsolidationAndPresentationLineItems', window );"><strong>Organization Consolidation And Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock, gross</a></td>
<td class="nump">$ 243,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">$ 223,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,317<span></span>
</td>
<td class="nump">$ 57,846<span></span>
</td>
<td class="nump">34,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,760<span></span>
</td>
<td class="nump">46,571<span></span>
</td>
<td class="nump">$ 32,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,043<span></span>
</td>
<td class="nump">$ 167,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OrganizationConsolidationAndPresentationLineItems', window );"><strong>Organization Consolidation And Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,529,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,188,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OrganizationConsolidationAndPresentationLineItems', window );"><strong>Organization Consolidation And Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="nump">13,529,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Convertible Preferred Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OrganizationConsolidationAndPresentationLineItems', window );"><strong>Organization Consolidation And Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock, Shares</a></td>
<td class="nump">28,188,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OrganizationConsolidationAndPresentationLineItems', window );"><strong>Organization Consolidation And Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Option to purchase common stock</a></td>
<td class="nump">1,764,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OrganizationConsolidationAndPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization, consolidation and presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OrganizationConsolidationAndPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315061793776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 24, 2020</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5.2651-for-1 reverse stock split of the Company&#8217;s common stock and convertible preferred stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split conversion ratio</a></td>
<td class="nump">5.2651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Accretion (amortization) of available-for-sale debt securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 628<span></span>
</td>
<td class="num">$ (550)<span></span>
</td>
<td class="num">$ (152)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2019-12 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Adoption of accounting standards update [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Accounting standards update, immaterial effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315064834496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount</a></td>
<td class="nump">$ 242,558<span></span>
</td>
<td class="nump">$ 310,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(466)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">242,113<span></span>
</td>
<td class="nump">310,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Priced in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">127,842<span></span>
</td>
<td class="nump">40,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">114,271<span></span>
</td>
<td class="nump">269,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount</a></td>
<td class="nump">106,861<span></span>
</td>
<td class="nump">40,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">106,861<span></span>
</td>
<td class="nump">40,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Quoted Priced in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">106,861<span></span>
</td>
<td class="nump">40,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount</a></td>
<td class="nump">103,755<span></span>
</td>
<td class="nump">227,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">103,591<span></span>
</td>
<td class="nump">227,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">103,591<span></span>
</td>
<td class="nump">227,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount</a></td>
<td class="nump">31,942<span></span>
</td>
<td class="nump">42,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(281)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">31,661<span></span>
</td>
<td class="nump">42,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government Securities | Quoted Priced in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">20,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government Securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 10,680<span></span>
</td>
<td class="nump">$ 42,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315061462128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,436,000<span></span>
</td>
<td class="nump">$ 3,507,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">106,861,000<span></span>
</td>
<td class="nump">168,960,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="nump">135,252,000<span></span>
</td>
<td class="nump">141,607,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, noncurrent</a></td>
<td class="nump">2,495,000<span></span>
</td>
<td class="nump">16,911,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">132,757,000<span></span>
</td>
<td class="nump">124,696,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="nump">103,591,000<span></span>
</td>
<td class="nump">99,362,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="nump">$ 31,661,000<span></span>
</td>
<td class="nump">42,245,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,960,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315061792944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 13,139<span></span>
</td>
<td class="nump">$ 4,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(2,184)<span></span>
</td>
<td class="num">(1,868)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,955<span></span>
</td>
<td class="nump">3,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery &amp; Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,448<span></span>
</td>
<td class="nump">2,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture &amp; Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmvp_AssetsNotPlacedInServiceMember', window );">Assets Not Placed in Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="nump">$ 2,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmvp_AssetsNotPlacedInServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmvp_AssetsNotPlacedInServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315061540416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315061736496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 2,897<span></span>
</td>
<td class="nump">$ 3,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development costs</a></td>
<td class="nump">4,259<span></span>
</td>
<td class="nump">4,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 7,308<span></span>
</td>
<td class="nump">$ 8,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315057057888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>ft&#178; </div>
<div>Lease </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>ft&#178; </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>ft&#178; </div>
<div>$ / ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_NumberOfNoncancelableOperatingLeases', window );">Number of noncancelable operating leases | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,215,000<span></span>
</td>
<td class="nump">$ 1,691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pmvp_CranburyNewJerseyMember', window );">Cranbury, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of operating lease property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_InitialBaseRentPerSquareFoot', window );">Initial base rent per square foot | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00<span></span>
</td>
<td class="nump">20.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OperatingLeaseExpirationPeriod', window );">Operating lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Operating lease, existence of option to terminate [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Operating lease, option to terminate</a></td>
<td class="text">In January 2022, the Company signed a lease extension for both leases for up to one additional year through June 2023, with the option to terminate upon 120 days of written notice, with an increase in base rent as per the lease extension.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot', window );">Operating lease maintenance expense per square foot | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Both leases include a common area maintenance expense for $3.00 per square foot with an increase of 3% on the first month of each calendar year during the lease term and a management fee of 3% of the base rent.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ManagementFeeOfBaseRentPercentage', window );">Management fee of base rent percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseRenewalMonthAndYear', window );">Operating lease renewal month and year</a></td>
<td class="text">2023-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pmvp_CranburyNewJerseyMember', window );">Cranbury, New Jersey | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pmvp_SouthBrunswickNewJerseyMember', window );">South Brunswick, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of operating lease property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_InitialBaseRentPerSquareFoot', window );">Initial base rent per square foot | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OperatingLeaseExpirationPeriod', window );">Operating lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Operating lease, existence of option to terminate [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Operating lease, option to terminate</a></td>
<td class="text">In January 2022, the Company signed a lease extension for up to one additional year through July 2023, with the option to terminate upon 120 days of written notice, with an increase in base rent as per the lease extension.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ManagementFeeOfBaseRentPercentage', window );">Management fee of base rent percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseRenewalMonthAndYear', window );">Operating lease renewal month and year</a></td>
<td class="text">2023-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pmvp_SouthBrunswickNewJerseyMember', window );">South Brunswick, New Jersey | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MA', window );">Lexington, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_InitialBaseRentPerSquareFoot', window );">Initial base rent per square foot | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OperatingLeaseExpirationPeriod', window );">Operating lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_InitialBaseRentIncreasedPerSquareFoot', window );">Initial base rent increased per square foot | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace', window );">Allowance on behalf of lessor for construction of office space.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Remaining rent incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_SubleaseExpirationPeriod', window );">Sublease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pmvp_PrincetonNewJerseyMember', window );">Princeton, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">That lease term extends through 2032, has a five-year extension option, and is intended to replace the Company&#8217;s two existing facilities and the space is expected to become the Company&#8217;s future headquarters.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Lease area of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OperatingLeasesExtendedYear', window );">Operating Leases, extended year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OperatingLeasesExtensionPeriod', window );">Operating leases, extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,889,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OperatingLeasesExtendedMonthAndYear', window );">Operating leases extended month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2032-05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,046,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ReimbursementsReceivedFromLessee', window );">Reimbursements received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,969,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod', window );">Sublease with tenant office space starting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod', window );">Sublease with tenant office space ending period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_SubleaseAndAdditionalSubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,000<span></span>
</td>
<td class="nump">$ 116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance on behalf of lessor for construction of office space.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_InitialBaseRentIncreasedPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial base rent increased per square foot.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_InitialBaseRentIncreasedPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_InitialBaseRentPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial base rent per square foot.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_InitialBaseRentPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseRenewalMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease renewal month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseRenewalMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ManagementFeeOfBaseRentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Management fee of base rent percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ManagementFeeOfBaseRentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_NumberOfNoncancelableOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of noncancelable operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_NumberOfNoncancelableOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLeaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLeaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease maintenance expense per square foot.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLeasesExtendedMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases extended month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLeasesExtendedMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLeasesExtendedYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases, extended year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLeasesExtendedYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLeasesExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, extension period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLeasesExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ReimbursementsReceivedFromLessee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursements received from lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ReimbursementsReceivedFromLessee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_SubleaseAndAdditionalSubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease and additional sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_SubleaseAndAdditionalSubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_SubleaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_SubleaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease with tenant office space ending period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease with tenant office space starting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pmvp_CranburyNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pmvp_CranburyNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pmvp_SouthBrunswickNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pmvp_SouthBrunswickNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pmvp_PrincetonNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pmvp_PrincetonNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315067703664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Components of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,215<span></span>
</td>
<td class="nump">$ 1,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">991<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 3,206<span></span>
</td>
<td class="nump">$ 2,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315064581840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Operating Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 9,539<span></span>
</td>
<td class="nump">$ 10,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">13,448<span></span>
</td>
<td class="nump">10,790<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 13,976<span></span>
</td>
<td class="nump">$ 11,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">9 years 29 days<span></span>
</td>
<td class="text">10 years 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315057316464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities', window );">Net cash paid (received) for amounts included in the measurement of lease liabilities</a></td>
<td class="num">$ (1,089)<span></span>
</td>
<td class="nump">$ 717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for new or modified operating lease liabilities</a></td>
<td class="nump">$ 987<span></span>
</td>
<td class="nump">$ 10,318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash paid (received) for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315061459392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo', window );">2024</a></td>
<td class="nump">1,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree', window );">2025</a></td>
<td class="nump">1,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour', window );">2026</a></td>
<td class="nump">1,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive', window );">2027</a></td>
<td class="nump">1,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive', window );">Thereafter</a></td>
<td class="nump">9,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">18,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing imputed interest</a></td>
<td class="num">(4,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 13,976<span></span>
</td>
<td class="nump">$ 11,193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments, net of reimbursements, due next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments net of reimbursements due year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments, net of reimbursements, due year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments, net of reimbursements, due year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments, net of reimbursements, due year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments, net of repayments, due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability to be paid net of repayments after year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315065172368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 25, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,188,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pmvp_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,321,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.1533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock | Common Stock | Initial Offering Price to the Public</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock, Shares</a></td>
<td class="nump">28,188,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, stock issued during period, shares, new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pmvp_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pmvp_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315065174416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">45,771,332<span></span>
</td>
<td class="nump">45,433,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">45,771,332<span></span>
</td>
<td class="nump">45,433,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends, common stock declared</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315057353472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">10,602,622<span></span>
</td>
<td class="nump">9,999,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future stock option and RSU grants</a></td>
<td class="nump">4,618,292<span></span>
</td>
<td class="nump">4,951,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan', window );">Shares available for employee stock purchase plan</a></td>
<td class="nump">705,559<span></span>
</td>
<td class="nump">801,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">5,278,771<span></span>
</td>
<td class="nump">4,246,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315057552240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 09, 2022</div></th>
<th class="th"><div>May 20, 2022</div></th>
<th class="th"><div>Nov. 19, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Sep. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,602,622<span></span>
</td>
<td class="nump">9,999,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total compensation cost related to nonvested awards not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, weighted average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, weighted average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted to employees</a></td>
<td class="nump">374,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,406,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum', window );">Number of additional shares reserved for issuance, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,406,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding', window );">Percentage of number of shares of common stock outstanding increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum', window );">Number of additional shares reserved for issuance, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,363,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,618,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period on an annual basis</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum', window );">Number of additional shares reserved for issuance, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,830,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding', window );">Percentage of number of shares of common stock outstanding increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum', window );">Number of additional shares reserved for issuance, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">801,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares', window );">Employees exercised their right to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,454<span></span>
</td>
<td class="nump">30,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_TwoThousandAndThirteenStockPlanMember', window );">2013 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,764<span></span>
</td>
<td class="nump">$ 18,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Stock options granted at grant-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.92<span></span>
</td>
<td class="nump">$ 20.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares reserved for future issuance, additional shares reserved, maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares reserved for future issuance, additional shares reserved, minimum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, annual increase of authorized shares, percent of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award employees exercised their right to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, shares outstanding, number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmvp_TwoThousandAndThirteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmvp_TwoThousandAndThirteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315061593456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan - Schedule of Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward', window );"><strong>Shares Available For Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Balance</a></td>
<td class="nump">4,951,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance', window );">Shares Available for Grant, Shares reserved for issuance</a></td>
<td class="nump">1,363,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod', window );">Shares Available for Grant, Options granted</a></td>
<td class="num">(1,419,197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod', window );">Shares Available for Grant, RSU's granted</a></td>
<td class="num">(374,899)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod', window );">Shares Available for Grant, Options forfeited / cancelled</a></td>
<td class="nump">97,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Balance</a></td>
<td class="nump">4,618,292<span></span>
</td>
<td class="nump">4,951,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Number of Options</a></td>
<td class="nump">4,246,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, Number of Options</a></td>
<td class="nump">1,419,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited / cancelled, Number of Options</a></td>
<td class="num">(97,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, Number of Options</a></td>
<td class="num">(288,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Number of Options</a></td>
<td class="nump">5,278,771<span></span>
</td>
<td class="nump">4,246,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, Number of Options</a></td>
<td class="nump">5,278,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Number of Options</a></td>
<td class="nump">3,281,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 8.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, Weighted Average Exercise Price</a></td>
<td class="nump">15.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited / cancelled, Weighted Average Exercise Price</a></td>
<td class="nump">20.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, Weighted Average Exercise Price</a></td>
<td class="nump">1.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">10.40<span></span>
</td>
<td class="nump">$ 8.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, Weighted Average Exercise Price</a></td>
<td class="nump">10.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 6.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract', window );"><strong>Weighted-Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted-Average Remaining Contractual Life</a></td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">6 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted-Average Remaining Contractual Life</a></td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted-Average Remaining Contractual Life</a></td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 17,244<span></span>
</td>
<td class="nump">$ 68,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">17,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 15,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, number of shares available for grant, forfeitures in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, number of shares available for grant, grants in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for grant restricted stock units grants in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, number of shares available for grant, shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options weighted-average remaining life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315062003504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan - Schedule of RSU Activity Under the 2020 Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Stock Units, Granted | shares</a></td>
<td class="nump">374,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Stock Units, Ending balance | shares</a></td>
<td class="nump">374,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">$ 13.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Ending balance | $ / shares</a></td>
<td class="nump">$ 13.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315061619568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan - Schedule of Estimated Fair Value of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.48%<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="nump">0.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.34%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.51%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">4 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.33%<span></span>
</td>
<td class="nump">76.50%<span></span>
</td>
<td class="nump">70.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 5 months 8 days<span></span>
</td>
<td class="text">6 years 5 months 8 days<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">79.90%<span></span>
</td>
<td class="nump">77.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315057343376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair Value of Stock Purchase Rights Under ESPP (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pmvp_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.44%<span></span>
</td>
<td class="nump">0.0004%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 months 26 days<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">77.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pmvp_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pmvp_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315060541776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan - Stock-based Compensation Expense Related to Recorded and Allocated (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 10,195<span></span>
</td>
<td class="nump">$ 5,340<span></span>
</td>
<td class="nump">$ 1,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">3,466<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 6,729<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315057455088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plan - Schedule of Stock-based Compensation Expense by Award Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 10,195<span></span>
</td>
<td class="nump">$ 5,340<span></span>
</td>
<td class="nump">$ 1,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">9,174<span></span>
</td>
<td class="nump">4,938<span></span>
</td>
<td class="nump">$ 1,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pmvp_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pmvp_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pmvp_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315067552560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Income Tax (Benefit) Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total (benefit) provision</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315064567968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Provision for Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax provision at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation', window );">Executive compensation limitation</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(30.00%)<span></span>
</td>
<td class="num">(37.00%)<span></span>
</td>
<td class="num">(30.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation executive compensation limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315064469232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount', window );">Net operating loss carryforwards begin to expire in 2033</a></td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OperatingLossCarryforwardsAmountsDoNotExpire', window );">Net operating loss carryforwards, do not expire amount</a></td>
<td class="nump">$ 147,236,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss carryforward, description</a></td>
<td class="text">Net operating loss carryforwards related to tax years after 2017 of $147,236 do not expire.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest or penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 2,437,000<span></span>
</td>
<td class="nump">1,654,000<span></span>
</td>
<td class="nump">$ 877,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2013 2014 2015 2016 2017 2018 2019 2020 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 174,736,000<span></span>
</td>
<td class="nump">159,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward, expiration</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_IncomeTaxExaminationPeriod', window );">Income tax examination period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryforward, amount</a></td>
<td class="nump">$ 9,749,000<span></span>
</td>
<td class="nump">6,588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_IncomeTaxExaminationPeriod', window );">Income tax examination period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 169,847,000<span></span>
</td>
<td class="nump">154,972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward, expiration</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 4,912,000<span></span>
</td>
<td class="nump">4,912,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward, expiration</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Lexington, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 5,277,000<span></span>
</td>
<td class="nump">$ 4,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Arizona</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_IncomeTaxExaminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax examination period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_IncomeTaxExaminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLossCarryforwardsAmountsDoNotExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards amounts do not expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLossCarryforwardsAmountsDoNotExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards begin to expire in future amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward, expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_AZ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_AZ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315064731632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 49,451<span></span>
</td>
<td class="nump">$ 45,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">2,905<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures', window );">Capitalized research expenditures</a></td>
<td class="nump">13,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">6,856<span></span>
</td>
<td class="nump">4,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_DeferredTaxAssetsOperatingLeases', window );">Operating lease liabilities</a></td>
<td class="nump">3,969<span></span>
</td>
<td class="nump">3,175<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">77,655<span></span>
</td>
<td class="nump">55,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(74,917)<span></span>
</td>
<td class="num">(52,728)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets recognized</a></td>
<td class="nump">2,738<span></span>
</td>
<td class="nump">2,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_DeferredTaxLiabilitiesOperatingLeases', window );">Right-of-use assets</a></td>
<td class="num">(2,709)<span></span>
</td>
<td class="num">(2,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets and depreciation</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (2,738)<span></span>
</td>
<td class="num">$ (2,891)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, capitalized research expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_DeferredTaxAssetsOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_DeferredTaxAssetsOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_DeferredTaxLiabilitiesOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_DeferredTaxLiabilitiesOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315067692448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, beginning of year</a></td>
<td class="nump">$ 1,654<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">783<span></span>
</td>
<td class="nump">734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, end of year</a></td>
<td class="nump">$ 2,437<span></span>
</td>
<td class="nump">$ 1,654<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315056922560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">5,749,575<span></span>
</td>
<td class="nump">4,293,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pmvp_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">5,278,771<span></span>
</td>
<td class="nump">4,246,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pmvp_UnvestedRestrictedCommonStockUnitsMember', window );">Unvested restricted common stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">374,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pmvp_UnvestedEmployeeStockPurchasePlanSharesMember', window );">Unvested employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">95,905<span></span>
</td>
<td class="nump">47,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pmvp_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pmvp_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pmvp_UnvestedRestrictedCommonStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pmvp_UnvestedRestrictedCommonStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pmvp_UnvestedEmployeeStockPurchasePlanSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pmvp_UnvestedEmployeeStockPurchasePlanSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140315061762832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2021 </div>
<div>Member </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Member </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options awarded | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,419,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmvp_BoardOfDirectorsMember', window );">Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pmvp_NumberOfConsultingAgreementsMembers', window );">Number of consulting agreement members | Member</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Consulting fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,000<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amount owed to related party | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options awarded | shares</a></td>
<td class="nump">5,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmvp_NumberOfConsultingAgreementsMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consulting agreements members.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pmvp_NumberOfConsultingAgreementsMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pmvp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmvp_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmvp_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>pmvp-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pmvp="http://pmvpharma.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pmvp-20221231.xsd" xlink:type="simple"/>
    <context id="C_58ef5181-20d9-4f31-9be5-bbaff729be34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_05247025-7721-46fd-b9a4-9209202d385c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_59228c38-0358-4b55-8691-88e77e7b5f20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_978ba6d3-3e46-4525-91db-17cd972dc4ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_11ed8784-858f-40ad-9cbb-1dbbf928a291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7f19e1fd-4356-482e-bb63-fcc3de69c641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2667deff-220f-4412-adb0-e8fc0d6ca3f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0599473c-789b-4f09-b3fb-e6b52320799c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7826d7cd-2cdc-4c9e-b57f-b6e1dfb7b459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_cba766c3-a95a-452a-8d08-ceb25213b983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e1d65801-b9d6-4c7d-ba94-0cee28a011c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1034c385-e799-4334-bd67-e7a75f20b60c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="C_e1989c17-cc2f-4cba-a956-12217925213d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_cc9e11c2-3eae-4c34-8935-47bc9239ba59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_7a13ba9e-9b6c-49f5-9585-76663577d207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c0cf2842-991a-497a-ad23-0d484ab89803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0044e892-3fea-44d5-872f-e25925415e12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="C_430e7e98-a75c-447c-94c7-2b300c9ae2c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:SouthBrunswickNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_14af34ae-ca01-4273-9ecd-fd1963bc0d32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_6ff7f970-97f9-4cb7-a2a0-8883a87d4dca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ed2937ce-4797-431c-bb85-119506b27457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e7ede4d5-1f79-4121-9b1d-f81bbef5bc5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c0a73230-1c9b-4996-8fdd-7164c9f9c45f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmvp:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_54e6aacb-2840-4e37-bef3-a3d7dc27785c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_eeba018d-c970-42c2-b7e8-39bb44c1c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cff8f1fb-dda0-4691-8c83-2a825ba5821d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:SouthBrunswickNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_de0eb331-80ac-42d7-a504-423cc2cfa8d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e30e375d-2146-4abd-ab44-0f83c21f02ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="C_50eb0442-301d-4fd1-8119-3f5ac5089ea2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b49092ec-8ffe-4a12-88e3-3c14783b877c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_01ffbae4-047b-4cdf-97c5-b607f5f8288c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmvp:AssetsNotPlacedInServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d7d7545a-22ed-48ea-9de9-36b175caa031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6997eaf7-2d14-4514-abb0-3d4e030cd2ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:SouthBrunswickNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_1e80c7c5-b3d0-4620-b5bc-d434b48624a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_069c5ae4-3c69-4167-b429-fe8497be6762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e6b007b1-2fc8-4c95-a477-b9b71fb8a813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_86745cc2-3f0c-450a-840f-efc74e3b9311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c5ec1baa-405a-4660-a084-861474f9bfdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_350081f7-b9c6-4878-9982-48ec05493f21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7f668206-d681-40de-bb20-c42cee8ec88f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5e800e2c-3450-44fa-bbf1-ab0a826218a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandAndThirteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6007dfa3-622c-49c1-9860-180a9069696e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmvp:UnvestedEmployeeStockPurchasePlanSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5f699388-d277-4279-ad4b-3dc305343bb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a77505cc-2f39-49ee-ad0b-48a03ab00343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0971ead3-d21f-4a45-a148-3e60a1cdbe48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8eb3a307-a471-4ef6-b42e-874598113768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0b75762f-88bc-457f-a72d-6cf0e39501d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_eecb9d6d-ac0a-487e-a86a-abf840012bdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f992ea57-8d32-4b0e-81ef-cb65a45d19d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_50c95562-5171-48b3-9b59-edd5b2537c4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_26d83b9d-f0fd-40e2-b4ab-7163ee3e8e1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmvp:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5c162453-8ec6-47e9-94ab-ae196146b8ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmvp:UnvestedRestrictedCommonStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d4c247c9-f1e3-4efe-9b18-0915c829f126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ee1cceca-c5e2-4901-967c-47736d420d59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="C_0e9b7374-006a-4280-8ffb-f7a56c5987fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a7da1954-d795-42d9-9a41-c04ab601e771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f9893b5b-4a1f-4410-b019-9a69763b7f7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6a05cc4e-dcbc-40a3-8e6d-3479699de18c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_abd743b6-67e8-483f-a3cf-127525d0673d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:SouthBrunswickNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2bfc2514-cfef-48de-a925-42f04c369057">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2f9792c0-bc7a-4f8f-9b3a-22089cbb1363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_845a7222-a0c1-4e92-a848-92db3ee210f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_6082b64b-c8b4-41e9-ba59-4bf5900eec0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmvp:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1f918825-5928-4608-b71c-9f4456b6f047">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3202e22d-2468-4cd8-9005-96d662a4e257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandAndThirteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7482c8b1-66e1-413c-a4f6-0956e9d78239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_95c6ff9a-7273-447e-b18f-9405d1b0061e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_498dfeb5-4f73-4ec9-8f1c-60dbf3d79a5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_f8e287d6-b299-4d5e-a156-3e903f57677f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_57689871-3d90-40ca-a6f9-460f78c06285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c875a660-6997-4368-89c4-d6bfbe6ef5e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-25</instant>
        </period>
    </context>
    <context id="C_01965527-3ea2-4759-b0e5-d6e7a69bf0ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_05748ee3-8f14-434c-b214-63235c977b9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9cbe3afa-3782-4ddb-a255-b2011580f639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0aac07e3-04d3-478a-9920-5fb843d4ae5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_bc64aa3a-019b-48b2-8343-7467cc9d0a91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_3f92056d-1339-471e-a03a-fba16e49f069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_abb7ff4b-f4ff-4208-b730-ff89fd4d2f48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7c1da20a-2594-4596-9560-1c31c1640622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_52495b65-0118-40a4-bfc2-7a226cb39fe6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_12649a32-1900-4175-a9b7-929ef30b495c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_00093d41-7321-438a-9568-7a6890ae8c2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0736b229-258c-40dd-838a-47547c627b77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9eac9d1b-d481-4882-beb9-94f63124f8eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="C_1dba3b6b-5641-4b1b-9e12-052771f7ced4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0b4380ac-1ddd-4289-8638-eefde924a0cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ee831443-0cb9-4eaf-ae6d-7a321beb8833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <startDate>2020-09-24</startDate>
            <endDate>2020-09-24</endDate>
        </period>
    </context>
    <context id="C_62a9b101-ab75-4638-a91d-240e17253b55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6d1c2064-9b95-4b0c-95f4-5061ac19468e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_026560c8-db2c-4e87-a51c-0c88050f90a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_72d9367d-2b3c-4d93-892a-028d7de01843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_1b95af3e-4692-4a4e-9684-b24ec983c018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a991aacb-ef93-40b5-b119-f3a9a2d28d00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_be6aad5a-a831-43c8-a05f-822cdf5cf4a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-09</startDate>
            <endDate>2022-09-09</endDate>
        </period>
    </context>
    <context id="C_1cbfb514-89c7-42d8-9873-9e01e255563c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e9a7f863-44e3-4b8b-a088-33b385350544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="C_016af1b3-ff49-4bb0-867b-902d174c68ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-09</startDate>
            <endDate>2022-09-09</endDate>
        </period>
    </context>
    <context id="C_4a6c24a3-d3cb-43ea-9818-038cc97b8e65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_afc8cc4f-8592-4a73-b6b1-bc62607689d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_efbb7361-2dda-41c4-81c1-8e49b935005c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_56fadc42-3ad0-4e3b-8b73-b2226b84481a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_bce60bd0-958e-42c0-9f7d-65828fc53e9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_41b52ed3-f105-4a33-84d9-920833d5abcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_720aa091-f1ff-40f6-9052-0af429d30c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_236fce2d-e055-4239-92a3-3e87093d5a21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_99e58b14-8dbf-449f-8271-666e6962200a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_99a529b5-6188-4ab9-8f9d-4322c6925579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f97e2ad4-444f-4f38-9b94-59f51d99a446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pmvp:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b2f1afb2-0883-4bf4-890d-a477cbd94b5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ee80540b-08ef-4bfb-a16e-dc6e2b4b20b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_502f3121-e154-46be-b42e-f83a002a53e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c9d8a5eb-415a-4f96-ba6c-84acbe6f1562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4fa2099b-812e-4e76-9690-196d1a864954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_05006ac3-674f-4f86-a1fb-57904ae43650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_96ef7e99-5645-4f46-9a50-9275689d19f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e3db700e-29a1-4ac9-b023-8c9049f6a691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7006422b-42e5-4830-9abd-4af424a83925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f825d4ed-c7b9-49be-993b-f8659d7899e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_95fdd9a8-ebe7-4208-ba3b-05e6405b6c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d23af98b-9ff8-4b89-9401-a895cac8088c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_4d1fa26c-38d2-4b57-a550-1a0282289c2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_313a014b-8256-4401-b4ea-e5d597a024c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="C_f21d65be-13a2-4ece-a7b5-17985dc50636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b870873f-a136-48b3-b1fb-15b46f12781f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_276e8ed2-4f66-40e4-bdb0-8985bcee8033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:AZ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dde39134-e5f7-476a-97bc-d31efae7f2a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5066952e-d95e-40c8-a2b4-77c7e137ae45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_394efadb-0831-4ded-a4d6-2abf18188b08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4e66fbef-977e-4452-91f9-9a4ee3656882">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-20</startDate>
            <endDate>2022-05-20</endDate>
        </period>
    </context>
    <context id="C_24c200ea-42b0-4b4d-9f36-e114465d1de9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cfda4846-cb6b-43ca-955c-e5766847123d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4bdae4ec-dd1e-490f-b8a5-74529602509a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="C_cd70bc18-5773-4da6-a7eb-54ca7d7cf4d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmvp:AssetsNotPlacedInServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6fb33a8b-4881-4337-b607-5aca6c7a973b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmvp:UnvestedEmployeeStockPurchasePlanSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cb839397-f2dc-4167-a221-47e4547f3e6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8894ea23-6468-4b4b-9fe0-13e05959ff40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_24ca9645-4213-432d-9825-b9d9754a3d26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
        </entity>
        <period>
            <instant>2023-02-24</instant>
        </period>
    </context>
    <context id="C_0f6a712d-9111-4481-8345-32cee4988f74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_77450a26-c91f-4546-8962-eb03770dbd9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b5a63292-5285-4e55-9178-b0cf6d47d493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e189a9e4-ad1c-4932-a0a3-75d29fa8bacd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pmvp:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_6b29a161-8a1d-462e-b2b3-67a19d48100c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f4cfd3a5-85b9-4820-af60-1d16ec12ddf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_205220c0-e91d-4339-8383-bedd964b0c1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2dfb4cde-06c3-4435-a144-2e3f21d7e9ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_00d11f95-a34f-4d02-91c8-51c60eec5c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pmvp:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b0735f3a-edd9-4d2b-84ba-f95bfad593a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:CranburyNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_a8260db6-bbe1-4939-9c5f-a844164fe721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_c7636c7c-5d0d-43b6-ae8e-cf22b92c32be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_27aea8e1-2efd-4fae-b253-57813f8540e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8daf283d-3684-4e97-b173-64076dd32fca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_341901e2-89fa-4177-845b-613f934b9099">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pmvp:PrincetonNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_9720ff11-f138-4224-ba3c-9c427709c9e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_46e3720d-b4bb-422c-94c9-0403252a56b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pmvp:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="C_cb5c078d-3484-49d9-922e-5414ab268c7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmvp:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_be4f127e-beed-49d8-9fd5-8cc013547c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001699382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="U_U_iso4217USD_utrsqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Member">
        <measure>pmvp:Member</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>pmvp:Segment</measure>
    </unit>
    <unit id="U_Lease">
        <measure>pmvp:Lease</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_637e6d3e-1c4a-4011-bf94-4da18c87eb69">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201912Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_abd743b6-67e8-483f-a3cf-127525d0673d"
      id="F_68272f31-ac51-43d0-89b6-b5574371c7f3">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_b0735f3a-edd9-4d2b-84ba-f95bfad593a4"
      id="F_2e41832f-24ee-4add-8485-3b9e6b7ae42f">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OpenTaxYear
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_82dfdf8f-411c-4717-af9e-206e2366f08e">2013 2014 2015 2016 2017 2018 2019 2020 2021</us-gaap:OpenTaxYear>
    <dei:AmendmentFlag
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_3a46e714-ad0c-48f4-96db-55dc5d713a9d">false</dei:AmendmentFlag>
    <pmvp:IncomeTaxExaminationPeriod
      contextRef="C_62a9b101-ab75-4638-a91d-240e17253b55"
      id="F_4604235b-11b9-4105-9a93-5870e969a273">P3Y</pmvp:IncomeTaxExaminationPeriod>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_b4874bf9-8bff-43b2-82b8-cb8c9e7dc9f5">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_af92f22e-15dc-40d1-892d-72674131cdfc">0001699382</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_e7ec3fb1-b42f-48c3-b7d7-ca1cbe27abc5">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_313cd79a-f3cb-47ba-8de7-26805f455f36">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_a44c37ba-f27c-4d38-bd87-a9683ebc63f6">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_7c852359-9c5b-4560-85d2-48840e9003f0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_b7d64782-be30-43e7-b609-b24413eff148">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_8ce9d4b1-b3c2-4fba-a081-7fca28cf7f0b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_db222691-512e-4ec8-afdd-0a853743f8db">001-39539</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_38d4bbf7-f54e-4a2e-978b-e8d82c700f66">PMV PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_5d408285-f8f2-4ecc-bed4-a6bbcdc301d2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_17943996-7dfc-4747-8b4e-ed8a54d0956c">46-3218129</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_2e81b61f-ed1a-4123-ad8d-84e58676e29b">1 Research Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_54bcb6e5-1e05-40e1-98ab-6f9dda006501">Princeton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_f09ed1d5-882e-4ccd-9443-fc17b5eed6e3">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_9a8ba0a1-7b18-4a27-a76a-29f50fcda992">08536</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_42aa5253-d161-4278-9c02-c9105fe32895">609</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_fd33b139-3661-477c-9310-8f44c26b2580">642-6670</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_9087f6ad-7249-4113-b8c7-f310b5a587eb">Common stock, par value $0.00001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_a609fe81-c3ac-4346-b2a0-53e18db26b03">PMVP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_f7cb6a23-4eab-459f-9689-725e73ac0c76">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_6723608c-008e-4702-ac3d-a88738c06e8c">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_968cf320-45c1-47af-888b-6196889b51d5">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_e1ced4e9-387d-40d5-a6fc-79a03c707d6d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_41124558-8b73-4127-9048-2ea45cb91454">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_1e3e7905-e92e-458b-b803-c00698fd220f">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_cf142b15-690d-4d32-b739-4c887a0860e0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_69246f14-b1cf-4971-9f73-e42f06145443">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_7044224c-b7f4-414a-b1b1-85341da8020f">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_739daef7-4f9d-4031-ba1c-dfcb48b28f2e">true</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_845a7222-a0c1-4e92-a848-92db3ee210f0"
      decimals="0"
      id="F_243577d7-2d72-455b-9c49-3d58d45af4f5"
      unitRef="U_USD">543361107</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_24ca9645-4213-432d-9825-b9d9754a3d26"
      decimals="INF"
      id="F_576825c3-499f-47f5-a478-0b6ae64c1cfd"
      unitRef="U_shares">45773361</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_035c6a7b-1692-4ec6-9192-f307b7ec068b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s definitive Proxy Statement relating to the 2023 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_cd3858cd-dc03-4619-a1d0-874bf699cc82">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_07266c68-8e87-45fa-b998-3fa85a4ff89f">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_0a88b6e1-d91f-4bcb-93a4-a7671656c8dc">Philadelphia, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_9040e09e-b08e-456c-bcb0-036eac8e492b"
      unitRef="U_USD">108297000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_b77b8c63-c3b8-4ab3-b41d-684845f06d6f"
      unitRef="U_USD">172467000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_d74940dd-c325-431d-aec9-97da0d3568af"
      unitRef="U_USD">822000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_9c643f78-e593-494d-ae3c-c6bc7f560499"
      unitRef="U_USD">822000</us-gaap:RestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_40523e03-c1d1-41ba-98d1-6c10b5658987"
      unitRef="U_USD">132757000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_0f1fde84-c0c1-4b4f-9620-e61587679e2f"
      unitRef="U_USD">124696000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_123a062e-0040-4719-b173-d780fb2cc817"
      unitRef="U_USD">5130000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_436ce222-d1df-4178-acd6-344fd66b69f4"
      unitRef="U_USD">3301000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_1474ab60-bd87-4944-ba69-9afa0a7905d5"
      unitRef="U_USD">247006000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_ab9e5c2b-278a-432a-b088-f342c282453a"
      unitRef="U_USD">301286000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_da4c22b4-cb64-40cc-97eb-5c4f0b939da8"
      unitRef="U_USD">10955000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_24816fab-fad4-4e6f-96a5-c532211b5c55"
      unitRef="U_USD">3090000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_450134ad-0517-411b-bd36-31778170a931"
      unitRef="U_USD">2495000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_71a9aca4-7ae4-4fc0-bd15-9669d9ae0a96"
      unitRef="U_USD">16911000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_0d32e803-3335-46a9-b0a2-1a5c5b7775e2"
      unitRef="U_USD">9539000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_09ed14bf-1f26-466e-933a-f76fc5790ab5"
      unitRef="U_USD">10060000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_a40e0226-f4dc-421b-bcc3-9449c5d158ab"
      unitRef="U_USD">313000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_8d658d64-b03e-43f6-bf81-31dfb8da139a"
      unitRef="U_USD">221000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_7f1bfbd4-a472-433d-8853-ec3bde2875f6"
      unitRef="U_USD">270308000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_cced5c27-95be-45f0-9b8c-e8cf33595ee8"
      unitRef="U_USD">331568000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_cdb186fc-c1f5-4ac5-817d-f243700ab840"
      unitRef="U_USD">2996000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_bf8ab56f-d498-44eb-8652-1805122f5e1e"
      unitRef="U_USD">3189000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_6cfc7492-0802-4af4-af76-35c3395b89d5"
      unitRef="U_USD">7308000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_a745dea3-bd23-4168-a969-b09720a7ed59"
      unitRef="U_USD">8627000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_cdbb12a8-8d43-42d9-ae31-198e40f61fc7"
      unitRef="U_USD">528000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_621bc82e-5529-414e-8e10-1cd3fa3a4389"
      unitRef="U_USD">403000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_ecb99b9f-c72a-4b28-91b5-204287b96792"
      unitRef="U_USD">10832000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_ab98f0f7-e7f0-440e-8c1d-5e3feca8e170"
      unitRef="U_USD">12219000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_5e3a219f-985a-4976-a727-59f56dc2f06c"
      unitRef="U_USD">13448000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_1347936d-4f95-473b-bf16-110d9e26fbd0"
      unitRef="U_USD">10790000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_5a7c459e-d726-426a-bfdd-7b81bd416c98"
      unitRef="U_USD">24280000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_4c336769-d90e-4019-bf42-9fef8fe35216"
      unitRef="U_USD">23009000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="5"
      id="F_0be922ee-2c64-40dd-9426-4451a30c1279"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="5"
      id="F_dacad429-67ea-4362-88b3-59c97c473b44"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="0"
      id="F_2f2545a5-5cf3-4f28-b3d1-071e9df95ece"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="0"
      id="F_a19211d2-57fa-4803-93b8-3319c3c29314"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="0"
      id="F_b40e4ef9-86af-4de3-95c1-a321002d537c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="0"
      id="F_7525bc96-a118-46fb-9272-e1d126bd61ea"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="0"
      id="F_e80d0776-ad49-4ad4-9e78-32f5f9930836"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="0"
      id="F_861b3eec-1ec8-4bd2-af60-c7598071ef0a"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="5"
      id="F_88be40de-661d-4a3f-9522-15f98dfa86c8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="5"
      id="F_26a3fef5-2540-4a57-8d65-076cde8576c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="0"
      id="F_fb854527-8c38-4f98-add5-81ef25714ef5"
      unitRef="U_shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="0"
      id="F_b205f1e9-0bf3-4b59-ac33-f4da932a5d97"
      unitRef="U_shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="0"
      id="F_8715b060-7ebc-4d51-9914-29e072863770"
      unitRef="U_shares">45771332</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="0"
      id="F_b9de6b0e-7f7c-4a01-b4a4-a8566ad02ed7"
      unitRef="U_shares">45771332</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="0"
      id="F_e1e0c432-cea0-4d52-b77f-44a503260890"
      unitRef="U_shares">45433684</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="0"
      id="F_b484c0f1-7e70-4707-9c35-86db570c8f6c"
      unitRef="U_shares">45433684</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_85aacb98-e02e-4985-a26b-75a30878e8fe"
      unitRef="U_USD">487516000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_8a3ba248-8638-4b06-82fc-65b5c8072139"
      unitRef="U_USD">476363000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_b2e07ce3-f57c-4b41-9d95-1c374adbc391"
      unitRef="U_USD">-241043000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_addfe286-314e-4657-a688-5a9524666bbd"
      unitRef="U_USD">-167726000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_6f22b73b-c837-4ea6-99b8-cd45b3800306"
      unitRef="U_USD">-445000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_b647cbf3-2c2f-409d-aab5-d09c0a3829a0"
      unitRef="U_USD">-78000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_6fdffa76-86e9-47d6-92e7-e4da1defc7d9"
      unitRef="U_USD">246028000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_30327c06-6d21-4f73-8fc0-41ca0e30a2ab"
      unitRef="U_USD">308559000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_e2c88a3e-16ee-48d1-8421-5c406cf7dbb7"
      unitRef="U_USD">270308000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_9e362c1d-b51c-4ae6-9a37-22fe0274cb1d"
      unitRef="U_USD">331568000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_d6b7b4ea-d1e5-4715-8cca-69df614e8f15"
      unitRef="U_USD">51988000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_5c8c13b3-4f29-4603-92ca-d787fcd7c4fd"
      unitRef="U_USD">36493000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_6d287beb-02ed-4d9f-8cff-a0c608315feb"
      unitRef="U_USD">23933000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_c5e339e6-9d46-491b-92a3-dd18ff45ff54"
      unitRef="U_USD">25052000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_158f6120-477d-4421-b4b0-408d3b82e0f8"
      unitRef="U_USD">21800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_534bc67f-de18-44d0-afd9-56acab5d9a03"
      unitRef="U_USD">11009000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_783a9a81-22ff-4a45-9a16-3892f76e01c7"
      unitRef="U_USD">77040000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_7da7c1d4-1f6d-4593-b192-0db9f1b8cc71"
      unitRef="U_USD">58293000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_4c4e6e77-c705-464f-af67-1d4f3f44b476"
      unitRef="U_USD">34942000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_241b33e9-0825-4796-82e9-599dfcf8d207"
      unitRef="U_USD">-77040000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_c51e2a9d-1580-463d-b66b-69f7c9312ef3"
      unitRef="U_USD">-58293000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_d72f57bc-9b6b-4790-9109-5987cfae294f"
      unitRef="U_USD">-34942000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_da58fd47-acdc-4c3d-b267-f5f877078d3d"
      unitRef="U_USD">3627000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_8f847b29-0c49-49e3-9071-7c41ff25da40"
      unitRef="U_USD">449000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_d7135e94-423c-444e-965a-74e4a0f09b9f"
      unitRef="U_USD">651000</us-gaap:InterestIncomeExpenseNet>
    <pmvp:OtherNonoperatingIncomeExpenseOther
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_d64bc5da-8cf7-4d72-88ce-2c7997221c33"
      unitRef="U_USD">87000</pmvp:OtherNonoperatingIncomeExpenseOther>
    <pmvp:OtherNonoperatingIncomeExpenseOther
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_61a66b45-3bfc-40fd-95a5-0a17ec4d2f31"
      unitRef="U_USD">21000</pmvp:OtherNonoperatingIncomeExpenseOther>
    <pmvp:OtherNonoperatingIncomeExpenseOther
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_a93868eb-796a-4b55-ac17-a93ac2384d4c"
      unitRef="U_USD">-143000</pmvp:OtherNonoperatingIncomeExpenseOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_99053f56-1787-41ea-84f6-45069b5c6018"
      unitRef="U_USD">3714000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_7dc6db10-573f-4a29-9d05-2ccb886a2975"
      unitRef="U_USD">470000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_fb3a6e5f-11ee-4386-a313-ba7c51400218"
      unitRef="U_USD">508000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_621c99ae-370a-4b1e-abf4-90e3d189d932"
      unitRef="U_USD">-73326000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_d5c08f33-aaff-486e-94d7-5620405e5947"
      unitRef="U_USD">-57823000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_91dac537-aa4f-4e0c-bf79-e95ab8982243"
      unitRef="U_USD">-34434000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_a2de4e3e-99c9-4cc9-a4cb-216875485ad9"
      unitRef="U_USD">-9000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_74635cc6-75d8-4aac-8619-73f6fbd1b756"
      unitRef="U_USD">23000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_14f0c761-a7d2-4fe8-b8ab-fdaf1926266f"
      unitRef="U_USD">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_75ac3260-33e6-4e75-9e9a-666f1d7fde4d"
      unitRef="U_USD">-73317000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_a16951ea-f36c-404c-a449-6d69289e32f6"
      unitRef="U_USD">-57846000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_da42584a-95dc-4724-ad84-2298001ccb28"
      unitRef="U_USD">-34440000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_462eefe4-edd7-464a-90d9-0ac185c42e17"
      unitRef="U_USD">-367000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_1efe9e17-8ac7-4f18-bce0-e760d4988207"
      unitRef="U_USD">-78000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_ebb7b16e-8ffe-4f40-ad99-09f6420db112"
      unitRef="U_USD">3000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_635d93f2-18df-49e2-9e95-258b66630756"
      unitRef="U_USD">-73684000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_beac0093-80ff-49af-a43c-bf331b250ffa"
      unitRef="U_USD">-57924000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_c3815fbb-10af-4459-8546-9ab8f71180bf"
      unitRef="U_USD">-34437000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_3f89426a-2bba-4909-acad-da47b9b88c15"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_efe84a1c-50b4-4449-9dd3-9aca128939b2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="2"
      id="F_4e7ff0bc-d698-47e3-a0ff-c2bc5f475463"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="2"
      id="F_29f588bd-224f-42de-a7cd-516a3b44284f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="2"
      id="F_746c6f8b-e2d6-43a6-b10b-4294f9e44a1a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="2"
      id="F_0e5c38b3-f52e-44b4-b51a-9072e063e15a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="0"
      id="F_f3149c70-2dc2-4452-924b-71732e38b72b"
      unitRef="U_shares">45594824</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="0"
      id="F_5d4138c2-3f1d-4998-a0d4-f7525ac9511a"
      unitRef="U_shares">45594824</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="0"
      id="F_6efbf1e2-0661-459f-80bc-fe76ec419d0f"
      unitRef="U_shares">45137656</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="0"
      id="F_0b42d126-8d09-4bb6-9a3a-9a206f651e10"
      unitRef="U_shares">45137656</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="0"
      id="F_4a11b0ab-8bab-449b-b1d5-8d678f74ce05"
      unitRef="U_shares">14364475</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="0"
      id="F_2abb9574-031f-4c3a-a74a-c934e5916dc1"
      unitRef="U_shares">14364475</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_afc8cc4f-8592-4a73-b6b1-bc62607689d9"
      decimals="0"
      id="F_e275ab39-205a-4521-b9e0-a5552e19300c"
      unitRef="U_shares">22866246</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_afc8cc4f-8592-4a73-b6b1-bc62607689d9"
      decimals="-3"
      id="F_7b58acaa-2d9c-408d-841e-ffa98fa22bd5"
      unitRef="U_USD">168933000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_41b52ed3-f105-4a33-84d9-920833d5abcb"
      decimals="0"
      id="F_08eb1e34-7692-420a-acb9-6690d8047a75"
      unitRef="U_shares">3046200</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_9720ff11-f138-4224-ba3c-9c427709c9e4"
      decimals="-3"
      id="F_e9a570a0-a299-419d-bdcc-ce057845865e"
      unitRef="U_USD">4969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d23af98b-9ff8-4b89-9401-a895cac8088c"
      decimals="-3"
      id="F_caf931fc-619e-4a77-8eb6-67e335ebcb2f"
      unitRef="U_USD">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cc9e11c2-3eae-4c34-8935-47bc9239ba59"
      decimals="-3"
      id="F_2199cff6-4d77-43ca-9861-05f1bddb3f39"
      unitRef="U_USD">-75440000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_14af34ae-ca01-4273-9ecd-fd1963bc0d32"
      decimals="-3"
      id="F_0d6ef5b1-4a28-4c8d-a9f3-59f304c6ed9c"
      unitRef="U_USD">-70474000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_d7d7545a-22ed-48ea-9de9-36b175caa031"
      decimals="0"
      id="F_2a545753-9b7b-4b42-856a-98d1657af6c3"
      unitRef="U_USD">208</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d7d7545a-22ed-48ea-9de9-36b175caa031"
      decimals="0"
      id="F_0204f37d-6b09-4383-8679-385a63ede869"
      unitRef="U_shares">5321864</pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_d7d7545a-22ed-48ea-9de9-36b175caa031"
      decimals="-3"
      id="F_b363dfb2-9b86-4212-9ef9-20d704aa1f3c"
      unitRef="U_USD">69790000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <pmvp:ReclassificationsOfTemporaryToPermanentEquityShares
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="0"
      id="F_eae22260-49ef-48fc-8629-c7e09a04ec11"
      unitRef="U_shares">-28188110</pmvp:ReclassificationsOfTemporaryToPermanentEquityShares>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_93aa48e5-63d6-4753-8113-01f38935bb9a"
      unitRef="U_USD">-238723000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_b870873f-a136-48b3-b1fb-15b46f12781f"
      decimals="0"
      id="F_9df28f3c-d9fd-4c69-bb57-bbddbab571f3"
      unitRef="U_shares">28188110</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_7482c8b1-66e1-413c-a4f6-0956e9d78239"
      decimals="-3"
      id="F_79f27a03-9fa2-4a1e-84ba-94dfafb0e7ce"
      unitRef="U_USD">238723000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_f9f9f786-4445-48c9-9575-36649fb9e492"
      unitRef="U_USD">238723000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <pmvp:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="C_b870873f-a136-48b3-b1fb-15b46f12781f"
      decimals="0"
      id="F_2f421ad8-fa6e-4ab2-a9de-b872989f8378"
      unitRef="U_shares">9688</pmvp:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <pmvp:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_7482c8b1-66e1-413c-a4f6-0956e9d78239"
      decimals="-3"
      id="F_b5ca4e7d-5d09-4d41-86ed-a7512d86596b"
      unitRef="U_USD">194000</pmvp:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <pmvp:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_5099d47a-f22f-417b-a712-1957cfcf40d8"
      unitRef="U_USD">194000</pmvp:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="0"
      id="F_1582b8d1-071a-417e-951e-7523bb82ec59"
      unitRef="U_USD">20359</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b870873f-a136-48b3-b1fb-15b46f12781f"
      decimals="0"
      id="F_22a77657-ae95-4897-93b3-dd5b8da3eef9"
      unitRef="U_shares">13529750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7482c8b1-66e1-413c-a4f6-0956e9d78239"
      decimals="-3"
      id="F_45c851db-816a-4165-acfc-2197ff17012b"
      unitRef="U_USD">223176000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_fbe433f4-0d37-437b-90c4-b5249c73c03b"
      unitRef="U_USD">223176000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_b870873f-a136-48b3-b1fb-15b46f12781f"
      decimals="0"
      id="F_c488ad0f-9c61-4115-901e-a627dbc89a20"
      unitRef="U_shares">4070</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7482c8b1-66e1-413c-a4f6-0956e9d78239"
      decimals="-3"
      id="F_989af349-3a8d-4616-a793-2e19f60bc86a"
      unitRef="U_USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_545e273f-6f4f-4f78-b711-6b385fd24863"
      unitRef="U_USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7482c8b1-66e1-413c-a4f6-0956e9d78239"
      decimals="-3"
      id="F_4ba34993-1ab8-4dbf-aa40-39cbba0c3745"
      unitRef="U_USD">1933000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_153e2d96-3ac9-45b2-b2d4-14973f2c26f1"
      unitRef="U_USD">1933000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_e1d65801-b9d6-4c7d-ba94-0cee28a011c6"
      decimals="-3"
      id="F_145b0540-7688-4857-8287-7175c8ee3e24"
      unitRef="U_USD">-34440000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_3753b995-0b49-4e11-830f-b71180929cde"
      unitRef="U_USD">-34440000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_7826d7cd-2cdc-4c9e-b57f-b6e1dfb7b459"
      decimals="-3"
      id="F_37818c9b-f8a0-462e-90c9-ee0087d948d2"
      unitRef="U_USD">3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_a3e0c022-e21a-41ba-8025-2485c4187c51"
      unitRef="U_USD">3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_c0cf2842-991a-497a-ad23-0d484ab89803"
      decimals="0"
      id="F_8cbb2b1f-a4f4-451d-bbc5-d485f8fd3ef9"
      unitRef="U_shares">44777818</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_77450a26-c91f-4546-8962-eb03770dbd9d"
      decimals="-3"
      id="F_d47b6a68-5b5c-45ee-9f62-0f344434bbd8"
      unitRef="U_USD">469001000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_394efadb-0831-4ded-a4d6-2abf18188b08"
      decimals="-3"
      id="F_dd9be9b2-e013-4966-9cb7-5a34e08eb055"
      unitRef="U_USD">-109880000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_abb7ff4b-f4ff-4208-b730-ff89fd4d2f48"
      decimals="-3"
      id="F_a81d9cf0-6dcf-4f07-8205-14df8a888226"
      unitRef="U_USD">359121000</us-gaap:StockholdersEquity>
    <pmvp:ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans
      contextRef="C_2bfc2514-cfef-48de-a925-42f04c369057"
      decimals="0"
      id="F_8a201683-3587-4361-913e-49ccf7173264"
      unitRef="U_shares">655866</pmvp:ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans>
    <pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
      contextRef="C_7c1da20a-2594-4596-9560-1c31c1640622"
      decimals="-3"
      id="F_e7d4f3b1-8809-41b1-b4bb-1fe04ddf4b0e"
      unitRef="U_USD">2022000</pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans>
    <pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_6e7b7252-4205-47e2-b3b8-83d1d093f1b1"
      unitRef="U_USD">2022000</pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7c1da20a-2594-4596-9560-1c31c1640622"
      decimals="-3"
      id="F_6f23f3f2-d50c-4d85-a3b5-b04b78ec64e4"
      unitRef="U_USD">5340000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_3bb9d072-431b-448b-8598-cd1c672a45d2"
      unitRef="U_USD">5340000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_7a13ba9e-9b6c-49f5-9585-76663577d207"
      decimals="-3"
      id="F_a29301af-55b1-4b36-8180-d5a0162bb9e9"
      unitRef="U_USD">-57846000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_9db4b0c8-e514-4bdd-96e0-656a422a1e36"
      unitRef="U_USD">-57846000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_99e58b14-8dbf-449f-8271-666e6962200a"
      decimals="-3"
      id="F_f65859f5-976e-4dfd-8398-4825b6d92ce6"
      unitRef="U_USD">-78000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_8e7965c0-3f13-431f-9078-5793d85d87ff"
      unitRef="U_USD">-78000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_4fa2099b-812e-4e76-9690-196d1a864954"
      decimals="0"
      id="F_074bb275-177c-4aa1-8263-a76c8dedfec8"
      unitRef="U_shares">45433684</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_96ef7e99-5645-4f46-9a50-9275689d19f9"
      decimals="-3"
      id="F_e792aa53-6a04-4d32-b7fa-220cf8c47720"
      unitRef="U_USD">476363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c9d8a5eb-415a-4f96-ba6c-84acbe6f1562"
      decimals="-3"
      id="F_fc64667d-bad1-4bb4-b109-8d99be5fb24f"
      unitRef="U_USD">-78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_57689871-3d90-40ca-a6f9-460f78c06285"
      decimals="-3"
      id="F_d57038c6-83d5-45b3-93e3-c2ffe4a77dbd"
      unitRef="U_USD">-167726000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_14b9856a-dfc8-4cd2-b60f-30ac68537bf8"
      unitRef="U_USD">308559000</us-gaap:StockholdersEquity>
    <pmvp:ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans
      contextRef="C_95c6ff9a-7273-447e-b18f-9405d1b0061e"
      decimals="0"
      id="F_295118f6-c414-49d0-9c7c-1681945cd1e2"
      unitRef="U_shares">337648</pmvp:ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans>
    <pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
      contextRef="C_8eb3a307-a471-4ef6-b42e-874598113768"
      decimals="-3"
      id="F_1d406c76-bfe1-4128-bd3e-4ba234044aae"
      unitRef="U_USD">958000</pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans>
    <pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_6948b9cc-0bfc-455d-a7f2-faa34d6e4f29"
      unitRef="U_USD">958000</pmvp:ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8eb3a307-a471-4ef6-b42e-874598113768"
      decimals="-3"
      id="F_c448abae-dc4e-4c7c-98e7-8bfd8014aecb"
      unitRef="U_USD">10195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_621cc56b-8640-4d98-a199-27c26b26d21d"
      unitRef="U_USD">10195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_05748ee3-8f14-434c-b214-63235c977b9a"
      decimals="-3"
      id="F_ebd60805-b0e7-477b-8322-700127124275"
      unitRef="U_USD">-73317000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_0e18e784-93ed-4b48-b274-e6cbbf587d5e"
      unitRef="U_USD">-73317000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_de0eb331-80ac-42d7-a504-423cc2cfa8d0"
      decimals="-3"
      id="F_0c238542-92f5-45f4-8282-08ab32d0dcea"
      unitRef="U_USD">-367000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_a1e06da7-ea96-4c19-805a-87a7d451b74d"
      unitRef="U_USD">-367000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_f825d4ed-c7b9-49be-993b-f8659d7899e8"
      decimals="0"
      id="F_50d0ca84-1674-47a7-8dd3-74e758e1e06b"
      unitRef="U_shares">45771332</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_6b29a161-8a1d-462e-b2b3-67a19d48100c"
      decimals="-3"
      id="F_7d9867e8-cb1c-41d5-ac3d-af50cebe656f"
      unitRef="U_USD">487516000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cb839397-f2dc-4167-a221-47e4547f3e6e"
      decimals="-3"
      id="F_797a7cba-9570-4432-ae52-b4d744b5b5dd"
      unitRef="U_USD">-445000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3f92056d-1339-471e-a03a-fba16e49f069"
      decimals="-3"
      id="F_8d4efbbe-677f-47a7-b82e-d99ee03bc360"
      unitRef="U_USD">-241043000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_da5dca84-5a43-426e-8577-9e0a5577e000"
      unitRef="U_USD">246028000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_82bc436f-2baa-4581-9210-7fa8efc438cf"
      unitRef="U_USD">-73317000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_1c5713c5-465d-4ba4-8a12-f1252d4edeb8"
      unitRef="U_USD">-57846000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_9f0b8580-21ba-4665-bc07-8c79291f0edd"
      unitRef="U_USD">-34440000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_90fb96c9-1eaf-4d03-9ab5-a88c00a02bf2"
      unitRef="U_USD">10195000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_0866b12b-642e-4907-8304-38439312eb3c"
      unitRef="U_USD">5340000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_1555c2ac-69e3-42ba-9eea-6e688eac6f52"
      unitRef="U_USD">1933000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_3ddf8f80-ac68-433b-95cb-ca6a13d154d7"
      unitRef="U_USD">315000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_94757e2e-bcfa-4819-a119-272f20836084"
      unitRef="U_USD">307000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_3591191b-9552-45a1-96df-767053faf3b1"
      unitRef="U_USD">318000</us-gaap:Depreciation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_c436db3a-55b6-440f-baad-a9c19c4ed99a"
      unitRef="U_USD">628000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_95426267-e4ac-446a-941e-2840e0d9d968"
      unitRef="U_USD">-550000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_f210d9e3-42c1-4d6d-b60e-4fa17569fcd7"
      unitRef="U_USD">-152000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <pmvp:OtherNonCashLeaseExpense
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_172b710d-416e-41f9-9d33-87e3a8e12f6a"
      unitRef="U_USD">335000</pmvp:OtherNonCashLeaseExpense>
    <pmvp:OtherNonCashLeaseExpense
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_08f3256d-f4d1-4d16-bf9c-bb413467130f"
      unitRef="U_USD">974000</pmvp:OtherNonCashLeaseExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_b90dafcd-e53d-42d4-ad1a-f27d0ed36ca8"
      unitRef="U_USD">92000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_113465e7-42ca-4645-ba22-384a57a880a1"
      unitRef="U_USD">19000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_be78e119-ea75-497d-920c-f3b35d3e73d0"
      unitRef="U_USD">-143000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_c3d519d6-43c3-4ec9-8326-e510aca5ef9f"
      unitRef="U_USD">1829000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_0273c0a9-bd09-45e1-bb36-7c1b96c9ec77"
      unitRef="U_USD">-38000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_e5e4bf33-7353-4de0-af72-7ae2f14c3577"
      unitRef="U_USD">2732000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_76d7819c-4872-46b3-af50-df1273874f9f"
      unitRef="U_USD">2969000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_53c915ac-2d03-47a0-811d-db539416bc56"
      unitRef="U_USD">-389000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_b77fb448-7045-4bf5-9ad6-27cb87e582d3"
      unitRef="U_USD">191000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_ccf3d39a-a435-4252-ba20-a8a747035563"
      unitRef="U_USD">-1230000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_a2df3b5d-b1a1-4f1b-ab5e-99906bd964fe"
      unitRef="U_USD">-1319000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_986252c9-b61e-4de5-973b-0f0f933e5497"
      unitRef="U_USD">3894000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_39867814-b037-4e45-847f-0c5cdb5ad16c"
      unitRef="U_USD">3117000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_1f928b79-731e-47d2-81e4-7d58884e1c46"
      unitRef="U_USD">-63760000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_de5ebe7a-e5d7-4b80-804c-848479057931"
      unitRef="U_USD">-46571000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_c2392a04-0756-4bad-b460-1b060fe45d15"
      unitRef="U_USD">-32739000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_6932b510-c523-4cdb-96a9-4f4a4c839e61"
      unitRef="U_USD">7984000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_3bdf9361-b670-4d8b-8401-8c54cce19fcd"
      unitRef="U_USD">1349000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_ed6f678b-9674-4948-802a-8a909e964c89"
      unitRef="U_USD">148000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_fcc9cdf5-b24b-41fe-b0c6-ed8e7b5f40a1"
      unitRef="U_USD">229199000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_a3069e32-f899-4d3c-bbaf-133577854613"
      unitRef="U_USD">256845000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_38db671e-18ec-4973-8756-cfb9ecd85d4d"
      unitRef="U_USD">14512000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_a03cb849-f8ef-4d69-8bc9-5a3b8d4f2315"
      unitRef="U_USD">235815000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_6d17e576-d17b-41e5-8bcc-64a1cc7a8bac"
      unitRef="U_USD">114610000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_80330007-3800-4d10-8bd6-e6f65951cd2b"
      unitRef="U_USD">42571000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_0ccf427e-59bf-4467-a0b2-9f19f1477401"
      unitRef="U_USD">-1368000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_e3672a2f-1673-470c-8b9e-92fe19aeee6b"
      unitRef="U_USD">-143584000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_715b7298-d6a5-4c49-b987-1f2c078dfaec"
      unitRef="U_USD">27911000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_3324c3b3-a07b-4e47-881e-38ac508e69e8"
      unitRef="U_USD">69790000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_f69ef35a-5a22-42f1-b4e8-1803c70f0666"
      unitRef="U_USD">223176000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_aad9b5af-58d3-4ad3-a8da-c9c9615814a1"
      unitRef="U_USD">958000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_9e6dcd26-13fe-4fff-ada2-4b51d2682a9b"
      unitRef="U_USD">2022000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_4dcb17f1-1131-42cd-9cd2-b0a75bff37df"
      unitRef="U_USD">6000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_baea27e3-7974-4f02-9cca-de3a5994cca2"
      unitRef="U_USD">958000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_f80e1b1c-ed48-4654-8441-cd8ba6e0971a"
      unitRef="U_USD">2022000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_18ef0dc7-a0ac-4bdf-b66c-a9291738cf0c"
      unitRef="U_USD">292972000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_ddaecb9b-b326-4ec8-b691-4cb657972ecf"
      unitRef="U_USD">-64170000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_1418d740-3f07-44cd-91ec-92488d1f5463"
      unitRef="U_USD">-188133000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_60a1abcb-d10d-4128-afe2-713dfcc6ea74"
      unitRef="U_USD">288144000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_a325cc56-1c2b-4eb4-8c67-fc706956a8a4"
      unitRef="U_USD">173289000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_abb7ff4b-f4ff-4208-b730-ff89fd4d2f48"
      decimals="-3"
      id="F_a0567596-9d15-473d-a816-d3e7ed4f8339"
      unitRef="U_USD">361422000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_14af34ae-ca01-4273-9ecd-fd1963bc0d32"
      decimals="-3"
      id="F_0bf9f97d-49f1-4655-a7ab-9ca4249fee13"
      unitRef="U_USD">73278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_62873dff-eed1-4b79-b068-b07962c2403d"
      unitRef="U_USD">109119000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_5d4ef860-6fe4-49fd-b92f-281cf61baf5f"
      unitRef="U_USD">173289000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_abb7ff4b-f4ff-4208-b730-ff89fd4d2f48"
      decimals="-3"
      id="F_fdb1d07f-edbc-4634-8a85-48b90fa3c16e"
      unitRef="U_USD">361422000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <pmvp:LeaseIncentivesUsedForLeaseholdImprovements
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_0f33ca38-88b3-431f-b887-f920f7b158e1"
      unitRef="U_USD">-88000</pmvp:LeaseIncentivesUsedForLeaseholdImprovements>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_5e22ed22-5ef7-4a3f-808c-05eaf24a5cee"
      unitRef="U_USD">196000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_a2c5d356-dd1f-4c2d-98c4-ea859289fc32"
      unitRef="U_USD">1391000</us-gaap:PaymentsToAcquireProductiveAssets>
    <pmvp:ConversionOfConvertiblePreferredStockToCommonStock
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_0fd05338-f58f-4ace-b3ab-8973ff0b21b9"
      unitRef="U_USD">238723000</pmvp:ConversionOfConvertiblePreferredStockToCommonStock>
    <pmvp:ConversionOfWarrantLiabilityToCommonStock
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_0df4bf4a-0451-44cd-b895-cd78f5d19ec8"
      unitRef="U_USD">194000</pmvp:ConversionOfWarrantLiabilityToCommonStock>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_49225348-face-4823-958e-84c9e74174b6"
      unitRef="U_USD">23000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_309a5932-c2a5-4a76-a509-1ac5e8e33491"
      unitRef="U_USD">6000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_87afb994-2791-43e5-b591-8d75397969c8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;1.  Formation and Business of the Company&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;PMV Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) was incorporated in the state of Delaware in March 2013. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities and raising capital. The Company is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company&#x2019;s headquarters are located at 1 Research Way, Princeton, New Jersey.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On September 25, 2020, the Company completed an initial public offering (the &#x201c;IPO&#x201d;) of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,529,750&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share including the exercise in full by the underwriters of their option to purchase up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,764,750&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional shares of commons stock, for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;243,536&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and its shares started trading on The Nasdaq Global Select Market under the ticker symbol &#x201c;PMVP.&#x201d;  The Company received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;223,176&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by the Company.  In connection with the closing of the IPO, all of the Company&#x2019;s outstanding shares of convertible preferred stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,188,110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has incurred net losses and negative cash flows from operations since its inception. During the year ended December 31, 2022, the Company incurred a net loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73,317&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and used $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63,760&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of cash for operations. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;241,043&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  Cash, cash equivalents, and marketable securities were &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;243,549&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  Management expects to incur substantial additional operating losses for the next several years and may need to obtain additional debt or equity financings in order to complete development of its products, obtain regulatory approvals, launch and commercialize its products and continue research and development programs. The Company believes it has adequate cash, cash equivalents, and marketable securities to operate for at least the next twelve months from the date of issuance of these financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0044e892-3fea-44d5-872f-e25925415e12"
      decimals="INF"
      id="F_5eb39057-cd80-4d54-a10d-6ff6c31ed12c"
      unitRef="U_shares">13529750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_c875a660-6997-4368-89c4-d6bfbe6ef5e5"
      decimals="INF"
      id="F_94998931-ef4f-4a2b-b8f1-1dbf362c5435"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_1034c385-e799-4334-bd67-e7a75f20b60c"
      decimals="INF"
      id="F_4ba42a4a-bad2-4565-8a19-82136e021489"
      unitRef="U_shares">1764750</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <pmvp:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_e9a7f863-44e3-4b8b-a088-33b385350544"
      decimals="-3"
      id="F_33c69c6a-028a-49c2-a30a-86b9860ace79"
      unitRef="U_USD">243536000</pmvp:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e9a7f863-44e3-4b8b-a088-33b385350544"
      decimals="-3"
      id="F_808b0d9a-56a3-470e-8844-5600b34392fc"
      unitRef="U_USD">223176000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_e30e375d-2146-4abd-ab44-0f83c21f02ca"
      decimals="INF"
      id="F_24b45272-fe12-4c4f-8a6a-82f8c9dfe4f3"
      unitRef="U_shares">28188110</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_c0e890c0-36aa-43c8-8cea-ce3f33273f2a"
      unitRef="U_USD">-73317000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_0faa8777-8154-4265-8bd0-7ef742ce2716"
      unitRef="U_USD">-63760000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_f3b33f18-cfcb-41f7-b47e-2fe1d5985f11"
      unitRef="U_USD">-241043000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_a364941e-0137-4253-a226-de921b4ddd2b"
      unitRef="U_USD">243549000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_2ff6d629-2c35-4d40-b444-203e597572a3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2.  Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2020, the Company&#x2019;s board of directors and stockholders approved an amendment to the Company&#x2019;s amended and restated certificate of incorporation to affect a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.2651&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-for-1 reverse stock split of the Company&#x2019;s common stock and convertible preferred stock&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which was effected on September 24, 2020. The par value of the common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, convertible preferred stock, stock options, and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 - Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument&#x2019;s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. The Company&#x2019;s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders&#x2019; equity. Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security and recorded on the interest income, net line of the income statement. For the years ended December 31, 2022, 2021, and 2020, the Company recorded &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;628&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of accretion, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;550&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of amortization and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;152&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of amortization, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash as of December 31, 2022 included &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;822&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; de&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;posit at the Company&#x2019;s commercial bank underlying a stand-by letter of credit issued in favor of a landlord (See Note 6) and is classified in current assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company presents comprehensive loss in a single statement within its financial statements. Other comprehensive loss consists of unrealized gains and losses on marketable securities, net of tax.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#x2019;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.  The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#x2019;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. Furthermore, the Company has elected the practical expedient to not separate lease and non-lease components by class of underlying asset for its existing leases. The Company&#x2019;s only existing leases are for office and laboratory space.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#x2019;s share of the lessor&#x2019;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. Neither of the Company&#x2019;s leases contain residual value guarantees.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight&#x2011;line method over the estimated useful lives of the assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, except for leasehold improvements, which are amortized over the shorter of the useful life of the asset or the remaining term of the lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-lived assets, are tested for recoverability whenever events or changes in the business environment indicate that the carrying amount of the assets may not be fully recoverable. Factors considered by the Company when deciding when to perform an impairment review include significant underperformance of the business against expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows resulting from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows resulting from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its current fair value. To date, the Company has not recorded any impairment losses on long-lived assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All costs associated with research and development are expensed as incurred.  Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes allocated stock-based compensation, salary payroll taxes, employee benefits; materials; supplies; depreciation on and maintenance of research equipment; the cost of services provided by outside contractors; and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. The Company records accruals for estimated research and development expenses, comprising payments for work performed by third party vendors, clinical research organizations, clinical manufacturing organizations and others. Some of these vendors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones.  For the latter, the Company accrues the expenses as goods or services are used or rendered.  Research and development activities related to patient enrollment are accrued as patients enter and progress through the trial.  In the event that the Company prepays fees, the Company records the prepayment as a prepaid asset and periodically evaluate the prepaid asset in conjunction with the related accrued research and development expenses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s share-based compensation program allows for grants of stock options and restricted stock units. Grants are awarded to employees and non-employees, including directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for stock-based employee compensation arrangements in accordance with provisions of ASC 718,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Compensation &#x2013; Stock Compensation &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;ASC 718&#x201d;)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option pricing or equity valuation model that is applied in a manner consistent with the fair value measurement objectives of ASC 718, is based on established principles of financial theory and reflects all of the substantive terms and conditions of the award. The Company uses the Black-Scholes option-pricing model (&#x201c;Black-Scholes&#x201d;) to value stock option grants to employees, non-employees and directors. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock units and stock options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to the lack of a public market for the Company&#x2019;s common stock until September 2020 and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the Company&#x2019;s IPO, due to the absence of an active market for the Company&#x2019;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for options granted, the Company considered the estimated fair value of the common stock as of the measurement date. Prior to the Initial Public Offering, the estimated fair value of the common stock was determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#x2019;s-length sales of the Company&#x2019;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event. Other factors considered were the Company&#x2019;s financial position and historical financial performance, the status of technological developments within the Company&#x2019;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#x2019;s competition, and the current business climate in the marketplace.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is typically the vesting term.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the Company&#x2019;s Chief Operating Decision Maker to make decisions with respect to resource allocation and assessment of performance. To date, the Company has viewed its operations and manages its business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating and reporting segment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is computed using the &#x201c;two-class&#x201d; method which includes the weighted average number of shares of common stock outstanding during the period and other securities that participate in dividends (a participating security). The Company&#x2019;s convertible preferred stock are participating securities as defined by ASC 260-10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Earnings per Share&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. During the periods where the Company incurs net losses, the Company allocates no loss to participating securities because these securities have no contractual obligation to share in the losses of the Company. Under the two-class method, basic net loss per share applicable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional shares for the potential dilutive effects of a warrant, convertible preferred stock and stock options outstanding during the period calculated in accordance with the treasury stock method, or the two-class method, whichever is more dilutive. The Company allocates net earnings on a &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;pari passu&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (equal) basis to both common and preferred stockholders. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company&#x2019;s net losses. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes in accordance with ASC 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ("ASC 740"), which requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Under ASC 740, the liability method is used in accounting for income taxes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and law that will be in effect when the differences are expected to reverse. ASC 740 also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates annually the realizability of the deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. In 2022 and 2021, the Company recorded a full valuation allowance for the deferred tax assets based on the historical loss and the uncertainty regarding the ability to project future taxable income. In future periods if the Company is able to generate income, the Company may reduce or eliminate the valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions in accordance with ASC 740. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax provision that an entity takes or expects to take in a tax return. Additionally, ASC 740 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. Under ASC 740, an entity may only recognize or continue to recognize tax positions that meet a "more likely than not" threshold. In accordance with this accounting policy, the Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2019, the FASB issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_637e6d3e-1c4a-4011-bf94-4da18c87eb69;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ASU 2019-12&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Income Taxes &#x2013; Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The new guidance simplifies the accounting for income taxes by removing several exceptions in the current standard and adding guidance to reduce complexity in certain areas, such as requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; this standard as of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The adoption did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;not&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and marketable securities. The Company maintains its cash, cash equivalents and marketable securities in accounts at high quality financial institutions. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds. Cash and cash equivalents include a checking account and a money market account held at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company&#x2019;s marketable debt securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#x2019;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#x2019;s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_2d99e72b-88d8-4f49-94e3-2d9f6a3ffb8d">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_e9aa0f4e-82e6-4a41-ade6-8f3903a65e70">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <pmvp:ReverseStockSplitPolicyTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_a47ad657-5c8e-44b1-a02b-c45db219f1fc">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2020, the Company&#x2019;s board of directors and stockholders approved an amendment to the Company&#x2019;s amended and restated certificate of incorporation to affect a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.2651&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-for-1 reverse stock split of the Company&#x2019;s common stock and convertible preferred stock&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which was effected on September 24, 2020. The par value of the common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, convertible preferred stock, stock options, and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.&lt;/span&gt;&lt;/p&gt;</pmvp:ReverseStockSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_17a27043-797c-4507-ade3-bf66c8d30e5f">5.2651-for-1 reverse stock split of the Company&#x2019;s common stock and convertible preferred stock</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_ee831443-0cb9-4eaf-ae6d-7a321beb8833"
      decimals="4"
      id="F_8f825643-30db-4519-b860-379ea6072865"
      unitRef="U_pure">5.2651</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_70ed12fb-6495-4890-82b6-5ef00e12d931">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2 - Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.6912346582651767%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 - Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <pmvp:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_cdef8786-2702-45ba-83ec-a7e900ab3f26">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument&#x2019;s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. The Company&#x2019;s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders&#x2019; equity. Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security and recorded on the interest income, net line of the income statement. For the years ended December 31, 2022, 2021, and 2020, the Company recorded &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;628&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of accretion, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;550&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of amortization and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;152&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of amortization, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash as of December 31, 2022 included &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;822&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; de&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;posit at the Company&#x2019;s commercial bank underlying a stand-by letter of credit issued in favor of a landlord (See Note 6) and is classified in current assets.&lt;/span&gt;&lt;/p&gt;</pmvp:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_9769d460-0175-4695-ad92-aed84f6c4073"
      unitRef="U_USD">628000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_b51c6963-1c89-4cc2-a4f6-759320bcdd63"
      unitRef="U_USD">-550000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_bebfb578-6c16-4cb9-b099-466a72ed506d"
      unitRef="U_USD">-152000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:RestrictedCash
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_bb201b64-fc69-44f8-a2df-e0b82cc1f6b7"
      unitRef="U_USD">822000</us-gaap:RestrictedCash>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_13140f64-f39e-4a05-bc6d-4f65bbd8a4de">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company presents comprehensive loss in a single statement within its financial statements. Other comprehensive loss consists of unrealized gains and losses on marketable securities, net of tax.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_a787f120-050d-41e5-9e04-d480eddafaf1">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#x2019;s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities at the lease commencement date, and thereafter if modified.  The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company&#x2019;s policy is to not record leases with a lease term of 12 months or less on its balance sheets. Furthermore, the Company has elected the practical expedient to not separate lease and non-lease components by class of underlying asset for its existing leases. The Company&#x2019;s only existing leases are for office and laboratory space.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company&#x2019;s share of the lessor&#x2019;s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Variable payments have been excluded from the lease liability and associated right-of-use asset. Neither of the Company&#x2019;s leases contain residual value guarantees.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_bdd69645-16ef-4102-9863-8c3b0608a8f5">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight&#x2011;line method over the estimated useful lives of the assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, except for leasehold improvements, which are amortized over the shorter of the useful life of the asset or the remaining term of the lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon retirement or sale of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Repairs and maintenance costs are charged to operations as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_c6a3f2a2-0f68-4a73-92ff-801a44f13ffe">five years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_a5ee411c-950c-468b-b385-a76250961535">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-lived assets, are tested for recoverability whenever events or changes in the business environment indicate that the carrying amount of the assets may not be fully recoverable. Factors considered by the Company when deciding when to perform an impairment review include significant underperformance of the business against expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows resulting from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows resulting from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its current fair value. To date, the Company has not recorded any impairment losses on long-lived assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_81a0a2de-2e1c-4be8-83b8-b09773bacd84">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All costs associated with research and development are expensed as incurred.  Research and development expenses include costs directly attributable to the conduct of research and development programs, including compensation costs, which includes allocated stock-based compensation, salary payroll taxes, employee benefits; materials; supplies; depreciation on and maintenance of research equipment; the cost of services provided by outside contractors; and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. The Company records accruals for estimated research and development expenses, comprising payments for work performed by third party vendors, clinical research organizations, clinical manufacturing organizations and others. Some of these vendors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones.  For the latter, the Company accrues the expenses as goods or services are used or rendered.  Research and development activities related to patient enrollment are accrued as patients enter and progress through the trial.  In the event that the Company prepays fees, the Company records the prepayment as a prepaid asset and periodically evaluate the prepaid asset in conjunction with the related accrued research and development expenses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_046c98db-ada6-4a4c-b4c3-f86e80d7b81d">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s share-based compensation program allows for grants of stock options and restricted stock units. Grants are awarded to employees and non-employees, including directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for stock-based employee compensation arrangements in accordance with provisions of ASC 718,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Compensation &#x2013; Stock Compensation &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;ASC 718&#x201d;)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option pricing or equity valuation model that is applied in a manner consistent with the fair value measurement objectives of ASC 718, is based on established principles of financial theory and reflects all of the substantive terms and conditions of the award. The Company uses the Black-Scholes option-pricing model (&#x201c;Black-Scholes&#x201d;) to value stock option grants to employees, non-employees and directors. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock units and stock options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to the lack of a public market for the Company&#x2019;s common stock until September 2020 and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the Company&#x2019;s IPO, due to the absence of an active market for the Company&#x2019;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for options granted, the Company considered the estimated fair value of the common stock as of the measurement date. Prior to the Initial Public Offering, the estimated fair value of the common stock was determined at each grant date based upon a variety of factors, including the illiquid nature of the common stock, arm&#x2019;s-length sales of the Company&#x2019;s capital stock (including convertible preferred stock), the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event. Other factors considered were the Company&#x2019;s financial position and historical financial performance, the status of technological developments within the Company&#x2019;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#x2019;s competition, and the current business climate in the marketplace.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is typically the vesting term.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_67dfe70d-0d8c-469c-b07c-a71965bd85b7"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_d7e72018-561f-4ee4-adfa-a799dcbd2168">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the Company&#x2019;s Chief Operating Decision Maker to make decisions with respect to resource allocation and assessment of performance. To date, the Company has viewed its operations and manages its business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating and reporting segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="INF"
      id="F_b2c4de72-f6cf-4431-9c2b-1c162b34726d"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="INF"
      id="F_23f39bfa-6da8-4941-8c7f-d9f9228f6b8c"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_8010a419-6655-4385-a753-97b10d75eb82">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is computed using the &#x201c;two-class&#x201d; method which includes the weighted average number of shares of common stock outstanding during the period and other securities that participate in dividends (a participating security). The Company&#x2019;s convertible preferred stock are participating securities as defined by ASC 260-10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Earnings per Share&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. During the periods where the Company incurs net losses, the Company allocates no loss to participating securities because these securities have no contractual obligation to share in the losses of the Company. Under the two-class method, basic net loss per share applicable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional shares for the potential dilutive effects of a warrant, convertible preferred stock and stock options outstanding during the period calculated in accordance with the treasury stock method, or the two-class method, whichever is more dilutive. The Company allocates net earnings on a &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;pari passu&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (equal) basis to both common and preferred stockholders. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company&#x2019;s net losses. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_3e363e7a-dfcc-42ee-9cbd-1ecb5b31c35d">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes in accordance with ASC 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ("ASC 740"), which requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Under ASC 740, the liability method is used in accounting for income taxes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and law that will be in effect when the differences are expected to reverse. ASC 740 also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company evaluates annually the realizability of the deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. In 2022 and 2021, the Company recorded a full valuation allowance for the deferred tax assets based on the historical loss and the uncertainty regarding the ability to project future taxable income. In future periods if the Company is able to generate income, the Company may reduce or eliminate the valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions in accordance with ASC 740. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax provision that an entity takes or expects to take in a tax return. Additionally, ASC 740 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. Under ASC 740, an entity may only recognize or continue to recognize tax positions that meet a "more likely than not" threshold. In accordance with this accounting policy, the Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_be6d7bc9-1da8-4afa-89e8-f6d58b7dcf2d">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2019, the FASB issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_637e6d3e-1c4a-4011-bf94-4da18c87eb69;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ASU 2019-12&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Income Taxes &#x2013; Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The new guidance simplifies the accounting for income taxes by removing several exceptions in the current standard and adding guidance to reduce complexity in certain areas, such as requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; this standard as of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The adoption did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;not&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      id="F_d903e981-764a-4927-8879-65d00722194a">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      id="F_60b8359d-3e8e-40d4-a294-b68208840d9d">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      id="F_1d2a2aad-1d11-424f-87ab-195851afbe9f">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <pmvp:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_a6e3db93-f3d7-458f-a940-b12481e9aa5a">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and marketable securities. The Company maintains its cash, cash equivalents and marketable securities in accounts at high quality financial institutions. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these funds. Cash and cash equivalents include a checking account and a money market account held at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company&#x2019;s marketable debt securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#x2019;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#x2019;s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.&lt;/span&gt;&lt;/p&gt;</pmvp:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_0b3ce88b-23bd-4f92-ad6c-2216b59e72d0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;3.  Financial Instruments and Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments consist of money market funds, U.S. government debt securities and corporate debt securities. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables show the Company&#x2019;s cash equivalents and available-for-sale securities&#x2019; carrying amounts and fair values as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:21.434%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.08%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.055%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.262%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.08%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.08%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.08%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.76%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="26" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted&lt;br/&gt;priced in&lt;br/&gt;active&lt;br/&gt;markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;242,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;242,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;114,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="26" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Priced in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;227,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;227,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;227,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;310,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;310,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;269,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2013; As of December 31, 2022, the Company had cash of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,436&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and cash equivalents, consisting of money market funds, of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,861&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of December 31, 2021, the Company had cash of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,507&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;168,960&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Cash equivalents consisted of money market funds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,960&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and corporate debt securities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;128,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  Money market funds are classified within level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets, whereas corporate debt securities are classified within level 2 of the fair value hierarchy because they are valued using inputs other than quoted prices that are observable for the asset or liability either directly or indirectly.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Marketable Securities &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2013; Marketable securities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;135,252&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as of December 31, 2022, consisted of corporate debt securities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103,591&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and government debt securities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,661&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. There were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;132,757&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; current marketable securities and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,495&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; noncurrent marketable securities as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Marketable securities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;141,607&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as of December 31, 2021, consisted of corporate debt securities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,362&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and government debt securities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,245&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. There were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;124,696&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; current marketable securities and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,911&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; noncurrent marketable securities as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, aggregated gross unrealized losses of available-for-sale investments were not material, and accordingly, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; allowance for credit losses was recorded.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_fc317aaf-b840-43de-b1a7-45ddfa38464f">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables show the Company&#x2019;s cash equivalents and available-for-sale securities&#x2019; carrying amounts and fair values as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:21.434%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.08%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.055%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.262%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.08%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.08%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.08%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.76%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="26" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted&lt;br/&gt;priced in&lt;br/&gt;active&lt;br/&gt;markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;242,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;242,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;114,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="26" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Priced in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;227,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;227,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;227,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;310,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;310,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;269,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_58ef5181-20d9-4f31-9be5-bbaff729be34"
      decimals="-3"
      id="F_839edbc9-cba2-447b-8844-2427b6478cf8"
      unitRef="U_USD">106861000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_58ef5181-20d9-4f31-9be5-bbaff729be34"
      decimals="-3"
      id="F_f885d733-f82a-4b04-b12b-17aa16e870ef"
      unitRef="U_USD">106861000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1b95af3e-4692-4a4e-9684-b24ec983c018"
      decimals="-3"
      id="F_f9a95d71-2300-4f65-9e28-a56879ea67b0"
      unitRef="U_USD">106861000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b5a63292-5285-4e55-9178-b0cf6d47d493"
      decimals="-3"
      id="F_f170b53f-4961-4611-8703-2a74c4aa053a"
      unitRef="U_USD">103755000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b5a63292-5285-4e55-9178-b0cf6d47d493"
      decimals="-3"
      id="F_a046f459-85da-4498-a5f9-548b8e9465ad"
      unitRef="U_USD">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b5a63292-5285-4e55-9178-b0cf6d47d493"
      decimals="-3"
      id="F_cbcede59-bd88-4518-9cff-462845cc536c"
      unitRef="U_USD">185000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b5a63292-5285-4e55-9178-b0cf6d47d493"
      decimals="-3"
      id="F_e93d4104-c1fc-4330-962e-2c1807b20f8c"
      unitRef="U_USD">103591000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5f699388-d277-4279-ad4b-3dc305343bb9"
      decimals="-3"
      id="F_6bb73c9a-7dbf-4136-8e46-140cbeaea9a6"
      unitRef="U_USD">103591000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a77505cc-2f39-49ee-ad0b-48a03ab00343"
      decimals="-3"
      id="F_049e9c7d-d916-49e6-8416-1c16f743db4a"
      unitRef="U_USD">31942000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a77505cc-2f39-49ee-ad0b-48a03ab00343"
      decimals="-3"
      id="F_54816023-3fb2-4ac1-9583-b9382aec4c1b"
      unitRef="U_USD">281000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a77505cc-2f39-49ee-ad0b-48a03ab00343"
      decimals="-3"
      id="F_5d537f96-261b-459d-b60d-2262c724b23b"
      unitRef="U_USD">31661000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ed2937ce-4797-431c-bb85-119506b27457"
      decimals="-3"
      id="F_9e64e97f-5d21-4d3a-bdfd-69861d3e0b13"
      unitRef="U_USD">20981000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a7da1954-d795-42d9-9a41-c04ab601e771"
      decimals="-3"
      id="F_87ec25cf-71c4-4a84-b4f7-dabd73b34541"
      unitRef="U_USD">10680000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_408f7cb2-c672-4647-982e-f8ac75f87a14"
      unitRef="U_USD">242558000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_97edee2c-0c40-4fc7-a0de-dc7489f923c8"
      unitRef="U_USD">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_104f8db5-b09e-4481-b656-e2d79e75017c"
      unitRef="U_USD">466000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_03c7f9df-199a-498e-8bc9-a62e3b0337c0"
      unitRef="U_USD">242113000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_720aa091-f1ff-40f6-9052-0af429d30c44"
      decimals="-3"
      id="F_4e925f6d-b1f5-434a-90de-5b127e925dfa"
      unitRef="U_USD">127842000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_00093d41-7321-438a-9568-7a6890ae8c2f"
      decimals="-3"
      id="F_ef990ac8-87ba-482d-99ff-60b4719121d6"
      unitRef="U_USD">114271000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_efbb7361-2dda-41c4-81c1-8e49b935005c"
      decimals="-3"
      id="F_698cf9d7-6d36-4176-b316-2c213ea2562c"
      unitRef="U_USD">40960000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_efbb7361-2dda-41c4-81c1-8e49b935005c"
      decimals="-3"
      id="F_e9e071b4-c7f3-4376-b01b-cf941fb643ac"
      unitRef="U_USD">40960000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a991aacb-ef93-40b5-b119-f3a9a2d28d00"
      decimals="-3"
      id="F_b69b3fcd-2ebc-40d0-bb02-642f87ac014e"
      unitRef="U_USD">40960000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_11ed8784-858f-40ad-9cbb-1dbbf928a291"
      decimals="-3"
      id="F_ae9b5583-43e8-4160-87c6-d0029a4c90fd"
      unitRef="U_USD">227378000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_11ed8784-858f-40ad-9cbb-1dbbf928a291"
      decimals="-3"
      id="F_136a072c-6846-4c5d-b587-5dac323773f1"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_11ed8784-858f-40ad-9cbb-1dbbf928a291"
      decimals="-3"
      id="F_6f33366a-6db2-4366-b41d-2cb8013ce318"
      unitRef="U_USD">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_11ed8784-858f-40ad-9cbb-1dbbf928a291"
      decimals="-3"
      id="F_affcdeb6-ea12-4b39-9366-ca5e8da82caf"
      unitRef="U_USD">227362000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b49092ec-8ffe-4a12-88e3-3c14783b877c"
      decimals="-3"
      id="F_e345c39a-d9c2-4c73-8ef9-5d7b51029580"
      unitRef="U_USD">227362000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6d1c2064-9b95-4b0c-95f4-5061ac19468e"
      decimals="-3"
      id="F_759b0e83-7e9c-4fef-9ab5-802433f31346"
      unitRef="U_USD">42307000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6d1c2064-9b95-4b0c-95f4-5061ac19468e"
      decimals="-3"
      id="F_ce85dff5-8f6b-420b-971b-72d1954a2d94"
      unitRef="U_USD">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6d1c2064-9b95-4b0c-95f4-5061ac19468e"
      decimals="-3"
      id="F_ff8fdad7-25c6-4223-995a-5d58607a8f5f"
      unitRef="U_USD">42245000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f4cfd3a5-85b9-4820-af60-1d16ec12ddf9"
      decimals="-3"
      id="F_c9a55b57-1b94-4582-a5e7-db6383a8ef0a"
      unitRef="U_USD">42245000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_42f5ff49-4880-4f42-90f6-01ae17aa2d04"
      unitRef="U_USD">310645000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_bc95bb5a-cf7f-433d-b371-6e0d400969b2"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_2b97a673-7876-49b8-82d8-3843f3beb6b3"
      unitRef="U_USD">81000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_fcf9cea2-b95d-48a2-b83e-89062f143619"
      unitRef="U_USD">310567000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7f668206-d681-40de-bb20-c42cee8ec88f"
      decimals="-3"
      id="F_41cd926b-e3dc-4a17-aff6-35395c23d541"
      unitRef="U_USD">40960000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0b75762f-88bc-457f-a72d-6cf0e39501d3"
      decimals="-3"
      id="F_753adcee-5c97-415c-8eec-11fe30b83ea4"
      unitRef="U_USD">269607000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_f65546eb-88a4-48e4-a172-2bb4a24ba8fc"
      unitRef="U_USD">1436000</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_879ceb86-1bbd-4a7e-aeb5-021b406392a9"
      unitRef="U_USD">106861000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:Cash
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_1fde43db-0ce5-4696-af54-dc40f0eb012f"
      unitRef="U_USD">3507000</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_307bc950-d768-4bc2-8370-168773c5ae99"
      unitRef="U_USD">168960000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_f8e287d6-b299-4d5e-a156-3e903f57677f"
      decimals="-3"
      id="F_0dba8082-45ba-4eb3-9358-31e4159641e2"
      unitRef="U_USD">40960000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_b49092ec-8ffe-4a12-88e3-3c14783b877c"
      decimals="-3"
      id="F_2fff331e-ebfe-478d-90fc-c9ca83d28bd8"
      unitRef="U_USD">128000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_97f554cc-3886-4ea9-bc0f-24f35338e0df"
      unitRef="U_USD">135252000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_b5a63292-5285-4e55-9178-b0cf6d47d493"
      decimals="-3"
      id="F_ae806a2a-32b3-4f98-adc9-0c8d544bbd58"
      unitRef="U_USD">103591000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_a77505cc-2f39-49ee-ad0b-48a03ab00343"
      decimals="-3"
      id="F_d631a10b-27d7-4aad-a108-5169645369d1"
      unitRef="U_USD">31661000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_deb3544e-e4fb-42ed-b66b-2c192ec473a2"
      unitRef="U_USD">132757000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_20c2652c-3a95-4884-bbc4-26165e681dd2"
      unitRef="U_USD">2495000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecurities
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_94247407-15cc-48e2-a08d-e30ccffdda67"
      unitRef="U_USD">141607000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_11ed8784-858f-40ad-9cbb-1dbbf928a291"
      decimals="-3"
      id="F_5990f664-8ce9-464b-8968-22dd0ff11b70"
      unitRef="U_USD">99362000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_6d1c2064-9b95-4b0c-95f4-5061ac19468e"
      decimals="-3"
      id="F_a5edec19-6459-4182-b0b7-d46caef877ee"
      unitRef="U_USD">42245000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_6eb91521-80a2-4061-a3f9-c9a861803ea3"
      unitRef="U_USD">124696000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_dbb88d9f-1ed6-4dee-a0ab-caabfa6baad3"
      unitRef="U_USD">16911000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_381c41bd-789d-4716-a2df-e93ad36d074f"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="INF"
      id="F_f1db483a-3414-4777-9150-20d563aaba79"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_1322076f-df8e-4ff3-8c54-4011e4dc8112">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;4.  Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.649%;"/&gt;
        &lt;td style="width:0.994%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.329%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.005%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Machinery &amp;amp; equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture &amp;amp; fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets not placed in service&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense for the years ended December 31, 2022, 2021, and 2020 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;307&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;318&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_780cb3d9-0d38-4de9-bd44-af8b7bef2340">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.649%;"/&gt;
        &lt;td style="width:0.994%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.329%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.005%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Machinery &amp;amp; equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture &amp;amp; fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets not placed in service&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2dfb4cde-06c3-4435-a144-2e3f21d7e9ea"
      decimals="-3"
      id="F_cdc2e46c-6d8b-4217-8546-b58451063b17"
      unitRef="U_USD">2448000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_24c200ea-42b0-4b4d-9f36-e114465d1de9"
      decimals="-3"
      id="F_ca1e1e5c-87cd-4926-9590-d2d841e5ba1f"
      unitRef="U_USD">2261000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e7ede4d5-1f79-4121-9b1d-f81bbef5bc5d"
      decimals="-3"
      id="F_48a18646-a645-4219-9acd-3c16b7ea8f08"
      unitRef="U_USD">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0599473c-789b-4f09-b3fb-e6b52320799c"
      decimals="-3"
      id="F_c009f8de-ba10-4ff2-92fa-bf8359d19094"
      unitRef="U_USD">8000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_27aea8e1-2efd-4fae-b253-57813f8540e5"
      decimals="-3"
      id="F_4af9be68-ef17-4448-abc3-d36eb65befe2"
      unitRef="U_USD">69000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_cba766c3-a95a-452a-8d08-ceb25213b983"
      decimals="-3"
      id="F_ac81a2b3-bd97-4a0d-b775-0f8dfa719df3"
      unitRef="U_USD">9000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_be4f127e-beed-49d8-9fd5-8cc013547c17"
      decimals="-3"
      id="F_80b505a6-d2ef-4813-a3e1-63547576a06a"
      unitRef="U_USD">409000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1cbfb514-89c7-42d8-9873-9e01e255563c"
      decimals="-3"
      id="F_e61463de-f1a8-4234-8a1b-2ed295be34eb"
      unitRef="U_USD">161000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_cd70bc18-5773-4da6-a7eb-54ca7d7cf4d2"
      decimals="-3"
      id="F_99027b3c-e52f-4373-9a65-22da30d3e04b"
      unitRef="U_USD">10200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_01ffbae4-047b-4cdf-97c5-b607f5f8288c"
      decimals="-3"
      id="F_d98271ed-02d3-4e6f-ad41-2d02fc6ae028"
      unitRef="U_USD">2519000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_618fd198-e2c2-444d-9f2c-6fe916ffbe44"
      unitRef="U_USD">13139000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_403515a1-e39b-41a2-b454-8acc38e80728"
      unitRef="U_USD">4958000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_ad7bc2ef-7b8b-433f-9018-c6a391bf5804"
      unitRef="U_USD">2184000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_a150a9ee-1713-475a-a34c-67af28fabc66"
      unitRef="U_USD">1868000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_59d3e626-946c-4f7e-8ebc-142649c0f1c2"
      unitRef="U_USD">10955000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_05093257-fd0c-4ece-a67f-cbf6c74642a1"
      unitRef="U_USD">3090000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_6a218ef4-3824-4a6a-8ef4-b47d04cfe20f"
      unitRef="U_USD">315000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_5435ada7-be3d-4708-97ca-bae46e724934"
      unitRef="U_USD">307000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_af8f9ccd-efb0-4dae-a6c4-52a0c662b04f"
      unitRef="U_USD">318000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_35697ee4-c604-4fc1-9d14-2d13f3a061f2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;5.  Accrued Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.42%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.904%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.654%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_b1228504-2f48-4c90-968d-8df0ac609976">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.42%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.904%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.654%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_d6a48963-1e01-4d9e-b51e-777c98e36881"
      unitRef="U_USD">2897000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_6feff41b-7dd6-44e4-af23-23e417a6d7ef"
      unitRef="U_USD">3797000</us-gaap:WorkersCompensationLiabilityCurrent>
    <pmvp:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_1b18c951-9a0a-4240-81e5-cae7e43a5fe2"
      unitRef="U_USD">4259000</pmvp:AccruedResearchAndDevelopmentCostsCurrent>
    <pmvp:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_0d882807-87b6-4557-98e4-a257b200253e"
      unitRef="U_USD">4734000</pmvp:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_36107cbd-6de2-4ace-b92f-5d5469e529c3"
      unitRef="U_USD">152000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_04821f0a-6d3b-444b-8a23-3a1225e5101e"
      unitRef="U_USD">96000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_91ae121f-1d2f-4a87-960d-3679df993f05"
      unitRef="U_USD">7308000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_a6e39f64-0472-4c75-971b-631f206c4b85"
      unitRef="U_USD">8627000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_2eb2b3b6-0a01-4938-ae0b-12d69056f41b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;6.  Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2015, the Company executed a noncancelable operating lease for approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of laboratory, research and development, and office space in Cranbury, New Jersey for an initial base rent of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per square foot. This location operates as the Company&#x2019;s current headquarters.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2017, the Company obtained an additional noncancelable operating lease for about &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of laboratory space in the same corporate center at an initial rental rate at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per square foot. As a result of the additional space, both leases expired &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;June 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2022, the Company signed a lease extension for both leases for up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_2e41832f-24ee-4add-8485-3b9e6b7ae42f;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional year through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;June 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, with the option to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;terminate&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; upon 120 days of written notice, with an increase in base rent as per the lease extension.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Both leases include a common area maintenance expense for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per square foot with an increase of 3% on the first month of each calendar year during the lease term and a management fee of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the base rent.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company is obligated to pay, on a pro-rata basis, real estate taxes and operating costs related to the premises.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2018, the Company executed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; noncancelable operating leases. One lease for approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet for vivarium, laboratory and general office space in South Brunswick, New Jersey. The initial annual base rent is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per square foot and a management fee of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the base rent. The Company is obligated to pay, on a pro-rata basis, insurance premiums, real estate taxes and operating costs related to the premises. The lease expired in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2022, the Company signed a lease extension for up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_68272f31-ac51-43d0-89b6-b5574371c7f3;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional year through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, with the option to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;terminate&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; upon 120 days of written notice, with an increase in base rent as per the lease extension.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The second lease is for office space in Lexington, Massachusetts, that expires &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, with an option to renew for a one-time, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; extension. The initial annual base rent is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per square foot and will increase $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per square foot at the end of each rent year.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In 2018, the Company received a lease incentive for the buildout of 420 Bedford Street in Lexington, MA. The Company was given an allowance for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on behalf of the lessor for construction of office space. Management recognizes this allowance as a lease incentive in its Right-of-Use asset and straight-lines the allowance throughout the term of the lease.  As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, the remaining rent incentive pertaining to the Lexington, MA lease totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2021, the Company signed a lease for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,581&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of office and laboratory space at 1 Research Way in Princeton, New Jersey. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;That lease term extends through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2032&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, has a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; extension option, and is intended to replace the Company&#x2019;s two existing facilities and the space is expected to become the Company&#x2019;s future headquarters.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Payment under this lease will total $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,889&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;May 2032&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company received a lease incentive of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,046&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from the lessor for a buildout of laboratory, vivarium, and office space, to be reimbursed to the Company in 2022 and 2023. Management estimated the timing and amounts of reimbursements and included them as a reduction of lease payments when initially measuring the lease liability and right-of-use asset upon commencement. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,969&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of reimbursements were received.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lea&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;se cost for the year ended December 31, 2022, and 2021, are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.752%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.851%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.16%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts reported in the balance sheet for leases where the Company is the lessee as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, and 2021, were as follows, in thousands:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.631%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.403%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.403%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets, operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.02&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other information related to leases for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, and 2021, are as follows, in thousands:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.599%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.049%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net cash paid (received) for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leased assets obtained in exchange for new or modified operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum lease payments, net of reimbursements, remaining as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 under operating leases by fiscal year were as follows, in thousands:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.773%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:14.835%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fiscal year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Amounts representing imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Rent expense recorded for the years ended December 31, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,215&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,691&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company currently subleases the office space at 420 Bedford Street in Lexington, MA to another company.  This sublease agreement expires in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  In April 2021, the Company entered into a sublease agreement with the previous tenants of the office space at 1 Research Way in Princeton, NJ, from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;April 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. For the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, sublease income for the Company was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_313a014b-8256-4401-b4ea-e5d597a024c1"
      decimals="INF"
      id="F_37027c20-4af5-4d25-b0e4-f5ce3d6ff26d"
      unitRef="U_sqft">13000</us-gaap:AreaOfRealEstateProperty>
    <pmvp:InitialBaseRentPerSquareFoot
      contextRef="C_313a014b-8256-4401-b4ea-e5d597a024c1"
      decimals="2"
      id="F_eb12f00c-bd02-49f4-8726-f82be35293f6"
      unitRef="U_U_iso4217USD_utrsqft">20.00</pmvp:InitialBaseRentPerSquareFoot>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_4bdae4ec-dd1e-490f-b8a5-74529602509a"
      decimals="INF"
      id="F_9aebdb47-8fd5-4900-9f8c-27487d1dad5d"
      unitRef="U_sqft">6000</us-gaap:AreaOfRealEstateProperty>
    <pmvp:InitialBaseRentPerSquareFoot
      contextRef="C_4bdae4ec-dd1e-490f-b8a5-74529602509a"
      decimals="2"
      id="F_ffbfd5cd-9132-4a85-ae76-bdb282676ce3"
      unitRef="U_U_iso4217USD_utrsqft">22.00</pmvp:InitialBaseRentPerSquareFoot>
    <pmvp:OperatingLeaseExpirationPeriod
      contextRef="C_05247025-7721-46fd-b9a4-9209202d385c"
      id="F_4f64ba16-364e-4509-ae92-41a41f46a7dc">2022-06</pmvp:OperatingLeaseExpirationPeriod>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="C_ee80540b-08ef-4bfb-a16e-dc6e2b4b20b1"
      id="F_a0bcd124-3e1b-4f8d-b1a6-a1ef79af960c">In January 2022, the Company signed a lease extension for both leases for up to one additional year through June 2023, with the option to terminate upon 120 days of written notice, with an increase in base rent as per the lease extension.</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <pmvp:LesseeOperatingLeaseRenewalMonthAndYear
      contextRef="C_ee80540b-08ef-4bfb-a16e-dc6e2b4b20b1"
      id="F_cff4567a-50db-4183-a5d5-8eddc7baa40b">2023-06</pmvp:LesseeOperatingLeaseRenewalMonthAndYear>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="C_ee80540b-08ef-4bfb-a16e-dc6e2b4b20b1"
      id="F_4738da7b-4103-4851-9f2d-cb3d1755c4f1">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_05247025-7721-46fd-b9a4-9209202d385c"
      id="F_61e4869b-312b-475c-8284-74472fd2ecbc">Both leases include a common area maintenance expense for $3.00 per square foot with an increase of 3% on the first month of each calendar year during the lease term and a management fee of 3% of the base rent.</us-gaap:LesseeOperatingLeaseDescription>
    <pmvp:OperatingLeaseMaintenanceExpensePerSquareFoot
      contextRef="C_6a05cc4e-dcbc-40a3-8e6d-3479699de18c"
      decimals="2"
      id="F_9f9af43a-787b-4ff9-8ab4-0c643619bfce"
      unitRef="U_U_iso4217USD_utrsqft">3.00</pmvp:OperatingLeaseMaintenanceExpensePerSquareFoot>
    <pmvp:ManagementFeeOfBaseRentPercentage
      contextRef="C_6a05cc4e-dcbc-40a3-8e6d-3479699de18c"
      decimals="2"
      id="F_ee7713e8-5bdb-47db-8083-9b4c17198af8"
      unitRef="U_pure">0.03</pmvp:ManagementFeeOfBaseRentPercentage>
    <pmvp:NumberOfNoncancelableOperatingLeases
      contextRef="C_0aac07e3-04d3-478a-9920-5fb843d4ae5d"
      decimals="INF"
      id="F_f313158f-5db8-44b6-af17-d3ef4a3e7bfc"
      unitRef="U_Lease">2</pmvp:NumberOfNoncancelableOperatingLeases>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_430e7e98-a75c-447c-94c7-2b300c9ae2c1"
      decimals="INF"
      id="F_fcc638dd-e13c-4f12-a2e3-30989ad4e89d"
      unitRef="U_sqft">6000</us-gaap:AreaOfRealEstateProperty>
    <pmvp:InitialBaseRentPerSquareFoot
      contextRef="C_430e7e98-a75c-447c-94c7-2b300c9ae2c1"
      decimals="2"
      id="F_4efce871-7238-4a8c-a92f-7a6cb953b92d"
      unitRef="U_U_iso4217USD_utrsqft">15.50</pmvp:InitialBaseRentPerSquareFoot>
    <pmvp:ManagementFeeOfBaseRentPercentage
      contextRef="C_430e7e98-a75c-447c-94c7-2b300c9ae2c1"
      decimals="2"
      id="F_962186f8-8bb7-4285-864d-19b4ace2b9e7"
      unitRef="U_pure">0.03</pmvp:ManagementFeeOfBaseRentPercentage>
    <pmvp:OperatingLeaseExpirationPeriod
      contextRef="C_6997eaf7-2d14-4514-abb0-3d4e030cd2ba"
      id="F_ebfeb86f-0de6-43e3-8965-4ad25cfbe6b1">2022-07</pmvp:OperatingLeaseExpirationPeriod>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="C_cff8f1fb-dda0-4691-8c83-2a825ba5821d"
      id="F_d00a5b68-1839-40e5-9c6b-4e746c6c2216">In January 2022, the Company signed a lease extension for up to one additional year through July 2023, with the option to terminate upon 120 days of written notice, with an increase in base rent as per the lease extension.</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <pmvp:LesseeOperatingLeaseRenewalMonthAndYear
      contextRef="C_cff8f1fb-dda0-4691-8c83-2a825ba5821d"
      id="F_486ea270-2886-4564-bae6-afcb9956b212">2023-07</pmvp:LesseeOperatingLeaseRenewalMonthAndYear>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="C_cff8f1fb-dda0-4691-8c83-2a825ba5821d"
      id="F_144eb738-498b-4bcd-8cfb-34787a91a6a9">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <pmvp:OperatingLeaseExpirationPeriod
      contextRef="C_72d9367d-2b3c-4d93-892a-028d7de01843"
      id="F_8e146ed5-1996-4199-9729-915c2d893dbe">2023-08</pmvp:OperatingLeaseExpirationPeriod>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_f992ea57-8d32-4b0e-81ef-cb65a45d19d0"
      id="F_74b89c4f-ff6c-4631-8439-92d2dc0ae5a9">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <pmvp:InitialBaseRentPerSquareFoot
      contextRef="C_f992ea57-8d32-4b0e-81ef-cb65a45d19d0"
      decimals="2"
      id="F_c49d5dcc-92f9-4cca-978c-59a4e4b9f0f5"
      unitRef="U_U_iso4217USD_utrsqft">28.50</pmvp:InitialBaseRentPerSquareFoot>
    <pmvp:InitialBaseRentIncreasedPerSquareFoot
      contextRef="C_f992ea57-8d32-4b0e-81ef-cb65a45d19d0"
      decimals="2"
      id="F_c39d2c16-4334-4ad5-99ee-7f03b322124b"
      unitRef="U_U_iso4217USD_utrsqft">1.00</pmvp:InitialBaseRentIncreasedPerSquareFoot>
    <pmvp:AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace
      contextRef="C_12649a32-1900-4175-a9b7-929ef30b495c"
      decimals="INF"
      id="F_74ad56c3-ed99-47a9-bd11-6e69ee331fea"
      unitRef="U_USD">165000</pmvp:AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace>
    <us-gaap:DeferredRentCredit
      contextRef="C_e6b007b1-2fc8-4c95-a477-b9b71fb8a813"
      decimals="-3"
      id="F_ce6c3a13-82f6-4767-9308-0a222061fe7e"
      unitRef="U_USD">25000</us-gaap:DeferredRentCredit>
    <us-gaap:AreaOfLand
      contextRef="C_e1989c17-cc2f-4cba-a956-12217925213d"
      decimals="INF"
      id="F_064f5c85-af38-4fbe-9e7d-1bb739ec725d"
      unitRef="U_sqft">50581</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_dde39134-e5f7-476a-97bc-d31efae7f2a7"
      id="F_ed3e43a4-3349-4c6f-bc6b-0c8a6078db27">That lease term extends through 2032, has a five-year extension option, and is intended to replace the Company&#x2019;s two existing facilities and the space is expected to become the Company&#x2019;s future headquarters.</us-gaap:LesseeOperatingLeaseDescription>
    <pmvp:OperatingLeasesExtendedYear
      contextRef="C_341901e2-89fa-4177-845b-613f934b9099"
      id="F_3e207d48-9da9-4390-ad6a-77bdceb51639">2032</pmvp:OperatingLeasesExtendedYear>
    <pmvp:OperatingLeasesExtensionPeriod
      contextRef="C_341901e2-89fa-4177-845b-613f934b9099"
      id="F_8673c421-2cc6-4b7e-9182-824a158e90ba">P5Y</pmvp:OperatingLeasesExtensionPeriod>
    <us-gaap:OperatingLeasePayments
      contextRef="C_341901e2-89fa-4177-845b-613f934b9099"
      decimals="-3"
      id="F_de5a866f-8519-4a7e-abce-258e99cceee7"
      unitRef="U_USD">19889000</us-gaap:OperatingLeasePayments>
    <pmvp:OperatingLeasesExtendedMonthAndYear
      contextRef="C_341901e2-89fa-4177-845b-613f934b9099"
      id="F_21dadedb-80b2-4b52-a9ab-33da75b07eeb">2032-05</pmvp:OperatingLeasesExtendedMonthAndYear>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_341901e2-89fa-4177-845b-613f934b9099"
      decimals="-3"
      id="F_853ccb65-d972-4a91-9075-779fb69b15e0"
      unitRef="U_USD">4046000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <pmvp:ReimbursementsReceivedFromLessee
      contextRef="C_0f6a712d-9111-4481-8345-32cee4988f74"
      decimals="-3"
      id="F_8ece269c-e2e0-4e29-8248-501a83df683a"
      unitRef="U_USD">2969000</pmvp:ReimbursementsReceivedFromLessee>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_5728f329-2ebe-4e88-b0c5-1bb4e1f7efbd">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lea&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;se cost for the year ended December 31, 2022, and 2021, are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.752%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.851%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.618%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.16%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_5fcffb32-dc12-49e9-b459-8041c827f019"
      unitRef="U_USD">2215000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_63ffbd14-5029-4dd6-9729-d936cbe88982"
      unitRef="U_USD">1691000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_8e71d09d-5127-4489-b017-e68ea9f483ee"
      unitRef="U_USD">991000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_8cdbcc73-be12-43b9-98aa-8cf39cf637d3"
      unitRef="U_USD">704000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_5f059912-ea03-46c2-8d30-92e330f79a2f"
      unitRef="U_USD">3206000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_3b9de31a-f69e-4415-9e20-aa552e55238b"
      unitRef="U_USD">2395000</us-gaap:LeaseCost>
    <pmvp:ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_6fa8a9b1-09f7-4841-813b-f52ac7e2b07e">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts reported in the balance sheet for leases where the Company is the lessee as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, and 2021, were as follows, in thousands:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.631%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.403%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.403%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets, operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.02&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</pmvp:ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_ce9af9f1-4872-4057-9e87-31b18395cb3c"
      unitRef="U_USD">9539000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_6dcd91f3-54b0-4383-80be-5f20cbafbb7a"
      unitRef="U_USD">10060000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_23be844a-ef7a-436b-b941-75e93353746e"
      unitRef="U_USD">528000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_d1ae1b22-bb7b-4c94-b2ac-ff7928cf9063"
      unitRef="U_USD">403000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_affa8591-aa9e-4c16-84c6-0dbab817a7b4"
      unitRef="U_USD">13448000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_dc76a8ae-c39b-4669-bf3f-9abcbd5e604b"
      unitRef="U_USD">10790000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_87566751-80c2-4696-a738-2d88f36b7eed"
      unitRef="U_USD">13976000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_e91bc201-5a4b-4a21-b6a3-cf0721f7a469"
      unitRef="U_USD">11193000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      id="F_abadf855-99b5-440f-9d3a-2ae38fe04f04">P9Y29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      id="F_888843e0-141c-47fd-88c9-fe01768a8651">P10Y7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="4"
      id="F_d63ed445-619d-4ad6-a8c3-a92275c4a805"
      unitRef="U_pure">0.0575</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="4"
      id="F_b0022c04-417c-46b3-8c71-586abd9b7580"
      unitRef="U_pure">0.0575</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <pmvp:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_5c61b4ac-fa2c-47da-a4fe-bcc32d6fd00e">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other information related to leases for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, and 2021, are as follows, in thousands:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.599%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.049%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net cash paid (received) for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leased assets obtained in exchange for new or modified operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</pmvp:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock>
    <pmvp:NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_d1845d0f-c0cb-4fb0-b09c-ec2863ed148a"
      unitRef="U_USD">-1089000</pmvp:NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities>
    <pmvp:NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_d3f5b339-2f80-4548-8ad8-d19551612ad8"
      unitRef="U_USD">717000</pmvp:NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_1979292e-5fb2-4528-b819-e7c151ae7484"
      unitRef="U_USD">987000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_314ddd63-ff61-4c6a-ae2e-e1c323cc56dc"
      unitRef="U_USD">10318000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_f8530617-70b0-4e3c-86fc-45311029dd20">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum lease payments, net of reimbursements, remaining as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 under operating leases by fiscal year were as follows, in thousands:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.773%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:14.835%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.165%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fiscal year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Amounts representing imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_084354b5-9c7e-478e-80ef-d0a6747fbfc9"
      unitRef="U_USD">1219000</pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths>
    <pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_6edc6f9e-3de3-4132-abd1-c83c567983d7"
      unitRef="U_USD">1814000</pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo>
    <pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_dd8d2ad4-8bb2-4b5f-8b6a-5d2874b177b3"
      unitRef="U_USD">1869000</pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree>
    <pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_cb8cc051-7067-4375-a4f5-01c1a6a7053a"
      unitRef="U_USD">1925000</pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour>
    <pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_609c31c0-7e6e-458e-9bf9-98f63deedeec"
      unitRef="U_USD">1983000</pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive>
    <pmvp:LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_b7ed9705-426d-4660-a11a-20fdbaa0ad0d"
      unitRef="U_USD">9494000</pmvp:LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive>
    <pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_22568179-ce89-4a63-9ff4-ac50eef2c72d"
      unitRef="U_USD">18304000</pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_9ad88b6a-ed4a-4cb4-8df4-6f34fd54ef9b"
      unitRef="U_USD">4328000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_e306c679-c142-4ba7-ba4b-e6ea5d358926"
      unitRef="U_USD">13976000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_544ef8b0-1a76-4ae0-8067-0d4d2ae0715d"
      unitRef="U_USD">2215000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_bc9ea41a-f205-4b8f-9b79-c020dad835a3"
      unitRef="U_USD">1691000</us-gaap:OperatingLeaseExpense>
    <pmvp:SubleaseExpirationPeriod
      contextRef="C_8894ea23-6468-4b4b-9fe0-13e05959ff40"
      id="F_f7d12feb-433f-453a-8f2c-935882fb177e">2023-08</pmvp:SubleaseExpirationPeriod>
    <pmvp:SubleaseWithTenantOfficeSpaceStartingPeriod
      contextRef="C_498dfeb5-4f73-4ec9-8f1c-60dbf3d79a5b"
      id="F_3d66f722-469b-4386-9dae-f6dd7a1edd9f">2021-04</pmvp:SubleaseWithTenantOfficeSpaceStartingPeriod>
    <pmvp:SubleaseWithTenantOfficeSpaceEndingPeriod
      contextRef="C_498dfeb5-4f73-4ec9-8f1c-60dbf3d79a5b"
      id="F_9873d22b-0e38-4591-85a7-b6689116d5e1">2021-07</pmvp:SubleaseWithTenantOfficeSpaceEndingPeriod>
    <pmvp:SubleaseAndAdditionalSubleaseIncome
      contextRef="C_dde39134-e5f7-476a-97bc-d31efae7f2a7"
      decimals="-3"
      id="F_4075cc0f-def6-4e05-9bad-54b54640d10c"
      unitRef="U_USD">107000</pmvp:SubleaseAndAdditionalSubleaseIncome>
    <pmvp:SubleaseAndAdditionalSubleaseIncome
      contextRef="C_b2f1afb2-0883-4bf4-890d-a477cbd94b5a"
      decimals="-3"
      id="F_f67c7519-9f37-4c45-84ef-721b7e90a187"
      unitRef="U_USD">116000</pmvp:SubleaseAndAdditionalSubleaseIncome>
    <us-gaap:PreferredStockTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_84c58345-b57d-4a76-99d3-b7148173e57e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;7.  Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2020, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,321,864&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Series D Preferred Stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.1533&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, resulting in gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  In connection with the IPO on September 25, 2020, all of the Company&#x2019;s convertible preferred stock, including Series D Preferred Stock, outstanding at the time of the IPO automatically converted into an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,188,110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c0a73230-1c9b-4996-8fdd-7164c9f9c45f"
      decimals="INF"
      id="F_a5230361-8561-4fe3-90a2-fa909fedafd7"
      unitRef="U_shares">5321864</pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_e189a9e4-ad1c-4932-a0a3-75d29fa8bacd"
      decimals="INF"
      id="F_1ed3c863-ff26-4d97-a60a-f02873193df2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.1533</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_c0a73230-1c9b-4996-8fdd-7164c9f9c45f"
      decimals="-3"
      id="F_ecd7d1f9-3455-498e-95a5-e9868d6165b2"
      unitRef="U_USD">70000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_e30e375d-2146-4abd-ab44-0f83c21f02ca"
      decimals="INF"
      id="F_b30b8a74-f5d5-4047-aca9-2f4ada1e8b7f"
      unitRef="U_shares">28188110</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_56f86b4f-a9a4-4ce8-8e26-e2ddfc568d35">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;8.  Stockholders' Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is authorized to issue up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of preferred stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,771,332&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,433,684&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock issued and outstanding, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stockholders are entitled to receive dividends if and when declared by the board of directors subject to the rights of any preferred stockholders.  As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dividends on common stock had been declared by the Company.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, the Company had reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.217%;"/&gt;
        &lt;td style="width:1.423%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.806999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.434%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.12%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,278,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,246,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares available for future stock option and RSU grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,618,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,951,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares available for employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;705,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;801,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,602,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,999,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_97c187b1-fecc-4533-b25f-f454b8188678"
      unitRef="U_shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_434d31ca-fe0b-4119-a936-58647089c5b6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_ad6809ad-702d-4566-975f-714377ce9361"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="INF"
      id="F_def7e542-1616-4939-a62b-d282fc0a0759"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_15d3bc46-d167-49a6-8c91-ce86bd0bd1ab"
      unitRef="U_shares">45771332</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_01ddd42a-2609-4d82-8f91-ce5d9bdaaeca"
      unitRef="U_shares">45771332</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="0"
      id="F_d377af62-df29-4b1d-8d01-c7b1fa3212eb"
      unitRef="U_shares">45433684</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="0"
      id="F_52bdad32-54d0-4098-b568-2e977bd6fd80"
      unitRef="U_shares">45433684</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DividendsCommonStock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="INF"
      id="F_e0dc0d1b-df86-47a6-8e33-19a715f98467"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_17f14def-53fb-4446-a6b5-cd35e1a4db37">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, the Company had reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.217%;"/&gt;
        &lt;td style="width:1.423%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.806999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.434%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.12%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,278,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,246,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares available for future stock option and RSU grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,618,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,951,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares available for employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;705,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;801,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,602,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,999,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1dba3b6b-5641-4b1b-9e12-052771f7ced4"
      decimals="INF"
      id="F_aaab9745-d460-44ec-b232-1e082682902b"
      unitRef="U_shares">5278771</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0736b229-258c-40dd-838a-47547c627b77"
      decimals="INF"
      id="F_78c469c1-658b-4e8b-a775-b698fca0dee7"
      unitRef="U_shares">4246007</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_1cd8bf12-77eb-46c5-b2bb-d96f2c6f11bb"
      unitRef="U_shares">4618292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="INF"
      id="F_cf87bf20-ed49-4c51-8cc4-723eb12a8a81"
      unitRef="U_shares">4951680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_eca134b8-8341-44f2-81c6-6033965b566e"
      unitRef="U_shares">705559</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="INF"
      id="F_20519a29-8188-4318-bfcc-3511fdf2a736"
      unitRef="U_shares">801464</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_d4e2194b-d177-496a-acc7-d53ddc017f26"
      unitRef="U_shares">10602622</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="INF"
      id="F_59b4defa-a79b-4a75-9859-6d06dede6f38"
      unitRef="U_shares">9999151</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_4088528f-3636-47c9-bcb0-13efad0df790">&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;9.   Stock Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) was approved by the board of directors on September 24, 2020.  The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#x2019;s officers, employees, directors and consultants. The number of shares of common stock initially reserved for issuance under the 2020 Plan was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,406,374&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, in an amount equal to the least of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,406,374&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, (ii) five percent  (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%) of the outstanding common stock on the immediately preceding December 31, or (iii) such number of common stock determined by the board of directors no later than the immediately preceding December 31.  For 2022, the board&#x2019;s compensation committee, as the 2020 Plan administrator, exercised its discretion under clause (iii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by a lesser amount of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,363,084&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, effective as of January 1, 2022. For 2023, the board&#x2019;s compensation committee, as the 2020 Plan administrator, exercised its discretion under clause (iii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by a lesser amount of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,830,853&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, effective as of January 1, 2023. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,618,292&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares available for issuance under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On September 9, 2022, the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;374,899&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Restricted Stock Units (RSUs) to employees pursuant to an employee retention program approved by the Board's compensation committee.  The RSU&#x2019;s have graded vesting on an annual basis for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of continuous service, as per the 2020 Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The table below summarizes the annual grant activity under the 2020 Plan as of  December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.364%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:12.678%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.100000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.843%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares Available &lt;br/&gt;for Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,951,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares reserved for issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,363,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,419,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSU&#x2019;s granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;374,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options forfeited / cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,618,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;) was approved by the board of directors on September 24, 2020.  A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;400,752&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;801,504&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, (ii) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (iii) an amount determined by the board of directors or any of its committees no later than the last day of the immediately preceding fiscal year. For 2022, the board waived the annual increase to the shares reserved under the 2020 ESPP. For 2023, the 2020 ESPP reserved shares were increased under clause (iii) by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;457,713&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, effective as of January 1, 2023. On May 20, 2022, employees exercised their right to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,454&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares under the 2020 ESPP. On November 21, 2022, employees exercised their right to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,385&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares under the 2020 ESPP. As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95,905&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares are issued or outstanding, and there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;705,559&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares available for issuance, under the 2020 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2013 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In 2013, the Company adopted the 2013 Stock Plan (the &#x201c;2013 Plan&#x201d;). On September 24, 2020, this plan was replaced by the 2020 Plan, and future issuances of incentive instruments will be governed by that plan.  Subject to the provisions of the 2020 Plan, the Company had the option to either forfeit or repurchase remaining shares under the 2013 Equity Incentive Plan on or after the registration date.  The Company chose to forfeit the remaining shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents RSU activity under the 2020 Plan as of December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.363000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.879999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.759%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average &lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested shares at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;374,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested shares at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;374,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,317&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of unrecognized compensation cost related to RSUs that are expected to vest. These costs are expected to be recognized over a weighted average remaining vesting period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:5.733%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes option activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.542%;"/&gt;
        &lt;td style="width:0.074%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.773000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.074%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.184000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.074%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.983%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.074%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.219%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in 000s)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,246,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.86&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,419,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options forfeited / cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;288,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,278,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.82&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,278,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.82&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,281,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.76&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted average grant date fair value of stock options granted during the year ended December 31, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.92&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.03&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate intrinsic value of options vested and exercisable as of December 31, 2022 and 2021 is calculated based on the difference between the exercise price and the fair value of our common stock.  The intrinsic value of options exercised in 2022 and 2021 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,764&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,534&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the total compensation cost related to nonvested service-based awards not yet recognized is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,005&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  The weighted-average period over which the nonvested awards is expected to be recognized is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company estimated the fair value of stock options using the Black-Scholes options valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.987%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:16.998%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:16.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:15.556%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.48&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.31&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.51&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.44&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.44&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.92&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.40&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76.33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79.90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70.70&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.60&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted average assumptions used to estimate the fair value of stock purchase rights under the 2020 ESPP are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.998%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:12.895%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:13.996%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:13.098%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.44&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.49&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.83&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected Term: The Company uses the simplified method to calculate expected term described in the SEC&#x2019;s Staff Accounting Bulletin No. 107, which takes into account vesting term and expiration date of the options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Volatility: Volatility is based on an average of the historical volatilities of comparable publicly traded companies for the expected term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk Free Interest Rate: The risk-free rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term of the option.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend Yield: The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in the valuation model.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense recorded under ASC 718 was allocated to research and development and general and administrative expense as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.28%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.176%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.434%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.649000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.429%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.301%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.173%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.430000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.636%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.429%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ee1cceca-c5e2-4901-967c-47736d420d59"
      decimals="INF"
      id="F_44a52fe9-c41e-4cbc-86f8-475801346261"
      unitRef="U_shares">4406374</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum
      contextRef="C_ee1cceca-c5e2-4901-967c-47736d420d59"
      decimals="INF"
      id="F_25b73d53-c47e-48e7-8c9e-008477d1b6f4"
      unitRef="U_shares">4406374</pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding
      contextRef="C_ee1cceca-c5e2-4901-967c-47736d420d59"
      decimals="2"
      id="F_399d29c4-e3ac-4a56-941a-6388a20eb9dd"
      unitRef="U_pure">0.05</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding>
    <pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum
      contextRef="C_56fadc42-3ad0-4e3b-8b73-b2226b84481a"
      decimals="INF"
      id="F_f5d381bc-11c0-4328-ad59-cd6259cc7486"
      unitRef="U_shares">1363084</pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum>
    <pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum
      contextRef="C_bc64aa3a-019b-48b2-8343-7467cc9d0a91"
      decimals="0"
      id="F_15b520b7-4b52-4bdc-9e6b-513d6cb06666"
      unitRef="U_shares">1830853</pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_978ba6d3-3e46-4525-91db-17cd972dc4ad"
      decimals="INF"
      id="F_f5d279cc-b1ff-4d3e-a3ce-5d977f12ab4b"
      unitRef="U_shares">4618292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_be6aad5a-a831-43c8-a05f-822cdf5cf4a7"
      decimals="INF"
      id="F_27ae3c02-e288-43ef-a39a-acea845b897d"
      unitRef="U_shares">374899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_016af1b3-ff49-4bb0-867b-902d174c68ec"
      id="F_7f8801bb-f895-4fea-b151-92e8d3edea4f">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_6a771154-38a1-4194-a353-695b5bd842d1">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The table below summarizes the annual grant activity under the 2020 Plan as of  December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.364%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:12.678%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.100000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.843%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares Available &lt;br/&gt;for Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,951,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares reserved for issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,363,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,419,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSU&#x2019;s granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;374,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options forfeited / cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,618,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes option activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.542%;"/&gt;
        &lt;td style="width:0.074%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.773000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.074%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.184000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.074%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.983%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.074%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.219%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in 000s)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,246,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.86&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,419,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options forfeited / cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;288,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,278,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.82&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,278,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.82&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,281,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.76&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="INF"
      id="F_22f2aca7-a5cc-47ab-8b97-7f50f1036cc8"
      unitRef="U_shares">4951680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="INF"
      id="F_b7900ba2-da8c-44ac-865d-0fa82e82de6f"
      unitRef="U_shares">1363084</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="INF"
      id="F_57349649-f549-4d27-83db-3b1402f8727c"
      unitRef="U_shares">1419197</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="INF"
      id="F_6dc968c4-1b00-4b4a-8fa4-21cf82bdd58a"
      unitRef="U_shares">374899</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="INF"
      id="F_8fe89a00-3f75-45cc-a7e3-57afd27d2f6c"
      unitRef="U_shares">97624</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_fbd5706b-fe97-441e-89ee-b3362e2db7a3"
      unitRef="U_shares">4618292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_46e3720d-b4bb-422c-94c9-0403252a56b3"
      decimals="INF"
      id="F_bc2edc1a-4e6c-40ee-9219-e321be9bab04"
      unitRef="U_shares">400752</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum
      contextRef="C_46e3720d-b4bb-422c-94c9-0403252a56b3"
      decimals="INF"
      id="F_f8c5b740-de0f-46b7-8328-d4fbedfcf501"
      unitRef="U_shares">801504</pmvp:CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding
      contextRef="C_46e3720d-b4bb-422c-94c9-0403252a56b3"
      decimals="2"
      id="F_08ec3d82-121f-4e91-8925-391389c8be6c"
      unitRef="U_pure">0.01</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a8260db6-bbe1-4939-9c5f-a844164fe721"
      decimals="INF"
      id="F_69f90998-b8ff-4e79-b4b9-204bd98aa56d"
      unitRef="U_shares">457713</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares
      contextRef="C_4e66fbef-977e-4452-91f9-9a4ee3656882"
      decimals="INF"
      id="F_ac73d25b-870b-40b1-abe1-62339817abc4"
      unitRef="U_shares">18454</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares
      contextRef="C_9eac9d1b-d481-4882-beb9-94f63124f8eb"
      decimals="INF"
      id="F_40a41b0e-d8c9-4654-88d5-0c4d1efabc32"
      unitRef="U_shares">30385</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_1e80c7c5-b3d0-4620-b5bc-d434b48624a5"
      decimals="INF"
      id="F_b9e4eede-b702-4dcc-bfac-9e41ace6cbbd"
      unitRef="U_shares">95905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber
      contextRef="C_1e80c7c5-b3d0-4620-b5bc-d434b48624a5"
      decimals="INF"
      id="F_102d2138-af61-474b-8050-29bbd61ecfb0"
      unitRef="U_shares">95905</pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1f918825-5928-4608-b71c-9f4456b6f047"
      decimals="INF"
      id="F_4a21a28c-151d-4b9c-b41b-1ed523485ef0"
      unitRef="U_shares">705559</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_fcdc8400-9249-4922-bcd4-fce4b43d2933">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents RSU activity under the 2020 Plan as of December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.363000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.879999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.759%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average &lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested shares at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;374,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested shares at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;374,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="INF"
      id="F_1a1cabc7-0190-4474-8fdc-830a18b62b13"
      unitRef="U_shares">374899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="1"
      id="F_ccfdd90f-ba3a-452d-a9c9-2568aa16142d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_1d86198c-fcdb-4339-8c45-1382aa724b3e"
      unitRef="U_shares">374899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="1"
      id="F_93148f30-6fb6-4f66-b515-6ad6e959fb13"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_c7636c7c-5d0d-43b6-ae8e-cf22b92c32be"
      decimals="-3"
      id="F_2d7e2e64-aadf-4a32-a1c9-d70f0fcc8983"
      unitRef="U_USD">4317000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_350081f7-b9c6-4878-9982-48ec05493f21"
      id="F_e5c55fc3-d246-422f-a29c-194841d08659">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="INF"
      id="F_3d20c4ab-b28a-4f3c-8c15-1ecdfe72df3d"
      unitRef="U_shares">4246007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="2"
      id="F_f3892331-8b28-4956-b5b4-bf6d5dbd3836"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      id="F_46787d1c-1399-4b19-a530-618024fe342d">P6Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_df9f501f-2356-465f-b834-e7dc663da5e9"
      unitRef="U_USD">68506000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="INF"
      id="F_df080ac5-0207-4fb1-9f03-e669e2abb0e3"
      unitRef="U_shares">1419197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_272e42e5-68a8-470b-a3ea-6047860cde8a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="INF"
      id="F_a20d7ad6-839a-4ede-a7b4-9fbaa4c491ca"
      unitRef="U_shares">97624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_3e9cb418-1593-4674-8418-b409e791d331"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="INF"
      id="F_d7c00b89-370e-4c07-a4d1-61f112a31284"
      unitRef="U_shares">288809</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_890c9365-6c2c-436c-906e-65ca254223b1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_2564756c-df6e-4d30-a07a-b730e331ebd5"
      unitRef="U_shares">5278771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="2"
      id="F_80cf929a-a4c4-4626-b8db-4e9beb1a537f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_29e18dd4-5934-45ae-99a1-bfe6daff98e0">P6Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_2950ff85-26c2-49b3-b1fb-9678abd2ae54"
      unitRef="U_USD">17244000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_5752287d-a0b4-4de4-9439-97bff5ec78b3"
      unitRef="U_shares">5278771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="2"
      id="F_335c4c6b-a733-4f13-989e-8f70eafd0312"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_d0b98064-b4b8-417c-8b9a-590c4b68a195">P6Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_c35ee171-ec65-47b0-b2b7-0f2c95d35602"
      unitRef="U_USD">17244000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_618fd17d-2611-4821-bc4f-bac7c9909c03"
      unitRef="U_shares">3281213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="2"
      id="F_f63d24e3-a876-4a0c-ad85-ab61a3c122bb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_3c7de38c-de91-4192-a0b7-d7f5cf22fa94">P5Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_c2f38160-1363-4f9a-be31-9bad8564fc39"
      unitRef="U_USD">15520000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3202e22d-2468-4cd8-9005-96d662a4e257"
      decimals="2"
      id="F_61a8fe03-c8a0-4621-8e0a-b611d1abe144"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_5e800e2c-3450-44fa-bbf1-ab0a826218a5"
      decimals="2"
      id="F_c58b886e-7d73-469c-bf45-aee2d756b102"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_3202e22d-2468-4cd8-9005-96d662a4e257"
      decimals="-3"
      id="F_aa971600-90e9-499a-8ac0-b8c0948472ea"
      unitRef="U_USD">3764000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_5e800e2c-3450-44fa-bbf1-ab0a826218a5"
      decimals="-3"
      id="F_14756d24-dc31-46de-8438-b6454c9b2860"
      unitRef="U_USD">18534000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_2abc6a73-fb2b-47d1-8bda-867d3cad4815"
      unitRef="U_USD">21005000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_402159d6-fa7d-4a16-b4ff-e294c5cd2e41">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_7788f073-fa83-4196-880f-4976e3184880">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company estimated the fair value of stock options using the Black-Scholes options valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.987%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:16.998%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:16.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:15.556%;"/&gt;
        &lt;td style="width:1.442%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.48&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.31&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.51&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.44&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.44&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.92&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.40&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76.33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79.90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70.70&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.60&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="4"
      id="F_277f2873-f0ab-4fa3-9313-48304a88180f"
      unitRef="U_pure">0.0148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="4"
      id="F_3ff0becd-8014-494b-9022-d2958d08c082"
      unitRef="U_pure">0.0434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="4"
      id="F_385a3bb7-88d9-443f-843f-675e55e13baf"
      unitRef="U_pure">0.0035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="4"
      id="F_c03b943d-c917-4409-8892-fa9b69577e28"
      unitRef="U_pure">0.0130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="4"
      id="F_0b69a50b-e9b4-47f5-87db-3932d28f4361"
      unitRef="U_pure">0.0031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="4"
      id="F_6dbed33f-f7a1-416f-9173-3c68d22043eb"
      unitRef="U_pure">0.0151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d4c247c9-f1e3-4efe-9b18-0915c829f126"
      id="F_258450b0-179a-4aec-8772-d5c72294ebb2">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_50eb0442-301d-4fd1-8119-3f5ac5089ea2"
      id="F_a4269a7b-0181-4109-b08c-12b329939222">P6Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_86745cc2-3f0c-450a-840f-efc74e3b9311"
      id="F_257f7964-2aea-4b18-9c54-6cf3aee299dd">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0971ead3-d21f-4a45-a148-3e60a1cdbe48"
      id="F_46e6267c-d5a6-4902-ae01-4d9c06d41b8a">P6Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c5ec1baa-405a-4660-a084-861474f9bfdc"
      id="F_43869823-b93e-4b5b-9f28-debc26069ec8">P4Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_502f3121-e154-46be-b42e-f83a002a53e3"
      id="F_0953349e-7a15-4c03-98b7-e4f618662dd7">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_9e6a9a02-185b-4ad6-8301-6cc5cbfb38cb"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="2"
      id="F_0338485b-84bc-4b0a-8966-766638e33863"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="2"
      id="F_c72e4fe5-ab2a-4ee2-8e4a-f9d529f7f5c0"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_d4c247c9-f1e3-4efe-9b18-0915c829f126"
      decimals="4"
      id="F_5710aca2-6efd-4cc2-905d-f40dd5a20d43"
      unitRef="U_pure">0.7633</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_50eb0442-301d-4fd1-8119-3f5ac5089ea2"
      decimals="4"
      id="F_9cc8cd38-1b5a-463a-a2bf-f7e10d7c3805"
      unitRef="U_pure">0.8100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_86745cc2-3f0c-450a-840f-efc74e3b9311"
      decimals="4"
      id="F_01683c58-fbea-4560-a6a0-b160472bb56e"
      unitRef="U_pure">0.7650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0971ead3-d21f-4a45-a148-3e60a1cdbe48"
      decimals="4"
      id="F_037b1d45-f64d-42ef-8c20-5608d17cf8df"
      unitRef="U_pure">0.7990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_c5ec1baa-405a-4660-a084-861474f9bfdc"
      decimals="4"
      id="F_553772d5-009a-4ec1-b552-e1cb3ae99853"
      unitRef="U_pure">0.7070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_502f3121-e154-46be-b42e-f83a002a53e3"
      decimals="4"
      id="F_3a3973eb-ffd2-4241-87ca-13839757eed1"
      unitRef="U_pure">0.7760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_5066952e-d95e-40c8-a2b4-77c7e137ae45"
      id="F_b7a1f282-ac6a-4dac-9f58-079cf7d44b92">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted average assumptions used to estimate the fair value of stock purchase rights under the 2020 ESPP are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.998%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:12.895%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:13.996%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:13.098%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.44&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.49&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.83&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_5066952e-d95e-40c8-a2b4-77c7e137ae45"
      decimals="4"
      id="F_45af4f84-77db-400c-b430-c3924d64af5c"
      unitRef="U_pure">0.0344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_2667deff-220f-4412-adb0-e8fc0d6ca3f3"
      decimals="6"
      id="F_0def21aa-e65a-4df3-8b79-4e5521bdfd5f"
      unitRef="U_pure">0.000004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5066952e-d95e-40c8-a2b4-77c7e137ae45"
      id="F_916fd685-90d3-4a8f-b5d5-768f1d9b4e40">P0Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_2667deff-220f-4412-adb0-e8fc0d6ca3f3"
      id="F_7f15783e-a5b2-4535-ba11-b66d161ab7da">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_5066952e-d95e-40c8-a2b4-77c7e137ae45"
      decimals="2"
      id="F_8287cdb1-33dc-49cf-bebc-c38b2230e8ce"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_2667deff-220f-4412-adb0-e8fc0d6ca3f3"
      decimals="2"
      id="F_8bf1cd95-e703-4e5b-aec0-2551f70b31a0"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_5066952e-d95e-40c8-a2b4-77c7e137ae45"
      decimals="4"
      id="F_7e7c7241-6edf-4a5b-b19a-7ce63e947a38"
      unitRef="U_pure">0.7700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_2667deff-220f-4412-adb0-e8fc0d6ca3f3"
      decimals="4"
      id="F_f072f799-f264-4d7c-9429-fe4e13d8f063"
      unitRef="U_pure">0.7783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_95b0e374-cf85-4fbc-bebe-64e660d2ab2b"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_10f47fe4-b0eb-4d69-883d-34169c19015f">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense recorded under ASC 718 was allocated to research and development and general and administrative expense as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.28%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.176%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.434%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.649000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.429%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_205220c0-e91d-4339-8383-bedd964b0c1d"
      decimals="-3"
      id="F_25888882-1ed4-4a0f-83d3-a1f8ce5ebc5e"
      unitRef="U_USD">3466000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_01965527-3ea2-4759-b0e5-d6e7a69bf0ed"
      decimals="-3"
      id="F_c116a2da-1138-4cca-b73f-1b62715ffc89"
      unitRef="U_USD">1440000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4a6c24a3-d3cb-43ea-9818-038cc97b8e65"
      decimals="-3"
      id="F_0cd82710-c793-426f-bb4d-2ec05dae0e43"
      unitRef="U_USD">836000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6ff7f970-97f9-4cb7-a2a0-8883a87d4dca"
      decimals="-3"
      id="F_0b400dd0-127f-4794-a4b3-7b5c400e94fc"
      unitRef="U_USD">6729000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_50c95562-5171-48b3-9b59-edd5b2537c4f"
      decimals="-3"
      id="F_b5789e6d-34c7-41f1-8388-ba420b7a5f58"
      unitRef="U_USD">3900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0e9b7374-006a-4280-8ffb-f7a56c5987fa"
      decimals="-3"
      id="F_b5e4a03e-a231-48cc-9adc-381686317a01"
      unitRef="U_USD">1097000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_488e4f68-aed1-429d-8484-5515d9def321"
      unitRef="U_USD">10195000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_1c1bc95c-f973-42a9-b98d-60b38bfa2167"
      unitRef="U_USD">5340000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_1ea07a61-a397-471d-875d-5b8dcd80539c"
      unitRef="U_USD">1933000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_98e51f83-0122-45ed-a410-b252aba9700c">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.301%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.173%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.430000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.01%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.636%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.429%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_026560c8-db2c-4e87-a51c-0c88050f90a2"
      decimals="-3"
      id="F_cc71383d-1eb5-4cae-9e17-542ce1b7986b"
      unitRef="U_USD">9174000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f21d65be-13a2-4ece-a7b5-17985dc50636"
      decimals="-3"
      id="F_68c379a9-8fe9-4684-a739-e61b2d6de15e"
      unitRef="U_USD">4938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7006422b-42e5-4830-9abd-4af424a83925"
      decimals="-3"
      id="F_ed88cdb8-6bcd-4eeb-82ce-41c2af8db454"
      unitRef="U_USD">1933000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_350081f7-b9c6-4878-9982-48ec05493f21"
      decimals="-3"
      id="F_07f16641-1cde-42ae-95b3-ace2e16c1138"
      unitRef="U_USD">790000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f97e2ad4-444f-4f38-9b94-59f51d99a446"
      decimals="-3"
      id="F_049f6fe7-12de-4937-888b-ab5ccc034937"
      unitRef="U_USD">231000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_26d83b9d-f0fd-40e2-b4ab-7163ee3e8e1d"
      decimals="-3"
      id="F_8bcf2a46-c8d9-40e0-bf92-6d1f0d4a4264"
      unitRef="U_USD">402000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_e20edb44-0746-4515-a554-d0f8f7c9d8be"
      unitRef="U_USD">10195000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_4dc07803-237f-4170-bff8-c8f18fe80fef"
      unitRef="U_USD">5340000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_5d95a45d-b604-4705-826d-339991f39cff"
      unitRef="U_USD">1933000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_f015e0cf-2e07-4a83-8476-7b6396f2a6b3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;10.  Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The income tax (benefit) provision for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.82%;"/&gt;
        &lt;td style="width:1.748%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.382000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.748%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.138%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.748%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.416%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total (benefit) provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of income tax computed at the statutory federal income tax rate to the (benefit) provision for income taxes included in the accompanying statements of operations for the Company is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.036%;"/&gt;
        &lt;td style="width:0.973%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.891%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.973%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.973%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.236%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Years Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax provision at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Executive compensation limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the years ended December 31, 2022, 2021, and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company&#x2019;s effective tax rate is below the federal statutory income tax rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% primarily due to state income taxes, net of federal benefit and the Company&#x2019;s position to establish a full valuation allowance on its deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets and liabilities are presented below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.233%;"/&gt;
        &lt;td style="width:1.667%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.679%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.667%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.753%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accruals and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Fixed assets and depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has recorded a valuation allowance for its deferred tax assets that it does not believe will be realizable at a more likely than not level based on analysis of all available sources of taxable income.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, the Company had federal net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;174,736&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;159,886&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, the Company had state net operating loss carryforwards for New Jersey, California, Massachusetts, and Arizona of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;169,847&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,912&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,277&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. At &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had state net operating loss carryforwards for New Jersey, California and Massachusetts of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;154,972&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,912&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,640&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; respectiv&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ely.  Federal net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; expire beginning in the year &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2033&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State net operating loss carryforwards begin to expire in the year &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2033&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards related to tax years after 2017 of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;147,236&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; do not expire.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company also has federal and state research and development credit carryforward of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,749&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,588&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. The federal credits will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; if not utilized.  The California state credits carryforward indefinitely and the New Jersey state credits expire starting&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; above net operating losses and research and development credits are subject to Sections 382 and 383 of the Internal Revenue Code. In the event of a change in ownership as defined by these code sections, the usage of the net operating losses and research and development credits may be limited.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accrues interest and penalties related to unrecognized tax benefits in the (benefit) provision for income taxes line item in the statements of operations and comprehensive loss&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t accrued any interest or penalties related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If the ending balance of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,437&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,654&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of unrecognized tax benefits as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively, were recognized, none of the recognition would affect the income tax rate. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarized the activity related to the Company&#x2019;s unrecognized tax benefits:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.128%;"/&gt;
        &lt;td style="width:1.657%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.667%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.657%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.892%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Years Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized tax benefits, beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized tax benefits, end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company does not anticipate any material change in its unrecognized tax benefits over the next twelve months. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company files U.S. federal and state income tax returns with varying statutes of limitations. The Company&#x2019;s tax years &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_82dfdf8f-411c-4717-af9e-206e2366f08e;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2013 to 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; will remain open for examination by the federal and state authorities for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_4604235b-11b9-4105-9a93-5870e969a273;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively, from the date of utilization of any net operating losses and research and development credits.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_bd601d6f-da70-47d1-ab5c-5d764a957dbc">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The income tax (benefit) provision for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.82%;"/&gt;
        &lt;td style="width:1.748%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.382000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.748%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.138%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.748%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.416%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total (benefit) provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_9c45a117-3c2f-40d8-9755-b5035455d3f0"
      unitRef="U_USD">-9000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_e47cac2d-b40c-4329-bae2-455849774576"
      unitRef="U_USD">23000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_6d702405-5266-4583-b02c-d10f43dc56cf"
      unitRef="U_USD">6000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_cfc6f825-fad5-4c46-bc00-10f9257cd32f"
      unitRef="U_USD">-9000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_fc213ca1-2cf5-4c28-93a2-de2a9975f698"
      unitRef="U_USD">23000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_982253af-3037-4e92-be30-81f40a58c5d2"
      unitRef="U_USD">6000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_b7398535-8b95-497c-9f64-ba05e70de8e4"
      unitRef="U_USD">-9000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_09b99690-f33b-4ad4-8e41-67f9cf7a3e6e"
      unitRef="U_USD">23000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="-3"
      id="F_31cd108b-4e03-452f-abbf-1d173d20abd9"
      unitRef="U_USD">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_473365d8-b294-473c-9c21-bac68e99094a">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of income tax computed at the statutory federal income tax rate to the (benefit) provision for income taxes included in the accompanying statements of operations for the Company is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.036%;"/&gt;
        &lt;td style="width:0.973%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.891%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.973%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.973%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.236%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Years Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax provision at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Executive compensation limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_7a37a647-8d5f-4d26-8be1-1fe3dd966256"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="2"
      id="F_27c0a022-0d63-4482-99d4-8403861c7b3c"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="2"
      id="F_e9aff90c-a14b-497f-ba84-b9c6ce8724f7"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_9b1432e6-2299-416d-86fb-317fa17d7e35"
      unitRef="U_pure">0.07</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="2"
      id="F_482a15e9-23f2-46b3-b479-8a0cb7449f04"
      unitRef="U_pure">0.09</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="2"
      id="F_15f07f7a-95bb-48ec-a1e1-12210e7b1a56"
      unitRef="U_pure">0.08</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_9ab89b81-08b2-4b55-887f-30315d2eb4aa"
      unitRef="U_pure">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="2"
      id="F_176b2497-c029-423f-b118-7ce46948aa9a"
      unitRef="U_pure">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="2"
      id="F_a8e8cce9-52a0-4751-ad57-02d792fd5632"
      unitRef="U_pure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_d087aa4b-0fb7-49bb-8718-508ed52b9bfa"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="2"
      id="F_5ff7569b-c7c2-4691-a35c-f2be680259de"
      unitRef="U_pure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="2"
      id="F_8b6ef6bd-f5a6-459b-9d4a-1fe3dfd5501b"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <pmvp:EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_ad47e74e-34d9-4116-a13c-42dd006858e3"
      unitRef="U_pure">-0.01</pmvp:EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation>
    <pmvp:EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="2"
      id="F_b1a1d0ca-59a7-4950-b438-6e929c8d75c5"
      unitRef="U_pure">0</pmvp:EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation>
    <pmvp:EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="2"
      id="F_74d9cda3-f1c2-458b-925b-1ff528788cea"
      unitRef="U_pure">0</pmvp:EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_270e63bc-3bd5-46dc-932b-02f5e47ebf95"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="2"
      id="F_c112ba4d-40dc-4089-98c8-97540e9cac99"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="2"
      id="F_fe9cf716-68c7-47ed-bdb6-0c0d00887ed9"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_0a46a16d-9891-49dd-9005-842dfb771d76"
      unitRef="U_pure">-0.30</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="2"
      id="F_ecbeb1d8-669f-4632-a2e9-2e30f213ae6a"
      unitRef="U_pure">-0.37</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="2"
      id="F_af190a01-c38c-4ead-9b57-17e400196f7b"
      unitRef="U_pure">-0.30</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="2"
      id="F_a5ae0f5c-9555-4e53-b710-c0c25a24d8d0"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="2"
      id="F_e10f5bdc-7a46-4520-8356-8dc15dda0b3e"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="2"
      id="F_531a8b8f-95f8-46a6-b643-cace6c95c928"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="INF"
      id="F_c717175a-1698-449e-a879-54c1ef0515eb"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="INF"
      id="F_eb82f3a0-3734-4150-b042-50f0c8298f53"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c"
      decimals="INF"
      id="F_ae69d03d-8e96-4d70-803f-a52eb3f95163"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_8f49fc18-938c-491b-8975-025d4b58cd2d">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets and liabilities are presented below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.233%;"/&gt;
        &lt;td style="width:1.667%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.679%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.667%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.753%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accruals and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Fixed assets and depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_c1e490a8-366c-4811-bc17-409a5df2c65c"
      unitRef="U_USD">49451000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_11f7b429-7c17-43b3-a6a8-8e2d5147a93a"
      unitRef="U_USD">45231000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_eedbb33d-387e-4a7f-9f6b-aa7b23681673"
      unitRef="U_USD">2905000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_f49c4f25-6678-4f21-9a6c-c1f6414182c1"
      unitRef="U_USD">1587000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <pmvp:DeferredTaxAssetsCapitalizedResearchExpenditures
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_6dde5e86-51ff-4fd9-91e9-67e66b3a24c8"
      unitRef="U_USD">13563000</pmvp:DeferredTaxAssetsCapitalizedResearchExpenditures>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_e9e8abab-a656-47c4-8f66-19caf1036fb0"
      unitRef="U_USD">6856000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_24ee3fde-cf70-4a03-90de-340b7cd37e2f"
      unitRef="U_USD">4593000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_aabb0e8c-ff26-4629-8949-3eb1183284ef"
      unitRef="U_USD">911000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_562d5ba7-67b8-4062-98a4-7929734c98f8"
      unitRef="U_USD">1033000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <pmvp:DeferredTaxAssetsOperatingLeases
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_659bbf99-47cc-4db7-b256-f40cbf804e92"
      unitRef="U_USD">3969000</pmvp:DeferredTaxAssetsOperatingLeases>
    <pmvp:DeferredTaxAssetsOperatingLeases
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_a542e54e-4ecd-4d38-b9b5-9816ba453afa"
      unitRef="U_USD">3175000</pmvp:DeferredTaxAssetsOperatingLeases>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_cd4e347f-aa3f-4ff7-b65e-6b9b84c4849a"
      unitRef="U_USD">77655000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_55776bd9-c2c1-4eb7-940c-44afad249779"
      unitRef="U_USD">55619000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_093b734f-4507-4e6b-a1ec-723e30036ed8"
      unitRef="U_USD">74917000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_264f1796-05dc-4df9-b970-bb61f9225c15"
      unitRef="U_USD">52728000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_f040362e-c020-4b08-835b-654b8ccfd038"
      unitRef="U_USD">2738000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_3da1fe4f-acb8-4817-84ff-6ff445ebb239"
      unitRef="U_USD">2891000</us-gaap:DeferredTaxAssetsNet>
    <pmvp:DeferredTaxLiabilitiesOperatingLeases
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_db8e4a03-108d-4e4d-96de-20665333d726"
      unitRef="U_USD">2709000</pmvp:DeferredTaxLiabilitiesOperatingLeases>
    <pmvp:DeferredTaxLiabilitiesOperatingLeases
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_6abd5d9c-9425-4618-9945-cfbe19f3779a"
      unitRef="U_USD">2854000</pmvp:DeferredTaxLiabilitiesOperatingLeases>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_6e962642-ee0d-491a-b264-182803f6194e"
      unitRef="U_USD">29000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_8903e446-f75b-4d5b-b6a7-ea69f73ba519"
      unitRef="U_USD">37000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_77ee60cd-3a39-4593-9f24-7e12cc36a7ad"
      unitRef="U_USD">2738000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_c4108bfb-90f7-4c77-b9dc-6d32bb94553a"
      unitRef="U_USD">2891000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0b4380ac-1ddd-4289-8638-eefde924a0cc"
      decimals="-3"
      id="F_95200b9b-ae61-4ee3-a33e-239268467798"
      unitRef="U_USD">174736000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_eecb9d6d-ac0a-487e-a86a-abf840012bdb"
      decimals="-3"
      id="F_c42e2dfb-5f03-4a1a-8ec8-752d842ddc5c"
      unitRef="U_USD">159886000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_bce60bd0-958e-42c0-9f7d-65828fc53e9a"
      decimals="-3"
      id="F_2ad3663e-6c75-44e2-872f-05430d5afa1e"
      unitRef="U_USD">169847000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_95fdd9a8-ebe7-4208-ba3b-05e6405b6c61"
      decimals="-3"
      id="F_76d5887d-8a7e-48d0-8b87-dc8763d1cdd8"
      unitRef="U_USD">4912000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_9cbe3afa-3782-4ddb-a255-b2011580f639"
      decimals="-3"
      id="F_5c29248e-f862-4cb3-b0e1-0b853c79113d"
      unitRef="U_USD">5277000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_276e8ed2-4f66-40e4-bdb0-8985bcee8033"
      decimals="-3"
      id="F_43315b13-11a8-4f5f-b27d-525b9959c7c5"
      unitRef="U_USD">46000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_2f9792c0-bc7a-4f8f-9b3a-22089cbb1363"
      decimals="-3"
      id="F_58005ef1-24fe-465e-b7e7-c623ae8a4030"
      unitRef="U_USD">154972000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_7f19e1fd-4356-482e-bb63-fcc3de69c641"
      decimals="-3"
      id="F_6778d308-c94d-425c-b292-52ab37b933d6"
      unitRef="U_USD">4912000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_f9893b5b-4a1f-4410-b019-9a69763b7f7b"
      decimals="-3"
      id="F_c3356579-b5bc-4be3-bb30-6d0ed3c69a73"
      unitRef="U_USD">4640000</us-gaap:OperatingLossCarryforwards>
    <pmvp:OperatingLossCarryforwardsBeginToExpireInFutureAmount
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_ae616e40-fc21-45f2-b748-43e0beab48d5"
      unitRef="U_USD">27500000</pmvp:OperatingLossCarryforwardsBeginToExpireInFutureAmount>
    <pmvp:OperatingLossCarryforwardsExpirationYear
      contextRef="C_62a9b101-ab75-4638-a91d-240e17253b55"
      id="F_63bdcc2d-303c-4861-a6e9-7c728afa9d41">2033</pmvp:OperatingLossCarryforwardsExpirationYear>
    <pmvp:OperatingLossCarryforwardsExpirationYear
      contextRef="C_eeba018d-c970-42c2-b7e8-39bb44c1c232"
      id="F_104aa205-99c4-4b42-aab7-eb1d9769bc63">2033</pmvp:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_23291c45-5e85-41f8-9af3-d2c06f2418d4">Net operating loss carryforwards related to tax years after 2017 of $147,236 do not expire.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <pmvp:OperatingLossCarryforwardsAmountsDoNotExpire
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_3c7c78de-abe1-4af9-b555-c43e8ebd4df2"
      unitRef="U_USD">147236000</pmvp:OperatingLossCarryforwardsAmountsDoNotExpire>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_99a529b5-6188-4ab9-8f9d-4322c6925579"
      decimals="-3"
      id="F_8023098e-a1f8-4075-ad48-f529ee505bec"
      unitRef="U_USD">9749000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_05006ac3-674f-4f86-a1fb-57904ae43650"
      decimals="-3"
      id="F_8bbb05a8-ffb6-4d70-92d4-d8160ab3b51c"
      unitRef="U_USD">6588000</us-gaap:TaxCreditCarryforwardAmount>
    <pmvp:TaxCreditCarryforwardExpirationYear
      contextRef="C_62a9b101-ab75-4638-a91d-240e17253b55"
      id="F_325c122d-1af3-4b7b-9a69-4cebf47e4a86">2034</pmvp:TaxCreditCarryforwardExpirationYear>
    <pmvp:TaxCreditCarryforwardExpirationYear
      contextRef="C_54e6aacb-2840-4e37-bef3-a3d7dc27785c"
      id="F_99ce279a-c8f4-4a2f-b757-85dec2f697a2">2030</pmvp:TaxCreditCarryforwardExpirationYear>
    <pmvp:TaxCreditCarryforwardExpirationYear
      contextRef="C_236fce2d-e055-4239-92a3-3e87093d5a21"
      id="F_7c5db4fd-bf97-492d-a937-0115a05afbe9">2030</pmvp:TaxCreditCarryforwardExpirationYear>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="INF"
      id="F_6aca4530-000b-4a68-ac50-d0dd19fc3193"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="INF"
      id="F_63dc4fa0-e447-4374-a883-5e45d8628535"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_af1b5e63-dfcd-4013-badd-20fbe4efbaed"
      unitRef="U_USD">2437000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_4834c7e5-4136-4006-83bf-cc57faf6b951"
      unitRef="U_USD">1654000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_82507501-e3db-48d8-b195-6e76c2108784">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarized the activity related to the Company&#x2019;s unrecognized tax benefits:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.128%;"/&gt;
        &lt;td style="width:1.657%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.667%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.657%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.892%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the Years Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized tax benefits, beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized tax benefits, end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_688483d7-c3c2-42d6-a8f4-769f8f43b2d1"
      unitRef="U_USD">1654000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_abb7ff4b-f4ff-4208-b730-ff89fd4d2f48"
      decimals="-3"
      id="F_c868bc90-6f9d-4620-8503-e9b3d4351c7f"
      unitRef="U_USD">877000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_1e172aa2-74b8-4d6e-b8b3-22179393abd0"
      unitRef="U_USD">43000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="-3"
      id="F_8220b151-b377-4514-93a9-470bb0af8d07"
      unitRef="U_USD">783000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="-3"
      id="F_78abb5ca-53ba-4b1b-8f6a-249ca900030a"
      unitRef="U_USD">734000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf"
      decimals="-3"
      id="F_602cc666-8446-4c62-b4cf-490d46613c63"
      unitRef="U_USD">2437000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_59228c38-0358-4b55-8691-88e77e7b5f20"
      decimals="-3"
      id="F_234119eb-b6f8-438c-80db-ca281645ce85"
      unitRef="U_USD">1654000</us-gaap:UnrecognizedTaxBenefits>
    <pmvp:IncomeTaxExaminationPeriod
      contextRef="C_eeba018d-c970-42c2-b7e8-39bb44c1c232"
      id="F_a8c9b087-e137-4a0d-adfa-21c13673a265">P4Y</pmvp:IncomeTaxExaminationPeriod>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_d5eec11f-0bde-48bf-b936-2c0c45a825d5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;11.  Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company excluded all outstanding stock options and restricted stock units at each period end from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect.  &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.44%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.596%;"/&gt;
        &lt;td style="width:2.017%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.878%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.157%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.455%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.898%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,278,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,246,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted common stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;374,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested employee stock purchase plan shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,749,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,293,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_233b9823-c08e-4677-8e0e-03e522249a3e">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share:&lt;/span&gt;&lt;p style="text-indent:4.44%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.596%;"/&gt;
        &lt;td style="width:2.017%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.878%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.157%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.455%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.898%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,278,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,246,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted common stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;374,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested employee stock purchase plan shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,749,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,293,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_00d11f95-a34f-4d02-91c8-51c60eec5c22"
      decimals="0"
      id="F_6a2b0c6d-0f7c-4bc5-84bd-0c34f3d498e6"
      unitRef="U_shares">5278771</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6082b64b-c8b4-41e9-ba59-4bf5900eec0f"
      decimals="0"
      id="F_1aba492e-5847-4ddb-bd17-6baf964d56aa"
      unitRef="U_shares">4246007</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5c162453-8ec6-47e9-94ab-ae196146b8ef"
      decimals="0"
      id="F_e871c05b-7244-40a0-838f-98b75611b6da"
      unitRef="U_shares">374899</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6007dfa3-622c-49c1-9860-180a9069696e"
      decimals="0"
      id="F_093ac16f-bd85-4a55-a19c-ab7c40b1beae"
      unitRef="U_shares">95905</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6fb33a8b-4881-4337-b607-5aca6c7a973b"
      decimals="0"
      id="F_f1bb788d-148b-47af-a7d6-dc714e2e92c2"
      unitRef="U_shares">47066</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      decimals="0"
      id="F_52d83167-5c3b-4db8-81a8-d09c690b8e82"
      unitRef="U_shares">5749575</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e3db700e-29a1-4ac9-b023-8c9049f6a691"
      decimals="0"
      id="F_562a3c5b-3f0d-47e5-be0c-5ab8e9cc279e"
      unitRef="U_shares">4293073</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_cfda4846-cb6b-43ca-955c-e5766847123d"
      id="F_d25125bb-fb21-4768-b27a-251273aa963a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;12.  Related Parties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has consulting agreements with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; members of its board of directors; one of which waived his consulting fees as of September 2021. Total consulting fees paid in in the year ended December 31, 2022, were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; amounts owed under the consulting agreements as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total consulting fees paid as of the year ended December 31, 2021, were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In May of 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; members of  the board of directors were awarded &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,781&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; options of Company stock each, as per their updated Scientific Advisory Board agreements. T&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;here were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; amounts owed under the consulting agreements as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <pmvp:NumberOfConsultingAgreementsMembers
      contextRef="C_4d1fa26c-38d2-4b57-a550-1a0282289c2b"
      decimals="INF"
      id="F_16ab11a1-536a-4645-a30b-3e08b49682be"
      unitRef="U_Member">2</pmvp:NumberOfConsultingAgreementsMembers>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_4d1fa26c-38d2-4b57-a550-1a0282289c2b"
      decimals="-3"
      id="F_e7175b4e-c10d-4cae-a2e8-6f1631dd35d5"
      unitRef="U_USD">111000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_069c5ae4-3c69-4167-b429-fe8497be6762"
      decimals="INF"
      id="F_e27f4709-5079-4810-87ba-6a2182e7fa72"
      unitRef="U_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_52495b65-0118-40a4-bfc2-7a226cb39fe6"
      decimals="-3"
      id="F_cf0123c2-4d57-4f5d-8ab1-ff195f5b467e"
      unitRef="U_USD">110000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <pmvp:NumberOfConsultingAgreementsMembers
      contextRef="C_cb5c078d-3484-49d9-922e-5414ab268c7e"
      decimals="INF"
      id="F_1dbb419d-d821-4b3f-a462-0a2be067eda6"
      unitRef="U_Member">2</pmvp:NumberOfConsultingAgreementsMembers>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_cb5c078d-3484-49d9-922e-5414ab268c7e"
      decimals="INF"
      id="F_81cf8c83-9de0-4fae-90e2-1617e12d8923"
      unitRef="U_shares">5781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_8daf283d-3684-4e97-b173-64076dd32fca"
      decimals="INF"
      id="F_8f3d77bc-4fd0-4964-b015-acdcfd500811"
      unitRef="U_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M*B\0WR\)X;LW\@;%0SAW_P)02P,$%     @ 4$!A5AT _$/H!   ,10  !@
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MO#Y"U!W)2K,+SYE4>[II9NK8!5P'J.<+QN2FHS?V]B 7_P502P,$%     @
M4$!A5FRGYQ4&!0  @10  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX;6RM
MF&V/HS80Q[^*14_5KG398/.\32+=)GTXJ=>N=N]ZKYW@!'2 4^PDVW[ZCH%
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MP"HS2_]F,;I1,+=H!XM,I%9R1YIF=)VQ*E&"PD%:'*$J5JN,JHRHI0:DSA@
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MK[;[:!^JW:/>]0=\OZIWPSHW]>;<)UKNTD*@C&W!I7T7P+#*>K^K/I%\7^T
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M%6^9)GG]K_;<;*M/M.4^+])-,[C<@TV\/?P??6TFXF0 80,#:#. =@909V
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M4^ -6*\])K7^@0\8?F.Y_B]02P,$%     @ 4$!A5C^O4"%%'@  &ET  !@
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MP&8B;X!-LM4ZXLQ2E^03T55LN@,(8-=]O;0M9"#'NK8HA1L6&+:H26J0'E;
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M HHX]^Z590P8!J2Y1\YKTAF #\AF:4^X#2J( =.6P%!M'/9L(+!2(JF>2 M
MQ]*3LWY QZE:RCDKA5_HMX%SM)$]JE&T']J,!1/+&U2:0Q#?MZS6;*6]&S<<
MX@VH9$OL:$HQW%'2BCJV#B 9QH2Y+'I,<H@,<3I2^[Q2Z%CL0?2Z\=OX+F_"
M;V//#14Q'LT Z,--9[H%2V[;$C3_FG;])K=D<XDEBIIGK)?:1;((]ZPG&U]+
MT%_T!,4.+:D"\,.QI[3HW_D;VK#[FKP/@A"Q@2'FSN(ON1V.K60/Y(5S\QM-
M:[&2+#,=YAJMR3@&M777MS?57R^_692L(WY=OI3&N.)1ULB,'\;D[%*'2G5B
MWE:")HIX"DIE)Q>QF0A=^SF# 5XAAV<+6CD[P$Q1,%V=[V<6H"I'BXV;H3 U
MZ^(NB7&=:82:F8;W-RBRT896$AI=4"]34YL&VT8ISF7-,#O7FBZV 5!GNG3(
MHV'MJ31"=1 MICQ4LW?4PZPQ:]Q<&[)B;^RK:?-&^J+;&&;01FD)V4)>'8AE
M@SO.N,6J?VNC$R7WBBPJA9GRBOCL=5>#(-\V$"3C[,2G<^43\T1%K7@U"IST
M)9EBDU5I<Z5;E!HGU=!"U<K=/E6=BYV+-G6NQ0SMC-3,&XG4)YH$\Y<3#*E*
MAD2YE;Z<N*?JWJ2''?<E:W;);<PC^S@ZLHPR[J>[<Z!<$@@]LM,W\RP#[2R]
M)&]AR_SY&CLHRE0:+O:1O7N<AFDM8C,(!)?5FS%B5UR\=*F,()V-=OYH4O[!
M_<#S#]VD;5?J SRJG'8XCWTH68,WY8)WK'6) =1R=!Q7,,>MU#_'(7;JQ^5E
M0XAIR.;*'ZZIEW4?S]/ GFW =^_QB? @F2?2>\VY82H$L ,X7+!839ADB!>%
M_:LW)(I@]"DT*. '-3FM08$:*^=D)&A?NV8,VKDX1SQ6D34WV6:@;5IOY.H;
M@N1!O$\I34E(3UB)0#M#M6I)U15IT6/YY/("6R&R!5,/?(^5/TF@E)]2SE.:
M]3S0"A/"'M28'=A$NX"]1#'EIF%$["C*X66N+DI1RP*/\J.B&48L9Q'BRWB-
MTL<L.:58N4G_N+R%ESWY@<-1>TQ=-NS,;,II-4\1;F;+CU2Y.EC3446%-C2V
M _YAO-..W2(ZIZ0:@<)H#8B9'+K'4!_308$Q\:'BWF5]6\J=N1DXCI^DL1ED
M8FTLYCZ"4'/@,@4FD:WSITHL[][_O- M(VZL@M%FNDESZ%?9J=DZ@ HV'@^R
M9A:QD6<!<&HH<I.MN=X9%)6>^KQA<0P_;OC  (SZGDV(' \CI_@+-5ZC>+WG
M8B^,8L&*_QJQ"!WPLW>PX=WA_!^XITKM#PQ;LO:[=]QX4H<"'RZ^@*2.-^U=
M'YVH9NJU7J[MK3-*/<W4I4;4(HM_[-C+(P@1JAQWX1:B\4YZ&H2K/^/Y$J!V
M\>]-A^<FLI(N(#ZJ%S)F)-W,@U>J$AIV%=)(F=MVRI5UTN38U\/H9R?%'/=.
MQ?&\,_T&/4G=I:K&D<C6>SM0CP[2_"C/$YT\-_%8.,''%?1L!E9;@L2G>AHS
M3IN-@.A:>MC2@:%T.H];FFBAU+U\1S4F;AM:'V?'Z=S(W,(2OHU)6#(ZR>QF
M;Z0\^"*6@4<F7D_SL:5.'C5HK]/<Y!K/:MUE5]"@%0?=0#& 11"<M]V:>H><
MTD";=-=CBJW9HD%Z ,7NP:NE7%0^6<SS-QUKKZR$+1S8XN9$ \NIE*"&2)/3
ME9(ND0_4H:;H85D&G%J.SR,_'O<HLDYGL1@O?6&BKVT[*%+8F;+FVJXUO,QC
MRO0Y)DK(.55O8RUY"B^68&VIJ1JK8]+<_G.L[ >C#=?8-D^G$K2W-6O)85=%
M>2+,!7+[!<\=NWJP0N#-D!]BLCW?_H#\MUE3,B<AD\R5A:@H$#=;:]89K6\
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M-.L?@]O3[=<K-PQN1__<FAK,"KX S]<.1%;^P GB=>BO_A=02P,$%     @
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M3I+!E:J;UJ(VD(P@']RT6G+;:CPX;OB#TPQ,IC =?$"Z4Y42)?"ZT>H>'=)
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ME#B"%EXDM;A[+RY^1EP4BP^0L'3BIR)5Z:Z "^C6*A@W"M[')R6^44E?#*)
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MKBKP5F->=7%7Y?$7<9/*[,U9!7GT]"QNYEZ9N=Z>N:XG?LJS:EF*ZRQ1R;:
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MX>B4.H)$/K0S=Y/F'!4:AE(^#CB[[S)>Q-"81X6*FM*J[*O$+NK^PUKMI'+
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MJ1,^.:'/9=W7L>9;6:X,U?!FDC;E\LFX!BU0'*VX,IMDWE(.-M7TTC))2R?
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MX'^4%D4&A%9+D/;/IN,NCM5\*QY>O-GP3?3">&_6_+A2$HZC#?A]:8RO7DA
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MZ4D$.@SD(%C5^"&X5)9&JE]6](:A=@:T7RIE=X(+T+V*D[]02P,$%     @
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MK^&<DIGUK@.M/=!>IGCKWYZT4!"BSW00:[4%D?POL:J2#",V0-DWK>70,MH
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M0+Y[0(ACGEMI0=AX!T_3#G#DB&Y$U2%$Q.D 8=^B.P9+!#X#O*ADEP;M*.[
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M<C*;]Y"!U74?&%+O8^0?T.; 16,U6S)9HU%\8@P?0YMB/>O\?20VZTAU,%Z
M>F&ITG(K@ICA#$N=)TJ2G00551%+39Z2@JO #<$C<)B_1>U-+]LVLXQX$HY6
MT F8'8XW:!>O$%#D.#^L$*2>XW]H5(B\HCDBSX*<Z>P.;*^5[L")'ED&.8H8
MM08GC Q8)]&3VX82'$CI#]K,N5V?@TL?<T,??DZYI2R.D$8Q8B:BY_R Q W@
M//I&,=@*U+Q&&6/6H#X;$A2\+1Y(:EFD&ZZ)XK;3][ OF]O_.:D8GP+8!W(5
MQ*W1GU'B>3VMA/>8NJ71\"KZ1"S7&0[1_2J':M*\L,S@*]62M4[9=3BGMX/#
MO8*DUR5=(PEI"9%S. 0]KQ#,;XR8Y@B/YW1+P SBK[/=>40PJW-/V24\<Y86
M2:Q'>B1?X#,(E'AP)VQ,VV'BJGR35/::1/\:(S<D?M0*(ZR8-",QRK,!S<BB
M8'D$:5FP"U)8I)$F@[ OSC^GA^3ZCB:5+V7PE,?LU8$-\I3,H <7(8U5#AP-
MHI"5<!:E[CA@5M@;="QFA]EBTX>,'LVS0,+F, 6]0[39F#:Q*\KJEVQUW1L_
M(H]AG )J6*R3-JV9A5&%6P<2G+@75V$4JK[ (0G>D.S@$RRYUS-T$D641"X6
M,9! (#-JQ?G]8)A-L%G&'X7@[2W".4*MF C1> '$)9@"I(+-+$@,9R2O ?^#
MX1FF:X:0KR(70]@$C/3@!=,RH'P_BS^$Z3!2E0&BB^K7\4\2RCZ5@^#@=B0W
M[ZU+[!/W(LDG> I*'P^1I D..6)0\M.<S@^"U V^C/G$'C$: BVVP*;3$CQ
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M LZU 1V&),ZUSF6^#J8!:NX0\R&[ K8CT&8I_+ABTXNT#274OMI8K.M"VS0
M2<E]V@!JP8XLBQD>I](%CD$&"Q:-#, <'62';!3E1Z@;A87E#<J3HU/6-<S6
MK%*<'3;LLO?(9!=8]9A\\J,@)!67'H RM/93Z:(8M!(:XO!R*$E-H8#B#**)
M$,?&=_D0?ALZKFZ*\87,AI^OCPU',)\?2$TFR_DN$ZX/?4U$<Y/)LTF%\H"I
MQ$$[GG R<$E1F0EI&N0T2:A[YMN-4Q)4*NH88U6II-_XX=!1V/WO/(8(Z%Z1
MZD8+3F2RC['9^$NN%V+YZTS>(5<'4=07.\DR'WZJ48:$M0^R]_KVIOIZ^6)1
MHH[PM7PIQ;S%HZP1!0?&X/]%F"H5D3"9D5T7S,4"4J&L1:PT1+OHG"TIWB%[
MW O:.2ODC'$Q'9*?9Q8 "1@M#FX"PM1L@:<DPGZB2G)B&3Y?'\S"T M 1!,V
MU,G25,/%LEJRXEFEW,XVNHTU0M19)!U.*.@[2OQ1EB^D"N<*>BSUH(0P1#Q<
MX[,JBUATU^2-4$6C!JP0&EW$"_=Y]BFFI>XXHAM+@AH3E3JI>T112<P4M\9G
MKUL%A'Q;;RVM3G@Z#WABG 12*UZ-!"=%B[HXY,"T.=,M2HZ3,H2"U<K3/I46
MC]76)I6UQ@S !-5,"XE4VYX(\Y<3"*E*A$2ZE:*]>*9!W4H/$IY+5@F7RYA'
MYG%4K!ED7&Q[9X&YQ(M\9,9OYH$C.EEZ2=["EJ?S-98NE:%:W.PC<_<X3=,8
MM!7!B[ZHW@S1EL;-2PG; -19A[+ D/29/0_L7VM'K0:2?^)9I5OM/!:I9;TQ
ME&O8,=<E!% ]XK%3QA@WDMT?^MCD%+>732&B(5LK?[BF^OM][(>$,]N +;''
M)X*#))Z([T-,%Z-;8,N  0 2J_:C#,2BD']J0Z0(0I]<E<(<H@K(-3!0;:3/
M42(>:UL//I0U3P&/Y1LA]MUD1N0XG\W9733:>]$^)34E(CTA)3R=#!6)2/2U
M"+L?TR>GKU@*D2P8:^![S"Q+]*D<2C%UJ>1U "LL"&>@,+2RB7(!B_AB%#6X
M-;&4+S=W<W8)$#5,\$@_@33]@.E2LD S7"/U,4I.,58NTC]>W,++CO3 X:@N
M3965<A.'<IK-D\>=R?(C5JX.1K>4L:,#C;7"_]+.AG+^(K1!$4DR4J,T(&1R
MW"/&23"6YME&/U3<V!#>EG1Z+@:._3GI>@":6&N#@2,OT!PX#89Y 6/=J13>
MN_<_+\*1$3967H=*VU'E^(/DU&2>*1 VMG<:/6FQD68!XU23)RE'<[W32"H=
M-8' YMC\N.$F)YCU/8L0:>\EI?@+=64@>;WG8@*8Q8 4_S7:(M2@;>[@P-O#
M^3_P3 .T/[#9DM6]ON.*+^4+^W#Q!4OJ^-#>=5&)AN1+J,<(M>\33#T.<Z8J
M]2(Q<ZS8R[:I:*H<E^@7I/%.:F8$JS]C:QY N_ACRV&O5U8R !8?Y:/99B3>
MS)UIRD)K5A5299W+=@HTME)=W*E^<).+8H)@%\CQO-7=!C6):E.BZHADU=[T
M5(&&,#_*XU8G>[T>"R:XQ2KTDV$"S8N_'+KIX[+9#&A=2_%HZK5,W=5<2T@;
MI=:&.RK-XJ*X]7%J@7K=IC:6[-L8P2:AD\1N]D9*(BQBF<' P(=N;);42:/Z
M4,DWM7CPKT,J;5? $-(UX0!% !9.>5Z3K]4.,14<?^)=AR&_>HL":<:*W8-6
M2[&Q?+&8)*E;YE[9"4LXD,7UB0*I4R'*X"*-NN,E?",#@D)-WL-%Z7"&<H_<
M\^-YCSSKU#_*]M(7%GIH64L1_\^8->?VD);--*8LG]M$R7).U0&Q5F%L7LQ&
M\E.+_W*^0_]64]<&)DVY>V8RT/('YZA^CA4L7H>N$.SMH=:I4-R>E9ZQRJ3X
M&<9(N<R(<1"KUS#-XW2?-X":CN\(0CHP65<"!V<3[9?9Q$B8-UNCUQFL;\#Z
MIZM_?E*?^'X.ZFQIY&<?TPK[<)&#]G9P=0A<)W8M6G$R63&3S\'<GO@.>4XZ
M,C:7<Z5,)=HX.BL52I<)9&B?I9'4_[V<[]W^)Q@P5,>,7;DWK#QN42A/TLJ?
MG MC?J ZJ?(^/.<B*1.\J:("0YS__MZ>4]6B./[!#Q@E3'#$/5V7A+0G-GLW
MD#L8 CA'/?N4K,"2=HJ^I>L7A&-C+#TWJ;D'-C2%LI1,9NDCE3WC<^*VA,?3
MHG/VS@"GIR>3MIK0+PO$CX&>J^>7Y\O+1?5#:)- !#/FT=,>;4X<H8)**4WF
MXPF-X],A)T4F.ATA6>8G %SI6DD9I]='34B=+7PE"U;5)G;B"U6$ECI.=18*
M[:+Z&"LV(X'$:.'J%*%EU_9037:BA'#-0$Z**_$W N+BA%^>1N31#$&&44*7
M&1T&3R+<_/'&M 3.%Q@G%HK9T_N7FJ.8DP":M5@0UV/MK^=B-R6!K9 'I9U'
ML%7#NE.U ?0(KL4 I:$* 0 X-=R+_79/<>G^@==D1'-_GD.S(,0)OZF/7C%-
M&TC$GJ(=$BODGN)]3A;KPV0[HZ!\8@;=9ZU)'3=A&O@'_*/J$045'HLA075_
M_38<?C*,(P:$@+!Z,F;Y0RMNR@DCWTV.B^YMPY7AQ&L8AC[-7V.)E+B?LW23
M=RH$'F.CZR1]*A$P7F'/E>(R_3$)Y1V-J>8"H\OG$?5S6B[=S+"<OT7A'?=X
M_8)Y\DG%]O#AI_,STDA&R?@IFJ20_%<@IHOI'IW)[V>/1YW/HG":<-HP\:G[
M&LHJ&E:DNE,<U(%ACL@U\&OFJH$1;1V6$O"5,^REA6L0\%V\ )'=!9B&;Q^B
M\'8H3IF$)\CHN&.2YK&"6-1X"*4+JN0FLC$F00H^  %<S9DJ\G.S?6IKR<Y,
M=E5PBF2GYDM71^&:L74\&2_'>.=P]#T?YSUFT5?$@W(.L90[!S34L=3"]')G
MR47 *3"GMP^@%**,9JA9J:DL^43I3KZ^#F,S4>BUYI,FEP2$!PH2FMI3/8'+
M,T%3J]'FI!@PM*25PC.DJQ$KW1"='[GOK72%)_=S$ L\H'MJ0XCP5;@@)KR8
MBA>YR"2\3=T8G<;2+H67JW%2B'W)D.KA)86, 3UF:]FMR^^IB[T$4F]'P1LN
M6H,-R'T(1-A$/=&AP=U1Z2"'[9%F-M'<K(-4Q&@X10 "/1!VHW4R@2N*KU$G
MJ/2H+D_TJ"HJW)S$9! 9DT>1,UD626%#29@IW7V'"VZ4BS95=F7&WEF*$$QB
MB[8A3X(V,H5)2/ZAF&1<\=.'P>6.L525N8'2L7B76!=BE1.[G\G%QVWQZ4D\
M9T[L)\Y%55H[L])\#5-*DF/_OZ=B\'%#7BA!2P<RT2U:S#71TJ<8UE #P/3%
MKCF= _C#5&/#8H=S2^@C4SZ:I)F&0\ [RZ(:Q_M$TK:H$LRG.UXLAG<SH!:C
MOL-%RFMP60O,R-5>F3[ [EA\R^S"Z2^R2_M"T! O\3&<3!JIGK1!/'WJ7HNJ
M,O2&FHXC_>E!>:J$J1V5KE=G4T+R+)T=D>NQ.6I\<0LI]14>LZ-D+4)ASC1Z
M\G 8=OY&O4^*2TK_)AKZDU:=-:K2?1S+^>LR/H#,'-WMZVQG!VGIG#:T_KTI
M$;>QT?WJ<OD-HQ!O*0UMZ->W'^G)^?*J&IE:L;2%,XN'((FN2^NC&,,RH-/W
MB:QC8E(2AJ=M%U1"U O!#O(=U2*R)Q:D11Z%]7()*^N'AB1E7)7(DT07'FJ+
M%UH=J,)+Y)!";R<OH$3+@'=8L'FX&:DT!.DYVRU<O5Z): .[A80"6S(",*MN
M&4Z5(&+K%*EQDUW $+F7P2EB-[1PEGTIA&YC]]P&BY?H1/R0:?9?"J  TY7O
M.UC*4=$(7+[!W$ATA&(E+-52UWW06Z<3!5D7_AR[I#L)EE^ZE*!#XDZ7H][P
M]0D?C&<+F[,:^)75Y\?\VMA)9OK_7#"[:\YD=\UQ#"PX_" "8W0_.S5T-/,6
MB1P0G]T<@0GN4.)$/]-U%EUS=-W-^!*6%%,JR87*@:G3GTO]\3Z?A\^5>2+4
MJHZW^%3HQ"/?K MT8-8UU>^,:_?3G:M<OB_;#4X]>LY6>S&4Z995,<!AH TF
M)XPKD)BAS,;[$@<JIKDYB;=@DX(JV.KZ$[DYO$,6,E@-K \ADQT>;3']JWJ*
M0D_N^X+N:C ['21.HTE;<C>0>#>Q6X)JMW7#=[<^$&6IS0%GC=//$<E_[AX=
M+@P*J,.$_>D+-OC&\*,KGK(162SGZ$JUX(!CDVIH'9G>AUC X:+8HM\9E[<M
MB;D4KW.1KXO[IU-+5N9?9/<GGU@WNPM"(. CH":A\@Y;JLYSAZ/K:_/&JP=<
M[JOV>*=CD7!EU;0HG K8::)>4*QY[Y>4/BWRY"?#0F6,7#HA+P4WW6WDOA6J
MOEK@XU['F\;AVQXS\[B_=#7W@HA$,!4\N)KM--SMUNR%[?4>:]7%./ZDZ5)O
M##1C^1&UJC(HDEG61\URX5*\NM7*\84EL?>)2H'>6LE>O''#!BQU+*WP40<X
M26J03NZ4Q.+ +\-(*I5]@O]$?ZM@'TH@ZG0I$)4.$'42X^!]F1C-IS9_ME$F
MZ">4G]48R6W(BJ H@=SG*0ZL>-_9OJA);N3D >:05^-+B_21'[?JP"T!+$Z'
M+KB%03'D8TV@_I&%0%?+\@VQD[;"I#GP)/N;&8"O#?UE$+K/N>OYSV?$7^-?
M'[GFO[F17N<_7?(3T"#*F%:O8>CEQ=?/SKB>(GSI[9[^ L?*]KW=T<>M5B!6
M\ 5XOK9 LO(%%XA_D^75_P%02P,$%     @ 4$!A5A[3K%2V P  4 D  !D
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M&F+<)DJC4?(=B=UP-'9'HX!$;A@EKN^/!EU[Z"LMF;FZEG/;Z$9")T+4[1)
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M(@'\OI+2- ]DH#W_SO\%4$L#!!0    ( %! 858P%;%'Y0(  #\&   9
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M(+=*U4!^OJ94O-RH#IIS2XO_ %!+ P04    " !00&%6K=LP!AT%  #_&
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MVUX^*)Z;Z^0GKA1/S<<YT B$'H#?QYRKY8.>H/[-8_P?4$L#!!0    ( %!
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MI@+D[VM*Q<M '?34!WO!?U!+ P04    " !00&%6$GX\QWT"  "F!@  &0
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MJ%856\/(VNG$0AI4';<L\4<"R@;@_E)*LS7L ?VO*?T+4$L#!!0    ( %!
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MTW.;@1:U;5LKH;$)VML"/U,@30'.KX703P/3";L/7_H/4$L#!!0    ( %!
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MBK1[@%/Y5W[>J&^HMP^EN5":!Z7Y%4W="]A?U*Q+Z^BZANR40FD,2N,HFJZ
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M69YLIG=6"]3NA]*\BF8NM_6A?090&H72&)3&431=!;6-[YAM?$1!L[F+SE*
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MJ@1$IC:0GZN'FW8O5 >;-/M2[L[=?P!02P,$%     @ 4$!A5MVX"5NK @
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MA4#B4FU</B ^N,EI:V''P7;:\>^QG2QTG<E0Q)<FCOT>/^]QTG-F!RY^R!V
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M17&>*#J*+_,M><:5WN#S9J+/8"!,@+X_YUQM.F:"ZE07_@-02P,$%     @
M4$!A5FB17,7[ @  A0D  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
MM59K;YLP%/TK%I/VD+;R"*]T"=*:;EJE3:T2=?LP[8,+EX!J,+5-TO[[V898
M>="HE;)\"+:YYW#.O1>;R9JR>UX "/18D9I/K4*(YMRV>5I A?D9;:"6=W+*
M*BSDE"UMWC# F095Q/8<)[0K7-96,M%K-RR9T%:0LH8;AGA;59@]70"AZZGE
M6IN%>;DLA%JPDTF#E[  <=O<,#FS#4M65E#SDM:(03ZUOKCGLUC%ZX!?):SY
MUA@I)W>4WJO)53:U'"4("*1",6!Y6<$,"%%$4L9#SVF91RK@]GC#_DU[EU[N
M,(<9);_+3!13*[90!CENB9C3]7?H_02*+Z6$ZW^T[F,="Z4M%[3JP5)!5=;=
M%3_V>=@"N/XS *\'>"\%C'K 2!OME&E;EUC@9,+H&C$5+=G40.=&HZ6;LE95
M7 @F[Y82)Y*%H.E]04D&C+]#7Q_:4CRA3V@ANR5K"2":HSEP8"O(T*+ #+A:
MFM&JDC708"1;"5UQWN(Z!?3^$@0N"?\@2;B.G]A"ZE1/L]->TT6GR7M&TR6D
M9VCD?D2>XWD#\-G+X>XNW);9,2GR3(H\S3=ZAF]&,.?H.N_M_ODA[Z,K 17_
M.^2M(_.'R=1+><X;G,+4DF^=3JR5O'WCAL[G(:<G(MOQ/3*^1\?8$U-W;NJ>
M=G7GINYE7_>A1'3L@697F\DJ<9W0\4)5T]6VR</ L?RY@6OB=O3[1K]_5'_?
MKG@E^Q'?R5Y6@O-6M QZ![3IMI(Z0_/%+5HR7(O!?O4/%/JA&WOC?2<#<>/
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M6@#5&%3C*$W-@[8\;6KK=F\,)IVA#RTX0S47JM%&VRTP.+8YVEN?0_OTH5H
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MA1)(\3J73VS[$VI_AIHO9KDPOVA;VSH6BM="LJ(&*P4%H=47O]5QV .X_A&
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M;8PYRG+VDVCR]2X&;]_\=-GGXO82I)\TM[JI;P5WW,J'X ,I^8*!7\L4ISI
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MNO=IAH5N3T$8 _U]R[EZFI@-;,.[^@]02P,$%     @ 44!A5M5WKIUC P
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MJPAW2^.V7A#N!_*-TUC0+ %_?L:EY%)")'Y5A3C#;5?CJNIT+A(ZAY&!Y4<
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M>X"STZ(0J\^"SV3&[.0/%AP-Z#K.F^>*_S%J4"I3,\ 4\9Z8TGS:'OFM:/'
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !10&%6X><IGXX$   0)@  #P
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M3=?'7Y;?)T?L7' .\ O(XQ=02P,$%     @ 44!A5K)H2=C5 0  OR$  !,
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M<F]P<R]A<' N>&UL4$L! A0#%     @ 4$!A5IEI9:7M    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 4$!A
M5IE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !00&%6XB1K"X((  "0,P  &
M@($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 4$!A
M5AT _$/H!   ,10  !@              ("!Q!   'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( %! 85:[\:9KU (  -0)   8
M      " @>(5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" !00&%6;*?G%08%  "!%   &               @('L&   >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 4$!A5I8AE$SO"   @E@  !@
M             ("!*!X  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( %! 85;216YA2@(  $X%   8              " @4TG  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !00&%6L";??,D'  #K
M)P  &               @('-*0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ 4$!A5B 9#IJ*!P  ;Q$  !@              ("!S#$
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( %! 858_KU A
M11X  !I=   8              " @8PY  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " !00&%6JJ]$L&\%  "I#P  &0
M@($'6   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( %!
M85;IRZ,0_P(  (4&   9              " @:U=  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ 4$!A5C[U+LJ" @  B@4  !D
M         ("!XV   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " !00&%6,QF$< 4*  "=&P  &0              @(&<8P  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %! 85;FXZRIYP(  &4&
M   9              " @=AM  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ 4$!A5B*Z9562 P  4@@  !D              ("!]G
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !00&%6(D"2
M:&P,  "<)   &0              @(&_=   >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( %! 858)U;$$\0@  *88   9
M  " @6*!  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M4$!A5ABM^F1" P  % <  !D              ("!BHH  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " !00&%6!I->T^X"   A!P  &0
M            @($#C@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( %! 858^7E766Q\  )]E   9              " @2B1  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 4$!A5A[3K%2V P
M4 D  !D              ("!NK   'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " !00&%68?;A?M("   7!@  &0              @(&G
MM   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %! 858V
M-(<4C (  (H%   9              " @;"W  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ 4$!A5CG(T0;C!   "0T  !D
M     ("!<[H  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %! 858D-5W.J 4  ,,D   9              "
M@?'2  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 4$!A
M5JW;, 8=!0  _Q@  !D              ("!T-@  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " !00&%6?__ %=D%  #_)0  &0
M        @($DW@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( %! 85:VWV]H(00  )04   9              " @33D  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 4$!A5CF<Y*_G P  Y!,
M !D              ("!C.@  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " !00&%6$GX\QWT"  "F!@  &0              @(&J[
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( %! 858@-+TQ
MF0(   0'   9              " @5[O  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ 4$!A5@#.<?W\#0  8:<  !D
M ("!+O(  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !0
M0&%6W;@)6ZL"   "!P  &0              @(%A  $ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( %! 8599!+L2%@,  /D(   9
M          " @4,# 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#
M%     @ 4$!A5J4:CKWA @  \@8  !D              ("!D 8! 'AL+W=O
M<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !00&%64V?M\$4#  ":
M"P  &0              @(&H"0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM
M;%!+ 0(4 Q0    ( %! 858>-]M1#@0  &45   9              " @20-
M 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 4$!A5BX>
M<.8$ P  X0D  !D              ("!:1$! 'AL+W=O<FMS:&5E=',O<VAE
M970T,BYX;6Q02P$"% ,4    " !00&%6:)%<Q?L"  "%"0  &0
M    @(&D% $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M %! 85;0E")/?PH  #)_   9              " @=87 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ 4$!A5DM'L@F;!0  P"   !D
M             ("!C"(! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " !00&%6$6U-F;("  #3!@  &0              @(%>* $ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( %! 858F;%C)Y@,
M . 1   9              " @4<K 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ 4$!A5G([AB5_ P  C0T  !D              ("!
M9"\! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !00&%6
MG'U>PVP#   8#@  &0              @($:,P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( %! 85;%OJ"TH0,  !02   9
M      " @;TV 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ 4$!A5GR+F+/  @  +@D  !D              ("!E3H! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !00&%6VNN? G #  "R#
M&0              @(&,/0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( %% 858-CZE[HP8  ,(N   9              " @3-! 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ 44!A5BQVA/7;
M P  E@T  !D              ("!#4@! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " !10&%66F1Z@^D"   ^"   &0
M@($?3 $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( %%
M858"(JG_B0,  /P.   9              " @3]/ 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ 44!A5M5WKIUC P  X T  !D
M         ("!_U(! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M    " !10&%60R1PI&$#  "^%@  #0              @ &95@$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( %% 85:7BKL<P    !,"   +
M  "  25: 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( %% 85;AYRF?C@0  ! F
M   /              "  0Y; 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !10&%6\R"+>>D!   2(@  &@              @ ')7P$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !10&%6LFA)V-4!  "_(0
M$P              @ 'J80$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..00!! +X1  #P8P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>158</ContextCount>
  <ElementCount>333</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Formation and Business of the Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompany</Role>
      <ShortName>Formation and Business of the Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Financial Instruments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements</Role>
      <ShortName>Financial Instruments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stock Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlan</Role>
      <ShortName>Stock Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables</Role>
      <ShortName>Financial Instruments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Stock Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables</Role>
      <ShortName>Stock Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlan</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Formation and Business of the Company - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails</Role>
      <ShortName>Formation and Business of the Company - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Commitments and Contingencies - Summary of Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stock Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails</Role>
      <ShortName>Stock Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stock Plan - Schedule of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails</Role>
      <ShortName>Stock Plan - Schedule of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stock Plan - Schedule of RSU Activity Under the 2020 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfRsuActivityUnderThe2020PlanDetails</Role>
      <ShortName>Stock Plan - Schedule of RSU Activity Under the 2020 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Stock Plan - Schedule of Estimated Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails</Role>
      <ShortName>Stock Plan - Schedule of Estimated Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair Value of Stock Purchase Rights Under ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails</Role>
      <ShortName>Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair Value of Stock Purchase Rights Under ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Stock Plan - Stock-based Compensation Expense Related to Recorded and Allocated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails</Role>
      <ShortName>Stock Plan - Stock-based Compensation Expense Related to Recorded and Allocated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Stock Plan - Schedule of Stock-based Compensation Expense by Award Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails</Role>
      <ShortName>Stock Plan - Schedule of Stock-based Compensation Expense by Award Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Income Taxes - Summary of Income Tax (Benefit) Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails</Role>
      <ShortName>Income Taxes - Summary of Income Tax (Benefit) Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Summary of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Net Loss per Share - Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pmvp-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Related Parties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails</Role>
      <ShortName>Related Parties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0540-EntityShellCompany-Value] In submission type 10-K, EntityShellCompany value "True", is not equivalent to header element shellCompanyFlag value "false" in the Required Context. pmvp-20221231.htm 169</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: pmvp:IncomeTaxExaminationPeriod, us-gaap:LesseeOperatingLeaseRenewalTerm -  pmvp-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="pmvp-20221231.htm">pmvp-20221231.htm</File>
    <File>pmvp-20221231.xsd</File>
    <File>pmvp-20221231_cal.xml</File>
    <File>pmvp-20221231_def.xml</File>
    <File>pmvp-20221231_lab.xml</File>
    <File>pmvp-20221231_pre.xml</File>
    <File>pmvp-ex10_15.htm</File>
    <File>pmvp-ex23_1.htm</File>
    <File>pmvp-ex31_1.htm</File>
    <File>pmvp-ex31_2.htm</File>
    <File>pmvp-ex32_1.htm</File>
    <File>pmvp-ex32_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img249132499_0.jpg</File>
    <File>img249132499_1.jpg</File>
    <File>img249132499_2.jpg</File>
    <File>img249132499_3.jpg</File>
    <File>img249132499_4.jpg</File>
    <File>img249132499_5.jpg</File>
    <File>img249132499_6.jpg</File>
    <File>img249132499_7.jpg</File>
    <File>img249132499_8.jpg</File>
    <File>img249132499_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="598">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pmvp-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 598,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 158,
   "dts": {
    "calculationLink": {
     "local": [
      "pmvp-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pmvp-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pmvp-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pmvp-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pmvp-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pmvp-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 518,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 4,
    "http://pmvpharma.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 8
   },
   "keyCustom": 62,
   "keyStandard": 271,
   "memberCustom": 13,
   "memberStandard": 31,
   "nsprefix": "pmvp",
   "nsuri": "http://pmvpharma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Financial Instruments and Fair Value Measurements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements",
     "shortName": "Financial Instruments and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Convertible Preferred Stock",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock",
     "shortName": "Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Stock Plan",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlan",
     "shortName": "Stock Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Net Loss per Share",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Related Parties",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables",
     "shortName": "Financial Instruments and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Stock Plan (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables",
     "shortName": "Stock Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Net Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e9a7f863-44e3-4b8b-a088-33b385350544",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pmvp:ProceedsFromIssuanceOfCommonStockGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Formation and Business of the Company - Additional Information (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
     "shortName": "Formation and Business of the Company - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e9a7f863-44e3-4b8b-a088-33b385350544",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pmvp:ProceedsFromIssuanceOfCommonStockGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "pmvp:ReverseStockSplitPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "pmvp:ReverseStockSplitPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails",
     "shortName": "Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Financial Instruments and Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WorkersCompensationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WorkersCompensationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_0aac07e3-04d3-478a-9920-5fb843d4ae5d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pmvp:NumberOfNoncancelableOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_0aac07e3-04d3-478a-9920-5fb843d4ae5d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pmvp:NumberOfNoncancelableOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Lease",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Cost (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails",
     "shortName": "Commitments and Contingencies - Summary of Components of Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pmvp:ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pmvp:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pmvp:NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Commitments and Contingencies - Summary of Other Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails",
     "shortName": "Commitments and Contingencies - Summary of Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pmvp:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pmvp:NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pmvp:LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Convertible Preferred Stock - Additional Information (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_c0a73230-1c9b-4996-8fdd-7164c9f9c45f",
      "decimals": "INF",
      "lang": null,
      "name": "pmvp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Issuance (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
     "shortName": "Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "INF",
      "lang": null,
      "name": "pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Stock Plan - Additional Information (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails",
     "shortName": "Stock Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_59228c38-0358-4b55-8691-88e77e7b5f20",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Stock Plan - Schedule of Stock Options (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails",
     "shortName": "Stock Plan - Schedule of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "INF",
      "lang": null,
      "name": "pmvp:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Stock Plan - Schedule of RSU Activity Under the 2020 Plan (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfRsuActivityUnderThe2020PlanDetails",
     "shortName": "Stock Plan - Schedule of RSU Activity Under the 2020 Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Stock Plan - Schedule of Estimated Fair Value of Stock Options (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails",
     "shortName": "Stock Plan - Schedule of Estimated Fair Value of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair Value of Stock Purchase Rights Under ESPP (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails",
     "shortName": "Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair Value of Stock Purchase Rights Under ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_5066952e-d95e-40c8-a2b4-77c7e137ae45",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Stock Plan - Stock-based Compensation Expense Related to Recorded and Allocated (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails",
     "shortName": "Stock Plan - Stock-based Compensation Expense Related to Recorded and Allocated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_205220c0-e91d-4339-8383-bedd964b0c1d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_14af34ae-ca01-4273-9ecd-fd1963bc0d32",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_14af34ae-ca01-4273-9ecd-fd1963bc0d32",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Stock Plan - Schedule of Stock-based Compensation Expense by Award Type (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails",
     "shortName": "Stock Plan - Schedule of Stock-based Compensation Expense by Award Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_026560c8-db2c-4e87-a51c-0c88050f90a2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Income Taxes - Summary of Income Tax (Benefit) Provision (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails",
     "shortName": "Income Taxes - Summary of Income Tax (Benefit) Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Income Taxes - Summary of Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "lang": null,
      "name": "pmvp:OperatingLossCarryforwardsBeginToExpireInFutureAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e88670fd-bd41-4f57-a207-bbdb1e22b8cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_59228c38-0358-4b55-8691-88e77e7b5f20",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_e3db700e-29a1-4ac9-b023-8c9049f6a691",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Net Loss per Share - Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss per Share - Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Related Parties - Additional Information (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails",
     "shortName": "Related Parties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cb5c078d-3484-49d9-922e-5414ab268c7e",
      "decimals": "INF",
      "lang": null,
      "name": "pmvp:NumberOfConsultingAgreementsMembers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Member",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_7f0cc19c-9eb1-40a5-bee8-48d5c8d49d0c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Formation and Business of the Company",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompany",
     "shortName": "Formation and Business of the Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pmvp-20221231.htm",
      "contextRef": "C_cfda4846-cb6b-43ca-955c-e5766847123d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MOROCCO",
        "terseLabel": "Lexington, Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pmvp_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development costs current.",
        "label": "Accrued Research And Development Costs Current",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance on behalf of lessor for construction of office space.",
        "label": "Allowance On Behalf Of Lessor For Construction Of Office Space",
        "terseLabel": "Allowance on behalf of lessor for construction of office space."
       }
      }
     },
     "localname": "AllowanceOnBehalfOfLessorForConstructionOfOfficeSpace",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_AssetsNotPlacedInServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets not placed in service.",
        "label": "Assets Not Placed In Service [Member]",
        "terseLabel": "Assets Not Placed in Service"
       }
      }
     },
     "localname": "AssetsNotPlacedInServiceMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_BoardOfDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board of directors.",
        "label": "Board Of Directors [Member]",
        "terseLabel": "Board of Directors"
       }
      }
     },
     "localname": "BoardOfDirectorsMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and marketable securities.",
        "label": "Cash Cash Equivalents And Marketable Securities Policy [Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pmvp_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments And Contingencies Disclosure [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, capital shares reserved for future issuance, additional shares reserved, maximum.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance Additional Shares Reserved Maximum",
        "terseLabel": "Number of additional shares reserved for issuance, maximum"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, capital shares reserved for future issuance, additional shares reserved, minimum.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance Additional Shares Reserved Minimum",
        "terseLabel": "Number of additional shares reserved for issuance, minimum"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMinimum",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of credit risk and other risks and uncertainties.",
        "label": "Concentration Of Credit Risk And Other Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pmvp_ConversionOfConvertiblePreferredStockToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible preferred stock to common stock.",
        "label": "Conversion Of Convertible Preferred Stock To Common Stock",
        "terseLabel": "Conversion of convertible preferred stock to common stock"
       }
      }
     },
     "localname": "ConversionOfConvertiblePreferredStockToCommonStock",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_ConversionOfWarrantLiabilityToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of warrant liability to common stock.",
        "label": "Conversion Of Warrant Liability To Common Stock",
        "terseLabel": "Conversion of warrant liability to common stock"
       }
      }
     },
     "localname": "ConversionOfWarrantLiabilityToCommonStock",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_CranburyNewJerseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cranbury, New Jersey.",
        "label": "Cranbury New Jersey [Member]",
        "terseLabel": "Cranbury, New Jersey"
       }
      }
     },
     "localname": "CranburyNewJerseyMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_DeferredTaxAssetsAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, accrued expenses.",
        "label": "Deferred Tax Assets, Accrued Expenses",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsAccruedExpenses",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_DeferredTaxAssetsCapitalizedResearchExpenditures": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, capitalized research expenditures.",
        "label": "Deferred Tax Assets, Capitalized Research Expenditures",
        "terseLabel": "Capitalized research expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchExpenditures",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_DeferredTaxAssetsOperatingLeases": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating leases.",
        "label": "Deferred Tax Assets Operating Leases",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeases",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_DeferredTaxLiabilitiesOperatingLeases": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities operating leases.",
        "label": "Deferred Tax Liabilities Operating Leases",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeases",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation executive compensation limitation.",
        "label": "Effective Income Tax Rate Reconciliation Executive compensation limitation",
        "terseLabel": "Executive compensation limitation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExecutiveCompensationLimitation",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pmvp_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee stock purchase plan",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of stock options and common stock issued under employee stock purchase plans.",
        "label": "Exercise Of Stock Options And Common Stock Issued Under Employee Stock Purchase Plans",
        "terseLabel": "Exercise of stock options and common stock issued under the 2020 ESPP, Shares"
       }
      }
     },
     "localname": "ExerciseOfStockOptionsAndCommonStockIssuedUnderEmployeeStockPurchasePlans",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of stock options and common stock value issued under employee stock purchase plans.",
        "label": "Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans",
        "terseLabel": "Exercise of stock options and common stock issued under the 2020 ESPP"
       }
      }
     },
     "localname": "ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_IncomeTaxExaminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax examination period.",
        "label": "Income Tax Examination Period",
        "terseLabel": "Income tax examination period"
       }
      }
     },
     "localname": "IncomeTaxExaminationPeriod",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pmvp_InitialBaseRentIncreasedPerSquareFoot": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial base rent increased per square foot.",
        "label": "Initial Base Rent Increased Per Square Foot",
        "terseLabel": "Initial base rent increased per square foot"
       }
      }
     },
     "localname": "InitialBaseRentIncreasedPerSquareFoot",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "pmvp_InitialBaseRentPerSquareFoot": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial base rent per square foot.",
        "label": "Initial Base Rent Per Square Foot",
        "terseLabel": "Initial base rent per square foot"
       }
      }
     },
     "localname": "InitialBaseRentPerSquareFoot",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "pmvp_LeaseIncentivesUsedForLeaseholdImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease incentives used for leasehold improvements.",
        "label": "Lease Incentives Used For Leasehold Improvements",
        "terseLabel": "Lease incentives used for leasehold improvements"
       }
      }
     },
     "localname": "LeaseIncentivesUsedForLeaseholdImprovements",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": 0.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments, net of reimbursements, due next twelve months.",
        "label": "Lessee Operating Lease Liability Payments Net Of Reimbursements Due Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments net of reimbursements due year five.",
        "label": "Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments, net of reimbursements, due year four.",
        "label": "Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments, net of reimbursements, due year three.",
        "label": "Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments, net of reimbursements, due year two.",
        "label": "Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments, net of repayments, due.",
        "label": "Lessee Operating Lease Liability Payments Net Of Repayments Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability to be paid net of repayments after year five.",
        "label": "Lessee Operating Lease Liability To Be Paid Net Of Repayments After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_LesseeOperatingLeaseRenewalMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease renewal month and year.",
        "label": "Lessee Operating Lease Renewal Month And Year",
        "terseLabel": "Operating lease renewal month and year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalMonthAndYear",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "pmvp_ManagementFeeOfBaseRentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management fee of base rent percentage.",
        "label": "Management Fee Of Base Rent Percentage",
        "terseLabel": "Management fee of base rent percentage"
       }
      }
     },
     "localname": "ManagementFeeOfBaseRentPercentage",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pmvp_NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash paid (received) for amounts included in the measurement of lease liabilities.",
        "label": "Net Cash Paid (Received) For Amounts Included In The Measurement Of Lease Liabilities",
        "terseLabel": "Net cash paid (received) for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_NumberOfConsultingAgreementsMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consulting agreements members.",
        "label": "Number Of Consulting Agreements Members",
        "terseLabel": "Number of consulting agreement members"
       }
      }
     },
     "localname": "NumberOfConsultingAgreementsMembers",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pmvp_NumberOfNoncancelableOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of noncancelable operating leases.",
        "label": "Number Of Noncancelable Operating Leases",
        "terseLabel": "Number of noncancelable operating leases"
       }
      }
     },
     "localname": "NumberOfNoncancelableOperatingLeases",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pmvp_OperatingLeaseExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease expiration period.",
        "label": "Operating Lease Expiration Period",
        "terseLabel": "Operating lease expiration period"
       }
      }
     },
     "localname": "OperatingLeaseExpirationPeriod",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "pmvp_OperatingLeaseMaintenanceExpensePerSquareFoot": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease maintenance expense per square foot.",
        "label": "Operating Lease Maintenance Expense Per Square Foot",
        "terseLabel": "Operating lease maintenance expense per square foot"
       }
      }
     },
     "localname": "OperatingLeaseMaintenanceExpensePerSquareFoot",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "pmvp_OperatingLeaseRenewalTermDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease renewal term description.",
        "label": "Operating Lease Renewal Term Description",
        "terseLabel": "Operating lease renewal term description"
       }
      }
     },
     "localname": "OperatingLeaseRenewalTermDescription",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_OperatingLeasesExtendedMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases extended month and year.",
        "label": "Operating Leases Extended Month And Year",
        "terseLabel": "Operating leases extended month and year"
       }
      }
     },
     "localname": "OperatingLeasesExtendedMonthAndYear",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "pmvp_OperatingLeasesExtendedYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases, extended year.",
        "label": "Operating Leases Extended Year",
        "terseLabel": "Operating Leases, extended year"
       }
      }
     },
     "localname": "OperatingLeasesExtendedYear",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pmvp_OperatingLeasesExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, extension period",
        "label": "Operating Leases Extension Period",
        "terseLabel": "Operating leases, extension period"
       }
      }
     },
     "localname": "OperatingLeasesExtensionPeriod",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pmvp_OperatingLossCarryforwardsAmountsDoNotExpire": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards amounts do not expire.",
        "label": "Operating Loss Carryforwards Amounts Do Not Expire",
        "terseLabel": "Net operating loss carryforwards, do not expire amount"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAmountsDoNotExpire",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_OperatingLossCarryforwardsBeginToExpireInFutureAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards begin to expire in future amount.",
        "label": "Operating Loss Carryforwards Begin To Expire In Future Amount",
        "terseLabel": "Net operating loss carryforwards begin to expire in 2033"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsBeginToExpireInFutureAmount",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pmvp_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock.",
        "label": "Options to Purchase Common Stock [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_OrganizationConsolidationAndPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization, consolidation and presentation.",
        "label": "Organization Consolidation And Presentation [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationLineItems",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_OrganizationConsolidationAndPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization, consolidation and presentation.",
        "label": "Organization Consolidation And Presentation [Table]",
        "terseLabel": "Organization Consolidation And Presentation [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationTable",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_OtherNonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non-cash lease expense.",
        "label": "Other Non Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OtherNonCashLeaseExpense",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_OtherNonoperatingIncomeExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other nonoperating income (expense), other.",
        "label": "Other Nonoperating Income Expense Other",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseOther",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_PrincetonNewJerseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Princeton, New Jersey.",
        "label": "Princeton New Jersey [Member]",
        "terseLabel": "Princeton, New Jersey"
       }
      }
     },
     "localname": "PrincetonNewJerseyMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock gross.",
        "label": "Proceeds From Issuance Of Common Stock Gross",
        "terseLabel": "Proceeds from issuance of common stock, gross",
        "verboseLabel": "Proceeds from issuance of common stock, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_ReclassificationsOfTemporaryToPermanentEquityShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassifications of temporary to permanent equity, shares.",
        "label": "Reclassifications Of Temporary To Permanent Equity Shares",
        "terseLabel": "Conversion of convertible preferred stock to common stock, Shares"
       }
      }
     },
     "localname": "ReclassificationsOfTemporaryToPermanentEquityShares",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ReimbursementsReceivedFromLessee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursements received from lessee.",
        "label": "Reimbursements Received From Lessee",
        "terseLabel": "Reimbursements received"
       }
      }
     },
     "localname": "ReimbursementsReceivedFromLessee",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_ReverseStockSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse stock split.",
        "label": "Reverse Stock Split Policy [Text Block]",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyTextBlock",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pmvp_ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of lease amount reported in balance sheet.",
        "label": "Schedule Of Lease Amount Reported In Balance Sheet Table [Text Block]",
        "terseLabel": "Schedule of Amounts Reported in Consolidated Balance Sheets for Leases"
       }
      }
     },
     "localname": "ScheduleOfLeaseAmountReportedInBalanceSheetTableTextBlock",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pmvp_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of other information related to leases.",
        "label": "Schedule Of Other Information Related To Leases Table [Text Block]",
        "terseLabel": "Summary of Other Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pmvp_SeriesDConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D convertible preferred stock.",
        "label": "Series D Convertible Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDConvertiblePreferredStockMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_SeriesSeedConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series seed convertible preferred stock.",
        "label": "Series Seed Convertible Preferred Stock [Member]",
        "terseLabel": "Series Seed Preferred"
       }
      }
     },
     "localname": "SeriesSeedConvertiblePreferredStockMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, annual increase of authorized shares, percent of common stock outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Of Authorized Shares Percent Of Common Stock Outstanding",
        "terseLabel": "Percentage of number of shares of common stock outstanding increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award employees exercised their right to purchase shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Employees Exercised Their Right To Purchase Shares",
        "terseLabel": "Employees exercised their right to purchase shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesExercisedTheirRightToPurchaseShares",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for employee stock purchase plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Employee Stock Purchase Plan",
        "terseLabel": "Shares available for employee stock purchase plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, number of shares available for grant, exercised in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised In Period",
        "terseLabel": "Shares Available for Grant, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, number of shares available for grant, forfeitures in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period",
        "terseLabel": "Shares Available for Grant, Options forfeited / cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, number of shares available for grant, grants in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Grants In Period",
        "negatedLabel": "Shares Available for Grant, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant restricted stock units grants in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Restricted Stock Units Grants in Period",
        "negatedLabel": "Shares Available for Grant, RSU's granted",
        "terseLabel": "Shares Available for Grant, RSU's granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantsInPeriod",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, number of shares available for grant, shares reserved for issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Reserved For Issuance",
        "terseLabel": "Shares Available for Grant, Shares reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, options retired in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Retired In Period",
        "negatedLabel": "Options retired, Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRetiredInPeriod",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options shares available for grant.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Shares Available For Grant Roll Forward",
        "terseLabel": "Shares Available For Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAvailableForGrantRollForward",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options weighted-average remaining life.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Life [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingLifeAbstract",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, shares outstanding, number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Outstanding Number",
        "terseLabel": "Shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOutstandingNumber",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_SouthBrunswickNewJerseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "South Brunswick, New Jersey.",
        "label": "South Brunswick New Jersey [Member]",
        "terseLabel": "South Brunswick, New Jersey"
       }
      }
     },
     "localname": "SouthBrunswickNewJerseyMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, shares, exercise of warrants.",
        "label": "Stock Issued During Period Shares Exercise Of Warrants",
        "terseLabel": "Exercise of warrants, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value exercise of warrants.",
        "label": "Stock Issued During Period Value Exercise Of Warrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_SubleaseAndAdditionalSubleaseIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease and additional sublease income.",
        "label": "Sublease and Additional Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseAndAdditionalSubleaseIncome",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pmvp_SubleaseExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease expiration period.",
        "label": "Sublease Expiration Period",
        "terseLabel": "Sublease expiration period"
       }
      }
     },
     "localname": "SubleaseExpirationPeriod",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "pmvp_SubleaseWithTenantOfficeSpaceEndingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease with tenant office space ending period.",
        "label": "Sublease With Tenant Office Space Ending Period",
        "terseLabel": "Sublease with tenant office space ending period"
       }
      }
     },
     "localname": "SubleaseWithTenantOfficeSpaceEndingPeriod",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "pmvp_SubleaseWithTenantOfficeSpaceStartingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease with tenant office space starting period.",
        "label": "Sublease With Tenant Office Space Starting Period",
        "terseLabel": "Sublease with tenant office space starting period"
       }
      }
     },
     "localname": "SubleaseWithTenantOfficeSpaceStartingPeriod",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "pmvp_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pmvp_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward, expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforward, expiration"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pmvp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, stock issued during period, shares, new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of convertible preferred stock, Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pmvp_TwoThousandAndThirteenStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and thirteen stock plan.",
        "label": "Two Thousand And Thirteen Stock Plan [Member]",
        "terseLabel": "2013 Stock Plan"
       }
      }
     },
     "localname": "TwoThousandAndThirteenStockPlanMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_TwoThousandThirteenStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand thirteen stock plan.",
        "label": "Two Thousand Thirteen Stock Plan [Member]",
        "terseLabel": "2013 Stock Plan"
       }
      }
     },
     "localname": "TwoThousandThirteenStockPlanMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_TwoThousandTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty employee stock purchase plan.",
        "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "2020 ESPP"
       }
      }
     },
     "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_UnvestedEmployeeStockPurchasePlanSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested employee stock purchase plan shares.",
        "label": "Unvested Employee Stock Purchase Plan Shares [Member]",
        "terseLabel": "Unvested employee stock purchase plan shares"
       }
      }
     },
     "localname": "UnvestedEmployeeStockPurchasePlanSharesMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pmvp_UnvestedRestrictedCommonStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted common stock units.",
        "label": "Unvested Restricted Common Stock Units [Member]",
        "terseLabel": "Unvested restricted common stock units"
       }
      }
     },
     "localname": "UnvestedRestrictedCommonStockUnitsMember",
     "nsuri": "http://pmvpharma.com/20221231",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r315",
      "r503",
      "r529",
      "r558",
      "r559",
      "r569",
      "r574",
      "r581",
      "r621",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r315",
      "r503",
      "r529",
      "r558",
      "r559",
      "r569",
      "r574",
      "r581",
      "r621",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r307",
      "r315",
      "r345",
      "r346",
      "r347",
      "r479",
      "r503",
      "r529",
      "r558",
      "r559",
      "r569",
      "r574",
      "r581",
      "r617",
      "r621",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r307",
      "r315",
      "r345",
      "r346",
      "r347",
      "r479",
      "r503",
      "r529",
      "r558",
      "r559",
      "r569",
      "r574",
      "r581",
      "r617",
      "r621",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r235",
      "r236",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r570",
      "r580",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r235",
      "r236",
      "r544",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r570",
      "r580",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_AZ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ARIZONA",
        "terseLabel": "Arizona"
       }
      }
     },
     "localname": "AZ",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "verboseLabel": "New Jersey"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "terseLabel": "ASU 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r188",
      "r189",
      "r190",
      "r237",
      "r238",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r354",
      "r355",
      "r356",
      "r379",
      "r380",
      "r390",
      "r391",
      "r392",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r438",
      "r439",
      "r442",
      "r443",
      "r444",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r579"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization (accretion) of premiums on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r57",
      "r154"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r161",
      "r525",
      "r537",
      "r541"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r19",
      "r22",
      "r105",
      "r465",
      "r532",
      "r533",
      "r597",
      "r598",
      "r599",
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r606",
      "r607",
      "r608",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r188",
      "r189",
      "r190",
      "r191",
      "r201",
      "r237",
      "r238",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r354",
      "r355",
      "r356",
      "r377",
      "r378",
      "r379",
      "r380",
      "r390",
      "r391",
      "r392",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r438",
      "r439",
      "r442",
      "r443",
      "r444",
      "r445",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r505",
      "r506",
      "r507",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r89",
      "r90",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r67",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation",
        "totalLabel": "Total stock-based compensation",
        "verboseLabel": "Compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Lease area of square feet"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of operating lease property"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r122",
      "r132",
      "r156",
      "r181",
      "r223",
      "r231",
      "r233",
      "r245",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r394",
      "r398",
      "r421",
      "r579",
      "r619",
      "r620",
      "r674"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "terseLabel": "Operating Leases:"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r150",
      "r162",
      "r181",
      "r245",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r394",
      "r398",
      "r421",
      "r579",
      "r619",
      "r620",
      "r674"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total financial assets",
        "totalLabel": "Assets, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "terseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r241",
      "r261"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Carrying Amount",
        "totalLabel": "Carrying Amount"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r50",
      "r240",
      "r261",
      "r520"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Debt Securities, Available-for-Sale, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r41",
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Formation and Business of the Company"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r542",
      "r543",
      "r579",
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "periodEndLabel": "Cash, Ending Balance",
        "periodStartLabel": "Cash, Beginning Balance",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r38",
      "r152",
      "r561"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r596"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities",
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r33",
      "r38",
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash - end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash - beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r33",
      "r116"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash investing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r144",
      "r145",
      "r187",
      "r237",
      "r238",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r377",
      "r390",
      "r391",
      "r400",
      "r403",
      "r404",
      "r414",
      "r422",
      "r424",
      "r425",
      "r426",
      "r429",
      "r430",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r460",
      "r461",
      "r505",
      "r506",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Adoption of accounting standards update [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r144",
      "r145",
      "r237",
      "r238",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r377",
      "r390",
      "r391",
      "r392",
      "r400",
      "r403",
      "r404",
      "r405",
      "r408",
      "r414",
      "r422",
      "r424",
      "r425",
      "r426",
      "r429",
      "r430",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r460",
      "r461",
      "r505",
      "r506",
      "r530",
      "r531",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r188",
      "r200",
      "r239",
      "r253",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Accounting standards update, immaterial effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r181",
      "r204",
      "r205",
      "r207",
      "r209",
      "r216",
      "r217",
      "r245",
      "r275",
      "r278",
      "r279",
      "r280",
      "r284",
      "r285",
      "r289",
      "r290",
      "r293",
      "r297",
      "r305",
      "r421",
      "r560",
      "r592",
      "r602",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r15",
      "r126",
      "r137"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (see Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r269",
      "r270",
      "r545",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Reserved shares of common stock for issuance",
        "verboseLabel": "Number of shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r606",
      "r607",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r579"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 45,771,332 and 45,433,684 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively.",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r23",
      "r167",
      "r169",
      "r174",
      "r521",
      "r526"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r289",
      "r290",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r3",
      "r4",
      "r68",
      "r71",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Common stock issuable upon conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r571",
      "r573",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Securities",
        "verboseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r604",
      "r656",
      "r658"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r604",
      "r656",
      "r658"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r242",
      "r261",
      "r264",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance",
        "terseLabel": "Allowance for credit losses",
        "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "terseLabel": "Accretion (amortization) of available-for-sale debt securities",
        "totalLabel": "Debt Securities, Available-for-sale, Unrealized Gain (Loss), Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r604",
      "r657",
      "r658"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r652"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRentCredit": {
     "auth_ref": [
      "r143",
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized.",
        "label": "Deferred Rent Credit",
        "terseLabel": "Remaining rent incentives"
       }
      }
     },
     "localname": "DeferredRentCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r604",
      "r657",
      "r658"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets recognized"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r102",
      "r655"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r100",
      "r102",
      "r655"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r102",
      "r655"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r102",
      "r655"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "negatedLabel": "Accrued expenses",
        "terseLabel": "Accruals and reserves",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r92",
      "r654"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Net, Total"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r102",
      "r655"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets and depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r36",
      "r55"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r319",
      "r350",
      "r351",
      "r353",
      "r358",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Plan"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r75",
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends, common stock declared",
        "totalLabel": "Dividends, Common Stock, Total"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r124",
      "r139",
      "r160",
      "r277",
      "r278",
      "r279",
      "r283",
      "r284",
      "r285",
      "r469",
      "r605"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Amount paid to related party",
        "totalLabel": "Due from Related Parties, Total"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r125",
      "r138",
      "r277",
      "r278",
      "r279",
      "r283",
      "r284",
      "r285",
      "r469",
      "r605"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Amount owed to related party",
        "totalLabel": "Due to Related Parties, Total"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r175",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r202",
      "r204",
      "r207",
      "r208",
      "r209",
      "r213",
      "r412",
      "r413",
      "r522",
      "r527",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share - basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r175",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r204",
      "r207",
      "r208",
      "r209",
      "r213",
      "r412",
      "r413",
      "r522",
      "r527",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r182",
      "r363",
      "r384"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax provision at statutory rate",
        "verboseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r653",
      "r659"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r653",
      "r659"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r653",
      "r659"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r653",
      "r659"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r653",
      "r659"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, weighted average period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r651"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation cost related to nonvested awards not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Options Issued and Outstanding",
        "terseLabel": "Stock options",
        "verboseLabel": "Common Stock Options Issued and Outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r67",
      "r146",
      "r171",
      "r172",
      "r173",
      "r184",
      "r185",
      "r186",
      "r189",
      "r197",
      "r199",
      "r215",
      "r252",
      "r306",
      "r354",
      "r355",
      "r356",
      "r379",
      "r380",
      "r411",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r465",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r286",
      "r420",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r415",
      "r416",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r107",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r286",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r416",
      "r476",
      "r477",
      "r478",
      "r567",
      "r568",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r107",
      "r111",
      "r286",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r286",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r286",
      "r308",
      "r313",
      "r416",
      "r476",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Priced in Active Markets (Level 1)",
        "verboseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r286",
      "r308",
      "r313",
      "r416",
      "r477",
      "r567",
      "r568",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "verboseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r286",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r416",
      "r478",
      "r567",
      "r568",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r286",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r476",
      "r477",
      "r478",
      "r567",
      "r568",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r266",
      "r288",
      "r303",
      "r401",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r566",
      "r613",
      "r614",
      "r615",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture &amp; Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO",
        "verboseLabel": "Initial Offering Price to the Public"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r53",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r24",
      "r120",
      "r128",
      "r141",
      "r223",
      "r230",
      "r232",
      "r234",
      "r523",
      "r565"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before (benefit) provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r182",
      "r364",
      "r370",
      "r375",
      "r382",
      "r385",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r183",
      "r198",
      "r199",
      "r222",
      "r362",
      "r383",
      "r386",
      "r528"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "(Benefit) provision for income taxes",
        "totalLabel": "Total (benefit) provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitProvisionDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r170",
      "r360",
      "r361",
      "r370",
      "r371",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income tax",
        "totalLabel": "Income Taxes Paid, Net, Total"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r600",
      "r667"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income, net",
        "totalLabel": "Interest Income (Expense), Net, Total"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]",
        "terseLabel": "Investor"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r458",
      "r578"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Components of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Operating lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]",
        "terseLabel": "Operating lease, existence of option to terminate [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2": {
       "order": 0.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Amounts representing imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Operating lease, option to terminate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r12",
      "r181",
      "r245",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r395",
      "r398",
      "r399",
      "r421",
      "r564",
      "r619",
      "r674",
      "r675"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r123",
      "r135",
      "r579",
      "r603",
      "r616",
      "r664"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r151",
      "r181",
      "r245",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r395",
      "r398",
      "r399",
      "r421",
      "r579",
      "r619",
      "r674",
      "r675"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery &amp; Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "totalLabel": "Marketable Securities, Total"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities, current",
        "totalLabel": "Marketable Securities, Current, Total",
        "verboseLabel": "Marketable securities current"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities, noncurrent",
        "totalLabel": "Marketable Securities, Noncurrent, Total",
        "verboseLabel": "Marketable securities noncurrent"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r33",
      "r34",
      "r37"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Cash used in operating activities",
        "terseLabel": "Cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r37",
      "r129",
      "r140",
      "r149",
      "r166",
      "r168",
      "r173",
      "r181",
      "r188",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r206",
      "r223",
      "r230",
      "r232",
      "r234",
      "r245",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r413",
      "r421",
      "r565",
      "r619"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity Under the 2020 Plan"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open tax year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r223",
      "r230",
      "r232",
      "r234",
      "r565"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r452",
      "r578"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r665"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails2": {
       "order": 1.0,
       "parentTag": "pmvp_LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumLeasePaymentsNetOfReimbursementsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current",
        "verboseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, noncurrent",
        "verboseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r448",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments",
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r446"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r457",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r456",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAmountsReportedInConsolidatedBalanceSheetsForLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "terseLabel": "Net operating loss carryforward, description"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r163",
      "r164",
      "r165"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized (loss) gain on available for sale investments, net of tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total",
        "verboseLabel": "Other comprehensive (loss) income related to unrealized (losses) gains on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r163",
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on available for sale marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net",
        "totalLabel": "Other Noncash Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r29",
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r176",
      "r660",
      "r661",
      "r662"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Accrued purchases of property and equipment",
        "totalLabel": "Payments to Acquire Productive Assets, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "axisDefault": "Portion at Fair Value Measurement [Member] [Default]",
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Fair Value Disclosure Item Amounts [Default]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r579"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.00001 par value, 5,000,000 shares authorized as of December 31, 2022 and December 31, 2021. No shares issued or outstanding as of December 31, 2022 and December 31, 2021.",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock, net",
        "verboseLabel": "Proceeds from issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net issuance costs",
        "verboseLabel": "Proceeds from issuance of convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities",
        "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r87"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options and common stock issued under the 2020 ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r149",
      "r166",
      "r168",
      "r177",
      "r181",
      "r188",
      "r198",
      "r199",
      "r223",
      "r230",
      "r232",
      "r234",
      "r245",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r393",
      "r396",
      "r397",
      "r413",
      "r421",
      "r523",
      "r565",
      "r576",
      "r577",
      "r599",
      "r619"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r60",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property and equipment, Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r56",
      "r153"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r58",
      "r136",
      "r524",
      "r579"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "auth_ref": [
      "r64",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "terseLabel": "Conversion of convertible preferred stock to common stock"
       }
      }
     },
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r314",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Consulting fees"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r314",
      "r468",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r466",
      "r467",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r91",
      "r142",
      "r682"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development Tax Credits"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r593",
      "r601",
      "r683",
      "r685"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r38",
      "r40",
      "r121",
      "r133",
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Cash, cash equivalents, and restricted cash",
        "totalLabel": "Restricted Cash and Cash Equivalents, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r593",
      "r601"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r75",
      "r134",
      "r536",
      "r541",
      "r579"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r146",
      "r184",
      "r185",
      "r186",
      "r189",
      "r197",
      "r199",
      "r252",
      "r354",
      "r355",
      "r356",
      "r379",
      "r380",
      "r411",
      "r532",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r455",
      "r578"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Leased assets obtained in exchange for new or modified operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Option to purchase common stock"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Public offering price per share",
        "verboseLabel": "Offering price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Stock-based Compensation Expense Recorded and Allocated"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of Income Tax (Benefit) Provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r85",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanStockbasedCompensationExpenseRelatedToRecordedAndAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense by Award Type"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r316",
      "r318",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r62",
      "r65",
      "r66",
      "r68",
      "r69",
      "r70",
      "r72",
      "r73",
      "r74",
      "r75",
      "r157",
      "r158",
      "r159",
      "r216",
      "r289",
      "r290",
      "r291",
      "r293",
      "r297",
      "r303",
      "r305",
      "r569",
      "r592",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r63",
      "r65",
      "r66",
      "r68",
      "r69",
      "r70",
      "r72",
      "r73",
      "r74",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Reserved Shares of Common Stock for Issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r594",
      "r595",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r594",
      "r595",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r594",
      "r595",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "auth_ref": [
      "r594",
      "r595",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D preferred stock.",
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period on an annual basis"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Stock Units, Granted",
        "verboseLabel": "Restricted stock units granted to employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfRsuActivityUnderThe2020PlanDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfRsuActivityUnderThe2020PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Stock Units, Ending balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfRsuActivityUnderThe2020PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value, Ending balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfRsuActivityUnderThe2020PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Shares Available for Grant, Balance",
        "periodStartLabel": "Shares Available for Grant, Balance",
        "terseLabel": "Shares available for future stock option and RSU grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable, Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited / cancelled, Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted, Number of Options",
        "verboseLabel": "Options awarded"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Stock options granted at grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options Outstanding, Number of Options",
        "periodStartLabel": "Options Outstanding, Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Options Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfStockbasedCompensationExpenseByAwardTypeDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited / cancelled, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r323",
      "r342",
      "r343",
      "r344",
      "r345",
      "r348",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanScheduleOfEstimatedFairValueOfStockOptionsDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockPlanSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockPurchaseRightsUnderEsppDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Weighted-Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Outstanding, Weighted-Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, Weighted-Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r41",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r181",
      "r204",
      "r205",
      "r207",
      "r209",
      "r216",
      "r217",
      "r245",
      "r275",
      "r278",
      "r279",
      "r280",
      "r284",
      "r285",
      "r289",
      "r290",
      "r293",
      "r297",
      "r305",
      "r421",
      "r560",
      "r592",
      "r602",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r18",
      "r67",
      "r146",
      "r171",
      "r172",
      "r173",
      "r184",
      "r185",
      "r186",
      "r189",
      "r197",
      "r199",
      "r215",
      "r252",
      "r306",
      "r354",
      "r355",
      "r356",
      "r379",
      "r380",
      "r411",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r465",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r215",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r17",
      "r67",
      "r68",
      "r75",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r67",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs, Shares",
        "verboseLabel": "Number of shares sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r67",
      "r75",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised, Number of Options",
        "terseLabel": "Exercise of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanScheduleOfStockOptionsDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r18",
      "r67",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r67",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r67",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r48",
      "r579",
      "r603",
      "r616",
      "r664"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r180",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r304",
      "r306",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split description"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r437",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r437",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r437",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureStockPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r94",
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r1",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r275",
      "r278",
      "r279",
      "r280",
      "r284",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "verboseLabel": "Carrying value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized",
        "verboseLabel": "Preferred stock authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Preferred stock issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares",
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred Stock Outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockScheduleOfPreferredStockDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r243",
      "r244",
      "r288",
      "r303",
      "r401",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r613",
      "r614",
      "r615",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r188",
      "r189",
      "r190",
      "r191",
      "r201",
      "r237",
      "r238",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r354",
      "r355",
      "r356",
      "r377",
      "r378",
      "r379",
      "r380",
      "r390",
      "r391",
      "r392",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r438",
      "r439",
      "r442",
      "r443",
      "r444",
      "r445",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r505",
      "r506",
      "r507",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r562",
      "r571",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Government Securities",
        "verboseLabel": "Government Debt Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndFairValueMeasurementsSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesCarryingAmountsAndFairValuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r359",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits, end of year",
        "periodStartLabel": "Unrecognized tax benefits, beginning of year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest or penalties accrued",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r218",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r453",
      "r578"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to Purchase Common Stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r203",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r202",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Workers' Compensation Liability, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "WorkersCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://pmvpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r583": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r584": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r585": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r586": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r587": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r588": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r589": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r591": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0000950170-23-005345-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-005345-xbrl.zip
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M&VV/*&&E'"I<]CXJ3$R(RL).2<$[JBC=XMTM0L\&87,3) Z 5=IFPC9<C>_
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MF/6M*'JS'HX7?]TR5_[B8"-C^9KI7?LJ4+5P0?-$R !LU'C "%G2S_>]%B[
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MOOF3SN!/?7](27=][@IX61L%.??& 1Z:.T$WQ]?YA^3Q;OHM&P_S]['!=3/
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MA:V[.0_!ESWVE>YHYS.M('T7LQK1:HMI\LTF'=&3UE&>8J^JA2"6:E/#V.=
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M,F!VD^ZS,'_ZQ$@*\=80\G#^"K:+=896<]B@#[:@%%>\)15Q9*4%,;HD-T.
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M(X:'@/>+&A$GC>^+I8IX_(OU'0QR,_ZV29'N0BLQ'B40Q-E;E)J#^Q/'ST]
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MI.:1%(]N^B3,8'>"NNX&'H@?RCF!KV#XU34F'JK3%Q#U/WLE>CIFV\Q&O=G
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M1+%V"L0?U=W16W>8%W*")34EPH<:>^:\'-S=S%>O."2TJ^UF;3?0RBDR*'A
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M*Y[!V^^EVG;[EEX,BYF=C,K@#,?%BMM0:&R*#22H1@98%RY3R@I&*XE+/GF
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M,#ONDM2]IP]2>M*_VU ;576-=X0J.;-=@7GU?;)G-D7G^2,XTEX5?KR4/GI
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M#:7*OIGXPYU:DV_!\^?T;$NBL\$WS[^1[F!.[O@^+OX+GJ71'/D5 [#)J6.
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MV<M-.21Q:W/@,7<_UY&OS_FL\,+. F2@!GWXC&JCH-&;V2\E3U4]F7XS2TZ
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M/'0(DS7%#DBNA6^!-?UG&OC]F-Z81USBM.2.]N.XUO6*!R!8A^IA!5'"*)5
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M]DX_LS22TE42M#8T>9K9[^--4,#&\[!N=%_?1@(2\+FFRBXZ?<L;DDX8XTD
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M$BC[] 4"LV5[2Q#0*GE)<<7Q\>!^N(Q>A82TV0:#'6%9%VD@T][W=-(R326
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M$_:S!GN(&N$SG^1-I1:6MW#(K(]<?.D$Q27+P:+FRNTC-J\$)K&TK[<RF*C
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MK0YH)BPP?N@2,5) 9\"$24P+;3YLE>F.OFQ9J@(/!S+O(I=:  T"_BJ9?8
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M/4EOVJ*29:X>?#X<*M(&['EEG)Q0)LY'$]:O60?_ AL7@-N6AU[=V)\&7;%
M$50_FD2O57O-F)N<OR)IY<QSMU:RPW(55S?2-"'4!_$S=$,C9RTF-4W]7)LS
M7Z2K/N_S,<:0#&; 87XZA:9V)C9%LZ?;L]7YA&_I@4JG Y7+I@W&=(D6+%,Y
MU2[,0B$]$D$E[5#HOGN+#<+,(:MMUXIL:-IXY&X>?:U;FJ);K)F[T6QM'>D.
M,7[=8&@E.WGXCK73E/_BUP6!S1X-HF!KR'1Q58[]+EVJZS6A=^R(U*32(:;
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MW8<$*TLD@N_6L$64QX74G3M;7K+H9KJI!X)0 ?J9QO1-<7OLSI1AO5)C -<
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MQ63%'F@6'.!&[_&Y'V3%]-W<@FCN)<PCGT0Z+7/AC73JWVP'@'10GEQ_"41
M#L571G<L&X-H.XM_G6FWZT'_ADVQ<./3R@E;&>@4;:S)AA_-^^- Q#(.P*'V
M3U:;_U-GZ+IKPA]A6#X2?Q\=#B AP#U>KPYL'0[PJ5A"\]#A@#X(& T6^C8&
M)E+Z[R1\@G4P*7A9H@!OB?$&A.YX+IK,=CC8F.8Y]P\O6U(N=B\[""UTK"HH
MT.FOWO\W\]O?Y;LL("8F#Y\V-^MFZSE^JMT'L95O]MH?'/SQR?TO\$+';A '
M@$'.%Y0I'Z";\!,<18MM*L0@^A"#\K^%'1V4&"X'$W3D;YVHT,?IO6^1178T
ME"!]I8G_NN0W%GM_G993>)@O17JVS=@Q+<#JP?V9/AG?D7W^R=/HOG'1%[#S
MATVL-X?*CAL;AK*"QX238DHDV8*L)HRF[25*)B8?65>E52C^LN1\\$E5P$RX
MJFQKD)@^OPCM:HA$A=J/J3NLKMFLDGBN&#_QDT4Y]E#W7XGB5+@1K#];]Q8]
MY,Z>N,,<5U_D*F;P! >X(FO)>,V1QO1*E3MPK#K_4]*DYQNO2=XG"['MI+D,
M[28R;R-,/B5H&1RD7=,>=^J%)]N/BP9-:RDS!XA-J9B%W3I0(.?'SWV0PQ+;
M*4$G#@"^AK'[[">)\M,J@V1\H[YO(_\,2;*DM8W')R)G74>N6WWF>$!(^A^#
M#%-G:DGI"#6V'GJ9LMX"$74@J)23'G*\Z2&6.LC@IA>!8$H3.37A_QXI<2?M
MLZ*&1TKQ T] 1L66+,<BA8X:=OCSL+G#;>']AP!)1-O#3"\'(Q0E]#S^V;'Y
M_0MF11>'?-Q/&=.]$/"6E60KOO"4O:'%YCT3M;Q( ZJ*":I#G8TGHZ3X&7KV
M)ZK[$]7]B>K^MZ(Z#S Y>#G#$%S-O0</6:+$0$Z%SO#W?QJ70^9B56^&G,6!
M^=8#[N  WW" #!R@"GK*XJQVON+#HH4E/)1+-U$6I^#<\E0NOCQ(9.TT'WYR
MVM(R[&6U=#$Y5YDRJ;)@H/(X9HU^ P>@/JR%4+Y@O)OMM'R]^(9@9J;@<(R#
MXK[J%Y0OVK=5__&G[5R548AV2 '49RF36T.@/AM<MY%/+V%=(RD4C0\L!Q T
MO8?T:KDOWJ*#A#>-?3-,VXA,U. +G0"4J6<'^/!4"4->P\8$[J0#'C:SK?(_
MBL]5D5\V'TXUBWYX#]T-OY5[V:?FOBN(,_"69#-]/\,2S EC@SPO.U5H#!7X
MQ.I3DQ69N<NQKCE49PXPWB1F>1Q.LF;Q /,H]F7#U4[FY6LOXH33M\,GBSA5
MBYCIX;8:&F[+V3!(6N%@P&7PMS7N\U?B#@_0LNYIY-W:V&FJ\YR;\=U[]Z?2
M)WKMT9PM0&28GX:_Q/8;Q-U@S3N"L_6E!L9E-\D4Y)2S59T3GH\%-E)A?!?!
ME.BTHK*,-]\5F5(=,><.,:F+Q5'9;Y27O=Y()X(.9%_Y(P8QUBAY(#DB5\.1
M;?L1.TBTY](Y?_QH@$A;OIW!W8<M6*-TD53,O,=:HVI7@DGX^62 #^-(W&K
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MS5=O>3\CPFPISL\O]A")P"KOXP"UP'WQKQA19.]::*KNV:UZ[VSOV[4-O3B
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MK&ZI4$7H-?77@[9UXM3RD[\,5@[L;_)7#&/IT%"M4K5&P<D)MAU8:ZK)7D$
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M>M'1IPTD,!].:K+#%#QIB!>H'\7](^XG_!3WH<:J1<S5.GBSBJLODSKE+QS
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M=5C^K+5_OY+Y4]O LJU3>4':CBH\O>YVO^<RG:^0NI"CK141OZ[[;'DKVET
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M^;K["!"1^HW1;C#NM@" OP>I'I<A<8_(=HO5P!B;X0?CM:AX\2-JN[VN;59
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M)O130E&,1PK RB^UN()\;XU%A> 33^V&#L9^V'%;5B7;O.6ZBF!5PNN1_.M
MF%LZ(UK382'*S?ZX)J6;HE0 P.DTYW&K2C,,RUN)$@J'97RVO)D=3Z1"@A+F
M]%PP:6K7&\XN+Q>.2[ SSCF6L^A(.9\+D;T@=%O9))BZM?A\^O]A[[OCHLJ2
M1B]!47(4)+4*2!:1'!M$D@@(2 XM@D0129)I!<D9!10D2,Y(SB Y2@Z2H4%
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M!8R:A1?>B.]Q=2'YB!WN\HI6#3>,I-D*(^\/-W*[F4$J#.U,^,KN+I$Q=M>
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MZLBR$PF*(UD5^J=]V*EM/Q\P+"']X&T'BK?W="+V?J[(J7%,6!S#\(SUIMB
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M$.:WI>SM*(Y;0V]Z$B9%7 O9P@"+VFZOT=YKOU#8$&QZ*^6OUDGQ=[XY=)
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MC!+74JXR/W?"[8<!_ ?@& "-_>.8'8P!*!11-Z"!&&#_^^8/,0R #)E>K\
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MDV1Z/_WJB_YSZG /3JJE\SF?&7+XI"]J$LP+V2ZA',$1Y;>BZW#(N[79D>V
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M0GXH.&3., A!F8Q; Q2/),2W@LCKM>&5/1"R=0_\UVEB-PLR<N4V9<1H,A?
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M2&V?\QC@@T4G^AB\)$-3'GG9"D)5;@Q1'9I: )65/[4,M1#!/2]63(NT7^)
MT]B>-$;#N&W?+EHT?WGWL/5#YP>:?;7 156B5@6M=.LH_<LE*^XRX5\.LFQ-
MR.%'01GZ0M[7QK=&TI7>1[;=)WCIIK4%H6P4AK;(TQ0$9T]WL5J8?M*FTTC1
M,A;I3,$SF6]H"A&LIM?G'63KDHTCE-XP^S_LO7=4%-NV[U^(@$J2G&DE"(*
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MX$GU:ZQ5; U.(L\):Q'^0DZCE<RLM #G+T'.:'5LF\D2KC;O%PO=:3YY?O+
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M?.ISS5-FYG]UKVD*HKW>+,;0]#D%^Z3Q1&/2X67"3ZWQ2L?C?B((O>55:SP
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M+\4J^MZBD@C;%^7;6?Y=\VR\%X1\QUR9H9'E-I<>&$V:^(ET++PF/-(9I$.
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MZ<"FT*TEU1?QW&9F4IL&),'RPL]7V"6#6KM>C85,/E&]_OK;]TZ"LSKG8WH
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M.GW+&Y).&.-) 'WAQM(\ZG,9M:!G4\'N<K1EWGFG*P+2[T0X-"O6'-E>("L
M"M[$F2E+O)I)SM&S9+9I@)M<:;5^XR<Y;^1+N;X]4ZBIY%5K4UMJEQ%R\T]P
MO^D?W9/Y%^.Y/!?*/ @+/8!N3H,W86:S"[CC!P=;'=M5K5(3TL?/]NDT/Z0?
M96PTG57TB$=>8#R03H)[#,$#[0-XX(H) @^< N =!QA.L+:;'UJH@W,]+''(
M],<# <(H/(#S!1U)G>W#H(*]&1F$!_;^\N15%Q[ U&SS9JYKXX'4TPTIS>:S
M8/@1 \,#"I38%#@>",W$T7:VXH%C +:P@ >PAJX?-/>_X(%>W %K[O^%';S'
M([!EF"?%4SL8ZK,\" _T$^(!'AX\@%SYK5V&B[3>5HV[C?5!?))@C!:(\BP;
M)< #L;%X .T$^WNKBG9"Y,NA1[,SK7&LH-^V!_SW1HVY*X'TBK';VR^[(RA_
MTQK0;XQ:K\N(_%^.^[JH0O*;QD3^QB;G&4V5T7P\('/RZ]S+YUX^]_*YE\^]
M?.[E<R^?>_G<R^=>_G_TLJ,\.\8;87ME5FXK/"N[O"<GWO1.UW72*?(-^Z%R
MIV%-W<<.R76IOUI">//^\!=]_Y;SA6[/^;TY7^CVG-^=?^F%;L_YU^#\VP/G
M_.Z<IV3G_-Y<84BH?+:53Q[;>ZF+ST/;=M/P'N[M'3PPJ_V5-YT,]M>?3V%6
M:Z"]RPFXX[\L90$ZT=$XJX8>-1Z.@"9J@DXOF.&!AGSC$* 3-S(,7J$1.MU7
M.2CZ=%9=)<*VO_S*\!7& ^7.E,<7>_" M^9I?BZL_P;T9*WB7.)<XD\@P9Q]
MU(=]F#T'\XC\]_Y?H@28X(%_.T#FO^_\6E.!$0_\]0BY?S50GU:#&/SO1H+_
M:M^S=EJ"R+_:>*YQKG&N<:YQKG&N<:YQKO'':YC@%)_\N3*R_V82#YW54 ]P
MW1].M@H]_BPV_?>0T"DH,J\.*SOX24CH6^ Q\N5\YN2<_QK.;V:=\[MS?C/K
MG-^=\YM9Y_SNG*=DY_S>G*=DY_SN_,.4;-<;,A_DOQ?^>!Y28XT'Y*>[Y2>]
MPB+O)?E11J:1))E&]C5$VG>L"J RUQR-M#Y9BC,O;Q(ZOLR;Z'2VY-IE"'D<
M=.E!L2(F&[7>K*?SMKBXL$"@;+U*RXF<JMGE^_S%707VTL]KS_3JW^G4>+>Y
MT@^&9;UW(+<WNH;I0H#)U[56=7:,6#Y2<.VD3Z4?FXMU^O0FC!&V2D\\VK I
M7'P6)J'4'?,+F]\]AQ;WF[TJYNW:QJP[4K@4<X^M1)),=2YV4X']--O+%N53
M\D7?<K38>WGJ 6>D=P,Q).^G\PP7^EDD0H; O<"P@"KVG5'!<C_%_B*48A\>
M*,\U^C*BKU7\V*B0Q?:MZ3*7*_F0V"#F!*&)[GO_>I\T53>CO%+C\^P;1::N
MSL\6%T:#T G--;CTBF>'WYI%4G@F3'9:00J.AJ=>I6C'AZCPP/S/NFYW)0/3
M<UZ73(@CHMSZ3G2+LV1O)^0AO(7%.-17*A3%/;8Z10D*_^@W_OXI#F,^<H,;
MVSSE,3.HNCNBK[49+OK[1R9/9."!@- L6%_YX2D*CM5VOD5_/3]7Y.V2V_V-
M-<ZBC&H0YGF-"O8$"IN]C ?:-?$ *<,#/ "WWCY!@#%?Y#/?XY2%-A^!L%@5
M0R4',*K$*?+HH $/--#@@9!,'+U@]%F_&YL];(&AGWJK4&'#P.6W8;MH-F>Z
M[WB@I7T0O#QQ@L- <'R1?Z^SSZJR<QLWW(P'^MJ<AW4X?Z,+1ABO@G8WO?&
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MLI*0+&[8KL\1HKC=KX2[H@3<=*PBK?:@Q(MY?#!WQMO8=KE$335A I4GD(>
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MP -3\#IP[3Y;?4/<\H>5!;<L74[CHJP[7R6O1>SW!;=VU$M<9OO(:HJ*BWN
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M@]KP%B/_[3@O?BFR+BV%O3BI87YZC JHLFU^]NLBPF-C:NXC]_>QE#"QI7?
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M:(]@DK*!@_\,E(C$=9F&3ZG-599)6SBDW?3.87G]TD("*B8]U?ID_RVAZN8
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M;0,FUZ5K9[&NR^I4;ACUG*HE7<+IE/?AD[&[TI'*RV,#1-[Q'<>8&Y>#M*0
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MZ01/PG(:J>UMC!SJ103!)\;)H_QP7[Y[/MSTM*3J\S#A5-BODIUJ%X1"6<4
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M'WOW@*IN?,TW!-%M'=^H)$LCB?OQ=MQM&'=TBMPVCH^8XHFJ</(2$9MDU ;
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M-5[:JFA5TBYD%!4&SMW8S)AIK_%]IGVB&)*&\+#6BW;L_?$:+NR?8*Z+BE+
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MH$%UX?+C24<K$-V3(+=QH3O>>Z5MK<3*@T+2M]X6.55S4)#\ \$2_F9HB):
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M7RU,F( /N'K-E#S>C<894U?('/%UG2.K;8LZ:;@)NC/28V8O';_NN<I9Y>V
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MY@D_)HP3AT!,+?W?<7A>L$L\N+T/_@PDT<L1Y>HR,GG\5Z9)DNBE("E?B?U
M?$IJB2)EJR-)6UR,UQT0Z'!+R+Z0@F_$Z<13*A(X\*TPR%6Q BABF13L<P'*
M298*;-)W<Q_\'G8X:V25T9L97-_-;L_O"Y)*GG?$\Q(_E<;D'++X9V>OCR6A
MWB#"84R(D=*WNGD1I]@F)N5U8>F<]^4."LG^W0VWTS3%P/(MMB\W>];,X$=
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M SO]HB9'EB[?"F;+_!I-LD#$4=8U]^2J9LCZ#16CCYUR4G+2LZ[8$O)3*0-
M>V2STK+QA;G@X,_Q&A=[:!BCX.6&V=".U);?_FY+K/=ZY6NU2=$8C"NQ+N[S
MH;V4AN(>\ZX"M(T&4<Q <34J_J.V()=D>#MT=^^G*BWXO-Q4]E>.*FC[N9+:
M47+U@C";BW$+UVW]B2WAN>8X**C7J2:[YRN9OD5,W/!I*S>(@]J5M%<3"Q<E
MSW8A1M6\-C.Y52=NR+A/*XO<F3Y04M;0H@G !C ! !&TT(J[%(_85VY,<GH%
M/DCP>9*4PX:>>$VC^(_T4$H.6>2SU'&L.%\:+M..HJZ43Q>RVQI(4'6VG>]M
MC'JJS)&0/%WWLOV#\96"<7JIHTAW2-]2.EFY.T.[55\F-O#V-?(9>:!?;VE:
M2Y(&"J<4-/)&*LJ]W68@7']5Y*Y)<'<?["G BB-2+2-ER([RWQ(O%+1IJ9WI
M:_,/(LJ^K/R.->/$[Z2I83$W1['>QT'C$E+-Z @+./GHG2]WE5=A!#G[DT5/
M$F"9)A2(F2Y2Y%%E\Y.%+%RWD+T\">O9/D75R+]F27+PL!T4T'L(C5V=:?R.
M]R+Z;:(< 1+!\C?/)URUFV[Y?OD1@,.1(E8P_N,_W"RA4?WV3S<B,S@M::3\
M(8%U\[S;7*_=(!JA^=TKE=U$R-COXI9'M&RP8!QOCQ2LD\WP[^G>(?""R_T"
M+NC'5I K[2]'SBJJC\5-_YGW1^UH0V%.D]1&<KD)J%'R:H/PRCQ0S2\8M'IR
MAD!Q-"IRO75[RXG(S6V+^RLZX9F96YF]"TLB>*!;<$0G+WO]0V@^&QXJAY*7
ME(2!FV)47UZB6RE%DFY+Y _W4@;K)<?L&YNW<Y_G=:X%\T$\3"IOU0]+X6W2
M&Q^?OR*7BT!SWTG-T-/JAF\2'(?C.N\NIE-XHKD[=\HZ32=?3]B7^758NNP6
M)/04JK]O4^)5!7&H*9EVY+,K!:DJ!W( F=C?95Q-'>A:,;=['F9#*LQ&4P[M
M-Q)IB++4E<R84KAMH_I2Y;C^2WK[<K#RC\NTZ><[IEAPWZKHZ%L\9#?&0OGS
MPGT:GRC77Z'G,@&>FH$CLR:1>>6[N-9)/Q-=LX'?Y$V:@XK<@PBIR: ^$, Q
M1@+H*21&\FZ23.1F4;@KVY$A."C1YO.B(1NJMVOS9,7TF!IJ\#0^DYR,' O>
M%I4*N5JV@VQ>/ +4NI\MM,350.F*+Z6^.C/J3+YS$^6BW'_S?M8<KC.CP;]+
MFJ.DE\T ?I:LF P6B66).5J5O[Q>![(Z2-<72$M."IA-*T%87+B8">K?*C4X
MS]^RCIK%3::&$<K\7(%KXROC1N%=D&P^ F:T:&_"\40%%UH^-#JHC"ZIS6]]
M$P%<ZMN.-YP(^/(T,@ONVN#X5V;[,^CY^:+%ATM),H0O[R'%?I5[A\,2X@_:
M_ZT9EDSHJF\(W?M_G4>> 799!D5:5;7 )Y%_EWTD"'!>7(-?3-C78CN:G(C5
M+&3'LU]N.-$]F]7VF/B8DRE7[GGR<Z5LK\7@CQ)5M=JMJZ*^6=LOCB G@]%8
M\5XOZT#A0-TA:,==8!J!]V&W1*W&[D?(]*VRL5=6S@G$7K$A;A/Z-1(;U,PR
M\IXG\67Q9KJ24G"@J7@SHP8BO4OSS"*DC&%KS*@@?>[::$=YT&8GP7<2WXK$
MPW!.RH6O":OT(+V&A'7:*6J+UGP=9#PR\?:COQV)7PVPVZ.CFJQ86D?^!./3
MC$O#4'ALM?7M1=^<*1:<YF9_2*.U^(8_J+V<F67UF,9N_&,P*#XF8W5\C >J
M?IB R1)F^!R.NR(G,T,=,.?S"! <ZYWT,/V65CN79K181".X16=$M3K$B(:O
M4LJ*4E9GBGA34)M:^U7G3+0UL;$#CA\!PM3'(Q<GA\U*K_ ]E[0=YY"7CJ^C
MNA049PNI;FMT)>J@;W'1/8 G/I(/6-3A\HRG0\5_!G>E^_D7!8R)-B>P@D/D
M.6 &1N4KM#T,7QPR#Z?!WS>OSL?A;HZOMQE;$C5NBVR52=;_2^.="H8J^[I[
M+GH0NV(\)6;NA>_.Z9:VG!NZ/93>X/!PGQ)E)VN!,@E$@@GQCY5+9M4E[XB%
MUZX> 5QBIQ/V0Z6?R]V;Y0MC%]__RZ/U)JBQ9\)8#%Y+=Y;49&1>WL*X4^+
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M"XI&B*5()>.]9Q-;Q&$5P[]W)M=(RTUSR5>UOTIC^Q,P<&5>%$G>GJ5%29X
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MY7K4"006%OA 9RE-V>WR616APA<99&+$8EZ28HX/@Y&U.)WKA6^:5^Z#7#B
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MK'[-276]CI$]+X/KK_#KQ95KI8(:E3Z?"H8Q#R?#<!-%*-$)EZM11$#Z^W\
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M<=&[# UJ=32NU[^@5OE"..+@PXH!/"%@G&:>6YF39[_ ]4A.4_Y1WDB$H^D
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M*B#[S0!C+TJ")=<ANU/^7K!=L^/A\.?XVK&XYZ5]$]PH24/-;=0;S,VE4O<
MTT]>M&-GZ;:+7O4)B@6MT$_ANF2%V'9X>E^*E%-_O+F\#%H"5#]I)_X?LK)?
MKG#F\I@N/H4I (=_-I=[ND=)=Q@TC0//FX=PZ<'F_GG\T51(-I]/0HG(S@])
MZ#)'9Z<"N_E4[")4OWB]K(J!;KSWD3.XC#>BIF_[@J(NAY@N)SK4JA_A$7O%
M.R>%_FGM7F^3(18+-)]4=P0$$M,</$MI:JK#B9E=0VZCEYE5(DB.DZTHELP3
MB\IG2\-RXM#&%.QX3H+>&RHOPU?1C99'IN//M'6J'/=>_.P^.BE8T]#6$<!G
M,TIM(-IJJ$),X5AQK9E DH:)ENF=A/9PP&1_<)FQ!P?3$8%E7'\GU7DPUF4H
M=DU+JY.4!"F$^9M66_@0Y SBN#'3I6]_Y147IB79%%/0%IEL3_"RY6R_*,]T
MZJ!Z$_UYT-A#5HGON]>ZYSOR>X'*BM5LIC3YG.3I?(DFP822*F^8;1V.N0YL
M?I O.[IH4WK5N[AJ0U'Z]SI]C<;6,$0]'ZX 5P1]\?1RRJ\]Z:S,T1B'U1J/
M-\YD"M_W-U?:A90[*F7,^/"NN4+?OJJK0F0R#N'Z;4LK:A:_/-^*?Z# W0LN
M#%P9",P%*;@O---G=+4^'>EX+"+(72Z=VO7?M&R&9/I$$%'LP3K)RW'![??;
M63[/;?&3H5<WSDYW\L5%HR?M,1V5AS8]?W1'?U;[JRS(WMJ+K]:Q83D-W"W'
M%4QVL]Y1&E! :B1<\"[H7*2VBF;BS59]CSUY?I=N,?H)U"^$^KT)5-&?\Z2U
M]DV59@LB+C JR)0.11"E96QF?KX#VFM5W1"@T%BFOFZMB]\+B/I&$%9Y$OA
MV=.^=:;.<1]OH[W>GP+74);61&F662KTU(S%1"LG [L92FE:HTM2\7F>1Y$"
M ;I?2@:CMGE2U/HM^,UR(]2S,:-I<V(;JBE]H&,6)5UN77$JZ29_TLP %3:N
M2W,\90($2M\G>9F-RW>^)/.!8BW'P:TM:4V5#9$[>IS)B!59T"'=>]@+"T'D
M"TJ',<E\"M[5\BJWYT\UIU(1 5P^-AY6?@XKY/K/C%(D9R>N)Y':-&+&JR]1
M).&&BA$C*NF^#/=3VPO3CX%>#'2MW!C#'I'*QPR@ YE"4\N'!T)@GO$NCIDO
M+V#_\6Z\9\:*F,5*0*VKY.7=W))"=1<-^\L+7<QS"BEL&$,6(>,\-=/R&=^-
M@P^U,.<TUGWK,A16E7QI-+FT8&(;O%/KQEJI"%T$OH1W 3]#WCX525R7T+-M
MC<"EFU$8O5]#-A("<!QJC?_.^]4%(A>(%%A688JU3XBSTIOB*I4H)_E,OKEW
MUMS2H<1WR@2P<VRRQ C&NRQLDJQ8G*>N6[?<'./K)A?ZMMV MS'28UK! Z4C
MIO.*=$IZWZ-CQ);OD*H%)I/YOUR;63.5?HBR@K9;PP2W<!MKG#ABNV4N+-OI
MB_"!-Z%!;D?CA(D-B&U0<GWH^#&F7#.^U@4 YS7#)=77T/'Y!9&F6WFZU,\6
M;-]UPI 84U)@$@#-/P 5$\OE1.=>G,C</6G DMXO7@<:R''5]<[ZJ8+Q3#$+
M9(Z(RCSER/WK0P</^>63\-:Y1%; L]#^,NF\IH^XVUR;HX\;]B=#MP7'-L<-
M>^L@IRUSF3LU (Q&K7.U!V?C8I] @C;;:NKLG=VZ[O:PZ L[YE?+NB%K$\4.
MBMJW.^0J7UA[H\B6[30KVH+S4=BG3#R)%Q-;U_\ (Q/RN*,W#Y</1>AI_44W
M:"]:*6\3+G4^I=J/@.@;_E03.!"(Y N*(0\^]4CB_:&?6]B^PW2;W]MQ3FTL
M:?ET4;<^CNDNIEU[6)1)[/\[0,6K=_57O>N8562NOL,*/V^[?8FQHZ?Q=YZW
MQ;(\+;ZC_C&)?PM(G2S]>7 *Z#1D_/\!O(^Y*@/\6KD3"5T/F9<BYCVC7J8*
M2]CK&R._M_H;CVCU9=6R2H9R6[J,*..B7D9/%YL7#']E!Z*)*YP'8.#3C:6-
MT7JB7EKD4E)+P3\$S\.=>1U^U.H?M7ZGOGK)2O@K;7@J2?!01_B"[HX)KKYQ
M]:"%S7CNS1(J?Y]M,SW8,D3GP(5N?"-F\0\ :1$N^F$CS]C5%+O43<\&"49M
M$.^3$+)MD%W<*8I'@2YU^;9R"3NY/&X 5\:O>ZO .'&,C^I_ZN:#Z1+ST>.[
M][(4[K(4MB[/XN>D'@[<<Z9=1SMRX!^;1<5'P(OZW&)RU'/P1S**2'S:^$Z&
M_'\ F8G;K[27#RRQ(OQBHT-0!HR#,O&\?6;F<_'VLR'[6_F-TL01.QNM((FE
M),"A&LL\R*4"E^;NT?4L2^S*8"WP'^"S4V@"#H]8UYJ);5I&GDK!$#P1Q CJ
MF1[ ;*A)*@J4_*,PB/$\/;'MD?[:=532LNW4^,<2$SF9<\;!</X')WJ*)=<$
M5"Z4"6A$N[J9VXU)O'\Y@1DB]/SEN<.TOE AI#2^.-;:N;W%EN^B?C2' [@S
M GD<W!#JZ5&\I (H0OR]MU#9_B@%Y3?[W6WM+Z96R:[/.L 7 P7RJN].K836
M;PJ7HY38M_.SQ.#8_Z6?+A 4%(NEW\SU:JN8WX;:N+<#7E]\GR*DL\7WSFN]
M8 8/%_/A6CJR<L/WYO9JQEGAS/@L=T:YG/VHFA>O9&'ZYY*T'0C81;8)^"-+
M@\82*_4L!62GHMW[BG 8GYK#7L*(<3K>[5C:-VQ\%_[I?4PBOVKZ9AG2+EPM
M0#A%23IDBA$<W9>NFN^FE<A7#*N94LC/K0.R3&YM=?#?(F"1J%3/,LUOL!\J
M0>G=JA#9*&_ZT=?6.]95]OU%4VAQ$AH.W2X_7[W6J4W?>Q/^77!7(9"2CU5'
MY[VRJ2O5$/B-VO#1@3>3XA_H.0D24"&)"S16BPSD';S(<%2I5R#$IHF6TQKZ
M!RC'2@V75_EZ[^2(-R>.Y6V6/O52D:A?B>IONKY>0ROFW-7;C("P%KL&877K
MG9C1B"_+NFE\1 BM8R$4!9VTOAF%>I.&9>*'^ESQ#%-36VZ+(+M7.XV(%P/2
M;3(:U1^K3M4JM<,6?#.]6R1T\Z13W(0E^ R>CT4248ILX&"\#1*X#\N2EA H
MIG*Z9NGMCSCJD]> HT/#<2JY/J..4ZE'/D/.Q7%--N6O33OS.&H)LK0$X$Z[
MIXZV3O'[XC^!NCXS(&%1 JBGC3'.[X#9:9,Y6?A8F5=<0SRJKA!21X1]_VLB
M6V$^;B,DX&(?U]Q9J26,]\[]7?D1]*1D+!SZ=6.6-]D!"K>^W1;2GF5J%^!L
M="8P3DJ%X&H2LY5N#3=FLLFQAA.\G,+[Z@AO#9#:Y:*^+UX/XB[Y![C2^'][
MN' ?W% !V7-2$BF6>\#PA!BQMI?[TMF,^6\\+Q2NEILVU&2;7>DCZ:&IJUQG
M4KBLA>;OT&B\<X- A@/-;Y#$,++O$[/K^P331$>!Q-R&R2@9\> 1WY*?K:T_
M)D[Y$1]VV6<;*"[K>4_Y8DIQILRMB(\<K57#=5\@/D3$7]<XDAJ:,\N5(M5T
M957X388+QIT"(*I_)W,&^#D-]/R2_.FPGT^B+&@+J_A%]"5U[]W)&A K1XD3
M'>U[?:TQ?L((Q!][O;_I;RL[N>C*PHF2@[$7MFY;+BD:6LZ&-T>8XDN_3"="
M:Q]:TJ_.;,D6^?1K,WK3<<>8BDG*F(?@EVA!G=W-?.NNO2&2?U\/75!=#BCX
M$5_>%V^RW.+/ECW.9LV+4%*P!:X:U4!^.[9,4>-Z73? O:U[ZH-B;J\K3??V
MZ^O0L/8ZQ=KRLO@Y PMJVI,W!\#D.Q<N/[?)$H-S NZW77R87,^RC7%>.3)"
M[U4>BKD9BQ>U'V-IWGEO.%U)4!7M]%MVDF]12K\S> PA4TAP:@A'%4RAJ' @
M&1"(N-R=/,,:ZM3XKV4@!./$[ZQ3FW#AT%)0YG0+X3CQM+7Y3;0'%$X@#"9F
MPY3WL6<"&#LQB/T#1'E\B7=W%OI+XDMN*W,ZS-[R2T/ON CAX1#Y(2DR+:Y;
M)CLD)!^+@"S;"-E+$N[+RD2D>M:@P$XC1S7H-0J46.W1'((>.(6>#T 5KMFL
M?"$S:&!*3+8^&F$</ -+7M!>)8_\7( )?(-TLK[^WL=M(?;'H<.C;P$<:$5>
M-X5+((YD QZHD2'9?:Z"A?4!F.?H[Z!LTA"2Q*]2="'<(K(.#_X(')?5\)UE
M@XO1.81U/JN%@W;G:7TNZR6XB^DQT#*.+)\\+$N!Z3R(I2RF/_S'O7]7 N<]
M_^%:=N,*^U9H(^.;Q-4"6FL&>#]_,7<5O-!A%XAEHLY=JAQETT_R#4+1&TP;
MJT43]BBL6G?/E7FR&Y1-UR,?'?F>F7+-U[UZWCCQ*/E&N>%-4:1J95T2:"25
M?L'SM<XB?VD_G=@S!9)?\P690^J).%Z&(<%HB*5PKRNW@=I*RL7G>7GTXW'&
M^!O)%\AFWJ#D51T'J%R3YY=0ZRHW17Q^X!:SO&CT=%YL91*\OJ9Y.('ORO'A
M=F[D^O0#"E=Y$**5_T:6>*_*D]3KB$4787 1_%M/ILES?[7^M& %DB>.BRXF
M>MQM0^8)3QPPQY%1#?MZ8L*&D;V=S8#TV[[L/FRV;*LB<9X.,%17+GO-?W79
MS#(Y=V&,T!A!1.1*O(5(X>(SAA6Y'\4J?-N:S_F/]L_M7*Y#5TZNW*;[VY'1
M<V;Z[UY&C+D?X'BP].$ITI4.NH#^ZTP7QP^@9ZF]$M'+;-FSCK^0[/2L6WHE
MS%B0#XUX.XF/>--SON_-K%SE:M,CZV$RV7G\R5S"0!S+>5W"0(T"]AU+K)C?
M?NYT?.JDEFIC-7<@J8Q>_5!MO:% ?;7_+*K=W +%(&/>(98DRC:73D7@PWB.
M#3DV3$DXFT@\1M4!L%TKJ@??'LJNE&J6"SS)U_>67I3DDS?!V!HIN+.%O5XG
M@(QKZQ 7:)^$Z9\APV(,'^2W?IFS6H@JJDH;/3;C(YXF_^]PCGTZW08V:0T_
MM+< -]0W>ZAK:^*'#0<:>=!C;>BQJ2MS?<#+"NB)2+'=AJS(6&455#W>NP4L
M@.[)J] (](,O.QU1#\&E+.Z& ]9'KTRIRHKSG<GJQDXW-U.ND.FSI)K$K.',
MXVM&!HJ"RA[R#0B,,5F^="*]NE3]FPMK&8*NU#>]3;,#'.O)K4,$.61K:L54
MF<%<$_';5TDB>V]3R5N__X"=D#_NDER%CVU%5]6E':TW@WVU8, XGQVN?"2.
M6C116 Z .R_0\LC.Y@J(N_#-V^S$V3.>*@0NX.RP8*)A!OP'L"U9XB-[*47\
M5A('.PL<H@!"Z?CLQ7K3QF9WK$D^+[,JK4T)?W'X,FE0( K-Z;&6SB1/.:Y*
M7I+)MD=71]MZ=+P%Y,0/484'BKD.R%Q"(\^&GX *Z^V!>[,&+-4MBF0$]"G'
MQ9SRW Q28!^#$/^0NT<7G[_8;!CS6N]KY3/_ 42*C&-,/[5X'9:<:D#!OV!R
MS38?HKB1]/VTTE1V@1P$3'$*)Q R])#(NL000L8YJR4>D?;0'Y9^W>$!#_>>
M?V3FFFQ(XUN6#IC:U;>RY-B@O_@H=?\!COKC*A,#@_"5H&RT87"1ETK8FD0K
M/]J-*;X%E#KM3Z42SC\7XRMI6 PW(X<M>_\!GK2 6/LC&&'%/$A6U%ZW$\N-
M1[XZ@=HW/7$4<K;' PP.R;R *MG5YV<#13J)(N"0[!6D:S>5"Y*6E-!MSLM9
M1_"0(EQ]8&@](73$E#G9VOJOC:I,K PN3UWS%-$24!6$K=N-O>&0I:PBF"-A
M*_Z)C=X)GA,747%=ZS<1F".HYERY)(%@G]:;ZU\D2C+$!%XIQD+\%4%,='=)
M<'0%QOLLL8NS.U+-Q1MN,=F#43J @LZ/D<; Z+A%\Z2%:QG1=\W!HSY04,'2
MI5HO4##)AV]3#%TG'*T'7BF8J71!+\F1CWLE$;B5ESN*[@ORA,X4]],<KWIW
M<#%$$I?T\W/H;"(_Z.I_;Y5GEL&/2ZQU*T+C&!PV>#X5/1LK3L'#0) >&QFL
M[)]?!BJ8F,3M!6@$@YH="(LC@PQ9/TVCK1L&3)K77<M<=$CKWA,0FKXDJ3 C
MJ3Q]-6CB-66 9L).ZF3ZDC:1)6&*QTT^Y&0BFV\DD(XA_EV">WL[8N?;D6)+
M SMCEYOH*WH3L'5$FPYJIE*@Z2'X^88*$IWA:@]!($E\]K)RJK*E42OYB)1=
MISZS! WWP(>DCB"GPV57WE7E(@TZDI2*XJR H&]=BY)47X<D!O>R*I9\ G(\
M'9F]5M@>C'>DZ96'-)WE4F DZOG%XNTP6A)O]:WURPE ;+RER_R>W;QM!RI3
M=%6?@I;DK=WN-["QI!X@^S#H)$@"]@^ ?3$K=Z=JK<:WJ5X3"8>KYZ,(XZC.
M.P?RL*E<C[)\V2;TS[9+:<;&"GYWQ6VN&W)@*6Z7W99>TY+X-]$.[,W?>;RT
M'YOP6GU*+_G]SE1^76_J9F=7,':E:JZT6I?_2#%0V*3+H)QI)"[IK8KED$\W
M3)=/]R0JMN>\T5 1AUNQ6B-HM&;0$4.:M&!Y]<J]XE<<7M^5EE9HJZ"GX[>Z
MK3?MP[S'^A]J]-*NQ9Q%JF->XD*H2=*J!2:J-J=&F>256>&=6, #8'[VF5#F
M_KJ7]AU!8<?3:U(O<:01E?8(I=Y)TS47O&MDK\^15>2)R\_MCTGB.?GVMGWI
M6QW@2SQN9LJI.)V";N6_01__VEQV()W@-,?GS..G4QX8%B?Y[XH+H%6M&?+-
M1>H;*<X#5D6"1,A(##LL9=/Z%C6,I"8DFTR6&N/OZ[6L0->6;FR3P$CHBWP#
M4SU]HQ'334B:K\QL'*XDAYTY?J[]UO.L3(B2^#] _"/QA+1!]^K( 8:I69II
M/%4E5897.?8H?TFY=@+SP!AQZ<R^9GF!]+O;-C*T@#K6N!QLV&#8N1H2[0Y/
M:GYBX1^ <>C+^<KG\UV>S_";CL00Y&+ Y<8'/??KD<$_G/Q4'T9PTL(576](
M9*""O^P-AUW[?,%$X6SV3\581@3QWD?CZXTU@SD)@Z3O3[QV-]:/2W9I16V\
M&..6C$T75BS?<.8G0F;D9%S+D4Q%18O*2<#DC.^%T<$P8E;G#3MQ"'J6UV9L
MT(+#S,D:,KSJA0"<,2G\V,BX#FT4*5I7>EA2[%X_-SQLCT*HTU8XL%3],(\%
M^P#B"7SIM>6SR8N9P@(NE1%-A0_K-2EH=M"K;?T.M4MU73-;=[=[_JK0Q>:9
M\XIMKX_.[H<'C<^$?%]C(E?L\;<$M6^T$C+LP"AEP2_390Q\]^E0-V("BY]J
MO-T^ZK_C*DGW%:H99SL<BPO2.AN/7K>N;JX52!]X"G<47QY;<'W'=5G_RO<>
M M(=&9;^2A,'QWTD)'V T:&C8=$M4T]DGW&/C6A'.&74[_M'+WT94PW?U10?
M*J"QH$U7-"OR+K>%]4"$Z C%)<6'-EP(MRVX+SI'CQY2/ //&)?O>/+VD;['
MGSFV:D9XL*4#%62^Z48W \*>MYZ)Q"Z??%OL;NJ\QBR,MWT_O,NR0LLG=$3Q
M^U[_85=9/S52R%M2 Q41: _IHH&"4O?N,&)AZW)^=UZ5VN,TEXVG/!%_FE](
MV5KT"IK)>&R(J^L@\U^D.@)\[B@VEQ49OVY7"&.LZY542PK,2.8 E.!6M5UU
M^P^'=1A56=G.W OLV@NGZNWQ[]@:VT@8E=NKY?+?)# ,1Y\=#$6M?-YW&;3#
MN=-9MO?JY1GIM@R61!W=)5RXPZQK5TR!22,V5-95'(4]N#2<:K11,UAYD@*\
M,1]@7O%Y)>^';'PS%T(P0W/0!H,_T(TE)4#W[Y-MM$$C_P#.FG%#O-N%<886
MTG&%;[P!N<]\L*\3,H/%]>@@[1V4/[98VMN,#G$L6T+>4&,Z'7:)DE"M*14B
M&I5D6WJ?-W73VB_2(J->XY^5??#CCJNOO;C[&V_YD=IMIDGUKI6.6=1.WY%0
ML.N.H@*[*LB,+MNV\FB-]EM,#'QX<RM>AYN9@%HO"2=_1C9.?R0EE676?T<2
M0_U%;W! 9V!TL9/_5&P)_+_R3]UT\)]YM-1AYC.QPL%-:B#?[7\ FKO'JYVO
M%6>7GNM%GE[*F4]EXD83D.:8\E:&MC,.]A^U;JT/*KH*[.[_ #F:TTR2G0L2
MCI=CPG:4/<K*<A3,?X,-;(805OIK'WX=E3T),L9Q6^FXS5.LM-K[$H]VC#?8
MVZZ9FJ%^Z]6F=R$H'.8)#^C++TIN,N8>"EW_4)P!E:5IJP?XV@(:A>AQM1V'
M\498EA5RO#OM!@ [GY)<*D+;0>4/9;>-@'N8JX4'G8]TFI_MK#>+\]O$%3_N
MAOBX8__PIJM$/UI.=;GP7$.V)[77Q=][Y+@%*%2*N-0J(\D*/!K'TPX:!*?,
M)+FS.P+NFZQQ6:YW*I.KMEM(9_^_O48/\]<Z%/ZROGA[X(*4MU=RWB5>#8BD
MA*+FTX-8[1P(*)[E'Q_]_:<GXA@FJU48?N(&GQC;#A]5MJ1Z4D!B'*H:,C9)
M+Y73-HF"<2_8S"/@41?ZN-81O[]VTW-#@YP>[RHX;E;%U^5N5 EMQY%IXR_K
MSH\-2/5]X<;%SD)]X7W:L8(/11I$+$$V/RVOJ](">-.KS4=8Z%()= Q24 .V
M-[QG1"-28TRR=J6D7H=K"1.JO8W/HD$BC'GN!$7B2R'P_;]Q/N)*H.RM<\4]
M%/:5I]_9E.14]]T [_PU357+MZ*;<$R1JF4X0SFW(%QA.#%+';:04[D2$.*#
MG? DD95Y>7)F1FT=)*QS51&X+XJNJ>B1D_W-L46B&>P?B69']WQ*2.<Z(09<
MW1Q=.5NMR'SRV[.&-:SPN;'W].2S7=7 (545I,<N2A)#>T_Y& ,;Q#-^2]SW
MRH,'W"A'#^WOU!L?FV#P_%:^2\%DB5_4UGMSN/H!XDHXNIV2!-(]/C11@,L3
MD_9)J*Q#8<50\>M6$U_>.=%.&/J"J'0(A++C*[.EO0L;#[ 32U"))C%+D17C
M#CL6FXF@,#VF;T!^2N124'KZE7S"55Q 4L./[$JZL!4'114A/.(1M[>RL4I;
MUQ%SX863C'%2&S!_UY/]#2D),P]+WCVVPJQUTY]%T[:6-3RE&$1_HG[0TT.+
MPX!Y281K0E  9I9TP'G"8Q UFM?,*1?5<F;&'=TW/*I>[0#8N(P@-]C\%1N[
MM#&DAQK*%)*C1E48AHH_^CK!&"+25NFULIRS'93(Y<)X37QX[WLPPR63LM60
M,F6_YIKT-&VGW"'+1N!?A%]<"$"QJE'!&!^+0B *R5++1[3B!H)?$S6<QD_B
M!VR4A\YQ3W7TRIKN%Z5C)HTQV7IFBNPAE(GS\2"NFI7@)+>DG >>!(+=@*#(
MSDG-&_?O Y@-OND\99PMD4*R*3O23&'A9(\_ROUO+[N R+BZRYY.Y^AHPOKN
M6 3]TK7+/;G^B=V"W^'$04,"C42UIN.P!C4?1LS%AC>7W?9Y$"N*ZA\@CO'W
M<RBR(N!3YNE-LX;*AZ6> =[O*ST16[F!XFY,M$NXM'_ PNPLL;A@'\8[@.NH
MN4_DDHE_[Z'A;HQ#PO(C3CW<F,\@GJU@YM (^A(JTPU4Z#:A"^P^F^JD(Y*Z
MED\-$@0(\_7='/=(./]UDC8=IB#$:%)YI\!NTX+L-$'I*P\SE?8&A8ZBE*C0
M-BN\Q9NOA0]A.FM?G%0<E4]EP\2$?PA<1M'K(W>TH H\[6(-\"F\3!20*8CE
M<O!F('<_8>(<F_Q3^^.B]%W@16]*[%\;SA3P._:7!HAUC@L4360\!LR?( AF
M.T\M\[B_>A70K$V\H7<H:*+[G$STM_]S=2I>>=_41(C#R>FRHM'R!!"I#)]E
M,S"7] A_:BG'#]8WBNY%TN$<4(VOWMU]1@2,W6$W9@\EM>9VPH\+<L9]^%X^
MJ]:=A:AO4D,)A"![T1 **K"T%-O+E[A[V?Q]9Y/6SM3_<R5/)B9"4W-M:;M<
M\#B]]([@;>UV,PK4*[6A5QX<%Q<59X ?WC1M)LQV3@O?0C9 AB!*^/4=CQ.^
M\"+8C+N!C8]-?E]MN<\/L:3M^U#^M]];BG"5&_E<BO6>QG3TTCZOK55GOOTT
M;9369*<U\H*=QND=24'49&9D1T;./8<R"(ZUY>J4:<0-,5]=5%_GQ4I2@RK?
M&DA!^US\A[W9J%P?$A[#722I;K,GI.;/=A]_!@FHBGT\^HW-]4+/! -K4NSC
M2@?MC_Y0AO[K!L Y6GXG?54CS@4X%!IK["%^J]L?.B!QF-5B;F:Q1?*^ZJB7
MOLV$^%[F'V"3&XLGMZAM97C/6.LW34EQOK(P":;\<X*'D'7[LMF\2E5?H)PZ
M,IP<F-WT8,UZ6T2>.'P[E_._[^G" 4SQ \:\;JD9$F?=96)1-'3WV/GQISA3
M.JQ]ORH?'/*O8!94, :*3HT558\T<DU"AJ]"('&)KZ7,%,(L8?\5U7P:L@ @
M7>DZ%8WD$0M/2KYW2?=  :*YIPQM-$'9!SYB N+3LU#_M$9WXR!V]?1'>EE^
M@K[1;M>>##GJ(\>FD(P#@&/GY2!)O/]FK]YN! IM<OOXQP11+@ROM@V(=5]^
MN\3#0Y:M>!__5=-*Y>'?1L\3J7_$DQ*7P[]S4U=\)%'\!Z"_X[X_:^^P[QV<
MB>*9Z@H2U%DG7DB5SJGI2P"&>(.7@9^\8\7N 4R79S?H"C6 9U^#M=%C_SKS
M@U+>[_=_O9_%C\P&22WCM-JF*$$@,B7W;" Z7(PE2V';]=@-( Y3-PUB=24X
M:8"]$)'3,NZNY"T5&)+A)S8H;#88&$37RM.2P@@A/AH9!)!.T(94E)D\23B<
M; MJ_W*<^'E"A9PH-4Y:/OD'L)R=%W?8$8K,SY7 B'H)SL#1C6Z;$F+*DJC<
MOO/#B T13YC#/!C$V<^K,B14-T]W U09<N9U0[.C#4@*UI6_[77;N]9CZ\<M
MBF<ZWA&?W5Z^N&N.N2$=(D=;\/XT-CTG99? \/P##T<F-H?= 9^X!R-6$-VZ
M\4&2X.+2_230BNN7-BFU,\9ZX5#S\VW@;+Q-_GN+<C47Z66H5=,B=NCN4IL.
M' >$\M[*"A)'/F4XC.C-+55[)_ [U"DTT3I[6%93Z7@Z(1LV(0NXEZCXK>UE
M?T(@68@2QD77CBQ,\G):]P=:5GDA[]$16:-Q'JME?BJ_-EL/G$Q\58(RZ!]
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M*M/1?DK45/80QR^SMS1YO?I8BEDV2 K-3$TE7=K=X6FH'H.0&3KO(OJP*V6
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M(V.ENS=NI4J\XF;0RC9]*^_@5$1R1;^;9H 1-X@D ?.;YJ&RLW!@H%EJL@C
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MP0MRVB.6-U+=TH*'E>W+92=A:D(]SLIT=(4 I<3-2Y]=A,-_@/JKDX1O*O\
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ML9DP3#5)$8='-;NA>[Z[X0 (,%1AS(\^K4Y'F)7] 'D2!.A)]ODEL?:#$YD
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MN=*?:;.K6U+0+YD@;TZSYL1!-^>!-@R\?]+,7YY8M/YBHK&G6\V8M,NR!](
M.0^("$DF[!@:F.)$9-HHJ">1%G6'H@Y3T<U^$P9-YE3;!U^^\8G".ZSG_0?0
M"U2D-_+Q=GYUP>#ZVSN FB!?\[-&^Q_  O!!.32\UZ&E)93$_T$[B/>S'U@
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MC0U9!&G(V?H\])+N59'^/X&6L.8]P-[,+#DK<HQ<S5 MJ_;U* 55)'78Y)'
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M%AET=[Y^LZST8\F 6&'UA\K6!=5L1>;F#$/C&MT=NU7^ 4BK!"M<D_<FP?\
M?@TH^!@=9%/U3B9BO YV'8)DN/4_#K'KFJ:Q2?&[".ZAN@J9?^E]@]QQE>/
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M[V7G+N+PR1UL(?1I+]>@UY> YQ/0FM_4@O&4LMQAU-DMSNC!47/.O-Q!S3^
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MP)TYI_2PTG-8YX\WJE:8N E#& 6S:&0+U%2'Z&NTD(+8^,2,#3!9U&3HZ2L
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M]'^VCB2<?TP_E(\G',2D5M0;5W!Q9%;<'/C^!+F65F(G$+0C'P5\WS^0:,S
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MCGU15_E'=TH5.KDC7V/SN@UPP\4620(K2*.I2H&<7@'XGPQR;!BJ(($\;#$
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MM7X[*TO(C_A:S<4*7ON0QU-G>^\))ZBL% IZFUC7SK'!@N@F;;(H9G^['=$
MA8$_9'YU_,@@Y#DW;W%R&8G_\DMW*:\K:R!A\EIH\*(>2B:%'&P),TJKK/!P
MK_5?\K/4_^"AG[3-WW[1GREZS3 _<LSUW.!@B?K(5"83HKI8A#"1GE@TJ2R<
M*"6A^XMR.*&T^:.MPSP>\/P3+F21VUN%T@,BV7;"Q&K/?%+_799NV&V#86PL
M[HK3_99*6-<%X1:OCRI<)NY6A:LD@^&N8/V4SC^%F<'!C$HTZ0FR&B^B8FDH
M&8/8<49C@#W$L@\>-^]0F'(C]DDH2%B?++7!_,L/:^^#EO^0?*+.TD)@;'$4
M(#.,HA#Y0P\'0$TN120^]T_W6I)Y># "1C[,3[_X1-;%I8;?A1=PEK@BJ:D)
MWPD?)>?(O[X0?;S\UOJ*>>)_^W06US)[L>PD6/VM*R>G NR!&O5,Y/,1>^9/
MS!,]8CC8-:\:^94D,$>,#(K9L>VI.__P[-^98KS!;_3FD(7[F D,(9(@A/>^
MR9.'>A/]N8#X8_"+!(V*3GR3M#7*8S%1L]JN2?,W9G!:+T;]N:1V^15ZPG/0
MD9WA3P\JUJ<1LM;06=3;L&"XVZ]F0%E3'R=7:E[NVT9FO"TI@ZI(^!..*^@1
MFIR7]QZF^H:R@TA1JU-VR968#Z9L!<>9Z KWW6LA&GFX!Z 4;+!W HK<C@R9
MN^<IQ&6"=Q+&4:4ZOV0>/)S8IR23,6"G[7WARW#8B%U(H7CD=I#[M4#0J?U)
M_5P;IG;=Q$+*.X&?8@)3O9/$J1%Z*=6_83^/I<,=;!7$HW=AQ8-G&VQ5S54]
MWBV9VR6<E%[49*%_<I!XLZHK&VJPIR$<_\5V!R2<(%!*WY' 6OKV5OR&H:[I
M%(/RM>\8<<*N9/=)1M2XE.?O8I_(FH=[<A$&O-!<J@3H5M'QJRY:U<A<0>=
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M-3R9*X4/!-1*'+X2"D Z-'@'B/QVZWV4P_98]_]^,7<)KQ"T(O0Y"PY_Y1U
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MHK^TU?"@ HC^5V>W=E/+SFA$]>SM"G]C0&'DAPW$S4O%<_(*_E0YF']_0,A
MHD3N+GX\[2LQ/ <1C/"@@$S97'K6H\J?7>MEU733*>H8Q9)494WY#4<HWN\
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MU'7Q$)B%Y+CN:\F&A_R$8W*'/J>'_!(2$J#O';>X"2Z!8TS-?P>PPGT R>,
MC\K+2Q>C8F.T:$2XO=-76E,6G9W+>L%S).7E-)U?%;J[/V&U1+=/'08!N+F
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M9 5OH.:I:/PM]-?S@^U8B7]O^^' N'73@$!)PA,I:1=F"&@[;3]!!3'.FRP
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MK-VNO9M'0X_,19J;/AMU=>_,E,/8D/JZ0?QT4!7VC+4-DX>%&HBF]XY[FZ3
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M0^*DS4>K^.6I$'%&_V\)+.^X:Y^I(Z<5(';R>NH_99[@UL6HWZ^,+5,>JQR
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MH-PK(SP#[;LOW-"W0A?)5@1:")PB9LT(13M</!>T)*@#@I2E+](5KEZJ?0(
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M;22YL?8=\E_<0OE?5G<WO"[(DN$]8P?]:UA_A$"W .3DD7['S45#:?:1CI&
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M[-..[3)=$8$Q/ET6N=$7Z/3P@Y+0"JCX+SY-(NA=,C$Q7GV'[EIUKF_I_U-
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M-"ADT60*-/"<.I[]^L=I(LWTT%J8(15K;)IB^W"_<P=FB70A;G=*1<BR2,B
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MJW,F:*CTI@P^'4.2^.0#.L$A%3BN=-'M"+WO4[QUG2YN3A>-:(^R 2JW&Z'
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MFRKK<K"+F_8:Q%(U%RT=[M*!NKIGXP1,'Y7;#SWX7[R]95!<4;0UV D)42!
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MH@+^N(VN7EMX;O<0&Y9G:GM$+-!(N7-M9UB[<RS[?)Y1@E=.^70TD;'F]_K
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M/;&*ME&D9_'4/WB=\#5!ZGM',SOIF0E[= SS&HJY;;?0)(YP6DG7L)9R6SF
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M/!!2(,_$J)GT.23+&K9^H?-BR#S 0R-TC;>I.^E3'V+MZ((\**.C)9>6E$;
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M\!\"%T98W@/\=W=5[P$YR_> Y9F/-V-GW/^0_';BO_\:8+5D2(R% &D#V3U
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MT93R\B3M:*&K\2:[(GVC8H9<^<BLVT/^[8][@!7/(.Y+P*GY!.X[O;<,BY4
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M2%KI;,_8',PVS&E&8A%($1O2SP\!EO%)P+T+>8?I&6<N TR25J@(G@X!=?2
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MGRUJW@U>W*ORI=@Q0Q,W@U:9\)LOWB;RKVM%SG<V^$1N1*Z\LJO;YZZ3S\B
MI<#_B?0$2A@ICK0R9SUOOZGP$P%7!SPX*!D(A$SE@=^X3Y+1YI^R<Y&:#YXN
M_3W:-0NWI)W,KB)N8C66OW]H_5?V.1G,8OBI/0 SA#,"F66!2V(^O\K.5)'W
M>B+/8KY )P<B9 -]F:7D.WUP!&K%TJWK])=G;$MUA,\AAR%_GV%)58^APG&R
M% A:N.)H>#/E7"A9@R:[,:6#N3ZJWIS<;1'B.3EI&9%K SQX5.[Z*D<#H\OV
M?;<M25@P<J(MN_,A0S4O]?$CRW&7;13*J""7&T7M_,.VQNM<;$'.7;[4<1PW
MLO4/MQ3%CNZ,R&\G^JG5AZP['F5N_I.E\B%6LZO\1=#9#RTVVO5*ICH[6@.^
MODM0B#M_S>LKCY\]*W(XYZ,$4A9E=BLVKEVC3MI(EP:F!,_VK8MB@D)3BGM(
MN9K//OFI)6\ IE[=DO=:G)G VHTM;#7HH82T=B&V^$9=Q7!SA\Q9/OD)4Q'I
M)*Q?L8 R+\>N[.>@Q>,9S\HH UW'>E9F$@%H5]<Z>0ABA.H#'WX1>3U(P1 <
M1_*C+_U^OM:D[EL9-$A-*)RMH/*_?FK\+G#^1B>D )\^:A%)T#3] 9C%Q!/:
MXA$/IC3D)A3L_1"=B=Z%C(<'TE3 V(R@[8%.9EP;PE'J5$*+V[R_83WX@O/B
M8R# ,\5J4&7(\_KV G=+2_GH]4<Y2GSZ50$P7?%B_K$SOGW4>KI?L/SQKO6_
M5VW_=6/P_&BBM\]/UYFT&51()D)_!.EN,I]IVKW'J@*%0^HOI()H?-?I7Z#0
MG+X,?LL;MR5QCY.>Y-T/LRXFEB32/Z,^M+KZ*/V@??Z=G^0XP"?ME%B] FIJ
ME&Z3W-059#)<EULMV0NC]'YJ*32I']MJ#E7O8D+WQ!+ZT%MY$+H'$&#@&6?'
MI+2;:HETZ?*3N_0#TKXW*"LI+"8),673KYQZR^Z;WV/ +ZQ1,OCYYMSJ <W&
M<(]O_9+CN#:J832$BO.C[!@-?3)/$G[LA_F[3:&ALY(NKG#^ZXZU+'355Z?.
ML?:'? 18"EN4 1M1K\(-1+U_^/2T0>#WM4\?27US!1R'&PAHC=R)MWJV>^9]
M,%"MV[)K0?7\3=2RB)(9.$C/./BGO%_8Q37WN<_8AG!9W?3%$HVSL=<YWMH>
ME9?[K88\E+V;GY)[(K;VM.2<J/8!%VO?88D%-G3+OX!'O94+LE^Y1A$DM'AM
M='T+Z?HXO,2JR_#B5I@4RRQ0K!S8 V4+N6<-??R&\\5RZ"DZ2\4F]\!BF>%X
M\BE**YH4E0*MZGP29S5!>ZDE/G*$3U:2/;B!#^%"%U$\P,&IA#G[E?:HA:3/
MZUF>4081"5-Y8W @7Q<]^U=TU80)"\[#&@9^LO\DUL\(2"0WJ0:*)XA-20T5
M#RA+H!D WL=6H./MWP_/&YS>N^ASZ0?_O,=D:1B*9,#6<WPZ102CO1N:IWY^
MQM*>U"1VM481X*GW]Y=GV75OA,G6U$ (O&_FTK# _#54GRU17N=QI9A@H(/P
M4=A^7:IKYS'&!Z>X/9*F/BEEP<P1^Q1QE3PCXF8A^:)\_< >O)&2NF2>PTT6
ML@G]Q[RHR+B>R2I!PZ1K7"V(;[7GD4MU50>+T&DI+!TB8-(X*;-F$KLX6SXT
MJUM $W8./D3_.@K=7TA?.U&NJ556;K"JD@M29?K7FN:O[+0OWR9%9XQ/X!WC
MZU)HL)CD+R=BGGY0$WQ#G2'8=[Y>UIFII="P-A2WVV2TZ<-E,['-*[;-;M+Y
M^4 A$:YX",K>U^DOZ"5D#VO$L^WWSN9%=L!PCNC1BNM@W22&^8X[;22/GXKR
M\W"W7FIYJ[ZC>45 2<3%(\\B'HA+9P[G1)V4WA$/Q7YH44.+G<N:+*QJ;&:9
M82,>',6C/U5NTDH+E)Z4E!L95N\B$9@(9Q>TK',=(:UBI.7N#R=C?XC]LM!7
MO -<;Q!>_>K5R0?@N'2/6WUNA;33\>I7K!G)'%@][/V'S1C_-O?UI*S">]W0
M#2Y5_+/4$?CO-L<_;$L +]59^(D$Y!--V*B'E(\*L6P*N)O/R9GZ?=XCY>Z8
M9\?H96[%=@E\;9Y%$DK;)@:BJ7\>&G2]8E>S#24]AVBD;?CMB0TWC:J@.$O\
MUU-:\N@SOJ)^FHV\8ZBF(L05KDS[Q8(OR^94V T7;0D$OU.?#&Q2/IP\% WE
M?/:6MTR I?_U/;M;L- 17R7R_L]ZK_^?";;"*WS!"2%O%%!7$/NC0$P\#0&)
M[N/$)'U;FDAV^O;@_II9A2_^K.9%L>;*0HHLY$GI\Q'<J^<F+W>4910OW;M<
MU.9ZTNVKQ^!EQMBB6=0NV] \V\L\O1,9OGMQAP6QS=.M7[9 GJZX]<"_YE5Y
M;LC+WG-TEY1W;[QB?[T/*9](H \P]I2WG21'CV%)E-3,A'H9#Q4UOY7KHVC9
M69H8GR1(ZK*[*Q+4G4?SH@HHI*4:YH"P\I4X  W;7QW].WPUP#Y?_H671>#Y
M<KV[#MU706Q2AHK+1U86S)&24Z/-FE53(LN>-8IR4+A>HTI/0$>.S!09C3"&
M#44+80*@JL/"KUUH)@F%>^JY\)Q]_^&E/L-4J'0ZTR1B9ZV[]<C6XG.?/\\5
MV7)R@'^*-3S5:8VFH\^5I)+(@';HZ10^6& CYF,MC"3@23=6LE*?N+]GE).X
M' 73#/D4,H%Y:M$HC#VG(87+%XBFU\T=VB+LI61FU;<5EFT0C%&K.'MF*!A[
M<?SQ/@],S7NVR^*UFOF'25!"(6Q2G2*&BU;E%_@F_O1CMA;?DT,%H6^&V$??
M0_6U,I;M4G7CW5X!T7TY9K==EM1;689.QD66_:ON[J%,VM VCZ;B=EBP-E,[
M6!V/7+(,K\]6]&U5<./FO94)G"4OU@",=]>/8F! WGW''+3*#!G\>DE+,T_2
M*FLQ"N]C-O)">@"Y<MLK)"(JQ.OY$+ZEK07_6K:'1.HQ3QA?,8EV:*%'38E;
MP_L>-D'"2]H/ED&Q:.D&Y>(A-)<GZ-V*G5[BD4[.MAZQA1>8-0>")%M/N6O3
MW<D'H7X,+H4M)O)MI639\[;S*6!C6T<P>^OF-:/4;QP0;LC#GR902]N9 Y^9
M+S7]P4AGJF;<P&Z7X TU_TXK>-4FT)[!EYOCV7GPI%BT78KY6^.:I56Q0WCV
M&2$)@95K?3<%/,I)J8ZTKG7GR0=Q3^#6N(QJH\Y/_5B4!.JB4:-PT84C?2/9
M"8\>N+"ER%',?H#VCC\I]V6YX-NF2YG9 L+JIW3^*E.2HQC#04TC'0VLC1:E
M:^_\ F&D_GN>V":T4.PTW1"Q..#+6_B/;WZ[P]#/C7>W1=M6<C@5RA;3))HR
M31^9MLE5RRW7_J]W1__W&K8ZGEIOMO(Z(O!.0X[J-X(<O'0_6WF/Q)PBJHIV
MP-;'I6EYD>: 6 A9*,"Y.O"!4F6O3Y6-JGRI*735O""_GW_QE> [W>%;LF$8
M\1^/?&X_XML4'M9].5%[HA]032UHHBF+40F6>&7,Q!^VGW5TTP+WEAE.06F^
M:5*P1V3FAK='JNO,Z#UAB0H<L2%750786*MI'AJ$O3_?=8GC^\>GZX =-NV<
M!K1-HP%F/!G#V]Q43.C=A/M2>&NF*XHV2L2'$>O2UX.$R8N#3&^?3:B>&RBB
M*@UERR^@"5X7&? P"ECEQOEVR&H7'MX5%FCP-%#\_:9H$#E*W.WM)MEWX:3(
MU.[6KH.09F(/4DM!PTOI#UMI/Z$5Y,NPV9F9:,Z,>5"=@)-9']+.L)4@.!0K
M:9YSB>^B)Y-5X#ULU8--LF,G'R7ZF7_8T&# UE$A L$N#PMKB'A(W/P]ZX),
M+#(O*&2T/1#7:J/%9TYYW9DT9W6H-0VVD\"VTXJ$A#+ITEAI_TD8)E?8Z(E*
M^Z]Z6>#5=V)"BLPS=] 8#-)\<ZU^77(CXGGI<'3C)2U+A2S<W?W5$&HY[%_>
M_[[CX!/X:%*2X6# "<@];>+'U&,=K$2V7F?!Z5MX"K#K#JNO/%X-1&Q20"Q=
MCI>T/O/T FGJ*BVDY/V2_.%*T<XZ0RF/!A"C$'UX#P22T*7NSLG(D7Y&*'D-
MV$S@-Q*P:& UQ:?V.T[9+41(J?>_9Q:(O@XZJ1O0<-(N&,YM99H=JI[>7GAU
M^67@F'>42=#[N&ZCUV_N'17!H"5NC*B@F1B_VHVIYA(8A=!I'@&8UL5V&\Y?
M_G6%.!K4(3,/C(S?6__:7O-%P:]!.*#4=OR1A[5?;2W@[<P046'K!4#)] <[
MK9%?F*N)<I<058*1LZ7/(<-76D5KC1;81?"J6$:AY)&?F)FYL?)'M<@<Z(HV
ME3Q9? L@4C&RQ;WV2TO%/GFR@U/:[JQ_<MFES.<JGI[M?_V[4_5_AU6=\^B5
M=(Q<BC=6+^):)=%IXH2.[J9YEDTICH;5.,3<8^5+O,"DW;D(#4'0G.Y4H3G
MI%/7-%3(4TK],^<?*CVR.R095WF6:U&<'J5^)ZS3C.7?:( HWKP7*K?"8R6)
M>^(VU$<+Q\O%),K)6!+KG:T]H7FM&(=L0PXBVFO8KYT%9SP;TF-OD)L [T/
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M5&P^%.PTGU>_%>7\VH\WN%#'M&9&(X]#5C!I4<GE,+A#!=M1T6X _RNZN&^
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MHN!R!46\XI5Q6!3"3+8F309FI%NZ)$W3)$W2 F+6-FV29FV;*EY7O HB.XJ
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MYOHG,2WU7:?:!^XW*QS:B<S0VYXJ#!$2S>?(%1IFK*O.:M%^,E4V[XW$6XM
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M74J3JF:C?F.+B8I4UK--'>OF!,;;7=SM'"@3^PFG:-J_#TSMF-J+:Z$H'U'
MND$3:U 4U&RQ9D2%7&Z#_#Q"2\D; :0TNZA'M-B=Z&;ZAR"^;GWVSZ&%,<O(
M5DB]#]<BU^>0.M9G )&!49<<G&\@W%W*J<<ZIKFX1,_++EK$KOT%H\//'LT/
M+T_P/QX 7A.[G"R/G-G(7T[Y&1:O2;[C&_*&YV:0$E5N?\IY$VY<?P@]K-<
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M@&]LE-(>31H2*=S*#;O@)JZ,5Q:FC>AZPUCCF#D*."+L=X1D7_J*/@-:< !
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ME+GMK6:HKR[ (D%DD-:52+)C!,CDXO[5SX?S(#H_/I,X'0ILFHW;7_YNJ#U
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MR7&D;N=JUE0=TPF;,#0D[%IDAY/M\F^![6;:^AV:A%FN>@^Y7$#!W?TZW=@
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MHO'L340[&6*AHY,]/8TXU4Y$N4.,WZL5WK;K\T@Q $,^ QJMI$KB5-L@J_5
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M]:J/I8NY Z$T/HV9:2M$:7!(/AK2+<C0=TV]VO6_+'W(S=R_ %!+ P04
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M.&)Q/A,@"@ZGH^!QQ!U.O\/A-MEB#C7I+=9R7GN3]MKK?G>H&G(X+#%>"#L
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M:*JNDQQ(::9R)1I6#3^*Y#01U4Q42VT@#O)&C-$YF8##[6CBH,X(@5#<#=@
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M&+I-(=5@N17H!34@JHR11R)<R8.)51>==;'%<)1S1-40F?A%NRV\P\.##G/
MB+6I2CK<M,)*-<K5@"B4]=G+4$G9\^#,!.<#4M23E7.JUF!8L0J84,;OHC-)
MH7O$,"XQ64X':CI0@<! V>T(>J&ZOPE&B81N2T<=-2@OF6BHO ?01!L%0=@!
M)X L _MAH*)D2_&TF;:KC):F"1EMACC"C&EAI@@XTD+=I&1I%+.@*@\'G#)0
M 8BP'Q+23#2AT=V :IA4*V&B7.0U"^,($@J<AQ >T]PL5J99,!1#"-3#52!G
MO(K7\DK,0?%^JN8A9*<1#N(%JU@KD.2>Y6N%  5(9BG))(E-)IM2<U4T"YD]
M3#[)4%X*CR"&\RHCBI6WUT7,B%*0A[#D:RS),A&,S#!*2C"1BBEE]T-XL^4<
MJA80AD [(P0;]6(R)$#V-$&6@F@C74]3"5X*,;D$V%TUQPA#1WD/SU.Y6I4F
MHS8I;ZA'8T_O7%:I59JY=#6@*"5KJ>+PIV4PQ"M\ /.Z+56;DT!1P17UT+$X
M))$<XZUSFC$?F9@+1"&<E4)(L-%(VK)BNESV9JM^N+55Y0HV7#]K1EU!S4R>
M#-8:Q4":SDO9LA)FXZP0<+I 5SP0-\I1IVY/1Z605$UR<8)RDT09P*IE7!5
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M017(1<@%V%5P%0RG$O,:%638\CL;X3]_"( $I,->L,I"!<AKBT-\+>$/,JU
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M"K>>+]L+,!921-%I#J0;S1@7#,!Q4]+45%")RN+Q6#"<*R)8PN*0N5)>(P,
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MA!0_J"9P%] ,R56CF,OF6KLBLB0A9!F%4G Y;.+@NJ88S@A&["X'%P\)"AU
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MPR=_^\*WTZYXIV>%&#;LM=X]SIGT][8C%XZ3TZ;3-W[[\*MG'=2Q?D#T\2G
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M8/,YG?)Z7-X2&%PV I-VB<X^Y]4/G[+O/ KI'\S&H@A.SSB%,YV$U=!*'?"
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MZTP9S:+5W9 >VD\,\YW1EME#CWXQ(+/<AJD53VF4NN50M8AX@5,0DTNRI.5
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MMV@+YRX\Q>F#[YARA#5Q1J>>RI,$M4&:1*LBW%V.4V(T+R&3L,L("E)9?$^
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M+R? 6Y< (B9!RR/#% Q4U12VB.S051@5!>N87%@DUC?J?&<P+T5E1UU$Y4Z
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M'F2-D^1W+=NON3W(C8I_&<X3:0.O0;7=W%SO5FF;T'_^&"EU@.Z!O"*^O84
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M5+\-L$@2<TSQL]&L7S?(7I27 A-S;3-DSC;C9GA0.D_)+3D\_-;"63S<@@G
M9%><.M0U=M2N,9P802V?VF4E=]M3E'JFBM%Y33\_F'RTW*GIZ.Z=G\9B'5W$
MQCLOY#/#GMU]W-,ZXSMW&/22M0L;25Z8"1RLGY6R:H#BN$]V!P:V@QN-$<X\
MG$K;%%T2*%5,*%A;!YMG1V!Y$W^B8&N1EY</]P[4?XL4/1KU[J==FI4W!EK(
MZN]C#?Y;%E')#$O*0RIFI2V(Q#40$ W(L8?AB%)H4@KST8D_A:CH -M<P#9>
M+7@[UT6-'J,!=@;WMPMKM';'M'Y9'M-WT<#;^$N7&=6%C@YK9W>#"3TC+"(Y
MF4!.;D4\+WKD=L3R2/YV/HC>_@+8.WRV5]4=X"&U-L<YO3406H$7G@-$4#E7
MW\CWX%8^>_UJ=J>87QJUUW-!(.;W.AMRW'GJM-45_T:PHV==0A#X.-3CK^;[
M"I7U"B5CQ[.Q!.1X5I]_V]#P%G-RX+%:PIIZ^EWF'[8.T[LI=;8*'P/0Z" <
MBPJKTH<L9LOL3$B=ZK_V%GX)#\B3 M[(&QIL^?5\%H*"CR3N$9[/6PO?%A.#
ME@D.V_M>;[[MKJ>8S3@-(>D'I1RVYUEMVCP[<R285>L%= 5@@8E3C'J"DOR>
M?28GP7(&,K*DK:L;GF7G1#M:E)2<Z#&$<:CW'''F/);(A'&*4P.>GPI^A93G
M?B"TL*O87X#@1:CUR\LI<C2T!W.QX/<,QF:?3VN\ PHZ04=9>&^WNV?1+53N
MZT6&"M?J9!C3Z;[VL5!G*?W[0@VTK#46@R5-G4]6GPY;<3N]\66267>#7%(8
M.':K)162H2(UGS&S/_Y>X<]+%>D=^GW>C2PZ)'@K;>^^M,(55;K\L+Z7+["A
M1[N?\316']WWF;BN&H?0"0[5J+FEY'1_%(T0\5KD88Z.R7O,O4CM$Y&: 3+!
MW!AB/64_O?+WI]WLEXBGW6>_J_.?6^@_4/%G[FK+9&##[)>)HDC*C6$HX=B-
M-1L#E,RQJ_T?Z2M!\GJ9L3WD@%!DN9G\7T]@<?[<OT+35]S$Y*1-TJ_QI']\
M('GLV4Z')U"Q0JY53.><\L9>',OQ+2<',:4E%<;Y*E@+"*0]I &ZAK7L :%U
M# =)M"S&F8E/.#KN(TNC8",S[;E49A1K5T(THKWCC]^#:GJ$?[WI^<CT#M]=
M@QC,@IB^WTS*-BD)-]),YD>Z6N;$/[[$="NDZN;&"<8GF,'+K_[H30W=Z(AJ
M<L ^4[[,NODTD02DD<>W24"?"),V/U'Y*JZJ3F3E__3X1E]O\J^Z,Y4=#3MO
M>\U5M&$Q!(^,][!T:,JO#;VW'L:NQ7;0D12K=E2$=4!N8>TLEBPI>@[EQ"=_
MC>TLWUNP/NVHG@(3XN_XL\:GQ//-36%*5H%3%1GKY49!#\:.*F8Q?*R7,1!6
MW/"1T)6W 5GAJK#C0%+D;YZ#P$PXB4"XV!FH!+54QND]#RPM _IIT=4KZ#]6
MQ!G4UP;]B.C_-3P9#;1LXNP]0DDNY7R&^C&%\_@.&(Y8G+>0@:/'U<:58]&#
MWV,D_1J2D29%U S5P%MZ]/1;@(:@L*!$!/C!/B8N7I0TSS:_?9G'KH'N&,E#
M\-/YJ@[T68(4AP9C+KU]O11FO8QE>&(1,*<F/[$[!,&J**HJ%V%U/XK@D!?7
MIKR:0 S)GCE=>86(-EO[X(;O5Y5;.;3VH1GI=_E%:C\=\JBXR\W##RUQ>9@&
MKO\I=[77LN+2839A6)GTJ3[@]>H<Y5=E=,K@-]4Q6ASKL6ZAHBO'WFP2PP3K
M27@I5%T:/$P,!S@O]'@9/H75INP$][E:J"#DJB6R&\>/SY7#_'N#'3YGYR""
MYA4/_T ,-R>!RY+T7*/*_7&F$O4<__T_=N;\HKO/&?F7^[+9FB8KGM"\#B2N
MUTT$23@5&(01KO4A1G8ME=GT2\H[U 3U+J<Y:0B/^KI>4PE@!^C5B?(!IBD!
M]G3<R$MS7@NB*FXWL1SM< ;6QIEQAUE,)52N@25M4[M0U$?\Q6.(3!DI(KK$
M,(GJ6N3CHP^Q8,/>42LD,>7Q2]!V$ VM5FL)B-C),)O0I.PDX?[0[V-_G9I8
M 1D;20X[&:+^*#5%% <Q26Q<?:*?("$F-0$Q-97TL>IWPF0"\S.7G-H/;V(7
M*V,6BV\DPG]U//UF(STU*PX];U,C;RWV-S6,7.</RVI/.4U[#C?-60Y./1<V
MANU:,@'M:G[GQYWD;7ENMYIR?R.BAH'1RMGQ#IB]3<O3>P=4:;E;L9[+&#Y!
M7LG)7-VENYP@LDOO@)7[PN)56?&LED] MZ&6XOD3)=OK9A#Z2T[7S]?0?BW^
MZV[\L.L!Y[UX?B$^+4F0"])@\&8<1WVO3;1D7I=S.6@082BWXLFA+S?2"98H
M^FGRUPP\JAAT,\F^9'?1!/\WF  BC/] YOYQ2((3I9<D(JRS[JR(25L0N%Y8
M'QXSR%\]:^@\IOP(D)+NE\5RJ+MH=JP#,=J/@>KG.65#+2DR,I3F7>.N:N*G
ML$_EY66'9/W2,%Y-;%)$!0GAMG->)%^068]L=62(_<BI$]I#W6?5IC2HI*D%
MUP1<A:5[QV+<X[Z1)*0_@LI- Q1:/KU]J156R4=L7LD1-Q?D?V4S1F<M"HK@
M16^CRCT%!14=! X>Y^(<2_KZ/#D^R@6(;K9/.V*C$-O_,;6[\5XV(2I0M[G<
M'E]'[_B,-]!U=Q4D]7GA4QH/3_,/\ ,QK MX/=7VP@/V"98E3RO\K%/+I_2
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M$"_P[9;.^/%Y&N.^S X5FQ*5>76_A>_A]Y:J(*B(-:#=%Y#T#3;A-=<<32
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MUN'NO47Q10Z()L/$JR#D \FQ4_X?KA*4_^8JH;^]T9A_DV/"VTP54QYK"T]
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MUKKB+N2<>AP?9&(ZU<J[1]T<]D?2&EM:G_E/7H4PV^86^2<8G6$P;^$]-T#
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M5NG%RV"=KN3G"11'?Z0$(10F^E_WV5Q/$5Q7>U3]7[=EAN=^R W=B*N&VO]
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M+ SV@6J\UE"?@XN.CH(@430J<"2&)]4QHK@%4[B19XY9M5]H:Y"K#/J=:HC
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ME= %?SVUPZ+O.78^;G#A3>0OOGX GG:$Y3\ X+U5H31]E-E;W,F YB@3N8R
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M(B5ZS^>K;X?OC"FHHFOHX_;!RV(&JXQ?K3-6.+:KG&0LDD&44%E4^<'M_H"
MM<C(R&BKNM=KOJ=/V^N7#*F+&,TJY7BWWYOJGNL%=A67"[::-2+X:G(!AF+
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M  6 @HZ*]M/K/'$PL;!QS][,AX&';&!&" !@GKTE#Q4-&Q\7"Q,+@'+^#C\
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M;>=>CN$;F[1D;DOA="L;KY\38KNU-<O?KQUZ!*UT]?";HYR9Q%QJ5P/?*A,
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M[:@%9HG=[#T1 WZ"$K;F  $;1C<K9>K2ZXVB"@Q#H=U<VMFB6=;S^]&AMK3
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MMN7R,=0B:4J^/2*42F8X0QHOD!R6<X>ML)F,'_<.*'WL$6.$/=]GUWU,Q;C
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M7$$/WT;LEPT:)FS*>GP5W!,J*H+L0V)=T^FV>NQ1UNQH+6(&W L?YO_9'E?
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M[#CC>G&@NE"(8I<@(4C8:=208Z;DD;Y'IE!.!(?Y8:%5WH@91\54T0!F!?$
M.7/#4Z/-XF!]FTY4CED],G)=_*) 5M$H8&(2<OH1OQX07G82?..72RDN][Y&
M'X(811X_W/1PX)U-?W#H/FX6?/+EA/%DK%-D$^4SX;%/+7!*^MVQ=YO[V9,#
MDE4+B@K;7]0Z@",ZE!69D2.C%*D8F::Y:\R40Y96X.F[3 ];VM1%X;.FNT,,
MP'"Z<#62$&'$=I$*F<:R>'YPZ?UR)?V-!F(%6&E!5N9C?= E"'J<T@+V\7;7
MXUI5'<>NS*[>9C%8TIIU=H;ER,IA@(_ X\&D9'TEP6KRO)IMLQKBEWB1P0ZA
M2>&T1/:XIMM9R9K8Z;LJZ*(=26V(X:G)'JDR9M 01(89I%F3*GZ+L6&.U8^3
MAGRV847IR5WR<+6&4D8"U/['=:HL2I$B.DX;:Q MC+=)+FK<1R-Q3L;FW6\O
MI5_FTGT MNK(EF<,(]LTC<' ]]X?F7EOW9 ^O.YA+B79KT(C6K3[%:ZBMFH@
MAV%AP/5(;,P\F-SYWE'Q!(0"QV#CH=ATUWC8K::%71&2O3OKXZ/BVRS8S\TP
M+-8OI:*4='R-G+^A^J3WV>HM_,S[+PLIT@=> E%\9^G,$"]5[[Z1#+#XY#4M
MEI?LG+VRMRKFZ/46GESB&\^M.A<[H5Y(8P&WR&@H8G:8)SAN*60"^(\.]J:O
MS)2L<DQ(YZR"!LK?.SCIC0MA-!K.9+7HJ=",^B'F\PP9G\=9Q"FKOO;OPFJZ
M7HI7,P'KL;8:6Z?MSZ7LP[_#M';]/7VMD>K)?:5!-'+I69130.5"HFI/JT@G
M_2_=5HF>&K>-T)9!"BXN?B;F(Y_-"!Z#V3S3@OVRFM@,7CQG,M]Z-=-WQ>G9
M-B\H+B-K1@>OD!WB,1F.. QPEOYLA*-46E4AN\9</B/TV5VOH%(/E-Y)*9(:
M%)8C-SG]\KG96"^Y*PO;K1:TW1"LH^V(49/->_6%2O/&.:,3F_V%YM Z"U/[
M9.4VN2MQXB\3(6D&'^*T[GG"1C6Y<N9G,2Q!U8J+#$'T(T#\+._;3T<-)WOD
M,ZH]1DH5DU@+[69UI%CL@IF$)$+8/K?0V$K>Z2^D%FEV"5[+RE\U;U@YY,VO
M-3^$>]PB.F&TVCS8X_9LRMFP#")2,A9E]5MD"E,S4Y6SU.W&(_1.N)V1$5&V
M\S!$O  ^ZG%T2;NM+3*RW,F.!S?;4?E^=8_"H9 ^>?>(8_%+&^+;F9XA'!B^
M6*@I]]E[)E<Z"D>'1@J52SF$BBAN1F6BYI?@5M:C\N7N/UCN4*EKC!/#BE_U
MR#2K7'-\_YEV[M@Y:62W"N\+A[,,12#DIKLEC3"S7HD[OIY? R?OYO9+].5K
M(<V+6&OXF\LJ0@M'CVZK.#\56746<QR9B&.U5FFJSZ:Q*>\9_%15L0>2KAID
MM &]]LUT+JV^9S4PNU/!#.:ZM\=ZYQ1P.5PO/)OL<\^>R"#'0[V].2J]H5-
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M[@[(_OD!J.I^'"P3>5O9_  ,N0Q$8Y97(/Z[$:':V9P;3S/+5N'_/W^0][P
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M<2%&EA8L,01"1>( J)'"WF'^^894(L)CN[P![]\)<M0/G=YAGBL_ &<^V!^
M-YX/P"CO"]D' &LFX#DJX .@56<*+Q 8MD)2O]NZ,BFQ%2UD7'T;\^:9=/3F
M%)=2?BTHZD0[]RAXP=A'\MI-%MS='=;]?2S4I#/K7"/;%X5T(\!H$^QU?P#V
M I@]OILMD2(TWWT C">1^FND1BZPK-=I'>7%6]W2$>-'(30 S9&V/45<G;)$
M0.$G=!,Z7X3Y)05<1,,1=/DR4RWO@^PI.3B('!!=;A NV^MA!QP@+*(<H+*5
MR8Q+O(> 9L!NVPZ29EOGUFUCR-W=QXH M\DH]NEL \DC$N$0(^1%OL' UE,Q
M4K6Q^U(QXIJ3OH_T! G+/3W1(FQF^ST1D_K](889)"/^ =BYO7^<_%'VI2Q(
M"@ + ,"( @   0\ ^GH@7(T'^GHWC_W@F]_PPYO<0<+S?RN?:-=>=G9V!#%M
MU]L^V:_C3(D&DDO&4V I!M)@(^*$T,NK8B/&F@#.*2F%M_D@"E@ZR;2[$#F1
M;17AWB7_X)UO"&1D:<#_#ESEOXG=F_8.F).0G:%CW23LF6\R7E+*6[HST^BX
M.4?GE+8(#R%G<#XGIQ4)_PM+3G61YAG_(C%TL<1KM,^ZPG?P^YPV4$3L[ .@
M"(!A L"_Q@%H'R$(P/>.G(=);W@L>X@U>1JF%.4O+#E*7,Y9<O^^B+A ]2^_
M,4P3<_\GU)@@2 [XW[[^&^_ ;#F1OGU1N'_.K_7-_Y=9'JG>*>8N!FO<SUVO
M=8U(:P<W4:^VZH2U"N2=#W0;8BK7\II\_CF7]CJ)99_^H+E+/T':1VS&=;5=
MV?;FNZ%E%WH5L*!,:S'A=&*?H$/[G#PNO:UOFW 6S%+584:/V"F[*>7^C$.U
ML*RO.Z;X/&=.I$BP>I=! #TPXY;[G_XEO7O,\N?BYNUYO?6N<T&'Z8?5XA.6
MR>6&U:T[_;KQF<</@&^KK>WJ>&1*LI<F#>NT8B9W&!X=9.&=JX(PHH,JF,UE
MP.2"PZ?@QC5:B,:M:J?2VB'] ^"JT[(^Z)M5D(!UY;-BI2J^='XTR)%A8?4K
MOHV[JZ5E9# >R9/:3M05$+5*))$NA06\C"Z?$ BQ.?ZM;AD;>J9MX[7[[,;N
MDK=W)L@&'X@!X$'E6Z6)DS&D;&L@U$_:X<"1L<'-3*[$3R*EAOP0M)VH' 32
M73#&_9F1J9KD+R6DG_@%O?(O&QJLU;9(LXV(\ M6F<$-Y[)G;V)4"NUFIC+%
M7UB(&(XX*B*1;' 2'-Z6Q1E;Y31 #<="\B!< ;UX"- =5_9?A#9DCR+$J+@B
MA; +VM"?H1ROW;#28]=:B$UDN%?-G^F!1TL9@8NFOPZG6NQ UCJ"\2W@'AUM
M%8V_CR99T>=7BI<=X21F8^C>UV3GT=Y6 V_E%>L_N$J([CK!M2?V"VA69E"%
MY6S-_%<.[-._SP<_:3HD!:,EI"")B"/F4676>U]C%,]4W<HF#VU[*VIA8$^B
M7'AP%^3C"96K5W?.6Q9QMV@WFZ2+#_'!VU&CK#_;R[2E4+N9_HS4Q0Z5HO0Z
M#P(1R%(F!<W=W';F#7^4$ZN68JOUNU)_ (B92Z@W=4"<;P=*H!-77&\W'*H[
M[)9E#W.AZW+BJ]F _E^AIOUM-&IS$>A118D())UZ;@[6NCYIS76Z<4RES]R+
MCW;BH!84TC*Y[%ZXC1X%K+_0>,CI^#+JP&E%4%E@Z9ZFRA[3V1J"[6_:6E @
MS@^%9-."W]1UBQIK9]KK#3L@AZH$CW-UAW!W(I)7HYF]\9LX"*(@>\AKP6Y,
M W<186F^_)>>.WK)[8(=#=4BUUU*QX']I@_ X=K]1@S:!T!?B;U6 RC$)V-C
MB'A/-2IC$C^AFKVL7C\.5"ZRT'04W;%O+BM-8M!/_IU5\8N D[_,P=[3 KC3
MI(!3-E>W4AKY=B*\52H!M*\3G\FE95_IAYNHU?,\PE#TY<'D'89#HF9T"=Q6
M=")AU#Z8/[0\$4Y0-]V]]S+H%L/O,VPQ.*SQL *(4C*)::%:"$Z,'FD'EYO'
M>Y+I6A"VDH3]P[SUN"@IE3,<Q=]>4D+O-3.]A0I(%BN@J;2TWD9-$IQ4N#NI
MG63C/Q,92A296E/YDL@Y,F3)++(MG5$,9$\,4QV=P7IR>(P;EYPYY K%?OV#
M_+;)D;2*%Z4)3F]B'-<H9ME1[VR_BS8 =^RBW^LEF,?\Z'PO/CJ3/Z.P"^Y2
M65MA8H,4)U?UHOEW$N^+CA,*6I&LSB8<"F'?,N9C_56;=Z=5G/R$W'1/V50E
M,'5J>:LJV"/Q"8ISPNKZVZ9/Z@74&LW^1?9I_HVF;KZ^;?V$.^/M- 6ZE%'Z
MG/S:GC67_)I'5<^]XNO!7&W&=PKF0/LA7^',$ )[<,D3S_[U/)O?LKZ(GVOD
M^BL+9=L,\C@K 1_T>^/NWCME-QH1JTV,L^_/QC1=W8;T >%, 6TFPL8$@6+%
MPIBCGU*MG<_&4VTV!4J;ZK,1W)R'9^DA>@KZAE"2+-[]>$NZ:="OU#+,'/[W
MT;YQ8E.IS[(->@I)#J+\^L:"W*QK]7RMQ%A20F462$)%-@LV+[N7I1ZJ'>R
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M7-P :4DVH34>.UM1;EO+DRIP9@"!NK-VLH68S-_OK878^>9BLEMX#>[2]5:
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M<W-UG&[3!\SUE8Y+)K 7<;8*7,+5\.LD01P!J17^P(_OL(D#F #8P/#PUT"
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M3(X8:_V(DKK&$H8^85'3,XH*_][X%M.@ %&1_+;#K9M);*Q1U+]!KK1W6XA
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M,U9P==+[#EO7/V0(55>KY9ICF$EL43HG0:=RW6B33/,/=>JN69YUJ]V@N;+
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MM16QHW,!)I&-T<L!\_J"KB^$@AXVTTOXW<K_^AM7=7'KIOG.?8?6IV;?K2K
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M<OWNY>M''W!.L]D9X9MQJ$@@C65;JRYIV4W)X&Z['ENR%J1$W3OD4(E =HJ
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M&5"N4]%F]R6D<W4GG!PG8\F\FE#G?3*,^2<GQ[!=/QL65A96TF.5%X"4>T
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M/$O&IY**S:O>^-5U.UAIYXN)6+,]L1!E0^82+J68]>U>GT,E7XETT7OE_+^
MW<"JKMSK1EK(C%V;Q"E'S'CGI,^0L;YU/9>J12!"N2E2U"95."$ZAD2I//:+
M'LYXJN#[!HPF0H2W6OB?+%Z74?U?H+:]X;E7BFUVW#=_(D6BV9$_2KG$Q528
MLV._[NI%Z[R,FF<ZGF3LQ2$ZN5GJT![&5K>)$&7)0?!20($? :-L-'.D()R!
M/,#M=.SXDNE[YY5&_<"69<PS=7-'[76G[S4&JDPJR?H?P%.UO1M$I/[,5HJ
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M5S+U6\@D)7MQKO.M;H.24,[ZW7%YWX2^;39O1HS'(9]L3H_=4R$>5DKXA 6
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MB01V0\#@G$.3SZH%!L3JM<HQNRQ1N0Y[HD,/+28@S0L2U+JSZPT5HBOBJD1
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M;,90^"(_QAJ\'" B(>ZU0&<.D1P!I PW=SDV%S=*2PIU\_CZ'!UJ8>:I238
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M[!/S4P-U/BIJA"Z.+RVR-AW=QLR"EZK_XMY3N2[':&QI7-,G>=!=;5(Z<<*
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M]6]<:5 N^R2>O%NJ8%]Y^W&5@D;9IZUC!6:M>Q9)K:;?XA DS9?/Z>E15K+
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M[RI8E?FX0&L%.@\ J\,_^*W?B,J&#3?>A$VFK>_60^J\YV'P]Z%V!!*<4K9
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MV;W(&RZU^ZRWP)JM0S8]!4\BIC=8X5^[GK 6_*&0#067CV]66-N1O>-LK'5
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M:81;$:J/OX:W,(C=V/ /-R[II8S-\)ARZ>*K"(#H'(]A3;FY5$HLS4*I2/_
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MCNYF0K@\L+\RVZ*M##3Q?V;._O$RIQM[K"X>O#R<[/L[4;5FF23?B1R/;1M
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M" SW_;8EMA%ESZJF]=%O]L\D'VY00GYCE1V5]/Y>0338WT'U1)5OB.4"9&0
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MP>"E)ONEI1R/_#QA75#><K7M94,T&/ATO#!-T0:+;K;.0-P8CPKWV%LZ8<D
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M&;?_NO<WU2W T*+9_^TY_Y_$XO#C?P%02P,$%     @ 44!A5B05??<\G@
M*L,  !(   !I;6<R-#DQ,S(T.3E?-BYJ<&?LNP=T$]?6-FQZA]!#C3$=@4>]
M&&Q'O7=I5"AF)(UZF9%&E1Y:Z&!:Z+V9W@DUA!9Z,9V 0\>4&##-@.$;6Y ;
M$I*;^[WOO];WKW5GH6%TSMG/V6>?7<='[R^^_R7E"XE +$BI4*%BA7B%>$K*
M^^M93B>&(1D X ^E0[: !4ZW!GQ #$( 4CH12.F1'4,@JP?&4BVPP^7/3"O:
ML2<MU67+3#/0Y$0YPH6=+E$B"&L3"ITUX;&R;&G9635[Q#)B/L0'8U!JS.?U
MAS)BF6GEX!GX<UDSD)9:/@3S9*:QRSI2C7)5*C<0A%-IZ91N5B*)E$JGIY.H
M-#J=U#653"21 2+^C]Z-1,V@T3/(C-0/5UI63?S>(VBS9VAX@@_3X=\RTSZL
M*QJ-ID<IZ8&@ R"Q6*PR&#*Y&SZB6RCNQZ!8-W^H;1+D(PX/#EF#+@1S!?RI
M9=\A2R",9::EU4S]W?5A73[DMXD^*\"_(!**?8Z_)W0 +I\#^(VQ,MYPN@QN
M$(8PF(=_LLA$,K$;D=&-S- 1F1ED<@:%1B#2,BC$'L ?1GX.(Q#4!0+>K*3P
MQ5YO.(0%RUI3N5IZ:B>#RV\+1$.=?P?U@> /6/* S66/_Q-^?C?RCQBX0M@@
M#/I'*+\?^P<<G3/LL_@AES>4]8G4RS>5[<4^;?W8X765;S("!4.P+H[ F6D:
M.!0(!ZUPVI\(/LQ4MGL949<-<V:1:?1RQG[7]'=$3MCE<&)9)"+Q7U0?VOZ.
MS!X(^B L2Z+B"_]%]Z'Q[^A</L@!9P$L-T!EL]5:CUFB<; Y; >?K65SQ&PV
M#V"HV2&]T!FQ"5D)2,B*BGGRL)S-IJH]7@6;0&277QPV/K[LXK,[M(VQN[/5
M9<3XI69S  *5S?,(/!:RQ,L6ZI($=L#"%N.=#C6?P];S.0Z]@./P"#EJDX0;
M=0@Y#H>,QPY(N=& M!R0QV'+>>QHV4?-8U-5?#93R>/(=0*.6L>/12W"6,@J
MBC'MOWVB?!$G:E7PV$03/H-)Z-1K!)I >5\YX">#_\,/P,07JG:PS?ARV5&^
M)KEDMEC#5LLU^-+X;*A\]2)VV>K4?/:_+K6 '14+<;&(N&P/OCR\SR'F_7'<
M!QFRN?AJ<;E8Q5QU0(9W<_$)>&R'FHNWX1+!@?QR?+/D&ES^ K%&'%.#?"&?
MS'=937R]'!$Z.3%#3.U2<<H!]9C(*8^974RN)NZ(\+WJA$;G0:5Q$T7%5>C5
M?@]=F5 X;7JS2,<CAL5B24 NX3H=9J<$%QVJ)8*8 I1R@G$JH.*7 Y*4.J+9
M:!!X(0,I9C-Z608SV8E /BQD,= B)HJ&9//;J+ 18=A%)(*=HN0[39#()?9)
M7=2XPAT@<#TT+>A%8)//7 Z(6OP2,NRG2=V(U.!#Z"X$1<.A($2/!#2X?/'E
MBWD<-:XN:A.?BRN$I4QF3CZ/P^5KY7J^0*]1.,4.<\QAYL?+ 0,6450@%VFH
M6@57 $I<U@@_(>%I> XGI-7'#2X30\;E4%1:!2SA.V(VO2?J*%^RQ&T6"%TV
MCTV@IS!192(:=R#E@$2"*N&4:#V87*>GJ31>F\D (A:C@ 0;21JOV6<+0 8D
M:!&2PA;ROUM^.2"!YY48#%Z:R^Q#PE:_F6[WH$H/ D%^5.I#47H<"Z*$" #A
MBL8KTPA^F8KQF&R6GHHR!$93\D:D2^E>83F@ #3QY3P*)P;2- J"443#]UEM
MUZOD7 #T>B"2QP5#H)W)MEK8 @,1=$<]M+A5!?+]819$PF5H"*CB0)274&&F
M)(>@D^12Q+@>*YL=1L1F@XL;88J" $@3<F,)I0B)*4"CDZB4(FZ:A>FS^U0(
M :% 1AC3  '80 R;@J 8$9D#".*3E0-JL"BD4&O=_$B"QF8P84<,Y!GL'B,S
M*E-*HVYB'"8375*EWFX46V!"&'&*X["+9],*(;%+'0[I49]8ZB H#&87&$MR
M6$;.8Y)41HP<L=DA'8MBB<;QG$/GI!)E9 O%SN8JU FEB>%V:34AD$+7@[I$
M7$<#F2S('O08 K )TQE83C>6Y-!'IL)A9DP><AN<_ !-HV%S-4$8) @!Q.D(
M2"A1:>)?LO_#C1D U"):0$V(V"D@PVY,<NBW0DXK'$$47JL&L;F(?&^,SM-H
M$\J0'@8"(I=;QA1 #(8)!#$]D<&D>IU>G<[LEDIX2%!.BEDU,BFJT0!TG2!I
M>D2KG1TB>E6@%8V(0:K+R>:BFCA=0X!#)@<A0!&0B=2PQ1D!PXC%[M0'>3$9
M*J&QQ; VCCL%*( P^6:53& P0#I3.2#@DP!.BT;@]_K=)"U/[X4!M\_C@K3:
M! N,,$A>6.MR:KEZ@X8,Q,-D*2*A:<H8#43D"@<YI++Y=2 L(^D4*DNX'-!!
M)<<,@!R-A0QFL\5/#4(.%&7!8G(,M*'",."7('(%"Z:[N2JBU2'A1:,&)C&D
M!0Q!&Q0+N $V!Z/S$@+8'B6)R@%C?!/J3= 1 LS%Y_,IE10[T4]D(3)7W*IQ
M< #4B\95+*-,X*"0/ FKE\L,LTUV2$I%64) %C0HC"1W'..A0C28C"E83*:P
MNL2):- 2Q]@>!L)FQ*1:-$2$4)W.$B5'I7'CAVWU&?TZ9E25X!"#"0YL,#A@
M(T#$S&2:$^2QC&$UHQPP(A$DS!PQPE(X.&#8).#$J P/B0."S"# EK@(5H8'
M\JN"$2\**Q,ADPD)T&20C"BTZ01T=UP?D9B\4I\SX,+BQJ3I02148 R$^/&$
M6I.0<@5>O3*@,KCQ+-@!NNQ>.Y,8D0(^HP%3$^VZ2) =42C#1DP2DPD%^K##
M&HKSY200L(FL1$9RE]$X\%=Z^_'F%4:8;!HS!FE0$@T!Z (%T8M9XV2740\2
M(TB(:+%J$T XKO]@>@#LMSLQ%AJ.(7HF,VCW)1!"V.!-V+1TLXULU0MH+!V-
MHY.SM?08:M:B#@T_1"'KR &(2@PJF=QP#"1+49X10Y.;PA"9O'B U2)BOU^K
M=*H88847]$D0M5T@QJ0LF**FHL'?^[X V<NP&#TZ+1E71Y+'ZS2C?'M$+!&Z
MR@$]0JJ(;%2[608I2I;BLSEAE&"QRS&,%G,2S3(I$6,((3\)@J@>C\<;MA%Y
M5M ! B@5I7$Q,<*A^A$GZ/-Q]&%F.6 <YTZJA() E!VUQ8 X9,'C#H)?7E0M
M]:@U#!XN0*85M"L!@,US*Z0R(*$*"A&GVA&F!>E6>\+.)D4T6JG?Q"T'I$=1
M@L>:%,1?W%Q"'VRQ62(X(&B%;'1!Q&RP\KPF!L1D&81,OXMCTUG5( =,QF6:
M!L-B=#MFH8)F,\OH(,A89'^,&;9'W7:OSFND$7$7YJ'X!:#(2X =[*#"PB<R
M_/2$R"70)9*2U7N,+!J-E)0A0+-A"AU")H1T$3R4D>P6NA7417ZG-WH/T^.*
M>(TZ,QY;O(B+@.'_:[4Q'Q#EFGU2A.(*AD#8!">SKPB*  I+W"0,8%&E1HVQ
M#"8^'%!X#7:W6,BBNG0,6 (*X3)9N9DAB&2C6U0!9@C70C7N@W1BH==@D_A$
MB$8J23H'"2UJE0K]^A DE7I!-EE$"XD2&D3EXY(P%B^LM"%X2B 40D*UWN>0
M">AQ'T6$N")1/F@F1/CZ&$C7('Y I,!4S&3VY>:) +9<(^08$PB^T]00Q$!D
M1FO8K[**%7J/76\F.M@26X#F- L1R"OET4,D!2 2: E>.6@K6^R_;N6 G[0E
MC X*(&5IB1:E7N%0&?2(E<.F()C:2;22:60$@&5QI@(U@7J[7$6C:N@R% 1,
M.DA,\X2"/FTR!'!@JEI !DTBK=JED,!\BTQI,+M# :.=ZH[%$)"HHOD,=I\_
M3K/S(;O-H-- 3AX4<Q-I9I**2W-3O+!2Y>120C1Z,C^DJ,P@W>;XH'($+^2T
M)>P^&<V!^4-F4Q BAQ1*K9)@"I@0 XTB=W(=(I^*0??K6!Z6 D5#@=]4-IDL
M:6@8R44E&N,4W.F2F2:O-Q1P*Z(F>92*:A(FU!_C2S$#'A!X=B]31K-+8(^:
M0@J1@E8#*2PS1<-N/%7 XB836:I,IL1Q)E%C"&@H,= C+)N)1J-1^"8F@6!@
M6 UR6T)@%W@C?D+(*+=(4;E*)_?PY2Z-,DRC^D 1:HLXV4$G2.?KU:%DLB1U
MA)1N/46DM\>4'#W&C&EB",U*,CH"1H#-E^(Y$L^D4:CM&A<:M"0 D,5S^1$C
M,0@: SJUG2<R!EW!J 7P\Q,:15(/"0&Z$_4'-''($;*JM31(Q:*)Z"$LZ@YX
MW#*#6\9UJOA,.Q)T(78UX:_LO?Q6#D@CV0PBKQSPRR"7)<Z(DV)!&3UFH3.)
M":M:0'.@(8%=ATI%U @&JK3^F EE\2"IQ*6-2[51,1004A5LM=VO-J&>2#G@
MOS%ZHMX*R$4^H86@A2D8Z@?87)E!:?"J"&ZW0,_XC;^0F4E*JHW;9%0 B-WK
M,5K5$9LF'*!)@D9?! 5 BP$CB75"G=$IH;/=2@K#( WY/B#0S#06OLNJA)D9
MX'(!C!0):M!$.:!!'B&)0R:*51A@07HC5Z[FQ5A2,8F,:IR@@&"+)+RZ>##H
M)2%6LC-!,9+,,A@TFVAZCE=+9:GM82+;2@(#83=?Z"\'%+.<<6[ $ 44B$I.
M]A!,,H-*$W0*,9F8Z7/:S%&[ ?<)K)A J[)3#0!$)PH%!I  ,0@J'6[[F V,
MF"4<OE@A]EG+ 96VB(L0Q+TNPXNR30(3!TBX$F:=FJ VFQ&)T</W4#A\R"]4
M: PFL5=!M],U<0K#+S"&_KS/R=SF=VTT93@0Q=T0D\9U43 +F1R6DCD&.B:F
MA.T&ETWL#K.4"M1.QGGP". H70 "/A63Y2'J##**3I+40[8/UB;"/DQI,7*E
M/*U2J9$8J$&QP(U(F&94&Z R0 6;B$9X!+/73T.886-,Z*> 'J(AH":'3"RE
MP::+ADTLFM'M+@>DJC&&$O8J$F00]IL$Y8Y,JXLSF"! <WKI7)T><^*R,C&4
M9)>*&B/%0"7S-W?'5S%5!@&#8 [2HPEM,@08%.)0P*YEFV"?V1(D42D\F8[E
MDP@8K)@K*/M :^+0W"$)I@;D08W!0X2I8:I"R8UKZ%XVS%7+8S(12:?B19.V
M3%+;&8F$,T&T::4\;E#E<@D<,;W 281\5+J;((E*O1&?5*E0R7PH4\#% Y-3
MYS:Q+5P)RJ/+09., *L" !.5D9)+)KFB.GK03)0Z^$P 7P/;PG*1I 2RU&G'
M0P.51;>+S( W!@F5N#N4ZUE:MLH%$1T@P>^@>W [E/YN5Y/)TI]V/Z)B*.P*
M18)@4<14$H$-"2B";%. )H"H6K+,:@]%1 JZ7 ?*\&).(@ESF":V%(_I3&(R
M^]+QO1Z]UZ$FJ151B.T E X\K$?^UL(-<L +H&$_%$1  ";CJ65,A7H)07FR
M7A8'B+8XG8=R#*@T:->Y@I+?@A:J(1A4%"(!@YPD X,D!,6 V:+@A^*XKGK,
MEK =B8&J#[$/A@C)71:"JH2*Z5>([!&++FS4,/#2FAL*V5$II!)",B4OS Z(
MI2S<GG5<U&[W\6B D^DC>Q$\X]0948HL+M5K"#(WD1I/[C)5%K/YS;X QE:@
M) E;R#'(\6"/26@^HC_!@6)TA55,0LPB#U$65/+H1(XI$A:C&@; I3",!D<4
M]>)QG>?QHTS,F2S =22_)494T37AH)3B$=C))B)$H]L %T:B4P4\,9['^$44
M+68E DQ,QJ='K"ZJ@LXPVEQ^OM1D,6CT?*N%S[:ZF9)DTAYQD)3XUFK_E =\
M<F,;\3312 24$IE4I3<+B09#G)> K&QW-"CF0VX!B^).>AL/CRK5BPDRKY%J
ME:(4FM/N<_)HRH@,(MMU0- 9-NFD0:Z%2%?0'1IUE*OE2]2A1%QD5BMI8B%'
MCS@!>3S!)!*,,FK28^L8:!R2Z<46@QSVRY0(U2B'F<%8C"DVL/PJK8^&)W4(
MF8,K#$)1Q'@6 Q-+**ENAT.#>S=E%.2+)"Z[A^-"]82D'HI%3B9*-])1I\4%
M<RP^&AN@ %8@0HM$/!X\/Z9_T'@N/5BF>SJ$B>?_;JN&[/5:' J92AH/.% U
MZO;$DMD7FN"S>6$;[F(H<574$G<C\G@XY#8JPMZ$G&GA>/%L';!K/7(I"8!Q
M82.TCXF5+@'[O'0G 5)Y:28;Y K9DAP2,8^<Y6*1F3Q=+(XE# J+2>VUN#T"
M%8'AC#%YQ"ANL%)4RU5S004H80B]BDC@3SF!&HF%DAPJG'P2AR641OQ&)L%F
M)_E!E<KHH<3= 31J9'H1GH4"&12P44KP2;@:BD H$FB$+C^*":P>'UZ":T5$
M&4V!*;0A(%F-&MQD&(G&R(2  ?-S>-:HVN\5XGF<DXOZ@B0V0J4&=.Z_+=Z8
M 8QFD;( 5=+;!-%X)( (L:"&86!A$CX&>D J-6$D^B UQ4DQ0T0WUV9WJ:PH
M"X24"@"3"E%NF,HA6U"5!S()M,:$"W7' 96:G4Q%?)@+LB589G>,FY2WR4DP
M"V@!4@PA!6FZ"$)TA^T*>9S,Y\L4,3,5QFTFA# $)HAI9P90)4$:0D)!)3ED
MD5+* 4-!K5QCP()"CYRO1M4A*^0$]2!J<\A!\(.AF"RTN!>W;(5,1!,YPU3$
MS,!B"I1IE:-"B(+)-%2:02;E:H/E@%JM0B!D1W&/B2>57J&7;K/0+0@I8C+0
M3%%RG*O@TM 8F^%A6*BHZ\,,>B(6M$D0"=&E,2-AL<\+JH5VAS3Y(BANLOC=
M1B@L17W2B"2"NS(ZG80J7; M(B4X\"K70L<0CYR+P!K0&A%)49V.!((2%T\M
M\&I0AI]@%!C] $T->,$DAT(/;&:H$DX:*L!+V1 $!SE<CX DI<?E?H[0X[%)
M51J>SD0419P&2@2,T>*A("R@T1@\O=Z%;[^5;"6Q5>&H%+4G;1EU '0LC-A9
M8BN%)0?U#'<",1FHZ@19&8BY-"27VI?P46P)#2BDZ/'(H ,$>A$ 8B09@/!\
M .)"_1)\D@#-%$@F2R$\:=&:/!H92^=#8WJK6V>)"J6HGR -J A!"VH$M"(%
MH!. BHC2Z\!((@@ST5TR%QYSW&X"D@"E&H' YL0(<;,@Z6"!S\WJB_BE<8@*
M4P1.5.)S:R0B'=VOT,O$!JX?H<@M=CS@(( +Y0%L:=GZ\&(2GS9IRP)0*<)7
MJ=/J8C&#,A!FA:@NO]Y@)>FM@9!#S[#'M=+R:"26:!0<D51@YH@#5C'=:Q2)
MP4#<;^7;8BX49TN9K +(&%6E9PDEX@AHC6OQU(#IA[P&R ^Z=4&<"SS%IS")
M0$+()$,1FHHDI# 1O)Y20VX31)8):6:Q/:@PR6QDD<*5?,T2]^A\-E/$88&=
M9 DE@*<Q0#SL!OSB2)S$M_B--HG7@_&E,1A!E;ZX.F9U*(D>;=3JPHV>8>!(
M=49C69"R$*PD6K)XI/#(W@3+J%7+F2#&@]3AD%80!M5&ERTN,$*(A1(S^/AJ
MV!I11$D>R(\* -1&L@>%?(@&T7R$$%=@X(70N"(N3;YFB3M)3*G<YB9*41/$
MH5%(1@U)[O6J4"N?;W7(U+$X/X8QI4297*GBT T1/9LA"#L,;@%DYM"\@$*6
MD%/H"I)$%C0D+<6HM\038:Y;IPGR,8E;QF/C99Q4(Y.Z$*G=36>2&"POI/%[
MW,RH3 HPV7*L[)4H#+'L="HQ ,6LZB"J4V-"I@=-_CU%Z@XSB2$\H\.S, >)
MH[?9G7I]W$4#5(F$( AXN8P( T_A, BTD/'"3VCQ:X)2NCK,D@H502SH)P8B
M&)LI1'4$S) ,HS8:#"@HS B Y_IVR$MPX]D*(VC#D)"&Q&6$J0Z=V QH@A*I
M62+TN-RPCNAR*V-&*N 44FE28D)( VAQ*]-C2)"3,DQ 8%!O#@?E%*;8@PDT
M/E? H$>%'H+$  I5J Q4,8-!M4SKE@ )KXPF5!O</"UF]!BH3MA,4(2\>JHL
M(29(-6I6\M4]JHW['$*"%(L"3)H*UKO-$&BE")UTDH#@A;51IL5L<)MQACP&
MKCH<"3+-*B>!;9>S&::@-AB( $HMQ:O#?8 FZ1Q41!5*"MM,81$60'P8H'?Q
MI+"*$8IYR3Z5Q,L!!1*!/0+"D?+:#V&2-/0 Q4O1.Q&^5DOW2MCQJ#@>H,@]
M>B3YSD%'%:KX/H>="K'PX RJ9&*2%3;:Y,)0P ,'N20G(8)'++4K8>4DV%R
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MK=^%N;Q7;XH;KSMY8MF "@VW/GK3\U3SH0<?BKV2+2LNKKL^V[QUS/'Z\2]
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M90Y=S:H%;A!81^1S_*-<><L:K-FPOFBH?=_;I:)^NU.O63O>O+)Q5K9N-7=
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M%W19J;DQI:!IN!96<+[NT"8EL6>;K]=[4LH5Z!H9!_D376X\/\[(^,KQ4\?
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MI)VEZ=W#9YK8<KW 65+NY)E>?F_-E2;#3KVMFY'K/KKTUB\J$50XQ4*K?6'
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MICV]^43RR*N3OST\XUC%.M#V1@?>GN_"^K[UA>BE]FUO+RI8'I ??+1-JEO
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M+1>@BK1+RJ:[$'!>Y!RZ&;*Z+4DX\]RO.@-<UE_P*+XCA[3ZWD9[Q%]C5R<
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M]YS^FOXE.=2"^IZNINF^9E#!_A^Y\[?ZSP6O@*/MM4^1=@\K,K[RWM*+*GY
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M4O.!KA5HZ9YI^7INK'.& IQ3DY^=)[Y<[FQ]WRW$T<3;X=GW*20$'+)<)W5
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MS?;M]&\-DJ%;/)8OKI\/Z[%I;71LGBW^AH3'?2^U60.++6NWPQ?7IQ@YGH%
MIB."X*58E 4ZL'0HF.9EWU/Y&J[YK.S!43SDNP0)NE@0&=:DG"X@E,& DOX8
M9:+[X8)@OL!Z$.B /,Z:,FKY]2D4$V)A]1,9+Y[A"\L;4\EF\HE5()JM@[N\
MDITJG=L%&SB.GUG)O:5AV>4X8RH[.P>YBIR*"ONY-JGUV])[6;&4$!75B?Y
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MXL8_:'WAPXHJ/+ZV]*<\=C-K;[O+_FJTUM\^,G_O\Z7'.DC( [8C%_JJV%!
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M[U6=+-=&K3%* [C0J984T>ZH6KC/Q)E*@Z[N1"8PK(Q'W1ZYI[S:2%?0A/*
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M]F[6BXDH2B6B=0J+UI5DM%C%8[UZ,EJO9^*H3L1Z.C$"&(^BV3C:&_XOQM%
M(8&&\_%HMHQ%B^6$T^.23IM/.6'IG_^]1"K:XW-Q%*QZ+523#:J$E?21>R.
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M<SF/RR*"UD^$;,%S.PSK$39#8!2AG79\X1@:!QM4@PT7L6@RPD 56$*RGB=
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MFGE=%1"U4N0J97^,1X0BE'1!7QIC:E($[R3(HB:7.FG9J?@-3\J4Y&D2,TC
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ML ;/I#)N$Q'#'9?%V&"Y9J$*#:45KEW&TPF/ADHHGLH4' Q%;3:.,53 5.U
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MAZW5C!#OTW4SEPI: E:@FGZ4;B5_/LE#@.''<%78AI!.V$I17+ WL.5,/A]
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M90<E+[WE, IP:#.?2X-,/E>4TZCIT28TVD;1+%T5S%P$\57Z_6B*94L<Z:N
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M]MU;WYPEG'9)[)1E[<[)B__\J?KA]??NZ-)731C:\I#BA-?1$W\]*])$[8G
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MCQQ;G^PN!!3\_7V>0 AJH7(;CK1Y./(JX*=#4/Q2X4XQF&1&)]S(X+SK5NJ
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M-O3552XXL*</";EK&]R.^S,'R3_E,(NT8],=7U+;&A$P$60U/TF%QF'XYQS
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M% INRKK(U1V)ESY!XSXA5/<+H$%VZ+^H0D0)U7^U1"NZ*+O<ML+3.+K-FMO
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M"JLBXGAGE.5P!U><>M[K* QLFP]<+0O%(2HT!3JG\ESWN.1/+GE[F$U9Q%?
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MKU:AZ'4>34:<4@F:2IWG$G#T>#9U':+;:NB$OBRQXW2X+-YTELL5PLQOZGT
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MWZH"]CK-M+0(+U4(+]5TWI<W*:T,B'W9<7F)G-D<?/P W(+H/P ? %/"W@_
MJ4$O5'3727G;6_9A $P7FL]AE<=VF<GQ0E/E&ZX4U^G3II[#\2(+OMO$!R#F
M<I-GX6ESUO>-H]+O/Z]*7QH<&/RE\'3/NJ]"8%F5_72 R^9DW'^2F)XT9TJV
MO<*"CB>EY9RJ3^@HIVH& CZK%'=<W<NT/E-6@J,N*3%46 [1.,"97SN_;1N0
M+.H'I#QIHXD([69Y_=;%<@.6:1))*(6A!1U%V9L9PU8(:73<"R'OHAE8M2N<
MCI+Y#RYO-'6$H-F;C2PX;)*1:PP'P,\Q<DPF+)3[7D'ON$A>O-_J:<SV^E$T
M8 O+?!]:F3R+[F+SZ+/F0DP<AL:"?<J_0@P#%T?WLE'Q,OL/1LG9X\U=@)RO
M[P]V[\5'."8W81(74VP<F.+,]!2VW6]O+2B4TKIMCXZ?*IMTI,353/8UH.T,
M=X?G1'M'Z)O'$%)IL>OQT()<CIJ3JO %0,%R6QPZOAHI(PXH["ZA<H?BMV8Y
M(8]KE]U(_%+M!83C:JM(/&-%]&?88HJ@3TU8'$"KD@?Z/8<6Q6*'%[)D9LF+
M%I7D=J</@&C#\U57<8"M17C1@2Z8 WPP4*"Q';]S[%GR*-S)4.(3'L&K+,_+
M(;<G$&SK.W69%X&^VT$P&]7BS\V-DI]YWZ3K'KO'=L_6U=39OUL%#AL]>'I?
M3AGRIWKG-E/\\J9'=,TG*_T)8^G\>W0)9YI<B+]2"T._WVI1/PI18XB]"=4K
M9D:;CEP7;\"#@078[5Y4336CZ- KP.\RDJFK%ZF_98'9J?!50Z'3"!YNA^>;
M=;G69Q BRERP")TC6V,\S\"S=46T!@GS(ORYW3NP_!?;0D-!BZP^]^*-VGJZ
MP#0A_L;G6RC-@I@9?>_RHC/J(4@EK):6LIBEWX&+S)V8Q$,3!D6F+NI$T*0]
M%XM:SVU2;?[J2B//$GI@P;)2[:2YLYN#;./Z0GZU1['?11N4MWB8S-"RJ;2T
M^0G3K;4M#18KK?E9QH"N#*7(-GD@WD[>J7>5N7HET8KK5<HE-RWL3[JPPQQ9
MFO.C10PKU70;+R>$EHOM$8TQ4%G:]0>@3^[F. +ROMCJ&61RG#8S>S"3LB0'
M.?%Y2$=SDK(.&E3;T\[U9"CE.+@@BN/.5K&!E[KD<JPJ+HM=HQ8*23)>,C8/
M*Q-5M&*UNF[:^/I_MA#!@6,>";_KSS*>5-G9KXEF+=W M]M)E8C'T7 ?9'FM
MU-Y\C5Q-9W3>?R3_?-)8D=+Q#68.-@P3#8H<OASH34T\?6^BJQZC(.5@M[$?
M^I\QZ<B,&_ID,JO(1V,*I::?,7]3S.9F#%, 4]J<);"%??#E^=LGLH [1K",
M2FM3%U."ZWYF\"1FO]$D"\XJA,5&W:T:,#BO)X[7Q1:.!GR'KQZS,]Y@.5J?
MF[(F I'- A K<R>--A-P0QIN[YXG9S207+@F]HLX:PE;:X)KI GN*N3AF\^L
M.*#@R"F)#O-YH9QKZI^I].TU%[[\:Y;CESC#PC"^U1*7@_U*,M^+"I7=*+;[
M[4RO< 4QM<-R]Q=NJ_7^)W2Q7K=9)0P0N'YNMXI[DP<R:_U5LE&MD(6X\K'.
M4#%I+/\^7:P<$:^KUD@); 5QOR?**QKN#J]Z<I-_V(T62A#7;F3<R/>53$+V
MNT2,,UUW315MTS=/EPB)E):N5Z$M?UY';V<S'XTV9I:&<2/)Q4JNG];?UAA2
MBP\\9'=0444/E8\U6$L71C:4W:^I1]VGKOI3X #I6)H67^)=%6G*C*>3P.52
M[!7Y6%W*??^Q>4A"9G.2Y.*8,+L0+M4!CU9D(ZX\M6V"='RT"P2,Z;=@[MS6
M(9Z]FA!A(JJ?#!SIVC6-E^K^J;*4^.)43"^6<:/TH'"ISK*)"(W=R483O#D%
M=V*_8468*/CTX^F[JW*%94DS1_$I6FV$>'&,SD[(<C+O#.R)EZ 7>07RG65\
M?TYBWKH(MR%T:#ZIKHP=JD<ZI<POZIXGVVK44>\B6D!]%)_*S%630_:@-<T,
MK":$OTK!"\4MW6<&&BKZ98+I;6";[WYH J;'C*YCMCR/BJ_3),]"/<M:XT:5
M3SKM/V61A@*$\[?<6,5(]=$6*=$B).H9JJIOX8(ZD[%_EIJ(KTI!BU,HAL@6
M3"5='\'W[DB*6<RH#^>-F$*,HJY'T!8S*!N6'.85HXV+7!^,W?0#D282\*D%
MQ:6060D*K,.?B^$,&T%[N4Z)MXJJ2JG*NL2W]NG75'#;N_7IITG'#*UA38<)
M7KN94,ZK7G:=!SO_CCB#&1#+"D7R[;6^#\YF=9VT*>Z!*XG.R%WAT?BY5E#G
MQJ-P_M;IZ1A>XK'(O:^:H.#G])O*:///!T!:Q%1I*ROXY^)D89S5FZ*AFM8!
M\R6-5R*/[10][Y/%%7K1P!HM7,2&BN8+Q SH 8KU5 )/)CC&\23/%;]+:!Y7
M35_; 1%?@7KDI$G..^_I$X(UEN;4F1<X6#B%%6?R%_JQ&I=U?ZN=SLU*!]BO
M=).J<*!5I1)<];SP?!J@!_Z,U/7O-A7,5O%D(#R1DNV^6G9)"<(^C/83V;-B
M94(9X$OQ7IV).8;AT^S*+A$B4&.$MI"NP>.DAB##31$LXV60]!%\K25ADU,J
MOE'1>*]ST"*!J@Z9&22SIYB)D:DG9JPS_U7 G^Q.DG!&Q8,%/]HTN:C8C2&H
M@;F=K%H#,<E[C!;>'(O'YE@@BGVLT@%E:F=H*@2#J;;[Y.!F7K7SM)_KWOSO
MD$]^C3$M=--+(W8[R:A_F^TFA]@JY5AF_JJ'[0;0J2>4V_KX$[K07[,]QXC[
M#[,]S?RAY P.9W?6Y*.'<;#M3;LHR=)#O: LI$+Y7!GZ8A,R%^7'OFV-V+?S
M!]TZ-/.+X_@7^-)PPJH^20"XZ6*;GN!RGJ*6[Q!,T5R77E!7&U'IL6</QO'$
M%B"7/V3%.-<_4R^@O51=-R8,%<\]%2J3W._WTC,1E0[WKXJ_,1KW!FT,]'>D
MUN-^QFGWYR$0PG(QSDRGTP[>%Q5;O;.BQ*4UED'^_^O/H'@L;L2#1QIPX>DK
M(,[3-,_+Y511AFRPOSQ6F^YSV&5^*R?E:^972K\7D:CGH#$^"DI,J[S'+FA\
M.CRWT:11WC$>GQ3=W)H2])>UFG)*=]O,VTF"R2X&8B0<U#;E6(GN)[=.)^NJ
M?6>X5W$_H-+L \O3PKB)IIBVG!T--1\-S5"CVM!LT43.GD^U,TQ[*=>G-VRH
M\^ "%X="(DUZX+)8O;\;DV&G8Z%X^ 6FEN>"K;TKW%9Y]68DQ1,=4XS8C)I?
M.Q)BK/RSXFKCQ;3%X;"IJ6)^DU'"KP[L;HH$J"3+^?GUS&0O.)@JY,N@>-/J
MC>2P?S)WHAP#QLBC>*#4&5\^V3"PIP>?-CI>XB!DL^M]DTUR7)?'6&)#) 1?
M5-C)_L]3JR%P'+6%!F2^OGEM[@>V@^#SCU]H-LCQ"8XQ&2>9*G.+S!FAF+WW
MV73JW>6:S;#9G5NE20)'+\M*'P;Q7>IJ'8P+Z>G7D"^:G_ !1V-YE$?2U@%"
M8X%S;GI@O"]H\F\H\Q$:J]>#4U2]CYPGDE_#G?551VP'O\/D\O[QY)PU[4,C
M'!:2U^,Q9$2<T+#I.QU:F7:(_0#@CG^*8<1MU42VUDFS,=8I1?X]F$*[F$-G
MA2^A1L3"+T\R=@PC85ORLPI'*Y^YG/LG=E2&L'NDQ0\'=%%\>FV.>2N/ZK?C
M>%.OW?E;B7*HY#C%ZYU9R4N[KQIUD[2G%.CHO5 &*?Z*S@3J <@13)D#4N^J
M'P!;,Z9BF-WH^DT?T6)O)<)VE*+:_,FZ=3-KR8K_NE%C-E)N(AGG[L+=;(_V
M9EB8"PZ::Z$ERW=V_XQ"R):%=?,@HALJ0>;&Q&P+U88>-863G<G4ZU+$2%)E
M+X-]_JB$T*9UL2&=#1D8O@H^>4^'M4;+FSZ8IK0'NW#_/K-ZC;;"3QRWLR(/
MT@XM@>=.?V#XF1V15\)]P/N953\N6&P'AN9^Y\E##S,2A<1LF]DSFTZXMN%P
M_92U(LN7=.>:;':*(+")$@;T)F#BE4:Y-[('Q+^:!CDR"5WE3$OUY]*PO\D'
M43M/YB-[1Z.+1IIS FF<N#, #^=C;!27+AI97A?X<@6-+A?SC<H/PPR^4;O/
MZ?V):]$-Q?<6.<ZCT.=I/K7CN7^FE-6(L;YP?8(4M?&,"M#IA;[M86?4_1$D
M3"HT3YP'HU?GZCL<&--GUWZ4/^VW64KS/]"C_-]%ML)I5;'J<._%_$,^]!T,
M9_6;\%J#)8FP&-8QX^[(^+"L(YF[=%ZI.'XQ3+=&Q'G+8_:+>M!ZDT$6>[+L
M+_.L/@3R*X'#Y:_&PCAF1@9U3UQ7<WLN$31^[!$RA4*&];PU<ROME9\'9;LS
M5:MIW:^-H:6EB&NEIQZ]\HM]J^D$>W_D)N&P]2V0,-HQY'D/E!V@P#P6?%_<
M"+DF6^!4RD.OCC3T@*)YYGS[8W'/N^-G.RH__+GYMS3S%&=0RB_N'3T.9@VB
M);C#X&'R\-C9 ^F(5R7%'<<'I]6D<JEU4]"&_"4&[JZ77B5[6<;HQE 5YI6Y
M\B&(+?=<12^!;2WSB'\-&-A+C&!ZK="9E+0W'B<@;F(ME7[)5@!RUBIII,J[
MF?CIQH%6Q+L*JIVFC??Y?]R"C^7_!5!+ P04    " !10&%64N_%LY.(  #L
ME0  $@   &EM9S(T.3$S,C0Y.5\X+FIP9^RZ950<X=8F6@3W$""X)$" H,&"
M:[ 0W((37(*[-A8(;@$2W-W=-;@%=W=IW&FZ;^><;^Z<\\U=UV;6FCMKW6*]
M/ZBJ?FOO9S_[V7MW%VP>M@X\_R@E*P4@/ , !/@? %L")  T%!14%&0T5%14
M='0T#"P";"Q,3"R2%_BX!!2D5)04I.3DU+2L]-2OF6G(R1G>,S*SO^/BXJ*B
MYQ/BY1!DY>3B^+L) CHZ.A8F%C$V-C''*_)7'/^/#U@G@(>&X/\,C(CP&GB&
MAX"(AP#[#5#![41&^,<!_,>!\ P1"1D%%0T= Q-^0]USX!D"(N(S)$1D9"0D
M^%4?^'4 "0_YQ:MW8BCXRE]07SL0</C'9J'1B%=U$:I,G-%R&CD&H&.\)"(F
M(:5[0\_ ^):+F^<]+Q^_Q =)*6D9V8^J:NH:FI^UM(U-3,W,+2RMG)Q=7-W<
M/3P#@[X%AWP/#8N+_Y&0F/3S5W)V3FY>?D%A47%U36U=?4-C4W-WS^_>OOZ!
MP:')J>F9V;GYA<6-S:WMG=V]_8/#\XO+J^N;V[O[A[]^(0"("/_E^#_T"P_N
MUS,D)$0DU+]^(3QS^WL#'A+RJW<H+\244;\XX+_F\$<C$(_-JNI"I^%4.2,T
M<IS >$G+M4%W_M>U?WCV?\^Q@/]7GOWOCOU7OQ8!+$0$>/ 0\0 1X/:!(=L/
MX_]?_W/61EU%6#+EMU+=@R2-Y/!QVRZ][$B,>#_WX<"UR9;D+2@C:)!WI@,<
M#8WZ"!3E>FO^J2O37I*OKYW6L Y!BZ2U(*#RYA/)<W/9]45OTA$)=!R;Z^MD
MR'BB?7-)^3GBV\#@7I3GW$\K#?8E2_:CEXK%0Q>ZA'KBZ[E,;SAOE3C?44>U
M=""(4LE/Z".7]3ALXI*YFS':YD99/_'\D><@?S]6X$&YC7\_$TU@8;_HWB!V
M9K6JB!-7'.+$/LS9\M)XOD$4A[<7\"HC7%_4D<N$R,Q&MBVM#A;,+WMP#$EP
M>MA#,K?*V8G.2C&%WJO..1^U64DF>P7]8.Q(4@\FC&SD-06E=*#:4R4 /@B;
M5/B6OD0U.FD*9I*.&MP?F,=\4&&  6$)08"%BCH24^&7]$;NR[V(TI/\LWS_
MDD--2M=,]>.%R8TWTI$D8?7;]"R7SQ6\/.?J[A2EZOYX"]@8F]-6?T#]U2R%
MM-,D!%QG8O G13NWL?5J0"G35\_+]]QC]? ^&38!)HFH'8*:JOIT6U3W+ ^*
M3]X+,&#?6C]C2UYJ3_;,M<#+K->6)GS[RXPLM?G9F 6B9]A]]IS,=/F5\^SF
MB[SA$=%IL]E7H;*H^7,]*%OEI]Z:.ILL;+VDM9XOBSP*VNM,ZJWHZQH:ETNW
M^+[V>8P/N;'Z,"#.73.='J\(6X]7+Z]XB%*]F16Z$*'V+EDKXY2=[JBKO6IY
M)-Q)WY2.]R!*HN[J9XK79S,MM-SK]&688LF983&+XG*K:?TI$[LIB6H^E$L>
M@R8\H['WN6/*%\_R9;UC*Z.;"__(OKV,QF/3%=\3 ^(^!E.W[3%H SAW#7 6
MTM#)<L<KB*A\+3J"L.YJZ#Y.0V$5')O%VK&I2*@SZ.%@1\#HP/=90;!/4T#"
M,R+]!\(5BY,OTWEYRCH,J 99B+FQ+38</_(S&=LN[S&+M#(EW[&Y"?5_*]](
MU'!?;UYZ;IR66<A+N0!UB3\?AQJ*W)S#@-I]1,^I+:I@V_(XHBCH@N[6:#+=
M?(=>J>*!?@ :#4VL@>"ATJ%G= 17&U6?9^QG=66C9.(D,BKB+@1W(0ZQ_CRK
MNPNY)^M-]K--VJF%SMA<'H?E4C(8X$KV*I5P98P/-9\!<=F:[/<J7<U9^8_F
M;U>J@^@_).N1D:O%A :VPLY77N_]IB2N/$?2N$6GJ%ZL'R!2"=Z4<UTM:4%;
M0'HF]DJ:]XHPUBV[AZC'2\_9*EYH=&>+=C:O2S5RGO>HT9CORFX$<3^-_T9(
M[E-MQS<]HZ9O;T3743 Z\5+==DOG H8?.RCN2-9V5+\4Q"@B$O=?%DVIQ/5L
M&H2[8+[13,3428H,H69?&E\')0!>:49W(;W:FL$T_G6,>OH;83WD%EJI$>;S
MQC1%%-8#K9P;9"+X[JY[O_DS0LUJ.G0"\G>U4.8?''>^\_%M[5)%2IZ3R0;0
M9!K  &L88#7J&8W5\%W3)("C&&-+$/(;/WX +$HY6.8>^$CJY=Y1S6U]*B B
M%-F07#3PV$]#86W4^GY3(]8F2R28:UB6-@[3)58]E[KJ:9V>%N"/7RR_^T9W
M'M(;?+9;X,5=GH;VVX$&>>4"96"@3U9(1E )M7K"0%A'?T7K0/C=V::^T&J*
M#9Z%;JJ?AK.2=+X8N)\PPR6'BPKGJN-YV=-@!KC,AERG729I[VN%O6,NE OA
M*NW+74ZO-BBH]NZ4&_G7K)9@K8S:2WJD/:0H%"&KFU#!)'Z<-,$1;2T;(S?C
MY02DY/.U[XN]P57G&..?.IK9#S20:"^060+LQ_T0^#K5#Z:54"OV/6<*OCN[
M<PN\@'[H7.=%^!$8@(9T&:O-O96!QKWQ=;$\9-=C**O<QC/R;L,/-=U7-;K,
M^,Y /'P3T9JTO*5<'GF$V,1G"V^/WF$%@DC<27,D2GDKZ2X2/77<_O(/M>)S
MR;)PCUVUEN^!?L^>YP9_C<W0#U(?)[5TNL/MKER8U]>M;2Y]/+4E:3=[F[.#
MY$I;=?WP![5>61_?S1@&H*&&.^-G'5:O8'9&"IKZOT QQ$6L0>SS(#[Z=/XF
MI&3!NKGMI"5K];"^6F8<>YL(JUW<)+4(\.]#(;%_)TIY*>G>5X"2LQF-8#&^
ML56XIJ4]^EIO<?D35EEDBQA39">6_QJ6"#J44O_@1I\S7@$Z-N/L-3A194S[
MN,Y+UG[$8&B/CDK?(?@'-><NY7>]+^%D<)8/P86X*9Z-O]C7&$5'WLTFW#L]
M7W@&9;!H0I^D84 _TR13'Y?!/5L#Z'H6]/32 G'&&=MVZ;<V2WN)15PN_LEB
M#4!L8U1 _8(_<+6VI'_[-=LB,U?0V_1O40@P0++_<K/)2U.+^GPK!T7C4P N
MDD^F$NH$@>9HTH/ @CN^^/D+@^647P5QM/(P@/EMZ?S",GF12/3>'SD;KXWQ
M[Y1$B4+:%[MZ,CJ#]E.R::O&X"]7_:(6B,O[%>BU53 @" ;T:E\>)9?6=QAI
M6CQG?\9.[-]UW+A'GCJK:DVT&-W=DF(]J&]2._WEL]Z8C$KTQ=X?X^M,W.RC
MQ'/%:*X.M!6=I;6E59G++!>>_5( E7SGF[DW[UDNJ<8OE/I;?$6OPD6I,9.O
M02KO@8[@B?$\5\VU"]PF&% N#XD$/&  A+4#&P:,)Y;  -\<&+"5L%\Y4",>
M5_A*3P+KNJOB]1W)G#X,:  ]%6E-Z66$M'.>LQ1#*O47!FX:><FB&>]?])QE
MXCIDMSO,7(&.QX.368;+W[0WQSD=-5A@B+S*N"/\NMS+]LW;:^.QA4+;ZZ .
MCR!)<AG_S4T/CL!S]S$'4<HC2>]-3=7SQ(82/3T)H:VN)C_2((UA6PX':"5Y
M8;]8M-.HC43^78_F&>;G+ON&(FM7]*C5![Y?6TRWCA&."'N60G<'G:C-ROIL
MZ^'#V$Q]9UK#>5:+%"O=QR_[UFM?F)#;:NHM;P4V7@@Q+3( V6'__:MT!?2A
M_OQEN$.>7FL1TJ,;%RT*V6?V+NJH3->RMPR(&55GKDFF&[*"?+_V*F-X3KG[
MH J>?OR4J9J"&2@0CL2+WMU#K$F\T$\E3>Q.W^X=[@/U R4!1V5OP<GLF:LV
M1;#FJ' *EGTWR92E&A+K:5(Z[E<-HEYL]K7EA::SMIO\(BHBC?=D>AX[&/=V
ML7_VEN?RE$4IA<Y.NQ^^GP<]M#XP-^NGQM1:(G?R\2$X7 **)+1;]W.2(EVG
MF*.><QAVV>)+K=]WR5 ;WBJ(D)[N9^*XZ9PIA)?O)RY^^M/Z<C:76'BLZY.W
M<40 WVERRP;XV5R/]@=/TQ_Q@F@CG2.=];*#VPC:M4JH9)LBP<WO0Z]=IRML
M[;9^Q2J5<E#KXJ2I9<SF3/B^W">EN-239 'WW:43A6U,Q"8$HU$SB)2YPH4M
MHZ!K#3-O/</EDOKK/3;[PM5C2]7=;'W-.C;9YXZ&#LV6RA9_0IKD/F5\9.5O
MQP[^_10EQ=E^?,3"Y/LQEJ21?G'G2TJ=C<UQ2E,\Q.]5WDU[JIV[8WY0Q*@(
M,=4J9YX9^7Y1>4D82D_MQ^XA5%*0[<<[BKD1$E*++<NV0?0>O\]-^B9) \U'
M%(/O8;?TP!=ALC926K6MH;'5TH5X.TJ9I@B#?!O<'>'+5UX<!G2=-00="]*8
M"I4%S7'03GI$F)O2DB/T 5>%WIKK9>_[J$R@?])/V*I/%V[<U,? 36-J,,!9
M4U82<**D/7L3N_F]=/+ZQ-A+<H$\AJ.$<"LP@>\@.43OSB7[+EA %42WT!1
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M T'L6-=GQN8,X-TK1S=#DP 4S\V6XJ$,\8:6F=WV1G.7.&*C"XGJBI.5)9;
MX$&'+HJV0Y.FM'DM\MFT]5-$J\'F/L8W9(1GK'NHUN;6AO7V]O:>Y!H1:S@0
M;B=RY7%+A[?B+<::;3^#2,90QWMU_W"1I;T1^.+F0SBEHTV7*L7DA(;6N!T
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M:&<E:=DX38=50ZD[;A_^X1S'0?J;QH#!#/:^A[*Q'>)]3QC ?XW!^/1E]<;
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M!'QN[7Y."83/B/F]5+IO[ 6'8D--,!6&CA;-LHMX$6#^@"1F4JYCJW;C7BO
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MZ-^0<RY:6#*0<G3U<L2<!DF!H"6U69=B?"(A@)5_E^'&$W"+H>^_IO%E\PG
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M?[2%[J!BVB?Q(<W$1K;7L@@HZ/V"QN=NXYX5>T-!2VC,29NKEH[L;/:-6+(
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MVF*;N8/S'5F_7M; IZA41,6GN[ %SG--:W-LPBJ9#X]V&A3":;!VD'*6O^_
M@E[&A1#3I).OT,-?A2CPA-3-F=/K >[)6-+^2P#R;0#<3Z \,C_/8- K=\E@
MQ(Q= ;?6RQ,&%3".N\TJ+JV#ZX#1[L]RWA!>RM7MSM)*UGN9KF 4Q]9RO^1P
M(=T9DUZ7XZ5Z7C4PE],CT]E].Z_!H#-M&R0IFT]J)7#/*XN-"+%B^0\$$\\P
M$3"[SMX2BXT@I_N3O4C%7]'_1]T.=ZB#GI>.\O<+U=\]'M6VJ6W>(8.M&9@,
M#AYO0& Z4E51 ZMO>S_$&;4-6GR$"'<_GKED(^Q!LM5$:2!1RWA]TMX>94\
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M]I?JK^ZIKEZ%\7@P<O=H^UH)R&S-4[K1!<Y]%71]T5Y:OQ,U/4CX!'!V!&J
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MYV,62A77)F[7F!.&K"*4>G9#%.G,7864CVEH= F[<D:+&")*A<1"*-N,XI%
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M 1MN#7*36-4S3\CD0_R$7-J]":;R8"0[E"RKZ7D">!\6(4VFR_>Y5^ @[\T
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MNCIW[,7_P1+J+P<,<XI8FO.^K[3DQRVC$34I.;'[7(*F/_20<(H2<_D@(GG
MS].SLTM[GP]5/>>6+'E@,J=HM/R ^_"7<*$%3@Q<]S+#T<# F#+(52E8J[JE
M*O66-,%'1T\*JN*I3LSP!,2IB[ZB+_OR =?F*GZI&T]AUZ $7PL2E/^Y\,6^
M3!PE=351,46/GJ1VC9Y<T5)>=>"/CT/P4-DEI4]70YZ7V2_X&9(OQY)$J=5J
M=Y7I/SU\>@(HWAD]+].!?WW=6@WICR,,Y5KD)<L_R<;":;60":0AALA?_/I-
M4C-EBY!,%55^Z(>8Y$HC&3(O_-+2@R/WN=!CQ"9<+U.Z.(GJ/D_BP6R,.LW7
M93:6^TM1\B/+R LF>!4/RZ>0/4&*@6FEQH(,]A/5T#/2-#M)RY2C;5SP4NO
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M2LC?*MGG(=N"AW6'QHGM7D \-A>![">9TG@W@@*)V2^U$:AD$@=MV^_:*LC
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MT=SY8Q41NN0AH?6$_K\?MO\#*D?C_P!02P,$%     @ 44!A5@WX$L.O>0
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M"<?UU<QWH$CKL@>$M20B(J-7C?:O501084] /16&>GC9'V0;3-)\P%E9013
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M'T'CIAC/*W>NL&$P4:_ Z$=^27M7C>DQ&:@<K(@SW". :70]BKCW'B<Q6#E
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MV&QY"K\LF&H#7X4D#UK@YBO]!'P57#Z 5@T2=Z:GU?*H/@$@6!:F>$X-0YW
M)D5*8B!FG,K.\JJFT[/*59ZT79\XC*@8),$2/R4$JH^JBLSTBWGC/%10.,!=
M9;6FBD+?3MI_."KNJ>$E\Q%R-676LD8G"K8_>$Q#QIB.8C@>!L7R? N_KI,J
M@1&'\\*Z;6RC#GR+( 3<CZ8I\+K]W<&I5<SWL$;^3/NE>D;V03ZL<$\GD?V(
MS.&R422=^J@<!7O/=XT-P\*V39G"F@G/TM1^8)5#0 8)?"=VW-/\V@[EV92O
M-]^IYKJ28X4>78IYB[EE83P(KCV\M\ V  N \__A?!N,0./W,O80,O<,A[O
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MGM,8EEN9U/VQO<IVDZ!]G!&W/^L?A8[#EB,A/65[H'+/GEY"T!/@)8^<&5*
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MSW3TMZV\BIZ#)VQ &EEXYZ:=]$RT(**T[LH7\]PW=@-75>U-8_W=!TE7IR>
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MQ++ZB[HR7(?K#%SV(>\;/7-RD4[E>L)(-EHF)5W%!>!-M#3%S&O%^DF*7).
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M/Q\^"O$'CE]BP3"E$,RV4Q<[<^;A^<MK>P47;9Q!MTRU/2]%8_<%Z"8.^LU
MZB*/D6_F""YI)HMFYY*+;/)=\-;@F@ I4TN0N>([8_VY?([Y'0(ETV,KF\1I
M]^ZQV<P1>]72,!EF5.OVDBL/?[.!N<_135A)P/K6#93RRT*XC1+Q%=ITE_K)
M]92>'?6<J=Z(%/0#!T,['&7J=YA]G"?@Y #WSN]&50?T*5"U@EE:NI0O>JJ
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M%R$GPYN[7XCW]\Z^1N1L,=IVXA_C>G2L>.>UL@K$\3S%RQM%]2FC);S,V6S
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M!+#SX"1DGX HBY8[WV)5"Z%P0?0K>(V_^=R**OJM0(NF:M3VVR< N.#X>GG
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M^'_26OZ)V<J_4/Z3/RHKXSGKD::%,?E__P/QNW<2_W@G3S/_'U!+ P04
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M[H%9E4\,K/#;KV("=A=JBD_PP%Q?'6I(!9<>Z (AHX"PT(^)X)X&HG2-%]'
M![9Z\>LG_U_W&JAD<<1 "I%8)D 0OJ0DIC*&=8@5-Y%6/ FZJ]B:I>_ =!7C
M>H3OX+/R^U;TW?U&">1)$TI!<L+F@N34'D@0JDE$PXAYOJ=THKJC? MRJ[H\
M@'$68GR8:?/U[^;R^T;H@L42<N[']-I(7RW+^\(DI@##WY2__HPFX%YIC1QX
MFV--PCW4R;^\*$'1C-'BL9^-"AP,D@!IE>KNUQ+>^_.KY6?4K^N^P_Y9YK/"
M_F5-WKUFAG;9#DZ#V"2!%X/9X*(T01',I0F(E"))(@J_^^Q%>ZNQ:];^E6K\
M.TE-X=@AF)46X<'AWY=7Z.K-[>-*<X944_^IX65?I^-4I56M11R=3E"9H?O4
M"IQW(BW^(<8S\]OE/HC0ZF LRG+_:UJ^^+6]Y -HX,L/HOC#5.]FF2Y;E;3R
M';^V@YL/Y=6J>4\M1<]7P=JGU:^X-:!+P+Z=3['YIOV[O>_5TCZLWA8WH"QR
M:4"BB((^#!--)!<@OJ@+_Z/:CP/5MVT!8VX/[(#*X/6_F_RL$--1"B*@WA(K
MPP[ *9"@BL#!_1MXP[ W:]\06/2B0@>WWA*0@NY\2Q;?S9=.+RY=VKWVF^_9
MO8!3&BN0NJX?@*D!TI;$(0>!%)LH,I$,$NH^]NY]&^EZZR-='L52@ U+? ."
MDX%M14#W@)J+E.81U6#8ZKZ1;BLN/HU%]A%41(=B3R[RDU$^*\&^/;F IUV^
M!:>BN@1EC*\[-WC+LR1BSS,ZCF)&X@#M0%=HPI6$?=02C $:"\J]ON[C/"QU
M"(1<6&MD62\<Y 6X<K T;XRLCHV:%6F5FL=5#VODL2CQN/% *3 _ !Z+P>R1
M,O1)HI2O3<A5R'JW-W>HAR:\L'>P?^/RWWO[YY;R_JP:Y;"UE\N[;X>QG^GW
M.;S^;[#WI4X5FM/;LO\T#"-MP!JGU 7>9/!@H:5+3)PH5X=*^. N]VS_;Y&Q
M;\'<S2^-.:YR]<<GL%9'X (_@6#U[B]8O?4)5C?@G$6^(E',P:E(7$ZDGTAB
M0AE0G[H1Y[VS[>:;5^0PU>H2-Z<"#D)E.,5G_':)T;6K0G8RG56FF%^T+>P5
MQ3348*X0JM"7!"^7R"!*B R-IQ,921;PON[07,36=@KN ?A 677%,=I7X*3/
MQG"M/JI&IL#K"C/"IYV;6GX^,O.Y]V<^=WW,IZ0 UUWY1/! H'4J2*S=F"@C
M:4 ]7_*XOY+S6YCOW:S(TFI6H)Y[EW[%W[;&O $N"X,8R$-R#>:-BL#[%9P1
M5QD#AJ?K>2KLZR;=D_\^FTJDF=%O!6Q3=O8(6],#9O-<GX$;'! #.@UL59\1
MJ<,(_A01^L R='NKZ8YGLDQU*HK+8S$V1XFU39;W\.C<%/OC<5[AHX^F]S @
MUTU%\/DDS^S0'I^ .*'!_0AHZ=*'$)#Q>,R5%Q&E*-BY(+Q1;H= H=2+N!78
MO8LEW"<,]JE(,V6J/'O$.-B2: ;N7X]H5F ,@?@%"6&$@1T!EHZY'Q 62<6I
MSZ78>M/H\47S8FL\OD:K58#Y(L!6Y3($JY4G >$!"%^P=T(_B"(-KL6P-?WW
M#Y6K$AHS2CCWP$3E$0@]C9E:FL5,R)C';F]-U#[HK8[@<]=X(N,R9F(.CTL,
M[ K3 8DC4$J&!J"(F!<8C_XPN[).*^KPT]&SM%V8[YK(\)B K0OBF$6*<'!E
M")6^ZRHN#%7;%J.UMLMQ/JM&OQ6SK+Q(U1]/8L!X<9TYN X^]IA(? :VBP(_
MDC :^80;I4FB/1[Z4KG:?W0^WIB)$"9)E/#()1S^07LZ(H(*E\1Q[(LXTDPK
MT3>:7 [JSZD38_?H<2T+D]]-9@H@UTSOZTF:I66%257GYNW7*3SOL4-:FSFH
M,YIR/U)@C4<\ B_;4T1*L/L\CP=N*&G$@M[:?7<>U'TY_CT'-SNSWYP9N-:4
MWW1F=_^A++))YK_^%28G"C6Z?&_.S?A*@*V]Z#";SJK27N%M2WX):"9MT(;Q
MD@B3SRBF_7@@!6-/2I,$4@6]<ZRWX QBC3ND7!'YU <+5N$I$><AB1.M2>2%
M3/&$*Q8D?=VAN9"V&5E+5E]M0L Z !L?Y!FP=H4)RI]LUEIA]!/%LJ)[!T/A
MTC4E!3$3"J$D =_.)<SX$0%.\XGP=:05C:+M2^EZIF?V?=#I1H)Y&FNBT%IC
M5%$B,6W=YU(RICQ%']]*?9BA-NQD(\>3)$Z\1!*MP=!F-@U0Q3ZA(J:!%$%,
MO=YIVEZY@=^_ATM![X?LH3:ND;X/.^<*<.6I!K<I<!G\YBM%52)B_>CYG _6
MQ7W/!]B0H/5=T,2!)M3#;%4A-1$@88F;Q+ZB7N+2_GK$MYA9"_/W^TRL=9/7
M$%I<9V@Q ''D,@8\X(+/QA*L=0%OG_A)(%3@QMR(WED'J%,^B^RL\<_PSP_B
M:SJ939ZE7)&,NYP:!4Y;@H6 \. X-C[QE<>BV)=Q%/7.VE]G)(2NB\V?>RJW
MZR6)% 8T#HO SU<Z(3Q2 9&A&R5!$M,X[BVAW"L28ZU%6Y]5?LPKN%09?9@=
MF^(\58]@4SS.+H&+'@4L$(12 Q(W-H)P;4#BAM*+ B6$Z_?N,.<;S(0F(//4
M49@-I*3!\D9&)!&AV@,#/L#B8"E=XFMF7-]5FLK>V7N]=<?J<[E[[>'5([P'
MI16:V%561B).  N!/F0@%=',9Y+%(64BZ-L>?E.%V8;*(39C*;DA5P$J0%^%
M>!011D0RRDEB8L8C:<(H[)TQN\A'LA[S)UBHRQ/$NQ$VD%7^=MG]IK/7O^6B
MT$?)F[0PJLJ+K:E'-J%TW4AZA"8JQHJ(@ @6P4YQ&7F)C$7L]2XGZ9[!ZP\W
M!Z][L_QQ&+% 8=9E@D 6@2M(S-R$F$1%S/B2^U[OS(]5#E^:/8'#MZ&LO< H
M3PH$[<'"DC!TB7"Q>C8$AX\E7":Z=W;\QK9H,[:?'[AN["4HM116S48QX3RF
M:,XK-V#<3VCON&@>G[T Q7']>/NS :<X555CLG_)TJK\?/SE61H*41*&,75#
MHL/80X07+'H&^E",*F-@#^.XMR?B_4\N6:.S'(!][AJJB ^:BC"6"-BH!-&(
M7!'3D'KQMMKG^V"BC]*B,J:.93_;&N40K#V=")^$E&(M@?((CT&E>;$K.%CL
M\%_3URW<AR?H%-%(S\TB'OCVJQK/M-'OBGQ2)P79],&CI*TE^&2*XY$H$$QH
MY0,Z%/$E.P>Y:_2-CII]T&-7)VP(VR:Q.Q833<'^9S3B1&@FB:^5[P8^\Z7L
M;0'0$-A^0I]%1%'@@M,"+J,/?CTW!F'X)%A;PO5!%;A *[TEE$=/2^W--ID8
MG$L7\<4T ZLJ"3 EW 4;66KI&4IEK![=JMK8Y%T>>49H'X29EQ F6$"$QV+B
MF] 5GM+2L+AO-+JQ@]3-6"*QD;[P@2 %BX ^31)B>-"0.&(!CSW/C\+>;=&W
MYMYHG:(M(L:?1*H/LP,Q32LQ?I;F@RNC( II0N)88B0K2HB(J":A2ESC\\#U
M='^UPA.8#[UQXHQ1B+ZAB5"NP& )J.\X%.#$)3&#Y:6@'_JZ47=EH+Z!;\LJ
M50=U"'A;MB3AG!H!"CK6/B5,NB %/9,@.&T JDM[O']IB!L.PJ^S<C!P%0^"
MD)+ 0TT42Y]P&7#$X0XD#?Q(L=[&G[:@>&XSY@4-=>R#H",)VL#,-13,"R&Q
MS,8WQC>QZ5]Z]@TQX1\02B]07DA9X)/88$0_,IQPW#UA/!YZ+)2QZ2U+/EV8
M:G%(T$G#M4<%S]+$U$Q1%BE.$L_XZ#$@(@HJ NX%*J8\\6COT,,V=A*WJ?(F
M3RFC!%$!"%S&80P\C+#11.2'FE%7]Q=%J#<8T4LX)YA;SM82$C%<1G[$B.N"
MM<]H[&(*LR1))()0@<L=);U+D-LB*V<S)]\BTL+C 2,ZX@$6,(&>%,PCR@5M
M&;J>B:+>GGQO5]#^^02&$QYS7P82BQ<LQK1+)(*1<!'R*/1EE$2]"P \W-O\
M1EG3BRK7QXDVA )/;Y@A6F&DSA5H98>:^"SBL&/:>/TK3.A)"Y)'.E"[3P.S
M'F[(=QU6K&6K-P!5=;7L^&%='ERE/*X(-Q(3GD1 I+%;K\&1T8SKQX?/W0[[
MALI$4:SE4(E)<'T,$9RBI9.X3/DA=_L+@=0'R,0>A')HPB-.%1@9*@*_ WL/
M<NECP94;8]\9SP][=S!TAPS"/K-['_\VV!IW;G[, A%1D)W"57C(R^&WF,6$
M4RU]8ZCG)CUKF 5B/B2^NQ9#RXVI#)DD*I:,,,]P@BC*A,DDX*YKC')_X"!F
MC:M>GN1M,/NY"T(OX5X<@_(*. 5=#]1!9.2!$9 P%H0R!(W66UW6L^JVQ['#
M?7B<H13;J898"Z5!3KG8O37484@%,[2_QD;OTILW5$K 8@K2UB-A:$#?>+XB
M@B4A<7D0&JZCF/J]C3_W.JEH,^8_#U28)%R0".%\&8L,D1X:D,P-M"==-_1Z
MFZW>._-_,QS)>*P3(\%E2W +C>(D3D#KA:Z6B:\C+H)MBS8^6:>/JT8+N[?1
M I<N;-B';%\2&QI'.B228J<?'8 #[@5@(1ON^DD0A5'46QOV0)0CT'SX#_+@
MN1A?9[]O["-][W?_6'5A41CS./*(K[E+F*L$$2'BD(=N$L7*#6G<V[JP>XKI
MI^P=L\ZM47$4"*Q91GP4PGPP;&.N&-&A3*0)31*8;=^:9P1!=^WD/U@'#;@>
M#X. 1MC:B1(6!9Q(UP1  R82(9>):WIWOO!-)_^?36E0L(*P?X.",[=85<\Y
MN]$-P-,QQD=;B@%;,P4*&GX+?>H'BD>1Y+U-YNB-Q.V!=<R5-+Y(!/$CQ"O0
M6A)!@P VT_6\(':3L'_^Z@]_%K_..C4AE!L!'[M,@W<4Q8)P#K(_2&3,?,V$
M>?QV#=_(*1O"!I,J9$+X MZ,;1-B24GL,Y]$+(R4XMH5O+>93FA.F#]G*/+.
MX<=UM(\K%ZS+C.EC1J._+&<?%*]-@%6"4!//QT+DR /?U 4*2:3P0L-XXH:]
M$YZ]4X*/E=(BHR1ADB0L20BC]JS#=TF2Q#S13-/D\>MOO]7>7E^_3N5I05T!
MYCM'*$H>$AX@QH;R/>6%#/SAW@+?]3H(O:%:%,IX(,, W@P*C;F"$<Q*(9&@
M-%32YXGI7=E!CW$,>["C'@T9%S[(.^ZZA'E10 27$>&4F\1W)>SWMF5 /DZ]
MY56[[YY[!9>NS]-U7>XC@D7D PDP'RWD((R!^\*8N\+$BO8V -W_NO)UNC*1
M'TI*,6@58UJQUF"@PVZQ*&"1"FDDH]Z>GM\ PK>4T5#GJVQ+W)<; 4Z1)XEF
MB*D7QY1(([&*,@E]C[(D-KT[=NMILLD5A>7!__@]%5;WT@<I+"V%+T-)@A"Q
M?"3L*S= *VY H\A+(F4TZ^MN]H2WUBGI)*@A;!CE:1!RC,:<Q*$?$V,2;3AE
MPE6],Q_ZB*"Q3K K$_L>8SYQ%0@Y9D1"!-:T1&#E>2#XXMA_]"3C;Q4E5VH[
M;T^I6;KT00"0%$Q=ST703C![&=*MX![FO+G&BVC@RZ"W!X(;)]X>G!B$VE/4
M#1GA$BL^I:O 'DX8"=S0$\KC+(Q[FQ+5]R++=7;_H6$0NBHF6B+.JHFQLZ"G
M0#[%L1NX";@NO8T!;5)C]X##(JJY'T8@$J4/6P=_D)A305P:ZT@;\&[[AV_9
MB^C )CK&@! 4B6^P_RI%G$=#>!@S(BEF&L:^@K?U;:^>,D7L>P9C6WK9EE(/
M2I7KC6TH./=L?VZ3 "LS5P9$8E/%Q!=<4 U<[?8.76V@D:=5UQ);N.M $ %^
M!&$^*&[A!@F)*54Z"53"Q+8%KS;608+#_^ZGLI<N?9 :4#*16"8<<X78Y5BY
M$T<^X:"M#0V"(/1[ZY'?J]=B>_%[(THSRL>ZQ*R7]H_#R;0 NQEOVAJ.,UQ$
M21QB50>"><E88EL=L M\Z<>!'[@!>_20UO=Y[$_=%!AF(!)/^B1)&!:/2I?$
M820)=ZGV(J; X>LM<:]5-MV?I?J2]](#T<A$J"@3/M$^F$#,QP:G,9K@?JP4
MCV1LPI['>WJ<_+LAT*]$P=XQL$X"Z_2 HI.A](A4(0U=K,70_<][6G]K^P>I
M-O 'UJ?:$BDC/_0(U5H0YBFP2SSED=@P+CDV*^M?>L$/8.,'82*T8O X@=UE
MC2])+)%W**6AC!F+O=[FS/=&HUT%1%I/)J=4)G0E[ H/8@/VNX+?DDB3,(AI
MG*C -_TK9_BQ,6+6&)]AG@RHT6#?>FX ZLSW2<P0R)*ZL>^#4RY5;U,5^E#D
M_3A*+**N$"[W8%<P@]=-0G X N!YD3#*M>^JQ_?/UJ#$>EI\NT;VH7Z8*$,U
M,6Z P&@^<@[8^[Z)(TR="T3_FI_^@+*S!P=;G)L@EA@ETQ*!7SG&-R/$2@E-
MR$-*7;=W6O9;\]*5FDUF-K/YJ!J9 J\KS B?=FYJ:GB6&<V<BX!R&9#0BV/0
MH1)1-K@&?Y]2%7(:!%%O7<+U9G7<^[7PP@/P+-/J0!3%99(7&*I:'5K8%E60
M\,A0H1GP-@,&3_P8LT08"7@2>!IHA+'>5BKTJ>?)9L2SI(DG$@DOCV.,B"=X
MG.%J[(\7*:DYDT'OQ'-?D7(V((*-B=V N1*V#Z%J92()EB$2K4)#)9/4E=MF
MAST5K/;W,]\2)/.#BKQ<FO@>T(/Q I"?H31U-\HD]H7K4A'XII=)/QMI&+J9
ML+?B.A:!D81Y 0()\Y!($2H2,Z&D"1,O"'N;4M=G\_5QHJTL$=3E7)+8 S9B
M)@H)#SF0 P^U)^*0\:"W\8-^1776FI8:8/<?Y9,PLA9B'(*2 DT%[H'+A&%^
M&/0V%^H']Q/661P6FB0RG&,Y$0(S,N!-$;B$TRC TT./)[WU%OM6H/Y(V3&^
MEI'K&D*Y\,"?5PC917T2*^!3GH0B?'RTD^TPNV&50D8I6 74!-@\!<A82 UK
MEC#*1.QSVMO\AMXDVF_&H$MB&FAF-%$1%FUQL+EAB278W&& 6,V<F]XF;_?,
M1%AC$(D'B=9<Q,1($S70+0)VQ0U,R-Q ABK<-C^V+7\X&"#)[MY_37V1\%@2
MGB0Q)F9BT3C6"\8\4$+%;MR_]F#;Y6:M\YB6:0\<+?""_5ACZ_@ Z\S E/.$
M2V-*8ZYH;P_/^PY.LYDPL._YPO48.,XT" E#UI/,"&("'? (MI6I;9._3]^>
MSPO6U\8GH9X. S!.8&,H(M@;(B(9$"_B<:!5X(;^MIRJ;,["W(QS(./(C2/L
MI^CY(8)&^D1BN,,+) L3CT:QUUOPH#Y8F#UP$F@4FMB@;DM"V$+7,"(UED
M\TF%ARZ/C^RP9G%HTUOV_^]@B]YMBVKC<\]GH/P2\$6B4! >246T[YE$F"BA
M_2O+Z^61Z&9,&5"-(0^H(9H'!OM"Q$10R4@4J<AX?B0,ZVUL9D7&]8^5CN!S
M!CRF\3P;2V*UP4P$'1(J9.+%7AQ+=]NC,T^*KKM&@%EFPC"1)@%A& %?L8 2
M[B78P9T9XX=!&,>]/0GM,[@; JH1ZMZ/T98N?9"%PQ1U7?#P& 6[ADFF"4_
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M=B"8?PE"D!>V!T2YVB[T$?RFQLU?6(>#KML6XG@R,WY0V;U5V3R,5>)3E[!
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M&R9I,:GA\V"/I@(O LZU[8RT';&8Z;1JQO6]@'G?[<1&+F.4,D5DE##"/";
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M8_$-=F,79V>@V5&23FP+=N=<C&>F%8+GN76/,0* X*W-GR!#)V HH)%173I
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MK8'#3Y.\.%W ;I6G->KOJ?GS><>(&AQR! N^!?#UK<5*WX%+QA8-K8/!YGS
MYFI%#7%VB(V$"N?3K% C4=8XLO6]'3"T(1PUA*-L.(H.NF_0?0_1?>&@^QZ@
M^T+0=_4!P?-6<<,QR*!W!KTSZ)WUZ9UHT#L/T#O1Z:+W<FE/XV<6#/FT[?%X
MFCQOA?1A1>OI-_-EL([4?J?=Y;MY6]:#/--UZW:\!O3:;%SWA3V:FGKT@W,U
M*+E:R?F#DAN4W(.4W(!*\" M)P;WJ@<$,VB>I]8\WL:SS ;-L[748S5//"B>
M!RB>^/0T:3V&TWF/FO*TG$VG8_N[>-X*:>$OS7L+U:=3QXL5*"Z=-Z(2@\X:
M=);564-(<-!9#])9?-!9#]!9_/2T[HU6GJ89A@3%66$:O84MTDZ%>MXZZZ">
M/;:J0TWUIKL"SC^QH=R^4C#;"G-3L%U=\V?;WGZA\][,JYL&Y38H-U1N?C@H
MMT&Y/4BY#:' !VDW >H-'EKDX[)&0]#/O_CTH)FP54^?YI,>E-*@E :E-"BE
M-2BE ;3T04I)GI[F!;A;">X5*H7GK8^.JI$IG,/%= =--&BB01,-FF@-FNA@
MT$0/T42J \F#-5BBP%%C11;L87;Z[UGQO%73(F2'-5CU[)UW]>R=O\V*M-2I
MLFE_U4A4X$R9<[@1=%DY-6K(^AMT68]TV8#PTRN,D"W?TJ='@@AV.-_QN-\'
M=N[MOFXUR,_-N[I^SNP'Q,/S9^!M!>\9T'L&F;W5,ONIC/$[A/9Z][ ?4GN(
M"FVM'U8W57.'J-!#FJJYIZ<Z+8SM='EJOAHUJ])S<YJDRA0(SU-,GWM4J)G\
MCO.VG;USE-3SMZ?J![ &.![C_)[#/F,&V)#T-42"ZDA0-.BO07\]2']Y@_YZ
MB/[R3CM:2^63J<G*'^"<?:&K#CIS'M32H)8&M32HI36HI:$AZ(/4$CT]+6LH
MSLO3_"(#7V*43D_!IZA$FIU*DYGGK9\:'-)+YZB=/ +H'-3S=WZ#^8.'A84T
M]??6T5H ]C3 .S>BH YZ;M!S@YX;]-P:]-S0?/1!>LX_G2NU N4UIDF!L"_K
MOXP^K9ZWGFLUVN?NY)?4UTDAP#NK$\AVFK+3.N3H',+PP'>#+1PBBH-*&U3:
MH-+6HM*&+J8/4FGL]'1:I)E*IV)\*N8  *>),>4I@K"ESUNE?6HGWT4_> >3
MK]%]< '44&$ZZ*N^Z*LA%WK(A=X*/3/DU?5-L ^YT,]/)F^Q=_ $N=#_Z!]K
M;\N.#R*[#R)[2(4> C];*-J?)/ S-"E]4. GP%2R42K3JER%[7Q:/G-TS+?-
MY'><%=C.SK$:&3T;#Y&?(?+31'[BNQ36H)G6K)EZ8I0,&F78K!]"+/=D"UN9
M"O\*.3;VUYO6Z2\_&J%O<#$65#LLQXW+L86F39I>6=#1W/>>BC-32T(B$ICM
MGAA?B,OR]0OGU<"6/QP=/FK ]OC3VX/#_??.QZ.3M\[GM[_O?WYS^/%WY]W1
MYW_"K^3]T='?\>_CD_V3MQ_>?CPYOL_J![N1[]^^_AX=@BIV TY&:>GL9]D,
M_.#/9IH7%;:$> <O=3R7_'W'R8OEKW<<O%FD6>DD>7$AP&@:Y_D?F#^QZ!!5
MH\NEV7D^/C=.D99_U(D5LZQ)I*Q24^XZ_S3.1/QAG'*F1K<];3HKRID _[S*
MX<EPO4B,,Q*%A,%-B_P\Q6:WMGLM?ONI2,^QDKE)SX<W.>_AGS,;8H!9(&RK
MLZ\JO-[C/+ CRRVF:V*T*6"JY>+6L;B D>Z/Q]T!U5?#)+.E3Q,'5K/*"[0-
MG40H^*Q9+*.Q'T=U;;%WX&,UGNDK$YXC%SKY#$8UJQ#0KU@TZ<WG37KMX.>!
M'&>:E[:K[XXC9R6\MBSAL5C7?7:YXVAS;L;YU$8ZIF.!J9KX#PX.2$^-T\P.
MO*Q@/$TFS/S#JH#'PPW7QW+M$O,5L03AH=BT4A2PM?BD[LM57F($!F8Y&PM8
MK\O.(*MTTG8B&:=_F'$ZRG.-[P$B43"?'4>4SH6!_8!_[2SJ_9/_1@##<V/'
MM.@*C635#GJQ:O 0^/MFBML=Q,R:8[<P^'QB'"5* ZM_F<_@U\Q)<2'3Y/(V
MYI>7#FBZ25E+"=CTNM.U@I6[K'_5\/KVPXMT/+[^:3G*9V.]XNK5']<4?/US
M2V[7/P;)E&(R666N?Z=6OR'%A5GQ>0748%:]N<C_O7)(=HDGT_'*ETM@'V"[
M%1,L@<U6W@+$@0BA*[[(<2N!P]NO4#-T1Y%F,]/]#D5Q9E#J@@JH17-IFJV$
MKVL16@*WCT6!,@.DA17CNZA];B*&.\1I(TT-BK_*\GB65R!')BG*HRK?Z3Y+
MR'Q6[5WA=)V>KPJ/(:][?[D:'OO+:YV6L/:7>\G8?.TR?IWN\.]9B=3=\H&]
MBL (BNJUY6Z",?ER3P)3V*#W*EFPX"BZ&_C17YZ=<%A:T_F"IAFN"+'K>NM[
MK\K36]:\NY0A]ZC/PB"F8>!%(:PKVO= O93.+?P.+2P/:^O7_,6OUJY8F VF
ML&#V8)XM_!N8?O-S8(R!,7X4QK#^Q0RQD5*3J4MK;<]008%EC\H(+)C1COWI
MF#]GX&F,3=L4%JR,HB*HX<  +?XP-I#9]27 ?4EF:*S.KMJD\& T.K*RM;O%
M-*V ,>V'.FUL;GA?42NO@4O[0C$#EVY*?67&VG1.(5(P+/'P!7T[]+QA)LA1
M$EU] \ZB]35JHQYO.#.9L5AG(KMT+ +^#$:0%/D$HPEZ!E>5P-8#D_5FPP<F
MVQ23"9F.$>("V":7M@IX!:-AC 4O[@98+D8FLRQJ=#?(U=Z2&0SF8/-T>#)"
M6HT-,&0R*ZQ;V T667683R:F0%,U_9\ZC->HY99?@<%UJH&GX<UIXH@IA@6-
M'CBX+]0T</"FC%FAP/X4'4NVB?UTH\RM[=F)[UJMN#,W1+O&IV5)9&U[!+ D
M$&J/,CL;&*\O1# PWJ88+T6EA@RSI+&:DXY4-8<7K>Z<G]<@<UU7:P-#]65S
M!X;:6%@&'ML>\M8!%K X,>P_R]!$;3GI.O/4)X3+UNQ$?$TG^,!JE)>F\Z!T
M8+;^;/S ;!O37L@*HLXEJ,_D=Y"SSHI61W73$8"U;CSLMS>)"28;7$\RV+F:
M/F!O3[-SM%+KC WX*H/AZV)VAG[=&"YN7$Q$E_KX9J>3O]'-*)C)25J?* [L
MW!?2&MAY4^PL%VBD:B3 'ZS@%E@]!7R$Z535Y8YC\-0#/45D*.0G,34SN 2_
M,&K!ZH-UVM_='CAL4Y'215RE,5&SV42"3H*_IJ"Q;. $350C0$DN.,GJQDZ
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MQ>&F=34K8"?$)*X3#:Z.O3Z4@*&1]F"B?>P03%JOI#^"#1AC!.-:XOZ.\^G
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M[(5NM-**4E-G>ZR,!:)186UD3,P 78]Y)1T%4UJ5LC W[&MO,CB'BI6^D,O
MHIM@T<[I1QT\P*0PT7$,FX2K3OC\?@YF??PR<%=/=GK@KHUP5UF*2\Q,5& ;
M9E?:O4UR;8"1,(X[J2.IH %M#\<VQM8J01MW@6>UF.3YM*K[-%X/W+=L>BV$
MCQ'$%5&9I(7BZH;ELS9;/[$IDZ-4IA:J$O/ NV'Y><QGP//9@NRMK><F;T@B
MW!P9>O'VT.'C9@XV!P$H'S\U<?<AVO(H64KK.@[IJLB=)JAL]V\$D[$QOQNT
MYDW'&'7FQN*,]Y%R1%8=$=7QP?:@N,ZV6&JF/B1=;/*X!;;A' O\;<&'4^<^
M=?K^MH29VEJ3BZR-JU=U;0M<>-&34HSOT5W7J: ?NNM1%F--Y+?69-D^K=E"
MW:>3,Z<LU"\OX!?*N.?##W[J[OY[>O;"$>-J]1<MS=EYAI1-O[X>U8M(>0A_
MH&W7SK=WQ+%Y3EE3B,5]WB&6ZT;MDT18[K:E'Q!@>>G]U,_8RAH7V];*OFD3
MUJQQ5,=8[ $<SJ-TQ)D 2ZMJSA5JW"H;C^DB[-0IDO.;=H> 93\VN#_<1'\0
M;GJ/C'!41Q;%W.68Y!JY!&W4)4ZQ/#2Q*9ZU0Z4N=^9^5%K!'].1@!$K1",P
M;<YLE7]-%1XW8!+'Q%0V&P*S,D:7I650-4+0G07J(V8#P6ORPGI0&(Y<!3LW
M<&U/"*D_7.O_(%Q[^/$->8O'!!@1.*YFVJ*V7,SA"99.',KV^]1F/.>%MD@Z
M-COU=\PU?M^VI;IT/F&KJE39\S[G]_>?=A9H)1;KW[X:$YDF:5DV_3Y02KQ[
MLW\3.P[1A2<JZ>B&IA#EYNX*CQNS@>NL]NL1K+;EV=6JC)65&BV23IVLUA8Q
M2&-Q:C 5+JUF55LD,B]LP#C;ZGJ&NB3@0>4?WU'?<5(C"6,)50W--48<H78O
MRGD_Q;9:PR;G-ZGL+:J5N+"=J&JHG28LU]Z/6>,KE-M.LSF=4IM.'=B*_/LA
MIO<X ?^KC)765E#+'Y8X@4;K<L:5$6%[Z;Q.M,--=Q0_(=_/:VNPTN02JSQM
M:<.U"/8*T3 '@&N353%'=B*^UF?(5_*L;0:IF2$7-'9=#30(A&DO1Z0PG':]
MZ/-@M2WUJJME02NM5#KM.N($ZN#G8M0YT%Q-U*(Q()V73U5MOR;RJ>_'8>ZE
M($]2=3,:RJY967W?X\G=-!7,:$A!#*2(A]:00BW)D!862N*ZF/JI1K7[:I,+
M,'.^3M;'I&A2%TK/*<&<H[>N:LG:G-[4E\!J752C-D6AK8HZ^?UPIV7"' ]*
M[+6%L4W=;85*)W%<G*$#X2PR\E?0;IUBK\T$)E?5.?8H!_!PQ\)F76:FP#1Y
M+ ZPD(GU$MC:H4X!D)W;IS?$:SN:]234/^1+/,]\"3KD2SP:&0X&U#>=YM^K
M?A?]RKFQ=;66]^I9^%*U+)C:?2N#O3Z#?R*B9]E4Q"9I <-M7CZO9KU>T%R#
MB:)N0I35HJKK@>H'HJ?55M-BB*R9;CU%>_^RQ6K.Q7B&9;"FA'?4G0!Q1&5W
MD6PB!;9.L77F:+"BH3C#=(*VO@SOL8KVP\F;G:8_DFU2G:%-6H^(VJNZ#[:
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M),;C.TC)22F,7QD]>/#MCOG>AMZOFC+P3I3*(>L078CWQ1IETC9YS-3=8LG
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M6K6M66]:)AFXM&L*W=2JKO9\CU0Q8Z:^J+=H<KO[HH*J29N\E'8G;,J&QSM
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M&R39K%)X0%;GVPJ6( NW&C]FNZ:IES0!3"SH$5%0!.X_B?&U22VJ9)'&H 9
M\:*VF(%JS\J.QOSJY8N]PQD!,IIN+<K8O1!#>T84.+W$><$7QF<> J4Q-RT6
M(,@KST'(@RL961AN(4$_%4W/<G"FPDN?'R,]&H9 XWM"W_NXJT+C';LB.XX)
M?4FF=$GT!#=58ZT:I#TWX=CNV+7B[^,PGQ4M:+=L]T4#&Q#.7E/?L1GNG$^
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MF*3J!$Q0?!16UU";QP!,@LO84%G%.J@&1'N&AZ!86319= C4P5*Q,[/!.N
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M?8N_ >\!M4)>L31H*.8N!A2F9@;WZ*+NREP[B(0I$[";LE2*:X6"#]Q4.P
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MIFJ"BIPXV!M9?YBI'/GFV$<E)$@5W%%,<(8N'ME6Q N&-8$RV$%84>2^#II
M'_'#W,2B>#=X"ECTS0@@4LZ.CU@!=\Q2&OH67(H?H??@S]834^TGK\"X8#HK
M;"')9R)V$01^[7>AX^0QF<!\8QC'U+\RG-=R86Y-.,>Y\1A7:YV2]-?V4I8
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M(XN:<6"1VE"#(>57&P-::96!5>TCF7:\CX40HK8^<=[>2$FYM6B[C?9G%%S
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MQ4%Q*J>158CM]S19UI(V-%2LW:ZL!QA0?!+^QA/(GC,Q+_^4/Q?O&?E2$-&
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MO$DO^D=@/_D12S\*B6U330/CI'8$Z>/2P[Z<Q*&.RL=)*'Z60MQ%J(CBZKO
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MR =P?GT08I?BC# ([L^:D]:"K> F=8X=F4K:Z$@N/3X\K,6)&IR*U&@:CT#
M,PC.AH: R<&F#1$29JY)T=N_<RFI>^"NI61'0#B?U3<@<D*XTT1N"<]&2H/X
M6P[8C^5KZC=+32U>_LHXQ#TF3R5+#!N2!G27.FLED9-D .>$N11J_$#ZPK*4
M#CFE2<,J?/>ER3V_0?(K'Q2_I !N!P6J]B(1M_L:*^#VDU_8:2YLAM&]+9\X
MN$=U9XG_F0LZW:,%3>*44H XB;H_X'-0P@H[.76(Y$1=X@%FV=:57._B+YDI
M0I^*5FM>L>VEJZ42".O/$J(A.6<:JX%J=9J2<7:D4J7<(2CK?L[BPZ7]QBH
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MYIQSJ&>:RDLIY?NGE+],*>7$-75V03[&U#< )/]=W*6^AW=LE,0-02/.H)C
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M8QXZ2-36]9MFA6"N9/!H;1PO#EQ-J^G2A[B^7RK"=7]%WT)"2WP;.;0PZ>7
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M9=?8#^A:QM8K-TU#77+2N)SD_%S.7)+S$\DY%2$J/X!![8_@SP5P 5N+2VY
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MV@'#=XO6X^(M-VZ+%1'[,0B7WLUM(R$!,RVR#Y<(NDD^OP>]QMG?-W(PP]M
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MAOC%C'08O6P\%+.)-*6ROBTZ]'P0.+!C>!Q><>H&Q4/LEIN:6!H<8_4QY&@
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M72,!1P!GIH$$_$(0(\8W).1!1.T9/+R0F=+J%@:-_B'A]QR3438[ML4_T=U
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MZHTIDPFK;\]#A6,T:.(78*B6J/($6?HR>['.7CZ[>O+Y5U\H/M+!>6@I0(-
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M3@.SR%9UDSOCDLQ#1U+\B"E4%(HM2$(J&2SM<"[4@(^F54>HJV*]^=*A,"I
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MLP(R;<TJ-.".5MT)0+U:?]D:22?$O;B-<,QL<C5/M9;9$H6S98#*OE:D !W
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MIS)J;ZV\(B]R?,+.R//6'MVX&*KN? ?[XE>Q!=9R47-)CUMSJN96>=:C0/J
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M!'7#7,PB?-HO^>9NAM"/M-]7)5N7NJ/W(_W(,'/+%*ET4[8=XP)K)]9S;HC
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MM.BB0/[B,OXS6;Q872YDP_WI0+4<6G4 .6FM)EQ':0Z:[LKYW3[?.(\H@9#
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MOK-47\P)FZ7Z@5=R&%EE#Z0>RVEQ)XU"5HQG+9I1"7B6QHLY&;,TWI<TLM
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M5WYMQQ,K\4>.?LDY%W?6]!3JNLSE0<Y/G1Z1'/$^8!W%'6FX#SW?X%UR!7
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MAR>LD@E)2VE>(5>Y.^[VI%"Z,)V@HW=D7.AK )0-P+ST:7Z 6L.>N')MS*1
MAV[A9^F2D,56T)%'SQ*%B'@0>86N#(Y>/&\>\P!RSZQX3P73U\=,0GB08*\8
MG&@)]8<'T.>"7X\\:@#Z.C!N[:U?<]H__%:O(@IW(I@3+T2J3CDH73L+0Z7=
MQ5:UWQZ[DG3TM2!D:+8W##></%_T 86-LAU/P1?BI*,$>L<8#JI !MY+N]E!
M,?Q@3?82F&_RFZ;E$1 @F];BF4 !49AV_:D1$,[-'',SQW0SQ^.YF6-NYKB
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M6N.ARC%)3AZ9$"-C-[<B_"9',;-PZ@2!4>HMWG&W,I[3W@H?7L"3M&D6Q^C
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MT->TVKG'Y-,5SA\9IH61FAK\BJ,A9TRTK,_-#C+UPK/Q$M^<ZAEY2XYR;JM
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ME!$&WNIB2MOMUJU.!3=Z.O$:_C.O>X1/CU&)>O)%I QRI^"IQA2A],490MX
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M6GND*T?/7YY0)WXLWR$98M-/R6N%T)[A+TASCLN#6B()U(B0+CE?HU<BDR2
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MT/+-KG37[C;,TJBJ<-4\.::?!71Q%M/Q",W.UY\OH(L%='%VB(!7-BL-WM8
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MYA99MGKGCF8!L2=9=CL_CJNF*=(NU ZD(B#)D7:@6H<7/":<PXP(G]0)Q5D
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M!"OLEF@0=P.)/O>.'%D0F:H_0,K4)O3>U<W-Q:ZYT7@; WV\/?B#F/#<(($
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MNBE,D^6H[D.M('&&A/W')=YY+(O^8[,L!E#<R;26+F>S0#$M&[*TA7?M_,.
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M$.]V.++U/;UFO5?1R%F8X ?E=XH)[*QH0Y @X&.53E+= P30UQU 7FFT">A
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M='W[:Y*$VHIJ./_#_>J!N%?3$))SH1YB:8&WXPCB));VO@<?QY^2\,R=3$\
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M,3@C$8'\,%2MX./$1SG0WE"JO35XOPAY,FZK6(IPCV3]?FSGA/M^''8&LJH
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M1^\8]>=]U]1^876F3U58632E']@KX?:'W']9LGFPQO91\A^'B1Q>V.H@7O6
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MEJ/46Y.;MG(^.'7BCW4XP;3];75+H_YI'.&H,S5W!W:HHR.<&ZC=_ZPK:&V
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M8XN.Q8R^U+R@]S*N*]#[,/\4'B/R0XI2$UU(I4OE''WV*K*B)<@HR8&M3S+
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M:^TQJ#^=YM24V6HD!1=59*45%&KVZ*K9//B:RDN1?J5QD1(+@P_#>AYT@-W
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M'X/<Y(E4E(G_0WUMOB=3U0@@^1ZP:*=7<90C3[M<(=(@L&)7.#X#6$I6$U>
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MM13>"[F-,%E:64+PNZ2PDDIGRAF\E%+:"T]/AM=\_@7N7&B?40X0*+AAD&I
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M['M.Z"J./%Z<PXM7Q?<:?5X .8.%G:GBRM]BP'8\JU1>:EN_=9VB]DUEMWW
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MQ,NR708[$8U[0*!>E.TFP5BM]& >Z9X%7.^2ONODLKP2J>ZV9U4[NQ$0=(Q
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MD&6E?!%AD,G[3DWRD1$W6.DANW$/ N![+[OVD,\-PI.^CXL\38)R#.1>DKB
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M K0*1#P7602"+LCK(DBEX ).!$_P\:(W/#X[ 8$(X+J<D&#\.,$O]W[I!Q$
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M"$%/3[)TL5D8TY-@)@%&V5TP0YS#BL#U"B+N:V6YL35(WDZ(\\*SDF2DXB7
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M%'@I84LY>J?1RC/N\,93:OS7MW6R&I5T176D11N/,W-*>Y.6;Z_9)0D@6^C
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MVE(R"A70P%6#JP(6.>@V->4@4S.H4E^+2D:3#+C&);VNK']->; /">9]V'@
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M53<J4GBXDBN<1D%+9*L#:6_]N6 $0,4CZF#EK"YFB$(<U,N,FMOC+?-JGA@
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MB4[.CL[DV>G1\'@LCD;GYV='@[$X.Q;#\?CL?+RE009_P"_V'CMK9W#<,-C
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MS!5JP Q8ZB4P(IC1WBIM.UF/NJ7$!25CPQEF+M#O5"CR_L0#\.!7+G $W*$
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M7A<_WQ@LTGE'SX$<@?Z0R4YS\D@FJRV\0S(Y.#*I#7?6&=HNR<T@G)!@'57
MC659JT1HT%VDDC[/F[I@CTTG]%'K,1&=18]VZ<:0/E;@SRH3.0(^ GY=!H*
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MR('NC%-)/;8,.=4A^GOD5,BID%,AIT).A9QJGYPJ<$-E]AXH*71*"&G!2*'
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MC)YG;J_3M1!LHC0PX,D5BA>X &.Y!*%]L(Q;[^1&7?&VZ9J68R$>4)R"G.V
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MEO/;6E+#_/1T/EM_&XZBZ7'O8:?3 ^K2P1#$W?O6A_ZY1YS7<L?N"9<88XJ
ML"F#,#F 4<Q"T(E81T0*E%[OX-"9A$!M )O:02_$2? IF?+34083A8TD?-5"
M^6L*4]<TDUS.>_N[FS?Y<T?'N_EQ*H\]*V_RHKGCHEOR6PV4]YGBPLR8FO(?
MK7,U9%W>M7^C5OKDGG=T.T2:LG]#&H*XD:8@3:F(IECNG#!)@N)1@6@G 1E*
M.1":>3O?UWOK'D-3+AM-OXNI=#MQCG$SUNP!JQT.SK\> %'95;,J\IG! 2PJ
MYF <X1#$W7NBB0QMS=!B9B;S -'F""(H"]Y+7?Z(T;OR46%JUQF:-YH8S3,X
MR@NK,YZ#I]D#E5ZH3)DV--\X^/>V^5M?$B%O\O,O:9"W*91O74X>.9<+HTGH
MFQ"C:U ,V@':P:!C08\LF4%[0GM"7$$[J%S<>/?K&R[=?/?3-C/M" >;'0/A
M: (CO ,K8G;9DZ1#VHC."\."\1242A0$+3=')[("8J5*-FK#^,V+^FZ9^_A]
M5[^'SH/$(#WZ)\3IO2L&[0#M .]_:$]H3X@K: >]%7??[0!Q!>T)[0EQ!>V@
M+G%C7+%ON'1S7#';\G_=;I810H(PP8*56@)72MCL;1*6=5'UBW%%]$\[:)G?
MQS[G:BNR]^QP7GY,BS!I5NN<_^T6"S=;-G4,(*E+L[VA9#@EI&IQ]_UJTC\/
MAU-W#MB>ZA(XSFW#$X\(@@B"]H3;3A%H$.O[IP+T336=> S@5\<5;@[@LRP8
M==&47Z 2".<9.!L3>*.9-38;KLUCFD)7T\7N[ B]C/.]R?_G(LKWJ!90.U;&
MX#IX=$*U"1QA%T]\O;"+5VR\8J,]]<Z>,/F'=E"U'>!U;J?7.2^#$TE'D)%8
M$%%0,"I%<%I2%HV25OG']'G>=9U;%6-]XS;WT.HK:@7>Z= 3(2(C(J,=],(.
M^H>H>--#>ZK7GA!7T [0#A!7T)[0GA!7T YJ$S=&$/N&2S='$"6Q-@KM(#.6
M05#MP6G*@%JI0PY9D+A1$/+=Z^8P@HB>: CKCK?@FX;1O-G:MIN%M-YV_&5O
M\7@T2\OVDY/+;PCS9MF4S]RV]?@'W+EUJZ^FTC!O(@6BJ6M]=0(K:0(M&??>
ML!2D[:+[_BC^\[Q9GI:WTKR;'\4X:=^#FQZ[27PU>^[.)DLWO>+2+Y7_O%7M
MIO.^]S(',N;2[JOA_A!JR^J?$X+0.8RQ+!@<VDYP".T)[0F#0V@'E8N[[W:
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M%A.!!K&^?RI WU33B4>L1ZQ'>T($003!$X\(@@B"]H3V-)1Z([2#JL7==SM
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M"ADB36RC:44&E;-UH)GF((1.X,MK@!5$1NH)431=Y@3.3C^</;N,"[[)J]3
MFW50\&@6GZ]"@JM/OEH%!']KXX$O3\^F\T\IK3Y_?+X()ZY)QU,W:QXU%H)S
M/5:BSF'>Z* 0E1&5\=#7BLIX-<>K.=I3W0)'$-F_#H8@;KS:]0V$;BGWBH*H
MH!7XG"@(R@SXR!,([Q@71 CGTO6KG4F>.TXT.*'+SZ1R,?2")3!:2&LHY5J9
M[[[:_<--S]/WW^\>6B=F)=[QT%-5)W"$Y_WK8 CBQCL>WO'0GM">$%?0#M .
M$%?0GGII3W4)'$%D_SH8@K@Q=M@W$+HY=JBL,-Z& ,3G $+*"$YG5GZ?XR*J
M)#*S&X.]<G3"" 7!*P^"!P=6R@!):J6,T)3QB+%#]%1[;1?%U>OUN)Z5#8,O
M!KQJ#CU+L\:M?%#ZV'Z<ZAB#4)>6>T/4.FVOKTL'0Q WWO9[=MM'>^JS/=4E
M< 21_>M@".)&$$$007NZK[BQ$W3H\(,DH 8MH-.JZ=!7[XV0!* ]]<B>ZA(X
M@LC^=3 $<2.(((B@/2&(((C@H:\/1+#X:*?%1T$(X[Q+$(-((-IQ--8D#<;G
M: IFN13\8QH7+^?4'\5_GC?+T_)6FG?SHQ@G[7MPTV,WB:]FS]W99.FF;]LA
M,ZL2A>=7*A1^3?\ZGS1%=&_3XL,DI./RE//X:PKS][/5JZS*ECJI2*)%3U96
M.?0>/1C"-L(V'OI:81OO?GCW0WOJG3TAKJ =H!T@KJ ]]<J>ZA(X@LC^=3 $
M<6-,L6\@=$M#(Z,A2.7!*$% 1&O 46N!Z<"49RHRNK%Q^WL:&C&FB!ZLJD9'
MW(M9CTMZG9:CZ;QIZFC"KTN;O2%JV,]=M;CQMM^SVS[:4Y_MJ2Z!(XCL7P=#
M$#>""(((VM-]Q8T-C4.''R0!-6@!G59-A[YZ;X0D .VI1_94E\ 11/:O@R&(
M&T$$003M"4$$000//8((@@C:4_WV5)? $43VKX,AB!M!!$$$[0E!!$$$#WU]
M(+*K-HC^H<B/EZK%;HZ-;H[DHR*&2/ D:1!:>S"<,="$4*8I$TS+Z]T<1&IA
M4N)@,A4@N C@6?E(<<9EL.4UK+O>S?$Z+5_-POPT_3)OOF/!5%..8?GHSAX,
MS<><:EPVM8UR_]T=SY_J\+]U:0Q)Q_YU, 1Q(^E TE$1Z2")FJ2- ,M3!.&%
M*01""T@J>)^ET5&F+EI(D73LWWWVCW3@BLRM:'7/GNBW69'YM+QL7#60CHHS
M<A_<9.K\-+6&/FJ*,Q@54?R1EJO/-2F<+R;+27IHLRE.!:F!*G7:4W]1I_]9
M4+<5ZM>EJR&HY1O&<5_%8(ZFMAS-+NWS*L\JZD!#[=.8'^Q 0F [/'M!8$-@
M0V#;OJ%B!^[0\0\54ZEBD)A4J18D)DA,D)CTWU"K-T $-@2VBNP%@0V!#8&M
M!X9:O0$BL"&P560O"&P(; AL/3#4Z@T0@0V!K2)[V3ZP89D[EKD_H,P],&ZD
M8&!9EB!D%F"884",\YQ%$D-RU\O<8R+)<T[!$!= L*C!22+*1SP$%K(SD5PO
M<W^S/$F+=@'2(IVD63/YD-95[U]*7O]W/HV3V?O_<9-96PK_9O;V<W'KT6+2
ME"^]*/^<O5]O2GJ=EF_R._>QVXIYKCHKET<^U.?Z>B142*B04!TVH<)( 48*
MT% 1V'JK& 2V*M6R=V##2 %&"KX_4N!H(BHZ#<E9!2)06^[_TH'13D<AJ=>B
MDYW*&"DX8#[4OT@![G#>BE;W[ +_YJ9N%M+(+4<O4DBG/BU&G(Y'C#!6QSR<
MNC3\0 []O+RB7TP^Z\3-&JAH)-%W>%KVE+6N-L[/V[D,2*'W:AOW5TWUE]/^
MN<Z:YB%_\R#4SH<.P%CK$C@"66^ K.J[P@]U&!<B(2(A(N&P%F37I9=A B:J
M8.\J&"1GJ=^+]8)R["J#A:F?5>I'DDB",P*HT@*$=AI,C!RT2%J:U":&_/74
M3S9,1I'*DVMO05B?P%KN(1LE;=3&VF2NIW[>GKA%:MZ<+YNEF[4IGJ]R-LWJ
MJU>3->3.%(V08ZWIF'-6Y0AD9&3U^[*Z!(XXWQN<Q]A$'40!8Q,8FT D1"3L
MBQ80#!$,\=;<-S"]^=:LHS5*)P/!TP""1@DN\ @N2Q*23TJJ?/W6K#RSCBH*
MQM$(0K$$GGD.2CMJHS"4D+!Q:U[.PQ\G\VDY/\W+?YU/EI_N7^IXU_79Z+&D
M"N_.R!B0,=2K!60,R!AZSQCZ!_G8*7('\;':Z>#;7@]-0 C.P"7)P(NHA?#2
MR[C9*>(-M]QJR"RV9$EI<(Q1$#H)*73F2:4NB<]]>CR$D,A^#LZ]XY)GI$](
MGY ^(7U"^K07^F2B2-G[!$KKO*ZV\(8EB-:F1+@/7)'K](EGRXA4$2CGMOP,
M3> (=Y"]HRH)FXFRNZ9/3- Q$1PIU,&Y>*102*&00B&%ZA&%0NZQXA[1R;BJ
M])1.<!!,)3!2:[").%D^2(1L<(]DC-(DE[,4!06191NZ(86T^.AI8LR;D'>4
MLV)"C0DS2#D&D;.Z'*U1_G9%2JL/;Y/'G[;K,QX Z)1M54I[%,87%[[S2RC=
M?//W$.KZY]NW^6RR+,\0;A7SNY,T<B',3\N#?9K,WH]F\V5Y7;<HGRX^LGS;
M^X6;CL[<8CF:Y]'R)#5IE"<S-PN3\OEFZ9;IM+Q4\[1F57WKY#Y(R'ARMW!R
M;Q,JI?J:1$\^3Q\Z<^_3&J? Y?*XS]STW^Y3\_.3T9_[YD+Q(#[Z(/I"LK8F
MTN.__V-T?.+*40_I?,5YFO'HU2Q4YOU6Y/:+;_X]N.;D]SR=_[OINP+>?GZH
MT?RFD&KO'BB/GA?EC/Z[54Y=AZCG@OUQ,BMT97[>N%EL?JI#M'5"PNJR<?EV
M+IZ@?:?/W/ER?GF-:]]@X8?/R,^K;X>I^S0_7Y:7_YC*G7#UJRA92?#B!\J)
MF+JS)CUK4F&/Q6HOA;.>%[!Z[2?7!PE^F#03/YF6Z_&SRY^_89[@^M=)^90)
M^:=6GC==<2_>TU,AZ#>_AWSK.]J7^?:O^N;+/!62#>[-2&J_\V7N&"%I5J=]
MYR,DOS. 7IZZ!M= ;W$-E3= ;FU^^A;4\I !ZKO32]%"^Y6_/*'DR3Y#X?<:
MVGUYPN^E2C,<6F.Z!/#_F]QB]++(+-9AK-\]?KGV _$-V^Y4F=^.!%>'D*B^
MH8%F]YIY"&;N4C&?49,A:!X$:%Z=:/Y??C'Z\U_K&6N. #H0#[P_/3S@ZHCN
M%MWM;MTMK<-*T=VBNT5WB^YVZ.Z6U&&EZ&YW'1ZZR!?>.S[4U3+'[UG"M:/,
M:N]2UJM*@%69QB@OYJ>C^5E:N&5;E=>6]7Y8+?Q[MN>EG:V>ZZ]NWV]2_:&
M7,TBXD-4$ZH&5?-=-0"'4!Z$G@S-!5734]6@)T-/AN:"JJDX^M!5N.E H@];
M;K)ZG9:CZ;QI]AP[Q!!#Q?,M^F]E.S2H2N96U&],/726WYCH];!?UD,YW#+3
MB_D@N,K O',@I*%@&26@LS,IER^M9F1<&XF:HQ-&* A>>1 \M -598 DM5)&
M:,IXO#Y7XW@Q+V_GEP):W<[RTGS,VY;C"N=JH <>[F2N [R*H^74:3G(79"[
M'"9WH4%JRH,$H60$X9UHM],PR)1)UJYX3=YLS 3CT6M"$K3K;$"X8,$3QL$$
M2X3-RBE+=\5=I!X7%H7<I>\>&+D+<I=:M5"WY2!W0>YRF-S%9N*-- 08]:X0
M&"7!!Z(+#]&669I)VEQ%HS,)@=H -OG"78@K/Y.2 6&B#"8*&S=W\&V+NW Q
M%H(@=^F[![Z1NV#9\D 3AT?QG^?-<CV6;3D?+5+Y4IA,TVAVD5%L/]M^W ZB
M&YTW*8XF,RQO'D3N$4MI>J$F5 VJID(64Y,>T).AN:!J>J,:]&3HR=!<4#6]
M*6^^*N.+5^HN<'%U;C.](F^,97SWA/EY^ .\:X,4[5Z4-&O<*L":/K8?ITY"
MD9T?A;NM>_^'HV:#/_! \B $WGOPPPS690:+9&]5L$"3RR BX6"=E^","80X
MPGQF750.OSUQB_2WULT_O^+E.]G*1XMXK<0D%OJ>"D6.H%N#%@8A< 3=H8 N
M,4IYRCPHP1((VU:,<"* &\$MIRQY'KHH>=TBZ,HQQ\(1=#U5BAPQMP8M#$+@
MB+E#P5PJRQ65N0#*IG;UO"^7UI0<J*2,22ZH+#<NN@\IU=SF17=L.4?,K='U
M;*W6$K,8?7 Y+U+YK6&R,O5.\H^8L>@7D?O>[#%Z4TS7(Y%[$)'C,6:3#8'"
MV0H5X]R#E<%#<,I1'JD447>1L;CJTSNA;YQVEJ1 =]-O=U.9R!%G:]#"( 2.
M.#L4G+5"2YU8 A^R V&H!4?+'TRSS(CABAC119*B>YPEG4T20W?3;W=3F<@1
M9VO0PB $CC@[%)SETA98I>TM5C(0L@"G53&#5II(GEWFGG:1F-C"?=8@SM;H
M;K"EXJ"3$4>G\R+H_[=NH_C1A;!([8<_C>9Y5-[/Z>3\M!F5+Q5I_)&6SD]3
M><%POEA-A,!^BP/,7F NN'*!]Y[M]="-XN2SNUAK.VX^>NY 2J] ")+!.Q?!
MV9:7BA2M=5UD88XNX>LJJKW)+R9-*%)<-D>S>'R!::]F']+%6*1.^*UBG?';
M(3O8'DY&PPI9I"85:&$0 N\]-4%(OTSX2,$44QJ2<*% NBKP+&@"9@1))-IH
M52>#V+<-Z?<:VBZQ>04]5(TB1VBN00N#$#A"\U"@.3-: 'C5MQ(*S$95-*\*
MZHKLJ);*YK!9\_B0'%$-T$PE0VBNT4-AC\M!IY5>SV>P&B@^3:Y)CYS/A=TN
M?<X78;J^<H$C\^N??[VE;5DSKPOY T%5X7LT6["1<S Z<6<295D]*L]R=OKA
M[-F;Y4E:%/_^O+CW7UKO_G+MW+LI$^+8]H)^IT:1(^#6H(5!"!P!=RB 2TSF
M3*H(6<0VU$(5^&P#>"\H%TI33O)CLB#;!URK!0(N^IT*18Z 6X,6!B'PW@-N
M#P'S/__C(R-4H$W58%/8Y''0T?@5@QRW6SZQ8^, (_"8V:Q<X,A/L&.CKL"&
MMR2Z'"(DR2,(%@6X2!UDIB-)D:O@-LH[']*Q<1G;:'/%KV9A?MIM< .+0[9#
M:+ G X,C:#E(/I!\(/G80AE#FSN12;<%K Z$$A*\8ZS=>.*D=L80MS'DY"&]
M)=LE']0B^4#R@>2C3UC8)\L9A,![3SX0M"\C!DF;U([\3$Y+$%9'L(P$R-QS
M&7G2/)(NNDXZ .U[-98(7)Y2I1/"QI*#3F4]/W&S]VDTF8WF9VGAEI/9^Y%K
MFK1L1FX61].)\Y/I:CC9,^PV&62NJ^BJ_<I?GK G6"92KYI0-:B:"@E+37I
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M9<G@,WW X9PO>Q-RY&$11]QTPCGW7YB6FQC)$08@#)B6@" ,.#L88'EL$IF
M#=>,$Y9GC'#&$J(TER(W<5DDX@$'43X4##CJ[A,"@2],STV,Y @$$ A,2T 0
M")P=$$BXL;%6!1&Q4(1);8G,<T5$2<ND2+FR\4,.CWPP(%#265D@%#@/3?=@
M)4^X&74*FLMM1H%D S=:$U4+OS$U"]M3YM^KZAUHA\6RG?FBJ,:TRZ922Z/]
M 4?9?,;MJ=."H]BV<.($/_FZ]Q-4HE_UO$48O <&:RV,DJ4D,J4Y849Q@,$E
M@%LE\ZP )&G43A+6YVR+.0SL_O_]VF[],E@L]\/E0F_^873D&WBQ&D!SL(0O
M.HL(W^<K#1#Z^P_J6BRNS"]B:;ZWUJCEIT/I%I8Z?+H_M8O-D@)[RSX,QGI$
M"?AZ&EI^8CQ#>#,%+IP%P1'>(+R9%KQ)6,)UP6*2VK@@C+D<\\0H4E+&N4YL
MQO+T&-M]IPQO$LYG29HBOD%\@_CFE,SM*4G.61#\Y/$-XH(.%^2Q2(14DN@D
MUH0EE!-A#25%DFJK5&Y$P8ZQ^S=57'#?#J*# XPA')BB4L-1.D^UU2?KN7XP
M)?7\P3?V<(C.4V$^X(+[Y>_/Z+/'35I"-DTVGPQ9,UG63,R438D/J,E07) U
M)\,:U&2HR5!<D#43CD'@'(8IA4K_0!0B(I$T0)*%:XI3V^C6ARIQLL+I2/'$
M.I%A=1OV5L3]K>--5DAIIE26DT1129B1C'"5%\2J(L[++!=<[.QO926E7*6<
MQ&G&71?FC'"7"LRY*0I3R,S2^*C[6\-.UHNJO:U;,?\!2'\+9\!W]VC58F7T
M:S MPO=K/,KN5E*D,\K+2>YN87W<]'7EQ$B.8 +!Q+0$!,'$^8&).,N+K,Q)
MJ9.,L"+51/ D)SHUA=',\C0MM\&$D+*PEDEBF;6$T9@36:0QL9:75C--+>,G
M#R;2/)DQG/J NA+!Q+3Y@&!BHHQ!,/&E@8E8VM*6A2:LM(EKP)<140A)2B48
MA;\9D^Q4Y"1,V)0)0Y2(W:2((B6E49I8G91Y*E6L4WKR8,(%)@J<('D>JA+S
M='&/+"*1@;_^V=TQS-R=)@9]P-9H]((Z%:OKE9R;::/0:5=$_N<T4DL^G;O3
M%U $LGT)&>5%JJTEQF@ I;)P9>(YAW^*,J<*T)?K@K-56LYY7L065I-F<([-
M"B( JA$IM4P,I9*[;CLG#F23N)PER=&VV!Y7SR*6G8"^G!C)$9,@)D%,@IAD
M^I@DT\Q8GL<DMX:Y"!NLD9):0GFB;)Y(8;.=;GZ8]C-U/8N89 +Z<F(D1TQR
M6ICD+%B#D.++@Q16RT3'A25&2T58GC+"!<\(X[*,K4A5DAM,_D%(<?+Z$LO:
MGFK+[D%;Z[Q=W=[.S0U\$?-(@SJ8U^VJ@>O4-@*Q]1MUU>(=:):CS'?'6K;I
MUW1_<6W_IL0F9 VR!OUIU&0H+LB:\V -:C+49"@NR)H)!R0PAWA*@=8?NWF>
M;OE7[^#\56NT"S5&<_?+=3W7475SV]3O?-SB<T,1F#@\37UZU$COZ4OCEY=Z
M,WUA.D&E^E__\8'&"4.AG,)>"J9GH#6: !?0&J$UPJF,T\LIB6V:*I%RPKE,
M"4L32R3G!;$EC6TADXR;Y,],9;R]>7?[S8_=L*3.R?H-?*R7=?-C[V&]&CE8
MQYVGR(]6Q(VZ^=1&*2*J053S94L.HIKS137H8T_(Q\9\Q3/='KA4JED9'=VN
M&G4-:-6G*@)8O05BW_E&(Z[SR*U#KIBD>%8[ ^<\*_4\4<L7MS>.,8R^U-90
M:C2E)#.V($RDEO"8*Q)G1EC*1*;,3EV,LEHPSG*B9"X)2Y4@998I8K(BSSDK
M$NI:AFS6Q;P1=SY&\6M]J4#M-^9-4^N52U,WEVUK_DCPXK[ZV#*?9.>YB2FQ
ML[ :&'.8!A].:>&C]4;K?4[66U"5Z33+B=:))4Q134JN&#&"9R7EI56NH^SG
M[T \LO6>I66"]AOM]P1)CO9["EQ ^WT6]OL$[>^?W#,X9Z$\Z3T#+"DXK1X'
MMEJ(A3I*CP,L+'@J (-SZT^"3<@:9,T$\<:4^(":#,4%67,RK$%-AIH,Q059
M,^& !"8Q3BGL][Q> %U;M^-66[>1YJGL^H_"TUC3-,;QLU:_1\L:?KZYJ1?A
M.Z8TGH[T?N'Q6]Q4.0M3>(+:%3=5)K2I@EO\:(TFP 6T1FB-T!I-3"C/0@NB
M-9H&'TYIX:,U.@MKA GC0\L:'6=IRHG-N'7)WX;(5$C"RR*U-I8TD>5VPGAA
M8Z624I'2R(2P6&1$&L,)XSI37+-2QVJC9<TZ:/;:/E^'S-[T$;.W+D#V:_W<
MA\O\EZ.DC].4SPJ:8@+Y%.TYINQ]$1'R]Z)IQ&(9S2LAJWFUO#M27!QS]::)
M_<ZY%\IY8K\O;HOX!'4J-BB:$'+!+"6T1A/@ EHCM$9HC28FE&>A!=$:38,/
MI[3PT1J=A37"N'@?%]>62<L$B5F6$,84<)Z7&5&ZX#;326D4/VI<_/^%0-F/
M?9SL^.'PI&38P'V*)AR3Q9\J%/YDU>NA='U>OX^J11!9D$9,$3^Q4/BGETA]
M<1OL4V(3L@99,T&@,24^H"9#<4'6G QK4).A)D-Q0=9,.!*!27E3"G(^=_&&
M6U%I%R",JH6J;TRT%!^.$O\;LZ1[[(>,0G0<<YSI;X<BC-%;W(<Z(WMX@BH6
MLR(FM*6"61%HC2; !;1&9V&-,"NBRXI@):59RCC<0!G".$U)F7%#.%.E*5A2
M,)D?8[S,*^^@_"H^F/8-."T_F^61"@(Q 0*M]01)CM9Z"EQ :XW6^IRL=1J7
M(BM32A05&5C>(B<BBTN2")49;M*4.<O[^3F,#VRMCS:Y]9QUUM/M$<!_A9P;
M__$01?[RI9G2)R3&6AN?2" MG.\>\YMJ">^@#I+YUVL3"05*!E[LSHWZ6=1+
MN*YHX,^@[."PJT;,HUO1+%URY?+:M*8?# 1_;Y=BZ?,PVXLILPI7[JFLW$-$
M31*^1='K81OU5ER98':(L/"ZWXCY>W'7?OLL^NNIJ5!<AY/..W_STS^C-]<"
M5KHR*X]@VED$&&UBRL^#5*_(_[6L_S5HZW^MM?6I,^)G;Z66=?1R,$5OAY>;
M%C-.G-(OC#(WTC11FLPB&E,*N$"[#PF2^8AD_JI: +BJ5RU0MXW,!V5NEU%[
M'7"8CFZ! =VW&WBK9?OUE*G_]'!+5^^.Y<8-(8"?5S?P!]5% '@AK"Q+1FA1
M@C>?&O#F,_C$=9&E95'FY6X5H[):,,YRHF0NX1PE2)EEBIBLR'/.BH2F>CL"
M\-VJK1:F;5^85C75K7/6+Q?Z.]%6[6O[I@$XOECZ$J=?X3[?S7U%(QPJ;MU:
M:%;F'J?Z"?#/9.7RTSVFY"**7O9U95XX>Q9U#E+T/'A38P__\UB0(POVLN!U
M<R46U?_L5/;MI7)V4:3IF=#Y@9VL@_ V^LJMZY"&H[[MUG?XJK_].GHO6I_X
MV-S6#8 P'7EC9D)TP$G%"S,7[YWU@A]^$HVZ!@"1I!?16SC+_=%9.^#E;"P^
MT35<59MWM;M@NY)PL<42@-[\+H)_W%6K)4! >$\OA,;:NEEZ3 C&TL4^733#
MZ4=_/W<(7,S,ZUN'$4<3C?U/C:A:=SSH3;?V+J)?1P]2P3%N!I&J0NO%A>/=
MU5W414VB6_BK <+"^>[Y73UJ_<XT=SLWA6=N;]S#W]1SHU9S R^\NJD;(JX6
M=0L$=^<#S]U3+6'%F:6[YFV6;CQ/H'OY;1M=&Z'_O1(-F. 0L@'U[^DOEE$2
M_=*_^_\3=[/H3>/(O'1$=JOB_\ IYF[P6\8+=XHK,SJ&F"<4Y7P(^HT6-PC7
M?QNU=*+35.WO02)6L%J:I:@67D:ZMJ)P!"RI^1VH:7%E.@%POW<"+RN05G6]
M"/(!G%FUR\9]4/.5AK4\B^1JZ4*,T;RZJ=Q*7=8@ ^X4IVWZV[=M#2Z=^_E]
MM;P.JF2E%)A8NYH/,CW;%&AX9B# RH)DK[PL@K3=-K5>P9LI^+72<,5V\R09
MA!CD;%DW8?8Y4')X!?],U6)1O_.FQI]\:]QZ ZT%Y/C=W#EET]:+A9G/W-W@
MU&77GA6^W3:5 3F^6U\1!-'=<%X)=PG_=E=.5RS\XS3F:C4/M_+OXUY\U-NU
M!9WA/ "M*W<,/%NGKMR/%A9@5,/3A/,OHN>KIND)8U=+=R8\TE4C;EJX\=S1
M\=^K"O[:PLJN++RK?X(#^K)3K[,U+\%)@>745N_\?#8UKP(+W8G#%R"X5V%>
MQ8:7JYU>O(4G>>?"RDU5-WW;6M,X/[XSZU[CM690Z_L>MG.%'+%W:3*#O\$Y
MS@ -+/+/42UL(V!9KMPZ,1?1]^_,(JHVD-M:P_8+: \IO,)=+TN@S-()TR W
MT?MK \H6K@SG-INFK:._>]MM^L/3K$QDF_IFN'DKYF8COHX:\,]JP->+Z"U@
MCA#9H)F/;,2;//)R:KPU=1LAE<,>T>U* C"%%6>#O=_ 1:_>O%YC(EB4^XPK
M[J!W_G-F9%K&64&4YC%A.F-$)+$FN;6Y2A.C$ZJV_><X9LSPDI+4&D$8G$1X
M02TQ-"MIQI+,)'3;?_9-?EZU[<KH%]XNO(&'K?5;%TQIX4W\3^W&KKH/M+3C
M[?17/[^\O_]/.LMH.2NR^.#&^HD+3(@^A08KHQ;C,P<UQ8Y8@%Y7'OC_)\K
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MBM@0SAF#KW$L4Y:6U.[X(7]$IGI3\U&Q.HY$T726%.<K48"Y%B 6@\GP^5Y
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MJV+6@DHOLK3XR]GIG V:#@2M%HXBQ-/UWOMNJ^E[:#XF95Z"S6=YQIW_4>1
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M7BT=Y!FJ#  &?3MXC.&U?)Z4V[EQGAU<QPH5L%M'"Y=/XOC6^)H)GTL2TD$
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M:>(BD8RHPJ:$I2YX&B>2*%NRQ,J<I>)!@J?KP.EF&!6#IFCB)Z:1T,1_4?*
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MUS)E=2HRPC-9$L9I3(3-8Y+H)#<JH5K;\I'G=Z);B[H- <#)< (!P&19\^0
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M+](>X&A Q%V(NQ!WG2CN0L 22D^5+941E,@RTX1Q]XFGAO RSJE-6)HGY4,
ME@<M/77;1UE^U):4"$PPGH.X8JKR@K@"<07BBBGA"I8H7=)<$I-JY<9=%418
MFY,T2\M,T51G+-G&%87-<T[CG.B<)X3%VA I:4P4H\H8;A3G]I&+?>)9F<>(
M(Q!'((XX#4X@CD <@3CB?'!$D:5"@_4GF2H+PI),$6Z,(DEB31J[4(7827.-
M99$5.;6$<PG8(RLL$075)%<V-@ _XD2GCSQJ,R]G^7%G9""00""!0&*J\H)
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MUXFB,<A$*1WLD[$B9689R>(\$7 MEG/S:.O[(Z/H3WQ]H]/]R2LY-[),,@I
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M(LW-."-RAB8D@N#21$&-9_NH%&M-\G8/KWV";R)H9Q/*?9]+^%PT7,?(7J!
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M1X9B^(\&IH4_M]!.LU5MLNK7_)9MQ M67#T-YY=,R X-W.[P) (E)_W'%"M
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MCH.C>7\<0XH#UO$F8&O(4VH#?(TNT R/M&#/7!>P@VK8 [I'RXA!]2W_593
MU9" *C#]R)&4$ \L(LM\1"(8I1*AUO&M1F=&:6=E8(A%+A$75"!#@D-$>3B+
M EJP6RF[.WL[2RWPKITB\FX"ODT]#0_>W:SG\K VI^=[3EQE/P\V\T! E/C=
MCQ<A/MDL^CN-+WKHZH1.T:*'RY)0<[XD(5=V')[N#SJV7^*RS@:UH=Z7=OS-
MGC2O7E1_>@:TWTM&>!?E/_SVC^H#Z(0CN/VBK5$"C/!NX@^>U?)^4!+_/IW'
M-AWYMIZ EJWMN/HTM_/6MC6%S \&]=ITT<6Q@87&]Z'QCW6.,$X7#9"V 0??
MQ[SO-4.*EMC'0/W53ZVCW?S46=(_=9G]M4CJ!M4UEU3H/<_RFO>;A2]FP]%;
M5W\L:UQB*![?E;E?92/SF*)(VR8$,8''9_*>L6@U%TX;M97<<E%:&P0<I!G)
M19H:62P2TI3ZD(1/W&[-*;FSQ[>LGGHW:>:S16L]WV=G_O.AG:QF2K;=,9L]
M.8-,\9$VN_L:]5QHJH]GI5;+XLL_<G56]>/'3W\T;43VM#XJ=R','N(\_Q9>
M^K1'X2SFB^45=#R;@HP=;96I_9QCR?]G5Q!Y59P&=SP+-Q_:KVU-6H"+?(5'
MS+FKZ;*RHTUO5LXV];)Z[2&D>4<!LTI:8^(<2MH(Q%.TR!%!D*%1!Q9#M#QM
MS? ATB;B&$HIMYEU#B,ME4,&TT 4]U)'OS?9:/_ZQY)>R^5/SJUNU$3_,BQF
M>8M"$R?]5_KS;]/J)-K9&82^6.L_##%M,Q\@9),%X*Y\\-?:+[,OQSMC-9OO
MW,F7VL1"#[_[0%JE"!$<,6W!2!'#P; )AJ013KB@.0U;A81WV7WPR1_&L!C'
M5:><+3%>%EPL3=7K'(0':_8Y1^%V;4!8<SZ&U_.;OLB_R*Y]"P52WJYBN]U9
M5+DXGGZKFL41O#C<9YGT7)FB9>FT7;'RTO3C,LM2;7FG+Z]UC6ZPHV28^Y&6
M6_%:XE^R^\,NYM/UUKG\D&#O7N)7[>%H;$^FBSG<XGL,KY:W([AU,5<GP%(;
MV^,FOFSBL9W9>5P3J"T:7U[[Q64MBK[63>WJ,7#YY?H:.QH5+6\K]0&3_(=,
MVUU;#%?/=X"QNLEQ]$ JO<\+9K)<?Q0[  IN_"'[N_2!YFSKN&MZ1.EV\3U)
MBZCM.0]KZ;G1EDS=C<B&'O(&]<*;PIO"F\*;!^8-<")_VU9"/PZ?CNH0QO$N
MG5\[R<]'2'SL=4VL)G6<=CZM_NQFU9_^FF-0;<BQ Y)\LQ6RW5&BZTNE8Z)?
MU'(G>=/ASK+=;#/6N]3SSW:<2]2:T58HA71'8#O&Y*=.<C\-+SK8ROEY,J((
M1<<:+':,$X,A>ID,V[\$SXX2&)JH]58A*WS>H6WSGD:CD$H")X*9]'XOS1#+
M9-BBPOJDPCI&]@[9\ Y/Z>TF[WIH*U;AOTOW''=G+%C'^-PA&2V\*+PHO'CZ
MJ6D=X\1@B%[\S_YABLO]3Z<,QLY2%*P&_Y/;W/)2!(23U31JFMOQWZ=2]:'F
M0+;.YU;_CGV-^[FV44]1;,]2L76,[!VR["4?.GRO=+618+VWL02+NB^6A1>%
M%X47)8O0%[SV[!*A/80!I6'W50ZU4(P;R0U*(N_!#E0AS8)#S!&.:=***M]9
MAWJO[0S(B!,S(D:5W.Z#N02/N-Q_ZHY:[QC?.H1K2G)X^&[XN>8E]_?%A\W?
M#LEFX47A1>%%R9WTQ1=_=DGA'F*!XHM?Y8O+X(W4GB/B,$;<<8MTLAQ1XI.F
M+@2A;6=]\;-N>6T7I[97WJ.V&RQZ^IEXYP7I]-<['W9DI8>6:)TD!\6;8IU[
MG?ZI\KDF:3PN*?,^"&G)4FTCXV?-GB(J)5_3+\_]V>FGXO&N/%Z=HC86G%V6
ME$ \[RFV*C(DE$V!JD"3[&[V^>T2,BWRD+7]N+A&C23=:Q5WT6?]UV<=(WN'
M#'I)'W? 07V4KE;;_<%+ *G[\OF(O"A-K3K"B"(4M^'%LAOI\K5W-:M]C.3%
M^;:H](#FAPG31>[E>OYI.L;8Y\7#:X3NYEPL/G)O?.3D@E 87-T4C4*<DXBT
MB1$YQB2--#AEV44?.6HM%4ZPF@(GB">AD(7%AIP+CD1*G?:I-RVWKALY?E?A
MW.[UW E-N_U81>46"-,I"+/I=\/G+.T;M-H<1K2:T72!?,]N:-/V[+U0?]U!
MLM44LEN13#ZK8,'R_/R0+^LY/+_?R8AVS-BOZVF<RRF>'Q8S?P@VK!T_=NV0
ML1O,A.L-\1]A)-RU!*]^S./?EAL"_*OEX9\^?%C^(KSZJ?IFFZTAJ2X/2<UC
MXD(]BWX^G35YXNG92&/*VY@0/JBJU]5\"FLB'UQJ#:]JI.-I#)Y8Q*/TB&,
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MZB-0>',KW@ G\K>YUN9Q^71^A]#N/85=Y^<CH/:]KHEEE!APSY_=K/K37W?
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M.<254_0.ZIK;0)P4J':2>$C6EZFHSA*,CAZXY2PRDP57.Z?6="8A4!O )E]
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M-D<:VZF$$#3EAD>@R4L0P26PB6J0@H5$O;9&^9V*:TQ)18*!Z%D D8P&)VF
M\I(ADF1+''O"4PGVB&K1[*F$QC!M-$2"I-Z.+X84 $CJ2.IC(W5E M?663 Y
M61#*"'":6TB*>A953%2F3TD],QJ5] DHKVV,4TCE/442T"(!9 R2**Z>D-3%
MD>4&21U)O6&S(ZFWX@DD=23UL9%ZBL:$Z TH'V(AZ.3!E#DZ"!J8RR9Z(<5.
M_0!"E&#,@V"IS.X-)V"=+^]V63#A#+?L*=L8MUT_H#%,:Y9(L!C <#?$L)%Q
M2\#_>UJN%I.P.?5=]\8JQG[-SAB&YG!A$KFI/6Y"N=P@:M[2=%AGJI2@0$-,
MM91G BL]A_*4+%$5*.4[_06Y),30K,';H(I<U@:L-:S\E *1PO+,GK*4I[;M
M=A=$0$)&1D9NQQ.C,?K@&7F C/I?__&!$2HPMIYW;#5F=B275CPQ&J,CN2"Y
M8&PAN31%+GCN9>3+_-M:OA>+_&?K13AQR]2=31UV*AU @#YM(?O;3P$WYK'1
M.&?_A[0;59.X>;#=/*B-NW+20%G=/+!<@S'&@_,RA$!X?64G@=;JQ%P4((3(
M(#(W8+T5(&V6-%KKA'C*!%K&:;.9-I]]P!V1#B4!2@*4!*T&"DJ"T4D"XT-F
MKK9O,=&"((F SY:!BC23*)Q@:B?]EJEHN+<1,LFQOH>!%\Z#IHJGQ)-)]"G[
MC@O"4!(@TJ$D&(HO4!(T[)QG(PD&2.E[V'-"=AM"T.(FU7 WJ:[[[JJY+^ZV
MOWVKJRW@Z!73XU;69PZ2-_.5FV[VL6YH?HB!W'X@/W:Z!7:O;^Y,^4'+U6+W
M^H%!^BVGSQE)T0L!1 L%0E()3DH!D623=;#1^)V2,E_2\?@Q3Y\7<UO9[(D:
M;%_?#*&AN&C'%R@N4%R@N!B7N! Q$&T(!\9U!D%UW5O+!H+)U.1D2$[Y4W&1
M>/2:D 3,.@K"!0N>, XFV#Y[QRG[E&=UY1$7[9[616W1#)^AMFC'%Z@M4%N@
MMAB7MI#12B=D&1F*"!":2#!,1>#<6DLSMR'O: N=20C4!K#)%VU!G 2?D@%A
MH@PF"AM)&%/9/-06J"V>WNP-:8NKNYOE9U?&[M^V ??+^K3<.93?X^3=+:^6
MM]YJVF_:LRP[J&6K,7I37;/4!3QG0F4B(0-+1$,M20I&: 7:*VY59DYYOH]U
MY9]G87Z:WK@//TR683I?KA?I3;GC=P6T_WC1I8+"9]55BW6Z(RKN=IUJ1+Q]
M;N?$+PNLS?OK0[Z<K,KSAUL'1+E_UVWLWQ4'I&L%#<O N %VOVA OKAYA/FH
M"(TJ0W2:% $0:7^,!V342C@K=?1A'R/L=3A)<3U-O^;*^_-9^?++7_/EN+L0
M -^E62KF>5,AY3,'H#S6G(]D"!XZ+>$D=9/-B%NY#]V?_,;J?^[.%O-WDV55
MAT5?=:MRV7ERBV67BHECMQV8 __V/Z203GU:=)P>=8PPUO];?G:S6'\B75&H
MG5L6&Q31^G[9_6DR*[:8KY?E@N6?7UZ-SQM'HCB6]XW$<?+81J;5V+TID\BM
M5_.M_*T/.9F]?4F^[2^'J3N?KU?E(SZDHM'ZCZ.DIY2+-Y2!-'5GR_1RF<[<
MHDPDM@;JIW>;>[^X*>.JCF<_F4Y6YR^W][@E[VKSL9(>&_9-->UMZO/B\8ZU
M, ^ZCCSD*G;,#2,?_T?W=^M]/RCE>[S=OA].4/6%M[LG9<]\;<;>H\U']M\*
M]PO 9M1-BM$3=WCBLAL\)=@._AYWCJ,=_$\76O'?O5;\L=>*5T56.X&+K>*?
M*N,=Z;-5QZ$GFO+$)7TR9,]GP9YU!:*=V$2&'!'0HF\0>A%Z[X1>VDZT(O0B
M]#Y7WR#T/C_H)>U$*T+OD"HA$''$N!EKGM< =]2_7R\6U6)?4S]FU#YM*'?O
M,^D6_=*.1$5?H"^>IR\0K]KT"_H"?8&^0+P:BE_0%TWXXE&K(\K^9GOUYM6L
M9OG1]KAN\+F)8RFFA9NVLPZ((=O*,=G&/(%% K G[-/A)&!4XDGT=LR.M-2*
M)Y"6D):0EEJ+RM% (=)2.[X84@ @+2$M(2VU%I6C6>N]ODZ/:[V#B,K7*[=*
MN#DS"NWRN;[ QHP-.P<;,[8+FG^ZJ>36UW[8 .UP<^U:&X1TE&K@@640)!JP
M6DKPDG II(P\DWV4KKM(;^X9[-4L_GU>@F2G9-W#2]<NRP@M/]U9P];NM?/T
M(\)U\]5KVYZ;_KD=X&_,;ZB04"&A0L*J^(_3SD_HX (KXT*04%0"L^!=8E!$
MA1%6:U'4PCXZ[NQ96=PA*-A>*^*CHGB&.->8V5$0H"!H,U!0$(Q.$*BH"1-$
M@F2J]O<UO))[@$A)%CP&J<)>VN0\GB!0J =&!7./>J;BXFX'VVBC5PP]N.6B
MIT:P-_.5FW9A@R3MY#HT%J7#DH][S4M ^=AT6MUXY., P1-WW.Z2P2$'E0V3
MY0.B!!&$ A\(@:*"+9,Z1,YV9/!7[+A=G \<[,;;8Z)V\[)XO!MO*)2&R\4H
ME!IVSK,12B@PMOU. Z-%(5!@(5>!P0Q8[AC$Q)RU6F9ES1XWWO8L,!YM_PV%
MQ3.$N\;,CKH =4&;@8*Z8'2ZP!K&)'<9..$:1+(,?.($#,UU8\T$&=D>]]\>
M3Q?L=1L.9<&3HQV6.Q__!ML/*:<"$Q'KG0]%&V(]SC;]@KY 7Z O$*^&XA?T
M!?H"?8%X-12_H"^:\ 76.\>% ZQW/JB0?>:UPMI.UL(*?N-.PL4*?BUM:2 M
M(2TUX@FD):0EI*76HG(T4(BTU(XOAA0 2$M(2TA+K47E:-9ZL=[Y *,2ZYV/
M1[M@\:Z&13X6[T(I@S6HGFFT-F9VI#6DM38#!6D-:0UI;2C1VIC9D=:0UMH,
M%*0UI#6DM696JK%B\" #>5,Q.%X<:VYGN["Q,!V6#,**-PW+(*QX@S((*[8\
MTVAMS.Q(:TAK;08*TAK2&M+:4**U,;,CK2&MM1DH2&M(:TAKS2Q:WYY>30^<
M7TTQP?IK%ZW_Y#?%>/_<G2WF[R;+R7S6SNYD8Q$[+$5TP!U"=LPJVL;YVD]3
MVYIHO$?+#IH)<)>'459AW[R#V>'F\O5><VLDEV"\E2"L#F"S$N =D4F3F$P2
M^^B;]_,LS$_3D%KD/2[*-R^JVX;[KVF2A](*I55;/FL[UE!:'41:H22YD"3$
M>FN5)9 Y+_+"10%%A%!0.MN0M>-)I7UTVOMJ2?)H3?50BC2POH=* I4$*@E4
M$J@D!J,D. V1$E-$1"(<A&09G/<9:*2:1T:<CW8?O?D.J23VVH8/A40#0N+J
M1F'YV15[W6Z6;YX=SY?1GCZ$Z3H^G54^XGI#=FG*%@.D",K9%7->!N/)Y4;]
MF7N;-G (+I?O_-)-W[OSY;<ONK\\ ^O[^30>S/:__>-?W6\GKO@WI'5/)<NC
MKK#F\;,:X <U\2_S57G3:M[]-)FY69BX:=<7>CLM?UZBF?=EYA]22*<^+3I.
MCSI&&.O<+-8?*-IX;SNVDUFW.IFOE\6TRZZ(@503T I\I-[89\7Z%[^=EF^U
M6OZY6=,_]9+)O5I*'$O.&]28[/"&*5.J7]:GY8VA_!XG[_[VU_+/#3.#VQ[E
MU:)@[.4#N-D2-D]Q.1F]N/O%7%1HSI6,!CRS LIO9889&(42G<HD:XD5;A\;
M[:_#28KK:?HU_YAS*C/&=^ER>OI[X8/?4_F,,)E.7)U,OJFSCS?E$[^;SL,?
M+[I49JAG=8PLUNFVR9H\UD\R9@:H.5]UBVOF[N:YF_3>Z%;N0_'VZ=EZE6+G
M5@7P4OFB;K5>S1?G7=[TX[IZ\:(XK_)[O?"&W,*ZAG#E\O*LY9<:^;'KX;2@
M9:B?YV;GD]G;_J,VVJ ^T[Q@:O^ R_XV]>KO-]=VDV7GZJO3Z?S]\F4#2+M/
M.+DMAA^,)-MI?#^+ORF1UA5_;E=*ZO,5V[\DW_:7P]2=S]>K\A$?4OQV\W&4
M] :\>$,9TE-WMDPOE^G,5?]O;=,O^VWN_>*FG.,Z)'P9=*OSE]M[W))YO/E8
M28\)5]]4L]ZVHK2YD!Q;S1]P':W?XOZKQ+&Q=&^WV_/#L6-+=;L/QQ[DL)MN
M=T^FNOG\1/4G.J]E6@ 7T]2V%WKB\3QQV5N8DON:"S_].:VM/9_(G4\V-=WK
MH/CI0AS].[G%LONQ&*^AFD2??6RK]='13K@C8PX9I]$3K7CBDC$9$N:S(,RK
MR^5_]8ON+W^K:^;M1"MRYHB@%WV#8(Q@_)E@3-N)7P3C$8$QZF"$7H3>.Z&7
MM!.M"+W#K0LTMG-& ]SG__GC-OW'#7FWNK*AO\">J\UFG#_E(8K&/#$:HP^^
MW?O7>F* *'KS(2[MN'9*:#!19A"1*3 ^4: Y\1BM4DRJ?23./21=[M7JITUB
MUNLML%^[^-J!K[/U(EV>^ )V]<@7N_OL.&WVR%=C:-7VZ=9OVH&[QOR&?-^*
M)T9C=.3[L? ]TX$XPAB0J#@(81A86VO ",*-HD%['O91_@7Y?G!HA7R/?-\>
M]0PI@D9C=.3[L?!]LBYG2P(X*GRM0)O!.R/ VZ!",IJ)K/=1I 7Y?G!H-5"^
M/WC[XK'I@P%B65];X=IYRZ-NEE;U,.7V[.;%&<UV-GD;\_JP5.%>.^PTYHG1
M&!U5X?"0]&95:#T5G"4%C%D+@JH(1F4/G.KLJ(XZ<?E8NSX]UK^:Q;_/RXBZ
MO"XM]R,']3[5X)A1:J!J$'D>>;X13XS&Z,CS8^%Y89BC,EE@/#,0RG/P0ELP
MC@2OA;"9[/0?.M1NSV%Y?J_-B<:,4LCSR//M4<Z0(F@T1D>>'PO/4YF)SKK.
MR'V9FYM4]WMJ%B=CE"3MJ=O-XCS4+L]A>=X@SX^:Y_$\S_AW=][4XIR+%"?7
M2V=C4L]@Y=Z8M\E'8W24>\.#RENV;YPWUAL*Q'@&PDL)QN@,G' J(TM>N+U4
MNWY8C>L/WV^P?#\"K]W6CHWATD %'C([,GLCGAB-T9'9Q\+L5"O/A-40"+,@
M&,_@*36@0Q+*"N.<W6'V0VW8(+,CLR.S([,/,()&8W1D]K$PNS/)A) L2.8(
M""TIN"@U$!:U93E*Q=EC;='LF]D9,ONHF1V/W(Q_4^;U:A[^Z'NFI=FR1XEV
M,A$:\^ZP=-Z8-[E'8W34><-#S)MU7B1&.R<\D.PU".L]&$T-2&)2E,Q;GQ]M
M;^:7>>VAM"Z7^6GZ\4-%]O2Z]O;]SBU3_/X*UG\_7Z[VHP4))NB,6@LB^R/[
M-^*)T1@=V7\L["]SUE)9#T&'>N#&4G"\,'EF/BE#F+0Q/=;^S5.POT3V1_9'
M]A\J$0TI@D9C],&S_P#9^T];_Z**N4'%&*]25CY"EDZ!D$7/V"C<IBA\CE(2
MZA]KK^I@*F99QG-Y^4XYL]=:<F,&X[;ES)_QN-$SWMGZ\4,*ZXHRUW:WNNGD
M=++ZVHVN<3M[6&)WS(D#HS$ZBET4NVV)71>%3EHDX"+66GA4@:,\@& Q$J*,
M-(E_S8;=V>F[ARG=2YZZ*FK_?LE2+4O;,4/O4*4MJA=4+XUX8C1&'[QZ0=:_
M8'U/'8VD\+:TKJ;I2 )>< ,J66:#B5J&G0JXG[-1]P2L_UA).6-&JK;)'KD>
MN;YU3XS&Z,CU8^%Z72;V(3H.F=:D'&D\6"8]T)PE,]J8D'92<C]G.PNY?I!(
M-5"NQ\-8X]^R^G5UDA;MI* TYM!AB;TQ;_N/QN@H]H8'DK<UN"9)<1^ ^RA!
MJ%@D'&<>",LR"9U\MH_6VJB'\5?Q_ZR7J]/RS'LZ;8\GK,8M\)#?D=\;\<1H
MC#YX?A\@/V/:R5TZ)5#*O!,1!"D211!CP9I@P&HI2++!!6L?ZZ385^@4S*)^
M-H+EJU)-4+$,ESR'%$*C,?K@%0LR_073Y\+F65,%R@0-0J?B^>@5D$ B(<:4
M%W:8_E"GJ7!% @F^B2VG<:>C#!"[OC]QL[>IF\RZ=VZZWAR1<M/I_+V;A=1.
MVD5CCAZ6\-OK;KXO5Z?%1VO)LU6WG$\GL;L^L!OSV&B<<T^@/-0][0O) 8(I
M+GW=)8B)$\I1%<$:6\2MC>4G0B08P6+V6M.H=[J5'FJ+;D-[/\]^2#DM%BF6
MBUXMEVFU_->6!5]M27#/JV*\W42M>[#CJD0OPZ4]C&];9N.1+913**=:<P[*
MJ79E!,JIN^14"CYY&@TH93,(Q1DXEBRPQ$EFE+ND'JUGV!/**8UR"N44RBF4
M4RBG&G .RJEV903*J3OK 65JB2,4 C<!1'(1K)<:J$Z"$&I5UH]6_!)7IU!.
M-2.G\.#A^'>!+T&IF_2HU*W<AVY1<*F=S*?&G#PLC;W7Y)KK0,R.647B.%_[
M:4*5W4*H/-Q![>MLU*=;?2I=(EF&NO\IBSZ5'+RF! ()3#HFHHGD<+NGWY?[
M3F;KR>SMKV=IT4O0T2<1WAM&*#GQ)"2*"Q07*"Y07 Q;7"1:I(6/ ;03M?,+
M(V"X5&!BH#)&1SP_8/\Z%!<H+E!<H+AX^J!#<8'B L7%GL6%Y-09;S)8F0V(
M(@S *\$AE,=4P<I@F3G<SAJ*"Q073W)BLOSLBL%OM^LW[7$_N\5*KQ83-[VT
MC9LMX;-Y91,JOZQ/RQM#^3U.WMUB&GFL.7\"XPP0<'^:+[K52>K.DULLNU1;
M9G8_I)!.?5ITG!YUC##6_UM^=K-8?R(WI8$,\+L?]=^\EE1VL_/_^H\/C%#[
M;3'"Y5;F=@^SFRP[GZ;S]_T;<BK0Z*;EB[O5>C5?G'^ZY=G-<X>9,G>5,-*T
M_%\ZH,H61A8V@3/:@A2!IDPDE6DG4^90Y[A>K7[:^//UUIW7+GXHT?_\RT^W
M+HUXPS)W!+CF @2M'4.(8"!)D2B&69/E3I^P0Z59'_[;NJ2*M.(13+(*1-0$
M#.$9G&3)\VPE53O?]E!94/O\MNRF8E3WOS *H/RF.UL46RS*;;JX+D W[\'O
M:JY'6AYUL[2JT+?%1Y]FJ=RG9XT;@?9LOIST(Z?<+RVKUIDL3SK7Y?5T>E,Q
M@:X.LM6R>&:3U-8#KNO3VHZO*H4B#&Z W-N4R9T6N1SE%[)CV^<ZER ,U(#M
M4_TL]6"LED"8C,)+$R*+^P"PU^$DQ?4T_9IW$OE>S>+?)\Z7H;Z:I.6;*A3?
ME _[;CH/?[PHY@SNK*JBQ3K=)LP?H))N,-KSE$EO3C;TOM$&=92OTNG9?.$*
M^\=)>7&1R@!=]F,]N,7BO,SZWKM%7):1[U;=VZHF%I/E)G2*72:YS+EFJQ("
MBWX^V=^Q?,8-0[N_Y_2CJSNW2"4>T[(N6L2-+GEY=?@W)8F_=+ZPG\6H[42J
MGT=M'^GB6]2G?>D**VPGN_4ARR3_)?FVOQRF[GR^7I6/^)#*S+G_.$KZ6=?%
M&\I G;JS97JY3&>N"K^M@?K5G,V]7]R4^/ANLIST[CQ_N;W'+>F/FX]5]IA5
M[[VX?5'@XOF.E=(/NHX\Y*IR.VWW=[M]/YR6#[/)[NWNR4@U@TE(-2T$L1GS
M@C)ZX@Y/%+O7O_[W"_7B*9?Y'W0,:&O.)_+FQSV&0TLA/Y_&0XV)5[U2N;I
MU$ZD?O;QCM8'1SO!CGPY9)1&3[3BB4N^9,B7SX(OZ^Y).[&)##DBH$7?(/0B
M]-X)O;2=:$7H?:K)"189'\'^RP^[^R(OOR*XQ^W?UO*S'TZ]Z)=VY"KZ GWQ
M/'V!>-6F7] 73?CBX.6<KIK[XFY[=>?5!!!ZQ?JHRC]SG/Q2$_XV9V)F;[OI
M?+F\GOS4SO0;H[F5DT6->:+M8T+_V4X$X7')!@'XM@[125CB#'"E @A#*?A
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M7:K]&[?HOA==9RD>GT: :MGLR-"M>&(T1D>&'@M#2\6B]$Z#TMZ ((J!-4Z
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MXQS@OCD #T6GF9B*$DM%S[M<I_120BB3 ).*R(^9'7 .L)'[RQ_FO\Q7FXG
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M[_)("WLD]5Y7^[#]X[.$PL;,CJH!54.KH8*J88RJ03''@_3 ,XDU]5N"3R2
M=$4PV!"8MCL;A(E'KPE)P*RC(%RPX GC8((EPF;EE*7MJ09QQ"P_(IJC:D H
M1-7P" M_0VS@?6!3%>2YZ'?T9%;YHI*$A[9+4[88(+E3+G:;*W5_/;E<>#]S
M;],&\L#E\IU?NNE[=[[\]D7WEV=@_;WT9[S-]K_]XU_=;T6,G):/7_=DL3SJ
M?IZ%^UNNHXD?:.)?YK5'^FK>_329N5F8N&GWNC:DKDU3EVCF?9GY:E>8VO^<
M]3TM/RT&C#;^&AO_:3+K5B?S];*8=EF;'Z:ZN;_I[UF,?:7;9S_E6?ZY6=,_
MM>J\JJ7^\DECQK]MVB3?WCQY0)+TX(T8;^F1^47^>W%+2VHF*9/>0_:,@M#*
M@&?:07U9<^>LXCNGTK]D<^+W-*W-;G]SB]7YFX6;+3=3_.4/DV68SI?K_3>I
M'DS#Y,?N4<V.N^["'5WUQR3=S]38H/KAV1=7&E2?N&6-G>5ZVG>:=V\7:2.-
MNO>3U<E!.C</T&*W%*-3SE/J*$BN' @E:D58XH$G8KRPRC"_LP J(LV.J0#<
M1 ;"2PU.2@+4$688,S:PRZ3'L]-W9R\+&!99]6O^_M))KRY]](]><BVOK6UN
M7KNZMOGS+S]=6]V$90IUA;.N7"W3[,7?5N_GMRYL#GRH=Z<;$]7&A;6;NI^[
M1=QTAEZDL)HOEM]V\UFJKY1'#2?=>S=Y5U#G9'(M+'(J'^WZN[PNHFNC=*NX
M/>[Z5*:=:\_<)'9%KO6*+77GR2UJZ_9RYQVA?+3I9?V?&&IWE:;15$LO$@1:
M]QJ"2^!8,J R59S&R&647Q-J]XB 'S^<I=DR+>MFPU5M\/\6C+SZEFN1^,_7
M/[SHBDZHCN17 Q+XG;L-E-Y>HGG@X5AXO9!/&>W]D,<1?]>(9SH+32Q(HBT(
M0PD8[1THQZAA26>G=W)RB+)!NB2 !U7>4S-ZO& 6<C+":I^45CN%R7]8IS?S
M*V.X:*WOUXM%>;17L_C+?!8VO^R.[,\@F-EX^>5BJMW-WQ=L+T]>@+T"_LV2
MRNTTT.T9X/[5O@>(VQOF>L]4W=Y.R!O[WT/(% GY ? 4,BF3Z%!X-19>%5E&
M,$4-0\[4RERH6ND=[2N9L-(K"8124^O+"?"YW$([5FC:<YMKKX46"9F,%;^.
MNY]GW3_<>8V+S=C'47_7C"_Z_[^];VMN&\>V?O]^!2I3_57WC"23E&1+SLRI
M4ARGXT[2=MF9TS-/*HB$+)ZF2 TO=G1^_=D =;-C1W9B6]CD>NB.+/&Z%M8&
ML+$ C#IN/V@&/9V+&K7'3=G9]YJ.I*Z>0T4^D%_M%N*/NKYST N:[4ZOT^ST
M@WZS[^D5S#MN1XZ\_9Y_H-#C>Y8>GPGU7W?YRO@NK^E[BO\H\-\H\#W7'_?\
M7KO9#Y1#89[Z77U'>4UWWSU0KA?T^E[[1PK\,LP;I]8;F:E )Z8HM)M4_""E
MT'YI2OZ;^?J0,SG77PTT@8M=T7ZE _/L)#ZC=TR"7],DR[8XOFYKY ZG>*^R
M_3"1+#:3(UDL,X'E>DQ*^I.&;BC-RI9LF(IB%IA,[(4?TMGA./3%(+@*LR2=
MBS=&7.LF;DM\K@A$Z*8^+$",V\'!P<BGV!!0@.CO4YO.<;M-Z0?^..@Z3L]U
M;P>(7B#'7J]- 6)?!PC5IVZJ>]!N[G><@_T@:'MC7Z*;:ELWU6W='D*U:734
MQG%FZ^!@6'+==O<6H@\SIC$;J*]L02S!,)4%(3 =]H=#?Z(;==DPC(=!F*WC
MSE"/. ZESV5 ^S[X3^@]1;^E791'Y:OJ82#MT'F[^;KE .O ]U^JCGG6E];5
MBS0U3*S?2?]I:A5ZZ[7Q;FVE:#VD=&)(_Q$NQWB-Z>:[V/BPXDE"D_OU7O<_
M&ILD!2>Z7)I$V7"6)KX*"MUK9"[-,AX-RH!4OEXE0DYFHLO9BJ>G*__/^MA/
M4_K9!+YGQ9**LQ\5F>Z.GJM+F0:ZSM$=F^/Q6/EZPF"LLK(WLZIZEAJX77Q0
M(STI-:=%*NA@6:;OZ&-(#80PSD2P9L+?9&(=<(E!F0MM9 Y41I!0ES5/A(K-
M.>:W,"[[\9KX5/VG"-/RF)%:7EX9^TU"#S$S*<'0-S=9I GHI%F2YHL[72LQ
M#B-5-LATZ;DX/A)A1@?Y>EIET"B?+<OTQZR8$H&$5V N6%Z(_M G+]P^.>&U
MN&TFLIGRPW%8/L_BXN6.$/W7=(LB4N7KZQ?*&N:C>:BL\"<WWI,>2/I^,2U*
M7Z1YFV0Z+>+0-U_0ZR<W,&_0Z=KCK#5A@$CI[W!&[3#U1?EF.BTI8QSZU,<O
M"5C^/EZUV!:_FXR@G!$,=!#=K:'O)J,HN38O&\U-FB4S*<5T)<05,\&3M_LP
MVKV0V>!N2T'#%+5E:I<.#PJ_+#5"7<FH=+HW-C)!64$%]LI0: K#2@LSG6S3
MQ<(40KK7MPO9T2148W&\*F"G&P6L_&W='3A=%J[%5;='!E,.C3*HNS_5D@@4
M%=953NN<Y"3<MFRZW9_5+_I$DLNED<?Z5==SR.DYR\XH=5ER_11NO]TIR_JT
M- ?\7$K5?VTJE8VCR^^#U[^TA!F3T/V>7+L&-^']3D#TVY>3V\M0\#!LRF2U
M6E9\@D[4#YTJF26QGDQ+[T7GTZV4B-25BC;L$/2RRX]EW**;7"DMW=&\?*U!
M'!?TA.<FW.F7?4?E6KA.\\.#)/UBK7GF#9I/*V&MZX@UYB<ZJ1<3#8LFC#@E
MDC;*3WDD21%MF>=LR^B:.,H2O07MC&J\4&N+ZFFA,CUI/<PFR\S'LM%C7$AT
M0$$G!E0I4D"BL+G@<B%GH06W4?.F2R[OCWG4H+@1P#:CWY@"TS\MB>XWT;NG
M,EJ%HMLM=WWZ@\$2HW4POGODSN+B5Y[_D!DRMP/!<HLQ_?UE:NH[9N]^WYN^
M2ZDJOD[2/\7/](9M,5[^_0LI(2N6-91IZTS#/%?&RW^A=9FDND"<II<R#O]7
MKL:[]<&?J58,KN6\/"O3NMBHQW6)VRB8RY8#*6]U][M*]>TJ^^&%]IH4OE%Q
M;W>)HI[]T<3!.C&/2G5'/9<;T5]+P%2J5%'I/N^-%ONN.R>F#[4N,8\3=QD/
M?)-YH*YPD2Z?)I)93F=H0ZJ@-D&:+Y[$G*#GY5''GQ"D;O9<2!,==/Z!FA$F
M-;%HU<]%%/ZI.^#4(?_J^,;C'K4E/NM;;[ 2A(&($VKQ!,;Y,]] XO% +%Y=
M\S:F,XG"Y5MO-V5[.T3%JKB[,5HQ&@Z3=+B1(N(>E,N!BC=FH.*4"D0E1BE2
MJF!6#%5IB )5'49G7S3>^<-U$FRXRC(/25R$2SS\GR*M1@ \,@%P8\!J/;3U
MKGQ7\5LE0B.U![(@+"?NE/7[6:JN=&_J)-;#)N8'.$6>?#TL/9(3A;[."3]-
MXP;N3;@W[W%O[L.]68&":&IAW=D>AF'(O98]&YQ_%B<G)Q5JBV]OCCW1>/FZ
M.>8ZP^%J1MUPY2@8FJQ)-O23=,:]H)CF&%VR;(XM7K6QF3^J1#.L3'25P\E'
M1%NB!Q#$KSH?HI,A\.H^P_);=QJ8EF/M6E_B.HPB[6<*E^,*&[-VY&+VWM*<
ML"J<]W+86/H55N?H(Y>?=;(E%9]D3L$^6XXE790-<.'N_RQ_$6]4K*B<F,SH
M=4R'3<+9.C5NG"91J.^TNM$B/V@&*T,CEUF:?-'S#!>KKYHA4?T^LO063)4R
MUTK&Y5S$"15Z72Y+7]=$16;$\[<B5CHCV%Y\KYU;P4WKEDX%I_2;[AF*P2P-
M(]%V3!JQ;3*%^K@S\RRKE6!+XY7&/O:7\ 5"SP&D6Q(OJ1K3YX>*80>]8]<=
M;@1A?V,2;36BL&NB<!EZ*Q%UM2 VYSHCRMH>9=?U_B9OZ\BZ&5&W1^3-.'E'
M0&(?C[SA,"N-=O-ALJPQAM30T(:8X8BJDVH$)L\$IH6G<+Y1.>JI]>7;WJ@\
M*Q&\S$N:(KHVK)D_EZNV7JPK\&6[ @'.]@!W9QM/NVG,XAF+M2*F="O#[IUQ
M[^X8N6Q2'M,3YO,;/XFS2,:;0V15CXOMX2H(IEHLF@'".2O_4L$PKT9<;)?S
MS181\'SS53<B126B82 VER!K+*;ZE@T *MJ!FFE3 WK2#$+@MO(:B#.*BW2K
M3<;1 KPSTG6&P]64HJ%<S0D?ZO48J6V87K'/))>1KF,BW=EJ]I2>_EZ)N+:8
MP_].+::H76C.?(66G/5A[%R:=;I6MLC!;):$<6[""OVYKI-R;2X(L]S,]3DK
M1I%>W&N]?,.[,)U:%:8PTHR1YGM&F@\PTER!@K@QTGRUQ&;9I' [KUYL0;87
M&('^;PQ _U#[LJM'/";A*,RSX<JW/5P-+PVS:JPDY7870Q_EJZZ75*J$%&YN
MR"@N_(D*])H(57)*OT#GJR(['![_Z_W)FQ.*C;^_/?Z7'163G=ONF=VQEX^S
M> /]I(>RR)/E;O#Z :D5?^B\-H<W(SE/BIPN_T4%K\M;N8Y!<'$"%8A(SC)U
MF"FJ@DF32W!20[VY]BNS1?#?\U7K2L_+&H51F,\/E^<O#MK<7+V\7:_5;WL_
M:3A7&W]_=8S3ZO<[6X[ID&"<;1=RZ9AM%]JGF_6V7J?CN5N.Z;6Z6^_E/N!>
M!RW/V_Y>;O]@RS'MUOZ6(_HMU]O^Q+<17.W1OE$ )F5@*&/8U\QO"4)Z]=VR
M<7Y8-M'U%W>'H2N5FCV2%\HL%;LLNRO]=O6FJ$D4!J^_L3'C4IY&K[T7"1HO
M$(R_KD9^)!:7#8Z'["$+-+?;[LVF#C=64+Y#=CO3BC W\KK=QO(_8H$PLTM"
MUK$JQ!V;"]O$ZUV([HC0G351GY3QMRKST]"D6W=&.M'Q>"7;7A"VM*F?E$2(
MMEZBU6N56<LV! O!0K"W!*N78_T]:5G+.$0+T4*TE>CBVEX,+)(L$:9_^<<K
M[]7.Z;2>-V[RI3I76W[>;KAR[>K96L_X;I4**+XJLYNC%2]7B*=A$$3JP:5S
MWX8ARZ^MF-6H1<#%;AOA.J #?( /\ $^P ?X !_@ WR #_"KV^<"$=NS$;>\
MDPO?\@N:)Q]#T@NYJAG..BO)+O_?;KF['ONPC% ;&=NY8\\2X4DQ2=68 E">
MS[+#O;WKZ^M6IOS697*U-TC]27BELCT57,IT+Y"YW'/W^_UVS]MS',=U^VW7
MZWJ.USWH><Y>T.]VO6Z@OK3=UB2?_I"J];#<(TJ)>;% ;]-JICH?FBG141BK
M9RL_@\7&D.62$&:R66!6.2GG6ZMR>O5R*O3&OF;E/.M4FK4&5QM,FL^+36FC
MN9YB7>X#M78^R!V5T>\=;*G)G&T04H59X[WF!W *D3$BA*'(J,70;/>[[3Z8
MA=08$<)0:KOL@[+@U":1O71.SGIR& KN0LWR<J-*KV]6F'?JGEBP4&VP@5F6
M"8<-S#(N;(I- !_@ WR #_ !/L '^  ?X -\?GTN$ $;6"UM8!YL8+"!,1'>
ML]C O)K:P-[,(WF=W6/X@LF+^W@=".%9.\/D!9'Q(H2AR&#R@M0X$L)0:KOL
M8;+@U":1P>3%7W P><'D!6.1]>$/7.R^O0?P 3[ !_@ '^ #?( /\ $^P*]N
MGPM$P.150Y-7!VM]P>3%1G@_8O+J[G>Z?<=S'=?I'O3V9M.K65-]Z;A#;]^I
MOLUK8[=/;>NZ4'Z1AGFH[C!YK<Q<WU#%(]_WV72Q<]^9!:*P< @#([B,FP>N
MLV.;&30%355,4W:8RB L"*MBPMIE_Q62LBI[!WD]/<6?)/6J1=MXQ2 T^X0&
MKYAEZ7)XQ2SCPJ;8!/ !/L '^  ?X -\@ _P 3[ Y]?G A'PBM72*X8%P> 5
MXR*\QWK%M$?LKC7!.H[;]O:"ON=U#IQ .\:J[Q:[<U&PDY@0RY,T^_]_^>(Y
M;O^U.-=/F8G!9:H4G9$W1&"._*V(YL(]*&>8-\1H;BXDITE\><MK9G[PJ?S(
MT/C20KH<W</_<Y)$])+9C87%./G1,+YL^7(6((1G@^2BB8W!(#).A# 46;O=
M]#J]?>\ S$)JC AA*+5=&]BLY]0FD<'2QE]PZS70.E@"S5*Q[<;6AK3^#ML7
MCTSP G\4_FJ!_[UU_=.3\5WM,- !.D 'Z  =H -T@ [0P9$.+@FN&E*##B!,
MC3:F#!FF@&^:&MM<<E[UR@'724]/YE7L=P^<3:]B#38PO9@IG\Z+J>TRG29Q
M:1\TGL)P3$SGZALKW&&[4@ZCKB"$9S5[T73W!F 5,F-$"$.9M>'6@]8X$L)0
M:[N< L>"4YM$QB69"<$]:,=2%W8]2]4&NYY-"6L;4Y? 'X6_6N!CY!)T@ [0
M 3I !^@ ': #=,"N!VK0 81=S^:4(<,<\$V[7H=+SJM>.> ZZ>E'MJ%=>/5<
MK^_T#[R]P*,_>Y[VZG6J[]5[1S?6=KP30UF1*CCQ6(VH@A">->A%LSVX. >M
MT!DC0ACJS%CQ]JF6ATL(6N-$"$.M[;(GR()3FT3&)5$)P=U/\:F?)^ME\[ ;
MK'U2PVZPEB6CL1NL95S8%)L /L '^  ?X -\@ _P 3[ !_C\^EP@ DZLFCBQ
MZ&KNW^"_PAZP3.3V7'O NDX--H'=-&M-XW(Q-;KS>KM7,5+YM5+Q77NZ*NE/
MEANZ!F&J?+UQ;/G+%^47.2%//],U;V_RBK$\V\?R0 C/RAL[IT)DO AA*#(L
MQ@:ML22$H=9T;Q2D<E$9+&#\%8>]4V$"@_'(]N@'+OBV][!2 N@ ': #=( .
MT $Z0 ?H !W5H(-+!JQ>U,"F5D6;F@>;&FQJ7.3V7-M_NDX-]O_T'+<MCO]3
MA/E<G,2ZIM'>LK-(Q@TA,R&GBAXA:!COV9@>,M.V-+GRL.43E2KSE+"AL1I/
M!"$\*V?L"@J9<2.$H<Q@1(/66!+"4&NZOPE2N:B,2QH.BL.VH'"BP?W$./R!
M"[X-OGJ- H$.T $Z0 ?H !V@ W2 #M!173JXI,#J10V<:%5THK7A1(,3C8O<
MGL^)UJZ#$\US[G:BW6,^R^ ^XSJ("$)X5LAPGT%FW AA*#.XSZ UEH0PU)KN
M8X)4+BKCDGJ#XN ^@_L,CB?&X0]<\&WPU6OD!W2 #M !.D 'Z  =H -T@([J
MTL$E!58O:N ^JZ+[K /W&=QG7.3V?.ZS3EW<9]-9E,R5$A=YXO\IS@I"368P
MH55S+!&$\*R784*#S+@1PE!F,*%!:RP)8:@UW=4$J5Q4QB4#!\7!A 83&HQ/
MC,,?N.#;X*O7 !#H !V@ W2 #M !.D 'Z  =U:6#2PJL7M3 A%9%$UH7)C28
MT+C([<E,:([;]FZ8T+K5-Z&5_C.SL>;I>*Q2\5'E5-DT!$&E C$H+HLL%^Y!
M.6#1$*.Y<:6-5'ZM5*R=:.)<7899GDJZA/[IK;P* _&^)3X14@UQ-FF]A4N-
MU6 C".%9<5\T77 *D3$BA*'(X%&#UE@2PE!KNB<*4KFHC$N"#HI[B$>M XN:
MI6*#1<VR'#@L:I9Q85-L O@ '^ #?( /\ $^P ?X !_@\^MS@0@8P.IC -N'
M 0P&,"YR>SX#V#X,8(\W@/T1QEF>Q.)#$5]N&K]>#,3G@JJ%L4@N8Y$@A&?3
M Q8VB(P7(0Q%!@L;M,:2$(9:TWUID,I%9;"P\5<<+&RPL,$V97OT Q>[;^\!
M?( /\ $^P ?X !_@ WR #_"KV^<"$;"PU<?"=@ +&RQL7.3V?!:V UC8%A:V
MWL,M;!]5&$DQB"+ZHR$^804S9N-X((1GM0W[%T3&BQ"&(H/]"UIC20A#K>E^
M*$CEHC+8O_@K#O8OV+]@.;(]^H$+ONV]>FUP SI !^@ ': #=( .T $Z0$=U
MZ>"2 :L7-3"H5=&@UH-!#08U+G)[K$%MTYW6W>]T^X[G.<Y!;]_9FTVO9DUM
M3>L-VVVW]O:T=VJ4%C*="\\S Q;N@S;95&H6_BG%;S)*<JEWV93I%#8U9N.-
M((1KY=W\ %*A,D:$,%09M1R:[7ZWW0>SD!HC0AA*3?=&02H7E7%)TD%Q]U/\
M25*G6;BFQ^?5/;E@H=!@4;,L!PZ+FF5<V%SSU&MX"'2 #M !.D 'Z  =H -T
M@([JTL$E^U4O:F!1JZ)%K0^+&BQJ7.3V?&NH]>MB4E-*G,2ZFB&LQ%$RG:DX
M,T\@SB(9PUW&:I@0A/"L=[$(&D3&BQ"&(L,B:- :2T(8:DUW)$$J%Y5QR:]!
M<5@$#0XSN)KX1C]PP;>]5Z_1'= !.D 'Z  =H -T@ [0 3JJ2P>7#%B]J('#
MK(H.,]>!Q0P6,RYZ>SZ+&3UTY3UF1Q,97RH1QN*(ODN3R"QE=J&(:QG[2IPE
M4>C/X3)C-5P(0GC6O7"9062\"&$H,KC,H#66A##4FNE,@E4N,N.29(/D8#.#
MS0S6)K[1#USP;?#5:X@'=( .T $Z0 ?H !V@ W2 CNK2P24#5B]JEOD2^E>.
M(F4^W@?33_5+XEH'!\.TJ=ONW4)TLG(TSN2E*B7>E&-ZW4,97<MY]OJ5V-LE
M]O8E.#481J'+QUF\@7[20UGDR>L1!4>5F@<,X\M#Y[4YO!G)>5+D=/DOBF*G
MN97K& 07)U"1B>0L4X>9FLE4YFH)3FH*A[GVJ]M.U*LP"T=A%.;SP^7Y=_A1
MR]OU6OVV]Y.&\Z[JN3S&:?7[G2W'='HMQ]EV(9>.V7:A?;I9;^MU.IZ[Y9A>
MJ[OU7NX#[G70\KSM[^7V#[8<TV[M;SFBWW*][4]\&T%8D2MI179A1885F8O>
MGM&*7(,]F0=31?<(C 'Y7&6YV8GY8?YD<29U>0AGY<*8@\M4*;VY\W(_YT%Q
M662Y< _*(?$'[>8LK\) O&^)3X2RWLP9.SE;WQ$"(57HBL$%#9'Q(H2AR.""
MAM98$L)0:Z8?"U:YR(S+&! D!Q<TPT$"N*"M=M["!6T/%S;7/O5R(( .T $Z
M0 ?H !V@ W2 #M!173JX9,#J10T<;I5TN'EPN,'AQD5OS^AP\^!P>UF'VQ]A
MG.5TK0]%? EK&ZLA2A#"L[Z'M0TBXT4(0Y'!V@:ML22$H=9,!Q:L<I$9E\0>
M) =K&ZQML%/QC7[@@F^#KU[#2J #=( .T $Z0 ?H !V@ W14EPXN&;!Z40-K
M6R6M;6U8VV!MXZ*W9[2VM6%M>P)K6^_AUK:/*HRD&$01_=$0G[!T&[-Q2A#"
ML]*'OPTBXT4(0Y'!WP:ML22$H=9,+Q:L<I$9E^P>) =_&_QM\%3QC7[@@F^#
MKUYC2Z #=( .T $Z0 ?H !V@ W14EPXN&;!Z40-_6R7];1WXV^!OXZ*WQ_K;
M-LUMW?U.M^]XGN,<]/:=O=GT:M8TSK;.L-WNP=WV ^ZVWV1<R'0NW'*TPWO0
MWJ1*S<(_)9T;);G4FY/*= J3&[/!2A#"M>9O?@"I4!DC0ABJC%H=S7:_V^Z#
M64B-$2$,I6:ZLF"5B\RXI/@@N?LI_B2IQRW<LLM7]\R$A4+;C<'M,7S 4;7;
MC"KP1^&O%O@8R@,=H -T@ [0 3I !^@ '?"O@1IT &$>M#EER##]JT=<NG_[
M*Y=<5[UROW72T=(4N'+T#=UN?>Q\IT6>A8$2;\-4^7F2BJ-D.E-Q5EKU2O\>
M3'6L!D=!" @!(2 $A( 0$ )"0$B=LW2U)*<F75<+X8=KS*:\J8V9-."/PE\M
M\#& !CI !^@ ': #=( .T $ZX!H#->@ PC5F<\J0J6MLGTNFJUZ9WSJIZ!DW
M2MVOOO?L*(FS(LK#^/(;:\'I=0'<_8<L!3=(XR32&YY>T4/KE>"P#!R&Z_@1
MPK VQEZG$!DO0AB*#'N=0FLL"6&HM=UV+UFP:I/,N.0\(3GL=<HYM0-3GTUI
M;1M3G< ?A;]:X&-\$W2 #M !.D 'Z  =H -TP-0':M !A*G/YI0APQ2P'G79
MW> F3'V<0IU%IC[W(;O#'@R[==@=]EN6OD]R+KQRGQ_W(7Z^\]"?R#00[]6<
M[K\P]#6$S(1<+%J7Q.*W(IH+[0_45X7;C].H+0CA6DUCTU>HC!4A#%6&35\A
M-8Z$,)3:;ON=+%BU269<DJ&0'#9]Y9KO@=//IERWC?E/X(_"7RWP,>@).D '
MZ  =H -T@ [0 3K@] ,UZ #"Z6=SRI!A^E>/N/2X9+KJE?FMDXJ><?F^&GC]
M/BJ9J;ML?GIHIVW6[>L^Q.=WI *9BC=IDOQ)YSATSL>S&S8_NH0^[5V89KDP
M&];J^XD\$>4CE/<=S-(P$IY9/<(]P,I_K,9T00C/BAPK_T%DO AA*#*L_ >M
ML22$H=9VVS-EP:I-,N.2+H7DL/(?YZP0_( V9<1MS)("?Q3^:H&/H5'0 3I
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MR-B(C$NV$X+[1E_P9A^O[CD%"Z4&,Y]-Z6P;4YS 'X6_6N!C7!-T@ [0 3I
M!^@ ': #=,#,!VK0 829S^:4(<,$L.>V=I?UA9>/4Z2SU,NW6)K/<YR#WKZS
M7)K/<]UANUT#-]_',,NU6^^B&&5A$$IMPH,!C],X*@CA675B*3VHC!DA#%6&
MI?0@-8Z$,)3:3ON"+$BU265<\I-0W+:5]%QCOMNM\]6")("%0H/YSJ;TLXTY
M2>"/PE\M\#$."3I !^@ ': #=( .T $Z8+X#->@ PGQG<\J08?K7:[?<OW+)
M=-4K\ULG%2W==TOK7'M8@QUMCY(XHT_:.G="-YLI _MB73N5JD"<%:,H],7
M]^FE\S"^%._"=(I]:EF-DH(0$ )"0 @( 2$@!(2 D#JGZVI)3DUZL1;"#_N8
M30E4&Y-JP!^%OUK@8R0-=( .T $Z0 ?H !V@ W3 /@9JT &$?<SFE"%'^U@'
M]C%+,[]U4M'2/O:767*MTJ&DH]-8S:MM'SO3[ZK-8X/%ZXJ?]8^2[AF(L-PC
M-2.49%ZD2LSDI1)Y0M^&F1C$<2$C<:YF29J+)!;OZ"6$7DWJ%YC+,+(&0D (
M" $A( 2$@! 04GM"N"3S:DE.3?JX%L(/<YE-Z54;4V[ 'X4?X -\@ _P 3[
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M'/C!<JVJ-8;__*$G8/K?$]^Y\*%*ZRMP%\  Z[-'7!C3UR?7E=353 S^]?
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MX.N$VB%S,4A\9C&V!ON=+-&0&=Z\TG-UH6+5,/[81N0L WVYWS<E@,P9BS
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MEZ1V9=ERLLFXXJ3\&$^YRAY/R78V>TK1%&1CAR(5@)2M_?7; "6*#X $J >
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MMGM9*/^C=0G+YCA'L@5<(=[:06/%=5%)-HV&9M4K,""Y>HO$-HC=M%!3P]+
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M\.MA[ 4+'QX>=Z8)?X8A61I'+IR!U$]:4LAMIS]ZHP!X87=R2\VHII8V?A3
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M2I)GQ"M=78TZUH_35CAH9C93"@FO#YN64N8S6D]JO&+U:90068K/)&'L.;\
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MZ\1E.Q(;0^?#<_1R'"<+E!%+/A4(Q7]]O_MGE:3\VZ&06AG/B^/G9([EE]7
MYT2\(8@WFW. T#)/]2XP'/'+FT)\K9&RKM:N#$1GW-#*82852Z-/RF]OD[7!
M<EN%C2"[E3*@DT&H$,3J/7$V^O],D1>[^ A49V>OJZ5A(&-\Y 9$/;R)XKBX
M$'EL)*B@:*=T,N4IHS[_8T-X_L7W\U&%P,(/RHS._,&>P6<OG$:7;PN/G'RN
M4O*&U"@@-+!,T>T:&A306QZ@MX, F@TYOHCNHB0#HQF.C/I#:&ZC_V5I;OC;
M 2"CPZ0*][_Q1M0,KDI=HR3/C1=X":4M'H>/7#=:@P9,T8F8 D*FAC)N8G92
MST@RU32 _!BB=7@8)O$,AG#FD<=#<XWA'H; 3SP8XTUW=2EUY#@HW9B]*I/0
MI45S &@V.$VK/\0D,/B-54(9^Z_G\?(-!%Y(F7?UF-HVUPM*6^@[EK*";L>B
M,BV.9CJ0I(,%^6>/XO@YEC_[QR[+ $JLB-;!)64ZI$E[5Z8[0X=8F^*\UNRW
M2DTL@,/&L4M;#XN+H=;(93P2HFL**J'8@6L*DA9-5I"]V=N$=(Q%K;N1J2E4
M#)%F8M#D#A//N"H>_4Z(A.X ]"4(!K]<(J<OUAJ%[4=!5G,4F96M0T%:(2S:
MILT<I5KQ7Z-#6AOZ)<WN79P$UJ'3>!G<*E\&JD;9CQ8DT*&M30BE:BFPW#O6
M@=+,,D!<0]8^MZ%JWJNN!6O?PE"H FW[MZQ]IJ(Q*D*WF%H8_F(@#/(^.+58
M_&P@%DJ<>&IA^FP?3,I/&B8[)$I>0\7C-O$X7>NS-/EZR.9FR!U,R":(B:87
M9C;7M\ZC((BR5)B7OZ7>"_#)O9K+-\=/<==7&+1SX#NIG^>"N?#\-(%NI3E]
M]TI&>/9<0I/W A^@D^*9P&*J1'X4+-(D)_\2H!#/]IKPK2FOWA-7U;S6E!8=
M1R&7UT)))QI@.O=!'.<96X1!L(R".LB-PA>($@^C=8];A CEM_Z$8:]UM73D
M;^C&+V=+=@.BE!4]]F@,@+4Q_[75=F<HVL/3B9FB*#8$S,DO;\Q\2*\488RE
MFK8U@/(K(!>/$Z&<+9=Y9WF'N-'3U,XRC5:7JPLJ)S]SC$0M910^XLTQQEKM
MYAY]H3-ZFYY/IW1=Y=1R+Z[3=2)!LEP#%H99JCX4L!/UJ-&J#8U/J#]!\_7F
M(ERUZJJAXY?+N-._"EM*BU*K)1D/IBC8Q3 TC0^ADV+16C6TM%@92]K0P=?+
MISXW 47Z\8YA*P[.K*C/9HZ]1?XKE<8UA3PF%H=FAD;UQ'F#Y?L;/$2L?RX4
M[!]FQA4IYB'I$ZQUD32MT9 _+5L;>M,:$\DSN<D^PTI*N?P=O'N Z.YA5E:Y
M G'+*=8N8N#DJ B]>K75M'KK.-3%9\O2+U).N29M:4GR(T.>P&K>H '-PQ,Z
M,A@%[2*W@Z>%8^4\BP!R2;P!@@ZN(S!G<DHJH^0N)>V12(DPQD/$:M/H&<$L
M_VC65Y4[I:MIR?Q$=JH(";T"E4+F2(8\?7),%-KB>O_52^;%*LW$A72K.G)?
MII"\05O<A,]3A$BBV]"]BT(G^X,S8-G:)CXJPLOMFVOCWX@U(;[.X["^H2A6
M_B*-H"<]G$ 8M#R;_'EGE+70E2.KX;%=-(U4*3,M4G)FWN:*5/G>]/;&;SP:
M(E>":CB,]P74'VGYRMWZ$,M3N79BS'7"0U[5,Q..%C;#%@=-WC*I6V1FVED[
M+QN>4KT3PY7=;CNKZM8:DMN@):W/6VM0;J6R]7$8L-;\W)*O6*<#39;FK?,-
M'3J$;G!\2>K%)"#H,DP#F%VXN_'B1(<!F3P1,YZ-W*@^4I)95$=LKD,O]V/=
MY"$!H4MNLSXN7#SIIQ]//I^<"L<@5]=LI4XT927_N1Q.+1=(_C7YASSS^[?_
M!U!+ P04    " !10&%6+T5&\4.K  !H!P@ %0   '!M=G M,C R,C$R,S%?
M;&%B+GAM;.R]>7/D.)(G^O]^"KR:M>TL>Z&JS*R9GNF:8TUGCGJ4"CTIU+4]
M9<_**!(A<8I!1O.0,NK3+]QQ$&#PBB#!(VO&IBLS)=(=#H" GS__E__]91.0
M5QHG?A3^ZS<?OGO_#:&A&WE^^/ROWSP^G)P^G%]??_.__^U__,O_<W)"+JZN
M;\DM?2.G;NJ_T@L_<8,HR6)*WCU\_I;\G[/[&W+CA[\^.0DE%Y&;;6B8DA/R
MDJ;;'[___NWM[3MO[8=)%&0I8YA\YT:;[\G)B2!_'E,'?DXNG)22'S^^__C#
MR?N/)Q__:?7^3S_^_3_\^,.'[_[X_A__]/^^?__C^_?::]%V%_O/+REYYWY+
MX"W&.PQI$.S(E1\ZH>L[ 7F03!?D.G2_(Z=!0.[AK83<TX3&K]3[CM,,F 0_
M!E*,+XG_8^*^T(US$[DXO'_]1I/GRU,<?!?%S]]_?/_^A^_56Y5/P+].Y&,G
M\*.3#Q]/F&1?$N\;PE8C3)!W"R;R\2][S[_]@$]_^-.?_O0]_E8]FOAE#S*R
M'[[_/Y]O'E#.$[9"*9LU^LV__0]"^'3$44#OZ9K GX_WUY6C^]/W\,3W(7UF
M2^C=.$\T8+R1Q$M,U^7O!7%LO ;3\B>8E@]_A&GYNS)JZ6Y+__6;Q-]L _K-
M]UT'NHI2)^AWM/LD#QWRVDF>D&.6G#P[SI9S#8#D]\X7/[F@:R<+TOT1)^QE
M'.X>!?9Q?/R>!FD"/P%RR0G\",==0K)JQ#@&^-#%<T"I9L/R<?-MR.GZ*;R@
MR)C\Z)>4AA[U</LIEI%K/!3 QQC%-<(GU/WN.7K]WJ,^EYO])9>6_>.7RY -
M9'?J>3%-DG/VUV6\BMY"21.']Z_?U#WY?;<AUJ\/_"0?L/C!+VR):!RS_>5\
MN?&=)S_P4Y\FMS0]?4K2V''3PO#;OW>X,-O-*Q_AAX_\!/L[^,DOR_C9"?W?
M\+ \C^"X]SW\QVGHW;$99)<"_I,M/;U.Z28I#/E((B,L!AR87A;0Y?IRO:9X
M*;++)=I0-LOW[!2XIV[$KI_ QZ&NG*> KMCV/F.C^;5BG3J1'&$*KAP__HL3
M9)HVD#1LQ=I71A#ATHE#IO D=S1^>'%BVC#\RL?'G/WK<)NER0U]I<&'SW3S
M1..FR2]Y8]0OZ-1UXXS=\OGA=.#WTDA@!/%NV'U!Z7)+8_:YAL\WE.EMRRU^
MN=&*QANFGJ:T0K)V[XYQ!;'3*$E]]SS*PC3>U6ZW\F?'V&@IVP+72<)VR$46
ML_EDGZ\?>?@I,),&?U.\B Y[=P2AP')Q8O>%W8D7\"%'6["X+K]L:9C0.W9E
MNKL*D=J\.8) 3!\Y=Y*7NSAZ]9D*>+9[3*AW'0HS+GQ&PQ._[89#^@A"8VQ*
MN#_.V'?MG4<;F'JNX<2Q$SY36)"S7?[(G;.#'YV^.;&G3O%3MO<V>"@DL'@N
MLSPN?! Y].ZKCQ;[?*>AB8!B>+J!HR=A!Y'C%W7[@U[M*)*T1Y)T&W-QX&^Y
M&/"O7T[_LS!"^=.>F%<;0Z=LC3U8YZO >2XQ@<S?C_&M9$\)_5L&I]0K^\^*
ML:I=T^KG1QB\>8NCWVFY9D<2^XQHU1%6_TYOUEJ9FG%/0_KF!)^C,(4;XJ_L
MJBBST=J^VMM8-2,69R$Q>9<:DHWO3$0ME'KK[C'TV"D$)P_U+K^X[%%^#AV@
M)C;3FH"9Q;6,)OV^Z:UQM*XT]N'* Q6#;7+XX_)OF?_J!.RD2<I_6JLF=R(Y
MBC;-+GFX#=#$JE2;C8=&/W;55W$;A6[&SH3*;ZKYO1&$.7\![>PZ9'8N?,)@
MAC!;Q/6W <U_Q.8\])BBECQN/3;[UYL-^V_L.P'W)E7(VPOIT==7**I55ES%
MP[U=3A56(IY:3$FFL>LS W[]DP-J]MXHCR)A50E0VUY.%;.IENM[ZF^>LCC!
M#SNYR"C<\%?^:_$0Z(UL;S)>;K9!M*,4)_DN8\8O;(/ "4M/YE:OC&$A9\!Y
MN5:3^D"?ZW9]]?,C#/XN%LH83BC?ULLLA7 CA)PK1&AZ:P1!/CONBQ_2>,<N
M9;B0T7M2>\/7O3'&91)M-E&($WKN;/W4"?B\RECX511?92G8P>PTPF!PQ<UQ
M,)TQM!5VBM+DS-Q'M:M5]X9]4SSS?$;CRH\WUUZ9*6[\?DYN*]CXZ>XZ9,HN
MYH8DR_2%QBNF?7#'=L(TK%>F"E/O)PKV+O5.7]FQ]4P_P7T':2'*4].W9ZO/
MH8UQLHK+=!6=NDP29B?%D9=A^)!;O55G:^-[(PBC IZG6?H2Q6Q=:CT]E8^/
M,/1*=?GC^P]_^O"Q]M!I]VY_^NJQGXI4*?A)?_KJ^ $8>.RHQV^!_;FF/ISY
MR77(%=A277= ]E/0DV_IEW3U1H-7BKZQ4OV_3_*3WR?2GO'&V"7[S,?PB.GF
M!;]F:@^(ZN='M[T+E^(]A0-8_A*BU1]:6>4MR(SAKLU3"ICVCK/_$@4>C1.N
M-51Y9IM>&U%/8-\!N^E=2KWD*HXV*QJRC^(T"**W&F6_Y<MCB,5L\EMG4Q\1
M*CS4WP&I4E!PFW(/^SW=1G$*Y\N9$\"T/+Q0FM:FM'0D-A.7Y*D7;9DH/7HB
M)47KAAE/ P5U,V;K@3<1^KA%<LMYY!6_G+9OC:9D*Q]]0SY%U=.]?43G[%9F
M"LWNEK[]F9V0M#RMJ/;1L;**C$/]GD(Y!;^B'[;L]*_+*6IX<PIJ*_IAHZQU
M_/=0LKW)>$_=P$D2?^WS,HUDN5[1#7QQ\6X5,25OXX20#(!SS;7",IF.(3/&
MQG/@BL"] E<:&R3[*!+V1;(AUZ=%-+\XE6VW8L1MA!4XW7'UR//:^&/)@Z-J
M^%&2G#MQO%M',=A6S1&VO1?&]"*U2S2H?'P,+Y+W7UF2\FT<A:Z3O&")PRJ2
MV?_,W$_Y@&&J5U%9KJ-:C=9)D];93B3D)/R$OU5JH0TO3=ZULA>#J8CBC#2(
MR91-'50K-7*!D?3]L-GTP0 L7;0@$$6J</6YT7,(^Y4[N,ZC)$UJTW6L\!IU
MTF"\48C1G+4ZWT62^QD-Z=JOM\C[H#@UU]R%2 B$-&VV6F[;+*@69 8RP!\V
M3A"<98D?,CVPTN VGQHQ4X,[;V!3M$S5*'EAM*#Y^<%!\_(WQE"B8NHLUS=.
M6'7+:P^,,3P,K];; >8SHVA/$3L$F%$5@(=7RURYJ:C=/>#%$<0IG&&F J.E
M%+'+SG<K)#N,1G]%U<9AS&X<G[L2JT-G#6]8/ZRA3AX^L0JWJ/'K.26QB'P0
M;:FOPS3V0[;<5C)3&OF-;XZ((59&[_QU55'U<'Q'V&)2^[B@B1O[6X%>  <#
MTQYU$(,F_?,(0C/\HIH31VQR&L,H5=6&W+"0@MS3 "!DT(I".9XT.9J<.!V)
MCNL6;?:'VK^W)' 5WQ>7H7>Q7TA;_9R-6C=-_,,*WFI>'-<'PQ5;]A?Y,V%"
M&Y\S.^&X19V4?^^PE9L]./VQFN&1BHXX=<8-GE1[Y"@F4I$I2EDA[:CJ7&IX
M:PRS4G/#0JSO@CZE#]3-8NZ)WT1Q"GXZV-"H/U19GH>2Z>W<DP851B!"E^(H
M6AQ[K=X;7U66OE55SN6M7J@?8WGW*I(U1M7QZ6$8]S9/J[=H]1)E"3-<5F]L
M*+LCJK .IM'79Y?$J?;)L7]I: UQ^LL]3/GIE[UOR/S=*-'TK?CGQ=Z9WHG4
M*,76J+;>.7&ZTU(5DK.=_IN253B"P&A>P%KWW]3*&/[X_O@RAOS=Z4! \2/O
M',I[$ <7S";X>^JC!U[>>75Y7,<3':MVGVF\-XQZ\&<VD,3SW<;<\Z:W)@ H
M<>$'675F:=73XX+>L>_$@X'XK]JNN/SB!IE'/4BNAEL^2T6<M2C# >!X?3'J
M+^&3Z6GL7HD%QW-FF?GIO9_\RC89UM[!WR%Q_I$]%Z>.'\*(ZW-Y>B0\4"Q3
M8,K>,3W:"?[3W];F$)<^/)@_Y,I/V*?/C[<K]K.RT&OUL[WMFT=1AJE!IN0U
MR(^A7X&T<MB[O8WVFA'UG>",&X;@*WKX6\8^J*LH*G6%USX_.M9-I8IE/#2,
MQKN*SNB=XWL%-?5TG=+X:$R*5D2GX#H#1XE*PZFKV6GSYNAI>77.I[(GQTW)
M7$7L(/9A"MD1QS;+=:A#'SP5;?-[^K?,3_Q4IE/Q4U&D3,$#==);9SM*8B[[
MFMB1P?.GA#OVMA('K_+Q_IPY49:^G,59F+SY[J\M*E#J7Q@]XTL=9ZT2N_*G
M)PWX6I4TU9[ F#GH3"F%":>AN[MI2)VI?V<RN;.5&3X')=564QD3U6ZY5HUC
MF+*-IV5#U+75JR.(I&J7]((E[JZHD*3NC8&,HBNH-,A*#M_21\;=*'#X7#%%
MJBDL7_N*A5)DM'2OPW44;_3P_RKBD9!#"I$/(S60\UVDQGZBT7/L;%]\9FZ6
MUKW5/SMDI*!4G2C^=MS-O%^4VGY7U[P[1J9G%/_*!J(KQ$K/J<^Y;?/F2/#7
MON>S<UFKX*P)>U0_/Q1^V8TH#RDYPXM/C %= %6^8EIJ"V9+'APE/\&!E)6D
M7;U*U=/CA[\;:L9R3U+NDC.S1WJ-B7<?S33Z'"1-&Z+^G;$2F_9\%OM+]E21
M4B22&&"UJK)_P7R"ZR?CR3A5 $1CC&2<2@X%V*/A1^79(-6%' WO]0?0VZ+A
M&6/K8A#+O)\W?EIVU_1&=N0%DY6SF-$KXQ4M%JS\O0F8H1V:,1U%:OR+[S0,
MV>?/MF",?;S6>3DYOWQ$#:6Q4M70R...90H!$/"/8637P)F0;:T.2 NNHS*E
MBKNF*[[%BU-*)+J$+J\)9,/<^)5IW&W?'D.P;@D59[MR C46G4V.TTGL$_$=
M#BRHI>O]Y*<O^BN'9?NUIFJ[&P3>2YV:0511&#V(RR9P&:-#B(]1;KQ6<=W*
MEZ>70N^ZV2;#+?,ICI+D,62W: "7YR>F[9]1=HF CGE<7GU+VF/X2YSDI=!^
M"$!-F=Z0@DUSC9DU=>@&!Q"83F6X2!)LVZGB4"IC*%(9!3PG=>3E$&-L-1H;
M([5]>Y2.%AQ>L_!)U2:UUK\SQHD*=35,AT^5PZ;$<U,KTB$4QND[PE04&K=K
MFE+U='^W=,:.8@"W87H AS%>KM< >;1U7$ [C5-U[Y9>T0>\;@$)HHBRI_J5
MWD8IXCV4)L =]/X(6^03#=D  W:@G'H;/_033.5]E9D_M1NFW;NC['N5_5\&
M+L?5O,<M5)K*DH'*;^)P2F-BV]=AB*F>*NB62%91Z@3%LENV%_]*TQQA3'="
M5J7Z#\*[OQJY5AXMOKQ5WK$.A.P#P7"E@.>$0Q9M=4U]Y:.CN)RV,77],K]R
MZ2-CN%7!E&5' &K2N-G9*FL92%H[HQ4;1E+^J]KP9Z\L>OMDSB((P##%FDT_
M>Z<FY;_BR<E@'+]%!R>IMZ,Z#1MQK[&M^0/MR>L0'%E,6*:F;J/$"9@%G&W9
M&X@T"$Y =HZ)&:D^^@<=PNCU&/LM@5M5:)2\-D;.,J25<3=\<T/>TF>'K=$2
M?]SX(2W&DNN?':Q"B\=U.'QD37&6\=AH-<]02YKG ?,#KPF?NOG%_JRL^-EA
M.I]0!<,D"GQ/8L48B%LEB+I'$!@EHVR[#?#:8(JO2$G5LCR;,O]:OMW;@LBO
M/[T+F''M78="NZ^^^AO>&+,<P$0,;BH$*#P]SL Q5GQ!^9\:S'NKBI/V[_=8
M7[S9^-RA#/>=JJ5@9T;N"+NIJ,4XAL(X93_L_/@"*E]UJ8]Z8A1UY8!N*I6Z
MRR$TQORJ\UW1NME$V2NC1_):5(G4O#":*NFZ,>/?NLE*PTMCK$)),]Z#:JP.
M(#"&2[!%(A[3[CV*#8B95B3NO8/1_RPPFL:QTJI)6_D;8[@#CNWE!ZVH]OV#
MO9'M5<40Z7%Z*;;>\^0J Y19F8>9%W";#W[V0W^3%5$&[?"8&O!24[ZG-2^V
M)1#L>YJR@]=.4^,*%C;0^MAEL7KQXY12OOE:0_35O#B1O-$"$*SX0$#'1VW
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MWC D9E/& =!&B@S'<NP;F%^W44K;A\';OS\)X5I+,4ZX$,H9HKC6O5EX:!Q
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M/CZM_/3XTPG>A8/HP\=W3]]*3Z$E'.FN8S;.G*$&+C?O=>C&<*-=4/[G=5A
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M;#^"3,@%.R'SHJ>M*GJRVB#.CH#*82@$&Z=,S:* IFNQ64J[U>)^B@YDS"9
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MLM!MJ<5Z6OP(N0A7U*.Q$R"6-^!R1*X3L M:(*F)6[UK J>XDP4OB:R.\#?
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M!:Q]S8VY!4!LO97Y@H0<1V'-'8SDB;L2!ZG1A UYMD.XWLYUJ7NUETP!YT#
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M#C,4<Y5(?GA.0F"4R!Q9>/UM#4T%J_05>SL'FIE:V8C+\-$N3:$<I-*C#'%
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MQ_R1X4.A?L3 B>^[K2/=8U";VZMH%]!5^(&\I7'(LEQ(/4;+>D>?F0@Y\*F
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M[!@S$!E\LCE]VE/RY$>&^6G":OVT@W>CJ[Q25P=JH\-ZG3'.,K98'.1?T@"
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MNMK.41AH ^-Z-"<_BX?]2QRM;^(TL!R UH#Z"YB\P%H[W.G4<Y,+Z=S.^1
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ME<OIT^X^H<VM;J6D(X7LKG[)0S$0$6PSR"@N2H5__0#@$ERP,D "!/F2BP2
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M(8T"D4_30Z0=12G ^&&J8#2C-P4@?YDJ()R(48'/7Z>*#S4L52#SXU21(4;
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M8V=^25FT''CY<<Q9;+8-"E;+&DB9##GR>/5#V>7OV@-'V?R>@Q6(KG9[/SR
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M&8[2:!_&0*15Q@3)A1-O'QQO50:!PRCWE-P$KI^ND*=DN05?X S@_J"=R>,
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M( +<(B96D9'C0."FHHXLOV5J#!8<;17LRDNT=FX_&M9:HQSD,#:5!#83H.G
M4/*2@AWS14@"N[H%^$=(5,YAI8$XI9W4N<OFO>>YQ.ZW.'.^\V#BB;PVU1Z
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M#[PPQ%!Z:S!TS9F2]ZGHPT\(:1V(W;<3(%A!DLH]C<2344)]D@W%@73Z1GJ
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M31W49![?%IIZ]&:L_,7;GX_>S&P8O/T_4$L#!!0    ( %% 85:C0<Z,S 0
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M%KXWFZZ+"CE>D&K+8^%$$^ECML0K9<H+TT'YXO?L]71@7AC_!U!+ P04
M" !10&%6K#JI5(X)  "H6P  #P   '!M=G M97@S,5\Q+FAT;>U<_U/;.A+_
M_?T5.F[>>S"3A#@!VCHI,VE(KYEK@8'T3>]'Q983';+E2G)"[J^_7<DA7VG#
M*[2!N)T!;*^EU6H_'^VN;#>')A:GOY'FD-$0?I.FX4:PT\Z7<MUK'KH#N'R8
M7V_V93@AVDP$>[L74S7@B4]H9N0_>)Q*96AB&BD-0YX,?/(ZO6WLV4;3Z2V&
MW9HR3T*6&+]:J?[>B&1BRIK_C_D>'*>FX1HM&YGZ[H25B&C,Q<3O\9AI<L[&
MY$K&-)D*]Z4Q,L[E;1=4\$'B"Q89T*")34PU& ^Y866=TH#YJ6+EL:+IJA;S
MG?[Q-9.FL=2U.UDBFBD>-6)08LQ#,_0C;LH!W P#A)[_^*=W4FTT#[&YT^9A
M^BN-H?A@"#H1'K[=TRPP7";>DFWZ-+@9*)DE(8Q!2.6K09_N5TOV_T%CY9QW
MT+C?G&.&'?I]*<(GLV_G=LC[W)"Z5_$>Q<I>[4?-'$ _3"U[W;.S;+MSU>N^
M[[9;O>[%.;EX3RZONN?M[F7K(^E\Z;0_][I_=> T2'2NML._7XCA+S]?77]N
MG?=([Z*PZV-2Q9?VA];YOSJDU>Z1J\\?.]?$J].R=[1/#TCK_(QXQZ$[*A5V
M?T2[MZY)Z^SBLM<Y(X5K/XV)KSMMR]+U:@V9NO>A0ZY;5^]:YYWK\L67CYW_
M6)^'*[5JM;8ER^2ZT.PI#)](%5/Q9*;OEL@9'?&0?*B03Z!^B01,&1Y-B!E2
MXT^-/3_*;1P&6?**D(_N]8N0ZU30B1\)=KO&)_Z;:1S_M'$K5M:&*M.P,U^&
MD<;:[U/-!$_86C^9J5FOU.OUWU^<XRP8]<ZB/$&+E*UAO]GO,M:^8?,54^Z=
M>I7I;,]-\Z(.S][ @$PRI"-&%!MQ-F8AX)%KTDJ2C IRQ3!7)3(A[T$)XE7+
M_R8R(I>?_B*70PIJ!2PS/*!"ET@W"2JS# XLEO\L8/+"85+;"9B\ P<+$0GQ
MA-PD<BQ8.& EAQ;E8!)*:#:1AN!=E">$)A.2)49E# 9.P4^A*<0/)3$<*0X(
MBV@ IQ21,63G1CJYAPLD+&!:4S5!D9C>,%!LKE,-YT+0%G02:"Q4 @4"KH(L
M!K$$;@=50Z8(&#H8$IWAC]G]8Z98W@B.,.9:,(K5*S+F9@@6T"D+K(+8;@JJ
MR1#L,(+;0M*?S-NI((D=)(GZ;I,$(Q%/ &4(V!FJ2L 0( Z7U=QUGD2H)=8=
MX>] 9"&T"<B=@U )4,^5F! 8I$920;(18D8*.1[U4M>@:<BQX1)*9 ($@ DD
MP-5VIZT^ =5#$@DYUE.:4&S M5$4.J)XTND-6I;FT*ZGRJQH6P!^!P%_M!.
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M,2BB&H@(JQ+(,%2%4[0#_W#:YX*;"28GZ[I%[K/$8#'O:&M!=*ZJ86.OVWQ
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M@-!#8V@#O[$$,V4X]C7CH++EM"RQ#ZCK@^=00RWHH"BA/L63LP*2>O >#@2
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MQ!!&A($9O8BK =Z!8C&$#QA"X#$8S8^$RN ^[%B*R.(TE<)G 9Q69!=@&3#
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MR^-? \L/N.0'7/;:COR 2W[ Y3D/N#1*XFWIYJM&*7[+^G]02P,$%     @
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M<E>@'POS49?U]VB^UX+<27.7?MN\6U6D')F&:AC&*^L:2"Y-X@ O32\@B^L
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MX\F+3C7]5.1_4$L! A0#%     @ 44!A5B=0S_\\Z   P? ! !(
M     ( !     &EM9S(T.3$S,C0Y.5\P+FIP9U!+ 0(4 Q0    ( %% 858G
M4,__/.@  ,'P 0 2              "  6SH  !I;6<R-#DQ,S(T.3E?,2YJ
M<&=02P$"% ,4    " !10&%6!QEQ+002 @# 30( $@              @ '8
MT $ :6UG,C0Y,3,R-#DY7S(N:G!G4$L! A0#%     @ 44!A5B&4&A#=C0
M?,(  !(              ( !#.,# &EM9S(T.3$S,C0Y.5\S+FIP9U!+ 0(4
M Q0    ( %% 85;(;>_W*@8! +,R 0 2              "  1EQ! !I;6<R
M-#DQ,S(T.3E?-"YJ<&=02P$"% ,4    " !10&%6.G*EK<1/ 0!&J@$ $@
M            @ %S=P4 :6UG,C0Y,3,R-#DY7S4N:G!G4$L! A0#%     @
M44!A5B05??<\G@  *L,  !(              ( !9\<& &EM9S(T.3$S,C0Y
M.5\V+FIP9U!+ 0(4 Q0    ( %% 85;#5V&T\/   #X@ 0 2
M  "  =-E!P!I;6<R-#DQ,S(T.3E?-RYJ<&=02P$"% ,4    " !10&%64N_%
MLY.(  #LE0  $@              @ 'S5@@ :6UG,C0Y,3,R-#DY7S@N:G!G
M4$L! A0#%     @ 44!A5@WX$L.O>0  ;(T  !(              ( !MM\(
M &EM9S(T.3$S,C0Y.5\Y+FIP9U!+ 0(4 Q0    ( %% 85;GW0]RCS4$ )'3
M/0 1              "  959"0!P;79P+3(P,C(Q,C,Q+FAT;5!+ 0(4 Q0
M   ( %% 85;O]S-X]Q,  .7D   1              "  5./#0!P;79P+3(P
M,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( %% 858,GO"O"@\   +9   5
M      "  7FC#0!P;79P+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4    " !1
M0&%6F[ZYR^ K  !C/@, %0              @ &VL@T <&UV<"TR,#(R,3(S
M,5]D968N>&UL4$L! A0#%     @ 44!A5B]%1O%#JP  : <( !4
M     ( !R=X- '!M=G M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( %%
M8599::O;ZTD  )O,!0 5              "  3^*#@!P;79P+3(P,C(Q,C,Q
M7W!R92YX;6Q02P$"% ,4    " !10&%6BD:.FUX/  "1I@  $
M    @ %=U X <&UV<"UE>#$P7S$U+FAT;5!+ 0(4 Q0    ( %% 85:C0<Z,
MS 0  #<N   /              "  >GC#@!P;79P+65X,C-?,2YH=&U02P$"
M% ,4    " !10&%6K#JI5(X)  "H6P  #P              @ 'BZ X <&UV
M<"UE>#,Q7S$N:'1M4$L! A0#%     @ 44!A5L#XW6VC"0  >%L   \
M         ( !G?(. '!M=G M97@S,5\R+FAT;5!+ 0(4 Q0    ( %% 858M
MN8<52@8  &P]   /              "  6W\#@!P;79P+65X,S)?,2YH=&U0
M2P$"% ,4    " !10&%6H7>0L@T&   <.0  #P              @ 'D @\
E<&UV<"UE>#,R7S(N:'1M4$L%!@     6 !8 >04  !X)#P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
